head,relation,tail
NCT04683679,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT04683679,has_status,RECRUITING
NCT04683679,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,tnbc - triple-negative breast cancer
Pembrolizumab,targets,metastatic breast cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT04683679,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,breast cancer
Olaparib,targets,tnbc - triple-negative breast cancer
Olaparib,targets,metastatic breast cancer
Olaparib,targets,triple negative breast cancer
Olaparib,targets,TNBC
NCT04683679,tests,Radiation
Radiation,has_type,DRUG
Radiation,classified_as,OTHER
Radiation,targets,breast cancer
Radiation,targets,tnbc - triple-negative breast cancer
Radiation,targets,metastatic breast cancer
Radiation,targets,triple negative breast cancer
Radiation,targets,TNBC
NCT04925284,sponsored_by,Exelixis
NCT04925284,has_status,COMPLETED
NCT04925284,tests,XB002
XB002,has_type,DRUG
XB002,classified_as,OTHER
XB002,targets,scchn
XB002,targets,pancreatic cancer
XB002,targets,tissue factor-expressing solid tumors
XB002,targets,metastatic castration-resistant prostate cancer
XB002,targets,esophageal scc
XB002,targets,triple negative breast cancer
XB002,targets,epithelial ovarian cancer
XB002,targets,cervical cancer
XB002,targets,hormone receptor-positive breast cancer
XB002,targets,endometrial cancer
XB002,targets,non small cell lung cancer
XB002,targets,TNBC
NCT04925284,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,scchn
Nivolumab,targets,pancreatic cancer
Nivolumab,targets,tissue factor-expressing solid tumors
Nivolumab,targets,metastatic castration-resistant prostate cancer
Nivolumab,targets,esophageal scc
Nivolumab,targets,triple negative breast cancer
Nivolumab,targets,epithelial ovarian cancer
Nivolumab,targets,cervical cancer
Nivolumab,targets,hormone receptor-positive breast cancer
Nivolumab,targets,endometrial cancer
Nivolumab,targets,non small cell lung cancer
Nivolumab,targets,TNBC
NCT04925284,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,scchn
Bevacizumab,targets,pancreatic cancer
Bevacizumab,targets,tissue factor-expressing solid tumors
Bevacizumab,targets,metastatic castration-resistant prostate cancer
Bevacizumab,targets,esophageal scc
Bevacizumab,targets,triple negative breast cancer
Bevacizumab,targets,epithelial ovarian cancer
Bevacizumab,targets,cervical cancer
Bevacizumab,targets,hormone receptor-positive breast cancer
Bevacizumab,targets,endometrial cancer
Bevacizumab,targets,non small cell lung cancer
Bevacizumab,targets,TNBC
NCT06533384,sponsored_by,Guangdong Provincial People's Hospital
NCT06533384,has_status,RECRUITING
NCT06533384,tests,"As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy."
"As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.",has_type,DRUG
"As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.",classified_as,BIOLOGIC
"As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.",targets,triple-negative breast cancer
"As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.",targets,TNBC
NCT06533384,tests,9 cycles of Camrelizumab as adjuvant therapy.
9 cycles of Camrelizumab as adjuvant therapy.,has_type,DRUG
9 cycles of Camrelizumab as adjuvant therapy.,classified_as,BIOLOGIC
9 cycles of Camrelizumab as adjuvant therapy.,targets,triple-negative breast cancer
9 cycles of Camrelizumab as adjuvant therapy.,targets,TNBC
NCT00203502,sponsored_by,University of Arkansas
NCT00203502,has_status,COMPLETED
NCT00203502,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,breast cancer
NCT00203502,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
NCT00203502,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,breast cancer
NCT06036121,sponsored_by,Adcentrx Therapeutics
NCT06036121,has_status,RECRUITING
NCT06036121,tests,ADRX-0706
ADRX-0706,has_type,DRUG
ADRX-0706,classified_as,OTHER
ADRX-0706,targets,solid tumors
ADRX-0706,targets,cervical cancer
ADRX-0706,targets,triple negative breast cancer (tnbc)
ADRX-0706,targets,urothelial cancer
ADRX-0706,targets,TNBC
NCT02900664,sponsored_by,Novartis Pharmaceuticals
NCT02900664,has_status,COMPLETED
NCT02900664,tests,PDR001
PDR001,has_type,DRUG
PDR001,classified_as,OTHER
PDR001,targets,"colorectal cancer, triple negative breast cancer, nsclc - adenocarcinoma"
PDR001,targets,TNBC
NCT02900664,tests,ACZ885
ACZ885,has_type,DRUG
ACZ885,classified_as,OTHER
ACZ885,targets,"colorectal cancer, triple negative breast cancer, nsclc - adenocarcinoma"
ACZ885,targets,TNBC
NCT02900664,tests,CJM112
CJM112,has_type,DRUG
CJM112,classified_as,OTHER
CJM112,targets,"colorectal cancer, triple negative breast cancer, nsclc - adenocarcinoma"
CJM112,targets,TNBC
NCT02900664,tests,TMT212
TMT212,has_type,DRUG
TMT212,classified_as,OTHER
TMT212,targets,"colorectal cancer, triple negative breast cancer, nsclc - adenocarcinoma"
TMT212,targets,TNBC
NCT02900664,tests,EGF816
EGF816,has_type,DRUG
EGF816,classified_as,OTHER
EGF816,targets,"colorectal cancer, triple negative breast cancer, nsclc - adenocarcinoma"
EGF816,targets,TNBC
NCT06136884,sponsored_by,A2A Pharmaceuticals Inc.
NCT06136884,has_status,RECRUITING
NCT06136884,tests,AO-252
AO-252,has_type,DRUG
AO-252,classified_as,OTHER
AO-252,targets,high grade serous ovarian cancer
AO-252,targets,endometrial cancer
AO-252,targets,triple negative breast cancer
AO-252,targets,TNBC
NCT01372579,sponsored_by,Northwestern University
NCT01372579,has_status,UNKNOWN
NCT01372579,tests,eribulin mesylate
eribulin mesylate,has_type,DRUG
eribulin mesylate,classified_as,CHEMICAL
eribulin mesylate,targets,stage iiic breast cancer
eribulin mesylate,targets,progesterone receptor-negative breast cancer
eribulin mesylate,targets,her2-negative breast cancer
eribulin mesylate,targets,stage ib breast cancer
eribulin mesylate,targets,stage iiia breast cancer
eribulin mesylate,targets,male breast cancer
eribulin mesylate,targets,estrogen receptor-negative breast cancer
eribulin mesylate,targets,stage ii breast cancer
eribulin mesylate,targets,stage iiib breast cancer
eribulin mesylate,targets,triple-negative breast cancer
eribulin mesylate,targets,stage ia breast cancer
eribulin mesylate,targets,TNBC
NCT01372579,tests,carboplatin
carboplatin,has_type,DRUG
carboplatin,classified_as,CHEMICAL
carboplatin,targets,stage iiic breast cancer
carboplatin,targets,progesterone receptor-negative breast cancer
carboplatin,targets,her2-negative breast cancer
carboplatin,targets,stage ib breast cancer
carboplatin,targets,stage iiia breast cancer
carboplatin,targets,male breast cancer
carboplatin,targets,estrogen receptor-negative breast cancer
carboplatin,targets,stage ii breast cancer
carboplatin,targets,stage iiib breast cancer
carboplatin,targets,triple-negative breast cancer
carboplatin,targets,stage ia breast cancer
carboplatin,targets,TNBC
NCT01372579,tests,biopsy
biopsy,has_type,DRUG
biopsy,classified_as,OTHER
biopsy,targets,stage iiic breast cancer
biopsy,targets,progesterone receptor-negative breast cancer
biopsy,targets,her2-negative breast cancer
biopsy,targets,stage ib breast cancer
biopsy,targets,stage iiia breast cancer
biopsy,targets,male breast cancer
biopsy,targets,estrogen receptor-negative breast cancer
biopsy,targets,stage ii breast cancer
biopsy,targets,stage iiib breast cancer
biopsy,targets,triple-negative breast cancer
biopsy,targets,stage ia breast cancer
biopsy,targets,TNBC
NCT03414684,sponsored_by,Dana-Farber Cancer Institute
NCT03414684,has_status,ACTIVE_NOT_RECRUITING
NCT03414684,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
NCT03414684,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,breast cancer
NCT05451784,sponsored_by,Fundacio Clinic Barcelona
NCT05451784,has_status,RECRUITING
NCT05451784,tests,PD1+ TILs (NUMARZU-001) product infusion
PD1+ TILs (NUMARZU-001) product infusion,has_type,DRUG
PD1+ TILs (NUMARZU-001) product infusion,classified_as,OTHER
PD1+ TILs (NUMARZU-001) product infusion,targets,metastatic triple-negative breast carcinoma
PD1+ TILs (NUMARZU-001) product infusion,targets,TNBC
NCT05447702,sponsored_by,West China Hospital
NCT05447702,has_status,RECRUITING
NCT05447702,tests,Camrelizumab
Camrelizumab,has_type,DRUG
Camrelizumab,classified_as,BIOLOGIC
Camrelizumab,targets,triple negative breast cancer
Camrelizumab,targets,TNBC
NCT05447702,tests,Apatinib
Apatinib,has_type,DRUG
Apatinib,classified_as,CHEMICAL
Apatinib,targets,triple negative breast cancer
Apatinib,targets,TNBC
NCT05447702,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT05447702,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,triple negative breast cancer
Epirubicin,targets,TNBC
NCT05447702,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT04877821,sponsored_by,Guangdong Provincial People's Hospital
NCT04877821,has_status,RECRUITING
NCT04877821,tests,Sintilimab
Sintilimab,has_type,DRUG
Sintilimab,classified_as,BIOLOGIC
Sintilimab,targets,triple negative breast cancer
Sintilimab,targets,TNBC
NCT04877821,tests,Anlotinib
Anlotinib,has_type,DRUG
Anlotinib,classified_as,CHEMICAL
Anlotinib,targets,triple negative breast cancer
Anlotinib,targets,TNBC
NCT04877821,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
Nab paclitaxel,classified_as,CHEMICAL
Nab paclitaxel,targets,triple negative breast cancer
Nab paclitaxel,targets,TNBC
NCT04877821,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT04877821,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,triple negative breast cancer
Epirubicin,targets,TNBC
NCT04877821,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT06840821,sponsored_by,"Mainline Biosciences (Shanghai) Co., Ltd"
NCT06840821,has_status,RECRUITING
NCT06840821,tests,MB0151 for injection
MB0151 for injection,has_type,DRUG
MB0151 for injection,classified_as,OTHER
MB0151 for injection,targets,advanced solid tumors
NCT03125902,sponsored_by,Hoffmann-La Roche
NCT03125902,has_status,COMPLETED
NCT03125902,tests,"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",has_type,DRUG
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",classified_as,BIOLOGIC
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",targets,triple-negative breast cancer
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",targets,TNBC
NCT03125902,tests,Atezolizumab Placebo
Atezolizumab Placebo,has_type,DRUG
Atezolizumab Placebo,classified_as,BIOLOGIC
Atezolizumab Placebo,targets,triple-negative breast cancer
Atezolizumab Placebo,targets,TNBC
NCT03125902,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple-negative breast cancer
Paclitaxel,targets,TNBC
NCT05336721,sponsored_by,"Chipscreen Biosciences, Ltd."
NCT05336721,has_status,TERMINATED
NCT05336721,tests,Chiauranib
Chiauranib,has_type,DRUG
Chiauranib,classified_as,CHEMICAL
Chiauranib,targets,triple-negative breast cancer
Chiauranib,targets,TNBC
NCT05336721,tests,capecitabine
capecitabine,has_type,DRUG
capecitabine,classified_as,CHEMICAL
capecitabine,targets,triple-negative breast cancer
capecitabine,targets,TNBC
NCT03945721,sponsored_by,Massachusetts General Hospital
NCT03945721,has_status,ACTIVE_NOT_RECRUITING
NCT03945721,tests,Niraparib
Niraparib,has_type,DRUG
Niraparib,classified_as,CHEMICAL
Niraparib,targets,residual disease
Niraparib,targets,triple negative breast cancer
Niraparib,targets,TNBC
NCT03945721,tests,Radiation Therapy
Radiation Therapy,has_type,DRUG
Radiation Therapy,classified_as,OTHER
Radiation Therapy,targets,residual disease
Radiation Therapy,targets,triple negative breast cancer
Radiation Therapy,targets,TNBC
NCT04916002,sponsored_by,Regeneron Pharmaceuticals
NCT04916002,has_status,TERMINATED
NCT04916002,tests,vidutolimod
vidutolimod,has_type,DRUG
vidutolimod,classified_as,OTHER
vidutolimod,targets,basal cell carcinoma
vidutolimod,targets,non-small cell lung cancer
vidutolimod,targets,merkel cell carcinoma
vidutolimod,targets,oropharynx squamous cell carcinoma
vidutolimod,targets,triple negative breast cancer
vidutolimod,targets,cutaneous squamous cell carcinoma
vidutolimod,targets,TNBC
NCT04916002,tests,cemiplimab
cemiplimab,has_type,DRUG
cemiplimab,classified_as,BIOLOGIC
cemiplimab,targets,basal cell carcinoma
cemiplimab,targets,non-small cell lung cancer
cemiplimab,targets,merkel cell carcinoma
cemiplimab,targets,oropharynx squamous cell carcinoma
cemiplimab,targets,triple negative breast cancer
cemiplimab,targets,cutaneous squamous cell carcinoma
cemiplimab,targets,TNBC
NCT04067102,sponsored_by,Hebei Medical University Fourth Hospital
NCT04067102,has_status,WITHDRAWN
NCT04067102,tests,Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,has_type,DRUG
Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,classified_as,CHEMICAL
Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,targets,triple negative breast cancer
Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,targets,TNBC
NCT04067102,tests,paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,has_type,DRUG
paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,classified_as,CHEMICAL
paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,targets,triple negative breast cancer
paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,targets,TNBC
NCT04260802,sponsored_by,"Ocellaris Pharma, Inc."
NCT04260802,has_status,RECRUITING
NCT04260802,tests,OC-001
OC-001,has_type,DRUG
OC-001,classified_as,OTHER
OC-001,targets,merkel cell carcinoma
OC-001,targets,metastatic cancer
OC-001,targets,urothelial neoplasm
OC-001,targets,urothelial carcinoma
OC-001,targets,squamous cell carcinoma
OC-001,targets,cancer
OC-001,targets,locally advanced solid tumor
OC-001,targets,cervical cancer
OC-001,targets,hepatocellular carcinoma
OC-001,targets,triple negative breast cancer
OC-001,targets,neoplasms
OC-001,targets,gastric cancer
OC-001,targets,ovarian cancer
OC-001,targets,bladder cancer
OC-001,targets,locally advanced malignant neoplasm
OC-001,targets,renal cell carcinoma
OC-001,targets,squamous cell carcinoma of head and neck
OC-001,targets,sarcoma
OC-001,targets,non small cell lung cancer
OC-001,targets,TNBC
NCT04260802,tests,Drug: OC-001 in Combination with Avelumab
Drug: OC-001 in Combination with Avelumab,has_type,DRUG
Drug: OC-001 in Combination with Avelumab,classified_as,BIOLOGIC
Drug: OC-001 in Combination with Avelumab,targets,merkel cell carcinoma
Drug: OC-001 in Combination with Avelumab,targets,metastatic cancer
Drug: OC-001 in Combination with Avelumab,targets,urothelial neoplasm
Drug: OC-001 in Combination with Avelumab,targets,urothelial carcinoma
Drug: OC-001 in Combination with Avelumab,targets,squamous cell carcinoma
Drug: OC-001 in Combination with Avelumab,targets,cancer
Drug: OC-001 in Combination with Avelumab,targets,locally advanced solid tumor
Drug: OC-001 in Combination with Avelumab,targets,cervical cancer
Drug: OC-001 in Combination with Avelumab,targets,hepatocellular carcinoma
Drug: OC-001 in Combination with Avelumab,targets,triple negative breast cancer
Drug: OC-001 in Combination with Avelumab,targets,neoplasms
Drug: OC-001 in Combination with Avelumab,targets,gastric cancer
Drug: OC-001 in Combination with Avelumab,targets,ovarian cancer
Drug: OC-001 in Combination with Avelumab,targets,bladder cancer
Drug: OC-001 in Combination with Avelumab,targets,locally advanced malignant neoplasm
Drug: OC-001 in Combination with Avelumab,targets,renal cell carcinoma
Drug: OC-001 in Combination with Avelumab,targets,squamous cell carcinoma of head and neck
Drug: OC-001 in Combination with Avelumab,targets,sarcoma
Drug: OC-001 in Combination with Avelumab,targets,non small cell lung cancer
Drug: OC-001 in Combination with Avelumab,targets,TNBC
NCT02876302,sponsored_by,Dana-Farber Cancer Institute
NCT02876302,has_status,ACTIVE_NOT_RECRUITING
NCT02876302,tests,Ruxolitinib
Ruxolitinib,has_type,DRUG
Ruxolitinib,classified_as,CHEMICAL
Ruxolitinib,targets,inflammatory breast cancer (ibc)
NCT02876302,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,inflammatory breast cancer (ibc)
NCT02876302,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,inflammatory breast cancer (ibc)
NCT02876302,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,inflammatory breast cancer (ibc)
NCT04927884,sponsored_by,"ImmunityBio, Inc."
NCT04927884,has_status,TERMINATED
NCT04927884,tests,N-803
N-803,has_type,DRUG
N-803,classified_as,OTHER
N-803,targets,advanced triple negative breast cancer
N-803,targets,TNBC
NCT04927884,tests,PD-L1 t-haNK
PD-L1 t-haNK,has_type,DRUG
PD-L1 t-haNK,classified_as,OTHER
PD-L1 t-haNK,targets,advanced triple negative breast cancer
PD-L1 t-haNK,targets,TNBC
NCT04927884,tests,Sacituzumab Govitecan-Hziy
Sacituzumab Govitecan-Hziy,has_type,DRUG
Sacituzumab Govitecan-Hziy,classified_as,BIOLOGIC
Sacituzumab Govitecan-Hziy,targets,advanced triple negative breast cancer
Sacituzumab Govitecan-Hziy,targets,TNBC
NCT04927884,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,advanced triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02850302,sponsored_by,Centre Georges Francois Leclerc
NCT02850302,has_status,COMPLETED
NCT02850302,tests,PET with FDG
PET with FDG,has_type,DRUG
PET with FDG,classified_as,OTHER
PET with FDG,targets,breast neoplasms
NCT02850302,tests,Tumor exome analysis
Tumor exome analysis,has_type,DRUG
Tumor exome analysis,classified_as,OTHER
Tumor exome analysis,targets,breast neoplasms
NCT06078384,sponsored_by,UNICANCER
NCT06078384,has_status,RECRUITING
NCT06078384,tests,Pembrolizumab 25 mg/ml
Pembrolizumab 25 mg/ml,has_type,DRUG
Pembrolizumab 25 mg/ml,classified_as,BIOLOGIC
Pembrolizumab 25 mg/ml,targets,triple-negative breast cancer
Pembrolizumab 25 mg/ml,targets,TNBC
NCT06078384,tests,Paclitaxel injection
Paclitaxel injection,has_type,DRUG
Paclitaxel injection,classified_as,CHEMICAL
Paclitaxel injection,targets,triple-negative breast cancer
Paclitaxel injection,targets,TNBC
NCT06014502,sponsored_by,ImmunoGenesis
NCT06014502,has_status,RECRUITING
NCT06014502,tests,IMGS-001
IMGS-001,has_type,DRUG
IMGS-001,classified_as,OTHER
IMGS-001,targets,solid tumor
NCT01147484,sponsored_by,NCIC Clinical Trials Group
NCT01147484,has_status,COMPLETED
NCT01147484,tests,Foretinib
Foretinib,has_type,DRUG
Foretinib,classified_as,CHEMICAL
Foretinib,targets,recurrent breast cancer
NCT06225284,sponsored_by,National Taiwan University Hospital
NCT06225284,has_status,RECRUITING
NCT06225284,tests,Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg
Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg,has_type,DRUG
Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg,classified_as,OTHER
Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg,targets,premenopausal breast cancer
Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg,targets,triple negative breast cancer
Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg,targets,TNBC
NCT06409221,sponsored_by,Concr
NCT06409221,has_status,ENROLLING_BY_INVITATION
NCT06409221,tests,"Non-interventional study, Observational only"
"Non-interventional study, Observational only",has_type,DRUG
"Non-interventional study, Observational only",classified_as,OTHER
"Non-interventional study, Observational only",targets,"cancer, breast"
"Non-interventional study, Observational only",targets,early-stage breast cancer
"Non-interventional study, Observational only",targets,triple negative breast cancer
"Non-interventional study, Observational only",targets,TNBC
NCT03742102,sponsored_by,AstraZeneca
NCT03742102,has_status,ACTIVE_NOT_RECRUITING
NCT03742102,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,triple negative breast neoplasms
Durvalumab,targets,TNBC
NCT03742102,tests,Capivasertib
Capivasertib,has_type,DRUG
Capivasertib,classified_as,CHEMICAL
Capivasertib,targets,triple negative breast neoplasms
Capivasertib,targets,TNBC
NCT03742102,tests,Oleclumab
Oleclumab,has_type,DRUG
Oleclumab,classified_as,BIOLOGIC
Oleclumab,targets,triple negative breast neoplasms
Oleclumab,targets,TNBC
NCT03742102,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast neoplasms
Paclitaxel,targets,TNBC
NCT03742102,tests,Trastuzumab deruxtecan
Trastuzumab deruxtecan,has_type,DRUG
Trastuzumab deruxtecan,classified_as,BIOLOGIC
Trastuzumab deruxtecan,targets,triple negative breast neoplasms
Trastuzumab deruxtecan,targets,TNBC
NCT03742102,tests,Datopotamab deruxtecan
Datopotamab deruxtecan,has_type,DRUG
Datopotamab deruxtecan,classified_as,BIOLOGIC
Datopotamab deruxtecan,targets,triple negative breast neoplasms
Datopotamab deruxtecan,targets,TNBC
NCT05741164,sponsored_by,Roswell Park Cancer Institute
NCT05741164,has_status,RECRUITING
NCT05741164,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,unresectable triple-negative breast carcinoma
Biopsy,targets,refractory triple-negative breast carcinoma
Biopsy,targets,anatomic stage iv breast cancer ajcc v8
Biopsy,targets,metastatic triple-negative breast carcinoma
Biopsy,targets,anatomic stage iii breast cancer ajcc v8
Biopsy,targets,TNBC
NCT05741164,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,unresectable triple-negative breast carcinoma
Biospecimen Collection,targets,refractory triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iv breast cancer ajcc v8
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iii breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT05741164,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,unresectable triple-negative breast carcinoma
Computed Tomography,targets,refractory triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iii breast cancer ajcc v8
Computed Tomography,targets,TNBC
NCT05741164,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,unresectable triple-negative breast carcinoma
Pembrolizumab,targets,refractory triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iv breast cancer ajcc v8
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iii breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT05741164,tests,Propranolol
Propranolol,has_type,DRUG
Propranolol,classified_as,OTHER
Propranolol,targets,unresectable triple-negative breast carcinoma
Propranolol,targets,refractory triple-negative breast carcinoma
Propranolol,targets,anatomic stage iv breast cancer ajcc v8
Propranolol,targets,metastatic triple-negative breast carcinoma
Propranolol,targets,anatomic stage iii breast cancer ajcc v8
Propranolol,targets,TNBC
NCT05741164,tests,Questionnaire Administration
Questionnaire Administration,has_type,DRUG
Questionnaire Administration,classified_as,OTHER
Questionnaire Administration,targets,unresectable triple-negative breast carcinoma
Questionnaire Administration,targets,refractory triple-negative breast carcinoma
Questionnaire Administration,targets,anatomic stage iv breast cancer ajcc v8
Questionnaire Administration,targets,metastatic triple-negative breast carcinoma
Questionnaire Administration,targets,anatomic stage iii breast cancer ajcc v8
Questionnaire Administration,targets,TNBC
NCT06264921,sponsored_by,"NiKang Therapeutics, Inc."
NCT06264921,has_status,ACTIVE_NOT_RECRUITING
NCT06264921,tests,NKT3447
NKT3447,has_type,DRUG
NKT3447,classified_as,OTHER
NKT3447,targets,platinum-resistant ovarian cancer
NKT3447,targets,ovarian carcinoma
NKT3447,targets,endometrial neoplasms
NKT3447,targets,small cell lung carcinoma
NKT3447,targets,ovarian neoplasms
NKT3447,targets,small-cell lung cancer
NKT3447,targets,"solid tumor, adult"
NKT3447,targets,progesterone-receptor-positive breast cancer
NKT3447,targets,endometrial diseases
NKT3447,targets,advanced gastric carcinoma
NKT3447,targets,triple negative breast cancer
NKT3447,targets,advanced ovarian carcinoma
NKT3447,targets,metastatic tumor
NKT3447,targets,gastric cancer
NKT3447,targets,solid tumor
NKT3447,targets,metastatic ovarian carcinoma
NKT3447,targets,advanced solid tumor
NKT3447,targets,platinum-refractory ovarian carcinoma
NKT3447,targets,ovarian cancer
NKT3447,targets,ccne1 amplification
NKT3447,targets,hormone receptor negative breast carcinoma
NKT3447,targets,triple negative breast neoplasms
NKT3447,targets,endometrial cancer
NKT3447,targets,advanced endometrial carcinoma
NKT3447,targets,metastatic gastric cancer
NKT3447,targets,metastatic endometrial carcinoma
NKT3447,targets,metastatic gastric carcinoma
NKT3447,targets,human epidermal growth factor 2 negative carcinoma of breast
NKT3447,targets,metastatic endometrial cancer
NKT3447,targets,TNBC
NCT04849364,sponsored_by,"Bryan Schneider, MD"
NCT04849364,has_status,TERMINATED
NCT04849364,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT04849364,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,breast cancer
Talazoparib,targets,triple negative breast cancer
Talazoparib,targets,TNBC
NCT04849364,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT04849364,tests,Inavolisib
Inavolisib,has_type,DRUG
Inavolisib,classified_as,CHEMICAL
Inavolisib,targets,breast cancer
Inavolisib,targets,triple negative breast cancer
Inavolisib,targets,TNBC
NCT05770102,sponsored_by,Cancer Research UK
NCT05770102,has_status,RECRUITING
NCT05770102,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,melanoma
Atezolizumab,targets,neoplasms by histologic type
Atezolizumab,targets,malignant neoplasm
Atezolizumab,targets,endometrial neoplasms
Atezolizumab,targets,cancer
Atezolizumab,targets,colorectal neoplasms
Atezolizumab,targets,neoplasms by site
Atezolizumab,targets,lymphoproliferative disorders
Atezolizumab,targets,malignancy
Atezolizumab,targets,solid tumours
NCT06419621,sponsored_by,Biotheus Inc.
NCT06419621,has_status,RECRUITING
NCT06419621,tests,PM8002
PM8002,has_type,DRUG
PM8002,classified_as,OTHER
PM8002,targets,triple negative breast cancer(tnbc)
PM8002,targets,TNBC
NCT06419621,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,triple negative breast cancer(tnbc)
Nab-Paclitaxel,targets,TNBC
NCT06419621,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast cancer(tnbc)
Placebo,targets,TNBC
NCT04521621,sponsored_by,Merck Sharp & Dohme LLC
NCT04521621,has_status,TERMINATED
NCT04521621,tests,Gebasaxturev
Gebasaxturev,has_type,DRUG
Gebasaxturev,classified_as,OTHER
Gebasaxturev,targets,neoplasm metastasis
NCT04521621,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,neoplasm metastasis
NCT05949021,sponsored_by,"Mridula George, MD"
NCT05949021,has_status,RECRUITING
NCT05949021,tests,Combination of liposomal doxorubicin
Combination of liposomal doxorubicin,has_type,DRUG
Combination of liposomal doxorubicin,classified_as,CHEMICAL
Combination of liposomal doxorubicin,targets,triple negative breast cancer (tnbc)
Combination of liposomal doxorubicin,targets,TNBC
NCT06291064,sponsored_by,University of Chicago
NCT06291064,has_status,NOT_YET_RECRUITING
NCT06291064,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT06291064,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,triple negative breast cancer
Epirubicin,targets,TNBC
NCT06291064,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,triple negative breast cancer
Docetaxel,targets,TNBC
NCT06291064,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT06291064,tests,Breast Surgery
Breast Surgery,has_type,DRUG
Breast Surgery,classified_as,OTHER
Breast Surgery,targets,triple negative breast cancer
Breast Surgery,targets,TNBC
NCT06291064,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT05694364,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT05694364,has_status,ACTIVE_NOT_RECRUITING
NCT05694364,tests,Fludarabine
Fludarabine,has_type,DRUG
Fludarabine,classified_as,OTHER
Fludarabine,targets,triple negative breast cancer malignancies
Fludarabine,targets,mantle cell lymphoma
Fludarabine,targets,chronic lymphocytic leukemia
Fludarabine,targets,diffuse large b cell lymphoma
Fludarabine,targets,acute lymphoblastic leukemia
Fludarabine,targets,TNBC
NCT05694364,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer malignancies
Cyclophosphamide,targets,mantle cell lymphoma
Cyclophosphamide,targets,chronic lymphocytic leukemia
Cyclophosphamide,targets,diffuse large b cell lymphoma
Cyclophosphamide,targets,acute lymphoblastic leukemia
Cyclophosphamide,targets,TNBC
NCT05694364,tests,PRGN-3007
PRGN-3007,has_type,DRUG
PRGN-3007,classified_as,OTHER
PRGN-3007,targets,triple negative breast cancer malignancies
PRGN-3007,targets,mantle cell lymphoma
PRGN-3007,targets,chronic lymphocytic leukemia
PRGN-3007,targets,diffuse large b cell lymphoma
PRGN-3007,targets,acute lymphoblastic leukemia
PRGN-3007,targets,TNBC
NCT06434064,sponsored_by,Roswell Park Cancer Institute
NCT06434064,has_status,RECRUITING
NCT06434064,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,locally advanced unresectable triple-negative breast carcinoma
Biopsy,targets,metastatic triple-negative breast carcinoma
Biopsy,targets,anatomic stage iii breast cancer ajcc v8
Biopsy,targets,anatomic stage iv breast cancer ajcc v8
Biopsy,targets,TNBC
NCT06434064,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,locally advanced unresectable triple-negative breast carcinoma
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iii breast cancer ajcc v8
Biospecimen Collection,targets,anatomic stage iv breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT06434064,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,locally advanced unresectable triple-negative breast carcinoma
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iii breast cancer ajcc v8
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,TNBC
NCT06434064,tests,Echocardiography
Echocardiography,has_type,DRUG
Echocardiography,classified_as,OTHER
Echocardiography,targets,locally advanced unresectable triple-negative breast carcinoma
Echocardiography,targets,metastatic triple-negative breast carcinoma
Echocardiography,targets,anatomic stage iii breast cancer ajcc v8
Echocardiography,targets,anatomic stage iv breast cancer ajcc v8
Echocardiography,targets,TNBC
NCT06434064,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,locally advanced unresectable triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,metastatic triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iii breast cancer ajcc v8
Magnetic Resonance Imaging,targets,anatomic stage iv breast cancer ajcc v8
Magnetic Resonance Imaging,targets,TNBC
NCT06434064,tests,Pegylated Liposomal Doxorubicin Hydrochloride
Pegylated Liposomal Doxorubicin Hydrochloride,has_type,DRUG
Pegylated Liposomal Doxorubicin Hydrochloride,classified_as,CHEMICAL
Pegylated Liposomal Doxorubicin Hydrochloride,targets,locally advanced unresectable triple-negative breast carcinoma
Pegylated Liposomal Doxorubicin Hydrochloride,targets,metastatic triple-negative breast carcinoma
Pegylated Liposomal Doxorubicin Hydrochloride,targets,anatomic stage iii breast cancer ajcc v8
Pegylated Liposomal Doxorubicin Hydrochloride,targets,anatomic stage iv breast cancer ajcc v8
Pegylated Liposomal Doxorubicin Hydrochloride,targets,TNBC
NCT06434064,tests,Tamoxifen
Tamoxifen,has_type,DRUG
Tamoxifen,classified_as,CHEMICAL
Tamoxifen,targets,locally advanced unresectable triple-negative breast carcinoma
Tamoxifen,targets,metastatic triple-negative breast carcinoma
Tamoxifen,targets,anatomic stage iii breast cancer ajcc v8
Tamoxifen,targets,anatomic stage iv breast cancer ajcc v8
Tamoxifen,targets,TNBC
NCT05862064,sponsored_by,Fudan University
NCT05862064,has_status,RECRUITING
NCT05862064,tests,"epirubicin,cyclophosphamide,paclitaxel,Carrelizumab"
"epirubicin,cyclophosphamide,paclitaxel,Carrelizumab",has_type,DRUG
"epirubicin,cyclophosphamide,paclitaxel,Carrelizumab",classified_as,BIOLOGIC
"epirubicin,cyclophosphamide,paclitaxel,Carrelizumab",targets,tnbc - triple-negative breast cancer
"epirubicin,cyclophosphamide,paclitaxel,Carrelizumab",targets,TNBC
NCT05862064,tests,"epirubicin,cyclophosphamide,paclitaxel"
"epirubicin,cyclophosphamide,paclitaxel",has_type,DRUG
"epirubicin,cyclophosphamide,paclitaxel",classified_as,CHEMICAL
"epirubicin,cyclophosphamide,paclitaxel",targets,tnbc - triple-negative breast cancer
"epirubicin,cyclophosphamide,paclitaxel",targets,TNBC
NCT05973864,sponsored_by,UNICANCER
NCT05973864,has_status,RECRUITING
NCT05973864,tests,Pembrolizumab injection
Pembrolizumab injection,has_type,DRUG
Pembrolizumab injection,classified_as,BIOLOGIC
Pembrolizumab injection,targets,triple negative breast neoplasms
Pembrolizumab injection,targets,TNBC
NCT05973864,tests,Capecitabine tablets
Capecitabine tablets,has_type,DRUG
Capecitabine tablets,classified_as,CHEMICAL
Capecitabine tablets,targets,triple negative breast neoplasms
Capecitabine tablets,targets,TNBC
NCT05973864,tests,Local radiotherapy
Local radiotherapy,has_type,DRUG
Local radiotherapy,classified_as,OTHER
Local radiotherapy,targets,triple negative breast neoplasms
Local radiotherapy,targets,TNBC
NCT06976021,sponsored_by,Maria Sklodowska-Curie National Research Institute of Oncology
NCT06976021,has_status,NOT_YET_RECRUITING
NCT06976021,tests,Baseline 89-Zr Pembrolizumab Immuno PET-CT
Baseline 89-Zr Pembrolizumab Immuno PET-CT,has_type,DRUG
Baseline 89-Zr Pembrolizumab Immuno PET-CT,classified_as,BIOLOGIC
Baseline 89-Zr Pembrolizumab Immuno PET-CT,targets,clear cell renal cell carcinoma
Baseline 89-Zr Pembrolizumab Immuno PET-CT,targets,uterine corpus cancer
Baseline 89-Zr Pembrolizumab Immuno PET-CT,targets,triple negative breast cancer
Baseline 89-Zr Pembrolizumab Immuno PET-CT,targets,malignant melanoma
Baseline 89-Zr Pembrolizumab Immuno PET-CT,targets,uterine cervical cancer
Baseline 89-Zr Pembrolizumab Immuno PET-CT,targets,TNBC
NCT06976021,tests,Proteomic assay
Proteomic assay,has_type,DRUG
Proteomic assay,classified_as,OTHER
Proteomic assay,targets,clear cell renal cell carcinoma
Proteomic assay,targets,uterine corpus cancer
Proteomic assay,targets,triple negative breast cancer
Proteomic assay,targets,malignant melanoma
Proteomic assay,targets,uterine cervical cancer
Proteomic assay,targets,TNBC
NCT06976021,tests,Follow-up 89-Zr Pembrolizumab Immuno PET-CT
Follow-up 89-Zr Pembrolizumab Immuno PET-CT,has_type,DRUG
Follow-up 89-Zr Pembrolizumab Immuno PET-CT,classified_as,BIOLOGIC
Follow-up 89-Zr Pembrolizumab Immuno PET-CT,targets,clear cell renal cell carcinoma
Follow-up 89-Zr Pembrolizumab Immuno PET-CT,targets,uterine corpus cancer
Follow-up 89-Zr Pembrolizumab Immuno PET-CT,targets,triple negative breast cancer
Follow-up 89-Zr Pembrolizumab Immuno PET-CT,targets,malignant melanoma
Follow-up 89-Zr Pembrolizumab Immuno PET-CT,targets,uterine cervical cancer
Follow-up 89-Zr Pembrolizumab Immuno PET-CT,targets,TNBC
NCT06238921,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT06238921,has_status,RECRUITING
NCT06238921,tests,Stereotactic Radiation
Stereotactic Radiation,has_type,DRUG
Stereotactic Radiation,classified_as,OTHER
Stereotactic Radiation,targets,breast cancer
Stereotactic Radiation,targets,triple negative breast cancer
Stereotactic Radiation,targets,TNBC
NCT06238921,tests,Zimberelimab
Zimberelimab,has_type,DRUG
Zimberelimab,classified_as,BIOLOGIC
Zimberelimab,targets,breast cancer
Zimberelimab,targets,triple negative breast cancer
Zimberelimab,targets,TNBC
NCT06238921,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
Sacituzumab govitecan,classified_as,BIOLOGIC
Sacituzumab govitecan,targets,breast cancer
Sacituzumab govitecan,targets,triple negative breast cancer
Sacituzumab govitecan,targets,TNBC
NCT06279364,sponsored_by,"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd."
NCT06279364,has_status,RECRUITING
NCT06279364,tests,SKB264
SKB264,has_type,DRUG
SKB264,classified_as,OTHER
SKB264,targets,triple negative breast cancer
SKB264,targets,TNBC
NCT06279364,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT06279364,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT06279364,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT06279364,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,triple negative breast cancer
Eribulin,targets,TNBC
NCT06279364,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT03799679,sponsored_by,Fudan University
NCT03799679,has_status,UNKNOWN
NCT03799679,tests,Chemotherapeutic Agent
Chemotherapeutic Agent,has_type,DRUG
Chemotherapeutic Agent,classified_as,OTHER
Chemotherapeutic Agent,targets,triple negative breast cancer
Chemotherapeutic Agent,targets,TNBC
NCT04134884,sponsored_by,Kathy Miller
NCT04134884,has_status,COMPLETED
NCT04134884,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,hormone receptor positive tumor
Talazoparib,targets,metastatic breast cancer
Talazoparib,targets,triple negative breast cancer
Talazoparib,targets,TNBC
NCT04134884,tests,ASTX727
ASTX727,has_type,DRUG
ASTX727,classified_as,OTHER
ASTX727,targets,hormone receptor positive tumor
ASTX727,targets,metastatic breast cancer
ASTX727,targets,triple negative breast cancer
ASTX727,targets,TNBC
NCT06337084,sponsored_by,Monopar Therapeutics
NCT06337084,has_status,RECRUITING
NCT06337084,tests,MNPR-101-DFO*-89Zr
MNPR-101-DFO*-89Zr,has_type,DRUG
MNPR-101-DFO*-89Zr,classified_as,OTHER
MNPR-101-DFO*-89Zr,targets,gastric cancer
MNPR-101-DFO*-89Zr,targets,"solid tumor, adult"
MNPR-101-DFO*-89Zr,targets,pancreatic cancer
MNPR-101-DFO*-89Zr,targets,urothelial carcinoma
MNPR-101-DFO*-89Zr,targets,lung cancer
MNPR-101-DFO*-89Zr,targets,ovarian cancer
MNPR-101-DFO*-89Zr,targets,bladder cancer
MNPR-101-DFO*-89Zr,targets,triple-negative breast cancer
MNPR-101-DFO*-89Zr,targets,colorectal cancer
MNPR-101-DFO*-89Zr,targets,TNBC
NCT06337084,tests,PET/CT Diagnostic Imaging
PET/CT Diagnostic Imaging,has_type,DRUG
PET/CT Diagnostic Imaging,classified_as,OTHER
PET/CT Diagnostic Imaging,targets,gastric cancer
PET/CT Diagnostic Imaging,targets,"solid tumor, adult"
PET/CT Diagnostic Imaging,targets,pancreatic cancer
PET/CT Diagnostic Imaging,targets,urothelial carcinoma
PET/CT Diagnostic Imaging,targets,lung cancer
PET/CT Diagnostic Imaging,targets,ovarian cancer
PET/CT Diagnostic Imaging,targets,bladder cancer
PET/CT Diagnostic Imaging,targets,triple-negative breast cancer
PET/CT Diagnostic Imaging,targets,colorectal cancer
PET/CT Diagnostic Imaging,targets,TNBC
NCT06112379,sponsored_by,AstraZeneca
NCT06112379,has_status,RECRUITING
NCT06112379,tests,Dato-DXd
Dato-DXd,has_type,DRUG
Dato-DXd,classified_as,OTHER
Dato-DXd,targets,breast cancer
NCT06112379,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,breast cancer
NCT06112379,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT06112379,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,breast cancer
NCT06112379,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,breast cancer
NCT06112379,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
NCT06112379,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT06112379,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
NCT06112379,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
NCT06112379,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,breast cancer
NCT05445908,sponsored_by,"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd."
NCT05445908,has_status,UNKNOWN
NCT05445908,tests,SKB264
SKB264,has_type,DRUG
SKB264,classified_as,OTHER
SKB264,targets,triple-negative breast cancer and hr+/her2- bc
SKB264,targets,TNBC
NCT05445908,tests,KL-A167
KL-A167,has_type,DRUG
KL-A167,classified_as,OTHER
KL-A167,targets,triple-negative breast cancer and hr+/her2- bc
KL-A167,targets,TNBC
NCT04177108,sponsored_by,Hoffmann-La Roche
NCT04177108,has_status,COMPLETED
NCT04177108,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,triple-negative breast cancer
Atezolizumab,targets,TNBC
NCT04177108,tests,Ipatasertib
Ipatasertib,has_type,DRUG
Ipatasertib,classified_as,CHEMICAL
Ipatasertib,targets,triple-negative breast cancer
Ipatasertib,targets,TNBC
NCT04177108,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple-negative breast cancer
Paclitaxel,targets,TNBC
NCT04177108,tests,Placebo for Atezolizumab
Placebo for Atezolizumab,has_type,DRUG
Placebo for Atezolizumab,classified_as,BIOLOGIC
Placebo for Atezolizumab,targets,triple-negative breast cancer
Placebo for Atezolizumab,targets,TNBC
NCT04177108,tests,Placebo for Ipatasertib
Placebo for Ipatasertib,has_type,DRUG
Placebo for Ipatasertib,classified_as,CHEMICAL
Placebo for Ipatasertib,targets,triple-negative breast cancer
Placebo for Ipatasertib,targets,TNBC
NCT05698238,sponsored_by,"Mabpro, a.s."
NCT05698238,has_status,NOT_YET_RECRUITING
NCT05698238,tests,CA9hu-1
CA9hu-1,has_type,DRUG
CA9hu-1,classified_as,OTHER
CA9hu-1,targets,head and neck cancer
CA9hu-1,targets,"mesothelioma, malignant"
CA9hu-1,targets,non-small-cell lung carcinoma
CA9hu-1,targets,clear cell renal cell carcinoma metastatic
CA9hu-1,targets,tnbc - triple-negative breast cancer
CA9hu-1,targets,TNBC
NCT01042379,sponsored_by,QuantumLeap Healthcare Collaborative
NCT01042379,has_status,RECRUITING
NCT01042379,tests,Standard Therapy
Standard Therapy,has_type,DRUG
Standard Therapy,classified_as,OTHER
Standard Therapy,targets,hormone receptor positive tumor
Standard Therapy,targets,breast neoplasms
Standard Therapy,targets,breast cancer
Standard Therapy,targets,her2-negative breast cancer
Standard Therapy,targets,early-stage breast cancer
Standard Therapy,targets,angiosarcoma
Standard Therapy,targets,hormone receptor negative tumor
Standard Therapy,targets,breast tumors
Standard Therapy,targets,her2-positive breast cancer
Standard Therapy,targets,tnbc - triple-negative breast cancer
Standard Therapy,targets,locally advanced breast cancer
Standard Therapy,targets,TNBC
NCT01042379,tests,AMG 386 with or without Trastuzumab
AMG 386 with or without Trastuzumab,has_type,DRUG
AMG 386 with or without Trastuzumab,classified_as,BIOLOGIC
AMG 386 with or without Trastuzumab,targets,hormone receptor positive tumor
AMG 386 with or without Trastuzumab,targets,breast neoplasms
AMG 386 with or without Trastuzumab,targets,breast cancer
AMG 386 with or without Trastuzumab,targets,her2-negative breast cancer
AMG 386 with or without Trastuzumab,targets,early-stage breast cancer
AMG 386 with or without Trastuzumab,targets,angiosarcoma
AMG 386 with or without Trastuzumab,targets,hormone receptor negative tumor
AMG 386 with or without Trastuzumab,targets,breast tumors
AMG 386 with or without Trastuzumab,targets,her2-positive breast cancer
AMG 386 with or without Trastuzumab,targets,tnbc - triple-negative breast cancer
AMG 386 with or without Trastuzumab,targets,locally advanced breast cancer
AMG 386 with or without Trastuzumab,targets,TNBC
NCT01042379,tests,AMG 479 (Ganitumab) plus Metformin
AMG 479 (Ganitumab) plus Metformin,has_type,DRUG
AMG 479 (Ganitumab) plus Metformin,classified_as,BIOLOGIC
AMG 479 (Ganitumab) plus Metformin,targets,hormone receptor positive tumor
AMG 479 (Ganitumab) plus Metformin,targets,breast neoplasms
AMG 479 (Ganitumab) plus Metformin,targets,breast cancer
AMG 479 (Ganitumab) plus Metformin,targets,her2-negative breast cancer
AMG 479 (Ganitumab) plus Metformin,targets,early-stage breast cancer
AMG 479 (Ganitumab) plus Metformin,targets,angiosarcoma
AMG 479 (Ganitumab) plus Metformin,targets,hormone receptor negative tumor
AMG 479 (Ganitumab) plus Metformin,targets,breast tumors
AMG 479 (Ganitumab) plus Metformin,targets,her2-positive breast cancer
AMG 479 (Ganitumab) plus Metformin,targets,tnbc - triple-negative breast cancer
AMG 479 (Ganitumab) plus Metformin,targets,locally advanced breast cancer
AMG 479 (Ganitumab) plus Metformin,targets,TNBC
NCT01042379,tests,MK-2206 with or without Trastuzumab
MK-2206 with or without Trastuzumab,has_type,DRUG
MK-2206 with or without Trastuzumab,classified_as,BIOLOGIC
MK-2206 with or without Trastuzumab,targets,hormone receptor positive tumor
MK-2206 with or without Trastuzumab,targets,breast neoplasms
MK-2206 with or without Trastuzumab,targets,breast cancer
MK-2206 with or without Trastuzumab,targets,her2-negative breast cancer
MK-2206 with or without Trastuzumab,targets,early-stage breast cancer
MK-2206 with or without Trastuzumab,targets,angiosarcoma
MK-2206 with or without Trastuzumab,targets,hormone receptor negative tumor
MK-2206 with or without Trastuzumab,targets,breast tumors
MK-2206 with or without Trastuzumab,targets,her2-positive breast cancer
MK-2206 with or without Trastuzumab,targets,tnbc - triple-negative breast cancer
MK-2206 with or without Trastuzumab,targets,locally advanced breast cancer
MK-2206 with or without Trastuzumab,targets,TNBC
NCT01042379,tests,AMG 386 and Trastuzumab
AMG 386 and Trastuzumab,has_type,DRUG
AMG 386 and Trastuzumab,classified_as,BIOLOGIC
AMG 386 and Trastuzumab,targets,hormone receptor positive tumor
AMG 386 and Trastuzumab,targets,breast neoplasms
AMG 386 and Trastuzumab,targets,breast cancer
AMG 386 and Trastuzumab,targets,her2-negative breast cancer
AMG 386 and Trastuzumab,targets,early-stage breast cancer
AMG 386 and Trastuzumab,targets,angiosarcoma
AMG 386 and Trastuzumab,targets,hormone receptor negative tumor
AMG 386 and Trastuzumab,targets,breast tumors
AMG 386 and Trastuzumab,targets,her2-positive breast cancer
AMG 386 and Trastuzumab,targets,tnbc - triple-negative breast cancer
AMG 386 and Trastuzumab,targets,locally advanced breast cancer
AMG 386 and Trastuzumab,targets,TNBC
NCT01042379,tests,T-DM1 and Pertuzumab
T-DM1 and Pertuzumab,has_type,DRUG
T-DM1 and Pertuzumab,classified_as,BIOLOGIC
T-DM1 and Pertuzumab,targets,hormone receptor positive tumor
T-DM1 and Pertuzumab,targets,breast neoplasms
T-DM1 and Pertuzumab,targets,breast cancer
T-DM1 and Pertuzumab,targets,her2-negative breast cancer
T-DM1 and Pertuzumab,targets,early-stage breast cancer
T-DM1 and Pertuzumab,targets,angiosarcoma
T-DM1 and Pertuzumab,targets,hormone receptor negative tumor
T-DM1 and Pertuzumab,targets,breast tumors
T-DM1 and Pertuzumab,targets,her2-positive breast cancer
T-DM1 and Pertuzumab,targets,tnbc - triple-negative breast cancer
T-DM1 and Pertuzumab,targets,locally advanced breast cancer
T-DM1 and Pertuzumab,targets,TNBC
NCT01042379,tests,Pertuzumab and Trastuzumab
Pertuzumab and Trastuzumab,has_type,DRUG
Pertuzumab and Trastuzumab,classified_as,BIOLOGIC
Pertuzumab and Trastuzumab,targets,hormone receptor positive tumor
Pertuzumab and Trastuzumab,targets,breast neoplasms
Pertuzumab and Trastuzumab,targets,breast cancer
Pertuzumab and Trastuzumab,targets,her2-negative breast cancer
Pertuzumab and Trastuzumab,targets,early-stage breast cancer
Pertuzumab and Trastuzumab,targets,angiosarcoma
Pertuzumab and Trastuzumab,targets,hormone receptor negative tumor
Pertuzumab and Trastuzumab,targets,breast tumors
Pertuzumab and Trastuzumab,targets,her2-positive breast cancer
Pertuzumab and Trastuzumab,targets,tnbc - triple-negative breast cancer
Pertuzumab and Trastuzumab,targets,locally advanced breast cancer
Pertuzumab and Trastuzumab,targets,TNBC
NCT01042379,tests,Ganetespib
Ganetespib,has_type,DRUG
Ganetespib,classified_as,CHEMICAL
Ganetespib,targets,hormone receptor positive tumor
Ganetespib,targets,breast neoplasms
Ganetespib,targets,breast cancer
Ganetespib,targets,her2-negative breast cancer
Ganetespib,targets,early-stage breast cancer
Ganetespib,targets,angiosarcoma
Ganetespib,targets,hormone receptor negative tumor
Ganetespib,targets,breast tumors
Ganetespib,targets,her2-positive breast cancer
Ganetespib,targets,tnbc - triple-negative breast cancer
Ganetespib,targets,locally advanced breast cancer
Ganetespib,targets,TNBC
NCT01042379,tests,ABT-888
ABT-888,has_type,DRUG
ABT-888,classified_as,OTHER
ABT-888,targets,hormone receptor positive tumor
ABT-888,targets,breast neoplasms
ABT-888,targets,breast cancer
ABT-888,targets,her2-negative breast cancer
ABT-888,targets,early-stage breast cancer
ABT-888,targets,angiosarcoma
ABT-888,targets,hormone receptor negative tumor
ABT-888,targets,breast tumors
ABT-888,targets,her2-positive breast cancer
ABT-888,targets,tnbc - triple-negative breast cancer
ABT-888,targets,locally advanced breast cancer
ABT-888,targets,TNBC
NCT01042379,tests,Neratinib
Neratinib,has_type,DRUG
Neratinib,classified_as,CHEMICAL
Neratinib,targets,hormone receptor positive tumor
Neratinib,targets,breast neoplasms
Neratinib,targets,breast cancer
Neratinib,targets,her2-negative breast cancer
Neratinib,targets,early-stage breast cancer
Neratinib,targets,angiosarcoma
Neratinib,targets,hormone receptor negative tumor
Neratinib,targets,breast tumors
Neratinib,targets,her2-positive breast cancer
Neratinib,targets,tnbc - triple-negative breast cancer
Neratinib,targets,locally advanced breast cancer
Neratinib,targets,TNBC
NCT01042379,tests,PLX3397
PLX3397,has_type,DRUG
PLX3397,classified_as,OTHER
PLX3397,targets,hormone receptor positive tumor
PLX3397,targets,breast neoplasms
PLX3397,targets,breast cancer
PLX3397,targets,her2-negative breast cancer
PLX3397,targets,early-stage breast cancer
PLX3397,targets,angiosarcoma
PLX3397,targets,hormone receptor negative tumor
PLX3397,targets,breast tumors
PLX3397,targets,her2-positive breast cancer
PLX3397,targets,tnbc - triple-negative breast cancer
PLX3397,targets,locally advanced breast cancer
PLX3397,targets,TNBC
NCT01042379,tests,Pembrolizumab - 4 cycle
Pembrolizumab - 4 cycle,has_type,DRUG
Pembrolizumab - 4 cycle,classified_as,BIOLOGIC
Pembrolizumab - 4 cycle,targets,hormone receptor positive tumor
Pembrolizumab - 4 cycle,targets,breast neoplasms
Pembrolizumab - 4 cycle,targets,breast cancer
Pembrolizumab - 4 cycle,targets,her2-negative breast cancer
Pembrolizumab - 4 cycle,targets,early-stage breast cancer
Pembrolizumab - 4 cycle,targets,angiosarcoma
Pembrolizumab - 4 cycle,targets,hormone receptor negative tumor
Pembrolizumab - 4 cycle,targets,breast tumors
Pembrolizumab - 4 cycle,targets,her2-positive breast cancer
Pembrolizumab - 4 cycle,targets,tnbc - triple-negative breast cancer
Pembrolizumab - 4 cycle,targets,locally advanced breast cancer
Pembrolizumab - 4 cycle,targets,TNBC
NCT01042379,tests,Talazoparib plus Irinotecan
Talazoparib plus Irinotecan,has_type,DRUG
Talazoparib plus Irinotecan,classified_as,CHEMICAL
Talazoparib plus Irinotecan,targets,hormone receptor positive tumor
Talazoparib plus Irinotecan,targets,breast neoplasms
Talazoparib plus Irinotecan,targets,breast cancer
Talazoparib plus Irinotecan,targets,her2-negative breast cancer
Talazoparib plus Irinotecan,targets,early-stage breast cancer
Talazoparib plus Irinotecan,targets,angiosarcoma
Talazoparib plus Irinotecan,targets,hormone receptor negative tumor
Talazoparib plus Irinotecan,targets,breast tumors
Talazoparib plus Irinotecan,targets,her2-positive breast cancer
Talazoparib plus Irinotecan,targets,tnbc - triple-negative breast cancer
Talazoparib plus Irinotecan,targets,locally advanced breast cancer
Talazoparib plus Irinotecan,targets,TNBC
NCT01042379,tests,Patritumab and Trastuzumab
Patritumab and Trastuzumab,has_type,DRUG
Patritumab and Trastuzumab,classified_as,BIOLOGIC
Patritumab and Trastuzumab,targets,hormone receptor positive tumor
Patritumab and Trastuzumab,targets,breast neoplasms
Patritumab and Trastuzumab,targets,breast cancer
Patritumab and Trastuzumab,targets,her2-negative breast cancer
Patritumab and Trastuzumab,targets,early-stage breast cancer
Patritumab and Trastuzumab,targets,angiosarcoma
Patritumab and Trastuzumab,targets,hormone receptor negative tumor
Patritumab and Trastuzumab,targets,breast tumors
Patritumab and Trastuzumab,targets,her2-positive breast cancer
Patritumab and Trastuzumab,targets,tnbc - triple-negative breast cancer
Patritumab and Trastuzumab,targets,locally advanced breast cancer
Patritumab and Trastuzumab,targets,TNBC
NCT01042379,tests,Pembrolizumab - 8 cycle
Pembrolizumab - 8 cycle,has_type,DRUG
Pembrolizumab - 8 cycle,classified_as,BIOLOGIC
Pembrolizumab - 8 cycle,targets,hormone receptor positive tumor
Pembrolizumab - 8 cycle,targets,breast neoplasms
Pembrolizumab - 8 cycle,targets,breast cancer
Pembrolizumab - 8 cycle,targets,her2-negative breast cancer
Pembrolizumab - 8 cycle,targets,early-stage breast cancer
Pembrolizumab - 8 cycle,targets,angiosarcoma
Pembrolizumab - 8 cycle,targets,hormone receptor negative tumor
Pembrolizumab - 8 cycle,targets,breast tumors
Pembrolizumab - 8 cycle,targets,her2-positive breast cancer
Pembrolizumab - 8 cycle,targets,tnbc - triple-negative breast cancer
Pembrolizumab - 8 cycle,targets,locally advanced breast cancer
Pembrolizumab - 8 cycle,targets,TNBC
NCT01042379,tests,SGN-LIV1A
SGN-LIV1A,has_type,DRUG
SGN-LIV1A,classified_as,OTHER
SGN-LIV1A,targets,hormone receptor positive tumor
SGN-LIV1A,targets,breast neoplasms
SGN-LIV1A,targets,breast cancer
SGN-LIV1A,targets,her2-negative breast cancer
SGN-LIV1A,targets,early-stage breast cancer
SGN-LIV1A,targets,angiosarcoma
SGN-LIV1A,targets,hormone receptor negative tumor
SGN-LIV1A,targets,breast tumors
SGN-LIV1A,targets,her2-positive breast cancer
SGN-LIV1A,targets,tnbc - triple-negative breast cancer
SGN-LIV1A,targets,locally advanced breast cancer
SGN-LIV1A,targets,TNBC
NCT01042379,tests,Durvalumab plus Olaparib
Durvalumab plus Olaparib,has_type,DRUG
Durvalumab plus Olaparib,classified_as,BIOLOGIC
Durvalumab plus Olaparib,targets,hormone receptor positive tumor
Durvalumab plus Olaparib,targets,breast neoplasms
Durvalumab plus Olaparib,targets,breast cancer
Durvalumab plus Olaparib,targets,her2-negative breast cancer
Durvalumab plus Olaparib,targets,early-stage breast cancer
Durvalumab plus Olaparib,targets,angiosarcoma
Durvalumab plus Olaparib,targets,hormone receptor negative tumor
Durvalumab plus Olaparib,targets,breast tumors
Durvalumab plus Olaparib,targets,her2-positive breast cancer
Durvalumab plus Olaparib,targets,tnbc - triple-negative breast cancer
Durvalumab plus Olaparib,targets,locally advanced breast cancer
Durvalumab plus Olaparib,targets,TNBC
NCT01042379,tests,SD-101 + Pembrolizumab
SD-101 + Pembrolizumab,has_type,DRUG
SD-101 + Pembrolizumab,classified_as,BIOLOGIC
SD-101 + Pembrolizumab,targets,hormone receptor positive tumor
SD-101 + Pembrolizumab,targets,breast neoplasms
SD-101 + Pembrolizumab,targets,breast cancer
SD-101 + Pembrolizumab,targets,her2-negative breast cancer
SD-101 + Pembrolizumab,targets,early-stage breast cancer
SD-101 + Pembrolizumab,targets,angiosarcoma
SD-101 + Pembrolizumab,targets,hormone receptor negative tumor
SD-101 + Pembrolizumab,targets,breast tumors
SD-101 + Pembrolizumab,targets,her2-positive breast cancer
SD-101 + Pembrolizumab,targets,tnbc - triple-negative breast cancer
SD-101 + Pembrolizumab,targets,locally advanced breast cancer
SD-101 + Pembrolizumab,targets,TNBC
NCT01042379,tests,Tucatinib plus trastuzumab and pertuzumab
Tucatinib plus trastuzumab and pertuzumab,has_type,DRUG
Tucatinib plus trastuzumab and pertuzumab,classified_as,BIOLOGIC
Tucatinib plus trastuzumab and pertuzumab,targets,hormone receptor positive tumor
Tucatinib plus trastuzumab and pertuzumab,targets,breast neoplasms
Tucatinib plus trastuzumab and pertuzumab,targets,breast cancer
Tucatinib plus trastuzumab and pertuzumab,targets,her2-negative breast cancer
Tucatinib plus trastuzumab and pertuzumab,targets,early-stage breast cancer
Tucatinib plus trastuzumab and pertuzumab,targets,angiosarcoma
Tucatinib plus trastuzumab and pertuzumab,targets,hormone receptor negative tumor
Tucatinib plus trastuzumab and pertuzumab,targets,breast tumors
Tucatinib plus trastuzumab and pertuzumab,targets,her2-positive breast cancer
Tucatinib plus trastuzumab and pertuzumab,targets,tnbc - triple-negative breast cancer
Tucatinib plus trastuzumab and pertuzumab,targets,locally advanced breast cancer
Tucatinib plus trastuzumab and pertuzumab,targets,TNBC
NCT01042379,tests,Cemiplimab
Cemiplimab,has_type,DRUG
Cemiplimab,classified_as,BIOLOGIC
Cemiplimab,targets,hormone receptor positive tumor
Cemiplimab,targets,breast neoplasms
Cemiplimab,targets,breast cancer
Cemiplimab,targets,her2-negative breast cancer
Cemiplimab,targets,early-stage breast cancer
Cemiplimab,targets,angiosarcoma
Cemiplimab,targets,hormone receptor negative tumor
Cemiplimab,targets,breast tumors
Cemiplimab,targets,her2-positive breast cancer
Cemiplimab,targets,tnbc - triple-negative breast cancer
Cemiplimab,targets,locally advanced breast cancer
Cemiplimab,targets,TNBC
NCT01042379,tests,Cemiplimab plus REGN3767
Cemiplimab plus REGN3767,has_type,DRUG
Cemiplimab plus REGN3767,classified_as,BIOLOGIC
Cemiplimab plus REGN3767,targets,hormone receptor positive tumor
Cemiplimab plus REGN3767,targets,breast neoplasms
Cemiplimab plus REGN3767,targets,breast cancer
Cemiplimab plus REGN3767,targets,her2-negative breast cancer
Cemiplimab plus REGN3767,targets,early-stage breast cancer
Cemiplimab plus REGN3767,targets,angiosarcoma
Cemiplimab plus REGN3767,targets,hormone receptor negative tumor
Cemiplimab plus REGN3767,targets,breast tumors
Cemiplimab plus REGN3767,targets,her2-positive breast cancer
Cemiplimab plus REGN3767,targets,tnbc - triple-negative breast cancer
Cemiplimab plus REGN3767,targets,locally advanced breast cancer
Cemiplimab plus REGN3767,targets,TNBC
NCT01042379,tests,Trilaciclib with or without trastuzumab + pertuzumab
Trilaciclib with or without trastuzumab + pertuzumab,has_type,DRUG
Trilaciclib with or without trastuzumab + pertuzumab,classified_as,BIOLOGIC
Trilaciclib with or without trastuzumab + pertuzumab,targets,hormone receptor positive tumor
Trilaciclib with or without trastuzumab + pertuzumab,targets,breast neoplasms
Trilaciclib with or without trastuzumab + pertuzumab,targets,breast cancer
Trilaciclib with or without trastuzumab + pertuzumab,targets,her2-negative breast cancer
Trilaciclib with or without trastuzumab + pertuzumab,targets,early-stage breast cancer
Trilaciclib with or without trastuzumab + pertuzumab,targets,angiosarcoma
Trilaciclib with or without trastuzumab + pertuzumab,targets,hormone receptor negative tumor
Trilaciclib with or without trastuzumab + pertuzumab,targets,breast tumors
Trilaciclib with or without trastuzumab + pertuzumab,targets,her2-positive breast cancer
Trilaciclib with or without trastuzumab + pertuzumab,targets,tnbc - triple-negative breast cancer
Trilaciclib with or without trastuzumab + pertuzumab,targets,locally advanced breast cancer
Trilaciclib with or without trastuzumab + pertuzumab,targets,TNBC
NCT01042379,tests,SYD985 ([vic-]trastuzumab duocarmazine)
SYD985 ([vic-]trastuzumab duocarmazine),has_type,DRUG
SYD985 ([vic-]trastuzumab duocarmazine),classified_as,BIOLOGIC
SYD985 ([vic-]trastuzumab duocarmazine),targets,hormone receptor positive tumor
SYD985 ([vic-]trastuzumab duocarmazine),targets,breast neoplasms
SYD985 ([vic-]trastuzumab duocarmazine),targets,breast cancer
SYD985 ([vic-]trastuzumab duocarmazine),targets,her2-negative breast cancer
SYD985 ([vic-]trastuzumab duocarmazine),targets,early-stage breast cancer
SYD985 ([vic-]trastuzumab duocarmazine),targets,angiosarcoma
SYD985 ([vic-]trastuzumab duocarmazine),targets,hormone receptor negative tumor
SYD985 ([vic-]trastuzumab duocarmazine),targets,breast tumors
SYD985 ([vic-]trastuzumab duocarmazine),targets,her2-positive breast cancer
SYD985 ([vic-]trastuzumab duocarmazine),targets,tnbc - triple-negative breast cancer
SYD985 ([vic-]trastuzumab duocarmazine),targets,locally advanced breast cancer
SYD985 ([vic-]trastuzumab duocarmazine),targets,TNBC
NCT01042379,tests,Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,has_type,DRUG
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,classified_as,BIOLOGIC
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,hormone receptor positive tumor
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,breast neoplasms
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,her2-negative breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,early-stage breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,angiosarcoma
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,hormone receptor negative tumor
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,breast tumors
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,her2-positive breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,tnbc - triple-negative breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,locally advanced breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab,targets,TNBC
NCT01042379,tests,Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,has_type,DRUG
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,classified_as,BIOLOGIC
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,hormone receptor positive tumor
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,breast neoplasms
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,her2-negative breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,early-stage breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,angiosarcoma
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,hormone receptor negative tumor
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,breast tumors
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,her2-positive breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,tnbc - triple-negative breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,locally advanced breast cancer
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab,targets,TNBC
NCT01042379,tests,Amcenestrant
Amcenestrant,has_type,DRUG
Amcenestrant,classified_as,OTHER
Amcenestrant,targets,hormone receptor positive tumor
Amcenestrant,targets,breast neoplasms
Amcenestrant,targets,breast cancer
Amcenestrant,targets,her2-negative breast cancer
Amcenestrant,targets,early-stage breast cancer
Amcenestrant,targets,angiosarcoma
Amcenestrant,targets,hormone receptor negative tumor
Amcenestrant,targets,breast tumors
Amcenestrant,targets,her2-positive breast cancer
Amcenestrant,targets,tnbc - triple-negative breast cancer
Amcenestrant,targets,locally advanced breast cancer
Amcenestrant,targets,TNBC
NCT01042379,tests,Amcenestrant + Abemaciclib
Amcenestrant + Abemaciclib,has_type,DRUG
Amcenestrant + Abemaciclib,classified_as,CHEMICAL
Amcenestrant + Abemaciclib,targets,hormone receptor positive tumor
Amcenestrant + Abemaciclib,targets,breast neoplasms
Amcenestrant + Abemaciclib,targets,breast cancer
Amcenestrant + Abemaciclib,targets,her2-negative breast cancer
Amcenestrant + Abemaciclib,targets,early-stage breast cancer
Amcenestrant + Abemaciclib,targets,angiosarcoma
Amcenestrant + Abemaciclib,targets,hormone receptor negative tumor
Amcenestrant + Abemaciclib,targets,breast tumors
Amcenestrant + Abemaciclib,targets,her2-positive breast cancer
Amcenestrant + Abemaciclib,targets,tnbc - triple-negative breast cancer
Amcenestrant + Abemaciclib,targets,locally advanced breast cancer
Amcenestrant + Abemaciclib,targets,TNBC
NCT01042379,tests,Amcenestrant + Letrozole
Amcenestrant + Letrozole,has_type,DRUG
Amcenestrant + Letrozole,classified_as,CHEMICAL
Amcenestrant + Letrozole,targets,hormone receptor positive tumor
Amcenestrant + Letrozole,targets,breast neoplasms
Amcenestrant + Letrozole,targets,breast cancer
Amcenestrant + Letrozole,targets,her2-negative breast cancer
Amcenestrant + Letrozole,targets,early-stage breast cancer
Amcenestrant + Letrozole,targets,angiosarcoma
Amcenestrant + Letrozole,targets,hormone receptor negative tumor
Amcenestrant + Letrozole,targets,breast tumors
Amcenestrant + Letrozole,targets,her2-positive breast cancer
Amcenestrant + Letrozole,targets,tnbc - triple-negative breast cancer
Amcenestrant + Letrozole,targets,locally advanced breast cancer
Amcenestrant + Letrozole,targets,TNBC
NCT01042379,tests,ARX788
ARX788,has_type,DRUG
ARX788,classified_as,OTHER
ARX788,targets,hormone receptor positive tumor
ARX788,targets,breast neoplasms
ARX788,targets,breast cancer
ARX788,targets,her2-negative breast cancer
ARX788,targets,early-stage breast cancer
ARX788,targets,angiosarcoma
ARX788,targets,hormone receptor negative tumor
ARX788,targets,breast tumors
ARX788,targets,her2-positive breast cancer
ARX788,targets,tnbc - triple-negative breast cancer
ARX788,targets,locally advanced breast cancer
ARX788,targets,TNBC
NCT01042379,tests,ARX788 + Cemiplimab
ARX788 + Cemiplimab,has_type,DRUG
ARX788 + Cemiplimab,classified_as,BIOLOGIC
ARX788 + Cemiplimab,targets,hormone receptor positive tumor
ARX788 + Cemiplimab,targets,breast neoplasms
ARX788 + Cemiplimab,targets,breast cancer
ARX788 + Cemiplimab,targets,her2-negative breast cancer
ARX788 + Cemiplimab,targets,early-stage breast cancer
ARX788 + Cemiplimab,targets,angiosarcoma
ARX788 + Cemiplimab,targets,hormone receptor negative tumor
ARX788 + Cemiplimab,targets,breast tumors
ARX788 + Cemiplimab,targets,her2-positive breast cancer
ARX788 + Cemiplimab,targets,tnbc - triple-negative breast cancer
ARX788 + Cemiplimab,targets,locally advanced breast cancer
ARX788 + Cemiplimab,targets,TNBC
NCT01042379,tests,VV1 + Cemiplimab
VV1 + Cemiplimab,has_type,DRUG
VV1 + Cemiplimab,classified_as,BIOLOGIC
VV1 + Cemiplimab,targets,hormone receptor positive tumor
VV1 + Cemiplimab,targets,breast neoplasms
VV1 + Cemiplimab,targets,breast cancer
VV1 + Cemiplimab,targets,her2-negative breast cancer
VV1 + Cemiplimab,targets,early-stage breast cancer
VV1 + Cemiplimab,targets,angiosarcoma
VV1 + Cemiplimab,targets,hormone receptor negative tumor
VV1 + Cemiplimab,targets,breast tumors
VV1 + Cemiplimab,targets,her2-positive breast cancer
VV1 + Cemiplimab,targets,tnbc - triple-negative breast cancer
VV1 + Cemiplimab,targets,locally advanced breast cancer
VV1 + Cemiplimab,targets,TNBC
NCT01042379,tests,Datopotamab deruxtecan
Datopotamab deruxtecan,has_type,DRUG
Datopotamab deruxtecan,classified_as,BIOLOGIC
Datopotamab deruxtecan,targets,hormone receptor positive tumor
Datopotamab deruxtecan,targets,breast neoplasms
Datopotamab deruxtecan,targets,breast cancer
Datopotamab deruxtecan,targets,her2-negative breast cancer
Datopotamab deruxtecan,targets,early-stage breast cancer
Datopotamab deruxtecan,targets,angiosarcoma
Datopotamab deruxtecan,targets,hormone receptor negative tumor
Datopotamab deruxtecan,targets,breast tumors
Datopotamab deruxtecan,targets,her2-positive breast cancer
Datopotamab deruxtecan,targets,tnbc - triple-negative breast cancer
Datopotamab deruxtecan,targets,locally advanced breast cancer
Datopotamab deruxtecan,targets,TNBC
NCT01042379,tests,Datopotamab deruxtecan + Durvalumab
Datopotamab deruxtecan + Durvalumab,has_type,DRUG
Datopotamab deruxtecan + Durvalumab,classified_as,BIOLOGIC
Datopotamab deruxtecan + Durvalumab,targets,hormone receptor positive tumor
Datopotamab deruxtecan + Durvalumab,targets,breast neoplasms
Datopotamab deruxtecan + Durvalumab,targets,breast cancer
Datopotamab deruxtecan + Durvalumab,targets,her2-negative breast cancer
Datopotamab deruxtecan + Durvalumab,targets,early-stage breast cancer
Datopotamab deruxtecan + Durvalumab,targets,angiosarcoma
Datopotamab deruxtecan + Durvalumab,targets,hormone receptor negative tumor
Datopotamab deruxtecan + Durvalumab,targets,breast tumors
Datopotamab deruxtecan + Durvalumab,targets,her2-positive breast cancer
Datopotamab deruxtecan + Durvalumab,targets,tnbc - triple-negative breast cancer
Datopotamab deruxtecan + Durvalumab,targets,locally advanced breast cancer
Datopotamab deruxtecan + Durvalumab,targets,TNBC
NCT01042379,tests,Zanidatamab
Zanidatamab,has_type,DRUG
Zanidatamab,classified_as,BIOLOGIC
Zanidatamab,targets,hormone receptor positive tumor
Zanidatamab,targets,breast neoplasms
Zanidatamab,targets,breast cancer
Zanidatamab,targets,her2-negative breast cancer
Zanidatamab,targets,early-stage breast cancer
Zanidatamab,targets,angiosarcoma
Zanidatamab,targets,hormone receptor negative tumor
Zanidatamab,targets,breast tumors
Zanidatamab,targets,her2-positive breast cancer
Zanidatamab,targets,tnbc - triple-negative breast cancer
Zanidatamab,targets,locally advanced breast cancer
Zanidatamab,targets,TNBC
NCT01042379,tests,Lasofoxifene
Lasofoxifene,has_type,DRUG
Lasofoxifene,classified_as,OTHER
Lasofoxifene,targets,hormone receptor positive tumor
Lasofoxifene,targets,breast neoplasms
Lasofoxifene,targets,breast cancer
Lasofoxifene,targets,her2-negative breast cancer
Lasofoxifene,targets,early-stage breast cancer
Lasofoxifene,targets,angiosarcoma
Lasofoxifene,targets,hormone receptor negative tumor
Lasofoxifene,targets,breast tumors
Lasofoxifene,targets,her2-positive breast cancer
Lasofoxifene,targets,tnbc - triple-negative breast cancer
Lasofoxifene,targets,locally advanced breast cancer
Lasofoxifene,targets,TNBC
NCT01042379,tests,Z-endoxifen
Z-endoxifen,has_type,DRUG
Z-endoxifen,classified_as,OTHER
Z-endoxifen,targets,hormone receptor positive tumor
Z-endoxifen,targets,breast neoplasms
Z-endoxifen,targets,breast cancer
Z-endoxifen,targets,her2-negative breast cancer
Z-endoxifen,targets,early-stage breast cancer
Z-endoxifen,targets,angiosarcoma
Z-endoxifen,targets,hormone receptor negative tumor
Z-endoxifen,targets,breast tumors
Z-endoxifen,targets,her2-positive breast cancer
Z-endoxifen,targets,tnbc - triple-negative breast cancer
Z-endoxifen,targets,locally advanced breast cancer
Z-endoxifen,targets,TNBC
NCT01042379,tests,ARV-471
ARV-471,has_type,DRUG
ARV-471,classified_as,BIOLOGIC
ARV-471,targets,hormone receptor positive tumor
ARV-471,targets,breast neoplasms
ARV-471,targets,breast cancer
ARV-471,targets,her2-negative breast cancer
ARV-471,targets,early-stage breast cancer
ARV-471,targets,angiosarcoma
ARV-471,targets,hormone receptor negative tumor
ARV-471,targets,breast tumors
ARV-471,targets,her2-positive breast cancer
ARV-471,targets,tnbc - triple-negative breast cancer
ARV-471,targets,locally advanced breast cancer
ARV-471,targets,TNBC
NCT01042379,tests,ARV-471 + Letrozole
ARV-471 + Letrozole,has_type,DRUG
ARV-471 + Letrozole,classified_as,BIOLOGIC
ARV-471 + Letrozole,targets,hormone receptor positive tumor
ARV-471 + Letrozole,targets,breast neoplasms
ARV-471 + Letrozole,targets,breast cancer
ARV-471 + Letrozole,targets,her2-negative breast cancer
ARV-471 + Letrozole,targets,early-stage breast cancer
ARV-471 + Letrozole,targets,angiosarcoma
ARV-471 + Letrozole,targets,hormone receptor negative tumor
ARV-471 + Letrozole,targets,breast tumors
ARV-471 + Letrozole,targets,her2-positive breast cancer
ARV-471 + Letrozole,targets,tnbc - triple-negative breast cancer
ARV-471 + Letrozole,targets,locally advanced breast cancer
ARV-471 + Letrozole,targets,TNBC
NCT01042379,tests,ARV-471 + Abemaciclib
ARV-471 + Abemaciclib,has_type,DRUG
ARV-471 + Abemaciclib,classified_as,BIOLOGIC
ARV-471 + Abemaciclib,targets,hormone receptor positive tumor
ARV-471 + Abemaciclib,targets,breast neoplasms
ARV-471 + Abemaciclib,targets,breast cancer
ARV-471 + Abemaciclib,targets,her2-negative breast cancer
ARV-471 + Abemaciclib,targets,early-stage breast cancer
ARV-471 + Abemaciclib,targets,angiosarcoma
ARV-471 + Abemaciclib,targets,hormone receptor negative tumor
ARV-471 + Abemaciclib,targets,breast tumors
ARV-471 + Abemaciclib,targets,her2-positive breast cancer
ARV-471 + Abemaciclib,targets,tnbc - triple-negative breast cancer
ARV-471 + Abemaciclib,targets,locally advanced breast cancer
ARV-471 + Abemaciclib,targets,TNBC
NCT01042379,tests,Endoxifen + Abemaciclib
Endoxifen + Abemaciclib,has_type,DRUG
Endoxifen + Abemaciclib,classified_as,CHEMICAL
Endoxifen + Abemaciclib,targets,hormone receptor positive tumor
Endoxifen + Abemaciclib,targets,breast neoplasms
Endoxifen + Abemaciclib,targets,breast cancer
Endoxifen + Abemaciclib,targets,her2-negative breast cancer
Endoxifen + Abemaciclib,targets,early-stage breast cancer
Endoxifen + Abemaciclib,targets,angiosarcoma
Endoxifen + Abemaciclib,targets,hormone receptor negative tumor
Endoxifen + Abemaciclib,targets,breast tumors
Endoxifen + Abemaciclib,targets,her2-positive breast cancer
Endoxifen + Abemaciclib,targets,tnbc - triple-negative breast cancer
Endoxifen + Abemaciclib,targets,locally advanced breast cancer
Endoxifen + Abemaciclib,targets,TNBC
NCT01042379,tests,Rilvegostomig + TDXd
Rilvegostomig + TDXd,has_type,DRUG
Rilvegostomig + TDXd,classified_as,OTHER
Rilvegostomig + TDXd,targets,hormone receptor positive tumor
Rilvegostomig + TDXd,targets,breast neoplasms
Rilvegostomig + TDXd,targets,breast cancer
Rilvegostomig + TDXd,targets,her2-negative breast cancer
Rilvegostomig + TDXd,targets,early-stage breast cancer
Rilvegostomig + TDXd,targets,angiosarcoma
Rilvegostomig + TDXd,targets,hormone receptor negative tumor
Rilvegostomig + TDXd,targets,breast tumors
Rilvegostomig + TDXd,targets,her2-positive breast cancer
Rilvegostomig + TDXd,targets,tnbc - triple-negative breast cancer
Rilvegostomig + TDXd,targets,locally advanced breast cancer
Rilvegostomig + TDXd,targets,TNBC
NCT01042379,tests,Dan222 + Niraparib
Dan222 + Niraparib,has_type,DRUG
Dan222 + Niraparib,classified_as,CHEMICAL
Dan222 + Niraparib,targets,hormone receptor positive tumor
Dan222 + Niraparib,targets,breast neoplasms
Dan222 + Niraparib,targets,breast cancer
Dan222 + Niraparib,targets,her2-negative breast cancer
Dan222 + Niraparib,targets,early-stage breast cancer
Dan222 + Niraparib,targets,angiosarcoma
Dan222 + Niraparib,targets,hormone receptor negative tumor
Dan222 + Niraparib,targets,breast tumors
Dan222 + Niraparib,targets,her2-positive breast cancer
Dan222 + Niraparib,targets,tnbc - triple-negative breast cancer
Dan222 + Niraparib,targets,locally advanced breast cancer
Dan222 + Niraparib,targets,TNBC
NCT01042379,tests,Sarilumab + Cemiplimab + Paclitaxel
Sarilumab + Cemiplimab + Paclitaxel,has_type,DRUG
Sarilumab + Cemiplimab + Paclitaxel,classified_as,BIOLOGIC
Sarilumab + Cemiplimab + Paclitaxel,targets,hormone receptor positive tumor
Sarilumab + Cemiplimab + Paclitaxel,targets,breast neoplasms
Sarilumab + Cemiplimab + Paclitaxel,targets,breast cancer
Sarilumab + Cemiplimab + Paclitaxel,targets,her2-negative breast cancer
Sarilumab + Cemiplimab + Paclitaxel,targets,early-stage breast cancer
Sarilumab + Cemiplimab + Paclitaxel,targets,angiosarcoma
Sarilumab + Cemiplimab + Paclitaxel,targets,hormone receptor negative tumor
Sarilumab + Cemiplimab + Paclitaxel,targets,breast tumors
Sarilumab + Cemiplimab + Paclitaxel,targets,her2-positive breast cancer
Sarilumab + Cemiplimab + Paclitaxel,targets,tnbc - triple-negative breast cancer
Sarilumab + Cemiplimab + Paclitaxel,targets,locally advanced breast cancer
Sarilumab + Cemiplimab + Paclitaxel,targets,TNBC
NCT02161679,sponsored_by,Gilead Sciences
NCT02161679,has_status,WITHDRAWN
NCT02161679,tests,IMMU-132 infusion is administered to participants in one arm for the study
IMMU-132 infusion is administered to participants in one arm for the study,has_type,DRUG
IMMU-132 infusion is administered to participants in one arm for the study,classified_as,OTHER
IMMU-132 infusion is administered to participants in one arm for the study,targets,triple-negative breast cancer
IMMU-132 infusion is administered to participants in one arm for the study,targets,TNBC
NCT02161679,tests,IMMU-132 plus Carboplatin infusion
IMMU-132 plus Carboplatin infusion,has_type,DRUG
IMMU-132 plus Carboplatin infusion,classified_as,CHEMICAL
IMMU-132 plus Carboplatin infusion,targets,triple-negative breast cancer
IMMU-132 plus Carboplatin infusion,targets,TNBC
NCT03777579,sponsored_by,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."
NCT03777579,has_status,SUSPENDED
NCT03777579,tests,JS001，an engineered anti-PD-1 antibody
JS001，an engineered anti-PD-1 antibody,has_type,DRUG
JS001，an engineered anti-PD-1 antibody,classified_as,BIOLOGIC
JS001，an engineered anti-PD-1 antibody,targets,triple negative breast cancer
JS001，an engineered anti-PD-1 antibody,targets,TNBC
NCT03777579,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,triple negative breast cancer
Nab-Paclitaxel,targets,TNBC
NCT03777579,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast cancer
Placebo,targets,TNBC
NCT06238479,sponsored_by,Eli Lilly and Company
NCT06238479,has_status,RECRUITING
NCT06238479,tests,LY4101174
LY4101174,has_type,DRUG
LY4101174,classified_as,OTHER
LY4101174,targets,non-small cell lung cancer
LY4101174,targets,recurrent solid tumor
LY4101174,targets,urinary bladder neoplasm
LY4101174,targets,pancreatic cancer
LY4101174,targets,advanced solid tumor
LY4101174,targets,prostate cancer
LY4101174,targets,metastatic solid tumor
LY4101174,targets,ovarian cancer
LY4101174,targets,triple negative breast cancer
LY4101174,targets,bladder cancer
LY4101174,targets,renal pelvis cancer
LY4101174,targets,esophageal cancer
LY4101174,targets,cervical cancer
LY4101174,targets,head and neck squamous cell carcinoma
LY4101174,targets,TNBC
NCT05675579,sponsored_by,M.D. Anderson Cancer Center
NCT05675579,has_status,RECRUITING
NCT05675579,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
Sacituzumab Govitecan,classified_as,BIOLOGIC
Sacituzumab Govitecan,targets,breast cancer
NCT05675579,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT06991790,sponsored_by,Peking University Cancer Hospital & Institute
NCT06991790,has_status,RECRUITING
NCT06991790,tests,Sacituzumab Govitecan (SG)+Toripalimab
Sacituzumab Govitecan (SG)+Toripalimab,has_type,DRUG
Sacituzumab Govitecan (SG)+Toripalimab,classified_as,BIOLOGIC
Sacituzumab Govitecan (SG)+Toripalimab,targets,tnbc
NCT02276443,sponsored_by,M.D. Anderson Cancer Center
NCT02276443,has_status,RECRUITING
NCT02276443,tests,Chemotherapy
Chemotherapy,has_type,DRUG
Chemotherapy,classified_as,OTHER
Chemotherapy,targets,stage iiib breast cancer ajcc v7
Chemotherapy,targets,stage i breast cancer ajcc v7
Chemotherapy,targets,invasive breast carcinoma
Chemotherapy,targets,stage iia breast cancer ajcc v6 and v7
Chemotherapy,targets,stage iib breast cancer ajcc v6 and v7
Chemotherapy,targets,stage iiia breast cancer ajcc v7
Chemotherapy,targets,stage ia breast cancer ajcc v7
Chemotherapy,targets,stage ii breast cancer ajcc v6 and v7
Chemotherapy,targets,stage iiic breast cancer ajcc v7
Chemotherapy,targets,stage iii breast cancer ajcc v7
Chemotherapy,targets,stage ib breast cancer ajcc v7
Chemotherapy,targets,triple-negative breast carcinoma
Chemotherapy,targets,TNBC
NCT02276443,tests,Immunotherapy
Immunotherapy,has_type,DRUG
Immunotherapy,classified_as,BIOLOGIC
Immunotherapy,targets,stage iiib breast cancer ajcc v7
Immunotherapy,targets,stage i breast cancer ajcc v7
Immunotherapy,targets,invasive breast carcinoma
Immunotherapy,targets,stage iia breast cancer ajcc v6 and v7
Immunotherapy,targets,stage iib breast cancer ajcc v6 and v7
Immunotherapy,targets,stage iiia breast cancer ajcc v7
Immunotherapy,targets,stage ia breast cancer ajcc v7
Immunotherapy,targets,stage ii breast cancer ajcc v6 and v7
Immunotherapy,targets,stage iiic breast cancer ajcc v7
Immunotherapy,targets,stage iii breast cancer ajcc v7
Immunotherapy,targets,stage ib breast cancer ajcc v7
Immunotherapy,targets,triple-negative breast carcinoma
Immunotherapy,targets,TNBC
NCT02276443,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,stage iiib breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage i breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,invasive breast carcinoma
Laboratory Biomarker Analysis,targets,stage iia breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,stage iib breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,stage iiia breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage ia breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage ii breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,stage iiic breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage iii breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage ib breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,TNBC
NCT02276443,tests,Lymph Node Biopsy
Lymph Node Biopsy,has_type,DRUG
Lymph Node Biopsy,classified_as,OTHER
Lymph Node Biopsy,targets,stage iiib breast cancer ajcc v7
Lymph Node Biopsy,targets,stage i breast cancer ajcc v7
Lymph Node Biopsy,targets,invasive breast carcinoma
Lymph Node Biopsy,targets,stage iia breast cancer ajcc v6 and v7
Lymph Node Biopsy,targets,stage iib breast cancer ajcc v6 and v7
Lymph Node Biopsy,targets,stage iiia breast cancer ajcc v7
Lymph Node Biopsy,targets,stage ia breast cancer ajcc v7
Lymph Node Biopsy,targets,stage ii breast cancer ajcc v6 and v7
Lymph Node Biopsy,targets,stage iiic breast cancer ajcc v7
Lymph Node Biopsy,targets,stage iii breast cancer ajcc v7
Lymph Node Biopsy,targets,stage ib breast cancer ajcc v7
Lymph Node Biopsy,targets,triple-negative breast carcinoma
Lymph Node Biopsy,targets,TNBC
NCT02276443,tests,Ultrasonography
Ultrasonography,has_type,DRUG
Ultrasonography,classified_as,OTHER
Ultrasonography,targets,stage iiib breast cancer ajcc v7
Ultrasonography,targets,stage i breast cancer ajcc v7
Ultrasonography,targets,invasive breast carcinoma
Ultrasonography,targets,stage iia breast cancer ajcc v6 and v7
Ultrasonography,targets,stage iib breast cancer ajcc v6 and v7
Ultrasonography,targets,stage iiia breast cancer ajcc v7
Ultrasonography,targets,stage ia breast cancer ajcc v7
Ultrasonography,targets,stage ii breast cancer ajcc v6 and v7
Ultrasonography,targets,stage iiic breast cancer ajcc v7
Ultrasonography,targets,stage iii breast cancer ajcc v7
Ultrasonography,targets,stage ib breast cancer ajcc v7
Ultrasonography,targets,triple-negative breast carcinoma
Ultrasonography,targets,TNBC
NCT05227664,sponsored_by,Akeso
NCT05227664,has_status,RECRUITING
NCT05227664,tests,AK117
AK117,has_type,DRUG
AK117,classified_as,OTHER
AK117,targets,locally advanced triple-negative breast cancer
AK117,targets,metastatic triple-negative breast cancer
AK117,targets,TNBC
NCT05227664,tests,AK112
AK112,has_type,DRUG
AK112,classified_as,OTHER
AK112,targets,locally advanced triple-negative breast cancer
AK112,targets,metastatic triple-negative breast cancer
AK112,targets,TNBC
NCT05227664,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
Nab paclitaxel,classified_as,CHEMICAL
Nab paclitaxel,targets,locally advanced triple-negative breast cancer
Nab paclitaxel,targets,metastatic triple-negative breast cancer
Nab paclitaxel,targets,TNBC
NCT05227664,tests,paclitaxel
paclitaxel,has_type,DRUG
paclitaxel,classified_as,CHEMICAL
paclitaxel,targets,locally advanced triple-negative breast cancer
paclitaxel,targets,metastatic triple-negative breast cancer
paclitaxel,targets,TNBC
NCT06103864,sponsored_by,AstraZeneca
NCT06103864,has_status,RECRUITING
NCT06103864,tests,Dato-DXd
Dato-DXd,has_type,DRUG
Dato-DXd,classified_as,OTHER
Dato-DXd,targets,breast cancer
NCT06103864,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,breast cancer
NCT06103864,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT06103864,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,breast cancer
NCT06103864,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,breast cancer
NCT06103864,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
NCT06103864,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT05252390,sponsored_by,Nuvation Bio Inc.
NCT05252390,has_status,TERMINATED
NCT05252390,tests,NUV-868
NUV-868,has_type,DRUG
NUV-868,classified_as,OTHER
NUV-868,targets,cancer of breast
NUV-868,targets,breast carcinoma
NUV-868,targets,breast tumor
NUV-868,targets,cancer of the breast
NUV-868,targets,cancer of prostate
NUV-868,targets,cancer of the ovary
NUV-868,targets,castrate resistant prostate cancer
NUV-868,targets,breast cancer
NUV-868,targets,triple negative breast cancer
NUV-868,targets,cancer of the prostate
NUV-868,targets,cancer of ovary
NUV-868,targets,triple-negative breast cancer
NUV-868,targets,castration resistant prostatic cancer
NUV-868,targets,prostatic cancer
NUV-868,targets,advanced solid tumor
NUV-868,targets,prostate cancer
NUV-868,targets,ovary cancer
NUV-868,targets,ovarian cancer
NUV-868,targets,prostate neoplasm
NUV-868,targets,triple negative breast neoplasms
NUV-868,targets,castration resistant prostatic neoplasms
NUV-868,targets,pancreatic cancer
NUV-868,targets,cancer of the pancreas
NUV-868,targets,pancreas neoplasm
NUV-868,targets,ovary neoplasm
NUV-868,targets,cancer of pancreas
NUV-868,targets,pancreas cancer
NUV-868,targets,TNBC
NCT05252390,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,cancer of breast
Olaparib,targets,breast carcinoma
Olaparib,targets,breast tumor
Olaparib,targets,cancer of the breast
Olaparib,targets,cancer of prostate
Olaparib,targets,cancer of the ovary
Olaparib,targets,castrate resistant prostate cancer
Olaparib,targets,breast cancer
Olaparib,targets,triple negative breast cancer
Olaparib,targets,cancer of the prostate
Olaparib,targets,cancer of ovary
Olaparib,targets,triple-negative breast cancer
Olaparib,targets,castration resistant prostatic cancer
Olaparib,targets,prostatic cancer
Olaparib,targets,advanced solid tumor
Olaparib,targets,prostate cancer
Olaparib,targets,ovary cancer
Olaparib,targets,ovarian cancer
Olaparib,targets,prostate neoplasm
Olaparib,targets,triple negative breast neoplasms
Olaparib,targets,castration resistant prostatic neoplasms
Olaparib,targets,pancreatic cancer
Olaparib,targets,cancer of the pancreas
Olaparib,targets,pancreas neoplasm
Olaparib,targets,ovary neoplasm
Olaparib,targets,cancer of pancreas
Olaparib,targets,pancreas cancer
Olaparib,targets,TNBC
NCT05252390,tests,Enzalutamide
Enzalutamide,has_type,DRUG
Enzalutamide,classified_as,OTHER
Enzalutamide,targets,cancer of breast
Enzalutamide,targets,breast carcinoma
Enzalutamide,targets,breast tumor
Enzalutamide,targets,cancer of the breast
Enzalutamide,targets,cancer of prostate
Enzalutamide,targets,cancer of the ovary
Enzalutamide,targets,castrate resistant prostate cancer
Enzalutamide,targets,breast cancer
Enzalutamide,targets,triple negative breast cancer
Enzalutamide,targets,cancer of the prostate
Enzalutamide,targets,cancer of ovary
Enzalutamide,targets,triple-negative breast cancer
Enzalutamide,targets,castration resistant prostatic cancer
Enzalutamide,targets,prostatic cancer
Enzalutamide,targets,advanced solid tumor
Enzalutamide,targets,prostate cancer
Enzalutamide,targets,ovary cancer
Enzalutamide,targets,ovarian cancer
Enzalutamide,targets,prostate neoplasm
Enzalutamide,targets,triple negative breast neoplasms
Enzalutamide,targets,castration resistant prostatic neoplasms
Enzalutamide,targets,pancreatic cancer
Enzalutamide,targets,cancer of the pancreas
Enzalutamide,targets,pancreas neoplasm
Enzalutamide,targets,ovary neoplasm
Enzalutamide,targets,cancer of pancreas
Enzalutamide,targets,pancreas cancer
Enzalutamide,targets,TNBC
NCT06257264,sponsored_by,BeiGene
NCT06257264,has_status,RECRUITING
NCT06257264,tests,BG-68501
BG-68501,has_type,DRUG
BG-68501,classified_as,OTHER
BG-68501,targets,gastric cancer
BG-68501,targets,hormone receptor positive her-2 negative breast cancer
BG-68501,targets,hormone-receptor-positive breast cancer
BG-68501,targets,breast cancer
BG-68501,targets,advanced solid tumor
BG-68501,targets,prostate cancer
BG-68501,targets,ovarian cancer
BG-68501,targets,gastroesophageal cancer
BG-68501,targets,bladder cancer
BG-68501,targets,tnbc - triple-negative breast cancer
BG-68501,targets,small cell lung cancer
BG-68501,targets,endometrial cancer
BG-68501,targets,TNBC
NCT06257264,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,gastric cancer
Fulvestrant,targets,hormone receptor positive her-2 negative breast cancer
Fulvestrant,targets,hormone-receptor-positive breast cancer
Fulvestrant,targets,breast cancer
Fulvestrant,targets,advanced solid tumor
Fulvestrant,targets,prostate cancer
Fulvestrant,targets,ovarian cancer
Fulvestrant,targets,gastroesophageal cancer
Fulvestrant,targets,bladder cancer
Fulvestrant,targets,tnbc - triple-negative breast cancer
Fulvestrant,targets,small cell lung cancer
Fulvestrant,targets,endometrial cancer
Fulvestrant,targets,TNBC
NCT06257264,tests,BGB-43395
BGB-43395,has_type,DRUG
BGB-43395,classified_as,OTHER
BGB-43395,targets,gastric cancer
BGB-43395,targets,hormone receptor positive her-2 negative breast cancer
BGB-43395,targets,hormone-receptor-positive breast cancer
BGB-43395,targets,breast cancer
BGB-43395,targets,advanced solid tumor
BGB-43395,targets,prostate cancer
BGB-43395,targets,ovarian cancer
BGB-43395,targets,gastroesophageal cancer
BGB-43395,targets,bladder cancer
BGB-43395,targets,tnbc - triple-negative breast cancer
BGB-43395,targets,small cell lung cancer
BGB-43395,targets,endometrial cancer
BGB-43395,targets,TNBC
NCT04335669,sponsored_by,Lund University Hospital
NCT04335669,has_status,RECRUITING
NCT04335669,tests,"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab"
"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab",has_type,DRUG
"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab",classified_as,BIOLOGIC
"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab",targets,breast cancer
"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab",targets,triple negative breast neoplasms
"epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab",targets,TNBC
NCT04335669,tests,"epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab"
"epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab",has_type,DRUG
"epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab",classified_as,BIOLOGIC
"epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab",targets,breast cancer
"epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab",targets,triple negative breast neoplasms
"epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab",targets,TNBC
NCT01176669,sponsored_by,Fudan University
NCT01176669,has_status,COMPLETED
NCT01176669,tests,Apatinib
Apatinib,has_type,DRUG
Apatinib,classified_as,CHEMICAL
Apatinib,targets,metastatic breast cancer
NCT06246968,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT06246968,has_status,RECRUITING
NCT06246968,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer stage iv
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,locally advanced triple-negative breast carcinoma
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,locally advanced breast cancer
Pembrolizumab,targets,metastatic breast cancer
Pembrolizumab,targets,TNBC
NCT06246968,tests,Cryoablation
Cryoablation,has_type,DRUG
Cryoablation,classified_as,OTHER
Cryoablation,targets,breast cancer stage iv
Cryoablation,targets,breast cancer
Cryoablation,targets,locally advanced triple-negative breast carcinoma
Cryoablation,targets,triple negative breast cancer
Cryoablation,targets,metastatic triple-negative breast carcinoma
Cryoablation,targets,triple negative breast neoplasms
Cryoablation,targets,locally advanced breast cancer
Cryoablation,targets,metastatic breast cancer
Cryoablation,targets,TNBC
NCT06700369,sponsored_by,Shu Wang
NCT06700369,has_status,RECRUITING
NCT02957968,sponsored_by,Virginia Commonwealth University
NCT02957968,has_status,ACTIVE_NOT_RECRUITING
NCT02957968,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,invasive breast carcinoma
Doxorubicin,targets,estrogen receptor- negative breast cancer
Doxorubicin,targets,progesterone receptor positive tumor
Doxorubicin,targets,stage iiia breast cancer
Doxorubicin,targets,breast adenocarcinoma
Doxorubicin,targets,stage ii breast cancer
Doxorubicin,targets,stage iiib breast cancer
Doxorubicin,targets,progesterone receptor negative
Doxorubicin,targets,her2/neu negative
Doxorubicin,targets,stage iia breast cancer
Doxorubicin,targets,stage iib breast cancer
Doxorubicin,targets,triple-negative breast carcinoma
Doxorubicin,targets,estrogen receptor-positive breast cancer
Doxorubicin,targets,TNBC
NCT02957968,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,invasive breast carcinoma
Cyclophosphamide,targets,estrogen receptor- negative breast cancer
Cyclophosphamide,targets,progesterone receptor positive tumor
Cyclophosphamide,targets,stage iiia breast cancer
Cyclophosphamide,targets,breast adenocarcinoma
Cyclophosphamide,targets,stage ii breast cancer
Cyclophosphamide,targets,stage iiib breast cancer
Cyclophosphamide,targets,progesterone receptor negative
Cyclophosphamide,targets,her2/neu negative
Cyclophosphamide,targets,stage iia breast cancer
Cyclophosphamide,targets,stage iib breast cancer
Cyclophosphamide,targets,triple-negative breast carcinoma
Cyclophosphamide,targets,estrogen receptor-positive breast cancer
Cyclophosphamide,targets,TNBC
NCT02957968,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,invasive breast carcinoma
Paclitaxel,targets,estrogen receptor- negative breast cancer
Paclitaxel,targets,progesterone receptor positive tumor
Paclitaxel,targets,stage iiia breast cancer
Paclitaxel,targets,breast adenocarcinoma
Paclitaxel,targets,stage ii breast cancer
Paclitaxel,targets,stage iiib breast cancer
Paclitaxel,targets,progesterone receptor negative
Paclitaxel,targets,her2/neu negative
Paclitaxel,targets,stage iia breast cancer
Paclitaxel,targets,stage iib breast cancer
Paclitaxel,targets,triple-negative breast carcinoma
Paclitaxel,targets,estrogen receptor-positive breast cancer
Paclitaxel,targets,TNBC
NCT02957968,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,invasive breast carcinoma
Carboplatin,targets,estrogen receptor- negative breast cancer
Carboplatin,targets,progesterone receptor positive tumor
Carboplatin,targets,stage iiia breast cancer
Carboplatin,targets,breast adenocarcinoma
Carboplatin,targets,stage ii breast cancer
Carboplatin,targets,stage iiib breast cancer
Carboplatin,targets,progesterone receptor negative
Carboplatin,targets,her2/neu negative
Carboplatin,targets,stage iia breast cancer
Carboplatin,targets,stage iib breast cancer
Carboplatin,targets,triple-negative breast carcinoma
Carboplatin,targets,estrogen receptor-positive breast cancer
Carboplatin,targets,TNBC
NCT02957968,tests,Decitabine
Decitabine,has_type,DRUG
Decitabine,classified_as,OTHER
Decitabine,targets,invasive breast carcinoma
Decitabine,targets,estrogen receptor- negative breast cancer
Decitabine,targets,progesterone receptor positive tumor
Decitabine,targets,stage iiia breast cancer
Decitabine,targets,breast adenocarcinoma
Decitabine,targets,stage ii breast cancer
Decitabine,targets,stage iiib breast cancer
Decitabine,targets,progesterone receptor negative
Decitabine,targets,her2/neu negative
Decitabine,targets,stage iia breast cancer
Decitabine,targets,stage iib breast cancer
Decitabine,targets,triple-negative breast carcinoma
Decitabine,targets,estrogen receptor-positive breast cancer
Decitabine,targets,TNBC
NCT02957968,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,invasive breast carcinoma
Pembrolizumab,targets,estrogen receptor- negative breast cancer
Pembrolizumab,targets,progesterone receptor positive tumor
Pembrolizumab,targets,stage iiia breast cancer
Pembrolizumab,targets,breast adenocarcinoma
Pembrolizumab,targets,stage ii breast cancer
Pembrolizumab,targets,stage iiib breast cancer
Pembrolizumab,targets,progesterone receptor negative
Pembrolizumab,targets,her2/neu negative
Pembrolizumab,targets,stage iia breast cancer
Pembrolizumab,targets,stage iib breast cancer
Pembrolizumab,targets,triple-negative breast carcinoma
Pembrolizumab,targets,estrogen receptor-positive breast cancer
Pembrolizumab,targets,TNBC
NCT06099769,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT06099769,has_status,RECRUITING
NCT06099769,tests,Enzalutamide
Enzalutamide,has_type,DRUG
Enzalutamide,classified_as,OTHER
Enzalutamide,targets,metastatic breast cancer
NCT06099769,tests,Mifepristone
Mifepristone,has_type,DRUG
Mifepristone,classified_as,OTHER
Mifepristone,targets,metastatic breast cancer
NCT06099769,tests,TPC
TPC,has_type,DRUG
TPC,classified_as,OTHER
TPC,targets,metastatic breast cancer
NCT05929768,sponsored_by,SWOG Cancer Research Network
NCT05929768,has_status,RECRUITING
NCT05929768,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,anatomic stage iiia breast cancer ajcc v8
Biospecimen Collection,targets,anatomic stage i breast cancer ajcc v8
Biospecimen Collection,targets,early stage triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iiib breast cancer ajcc v8
Biospecimen Collection,targets,anatomic stage ii breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT05929768,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,anatomic stage iiia breast cancer ajcc v8
Carboplatin,targets,anatomic stage i breast cancer ajcc v8
Carboplatin,targets,early stage triple-negative breast carcinoma
Carboplatin,targets,anatomic stage iiib breast cancer ajcc v8
Carboplatin,targets,anatomic stage ii breast cancer ajcc v8
Carboplatin,targets,TNBC
NCT05929768,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,anatomic stage iiia breast cancer ajcc v8
Cyclophosphamide,targets,anatomic stage i breast cancer ajcc v8
Cyclophosphamide,targets,early stage triple-negative breast carcinoma
Cyclophosphamide,targets,anatomic stage iiib breast cancer ajcc v8
Cyclophosphamide,targets,anatomic stage ii breast cancer ajcc v8
Cyclophosphamide,targets,TNBC
NCT05929768,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,anatomic stage iiia breast cancer ajcc v8
Docetaxel,targets,anatomic stage i breast cancer ajcc v8
Docetaxel,targets,early stage triple-negative breast carcinoma
Docetaxel,targets,anatomic stage iiib breast cancer ajcc v8
Docetaxel,targets,anatomic stage ii breast cancer ajcc v8
Docetaxel,targets,TNBC
NCT05929768,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,anatomic stage iiia breast cancer ajcc v8
Doxorubicin,targets,anatomic stage i breast cancer ajcc v8
Doxorubicin,targets,early stage triple-negative breast carcinoma
Doxorubicin,targets,anatomic stage iiib breast cancer ajcc v8
Doxorubicin,targets,anatomic stage ii breast cancer ajcc v8
Doxorubicin,targets,TNBC
NCT05929768,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,anatomic stage iiia breast cancer ajcc v8
Paclitaxel,targets,anatomic stage i breast cancer ajcc v8
Paclitaxel,targets,early stage triple-negative breast carcinoma
Paclitaxel,targets,anatomic stage iiib breast cancer ajcc v8
Paclitaxel,targets,anatomic stage ii breast cancer ajcc v8
Paclitaxel,targets,TNBC
NCT05929768,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,anatomic stage iiia breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage i breast cancer ajcc v8
Pembrolizumab,targets,early stage triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iiib breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage ii breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT05929768,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,DRUG
Quality-of-Life Assessment,classified_as,OTHER
Quality-of-Life Assessment,targets,anatomic stage iiia breast cancer ajcc v8
Quality-of-Life Assessment,targets,anatomic stage i breast cancer ajcc v8
Quality-of-Life Assessment,targets,early stage triple-negative breast carcinoma
Quality-of-Life Assessment,targets,anatomic stage iiib breast cancer ajcc v8
Quality-of-Life Assessment,targets,anatomic stage ii breast cancer ajcc v8
Quality-of-Life Assessment,targets,TNBC
NCT05929768,tests,Questionnaire Administration
Questionnaire Administration,has_type,DRUG
Questionnaire Administration,classified_as,OTHER
Questionnaire Administration,targets,anatomic stage iiia breast cancer ajcc v8
Questionnaire Administration,targets,anatomic stage i breast cancer ajcc v8
Questionnaire Administration,targets,early stage triple-negative breast carcinoma
Questionnaire Administration,targets,anatomic stage iiib breast cancer ajcc v8
Questionnaire Administration,targets,anatomic stage ii breast cancer ajcc v8
Questionnaire Administration,targets,TNBC
NCT05929768,tests,Surgical Procedure
Surgical Procedure,has_type,DRUG
Surgical Procedure,classified_as,OTHER
Surgical Procedure,targets,anatomic stage iiia breast cancer ajcc v8
Surgical Procedure,targets,anatomic stage i breast cancer ajcc v8
Surgical Procedure,targets,early stage triple-negative breast carcinoma
Surgical Procedure,targets,anatomic stage iiib breast cancer ajcc v8
Surgical Procedure,targets,anatomic stage ii breast cancer ajcc v8
Surgical Procedure,targets,TNBC
NCT06027268,sponsored_by,Wake Forest University Health Sciences
NCT06027268,has_status,RECRUITING
NCT06027268,tests,Trilaciclib
Trilaciclib,has_type,DRUG
Trilaciclib,classified_as,CHEMICAL
Trilaciclib,targets,metastatic triple-negative breast cancer
Trilaciclib,targets,TNBC
NCT06027268,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic triple-negative breast cancer
Pembrolizumab,targets,TNBC
NCT06027268,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,metastatic triple-negative breast cancer
Gemcitabine,targets,TNBC
NCT06027268,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,metastatic triple-negative breast cancer
Carboplatin,targets,TNBC
NCT03332368,sponsored_by,Sheng Liu
NCT03332368,has_status,UNKNOWN
NCT03332368,tests,Traditional Chinese medicine
Traditional Chinese medicine,has_type,DRUG
Traditional Chinese medicine,classified_as,OTHER
Traditional Chinese medicine,targets,progression-free-survival
Traditional Chinese medicine,targets,recurrence
Traditional Chinese medicine,targets,overall survival
NCT02499367,sponsored_by,The Netherlands Cancer Institute
NCT02499367,has_status,ACTIVE_NOT_RECRUITING
NCT02499367,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,breast cancer
NCT02499367,tests,Radiation therapy
Radiation therapy,has_type,DRUG
Radiation therapy,classified_as,OTHER
Radiation therapy,targets,breast cancer
NCT02499367,tests,Low dose doxorubicin
Low dose doxorubicin,has_type,DRUG
Low dose doxorubicin,classified_as,CHEMICAL
Low dose doxorubicin,targets,breast cancer
NCT02499367,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
NCT02499367,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,breast cancer
NCT01745367,sponsored_by,"AVEO Pharmaceuticals, Inc."
NCT01745367,has_status,TERMINATED
NCT01745367,tests,Tivozanib Hydrochloride
Tivozanib Hydrochloride,has_type,DRUG
Tivozanib Hydrochloride,classified_as,CHEMICAL
Tivozanib Hydrochloride,targets,triple negative breast cancer
Tivozanib Hydrochloride,targets,TNBC
NCT01745367,tests,paclitaxel
paclitaxel,has_type,DRUG
paclitaxel,classified_as,CHEMICAL
paclitaxel,targets,triple negative breast cancer
paclitaxel,targets,TNBC
NCT01745367,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast cancer
Placebo,targets,TNBC
NCT03207867,sponsored_by,Novartis Pharmaceuticals
NCT03207867,has_status,TERMINATED
NCT03207867,tests,NIR178
NIR178,has_type,DRUG
NIR178,classified_as,OTHER
NIR178,targets,head and neck cancer
NIR178,targets,melanoma
NIR178,targets,"dlbcl, diffused large b cell lymphoma"
NIR178,targets,urothelial cancer
NIR178,targets,pancreatic cancer
NIR178,targets,"rcc, renal cell cancer"
NIR178,targets,"mss, microsatellite stable colon cancer"
NIR178,targets,"nsclc, non small cell lung cancer"
NIR178,targets,"tnbc, triple negative breast cancer"
NIR178,targets,"mcrpc, metastatic castration resistant prostate cancer"
NIR178,targets,TNBC
NCT03207867,tests,PDR001
PDR001,has_type,DRUG
PDR001,classified_as,OTHER
PDR001,targets,head and neck cancer
PDR001,targets,melanoma
PDR001,targets,"dlbcl, diffused large b cell lymphoma"
PDR001,targets,urothelial cancer
PDR001,targets,pancreatic cancer
PDR001,targets,"rcc, renal cell cancer"
PDR001,targets,"mss, microsatellite stable colon cancer"
PDR001,targets,"nsclc, non small cell lung cancer"
PDR001,targets,"tnbc, triple negative breast cancer"
PDR001,targets,"mcrpc, metastatic castration resistant prostate cancer"
PDR001,targets,TNBC
NCT04297267,sponsored_by,Fudan University
NCT04297267,has_status,UNKNOWN
NCT04297267,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast cancer
Gemcitabine,targets,TNBC
NCT04297267,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,triple negative breast cancer
Cisplatin,targets,TNBC
NCT06974604,sponsored_by,Brown University
NCT06974604,has_status,NOT_YET_RECRUITING
NCT06974604,tests,Dexamethasone oral
Dexamethasone oral,has_type,DRUG
Dexamethasone oral,classified_as,OTHER
Dexamethasone oral,targets,breast neoplasms
Dexamethasone oral,targets,lung neoplasms
NCT03829501,sponsored_by,Kymab Limited
NCT03829501,has_status,TERMINATED
NCT03829501,tests,Alomfilimab
Alomfilimab,has_type,DRUG
Alomfilimab,classified_as,BIOLOGIC
Alomfilimab,targets,gastric cancer
Alomfilimab,targets,non-small cell lung cancer
Alomfilimab,targets,melanoma
Alomfilimab,targets,renal cell carcinoma
Alomfilimab,targets,metastatic cancer
Alomfilimab,targets,pancreatic cancer
Alomfilimab,targets,hepatocellular carcinoma
Alomfilimab,targets,squamous cell carcinoma of head and neck
Alomfilimab,targets,triple negative breast cancer
Alomfilimab,targets,esophageal cancer
Alomfilimab,targets,cervical cancer
Alomfilimab,targets,advanced cancer
Alomfilimab,targets,TNBC
NCT03829501,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,gastric cancer
Atezolizumab,targets,non-small cell lung cancer
Atezolizumab,targets,melanoma
Atezolizumab,targets,renal cell carcinoma
Atezolizumab,targets,metastatic cancer
Atezolizumab,targets,pancreatic cancer
Atezolizumab,targets,hepatocellular carcinoma
Atezolizumab,targets,squamous cell carcinoma of head and neck
Atezolizumab,targets,triple negative breast cancer
Atezolizumab,targets,esophageal cancer
Atezolizumab,targets,cervical cancer
Atezolizumab,targets,advanced cancer
Atezolizumab,targets,TNBC
NCT05581004,sponsored_by,"Genentech, Inc."
NCT05581004,has_status,RECRUITING
NCT05581004,tests,RO7502175
RO7502175,has_type,DRUG
RO7502175,classified_as,OTHER
RO7502175,targets,clear cell rcc
RO7502175,targets,melanoma
RO7502175,targets,gastric cancer
RO7502175,targets,nsclc
RO7502175,targets,urothelial carcinoma
RO7502175,targets,locally advanced or metastatic solid tumors
RO7502175,targets,hcc
RO7502175,targets,esophageal cancer
RO7502175,targets,cervical cancer
RO7502175,targets,hnscc
RO7502175,targets,tnbc
RO7502175,targets,colorectal cancer
NCT05581004,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,clear cell rcc
Atezolizumab,targets,melanoma
Atezolizumab,targets,gastric cancer
Atezolizumab,targets,nsclc
Atezolizumab,targets,urothelial carcinoma
Atezolizumab,targets,locally advanced or metastatic solid tumors
Atezolizumab,targets,hcc
Atezolizumab,targets,esophageal cancer
Atezolizumab,targets,cervical cancer
Atezolizumab,targets,hnscc
Atezolizumab,targets,tnbc
Atezolizumab,targets,colorectal cancer
NCT05581004,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,clear cell rcc
Pembrolizumab,targets,melanoma
Pembrolizumab,targets,gastric cancer
Pembrolizumab,targets,nsclc
Pembrolizumab,targets,urothelial carcinoma
Pembrolizumab,targets,locally advanced or metastatic solid tumors
Pembrolizumab,targets,hcc
Pembrolizumab,targets,esophageal cancer
Pembrolizumab,targets,cervical cancer
Pembrolizumab,targets,hnscc
Pembrolizumab,targets,tnbc
Pembrolizumab,targets,colorectal cancer
NCT02513472,sponsored_by,Eisai Inc.
NCT02513472,has_status,COMPLETED
NCT02513472,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
Eribulin Mesylate,classified_as,CHEMICAL
Eribulin Mesylate,targets,breast neoplasm
NCT02513472,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast neoplasm
NCT05099068,sponsored_by,Centre Leon Berard
NCT05099068,has_status,RECRUITING
NCT05099068,tests,Blood and tumor samples
Blood and tumor samples,has_type,DRUG
Blood and tumor samples,classified_as,OTHER
Blood and tumor samples,targets,advanced / metastic solid tumors
Blood and tumor samples,targets,glioblastoma
Blood and tumor samples,targets,chronic leukemia lymphocytic
NCT05490472,sponsored_by,"Jacobio Pharmaceuticals Co., Ltd."
NCT05490472,has_status,RECRUITING
NCT05490472,tests,JAB-2485 (Aurora A inhibitor)
JAB-2485 (Aurora A inhibitor),has_type,DRUG
JAB-2485 (Aurora A inhibitor),classified_as,CHEMICAL
JAB-2485 (Aurora A inhibitor),targets,"small cell lung cancer, sclc"
JAB-2485 (Aurora A inhibitor),targets,"triple negative breast cancer, tnbc"
JAB-2485 (Aurora A inhibitor),targets,solid tumors
JAB-2485 (Aurora A inhibitor),targets,arid1a gene mutation
JAB-2485 (Aurora A inhibitor),targets,er+ breast cancer
JAB-2485 (Aurora A inhibitor),targets,TNBC
NCT05490472,tests,JAB-2485 (Aurora A inhibitor)
JAB-2485 (Aurora A inhibitor),has_type,DRUG
JAB-2485 (Aurora A inhibitor),classified_as,CHEMICAL
JAB-2485 (Aurora A inhibitor),targets,"small cell lung cancer, sclc"
JAB-2485 (Aurora A inhibitor),targets,"triple negative breast cancer, tnbc"
JAB-2485 (Aurora A inhibitor),targets,solid tumors
JAB-2485 (Aurora A inhibitor),targets,arid1a gene mutation
JAB-2485 (Aurora A inhibitor),targets,er+ breast cancer
JAB-2485 (Aurora A inhibitor),targets,TNBC
NCT04265872,sponsored_by,Baylor Research Institute
NCT04265872,has_status,RECRUITING
NCT04265872,tests,Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis,has_type,DRUG
Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis,classified_as,BIOLOGIC
Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis,targets,breast cancer
NCT04770272,sponsored_by,Palleos Healthcare GmbH
NCT04770272,has_status,COMPLETED
NCT04770272,tests,Atezolizumab 840 MG in 14 ML Injection
Atezolizumab 840 MG in 14 ML Injection,has_type,DRUG
Atezolizumab 840 MG in 14 ML Injection,classified_as,BIOLOGIC
Atezolizumab 840 MG in 14 ML Injection,targets,triple-negative breast cancer
Atezolizumab 840 MG in 14 ML Injection,targets,TNBC
NCT04770272,tests,Atezolizumab 1200 MG in 20 ML Injection
Atezolizumab 1200 MG in 20 ML Injection,has_type,DRUG
Atezolizumab 1200 MG in 20 ML Injection,classified_as,BIOLOGIC
Atezolizumab 1200 MG in 20 ML Injection,targets,triple-negative breast cancer
Atezolizumab 1200 MG in 20 ML Injection,targets,TNBC
NCT04770272,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple-negative breast cancer
Carboplatin,targets,TNBC
NCT04770272,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple-negative breast cancer
Paclitaxel,targets,TNBC
NCT04770272,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,triple-negative breast cancer
Epirubicin,targets,TNBC
NCT04770272,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple-negative breast cancer
Cyclophosphamide,targets,TNBC
NCT04770272,tests,Biopsy Arm A
Biopsy Arm A,has_type,DRUG
Biopsy Arm A,classified_as,OTHER
Biopsy Arm A,targets,triple-negative breast cancer
Biopsy Arm A,targets,TNBC
NCT04770272,tests,Biopsy Arm B
Biopsy Arm B,has_type,DRUG
Biopsy Arm B,classified_as,OTHER
Biopsy Arm B,targets,triple-negative breast cancer
Biopsy Arm B,targets,TNBC
NCT04770272,tests,Surgery
Surgery,has_type,DRUG
Surgery,classified_as,OTHER
Surgery,targets,triple-negative breast cancer
Surgery,targets,TNBC
NCT05194072,sponsored_by,"Seagen, a wholly owned subsidiary of Pfizer"
NCT05194072,has_status,TERMINATED
NCT05194072,tests,Felmetatug Vedotin
Felmetatug Vedotin,has_type,DRUG
Felmetatug Vedotin,classified_as,OTHER
Felmetatug Vedotin,targets,her2 negative breast neoplasms
Felmetatug Vedotin,targets,endometrial neoplasms
Felmetatug Vedotin,targets,peritoneal neoplasms
Felmetatug Vedotin,targets,fallopian tube neoplasms
Felmetatug Vedotin,targets,"carcinoma, non-small-cell lung"
Felmetatug Vedotin,targets,gallbladder carcinoma
Felmetatug Vedotin,targets,adenoid cystic carcinoma
Felmetatug Vedotin,targets,triple negative breast neoplasms
Felmetatug Vedotin,targets,ovarian neoplasms
Felmetatug Vedotin,targets,cholangiocarcinoma
Felmetatug Vedotin,targets,hormone receptor positive breast neoplasms
Felmetatug Vedotin,targets,TNBC
NCT05194072,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,her2 negative breast neoplasms
Pembrolizumab,targets,endometrial neoplasms
Pembrolizumab,targets,peritoneal neoplasms
Pembrolizumab,targets,fallopian tube neoplasms
Pembrolizumab,targets,"carcinoma, non-small-cell lung"
Pembrolizumab,targets,gallbladder carcinoma
Pembrolizumab,targets,adenoid cystic carcinoma
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,ovarian neoplasms
Pembrolizumab,targets,cholangiocarcinoma
Pembrolizumab,targets,hormone receptor positive breast neoplasms
Pembrolizumab,targets,TNBC
NCT02977468,sponsored_by,Eileen Connolly
NCT02977468,has_status,RECRUITING
NCT02977468,tests,Merck 3475 Pembrolizumab
Merck 3475 Pembrolizumab,has_type,DRUG
Merck 3475 Pembrolizumab,classified_as,BIOLOGIC
Merck 3475 Pembrolizumab,targets,triple negative breast cancer
Merck 3475 Pembrolizumab,targets,TNBC
NCT02977468,tests,Intraoperative radiation therapy (IORT)
Intraoperative radiation therapy (IORT),has_type,DRUG
Intraoperative radiation therapy (IORT),classified_as,OTHER
Intraoperative radiation therapy (IORT),targets,triple negative breast cancer
Intraoperative radiation therapy (IORT),targets,TNBC
NCT02595372,sponsored_by,Kathy Miller
NCT02595372,has_status,COMPLETED
NCT02595372,tests,Omeprazole
Omeprazole,has_type,DRUG
Omeprazole,classified_as,CHEMICAL
Omeprazole,targets,cancer of the breast
NCT03901469,sponsored_by,Zenith Epigenetics
NCT03901469,has_status,TERMINATED
NCT03901469,tests,ZEN003694
ZEN003694,has_type,DRUG
ZEN003694,classified_as,OTHER
ZEN003694,targets,triple negative breast cancer
ZEN003694,targets,TNBC
NCT03901469,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,triple negative breast cancer
Talazoparib,targets,TNBC
NCT02755272,sponsored_by,Fox Chase Cancer Center
NCT02755272,has_status,ACTIVE_NOT_RECRUITING
NCT02755272,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,carcinoma breast stage iv
NCT02755272,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,carcinoma breast stage iv
NCT02755272,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,carcinoma breast stage iv
NCT02635672,sponsored_by,"Vincerx Pharma, Inc."
NCT02635672,has_status,COMPLETED
NCT02635672,tests,VIP152 (BAY 1251152)
VIP152 (BAY 1251152),has_type,DRUG
VIP152 (BAY 1251152),classified_as,OTHER
VIP152 (BAY 1251152),targets,neoplasms
NCT02635672,tests,VIP152 (BAY 1251152) 30 mg
VIP152 (BAY 1251152) 30 mg,has_type,DRUG
VIP152 (BAY 1251152) 30 mg,classified_as,OTHER
VIP152 (BAY 1251152) 30 mg,targets,neoplasms
NCT02635672,tests,Keytruda
Keytruda,has_type,DRUG
Keytruda,classified_as,OTHER
Keytruda,targets,neoplasms
NCT02635672,tests,VIP152 (BAY 1251152) 15 mg
VIP152 (BAY 1251152) 15 mg,has_type,DRUG
VIP152 (BAY 1251152) 15 mg,classified_as,OTHER
VIP152 (BAY 1251152) 15 mg,targets,neoplasms
NCT04664972,sponsored_by,Henan Cancer Hospital
NCT04664972,has_status,COMPLETED
NCT04664972,tests,Docetaxel +doxorubicin+ cyclophosphamide
Docetaxel +doxorubicin+ cyclophosphamide,has_type,DRUG
Docetaxel +doxorubicin+ cyclophosphamide,classified_as,CHEMICAL
Docetaxel +doxorubicin+ cyclophosphamide,targets,triple negative breast cancer
Docetaxel +doxorubicin+ cyclophosphamide,targets,TNBC
NCT04664972,tests,Docetaxel +Cisplatin
Docetaxel +Cisplatin,has_type,DRUG
Docetaxel +Cisplatin,classified_as,CHEMICAL
Docetaxel +Cisplatin,targets,triple negative breast cancer
Docetaxel +Cisplatin,targets,TNBC
NCT03945604,sponsored_by,"Jiangsu HengRui Medicine Co., Ltd."
NCT03945604,has_status,COMPLETED
NCT03945604,tests,SHR-1210 + Apatinib +Fluzoparib
SHR-1210 + Apatinib +Fluzoparib,has_type,DRUG
SHR-1210 + Apatinib +Fluzoparib,classified_as,CHEMICAL
SHR-1210 + Apatinib +Fluzoparib,targets,triple negative breast cancer
SHR-1210 + Apatinib +Fluzoparib,targets,TNBC
NCT00894504,sponsored_by,"SCRI Development Innovations, LLC"
NCT00894504,has_status,COMPLETED
NCT00894504,tests,Panitumumab
Panitumumab,has_type,DRUG
Panitumumab,classified_as,BIOLOGIC
Panitumumab,targets,metastatic breast cancer
NCT00894504,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,metastatic breast cancer
NCT00894504,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,metastatic breast cancer
NCT02768701,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT02768701,has_status,COMPLETED
NCT02768701,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT02768701,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02484404,sponsored_by,National Cancer Institute (NCI)
NCT02484404,has_status,ACTIVE_NOT_RECRUITING
NCT02484404,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,breast neoplasms
Olaparib,targets,colorectal neoplasms
NCT02484404,tests,Cediranib
Cediranib,has_type,DRUG
Cediranib,classified_as,CHEMICAL
Cediranib,targets,breast neoplasms
Cediranib,targets,colorectal neoplasms
NCT02484404,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,breast neoplasms
Durvalumab,targets,colorectal neoplasms
NCT06465069,sponsored_by,Eli Lilly and Company
NCT06465069,has_status,SUSPENDED
NCT06465069,tests,LY4052031
LY4052031,has_type,DRUG
LY4052031,classified_as,OTHER
LY4052031,targets,non-small cell lung cancer
LY4052031,targets,recurrent solid tumor
LY4052031,targets,urinary bladder neoplasm
LY4052031,targets,pancreatic cancer
LY4052031,targets,advanced solid tumor
LY4052031,targets,prostate cancer
LY4052031,targets,metastatic solid tumor
LY4052031,targets,ovarian cancer
LY4052031,targets,triple negative breast cancer
LY4052031,targets,bladder cancer
LY4052031,targets,renal pelvis cancer
LY4052031,targets,esophageal cancer
LY4052031,targets,cervical cancer
LY4052031,targets,head and neck squamous cell carcinoma
LY4052031,targets,TNBC
NCT06448169,sponsored_by,Shandong University
NCT06448169,has_status,NOT_YET_RECRUITING
NCT06448169,tests,PD-1 inhibitor
PD-1 inhibitor,has_type,DRUG
PD-1 inhibitor,classified_as,BIOLOGIC
PD-1 inhibitor,targets,neoadjuvant immunotherapy
PD-1 inhibitor,targets,sensitivity
PD-1 inhibitor,targets,triple negative breast cancer
PD-1 inhibitor,targets,TNBC
NCT05318469,sponsored_by,Yuan Yuan
NCT05318469,has_status,RECRUITING
NCT05318469,tests,Ivermectin
Ivermectin,has_type,DRUG
Ivermectin,classified_as,OTHER
Ivermectin,targets,metastatic triple-negative breast carcinoma
Ivermectin,targets,anatomic stage iv breast cancer ajcc v8
Ivermectin,targets,TNBC
NCT05318469,tests,Balstilmab
Balstilmab,has_type,DRUG
Balstilmab,classified_as,BIOLOGIC
Balstilmab,targets,metastatic triple-negative breast carcinoma
Balstilmab,targets,anatomic stage iv breast cancer ajcc v8
Balstilmab,targets,TNBC
NCT05318469,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iv breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT02644369,sponsored_by,"University Health Network, Toronto"
NCT02644369,has_status,ACTIVE_NOT_RECRUITING
NCT02644369,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,advanced solid tumors
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,squamous cell cancer of head and neck
Pembrolizumab,targets,malignant melanoma
Pembrolizumab,targets,epithelial ovarian cancer
Pembrolizumab,targets,TNBC
NCT01276769,sponsored_by,Chinese Academy of Medical Sciences
NCT01276769,has_status,UNKNOWN
NCT01276769,tests,Paclitaxel plus carboplatin
Paclitaxel plus carboplatin,has_type,DRUG
Paclitaxel plus carboplatin,classified_as,CHEMICAL
Paclitaxel plus carboplatin,targets,triple negative breast cancer
Paclitaxel plus carboplatin,targets,TNBC
NCT01276769,tests,Paclitaxel and epirubicin
Paclitaxel and epirubicin,has_type,DRUG
Paclitaxel and epirubicin,classified_as,CHEMICAL
Paclitaxel and epirubicin,targets,triple negative breast cancer
Paclitaxel and epirubicin,targets,TNBC
NCT02890069,sponsored_by,Novartis Pharmaceuticals
NCT02890069,has_status,COMPLETED
NCT02890069,tests,PDR001
PDR001,has_type,DRUG
PDR001,classified_as,OTHER
PDR001,targets,"colorectal cancer, non-small cell lung carcinoma (adenocarcinoma), triple negative breast cancer, renal cell carcinoma"
PDR001,targets,TNBC
NCT02890069,tests,LCL161
LCL161,has_type,DRUG
LCL161,classified_as,OTHER
LCL161,targets,"colorectal cancer, non-small cell lung carcinoma (adenocarcinoma), triple negative breast cancer, renal cell carcinoma"
LCL161,targets,TNBC
NCT02890069,tests,Everolimus
Everolimus,has_type,DRUG
Everolimus,classified_as,OTHER
Everolimus,targets,"colorectal cancer, non-small cell lung carcinoma (adenocarcinoma), triple negative breast cancer, renal cell carcinoma"
Everolimus,targets,TNBC
NCT02890069,tests,Panobinostat
Panobinostat,has_type,DRUG
Panobinostat,classified_as,OTHER
Panobinostat,targets,"colorectal cancer, non-small cell lung carcinoma (adenocarcinoma), triple negative breast cancer, renal cell carcinoma"
Panobinostat,targets,TNBC
NCT02890069,tests,QBM076
QBM076,has_type,DRUG
QBM076,classified_as,OTHER
QBM076,targets,"colorectal cancer, non-small cell lung carcinoma (adenocarcinoma), triple negative breast cancer, renal cell carcinoma"
QBM076,targets,TNBC
NCT02890069,tests,HDM201
HDM201,has_type,DRUG
HDM201,classified_as,OTHER
HDM201,targets,"colorectal cancer, non-small cell lung carcinoma (adenocarcinoma), triple negative breast cancer, renal cell carcinoma"
HDM201,targets,TNBC
NCT06598046,sponsored_by,Henan Cancer Hospital
NCT06598046,has_status,RECRUITING
NCT06598046,tests,Utidelone and capecitabine
Utidelone and capecitabine,has_type,DRUG
Utidelone and capecitabine,classified_as,CHEMICAL
Utidelone and capecitabine,targets,metastatic breast cancer
NCT03292172,sponsored_by,Hoffmann-La Roche
NCT03292172,has_status,TERMINATED
NCT03292172,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,advanced ovarian cancer
Atezolizumab,targets,triple negative breast cancer
Atezolizumab,targets,TNBC
NCT03292172,tests,RO6870810
RO6870810,has_type,DRUG
RO6870810,classified_as,OTHER
RO6870810,targets,advanced ovarian cancer
RO6870810,targets,triple negative breast cancer
RO6870810,targets,TNBC
NCT04606472,sponsored_by,"Sichuan Baili Pharmaceutical Co., Ltd."
NCT04606472,has_status,RECRUITING
NCT04606472,tests,SI-B003
SI-B003,has_type,DRUG
SI-B003,classified_as,OTHER
SI-B003,targets,solid tumor
NCT06910072,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT06910072,has_status,NOT_YET_RECRUITING
NCT06910072,tests,paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab
paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab,has_type,DRUG
paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab,classified_as,BIOLOGIC
paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab,targets,triple-negative breast cancer (tnbc)
paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab,targets,neoadjuvant therapy
paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab,targets,TNBC
NCT04331067,sponsored_by,Washington University School of Medicine
NCT04331067,has_status,ACTIVE_NOT_RECRUITING
NCT04331067,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT04331067,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT04331067,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,triple negative breast cancer
Nivolumab,targets,TNBC
NCT04331067,tests,Cabiralizumab
Cabiralizumab,has_type,DRUG
Cabiralizumab,classified_as,BIOLOGIC
Cabiralizumab,targets,triple negative breast cancer
Cabiralizumab,targets,TNBC
NCT04331067,tests,Tumor biopsy
Tumor biopsy,has_type,DRUG
Tumor biopsy,classified_as,OTHER
Tumor biopsy,targets,triple negative breast cancer
Tumor biopsy,targets,TNBC
NCT04331067,tests,Bone marrow
Bone marrow,has_type,DRUG
Bone marrow,classified_as,OTHER
Bone marrow,targets,triple negative breast cancer
Bone marrow,targets,TNBC
NCT04331067,tests,Blood draw
Blood draw,has_type,DRUG
Blood draw,classified_as,OTHER
Blood draw,targets,triple negative breast cancer
Blood draw,targets,TNBC
NCT06324240,sponsored_by,Emory University
NCT06324240,has_status,NOT_YET_RECRUITING
NCT06324240,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,anatomic stage iia breast cancer ajcc v8
Ipilimumab,targets,prognostic stage ib breast cancer ajcc v8
Ipilimumab,targets,anatomic stage iiib breast cancer ajcc v8
Ipilimumab,targets,prognostic stage ia breast cancer ajcc v8
Ipilimumab,targets,prognostic stage iia breast cancer ajcc v8
Ipilimumab,targets,prognostic stage i breast cancer ajcc v8
Ipilimumab,targets,anatomic stage iib breast cancer ajcc v8
Ipilimumab,targets,anatomic stage iiia breast cancer ajcc v8
Ipilimumab,targets,prognostic stage ii breast cancer ajcc v8
Ipilimumab,targets,anatomic stage iv breast cancer ajcc v8
Ipilimumab,targets,anatomic stage ib breast cancer ajcc v8
Ipilimumab,targets,prognostic stage iib breast cancer ajcc v8
Ipilimumab,targets,anatomic stage ii breast cancer ajcc v8
Ipilimumab,targets,recurrent breast carcinoma
Ipilimumab,targets,prognostic stage iiic breast cancer ajcc v8
Ipilimumab,targets,early stage triple-negative breast carcinoma
Ipilimumab,targets,locally advanced triple-negative breast carcinoma
Ipilimumab,targets,metastatic triple-negative breast carcinoma
Ipilimumab,targets,anatomic stage iii breast cancer ajcc v8
Ipilimumab,targets,prognostic stage iii breast cancer ajcc v8
Ipilimumab,targets,prognostic stage iv breast cancer ajcc v8
Ipilimumab,targets,prognostic stage iiia breast cancer ajcc v8
Ipilimumab,targets,unresectable triple-negative breast carcinoma
Ipilimumab,targets,anatomic stage i breast cancer ajcc v8
Ipilimumab,targets,prognostic stage iiib breast cancer ajcc v8
Ipilimumab,targets,anatomic stage ia breast cancer ajcc v8
Ipilimumab,targets,anatomic stage iiic breast cancer ajcc v8
Ipilimumab,targets,TNBC
NCT06324240,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,anatomic stage iia breast cancer ajcc v8
Pembrolizumab,targets,prognostic stage ib breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage iiib breast cancer ajcc v8
Pembrolizumab,targets,prognostic stage ia breast cancer ajcc v8
Pembrolizumab,targets,prognostic stage iia breast cancer ajcc v8
Pembrolizumab,targets,prognostic stage i breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage iib breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage iiia breast cancer ajcc v8
Pembrolizumab,targets,prognostic stage ii breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage iv breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage ib breast cancer ajcc v8
Pembrolizumab,targets,prognostic stage iib breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage ii breast cancer ajcc v8
Pembrolizumab,targets,recurrent breast carcinoma
Pembrolizumab,targets,prognostic stage iiic breast cancer ajcc v8
Pembrolizumab,targets,early stage triple-negative breast carcinoma
Pembrolizumab,targets,locally advanced triple-negative breast carcinoma
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iii breast cancer ajcc v8
Pembrolizumab,targets,prognostic stage iii breast cancer ajcc v8
Pembrolizumab,targets,prognostic stage iv breast cancer ajcc v8
Pembrolizumab,targets,prognostic stage iiia breast cancer ajcc v8
Pembrolizumab,targets,unresectable triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage i breast cancer ajcc v8
Pembrolizumab,targets,prognostic stage iiib breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage ia breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage iiic breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT06324240,tests,Vaccine Therapy
Vaccine Therapy,has_type,DRUG
Vaccine Therapy,classified_as,OTHER
Vaccine Therapy,targets,anatomic stage iia breast cancer ajcc v8
Vaccine Therapy,targets,prognostic stage ib breast cancer ajcc v8
Vaccine Therapy,targets,anatomic stage iiib breast cancer ajcc v8
Vaccine Therapy,targets,prognostic stage ia breast cancer ajcc v8
Vaccine Therapy,targets,prognostic stage iia breast cancer ajcc v8
Vaccine Therapy,targets,prognostic stage i breast cancer ajcc v8
Vaccine Therapy,targets,anatomic stage iib breast cancer ajcc v8
Vaccine Therapy,targets,anatomic stage iiia breast cancer ajcc v8
Vaccine Therapy,targets,prognostic stage ii breast cancer ajcc v8
Vaccine Therapy,targets,anatomic stage iv breast cancer ajcc v8
Vaccine Therapy,targets,anatomic stage ib breast cancer ajcc v8
Vaccine Therapy,targets,prognostic stage iib breast cancer ajcc v8
Vaccine Therapy,targets,anatomic stage ii breast cancer ajcc v8
Vaccine Therapy,targets,recurrent breast carcinoma
Vaccine Therapy,targets,prognostic stage iiic breast cancer ajcc v8
Vaccine Therapy,targets,early stage triple-negative breast carcinoma
Vaccine Therapy,targets,locally advanced triple-negative breast carcinoma
Vaccine Therapy,targets,metastatic triple-negative breast carcinoma
Vaccine Therapy,targets,anatomic stage iii breast cancer ajcc v8
Vaccine Therapy,targets,prognostic stage iii breast cancer ajcc v8
Vaccine Therapy,targets,prognostic stage iv breast cancer ajcc v8
Vaccine Therapy,targets,prognostic stage iiia breast cancer ajcc v8
Vaccine Therapy,targets,unresectable triple-negative breast carcinoma
Vaccine Therapy,targets,anatomic stage i breast cancer ajcc v8
Vaccine Therapy,targets,prognostic stage iiib breast cancer ajcc v8
Vaccine Therapy,targets,anatomic stage ia breast cancer ajcc v8
Vaccine Therapy,targets,anatomic stage iiic breast cancer ajcc v8
Vaccine Therapy,targets,TNBC
NCT03606967,sponsored_by,National Cancer Institute (NCI)
NCT03606967,has_status,RECRUITING
NCT03606967,tests,Biopsy Procedure
Biopsy Procedure,has_type,DRUG
Biopsy Procedure,classified_as,OTHER
Biopsy Procedure,targets,metastatic triple-negative breast carcinoma
Biopsy Procedure,targets,invasive breast carcinoma
Biopsy Procedure,targets,anatomic stage iv breast cancer ajcc v8
Biopsy Procedure,targets,TNBC
NCT03606967,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,invasive breast carcinoma
Biospecimen Collection,targets,anatomic stage iv breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT03606967,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,metastatic triple-negative breast carcinoma
Carboplatin,targets,invasive breast carcinoma
Carboplatin,targets,anatomic stage iv breast cancer ajcc v8
Carboplatin,targets,TNBC
NCT03606967,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,invasive breast carcinoma
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,TNBC
NCT03606967,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,metastatic triple-negative breast carcinoma
Durvalumab,targets,invasive breast carcinoma
Durvalumab,targets,anatomic stage iv breast cancer ajcc v8
Durvalumab,targets,TNBC
NCT03606967,tests,Gemcitabine Hydrochloride
Gemcitabine Hydrochloride,has_type,DRUG
Gemcitabine Hydrochloride,classified_as,OTHER
Gemcitabine Hydrochloride,targets,metastatic triple-negative breast carcinoma
Gemcitabine Hydrochloride,targets,invasive breast carcinoma
Gemcitabine Hydrochloride,targets,anatomic stage iv breast cancer ajcc v8
Gemcitabine Hydrochloride,targets,TNBC
NCT03606967,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,metastatic triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,invasive breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iv breast cancer ajcc v8
Magnetic Resonance Imaging,targets,TNBC
NCT03606967,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,metastatic triple-negative breast carcinoma
Nab-paclitaxel,targets,invasive breast carcinoma
Nab-paclitaxel,targets,anatomic stage iv breast cancer ajcc v8
Nab-paclitaxel,targets,TNBC
NCT03606967,tests,Personalized Synthetic Long Peptide Vaccine
Personalized Synthetic Long Peptide Vaccine,has_type,DRUG
Personalized Synthetic Long Peptide Vaccine,classified_as,BIOLOGIC
Personalized Synthetic Long Peptide Vaccine,targets,metastatic triple-negative breast carcinoma
Personalized Synthetic Long Peptide Vaccine,targets,invasive breast carcinoma
Personalized Synthetic Long Peptide Vaccine,targets,anatomic stage iv breast cancer ajcc v8
Personalized Synthetic Long Peptide Vaccine,targets,TNBC
NCT03606967,tests,Poly ICLC
Poly ICLC,has_type,DRUG
Poly ICLC,classified_as,OTHER
Poly ICLC,targets,metastatic triple-negative breast carcinoma
Poly ICLC,targets,invasive breast carcinoma
Poly ICLC,targets,anatomic stage iv breast cancer ajcc v8
Poly ICLC,targets,TNBC
NCT03606967,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
Sacituzumab Govitecan,classified_as,BIOLOGIC
Sacituzumab Govitecan,targets,metastatic triple-negative breast carcinoma
Sacituzumab Govitecan,targets,invasive breast carcinoma
Sacituzumab Govitecan,targets,anatomic stage iv breast cancer ajcc v8
Sacituzumab Govitecan,targets,TNBC
NCT03606967,tests,Tremelimumab
Tremelimumab,has_type,DRUG
Tremelimumab,classified_as,BIOLOGIC
Tremelimumab,targets,metastatic triple-negative breast carcinoma
Tremelimumab,targets,invasive breast carcinoma
Tremelimumab,targets,anatomic stage iv breast cancer ajcc v8
Tremelimumab,targets,TNBC
NCT05520723,sponsored_by,MedSIR
NCT05520723,has_status,ACTIVE_NOT_RECRUITING
NCT05520723,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
Sacituzumab govitecan,classified_as,BIOLOGIC
Sacituzumab govitecan,targets,breast cancer
Sacituzumab govitecan,targets,triple negative breast cancer
Sacituzumab govitecan,targets,TNBC
NCT05520723,tests,Loperamide
Loperamide,has_type,DRUG
Loperamide,classified_as,OTHER
Loperamide,targets,breast cancer
Loperamide,targets,triple negative breast cancer
Loperamide,targets,TNBC
NCT05520723,tests,Granulocyte Colony-Stimulating Factor
Granulocyte Colony-Stimulating Factor,has_type,DRUG
Granulocyte Colony-Stimulating Factor,classified_as,OTHER
Granulocyte Colony-Stimulating Factor,targets,breast cancer
Granulocyte Colony-Stimulating Factor,targets,triple negative breast cancer
Granulocyte Colony-Stimulating Factor,targets,TNBC
NCT07046923,sponsored_by,Eli Lilly and Company
NCT07046923,has_status,NOT_YET_RECRUITING
NCT07046923,tests,LY4175408
LY4175408,has_type,DRUG
LY4175408,classified_as,OTHER
LY4175408,targets,endometrial neoplasms
LY4175408,targets,"carcinoma, non-small-cell lung"
LY4175408,targets,triple negative breast cancer
LY4175408,targets,neoplasm metastasis
LY4175408,targets,small cell lung carcinoma
LY4175408,targets,TNBC
NCT02658214,sponsored_by,AstraZeneca
NCT02658214,has_status,COMPLETED
NCT02658214,tests,paclitaxel + carboplatin
paclitaxel + carboplatin,has_type,DRUG
paclitaxel + carboplatin,classified_as,CHEMICAL
paclitaxel + carboplatin,targets,stomach neoplasms
paclitaxel + carboplatin,targets,peritoneal neoplasms
paclitaxel + carboplatin,targets,fallopian tube neoplasms
paclitaxel + carboplatin,targets,esophageal squamous cell carcinoma
paclitaxel + carboplatin,targets,triple negative breast neoplasms
paclitaxel + carboplatin,targets,small cell lung carcinoma
paclitaxel + carboplatin,targets,ovarian neoplasms
paclitaxel + carboplatin,targets,esophagogastric junction neoplasms
paclitaxel + carboplatin,targets,"carcinoma, squamous cell of head and neck"
paclitaxel + carboplatin,targets,"carcinoma, pancreatic ductal"
paclitaxel + carboplatin,targets,TNBC
NCT02658214,tests,carboplatin + etoposide
carboplatin + etoposide,has_type,DRUG
carboplatin + etoposide,classified_as,CHEMICAL
carboplatin + etoposide,targets,stomach neoplasms
carboplatin + etoposide,targets,peritoneal neoplasms
carboplatin + etoposide,targets,fallopian tube neoplasms
carboplatin + etoposide,targets,esophageal squamous cell carcinoma
carboplatin + etoposide,targets,triple negative breast neoplasms
carboplatin + etoposide,targets,small cell lung carcinoma
carboplatin + etoposide,targets,ovarian neoplasms
carboplatin + etoposide,targets,esophagogastric junction neoplasms
carboplatin + etoposide,targets,"carcinoma, squamous cell of head and neck"
carboplatin + etoposide,targets,"carcinoma, pancreatic ductal"
carboplatin + etoposide,targets,TNBC
NCT02658214,tests,gemcitabine + carboplatin
gemcitabine + carboplatin,has_type,DRUG
gemcitabine + carboplatin,classified_as,CHEMICAL
gemcitabine + carboplatin,targets,stomach neoplasms
gemcitabine + carboplatin,targets,peritoneal neoplasms
gemcitabine + carboplatin,targets,fallopian tube neoplasms
gemcitabine + carboplatin,targets,esophageal squamous cell carcinoma
gemcitabine + carboplatin,targets,triple negative breast neoplasms
gemcitabine + carboplatin,targets,small cell lung carcinoma
gemcitabine + carboplatin,targets,ovarian neoplasms
gemcitabine + carboplatin,targets,esophagogastric junction neoplasms
gemcitabine + carboplatin,targets,"carcinoma, squamous cell of head and neck"
gemcitabine + carboplatin,targets,"carcinoma, pancreatic ductal"
gemcitabine + carboplatin,targets,TNBC
NCT02658214,tests,nab-paclitaxel (paclitaxel-albumin) + carboplatin
nab-paclitaxel (paclitaxel-albumin) + carboplatin,has_type,DRUG
nab-paclitaxel (paclitaxel-albumin) + carboplatin,classified_as,CHEMICAL
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,stomach neoplasms
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,peritoneal neoplasms
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,fallopian tube neoplasms
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,esophageal squamous cell carcinoma
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,triple negative breast neoplasms
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,small cell lung carcinoma
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,ovarian neoplasms
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,esophagogastric junction neoplasms
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,"carcinoma, squamous cell of head and neck"
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,"carcinoma, pancreatic ductal"
nab-paclitaxel (paclitaxel-albumin) + carboplatin,targets,TNBC
NCT02658214,tests,oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),has_type,DRUG
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),classified_as,CHEMICAL
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,stomach neoplasms
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,peritoneal neoplasms
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,fallopian tube neoplasms
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,esophageal squamous cell carcinoma
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,triple negative breast neoplasms
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,small cell lung carcinoma
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,ovarian neoplasms
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,esophagogastric junction neoplasms
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,"carcinoma, squamous cell of head and neck"
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,"carcinoma, pancreatic ductal"
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),targets,TNBC
NCT02658214,tests,durvalumab
durvalumab,has_type,DRUG
durvalumab,classified_as,BIOLOGIC
durvalumab,targets,stomach neoplasms
durvalumab,targets,peritoneal neoplasms
durvalumab,targets,fallopian tube neoplasms
durvalumab,targets,esophageal squamous cell carcinoma
durvalumab,targets,triple negative breast neoplasms
durvalumab,targets,small cell lung carcinoma
durvalumab,targets,ovarian neoplasms
durvalumab,targets,esophagogastric junction neoplasms
durvalumab,targets,"carcinoma, squamous cell of head and neck"
durvalumab,targets,"carcinoma, pancreatic ductal"
durvalumab,targets,TNBC
NCT02658214,tests,tremelimumab
tremelimumab,has_type,DRUG
tremelimumab,classified_as,BIOLOGIC
tremelimumab,targets,stomach neoplasms
tremelimumab,targets,peritoneal neoplasms
tremelimumab,targets,fallopian tube neoplasms
tremelimumab,targets,esophageal squamous cell carcinoma
tremelimumab,targets,triple negative breast neoplasms
tremelimumab,targets,small cell lung carcinoma
tremelimumab,targets,ovarian neoplasms
tremelimumab,targets,esophagogastric junction neoplasms
tremelimumab,targets,"carcinoma, squamous cell of head and neck"
tremelimumab,targets,"carcinoma, pancreatic ductal"
tremelimumab,targets,TNBC
NCT02658214,tests,nab-paclitaxel (paclitaxel-albumin) + gemcitabine
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,has_type,DRUG
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,classified_as,CHEMICAL
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,stomach neoplasms
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,peritoneal neoplasms
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,fallopian tube neoplasms
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,esophageal squamous cell carcinoma
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,triple negative breast neoplasms
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,small cell lung carcinoma
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,ovarian neoplasms
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,esophagogastric junction neoplasms
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,"carcinoma, squamous cell of head and neck"
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,"carcinoma, pancreatic ductal"
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,targets,TNBC
NCT02658214,tests,cisplatin + 5-fluorouracil (5FU)
cisplatin + 5-fluorouracil (5FU),has_type,DRUG
cisplatin + 5-fluorouracil (5FU),classified_as,CHEMICAL
cisplatin + 5-fluorouracil (5FU),targets,stomach neoplasms
cisplatin + 5-fluorouracil (5FU),targets,peritoneal neoplasms
cisplatin + 5-fluorouracil (5FU),targets,fallopian tube neoplasms
cisplatin + 5-fluorouracil (5FU),targets,esophageal squamous cell carcinoma
cisplatin + 5-fluorouracil (5FU),targets,triple negative breast neoplasms
cisplatin + 5-fluorouracil (5FU),targets,small cell lung carcinoma
cisplatin + 5-fluorouracil (5FU),targets,ovarian neoplasms
cisplatin + 5-fluorouracil (5FU),targets,esophagogastric junction neoplasms
cisplatin + 5-fluorouracil (5FU),targets,"carcinoma, squamous cell of head and neck"
cisplatin + 5-fluorouracil (5FU),targets,"carcinoma, pancreatic ductal"
cisplatin + 5-fluorouracil (5FU),targets,TNBC
NCT05809895,sponsored_by,Novartis Pharmaceuticals
NCT05809895,has_status,WITHDRAWN
NCT05809895,tests,Ociperlimab
Ociperlimab,has_type,DRUG
Ociperlimab,classified_as,BIOLOGIC
Ociperlimab,targets,triple negative breast cancer
Ociperlimab,targets,TNBC
NCT05809895,tests,Tislelizumab
Tislelizumab,has_type,DRUG
Tislelizumab,classified_as,BIOLOGIC
Tislelizumab,targets,triple negative breast cancer
Tislelizumab,targets,TNBC
NCT05809895,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT05809895,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT05809895,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT05809895,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast cancer
Placebo,targets,TNBC
NCT05809895,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT05809895,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast cancer
Gemcitabine,targets,TNBC
NCT03979508,sponsored_by,Mayo Clinic
NCT03979508,has_status,RECRUITING
NCT03979508,tests,Abemaciclib
Abemaciclib,has_type,DRUG
Abemaciclib,classified_as,CHEMICAL
Abemaciclib,targets,invasive breast carcinoma
Abemaciclib,targets,prognostic stage iiic breast cancer ajcc v8
Abemaciclib,targets,anatomic stage i breast cancer ajcc v8
Abemaciclib,targets,prognostic stage ii breast cancer ajcc v8
Abemaciclib,targets,prognostic stage ib breast cancer ajcc v8
Abemaciclib,targets,prognostic stage iiib breast cancer ajcc v8
Abemaciclib,targets,prognostic stage ia breast cancer ajcc v8
Abemaciclib,targets,breast fibrocystic change
Abemaciclib,targets,breast ductal carcinoma in situ
Abemaciclib,targets,anatomic stage iii breast cancer ajcc v8
Abemaciclib,targets,breast lobular carcinoma in situ
Abemaciclib,targets,prognostic stage iib breast cancer ajcc v8
Abemaciclib,targets,anatomic stage ii breast cancer ajcc v8
Abemaciclib,targets,prognostic stage iia breast cancer ajcc v8
Abemaciclib,targets,prognostic stage iii breast cancer ajcc v8
Abemaciclib,targets,triple-negative breast carcinoma
Abemaciclib,targets,prognostic stage iiia breast cancer ajcc v8
Abemaciclib,targets,prognostic stage i breast cancer ajcc v8
Abemaciclib,targets,TNBC
NCT03979508,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,DRUG
Therapeutic Conventional Surgery,classified_as,OTHER
Therapeutic Conventional Surgery,targets,invasive breast carcinoma
Therapeutic Conventional Surgery,targets,prognostic stage iiic breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,anatomic stage i breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,prognostic stage ii breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,prognostic stage ib breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,prognostic stage iiib breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,prognostic stage ia breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,breast fibrocystic change
Therapeutic Conventional Surgery,targets,breast ductal carcinoma in situ
Therapeutic Conventional Surgery,targets,anatomic stage iii breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,breast lobular carcinoma in situ
Therapeutic Conventional Surgery,targets,prognostic stage iib breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,anatomic stage ii breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,prognostic stage iia breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,prognostic stage iii breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,triple-negative breast carcinoma
Therapeutic Conventional Surgery,targets,prognostic stage iiia breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,prognostic stage i breast cancer ajcc v8
Therapeutic Conventional Surgery,targets,TNBC
NCT06732323,sponsored_by,"Qilu Pharmaceutical Co., Ltd."
NCT06732323,has_status,NOT_YET_RECRUITING
NCT06732323,tests,ESG401
ESG401,has_type,DRUG
ESG401,classified_as,OTHER
ESG401,targets,triple-negative breast cancer (tnbc)
ESG401,targets,TNBC
NCT06732323,tests,Investigator's Choice Chemotherapy
Investigator's Choice Chemotherapy,has_type,DRUG
Investigator's Choice Chemotherapy,classified_as,OTHER
Investigator's Choice Chemotherapy,targets,triple-negative breast cancer (tnbc)
Investigator's Choice Chemotherapy,targets,TNBC
NCT03997123,sponsored_by,AstraZeneca
NCT03997123,has_status,ACTIVE_NOT_RECRUITING
NCT03997123,tests,Capivasertib
Capivasertib,has_type,DRUG
Capivasertib,classified_as,CHEMICAL
Capivasertib,targets,triple negative breast neoplasms
Capivasertib,targets,TNBC
NCT03997123,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast neoplasms
Paclitaxel,targets,TNBC
NCT03997123,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast neoplasms
Placebo,targets,TNBC
NCT01333423,sponsored_by,M.D. Anderson Cancer Center
NCT01333423,has_status,WITHDRAWN
NCT01333423,tests,Liposomal Doxorubicin
Liposomal Doxorubicin,has_type,DRUG
Liposomal Doxorubicin,classified_as,CHEMICAL
Liposomal Doxorubicin,targets,breast cancer
NCT01333423,tests,Seliciclib
Seliciclib,has_type,DRUG
Seliciclib,classified_as,CHEMICAL
Seliciclib,targets,breast cancer
NCT03098550,sponsored_by,Bristol-Myers Squibb
NCT03098550,has_status,COMPLETED
NCT03098550,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,advanced cancer
NCT03098550,tests,Daratumumab
Daratumumab,has_type,DRUG
Daratumumab,classified_as,BIOLOGIC
Daratumumab,targets,advanced cancer
NCT04585750,sponsored_by,"PMV Pharmaceuticals, Inc"
NCT04585750,has_status,RECRUITING
NCT04585750,tests,rezatapopt
rezatapopt,has_type,DRUG
rezatapopt,classified_as,OTHER
rezatapopt,targets,metastatic cancer
rezatapopt,targets,her2-negative breast cancer
rezatapopt,targets,other cancer
rezatapopt,targets,small cell lung carcinoma
rezatapopt,targets,er/pr positive breast cancer
rezatapopt,targets,small cell lung cancer ( sclc )
rezatapopt,targets,breast cancer
rezatapopt,targets,non-small cell lung carcinoma
rezatapopt,targets,triple negative breast cancer
rezatapopt,targets,her2-positive breast cancer
rezatapopt,targets,sclc
rezatapopt,targets,her2+ breast cancer
rezatapopt,targets,non-small cell lung cancer
rezatapopt,targets,nsclc (non-small cell lung cancer)
rezatapopt,targets,nsclc
rezatapopt,targets,advanced solid tumor
rezatapopt,targets,prostate cancer
rezatapopt,targets,metastatic solid tumor
rezatapopt,targets,lung cancer
rezatapopt,targets,ovarian cancer
rezatapopt,targets,her2- breast cancer
rezatapopt,targets,tnbc
rezatapopt,targets,small cell lung cancer
rezatapopt,targets,endometrial cancer
rezatapopt,targets,colorectal cancer
rezatapopt,targets,head and neck cancer
rezatapopt,targets,gall bladder cancer
rezatapopt,targets,"er/pr(+), her2(-) breast cancer"
rezatapopt,targets,advanced malignant neoplasm
rezatapopt,targets,locally advanced
rezatapopt,targets,TNBC
NCT04585750,tests,pembrolizumab
pembrolizumab,has_type,DRUG
pembrolizumab,classified_as,BIOLOGIC
pembrolizumab,targets,metastatic cancer
pembrolizumab,targets,her2-negative breast cancer
pembrolizumab,targets,other cancer
pembrolizumab,targets,small cell lung carcinoma
pembrolizumab,targets,er/pr positive breast cancer
pembrolizumab,targets,small cell lung cancer ( sclc )
pembrolizumab,targets,breast cancer
pembrolizumab,targets,non-small cell lung carcinoma
pembrolizumab,targets,triple negative breast cancer
pembrolizumab,targets,her2-positive breast cancer
pembrolizumab,targets,sclc
pembrolizumab,targets,her2+ breast cancer
pembrolizumab,targets,non-small cell lung cancer
pembrolizumab,targets,nsclc (non-small cell lung cancer)
pembrolizumab,targets,nsclc
pembrolizumab,targets,advanced solid tumor
pembrolizumab,targets,prostate cancer
pembrolizumab,targets,metastatic solid tumor
pembrolizumab,targets,lung cancer
pembrolizumab,targets,ovarian cancer
pembrolizumab,targets,her2- breast cancer
pembrolizumab,targets,tnbc
pembrolizumab,targets,small cell lung cancer
pembrolizumab,targets,endometrial cancer
pembrolizumab,targets,colorectal cancer
pembrolizumab,targets,head and neck cancer
pembrolizumab,targets,gall bladder cancer
pembrolizumab,targets,"er/pr(+), her2(-) breast cancer"
pembrolizumab,targets,advanced malignant neoplasm
pembrolizumab,targets,locally advanced
pembrolizumab,targets,TNBC
NCT05461690,sponsored_by,Zhejiang Cancer Hospital
NCT05461690,has_status,UNKNOWN
NCT05461690,tests,Niraparib
Niraparib,has_type,DRUG
Niraparib,classified_as,CHEMICAL
Niraparib,targets,homologous recombination deficiency
Niraparib,targets,triple negative breast cancer
Niraparib,targets,TNBC
NCT06210438,sponsored_by,Fudan University
NCT06210438,has_status,NOT_YET_RECRUITING
NCT06210438,tests,SHR-A1921 + Bevacizumab
SHR-A1921 + Bevacizumab,has_type,DRUG
SHR-A1921 + Bevacizumab,classified_as,BIOLOGIC
SHR-A1921 + Bevacizumab,targets,tnbc
SHR-A1921 + Bevacizumab,targets,brain metastasis
NCT02370238,sponsored_by,Dompé Farmaceutici S.p.A
NCT02370238,has_status,COMPLETED
NCT02370238,tests,paclitaxel
paclitaxel,has_type,DRUG
paclitaxel,classified_as,CHEMICAL
paclitaxel,targets,metastatic breast cancer
NCT02370238,tests,Reparixin
Reparixin,has_type,DRUG
Reparixin,classified_as,OTHER
Reparixin,targets,metastatic breast cancer
NCT02370238,tests,placebo
placebo,has_type,DRUG
placebo,classified_as,OTHER
placebo,targets,metastatic breast cancer
NCT03243838,sponsored_by,Guangdong Provincial People's Hospital
NCT03243838,has_status,COMPLETED
NCT03243838,tests,Apatinib
Apatinib,has_type,DRUG
Apatinib,classified_as,CHEMICAL
Apatinib,targets,triple-negative breast cancer
Apatinib,targets,TNBC
NCT05722795,sponsored_by,Vastra Gotaland Region
NCT05722795,has_status,RECRUITING
NCT05722795,tests,Imatinib 400 MG Oral Tablet
Imatinib 400 MG Oral Tablet,has_type,DRUG
Imatinib 400 MG Oral Tablet,classified_as,CHEMICAL
Imatinib 400 MG Oral Tablet,targets,breast cancer
Imatinib 400 MG Oral Tablet,targets,triple negative breast cancer
Imatinib 400 MG Oral Tablet,targets,TNBC
NCT05546255,sponsored_by,Chinese Academy of Medical Sciences
NCT05546255,has_status,UNKNOWN
NCT05546255,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
Eribulin Mesylate,classified_as,CHEMICAL
Eribulin Mesylate,targets,triple negative breast cancer
Eribulin Mesylate,targets,TNBC
NCT05546255,tests,Lobaplatin
Lobaplatin,has_type,DRUG
Lobaplatin,classified_as,CHEMICAL
Lobaplatin,targets,triple negative breast cancer
Lobaplatin,targets,TNBC
NCT03761914,sponsored_by,Sellas Life Sciences Group
NCT03761914,has_status,COMPLETED
NCT03761914,tests,galinpepimut-S
galinpepimut-S,has_type,DRUG
galinpepimut-S,classified_as,OTHER
galinpepimut-S,targets,ovarian cancer
galinpepimut-S,targets,acute myelogenous leukemia
galinpepimut-S,targets,small-cell lung cancer
galinpepimut-S,targets,triple-negative breast cancer
galinpepimut-S,targets,colorectal cancer
galinpepimut-S,targets,TNBC
NCT03761914,tests,pembrolizumab
pembrolizumab,has_type,DRUG
pembrolizumab,classified_as,BIOLOGIC
pembrolizumab,targets,ovarian cancer
pembrolizumab,targets,acute myelogenous leukemia
pembrolizumab,targets,small-cell lung cancer
pembrolizumab,targets,triple-negative breast cancer
pembrolizumab,targets,colorectal cancer
pembrolizumab,targets,TNBC
NCT03761914,tests,Montanide
Montanide,has_type,DRUG
Montanide,classified_as,OTHER
Montanide,targets,ovarian cancer
Montanide,targets,acute myelogenous leukemia
Montanide,targets,small-cell lung cancer
Montanide,targets,triple-negative breast cancer
Montanide,targets,colorectal cancer
Montanide,targets,TNBC
NCT03761914,tests,GM-CSF
GM-CSF,has_type,DRUG
GM-CSF,classified_as,OTHER
GM-CSF,targets,ovarian cancer
GM-CSF,targets,acute myelogenous leukemia
GM-CSF,targets,small-cell lung cancer
GM-CSF,targets,triple-negative breast cancer
GM-CSF,targets,colorectal cancer
GM-CSF,targets,TNBC
NCT05303038,sponsored_by,Fudan University
NCT05303038,has_status,UNKNOWN
NCT05303038,tests,Cryoablation Combined with Tirelizumab and Bevacizumab
Cryoablation Combined with Tirelizumab and Bevacizumab,has_type,DRUG
Cryoablation Combined with Tirelizumab and Bevacizumab,classified_as,BIOLOGIC
Cryoablation Combined with Tirelizumab and Bevacizumab,targets,metastatic breast cancer in the liver
NCT05582538,sponsored_by,IFOM ETS - The AIRC Institute of Molecular Oncology
NCT05582538,has_status,RECRUITING
NCT05582538,tests,Ceralasertib
Ceralasertib,has_type,DRUG
Ceralasertib,classified_as,CHEMICAL
Ceralasertib,targets,triple negative breast cancer metastatic
Ceralasertib,targets,TNBC
NCT05582538,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,triple negative breast cancer metastatic
Durvalumab,targets,TNBC
NCT05582538,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple negative breast cancer metastatic
Nab-paclitaxel,targets,TNBC
NCT02708680,sponsored_by,Syndax Pharmaceuticals
NCT02708680,has_status,COMPLETED
NCT02708680,tests,Entinostat
Entinostat,has_type,DRUG
Entinostat,classified_as,OTHER
Entinostat,targets,breast cancer
NCT02708680,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,breast cancer
NCT02708680,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,breast cancer
NCT02365662,sponsored_by,AbbVie
NCT02365662,has_status,TERMINATED
NCT02365662,tests,ABBV-221
ABBV-221,has_type,DRUG
ABBV-221,classified_as,OTHER
ABBV-221,targets,non-small cell lung cancer
ABBV-221,targets,glioblastoma multiforme
ABBV-221,targets,triple negative breast cancer
ABBV-221,targets,colorectal carcinoma
ABBV-221,targets,head and neck squamous cell carcinoma
ABBV-221,targets,TNBC
NCT04032080,sponsored_by,Baylor Research Institute
NCT04032080,has_status,COMPLETED
NCT04032080,tests,Drug 1: LY3023414; Drug 2: Prexasertib
Drug 1: LY3023414; Drug 2: Prexasertib,has_type,DRUG
Drug 1: LY3023414; Drug 2: Prexasertib,classified_as,CHEMICAL
Drug 1: LY3023414; Drug 2: Prexasertib,targets,triple negative breast cancer
Drug 1: LY3023414; Drug 2: Prexasertib,targets,TNBC
NCT03109080,sponsored_by,Institut Curie
NCT03109080,has_status,COMPLETED
NCT03109080,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,radiotherapy side effect
Olaparib,targets,breast neoplasm malignant female
Olaparib,targets,"breast neoplasms, triple-negative"
Olaparib,targets,TNBC
NCT03109080,tests,Radiation therapy
Radiation therapy,has_type,DRUG
Radiation therapy,classified_as,OTHER
Radiation therapy,targets,radiotherapy side effect
Radiation therapy,targets,breast neoplasm malignant female
Radiation therapy,targets,"breast neoplasms, triple-negative"
Radiation therapy,targets,TNBC
NCT06534762,sponsored_by,Zhejiang Provincial People's Hospital
NCT06534762,has_status,RECRUITING
NCT06534762,tests,Mirabegron
Mirabegron,has_type,DRUG
Mirabegron,classified_as,OTHER
Mirabegron,targets,nsclc
Mirabegron,targets,squamous cell carcinoma of head and neck
Mirabegron,targets,tnbc - triple-negative breast cancer
Mirabegron,targets,sclc
Mirabegron,targets,dlbcl - diffuse large b cell lymphoma
Mirabegron,targets,pancreas cancer
Mirabegron,targets,colorectal cancer
Mirabegron,targets,TNBC
NCT06125080,sponsored_by,Huihua Xiong
NCT06125080,has_status,RECRUITING
NCT06125080,tests,Utidelone
Utidelone,has_type,DRUG
Utidelone,classified_as,OTHER
Utidelone,targets,tnbc - triple-negative breast cancer
Utidelone,targets,TNBC
NCT06125080,tests,Tirelizumab
Tirelizumab,has_type,DRUG
Tirelizumab,classified_as,BIOLOGIC
Tirelizumab,targets,tnbc - triple-negative breast cancer
Tirelizumab,targets,TNBC
NCT06125080,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,tnbc - triple-negative breast cancer
Bevacizumab,targets,TNBC
NCT03075462,sponsored_by,"Jiangsu HengRui Medicine Co., Ltd."
NCT03075462,has_status,COMPLETED
NCT03075462,tests,Fluzoparib
Fluzoparib,has_type,DRUG
Fluzoparib,classified_as,CHEMICAL
Fluzoparib,targets,ovarian cancer
Fluzoparib,targets,triple negative breast cancer
Fluzoparib,targets,TNBC
NCT03075462,tests,Apatinib
Apatinib,has_type,DRUG
Apatinib,classified_as,CHEMICAL
Apatinib,targets,ovarian cancer
Apatinib,targets,triple negative breast cancer
Apatinib,targets,TNBC
NCT01693562,sponsored_by,MedImmune LLC
NCT01693562,has_status,COMPLETED
NCT01693562,tests,MEDI4736
MEDI4736,has_type,DRUG
MEDI4736,classified_as,OTHER
MEDI4736,targets,advanced solid tumors
NCT04095689,sponsored_by,The Methodist Hospital Research Institute
NCT04095689,has_status,SUSPENDED
NCT04095689,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,anthracycline-refractory tnbc
Docetaxel,targets,triple negative breast cancer
Docetaxel,targets,TNBC
NCT04095689,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,anthracycline-refractory tnbc
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT04095689,tests,IL-12 gene therapy
IL-12 gene therapy,has_type,DRUG
IL-12 gene therapy,classified_as,BIOLOGIC
IL-12 gene therapy,targets,anthracycline-refractory tnbc
IL-12 gene therapy,targets,triple negative breast cancer
IL-12 gene therapy,targets,TNBC
NCT06171789,sponsored_by,Genmab
NCT06171789,has_status,RECRUITING
NCT06171789,tests,GEN1107
GEN1107,has_type,DRUG
GEN1107,classified_as,OTHER
GEN1107,targets,non-small cell lung cancer
GEN1107,targets,urothelial carcinoma
GEN1107,targets,ovarian cancer
GEN1107,targets,triple negative breast cancer
GEN1107,targets,gastroesophageal cancer
GEN1107,targets,endometrial cancer
GEN1107,targets,TNBC
NCT05712889,sponsored_by,"Vincerx Pharma, Inc."
NCT05712889,has_status,COMPLETED
NCT05712889,tests,VIP236 (Q3W)
VIP236 (Q3W),has_type,DRUG
VIP236 (Q3W),classified_as,OTHER
VIP236 (Q3W),targets,neoplasms
NCT05712889,tests,VIP236 (Q2W)
VIP236 (Q2W),has_type,DRUG
VIP236 (Q2W),classified_as,OTHER
VIP236 (Q2W),targets,neoplasms
NCT05209529,sponsored_by,European Organisation for Research and Treatment of Cancer - EORTC
NCT05209529,has_status,WITHDRAWN
NCT05209529,tests,olaparib
olaparib,has_type,DRUG
olaparib,classified_as,BIOLOGIC
olaparib,targets,brca2 mutation
olaparib,targets,tnbc - triple-negative breast cancer
olaparib,targets,brca1 mutation
olaparib,targets,TNBC
NCT05209529,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,brca2 mutation
Durvalumab,targets,tnbc - triple-negative breast cancer
Durvalumab,targets,brca1 mutation
Durvalumab,targets,TNBC
NCT02368691,sponsored_by,GTx
NCT02368691,has_status,TERMINATED
NCT02368691,tests,GTx-024
GTx-024,has_type,DRUG
GTx-024,classified_as,OTHER
GTx-024,targets,triple negative breast cancer
GTx-024,targets,TNBC
NCT04762901,sponsored_by,Wake Forest University Health Sciences
NCT04762901,has_status,WITHDRAWN
NCT04762901,tests,Niraparib
Niraparib,has_type,DRUG
Niraparib,classified_as,CHEMICAL
Niraparib,targets,breast cancer
NCT04762901,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,breast cancer
NCT04762901,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
NCT04762901,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT04762901,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
Pegfilgrastim,classified_as,OTHER
Pegfilgrastim,targets,breast cancer
NCT04762901,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
NCT04755868,sponsored_by,Yonsei University
NCT04755868,has_status,UNKNOWN
NCT04755868,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,tnbc - triple-negative breast cancer
Talazoparib,targets,TNBC
NCT04755868,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,tnbc - triple-negative breast cancer
Placebo,targets,TNBC
NCT05552001,sponsored_by,UNICANCER
NCT05552001,has_status,RECRUITING
NCT05552001,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
Sacituzumab govitecan,classified_as,BIOLOGIC
Sacituzumab govitecan,targets,metastatic breast cancer
Sacituzumab govitecan,targets,triple negative breast cancer
Sacituzumab govitecan,targets,TNBC
NCT03358004,sponsored_by,Mario Negri Institute for Pharmacological Research
NCT03358004,has_status,TERMINATED
NCT03358004,tests,Vinorelbine Tartrate
Vinorelbine Tartrate,has_type,DRUG
Vinorelbine Tartrate,classified_as,OTHER
Vinorelbine Tartrate,targets,triple negative breast cancer
Vinorelbine Tartrate,targets,TNBC
NCT03358004,tests,Capecitabine 500 MG
Capecitabine 500 MG,has_type,DRUG
Capecitabine 500 MG,classified_as,CHEMICAL
Capecitabine 500 MG,targets,triple negative breast cancer
Capecitabine 500 MG,targets,TNBC
NCT05154201,sponsored_by,"Orinove, Inc."
NCT05154201,has_status,COMPLETED
NCT05154201,tests,ORIN1001
ORIN1001,has_type,DRUG
ORIN1001,classified_as,OTHER
ORIN1001,targets,effect of drug
NCT05541367,sponsored_by,Tongji Hospital
NCT05541367,has_status,RECRUITING
NCT07038369,sponsored_by,"Atavistik Bio, Inc"
NCT07038369,has_status,NOT_YET_RECRUITING
NCT07038369,tests,ATV-1601
ATV-1601,has_type,DRUG
ATV-1601,classified_as,OTHER
ATV-1601,targets,endometrial neoplasm
ATV-1601,targets,breast carcinoma
ATV-1601,targets,ovarian carcinoma
ATV-1601,targets,gynecologic cancers
ATV-1601,targets,uterine neoplasms
ATV-1601,targets,solid tumors
ATV-1601,targets,fallopian cancer
ATV-1601,targets,ovarian neoplasms
ATV-1601,targets,neoplasms by site
ATV-1601,targets,prostate carcinoma
ATV-1601,targets,breast cancer
ATV-1601,targets,breast neoplasms
ATV-1601,targets,triple negative breast cancer
ATV-1601,targets,prostate cancers
ATV-1601,targets,neoplasms
ATV-1601,targets,gynecologic neoplasm
ATV-1601,targets,endometrial carcinoma (ec)
ATV-1601,targets,cervical carcinoma
ATV-1601,targets,breast diseases
ATV-1601,targets,"genital neoplasms, female"
ATV-1601,targets,advanced solid tumors
ATV-1601,targets,ovarian cancer
ATV-1601,targets,er positive breast cancer
ATV-1601,targets,endometrial cancer
ATV-1601,targets,urogenital neoplasms
ATV-1601,targets,cervical neoplasms
ATV-1601,targets,cervical cancers
ATV-1601,targets,TNBC
NCT07038369,tests,ATV-1601 + Fulvestrant
ATV-1601 + Fulvestrant,has_type,DRUG
ATV-1601 + Fulvestrant,classified_as,BIOLOGIC
ATV-1601 + Fulvestrant,targets,endometrial neoplasm
ATV-1601 + Fulvestrant,targets,breast carcinoma
ATV-1601 + Fulvestrant,targets,ovarian carcinoma
ATV-1601 + Fulvestrant,targets,gynecologic cancers
ATV-1601 + Fulvestrant,targets,uterine neoplasms
ATV-1601 + Fulvestrant,targets,solid tumors
ATV-1601 + Fulvestrant,targets,fallopian cancer
ATV-1601 + Fulvestrant,targets,ovarian neoplasms
ATV-1601 + Fulvestrant,targets,neoplasms by site
ATV-1601 + Fulvestrant,targets,prostate carcinoma
ATV-1601 + Fulvestrant,targets,breast cancer
ATV-1601 + Fulvestrant,targets,breast neoplasms
ATV-1601 + Fulvestrant,targets,triple negative breast cancer
ATV-1601 + Fulvestrant,targets,prostate cancers
ATV-1601 + Fulvestrant,targets,neoplasms
ATV-1601 + Fulvestrant,targets,gynecologic neoplasm
ATV-1601 + Fulvestrant,targets,endometrial carcinoma (ec)
ATV-1601 + Fulvestrant,targets,cervical carcinoma
ATV-1601 + Fulvestrant,targets,breast diseases
ATV-1601 + Fulvestrant,targets,"genital neoplasms, female"
ATV-1601 + Fulvestrant,targets,advanced solid tumors
ATV-1601 + Fulvestrant,targets,ovarian cancer
ATV-1601 + Fulvestrant,targets,er positive breast cancer
ATV-1601 + Fulvestrant,targets,endometrial cancer
ATV-1601 + Fulvestrant,targets,urogenital neoplasms
ATV-1601 + Fulvestrant,targets,cervical neoplasms
ATV-1601 + Fulvestrant,targets,cervical cancers
ATV-1601 + Fulvestrant,targets,TNBC
NCT06347068,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT06347068,has_status,RECRUITING
NCT06347068,tests,iC9-CAR.B7-H3 T Cell Therapy
iC9-CAR.B7-H3 T Cell Therapy,has_type,DRUG
iC9-CAR.B7-H3 T Cell Therapy,classified_as,BIOLOGIC
iC9-CAR.B7-H3 T Cell Therapy,targets,breast cancer
iC9-CAR.B7-H3 T Cell Therapy,targets,relapse
iC9-CAR.B7-H3 T Cell Therapy,targets,resistant cancer
iC9-CAR.B7-H3 T Cell Therapy,targets,triple negative breast cancer
iC9-CAR.B7-H3 T Cell Therapy,targets,TNBC
NCT06347068,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
cyclophosphamide,classified_as,CHEMICAL
cyclophosphamide,targets,breast cancer
cyclophosphamide,targets,relapse
cyclophosphamide,targets,resistant cancer
cyclophosphamide,targets,triple negative breast cancer
cyclophosphamide,targets,TNBC
NCT06347068,tests,fludarabine
fludarabine,has_type,DRUG
fludarabine,classified_as,OTHER
fludarabine,targets,breast cancer
fludarabine,targets,relapse
fludarabine,targets,resistant cancer
fludarabine,targets,triple negative breast cancer
fludarabine,targets,TNBC
NCT05953168,sponsored_by,Fudan University
NCT05953168,has_status,NOT_YET_RECRUITING
NCT05953168,tests,Trastuzumab Deruxtecan
Trastuzumab Deruxtecan,has_type,DRUG
Trastuzumab Deruxtecan,classified_as,BIOLOGIC
Trastuzumab Deruxtecan,targets,triple-negative breast cancer
Trastuzumab Deruxtecan,targets,TNBC
NCT05082610,sponsored_by,Hummingbird Bioscience
NCT05082610,has_status,ACTIVE_NOT_RECRUITING
NCT05082610,tests,HMBD-002
HMBD-002,has_type,DRUG
HMBD-002,classified_as,OTHER
HMBD-002,targets,nonsmall cell lung cancer
HMBD-002,targets,malignant neoplasm
HMBD-002,targets,metastatic cancer
HMBD-002,targets,advanced solid tumor
HMBD-002,targets,cancer
HMBD-002,targets,"tumor, solid"
HMBD-002,targets,triple negative breast cancer
HMBD-002,targets,TNBC
NCT05082610,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,nonsmall cell lung cancer
Pembrolizumab,targets,malignant neoplasm
Pembrolizumab,targets,metastatic cancer
Pembrolizumab,targets,advanced solid tumor
Pembrolizumab,targets,cancer
Pembrolizumab,targets,"tumor, solid"
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT03801369,sponsored_by,"Gordon Mills, MD, PhD"
NCT03801369,has_status,TERMINATED
NCT03801369,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,metastatic triple-negative breast carcinoma
Biopsy,targets,anatomic stage iv breast cancer ajcc v8
Biopsy,targets,TNBC
NCT03801369,tests,Capivasertib
Capivasertib,has_type,DRUG
Capivasertib,classified_as,CHEMICAL
Capivasertib,targets,metastatic triple-negative breast carcinoma
Capivasertib,targets,anatomic stage iv breast cancer ajcc v8
Capivasertib,targets,TNBC
NCT03801369,tests,Ceralasertib
Ceralasertib,has_type,DRUG
Ceralasertib,classified_as,CHEMICAL
Ceralasertib,targets,metastatic triple-negative breast carcinoma
Ceralasertib,targets,anatomic stage iv breast cancer ajcc v8
Ceralasertib,targets,TNBC
NCT03801369,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,metastatic triple-negative breast carcinoma
Durvalumab,targets,anatomic stage iv breast cancer ajcc v8
Durvalumab,targets,TNBC
NCT03801369,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,metastatic triple-negative breast carcinoma
Olaparib,targets,anatomic stage iv breast cancer ajcc v8
Olaparib,targets,TNBC
NCT03801369,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,DRUG
Quality-of-Life Assessment,classified_as,OTHER
Quality-of-Life Assessment,targets,metastatic triple-negative breast carcinoma
Quality-of-Life Assessment,targets,anatomic stage iv breast cancer ajcc v8
Quality-of-Life Assessment,targets,TNBC
NCT03801369,tests,Selumetinib
Selumetinib,has_type,DRUG
Selumetinib,classified_as,CHEMICAL
Selumetinib,targets,metastatic triple-negative breast carcinoma
Selumetinib,targets,anatomic stage iv breast cancer ajcc v8
Selumetinib,targets,TNBC
NCT04504669,sponsored_by,AstraZeneca
NCT04504669,has_status,COMPLETED
NCT04504669,tests,AZD8701
AZD8701,has_type,DRUG
AZD8701,classified_as,OTHER
AZD8701,targets,melanoma
AZD8701,targets,non-small-cell lung cancer
AZD8701,targets,squamous cell cancer of head and neck
AZD8701,targets,gastroesophageal cancer
AZD8701,targets,advanced solid tumours
AZD8701,targets,triple negative breast neoplasms
AZD8701,targets,cervical cancer
AZD8701,targets,clear cell renal cell cancer
AZD8701,targets,small cell lung cancer
AZD8701,targets,TNBC
NCT04504669,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,melanoma
Durvalumab,targets,non-small-cell lung cancer
Durvalumab,targets,squamous cell cancer of head and neck
Durvalumab,targets,gastroesophageal cancer
Durvalumab,targets,advanced solid tumours
Durvalumab,targets,triple negative breast neoplasms
Durvalumab,targets,cervical cancer
Durvalumab,targets,clear cell renal cell cancer
Durvalumab,targets,small cell lung cancer
Durvalumab,targets,TNBC
NCT03219268,sponsored_by,MacroGenics
NCT03219268,has_status,COMPLETED
NCT03219268,tests,tebotelimab 1 mg
tebotelimab 1 mg,has_type,DRUG
tebotelimab 1 mg,classified_as,BIOLOGIC
tebotelimab 1 mg,targets,hematologic neoplasms
tebotelimab 1 mg,targets,advanced solid tumors
tebotelimab 1 mg,targets,squamous cell carcinoma of head and neck
tebotelimab 1 mg,targets,ovarian cancer
tebotelimab 1 mg,targets,tnbc - triple-negative breast cancer
tebotelimab 1 mg,targets,cervical cancer
tebotelimab 1 mg,targets,small-cell lung cancer
tebotelimab 1 mg,targets,cholangiocarcinoma
tebotelimab 1 mg,targets,non small cell lung cancer
tebotelimab 1 mg,targets,her2-positive advanced solid tumors
tebotelimab 1 mg,targets,TNBC
NCT03219268,tests,tebotelimab 3 mg
tebotelimab 3 mg,has_type,DRUG
tebotelimab 3 mg,classified_as,BIOLOGIC
tebotelimab 3 mg,targets,hematologic neoplasms
tebotelimab 3 mg,targets,advanced solid tumors
tebotelimab 3 mg,targets,squamous cell carcinoma of head and neck
tebotelimab 3 mg,targets,ovarian cancer
tebotelimab 3 mg,targets,tnbc - triple-negative breast cancer
tebotelimab 3 mg,targets,cervical cancer
tebotelimab 3 mg,targets,small-cell lung cancer
tebotelimab 3 mg,targets,cholangiocarcinoma
tebotelimab 3 mg,targets,non small cell lung cancer
tebotelimab 3 mg,targets,her2-positive advanced solid tumors
tebotelimab 3 mg,targets,TNBC
NCT03219268,tests,tebotelimab 10 mg
tebotelimab 10 mg,has_type,DRUG
tebotelimab 10 mg,classified_as,BIOLOGIC
tebotelimab 10 mg,targets,hematologic neoplasms
tebotelimab 10 mg,targets,advanced solid tumors
tebotelimab 10 mg,targets,squamous cell carcinoma of head and neck
tebotelimab 10 mg,targets,ovarian cancer
tebotelimab 10 mg,targets,tnbc - triple-negative breast cancer
tebotelimab 10 mg,targets,cervical cancer
tebotelimab 10 mg,targets,small-cell lung cancer
tebotelimab 10 mg,targets,cholangiocarcinoma
tebotelimab 10 mg,targets,non small cell lung cancer
tebotelimab 10 mg,targets,her2-positive advanced solid tumors
tebotelimab 10 mg,targets,TNBC
NCT03219268,tests,tebotelimab 30 mg
tebotelimab 30 mg,has_type,DRUG
tebotelimab 30 mg,classified_as,BIOLOGIC
tebotelimab 30 mg,targets,hematologic neoplasms
tebotelimab 30 mg,targets,advanced solid tumors
tebotelimab 30 mg,targets,squamous cell carcinoma of head and neck
tebotelimab 30 mg,targets,ovarian cancer
tebotelimab 30 mg,targets,tnbc - triple-negative breast cancer
tebotelimab 30 mg,targets,cervical cancer
tebotelimab 30 mg,targets,small-cell lung cancer
tebotelimab 30 mg,targets,cholangiocarcinoma
tebotelimab 30 mg,targets,non small cell lung cancer
tebotelimab 30 mg,targets,her2-positive advanced solid tumors
tebotelimab 30 mg,targets,TNBC
NCT03219268,tests,tebotelimab 120 mg
tebotelimab 120 mg,has_type,DRUG
tebotelimab 120 mg,classified_as,BIOLOGIC
tebotelimab 120 mg,targets,hematologic neoplasms
tebotelimab 120 mg,targets,advanced solid tumors
tebotelimab 120 mg,targets,squamous cell carcinoma of head and neck
tebotelimab 120 mg,targets,ovarian cancer
tebotelimab 120 mg,targets,tnbc - triple-negative breast cancer
tebotelimab 120 mg,targets,cervical cancer
tebotelimab 120 mg,targets,small-cell lung cancer
tebotelimab 120 mg,targets,cholangiocarcinoma
tebotelimab 120 mg,targets,non small cell lung cancer
tebotelimab 120 mg,targets,her2-positive advanced solid tumors
tebotelimab 120 mg,targets,TNBC
NCT03219268,tests,tebotelimab 300 mg
tebotelimab 300 mg,has_type,DRUG
tebotelimab 300 mg,classified_as,BIOLOGIC
tebotelimab 300 mg,targets,hematologic neoplasms
tebotelimab 300 mg,targets,advanced solid tumors
tebotelimab 300 mg,targets,squamous cell carcinoma of head and neck
tebotelimab 300 mg,targets,ovarian cancer
tebotelimab 300 mg,targets,tnbc - triple-negative breast cancer
tebotelimab 300 mg,targets,cervical cancer
tebotelimab 300 mg,targets,small-cell lung cancer
tebotelimab 300 mg,targets,cholangiocarcinoma
tebotelimab 300 mg,targets,non small cell lung cancer
tebotelimab 300 mg,targets,her2-positive advanced solid tumors
tebotelimab 300 mg,targets,TNBC
NCT03219268,tests,tebotelimab 400 mg
tebotelimab 400 mg,has_type,DRUG
tebotelimab 400 mg,classified_as,BIOLOGIC
tebotelimab 400 mg,targets,hematologic neoplasms
tebotelimab 400 mg,targets,advanced solid tumors
tebotelimab 400 mg,targets,squamous cell carcinoma of head and neck
tebotelimab 400 mg,targets,ovarian cancer
tebotelimab 400 mg,targets,tnbc - triple-negative breast cancer
tebotelimab 400 mg,targets,cervical cancer
tebotelimab 400 mg,targets,small-cell lung cancer
tebotelimab 400 mg,targets,cholangiocarcinoma
tebotelimab 400 mg,targets,non small cell lung cancer
tebotelimab 400 mg,targets,her2-positive advanced solid tumors
tebotelimab 400 mg,targets,TNBC
NCT03219268,tests,tebotelimab 600 mg
tebotelimab 600 mg,has_type,DRUG
tebotelimab 600 mg,classified_as,BIOLOGIC
tebotelimab 600 mg,targets,hematologic neoplasms
tebotelimab 600 mg,targets,advanced solid tumors
tebotelimab 600 mg,targets,squamous cell carcinoma of head and neck
tebotelimab 600 mg,targets,ovarian cancer
tebotelimab 600 mg,targets,tnbc - triple-negative breast cancer
tebotelimab 600 mg,targets,cervical cancer
tebotelimab 600 mg,targets,small-cell lung cancer
tebotelimab 600 mg,targets,cholangiocarcinoma
tebotelimab 600 mg,targets,non small cell lung cancer
tebotelimab 600 mg,targets,her2-positive advanced solid tumors
tebotelimab 600 mg,targets,TNBC
NCT03219268,tests,tebotelimab 800 mg
tebotelimab 800 mg,has_type,DRUG
tebotelimab 800 mg,classified_as,BIOLOGIC
tebotelimab 800 mg,targets,hematologic neoplasms
tebotelimab 800 mg,targets,advanced solid tumors
tebotelimab 800 mg,targets,squamous cell carcinoma of head and neck
tebotelimab 800 mg,targets,ovarian cancer
tebotelimab 800 mg,targets,tnbc - triple-negative breast cancer
tebotelimab 800 mg,targets,cervical cancer
tebotelimab 800 mg,targets,small-cell lung cancer
tebotelimab 800 mg,targets,cholangiocarcinoma
tebotelimab 800 mg,targets,non small cell lung cancer
tebotelimab 800 mg,targets,her2-positive advanced solid tumors
tebotelimab 800 mg,targets,TNBC
NCT03219268,tests,tebotelimab 1200 mg
tebotelimab 1200 mg,has_type,DRUG
tebotelimab 1200 mg,classified_as,BIOLOGIC
tebotelimab 1200 mg,targets,hematologic neoplasms
tebotelimab 1200 mg,targets,advanced solid tumors
tebotelimab 1200 mg,targets,squamous cell carcinoma of head and neck
tebotelimab 1200 mg,targets,ovarian cancer
tebotelimab 1200 mg,targets,tnbc - triple-negative breast cancer
tebotelimab 1200 mg,targets,cervical cancer
tebotelimab 1200 mg,targets,small-cell lung cancer
tebotelimab 1200 mg,targets,cholangiocarcinoma
tebotelimab 1200 mg,targets,non small cell lung cancer
tebotelimab 1200 mg,targets,her2-positive advanced solid tumors
tebotelimab 1200 mg,targets,TNBC
NCT03219268,tests,margetuximab
margetuximab,has_type,DRUG
margetuximab,classified_as,BIOLOGIC
margetuximab,targets,hematologic neoplasms
margetuximab,targets,advanced solid tumors
margetuximab,targets,squamous cell carcinoma of head and neck
margetuximab,targets,ovarian cancer
margetuximab,targets,tnbc - triple-negative breast cancer
margetuximab,targets,cervical cancer
margetuximab,targets,small-cell lung cancer
margetuximab,targets,cholangiocarcinoma
margetuximab,targets,non small cell lung cancer
margetuximab,targets,her2-positive advanced solid tumors
margetuximab,targets,TNBC
NCT06059469,sponsored_by,Jules Bordet Institute
NCT06059469,has_status,RECRUITING
NCT06059469,tests,Ga-PSMA PET/CT
Ga-PSMA PET/CT,has_type,DRUG
Ga-PSMA PET/CT,classified_as,OTHER
Ga-PSMA PET/CT,targets,tnbc - triple-negative breast cancer
Ga-PSMA PET/CT,targets,TNBC
NCT06926868,sponsored_by,Bristol-Myers Squibb
NCT06926868,has_status,NOT_YET_RECRUITING
NCT06926868,tests,Iza-bren
Iza-bren,has_type,DRUG
Iza-bren,classified_as,OTHER
Iza-bren,targets,breast neoplasms
NCT06926868,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,breast neoplasms
NCT06926868,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast neoplasms
NCT06926868,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast neoplasms
NCT06926868,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast neoplasms
NCT06926868,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,breast neoplasms
NCT03579472,sponsored_by,M.D. Anderson Cancer Center
NCT03579472,has_status,TERMINATED
NCT03579472,tests,Bintrafusp Alfa
Bintrafusp Alfa,has_type,DRUG
Bintrafusp Alfa,classified_as,OTHER
Bintrafusp Alfa,targets,metastatic triple-negative breast carcinoma
Bintrafusp Alfa,targets,prognostic stage iv breast cancer ajcc v8
Bintrafusp Alfa,targets,anatomic stage iv breast cancer ajcc v8
Bintrafusp Alfa,targets,TNBC
NCT03579472,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
Eribulin Mesylate,classified_as,CHEMICAL
Eribulin Mesylate,targets,metastatic triple-negative breast carcinoma
Eribulin Mesylate,targets,prognostic stage iv breast cancer ajcc v8
Eribulin Mesylate,targets,anatomic stage iv breast cancer ajcc v8
Eribulin Mesylate,targets,TNBC
NCT03709446,sponsored_by,Joseph Sparano
NCT03709446,has_status,ACTIVE_NOT_RECRUITING
NCT03709446,tests,Leflunomide
Leflunomide,has_type,DRUG
Leflunomide,classified_as,OTHER
Leflunomide,targets,breast neoplasms
Leflunomide,targets,breast diseases
Leflunomide,targets,metastatic triple negative breast cancer
Leflunomide,targets,TNBC
NCT06229067,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT06229067,has_status,NOT_YET_RECRUITING
NCT06229067,tests,Adebrelimab
Adebrelimab,has_type,DRUG
Adebrelimab,classified_as,BIOLOGIC
Adebrelimab,targets,breast cancer
Adebrelimab,targets,triple negative breast cancer
Adebrelimab,targets,TNBC
NCT06229067,tests,Vinorelbine
Vinorelbine,has_type,DRUG
Vinorelbine,classified_as,OTHER
Vinorelbine,targets,breast cancer
Vinorelbine,targets,triple negative breast cancer
Vinorelbine,targets,TNBC
NCT06229067,tests,Cyclophosphamide (tablet)
Cyclophosphamide (tablet),has_type,DRUG
Cyclophosphamide (tablet),classified_as,CHEMICAL
Cyclophosphamide (tablet),targets,breast cancer
Cyclophosphamide (tablet),targets,triple negative breast cancer
Cyclophosphamide (tablet),targets,TNBC
NCT06229067,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT03199040,sponsored_by,Washington University School of Medicine
NCT03199040,has_status,TERMINATED
NCT03199040,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,tnbc - triple-negative breast cancer
Durvalumab,targets,triple negative breast neoplasms
Durvalumab,targets,triple-negative breast carcinoma
Durvalumab,targets,triple negative breast cancer
Durvalumab,targets,TNBC
NCT03199040,tests,Neoantigen DNA vaccine
Neoantigen DNA vaccine,has_type,DRUG
Neoantigen DNA vaccine,classified_as,BIOLOGIC
Neoantigen DNA vaccine,targets,tnbc - triple-negative breast cancer
Neoantigen DNA vaccine,targets,triple negative breast neoplasms
Neoantigen DNA vaccine,targets,triple-negative breast carcinoma
Neoantigen DNA vaccine,targets,triple negative breast cancer
Neoantigen DNA vaccine,targets,TNBC
NCT03199040,tests,TDS-IM system (Inchor Medical Systems)
TDS-IM system (Inchor Medical Systems),has_type,DRUG
TDS-IM system (Inchor Medical Systems),classified_as,OTHER
TDS-IM system (Inchor Medical Systems),targets,tnbc - triple-negative breast cancer
TDS-IM system (Inchor Medical Systems),targets,triple negative breast neoplasms
TDS-IM system (Inchor Medical Systems),targets,triple-negative breast carcinoma
TDS-IM system (Inchor Medical Systems),targets,triple negative breast cancer
TDS-IM system (Inchor Medical Systems),targets,TNBC
NCT03199040,tests,Peripheral blood draw
Peripheral blood draw,has_type,DRUG
Peripheral blood draw,classified_as,OTHER
Peripheral blood draw,targets,tnbc - triple-negative breast cancer
Peripheral blood draw,targets,triple negative breast neoplasms
Peripheral blood draw,targets,triple-negative breast carcinoma
Peripheral blood draw,targets,triple negative breast cancer
Peripheral blood draw,targets,TNBC
NCT04249167,sponsored_by,Mayo Clinic
NCT04249167,has_status,WITHDRAWN
NCT04249167,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,locally advanced breast carcinoma
Atezolizumab,targets,anatomic stage iiia breast cancer ajcc v8
Atezolizumab,targets,prognostic stage iiic breast cancer ajcc v8
Atezolizumab,targets,anatomic stage iv breast cancer ajcc v8
Atezolizumab,targets,anatomic stage iiib breast cancer ajcc v8
Atezolizumab,targets,metastatic triple-negative breast carcinoma
Atezolizumab,targets,prognostic stage iiib breast cancer ajcc v8
Atezolizumab,targets,anatomic stage iiic breast cancer ajcc v8
Atezolizumab,targets,anatomic stage iii breast cancer ajcc v8
Atezolizumab,targets,prognostic stage iii breast cancer ajcc v8
Atezolizumab,targets,prognostic stage iv breast cancer ajcc v8
Atezolizumab,targets,prognostic stage iiia breast cancer ajcc v8
Atezolizumab,targets,TNBC
NCT04249167,tests,Cryosurgery
Cryosurgery,has_type,DRUG
Cryosurgery,classified_as,OTHER
Cryosurgery,targets,locally advanced breast carcinoma
Cryosurgery,targets,anatomic stage iiia breast cancer ajcc v8
Cryosurgery,targets,prognostic stage iiic breast cancer ajcc v8
Cryosurgery,targets,anatomic stage iv breast cancer ajcc v8
Cryosurgery,targets,anatomic stage iiib breast cancer ajcc v8
Cryosurgery,targets,metastatic triple-negative breast carcinoma
Cryosurgery,targets,prognostic stage iiib breast cancer ajcc v8
Cryosurgery,targets,anatomic stage iiic breast cancer ajcc v8
Cryosurgery,targets,anatomic stage iii breast cancer ajcc v8
Cryosurgery,targets,prognostic stage iii breast cancer ajcc v8
Cryosurgery,targets,prognostic stage iv breast cancer ajcc v8
Cryosurgery,targets,prognostic stage iiia breast cancer ajcc v8
Cryosurgery,targets,TNBC
NCT04249167,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,locally advanced breast carcinoma
Nab-paclitaxel,targets,anatomic stage iiia breast cancer ajcc v8
Nab-paclitaxel,targets,prognostic stage iiic breast cancer ajcc v8
Nab-paclitaxel,targets,anatomic stage iv breast cancer ajcc v8
Nab-paclitaxel,targets,anatomic stage iiib breast cancer ajcc v8
Nab-paclitaxel,targets,metastatic triple-negative breast carcinoma
Nab-paclitaxel,targets,prognostic stage iiib breast cancer ajcc v8
Nab-paclitaxel,targets,anatomic stage iiic breast cancer ajcc v8
Nab-paclitaxel,targets,anatomic stage iii breast cancer ajcc v8
Nab-paclitaxel,targets,prognostic stage iii breast cancer ajcc v8
Nab-paclitaxel,targets,prognostic stage iv breast cancer ajcc v8
Nab-paclitaxel,targets,prognostic stage iiia breast cancer ajcc v8
Nab-paclitaxel,targets,TNBC
NCT04464967,sponsored_by,"NKGen Biotech, Inc."
NCT04464967,has_status,WITHDRAWN
NCT04464967,tests,SNK01
SNK01,has_type,DRUG
SNK01,classified_as,OTHER
SNK01,targets,metastatic cancer
SNK01,targets,pancreatic cancer
SNK01,targets,egf-r positive non-small cell lung cancer
SNK01,targets,advanced solid tumor
SNK01,targets,ovarian cancer
SNK01,targets,sarcoma
SNK01,targets,triple negative breast cancer
SNK01,targets,her2-positive breast cancer
SNK01,targets,her-2 protein overexpression
SNK01,targets,bladder cancer
SNK01,targets,esophageal cancer
SNK01,targets,cervical cancer
SNK01,targets,head and neck squamous cell carcinoma
SNK01,targets,endometrium cancer
SNK01,targets,her2-positive gastric cancer
SNK01,targets,non small cell lung cancer
SNK01,targets,colorectal cancer
SNK01,targets,TNBC
NCT04464967,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,metastatic cancer
Trastuzumab,targets,pancreatic cancer
Trastuzumab,targets,egf-r positive non-small cell lung cancer
Trastuzumab,targets,advanced solid tumor
Trastuzumab,targets,ovarian cancer
Trastuzumab,targets,sarcoma
Trastuzumab,targets,triple negative breast cancer
Trastuzumab,targets,her2-positive breast cancer
Trastuzumab,targets,her-2 protein overexpression
Trastuzumab,targets,bladder cancer
Trastuzumab,targets,esophageal cancer
Trastuzumab,targets,cervical cancer
Trastuzumab,targets,head and neck squamous cell carcinoma
Trastuzumab,targets,endometrium cancer
Trastuzumab,targets,her2-positive gastric cancer
Trastuzumab,targets,non small cell lung cancer
Trastuzumab,targets,colorectal cancer
Trastuzumab,targets,TNBC
NCT04464967,tests,Cetuximab
Cetuximab,has_type,DRUG
Cetuximab,classified_as,BIOLOGIC
Cetuximab,targets,metastatic cancer
Cetuximab,targets,pancreatic cancer
Cetuximab,targets,egf-r positive non-small cell lung cancer
Cetuximab,targets,advanced solid tumor
Cetuximab,targets,ovarian cancer
Cetuximab,targets,sarcoma
Cetuximab,targets,triple negative breast cancer
Cetuximab,targets,her2-positive breast cancer
Cetuximab,targets,her-2 protein overexpression
Cetuximab,targets,bladder cancer
Cetuximab,targets,esophageal cancer
Cetuximab,targets,cervical cancer
Cetuximab,targets,head and neck squamous cell carcinoma
Cetuximab,targets,endometrium cancer
Cetuximab,targets,her2-positive gastric cancer
Cetuximab,targets,non small cell lung cancer
Cetuximab,targets,colorectal cancer
Cetuximab,targets,TNBC
NCT04282044,sponsored_by,BioEclipse Therapeutics
NCT04282044,has_status,RECRUITING
NCT04282044,tests,CRX100 suspension for infusion
CRX100 suspension for infusion,has_type,DRUG
CRX100 suspension for infusion,classified_as,OTHER
CRX100 suspension for infusion,targets,gastric cancer
CRX100 suspension for infusion,targets,non-small cell lung cancer
CRX100 suspension for infusion,targets,"solid tumor, adult"
CRX100 suspension for infusion,targets,hepatocellular carcinoma
CRX100 suspension for infusion,targets,triple negative breast cancer
CRX100 suspension for infusion,targets,malignant melanoma
CRX100 suspension for infusion,targets,epithelial ovarian cancer
CRX100 suspension for infusion,targets,osteosarcoma
CRX100 suspension for infusion,targets,colorectal cancer
CRX100 suspension for infusion,targets,TNBC
NCT04282044,tests,Fludarabine
Fludarabine,has_type,DRUG
Fludarabine,classified_as,OTHER
Fludarabine,targets,gastric cancer
Fludarabine,targets,non-small cell lung cancer
Fludarabine,targets,"solid tumor, adult"
Fludarabine,targets,hepatocellular carcinoma
Fludarabine,targets,triple negative breast cancer
Fludarabine,targets,malignant melanoma
Fludarabine,targets,epithelial ovarian cancer
Fludarabine,targets,osteosarcoma
Fludarabine,targets,colorectal cancer
Fludarabine,targets,TNBC
NCT04282044,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,gastric cancer
Cyclophosphamide,targets,non-small cell lung cancer
Cyclophosphamide,targets,"solid tumor, adult"
Cyclophosphamide,targets,hepatocellular carcinoma
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,malignant melanoma
Cyclophosphamide,targets,epithelial ovarian cancer
Cyclophosphamide,targets,osteosarcoma
Cyclophosphamide,targets,colorectal cancer
Cyclophosphamide,targets,TNBC
NCT04445844,sponsored_by,"Mridula George, MD"
NCT04445844,has_status,ACTIVE_NOT_RECRUITING
NCT04445844,tests,Pelareorep
Pelareorep,has_type,DRUG
Pelareorep,classified_as,OTHER
Pelareorep,targets,locally advanced breast carcinoma
Pelareorep,targets,anatomic stage iv breast cancer ajcc v8
Pelareorep,targets,metastatic triple-negative breast carcinoma
Pelareorep,targets,prognostic stage iv breast cancer ajcc v8
Pelareorep,targets,triple-negative breast cancer
Pelareorep,targets,TNBC
NCT04445844,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,DRUG
Quality-of-Life Assessment,classified_as,OTHER
Quality-of-Life Assessment,targets,locally advanced breast carcinoma
Quality-of-Life Assessment,targets,anatomic stage iv breast cancer ajcc v8
Quality-of-Life Assessment,targets,metastatic triple-negative breast carcinoma
Quality-of-Life Assessment,targets,prognostic stage iv breast cancer ajcc v8
Quality-of-Life Assessment,targets,triple-negative breast cancer
Quality-of-Life Assessment,targets,TNBC
NCT04445844,tests,Questionnaire Administration
Questionnaire Administration,has_type,DRUG
Questionnaire Administration,classified_as,OTHER
Questionnaire Administration,targets,locally advanced breast carcinoma
Questionnaire Administration,targets,anatomic stage iv breast cancer ajcc v8
Questionnaire Administration,targets,metastatic triple-negative breast carcinoma
Questionnaire Administration,targets,prognostic stage iv breast cancer ajcc v8
Questionnaire Administration,targets,triple-negative breast cancer
Questionnaire Administration,targets,TNBC
NCT04445844,tests,Retifanlimab
Retifanlimab,has_type,DRUG
Retifanlimab,classified_as,BIOLOGIC
Retifanlimab,targets,locally advanced breast carcinoma
Retifanlimab,targets,anatomic stage iv breast cancer ajcc v8
Retifanlimab,targets,metastatic triple-negative breast carcinoma
Retifanlimab,targets,prognostic stage iv breast cancer ajcc v8
Retifanlimab,targets,triple-negative breast cancer
Retifanlimab,targets,TNBC
NCT04907344,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT04907344,has_status,UNKNOWN
NCT04907344,tests,Camrelizumab
Camrelizumab,has_type,DRUG
Camrelizumab,classified_as,BIOLOGIC
Camrelizumab,targets,triple negative breast cancer
Camrelizumab,targets,TNBC
NCT04907344,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,triple negative breast cancer
Nab-Paclitaxel,targets,TNBC
NCT04907344,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT06568692,sponsored_by,Processa Pharmaceuticals
NCT06568692,has_status,RECRUITING
NCT06568692,tests,PCS6422 and capecitabine
PCS6422 and capecitabine,has_type,DRUG
PCS6422 and capecitabine,classified_as,CHEMICAL
PCS6422 and capecitabine,targets,breast cancer
PCS6422 and capecitabine,targets,her2-negative breast cancer
PCS6422 and capecitabine,targets,tnbc - triple-negative breast cancer
PCS6422 and capecitabine,targets,TNBC
NCT06568692,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
Capecitabine,targets,her2-negative breast cancer
Capecitabine,targets,tnbc - triple-negative breast cancer
Capecitabine,targets,TNBC
NCT05763992,sponsored_by,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"
NCT05763992,has_status,RECRUITING
NCT05763992,tests,"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)"
"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",has_type,DRUG
"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",classified_as,OTHER
"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",targets,breast cancer
"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",targets,fasting
"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",targets,dietary exposure
"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",targets,triple negative breast cancer
"Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)",targets,TNBC
NCT06880029,sponsored_by,"Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E."
NCT06880029,has_status,RECRUITING
NCT06880029,tests,Morning pembrolizumab infusions
Morning pembrolizumab infusions,has_type,DRUG
Morning pembrolizumab infusions,classified_as,BIOLOGIC
Morning pembrolizumab infusions,targets,triple negative breast cancer (tnbc)
Morning pembrolizumab infusions,targets,TNBC
NCT02681562,sponsored_by,Istituti Ospitalieri di Cremona
NCT02681562,has_status,UNKNOWN
NCT02681562,tests,olaparib
olaparib,has_type,DRUG
olaparib,classified_as,BIOLOGIC
olaparib,targets,breast cancer
olaparib,targets,triple negative breast cancer
olaparib,targets,TNBC
NCT03168880,sponsored_by,Tata Memorial Hospital
NCT03168880,has_status,ACTIVE_NOT_RECRUITING
NCT03168880,tests,Paclitaxel + Carboplatin
Paclitaxel + Carboplatin,has_type,DRUG
Paclitaxel + Carboplatin,classified_as,CHEMICAL
Paclitaxel + Carboplatin,targets,triple negative breast cancer
Paclitaxel + Carboplatin,targets,TNBC
NCT03168880,tests,Paclitaxel only
Paclitaxel only,has_type,DRUG
Paclitaxel only,classified_as,CHEMICAL
Paclitaxel only,targets,triple negative breast cancer
Paclitaxel only,targets,TNBC
NCT03101280,sponsored_by,Hoffmann-La Roche
NCT03101280,has_status,COMPLETED
NCT03101280,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,gynecologic neoplasms
NCT03101280,tests,Rucaparib
Rucaparib,has_type,DRUG
Rucaparib,classified_as,CHEMICAL
Rucaparib,targets,gynecologic neoplasms
NCT05181462,sponsored_by,Cantargia AB
NCT05181462,has_status,ACTIVE_NOT_RECRUITING
NCT05181462,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT05181462,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast cancer
Gemcitabine,targets,TNBC
NCT05181462,tests,Nadunolimab
Nadunolimab,has_type,DRUG
Nadunolimab,classified_as,BIOLOGIC
Nadunolimab,targets,triple negative breast cancer
Nadunolimab,targets,TNBC
NCT01426880,sponsored_by,GBG Forschungs GmbH
NCT01426880,has_status,COMPLETED
NCT01426880,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,tubular breast cancer stage iii
Carboplatin,targets,breast cancer female nos
Carboplatin,targets,inflammatory breast cancer
Carboplatin,targets,inflammatory breast cancer stage iv
Carboplatin,targets,invasive ductal breast cancer
Carboplatin,targets,tubular breast cancer stage ii
Carboplatin,targets,mucinous breast cancer stage ii
Carboplatin,targets,her-2 positive breast cancer
NCT01426880,tests,background treatment
background treatment,has_type,DRUG
background treatment,classified_as,OTHER
background treatment,targets,tubular breast cancer stage iii
background treatment,targets,breast cancer female nos
background treatment,targets,inflammatory breast cancer
background treatment,targets,inflammatory breast cancer stage iv
background treatment,targets,invasive ductal breast cancer
background treatment,targets,tubular breast cancer stage ii
background treatment,targets,mucinous breast cancer stage ii
background treatment,targets,her-2 positive breast cancer
NCT05544929,sponsored_by,Novartis Pharmaceuticals
NCT05544929,has_status,RECRUITING
NCT05544929,tests,KFA115
KFA115,has_type,DRUG
KFA115,classified_as,OTHER
KFA115,targets,nasopharyngeal carcinoma
KFA115,targets,anal cancer
KFA115,targets,high microsatellite instability colorectal carcinoma
KFA115,targets,"carcinoma, non-small-cell lung"
KFA115,targets,cutaneous melanoma
KFA115,targets,mesothelioma
KFA115,targets,"carcinoma, ovarian epithelial"
KFA115,targets,squamous cell carcinoma of head and neck
KFA115,targets,esophagogastric cancer
KFA115,targets,"carcinoma, renal cell"
KFA115,targets,triple negative breast neoplasms
KFA115,targets,"carcinoma, thymic"
KFA115,targets,TNBC
NCT05544929,tests,pembrolizumab
pembrolizumab,has_type,DRUG
pembrolizumab,classified_as,BIOLOGIC
pembrolizumab,targets,nasopharyngeal carcinoma
pembrolizumab,targets,anal cancer
pembrolizumab,targets,high microsatellite instability colorectal carcinoma
pembrolizumab,targets,"carcinoma, non-small-cell lung"
pembrolizumab,targets,cutaneous melanoma
pembrolizumab,targets,mesothelioma
pembrolizumab,targets,"carcinoma, ovarian epithelial"
pembrolizumab,targets,squamous cell carcinoma of head and neck
pembrolizumab,targets,esophagogastric cancer
pembrolizumab,targets,"carcinoma, renal cell"
pembrolizumab,targets,triple negative breast neoplasms
pembrolizumab,targets,"carcinoma, thymic"
pembrolizumab,targets,TNBC
NCT06849492,sponsored_by,Fudan University
NCT06849492,has_status,NOT_YET_RECRUITING
NCT06849492,tests,Camrelizumab
Camrelizumab,has_type,DRUG
Camrelizumab,classified_as,BIOLOGIC
Camrelizumab,targets,advanced triple negative breast cancer
Camrelizumab,targets,TNBC
NCT06849492,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,advanced triple negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT06849492,tests,SKB264
SKB264,has_type,DRUG
SKB264,classified_as,OTHER
SKB264,targets,advanced triple negative breast cancer
SKB264,targets,TNBC
NCT06849492,tests,Lenvatinib
Lenvatinib,has_type,DRUG
Lenvatinib,classified_as,CHEMICAL
Lenvatinib,targets,advanced triple negative breast cancer
Lenvatinib,targets,TNBC
NCT03644589,sponsored_by,University of Washington
NCT03644589,has_status,WITHDRAWN
NCT03644589,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,recurrent breast carcinoma
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,estrogen receptor negative
Pembrolizumab,targets,progesterone receptor negative
Pembrolizumab,targets,her2/neu negative
Pembrolizumab,targets,metastatic breast cancer
Pembrolizumab,targets,TNBC
NCT03644589,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,recurrent breast carcinoma
Cisplatin,targets,triple negative breast cancer
Cisplatin,targets,estrogen receptor negative
Cisplatin,targets,progesterone receptor negative
Cisplatin,targets,her2/neu negative
Cisplatin,targets,metastatic breast cancer
Cisplatin,targets,TNBC
NCT05086692,sponsored_by,"Medicenna Therapeutics, Inc."
NCT05086692,has_status,RECRUITING
NCT05086692,tests,MDNA11
MDNA11,has_type,DRUG
MDNA11,classified_as,OTHER
MDNA11,targets,cervical cancers
MDNA11,targets,merkel cell carcinoma
MDNA11,targets,cancer with a high tumor mutational burden
MDNA11,targets,mucosal melanoma
MDNA11,targets,cutaneous melanoma
MDNA11,targets,cervical cancer
MDNA11,targets,cutaneous squamous cell carcinoma
MDNA11,targets,primary peritoneal cancer
MDNA11,targets,dmmr cancer
MDNA11,targets,clear cell renal cell carcinoma
MDNA11,targets,"solid tumor, adult"
MDNA11,targets,msi-h cancer
MDNA11,targets,triple negative breast cancer
MDNA11,targets,viral cancer
MDNA11,targets,gastroesophageal junction (gej) cancer
MDNA11,targets,pancreas adenocarcinoma (msi-h)
MDNA11,targets,acral melanoma
MDNA11,targets,gastric cancer
MDNA11,targets,solid tumor
MDNA11,targets,advanced solid tumor
MDNA11,targets,colorectal cancer (msi-h)
MDNA11,targets,msi-h solid malignant tumor
MDNA11,targets,ovarian cancer
MDNA11,targets,non-small cell lung cancer non-squamous
MDNA11,targets,bladder cancer
MDNA11,targets,non-small cell lung cancer squamous
MDNA11,targets,fallopian tube cancer
MDNA11,targets,dmmr solid malignant tumor
MDNA11,targets,endometrial cancer
MDNA11,targets,endometrial carcinoma
MDNA11,targets,squamous cell carcinoma of head and neck
MDNA11,targets,pleural mesothelioma
MDNA11,targets,unresectable solid tumor
MDNA11,targets,esophageal cancer
MDNA11,targets,basal cell carcinoma
MDNA11,targets,skin cancer
MDNA11,targets,epithelial ovarian carcinoma
MDNA11,targets,TNBC
NCT05086692,tests,Pembrolizumab (KEYTRUDA®)
Pembrolizumab (KEYTRUDA®),has_type,DRUG
Pembrolizumab (KEYTRUDA®),classified_as,BIOLOGIC
Pembrolizumab (KEYTRUDA®),targets,cervical cancers
Pembrolizumab (KEYTRUDA®),targets,merkel cell carcinoma
Pembrolizumab (KEYTRUDA®),targets,cancer with a high tumor mutational burden
Pembrolizumab (KEYTRUDA®),targets,mucosal melanoma
Pembrolizumab (KEYTRUDA®),targets,cutaneous melanoma
Pembrolizumab (KEYTRUDA®),targets,cervical cancer
Pembrolizumab (KEYTRUDA®),targets,cutaneous squamous cell carcinoma
Pembrolizumab (KEYTRUDA®),targets,primary peritoneal cancer
Pembrolizumab (KEYTRUDA®),targets,dmmr cancer
Pembrolizumab (KEYTRUDA®),targets,clear cell renal cell carcinoma
Pembrolizumab (KEYTRUDA®),targets,"solid tumor, adult"
Pembrolizumab (KEYTRUDA®),targets,msi-h cancer
Pembrolizumab (KEYTRUDA®),targets,triple negative breast cancer
Pembrolizumab (KEYTRUDA®),targets,viral cancer
Pembrolizumab (KEYTRUDA®),targets,gastroesophageal junction (gej) cancer
Pembrolizumab (KEYTRUDA®),targets,pancreas adenocarcinoma (msi-h)
Pembrolizumab (KEYTRUDA®),targets,acral melanoma
Pembrolizumab (KEYTRUDA®),targets,gastric cancer
Pembrolizumab (KEYTRUDA®),targets,solid tumor
Pembrolizumab (KEYTRUDA®),targets,advanced solid tumor
Pembrolizumab (KEYTRUDA®),targets,colorectal cancer (msi-h)
Pembrolizumab (KEYTRUDA®),targets,msi-h solid malignant tumor
Pembrolizumab (KEYTRUDA®),targets,ovarian cancer
Pembrolizumab (KEYTRUDA®),targets,non-small cell lung cancer non-squamous
Pembrolizumab (KEYTRUDA®),targets,bladder cancer
Pembrolizumab (KEYTRUDA®),targets,non-small cell lung cancer squamous
Pembrolizumab (KEYTRUDA®),targets,fallopian tube cancer
Pembrolizumab (KEYTRUDA®),targets,dmmr solid malignant tumor
Pembrolizumab (KEYTRUDA®),targets,endometrial cancer
Pembrolizumab (KEYTRUDA®),targets,endometrial carcinoma
Pembrolizumab (KEYTRUDA®),targets,squamous cell carcinoma of head and neck
Pembrolizumab (KEYTRUDA®),targets,pleural mesothelioma
Pembrolizumab (KEYTRUDA®),targets,unresectable solid tumor
Pembrolizumab (KEYTRUDA®),targets,esophageal cancer
Pembrolizumab (KEYTRUDA®),targets,basal cell carcinoma
Pembrolizumab (KEYTRUDA®),targets,skin cancer
Pembrolizumab (KEYTRUDA®),targets,epithelial ovarian carcinoma
Pembrolizumab (KEYTRUDA®),targets,TNBC
NCT05537740,sponsored_by,Bayer
NCT05537740,has_status,RECRUITING
NCT05537740,tests,BAY3375968
BAY3375968,has_type,DRUG
BAY3375968,classified_as,OTHER
BAY3375968,targets,advanced solid tumors
NCT05537740,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,advanced solid tumors
NCT03256344,sponsored_by,Amgen
NCT03256344,has_status,COMPLETED
NCT03256344,tests,Talimogene Laherparepvec
Talimogene Laherparepvec,has_type,DRUG
Talimogene Laherparepvec,classified_as,OTHER
Talimogene Laherparepvec,targets,metastatic colorectal cancer
Talimogene Laherparepvec,targets,metastatic triple negative breast cancer
Talimogene Laherparepvec,targets,TNBC
NCT03256344,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,metastatic colorectal cancer
Atezolizumab,targets,metastatic triple negative breast cancer
Atezolizumab,targets,TNBC
NCT01930292,sponsored_by,Debiopharm International SA
NCT01930292,has_status,TERMINATED
NCT01930292,tests,Part A: Debio 1143
Part A: Debio 1143,has_type,DRUG
Part A: Debio 1143,classified_as,OTHER
Part A: Debio 1143,targets,solid tumors
NCT01930292,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,solid tumors
NCT01930292,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,solid tumors
NCT01930292,tests,Part B: Debio 1143
Part B: Debio 1143,has_type,DRUG
Part B: Debio 1143,classified_as,OTHER
Part B: Debio 1143,targets,solid tumors
NCT01520389,sponsored_by,Merrimack Pharmaceuticals
NCT01520389,has_status,COMPLETED
NCT01520389,tests,MM-151
MM-151,has_type,DRUG
MM-151,classified_as,OTHER
MM-151,targets,squamous cell head and neck cancer
MM-151,targets,advanced solid tumors
MM-151,targets,triple negative breast cancer
MM-151,targets,non small cell lung cancer
MM-151,targets,colorectal cancer
MM-151,targets,TNBC
NCT01520389,tests,MM-151 + irinotecan
MM-151 + irinotecan,has_type,DRUG
MM-151 + irinotecan,classified_as,OTHER
MM-151 + irinotecan,targets,squamous cell head and neck cancer
MM-151 + irinotecan,targets,advanced solid tumors
MM-151 + irinotecan,targets,triple negative breast cancer
MM-151 + irinotecan,targets,non small cell lung cancer
MM-151 + irinotecan,targets,colorectal cancer
MM-151 + irinotecan,targets,TNBC
NCT06975644,sponsored_by,Zhejiang Provincial People's Hospital
NCT06975644,has_status,NOT_YET_RECRUITING
NCT06975644,tests,"nab-paclitaxel, carboplatin, and bemotuzumab"
"nab-paclitaxel, carboplatin, and bemotuzumab",has_type,DRUG
"nab-paclitaxel, carboplatin, and bemotuzumab",classified_as,BIOLOGIC
"nab-paclitaxel, carboplatin, and bemotuzumab",targets,triple-negative breast cancer (tnbc)
"nab-paclitaxel, carboplatin, and bemotuzumab",targets,neoadjuvant chemotherapy
"nab-paclitaxel, carboplatin, and bemotuzumab",targets,chemotherapy effects
"nab-paclitaxel, carboplatin, and bemotuzumab",targets,TNBC
NCT06975644,tests,"epirubicin, cyclophosphamide, and bemotuzumab"
"epirubicin, cyclophosphamide, and bemotuzumab",has_type,DRUG
"epirubicin, cyclophosphamide, and bemotuzumab",classified_as,BIOLOGIC
"epirubicin, cyclophosphamide, and bemotuzumab",targets,triple-negative breast cancer (tnbc)
"epirubicin, cyclophosphamide, and bemotuzumab",targets,neoadjuvant chemotherapy
"epirubicin, cyclophosphamide, and bemotuzumab",targets,chemotherapy effects
"epirubicin, cyclophosphamide, and bemotuzumab",targets,TNBC
NCT04517292,sponsored_by,Fudan University
NCT04517292,has_status,UNKNOWN
NCT04517292,tests,"Eribulin,cisplatin"
"Eribulin,cisplatin",has_type,DRUG
"Eribulin,cisplatin",classified_as,CHEMICAL
"Eribulin,cisplatin",targets,breast cancer
NCT04517292,tests,"Gemcitabine,cisplatin"
"Gemcitabine,cisplatin",has_type,DRUG
"Gemcitabine,cisplatin",classified_as,CHEMICAL
"Gemcitabine,cisplatin",targets,breast cancer
NCT06081244,sponsored_by,West German Study Group
NCT06081244,has_status,RECRUITING
NCT06081244,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
Sacituzumab govitecan,classified_as,BIOLOGIC
Sacituzumab govitecan,targets,triple negative breast cancer
Sacituzumab govitecan,targets,TNBC
NCT06081244,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT06954480,sponsored_by,Queen Mary University of London
NCT06954480,has_status,NOT_YET_RECRUITING
NCT06954480,tests,Datopotamab Deruxtecan (Dato-DXd)
Datopotamab Deruxtecan (Dato-DXd),has_type,DRUG
Datopotamab Deruxtecan (Dato-DXd),classified_as,BIOLOGIC
Datopotamab Deruxtecan (Dato-DXd),targets,triple negative breast cancer
Datopotamab Deruxtecan (Dato-DXd),targets,TNBC
NCT06954480,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,triple negative breast cancer
Durvalumab,targets,TNBC
NCT05928780,sponsored_by,Fudan University
NCT05928780,has_status,NOT_YET_RECRUITING
NCT05928780,tests,A1:SG with SHR3680
A1:SG with SHR3680,has_type,DRUG
A1:SG with SHR3680,classified_as,OTHER
A1:SG with SHR3680,targets,tnbc - triple-negative breast cancer
A1:SG with SHR3680,targets,TNBC
NCT05928780,tests,A2:SG
A2:SG,has_type,DRUG
A2:SG,classified_as,OTHER
A2:SG,targets,tnbc - triple-negative breast cancer
A2:SG,targets,TNBC
NCT05928780,tests,B1:SG with SHR1210
B1:SG with SHR1210,has_type,DRUG
B1:SG with SHR1210,classified_as,OTHER
B1:SG with SHR1210,targets,tnbc - triple-negative breast cancer
B1:SG with SHR1210,targets,TNBC
NCT05928780,tests,B2:SG
B2:SG,has_type,DRUG
B2:SG,classified_as,OTHER
B2:SG,targets,tnbc - triple-negative breast cancer
B2:SG,targets,TNBC
NCT05928780,tests,C1:SG with SHR3162
C1:SG with SHR3162,has_type,DRUG
C1:SG with SHR3162,classified_as,OTHER
C1:SG with SHR3162,targets,tnbc - triple-negative breast cancer
C1:SG with SHR3162,targets,TNBC
NCT05928780,tests,C2:SG
C2:SG,has_type,DRUG
C2:SG,classified_as,OTHER
C2:SG,targets,tnbc - triple-negative breast cancer
C2:SG,targets,TNBC
NCT05928780,tests,D1:SG with VEGFRI
D1:SG with VEGFRI,has_type,DRUG
D1:SG with VEGFRI,classified_as,OTHER
D1:SG with VEGFRI,targets,tnbc - triple-negative breast cancer
D1:SG with VEGFRI,targets,TNBC
NCT05928780,tests,D2:SG
D2:SG,has_type,DRUG
D2:SG,classified_as,OTHER
D2:SG,targets,tnbc - triple-negative breast cancer
D2:SG,targets,TNBC
NCT06022029,sponsored_by,"OncoNano Medicine, Inc."
NCT06022029,has_status,RECRUITING
NCT06022029,tests,ONM-501
ONM-501,has_type,DRUG
ONM-501,classified_as,OTHER
ONM-501,targets,"lymphoma, non-hodgkin"
ONM-501,targets,"uveal melanoma, recurrent"
ONM-501,targets,carcinoma in situ
ONM-501,targets,follicular lymphoma
ONM-501,targets,metastatic cancer
ONM-501,targets,diffuse large b cell lymphoma
ONM-501,targets,mantle cell lymphoma
ONM-501,targets,"tumor, solid"
ONM-501,targets,triple negative breast cancer
ONM-501,targets,bladder cancer
ONM-501,targets,cervix cancer
ONM-501,targets,head and neck squamous cell carcinoma
ONM-501,targets,tumor recurrence
ONM-501,targets,skin cancer
ONM-501,targets,TNBC
NCT06022029,tests,Cemiplimab
Cemiplimab,has_type,DRUG
Cemiplimab,classified_as,BIOLOGIC
Cemiplimab,targets,"lymphoma, non-hodgkin"
Cemiplimab,targets,"uveal melanoma, recurrent"
Cemiplimab,targets,carcinoma in situ
Cemiplimab,targets,follicular lymphoma
Cemiplimab,targets,metastatic cancer
Cemiplimab,targets,diffuse large b cell lymphoma
Cemiplimab,targets,mantle cell lymphoma
Cemiplimab,targets,"tumor, solid"
Cemiplimab,targets,triple negative breast cancer
Cemiplimab,targets,bladder cancer
Cemiplimab,targets,cervix cancer
Cemiplimab,targets,head and neck squamous cell carcinoma
Cemiplimab,targets,tumor recurrence
Cemiplimab,targets,skin cancer
Cemiplimab,targets,TNBC
NCT05629429,sponsored_by,National Taiwan University Hospital
NCT05629429,has_status,RECRUITING
NCT05629429,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,metastatic breast cancer
NCT05629429,tests,Chemotherapy drug
Chemotherapy drug,has_type,DRUG
Chemotherapy drug,classified_as,OTHER
Chemotherapy drug,targets,metastatic breast cancer
NCT02435680,sponsored_by,Novartis Pharmaceuticals
NCT02435680,has_status,COMPLETED
NCT02435680,tests,MCS110
MCS110,has_type,DRUG
MCS110,classified_as,OTHER
MCS110,targets,advanced triple negative breast cancer (tnbc) with high tams
MCS110,targets,TNBC
NCT02435680,tests,carboplatin
carboplatin,has_type,DRUG
carboplatin,classified_as,CHEMICAL
carboplatin,targets,advanced triple negative breast cancer (tnbc) with high tams
carboplatin,targets,TNBC
NCT02435680,tests,gemcitabine
gemcitabine,has_type,DRUG
gemcitabine,classified_as,OTHER
gemcitabine,targets,advanced triple negative breast cancer (tnbc) with high tams
gemcitabine,targets,TNBC
NCT02157792,sponsored_by,"EMD Serono Research & Development Institute, Inc."
NCT02157792,has_status,COMPLETED
NCT02157792,tests,M6620
M6620,has_type,DRUG
M6620,classified_as,OTHER
M6620,targets,advanced solid tumor
NCT02157792,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,advanced solid tumor
NCT02157792,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,advanced solid tumor
NCT02157792,tests,Etoposide
Etoposide,has_type,DRUG
Etoposide,classified_as,OTHER
Etoposide,targets,advanced solid tumor
NCT02157792,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,advanced solid tumor
NCT02157792,tests,Irinotecan
Irinotecan,has_type,DRUG
Irinotecan,classified_as,OTHER
Irinotecan,targets,advanced solid tumor
NCT04395989,sponsored_by,Fudan University
NCT04395989,has_status,ACTIVE_NOT_RECRUITING
NCT04395989,tests,A1: Pyrotinib with nab-paclitaxel
A1: Pyrotinib with nab-paclitaxel,has_type,DRUG
A1: Pyrotinib with nab-paclitaxel,classified_as,CHEMICAL
A1: Pyrotinib with nab-paclitaxel,targets,tnbc - triple-negative breast cancer
A1: Pyrotinib with nab-paclitaxel,targets,TNBC
NCT04395989,tests,A2: nab-paclitaxel
A2: nab-paclitaxel,has_type,DRUG
A2: nab-paclitaxel,classified_as,CHEMICAL
A2: nab-paclitaxel,targets,tnbc - triple-negative breast cancer
A2: nab-paclitaxel,targets,TNBC
NCT04395989,tests,B1: everolimus with nab-paclitaxel
B1: everolimus with nab-paclitaxel,has_type,DRUG
B1: everolimus with nab-paclitaxel,classified_as,CHEMICAL
B1: everolimus with nab-paclitaxel,targets,tnbc - triple-negative breast cancer
B1: everolimus with nab-paclitaxel,targets,TNBC
NCT04395989,tests,B2: nab-paclitaxel
B2: nab-paclitaxel,has_type,DRUG
B2: nab-paclitaxel,classified_as,CHEMICAL
B2: nab-paclitaxel,targets,tnbc - triple-negative breast cancer
B2: nab-paclitaxel,targets,TNBC
NCT04395989,tests,C1: PD-1 with nab-paclitaxel and famitinib
C1: PD-1 with nab-paclitaxel and famitinib,has_type,DRUG
C1: PD-1 with nab-paclitaxel and famitinib,classified_as,BIOLOGIC
C1: PD-1 with nab-paclitaxel and famitinib,targets,tnbc - triple-negative breast cancer
C1: PD-1 with nab-paclitaxel and famitinib,targets,TNBC
NCT04395989,tests,C2: nab-paclitaxel
C2: nab-paclitaxel,has_type,DRUG
C2: nab-paclitaxel,classified_as,CHEMICAL
C2: nab-paclitaxel,targets,tnbc - triple-negative breast cancer
C2: nab-paclitaxel,targets,TNBC
NCT04395989,tests,"D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine"
"D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",has_type,DRUG
"D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",classified_as,CHEMICAL
"D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",targets,tnbc - triple-negative breast cancer
"D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",targets,TNBC
NCT04395989,tests,"D2: nab-paclitaxel, with maintenance of capecitabine"
"D2: nab-paclitaxel, with maintenance of capecitabine",has_type,DRUG
"D2: nab-paclitaxel, with maintenance of capecitabine",classified_as,CHEMICAL
"D2: nab-paclitaxel, with maintenance of capecitabine",targets,tnbc - triple-negative breast cancer
"D2: nab-paclitaxel, with maintenance of capecitabine",targets,TNBC
NCT04395989,tests,E1: everolimus with nab-paclitaxel
E1: everolimus with nab-paclitaxel,has_type,DRUG
E1: everolimus with nab-paclitaxel,classified_as,CHEMICAL
E1: everolimus with nab-paclitaxel,targets,tnbc - triple-negative breast cancer
E1: everolimus with nab-paclitaxel,targets,TNBC
NCT04395989,tests,E2: nab-paclitaxel
E2: nab-paclitaxel,has_type,DRUG
E2: nab-paclitaxel,classified_as,CHEMICAL
E2: nab-paclitaxel,targets,tnbc - triple-negative breast cancer
E2: nab-paclitaxel,targets,TNBC
NCT06245889,sponsored_by,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06245889,has_status,RECRUITING
NCT06245889,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT06245889,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT06245889,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT06245889,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,triple negative breast cancer
Doxorubicin,targets,TNBC
NCT06245889,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT06245889,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,triple negative breast cancer
Olaparib,targets,TNBC
NCT06245889,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT06562192,sponsored_by,Novartis Pharmaceuticals
NCT06562192,has_status,RECRUITING
NCT06562192,tests,[68Ga]Ga-NNS309
[68Ga]Ga-NNS309,has_type,DRUG
[68Ga]Ga-NNS309,classified_as,OTHER
[68Ga]Ga-NNS309,targets,non-small cell lung cancer
[68Ga]Ga-NNS309,targets,triple negative breast cancer
[68Ga]Ga-NNS309,targets,hr+/her2- ductal and lobular breast cancer
[68Ga]Ga-NNS309,targets,pancreatic ductal adenocarcinoma
[68Ga]Ga-NNS309,targets,colorectal cancer
[68Ga]Ga-NNS309,targets,TNBC
NCT06562192,tests,[177Lu]Lu-NNS309
[177Lu]Lu-NNS309,has_type,DRUG
[177Lu]Lu-NNS309,classified_as,OTHER
[177Lu]Lu-NNS309,targets,non-small cell lung cancer
[177Lu]Lu-NNS309,targets,triple negative breast cancer
[177Lu]Lu-NNS309,targets,hr+/her2- ductal and lobular breast cancer
[177Lu]Lu-NNS309,targets,pancreatic ductal adenocarcinoma
[177Lu]Lu-NNS309,targets,colorectal cancer
[177Lu]Lu-NNS309,targets,TNBC
NCT03366844,sponsored_by,Stephen Shiao
NCT03366844,has_status,ACTIVE_NOT_RECRUITING
NCT03366844,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT03366844,tests,RT Boost
RT Boost,has_type,DRUG
RT Boost,classified_as,OTHER
RT Boost,targets,breast cancer
NCT07040644,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT07040644,has_status,NOT_YET_RECRUITING
NCT07040644,tests,Sacituzumab Govitecan (SG)
Sacituzumab Govitecan (SG),has_type,DRUG
Sacituzumab Govitecan (SG),classified_as,BIOLOGIC
Sacituzumab Govitecan (SG),targets,triple negative breast neoplasms
Sacituzumab Govitecan (SG),targets,TNBC
NCT07040644,tests,Toripalimab
Toripalimab,has_type,DRUG
Toripalimab,classified_as,BIOLOGIC
Toripalimab,targets,triple negative breast neoplasms
Toripalimab,targets,TNBC
NCT07040644,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple negative breast neoplasms
Nab-paclitaxel,targets,TNBC
NCT03838367,sponsored_by,"CytoDyn, Inc."
NCT03838367,has_status,ACTIVE_NOT_RECRUITING
NCT03838367,tests,350 mg leronlimab
350 mg leronlimab,has_type,DRUG
350 mg leronlimab,classified_as,BIOLOGIC
350 mg leronlimab,targets,triple negative breast neoplasms
350 mg leronlimab,targets,TNBC
NCT03838367,tests,525 mg leronlimab
525 mg leronlimab,has_type,DRUG
525 mg leronlimab,classified_as,BIOLOGIC
525 mg leronlimab,targets,triple negative breast neoplasms
525 mg leronlimab,targets,TNBC
NCT03838367,tests,700 mg leronlimab
700 mg leronlimab,has_type,DRUG
700 mg leronlimab,classified_as,BIOLOGIC
700 mg leronlimab,targets,triple negative breast neoplasms
700 mg leronlimab,targets,TNBC
NCT03838367,tests,AUC 5 Carboplatin
AUC 5 Carboplatin,has_type,DRUG
AUC 5 Carboplatin,classified_as,CHEMICAL
AUC 5 Carboplatin,targets,triple negative breast neoplasms
AUC 5 Carboplatin,targets,TNBC
NCT03838367,tests,Maximum Tolerated Dose (MTD) of leronlimab
Maximum Tolerated Dose (MTD) of leronlimab,has_type,DRUG
Maximum Tolerated Dose (MTD) of leronlimab,classified_as,BIOLOGIC
Maximum Tolerated Dose (MTD) of leronlimab,targets,triple negative breast neoplasms
Maximum Tolerated Dose (MTD) of leronlimab,targets,TNBC
NCT00528567,sponsored_by,Hoffmann-La Roche
NCT00528567,has_status,COMPLETED
NCT00528567,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,breast cancer
NCT00528567,tests,Standard adjuvant chemotherapy
Standard adjuvant chemotherapy,has_type,DRUG
Standard adjuvant chemotherapy,classified_as,OTHER
Standard adjuvant chemotherapy,targets,breast cancer
NCT04489940,sponsored_by,"EMD Serono Research & Development Institute, Inc."
NCT04489940,has_status,TERMINATED
NCT04489940,tests,Bintrafusp alfa
Bintrafusp alfa,has_type,DRUG
Bintrafusp alfa,classified_as,OTHER
Bintrafusp alfa,targets,triple negative breast neoplasms
Bintrafusp alfa,targets,TNBC
NCT02125344,sponsored_by,GBG Forschungs GmbH
NCT02125344,has_status,COMPLETED
NCT02125344,tests,non-pegylated liposomal doxorubicin
non-pegylated liposomal doxorubicin,has_type,DRUG
non-pegylated liposomal doxorubicin,classified_as,CHEMICAL
non-pegylated liposomal doxorubicin,targets,tubular breast cancer stage iii
non-pegylated liposomal doxorubicin,targets,breast cancer female nos
non-pegylated liposomal doxorubicin,targets,inflammatory breast cancer
non-pegylated liposomal doxorubicin,targets,invasive ductal breast cancer
non-pegylated liposomal doxorubicin,targets,tubular breast cancer stage ii
non-pegylated liposomal doxorubicin,targets,mucinous breast cancer stage ii
non-pegylated liposomal doxorubicin,targets,her2 positive breast cancer
NCT02125344,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,tubular breast cancer stage iii
Carboplatin,targets,breast cancer female nos
Carboplatin,targets,inflammatory breast cancer
Carboplatin,targets,invasive ductal breast cancer
Carboplatin,targets,tubular breast cancer stage ii
Carboplatin,targets,mucinous breast cancer stage ii
Carboplatin,targets,her2 positive breast cancer
NCT02125344,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,tubular breast cancer stage iii
Paclitaxel,targets,breast cancer female nos
Paclitaxel,targets,inflammatory breast cancer
Paclitaxel,targets,invasive ductal breast cancer
Paclitaxel,targets,tubular breast cancer stage ii
Paclitaxel,targets,mucinous breast cancer stage ii
Paclitaxel,targets,her2 positive breast cancer
NCT02125344,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,tubular breast cancer stage iii
Epirubicin,targets,breast cancer female nos
Epirubicin,targets,inflammatory breast cancer
Epirubicin,targets,invasive ductal breast cancer
Epirubicin,targets,tubular breast cancer stage ii
Epirubicin,targets,mucinous breast cancer stage ii
Epirubicin,targets,her2 positive breast cancer
NCT02125344,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,tubular breast cancer stage iii
Cyclophosphamide,targets,breast cancer female nos
Cyclophosphamide,targets,inflammatory breast cancer
Cyclophosphamide,targets,invasive ductal breast cancer
Cyclophosphamide,targets,tubular breast cancer stage ii
Cyclophosphamide,targets,mucinous breast cancer stage ii
Cyclophosphamide,targets,her2 positive breast cancer
NCT02125344,tests,Pertuzumab
Pertuzumab,has_type,DRUG
Pertuzumab,classified_as,BIOLOGIC
Pertuzumab,targets,tubular breast cancer stage iii
Pertuzumab,targets,breast cancer female nos
Pertuzumab,targets,inflammatory breast cancer
Pertuzumab,targets,invasive ductal breast cancer
Pertuzumab,targets,tubular breast cancer stage ii
Pertuzumab,targets,mucinous breast cancer stage ii
Pertuzumab,targets,her2 positive breast cancer
NCT02125344,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,tubular breast cancer stage iii
Trastuzumab,targets,breast cancer female nos
Trastuzumab,targets,inflammatory breast cancer
Trastuzumab,targets,invasive ductal breast cancer
Trastuzumab,targets,tubular breast cancer stage ii
Trastuzumab,targets,mucinous breast cancer stage ii
Trastuzumab,targets,her2 positive breast cancer
NCT02125344,tests,Ferric carboxymaltose
Ferric carboxymaltose,has_type,DRUG
Ferric carboxymaltose,classified_as,OTHER
Ferric carboxymaltose,targets,tubular breast cancer stage iii
Ferric carboxymaltose,targets,breast cancer female nos
Ferric carboxymaltose,targets,inflammatory breast cancer
Ferric carboxymaltose,targets,invasive ductal breast cancer
Ferric carboxymaltose,targets,tubular breast cancer stage ii
Ferric carboxymaltose,targets,mucinous breast cancer stage ii
Ferric carboxymaltose,targets,her2 positive breast cancer
NCT03671044,sponsored_by,Jina Pharmaceuticals Inc.
NCT03671044,has_status,RECRUITING
NCT03671044,tests,Nanosomal Docetaxel Lipid Suspension (75 mg/m2)
Nanosomal Docetaxel Lipid Suspension (75 mg/m2),has_type,DRUG
Nanosomal Docetaxel Lipid Suspension (75 mg/m2),classified_as,CHEMICAL
Nanosomal Docetaxel Lipid Suspension (75 mg/m2),targets,triple negative breast cancer
Nanosomal Docetaxel Lipid Suspension (75 mg/m2),targets,TNBC
NCT03671044,tests,Nanosomal Docetaxel Lipid Suspension (100 mg/m2)
Nanosomal Docetaxel Lipid Suspension (100 mg/m2),has_type,DRUG
Nanosomal Docetaxel Lipid Suspension (100 mg/m2),classified_as,CHEMICAL
Nanosomal Docetaxel Lipid Suspension (100 mg/m2),targets,triple negative breast cancer
Nanosomal Docetaxel Lipid Suspension (100 mg/m2),targets,TNBC
NCT03671044,tests,Taxotere® (100 mg/m2)
Taxotere® (100 mg/m2),has_type,DRUG
Taxotere® (100 mg/m2),classified_as,OTHER
Taxotere® (100 mg/m2),targets,triple negative breast cancer
Taxotere® (100 mg/m2),targets,TNBC
NCT02807844,sponsored_by,Novartis Pharmaceuticals
NCT02807844,has_status,COMPLETED
NCT02807844,tests,MCS110
MCS110,has_type,DRUG
MCS110,classified_as,OTHER
MCS110,targets,pancreatic carcinoma
MCS110,targets,melanoma
MCS110,targets,endometrial carcinoma
MCS110,targets,triple negative breast cancer
MCS110,targets,TNBC
NCT02807844,tests,PDR001
PDR001,has_type,DRUG
PDR001,classified_as,OTHER
PDR001,targets,pancreatic carcinoma
PDR001,targets,melanoma
PDR001,targets,endometrial carcinoma
PDR001,targets,triple negative breast cancer
PDR001,targets,TNBC
NCT05208762,sponsored_by,"Seagen, a wholly owned subsidiary of Pfizer"
NCT05208762,has_status,RECRUITING
NCT05208762,tests,PF-08046054
PF-08046054,has_type,DRUG
PF-08046054,classified_as,OTHER
PF-08046054,targets,melanoma
PF-08046054,targets,gastric cancer
PF-08046054,targets,"carcinoma, non-small-cell lung"
PF-08046054,targets,esophageal squamous cell carcinoma
PF-08046054,targets,triple negative breast neoplasms
PF-08046054,targets,ovarian neoplasms
PF-08046054,targets,squamous cell carcinoma of the head and neck
PF-08046054,targets,TNBC
NCT05208762,tests,pembrolizumab
pembrolizumab,has_type,DRUG
pembrolizumab,classified_as,BIOLOGIC
pembrolizumab,targets,melanoma
pembrolizumab,targets,gastric cancer
pembrolizumab,targets,"carcinoma, non-small-cell lung"
pembrolizumab,targets,esophageal squamous cell carcinoma
pembrolizumab,targets,triple negative breast neoplasms
pembrolizumab,targets,ovarian neoplasms
pembrolizumab,targets,squamous cell carcinoma of the head and neck
pembrolizumab,targets,TNBC
NCT06636591,sponsored_by,Fudan University
NCT06636591,has_status,RECRUITING
NCT06636591,tests,Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin,has_type,DRUG
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin,classified_as,BIOLOGIC
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin,targets,her2-negative breast cancer
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin,targets,breast cancer female
NCT06636591,tests,Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin,has_type,DRUG
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin,classified_as,BIOLOGIC
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin,targets,her2-negative breast cancer
Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin,targets,breast cancer female
NCT05064280,sponsored_by,M.D. Anderson Cancer Center
NCT05064280,has_status,RECRUITING
NCT05064280,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,brain metastases
Pembrolizumab,targets,tumor
NCT05064280,tests,Lenvatinib
Lenvatinib,has_type,DRUG
Lenvatinib,classified_as,CHEMICAL
Lenvatinib,targets,brain metastases
Lenvatinib,targets,tumor
NCT03318562,sponsored_by,Effector Therapeutics
NCT03318562,has_status,TERMINATED
NCT03318562,tests,eFT508
eFT508,has_type,DRUG
eFT508,classified_as,OTHER
eFT508,targets,hepatocellular carcinoma
eFT508,targets,triple negative breast cancer
eFT508,targets,TNBC
NCT01307891,sponsored_by,University of Alabama at Birmingham
NCT01307891,has_status,COMPLETED
NCT01307891,tests,Abraxane alone
Abraxane alone,has_type,DRUG
Abraxane alone,classified_as,OTHER
Abraxane alone,targets,breast cancer
Abraxane alone,targets,metastatic breast cancer
Abraxane alone,targets,stage iv breast cancer
Abraxane alone,targets,triple negative breast cancer
Abraxane alone,targets,TNBC
NCT01307891,tests,Abraxane + Tigatuzumab
Abraxane + Tigatuzumab,has_type,DRUG
Abraxane + Tigatuzumab,classified_as,BIOLOGIC
Abraxane + Tigatuzumab,targets,breast cancer
Abraxane + Tigatuzumab,targets,metastatic breast cancer
Abraxane + Tigatuzumab,targets,stage iv breast cancer
Abraxane + Tigatuzumab,targets,triple negative breast cancer
Abraxane + Tigatuzumab,targets,TNBC
NCT01186991,sponsored_by,"Genentech, Inc."
NCT01186991,has_status,COMPLETED
NCT01186991,tests,Onartuzumab
Onartuzumab,has_type,DRUG
Onartuzumab,classified_as,BIOLOGIC
Onartuzumab,targets,breast cancer
NCT01186991,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,breast cancer
NCT01186991,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT01186991,tests,Bevacizumab Placebo
Bevacizumab Placebo,has_type,DRUG
Bevacizumab Placebo,classified_as,BIOLOGIC
Bevacizumab Placebo,targets,breast cancer
NCT01186991,tests,Onartuzumab Placebo
Onartuzumab Placebo,has_type,DRUG
Onartuzumab Placebo,classified_as,BIOLOGIC
Onartuzumab Placebo,targets,breast cancer
NCT05645380,sponsored_by,University of Kansas Medical Center
NCT05645380,has_status,RECRUITING
NCT05645380,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT05645380,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,breast cancer
Docetaxel,targets,triple negative breast cancer
Docetaxel,targets,TNBC
NCT05645380,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,breast cancer
Doxorubicin,targets,triple negative breast cancer
Doxorubicin,targets,TNBC
NCT05645380,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT05645380,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT01232062,sponsored_by,Peking University Cancer Hospital & Institute
NCT01232062,has_status,COMPLETED
NCT03394027,sponsored_by,National Cancer Institute (NCI)
NCT03394027,has_status,COMPLETED
NCT03394027,tests,ONC201
ONC201,has_type,DRUG
ONC201,classified_as,OTHER
ONC201,targets,endometrial cancer
ONC201,targets,"hormone receptor positive, her2 negative breast cancer"
ONC201,targets,triple negative breast cancer
ONC201,targets,TNBC
NCT05460273,sponsored_by,AstraZeneca
NCT05460273,has_status,ACTIVE_NOT_RECRUITING
NCT05460273,tests,Datopotamab Deruxtecan (Dato-DXd)
Datopotamab Deruxtecan (Dato-DXd),has_type,DRUG
Datopotamab Deruxtecan (Dato-DXd),classified_as,BIOLOGIC
Datopotamab Deruxtecan (Dato-DXd),targets,"carcinoma, non-small-cell lung"
Datopotamab Deruxtecan (Dato-DXd),targets,triple negative breast cancer
Datopotamab Deruxtecan (Dato-DXd),targets,TNBC
NCT02637531,sponsored_by,"Infinity Pharmaceuticals, Inc."
NCT02637531,has_status,UNKNOWN
NCT02637531,tests,IPI-549 (eganelisib)
IPI-549 (eganelisib),has_type,DRUG
IPI-549 (eganelisib),classified_as,CHEMICAL
IPI-549 (eganelisib),targets,squamous cell cancer of the head and neck (part e)
IPI-549 (eganelisib),targets,high-circulating myeloid-derived suppressor cells (part h)
IPI-549 (eganelisib),targets,melanoma (part e)
IPI-549 (eganelisib),targets,advanced solid tumors (part a/b/c/d)
IPI-549 (eganelisib),targets,mesothelioma (part g)
IPI-549 (eganelisib),targets,triple negative breast cancer (part f)
IPI-549 (eganelisib),targets,adrenocortical carcinoma (part g)
IPI-549 (eganelisib),targets,non-small cell lung cancer (part e)
IPI-549 (eganelisib),targets,TNBC
NCT02637531,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,squamous cell cancer of the head and neck (part e)
Nivolumab,targets,high-circulating myeloid-derived suppressor cells (part h)
Nivolumab,targets,melanoma (part e)
Nivolumab,targets,advanced solid tumors (part a/b/c/d)
Nivolumab,targets,mesothelioma (part g)
Nivolumab,targets,triple negative breast cancer (part f)
Nivolumab,targets,adrenocortical carcinoma (part g)
Nivolumab,targets,non-small cell lung cancer (part e)
Nivolumab,targets,TNBC
NCT04373031,sponsored_by,Providence Health & Services
NCT04373031,has_status,ACTIVE_NOT_RECRUITING
NCT04373031,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,breast neoplasms
NCT04373031,tests,IRX 2
IRX 2,has_type,DRUG
IRX 2,classified_as,OTHER
IRX 2,targets,breast cancer
IRX 2,targets,breast neoplasms
NCT06358573,sponsored_by,Swiss Group for Clinical Cancer Research
NCT06358573,has_status,RECRUITING
NCT06358573,tests,INT230-6
INT230-6,has_type,DRUG
INT230-6,classified_as,OTHER
INT230-6,targets,tnbc - triple-negative breast cancer
INT230-6,targets,triple-negative breast cancer
INT230-6,targets,TNBC
NCT06358573,tests,neoadjuvant immuno-chemotherapy
neoadjuvant immuno-chemotherapy,has_type,DRUG
neoadjuvant immuno-chemotherapy,classified_as,OTHER
neoadjuvant immuno-chemotherapy,targets,tnbc - triple-negative breast cancer
neoadjuvant immuno-chemotherapy,targets,triple-negative breast cancer
neoadjuvant immuno-chemotherapy,targets,TNBC
NCT00817531,sponsored_by,Baylor Breast Care Center
NCT00817531,has_status,TERMINATED
NCT00817531,tests,Dasatinib
Dasatinib,has_type,DRUG
Dasatinib,classified_as,CHEMICAL
Dasatinib,targets,breast cancer
NCT05466760,sponsored_by,"Taipei Veterans General Hospital, Taiwan"
NCT05466760,has_status,UNKNOWN
NCT05466760,tests,PET/MR
PET/MR,has_type,DRUG
PET/MR,classified_as,OTHER
PET/MR,targets,breast cancer
NCT02393794,sponsored_by,Priyanka Sharma
NCT02393794,has_status,UNKNOWN
NCT02393794,tests,Romidepsin
Romidepsin,has_type,DRUG
Romidepsin,classified_as,OTHER
Romidepsin,targets,breast cancer
Romidepsin,targets,triple-negative breast cancer
Romidepsin,targets,TNBC
NCT02393794,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,breast cancer
Cisplatin,targets,triple-negative breast cancer
Cisplatin,targets,TNBC
NCT02393794,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,breast cancer
Nivolumab,targets,triple-negative breast cancer
Nivolumab,targets,TNBC
NCT02929576,sponsored_by,Pfizer
NCT02929576,has_status,WITHDRAWN
NCT02929576,tests,Enzalutamide
Enzalutamide,has_type,DRUG
Enzalutamide,classified_as,OTHER
Enzalutamide,targets,breast cancer
NCT02929576,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,breast cancer
NCT02929576,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT02732860,sponsored_by,"University Health Network, Toronto"
NCT02732860,has_status,RECRUITING
NCT02732860,tests,Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,has_type,DRUG
Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,classified_as,OTHER
Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,targets,ovarian neoplasm
Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,targets,breast cancer
Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,targets,breast neoplasms
Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,targets,ovarian cancer
Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,targets,colorectal neoplasms
Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,targets,colorectal cancer
NCT03205176,sponsored_by,AstraZeneca
NCT03205176,has_status,COMPLETED
NCT03205176,tests,AZD5153
AZD5153,has_type,DRUG
AZD5153,classified_as,OTHER
AZD5153,targets,pancreatic cancer
AZD5153,targets,breast cancer
AZD5153,targets,prostate cancer
AZD5153,targets,ovarian cancer
AZD5153,targets,lymphoma
AZD5153,targets,malignant solid tumors
NCT03205176,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,pancreatic cancer
Olaparib,targets,breast cancer
Olaparib,targets,prostate cancer
Olaparib,targets,ovarian cancer
Olaparib,targets,lymphoma
Olaparib,targets,malignant solid tumors
NCT02593227,sponsored_by,"Marker Therapeutics, Inc."
NCT02593227,has_status,COMPLETED
NCT02593227,tests,Low dose FRα vaccine
Low dose FRα vaccine,has_type,DRUG
Low dose FRα vaccine,classified_as,OTHER
Low dose FRα vaccine,targets,breast cancer
NCT02593227,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
NCT02593227,tests,High dose FRα vaccine
High dose FRα vaccine,has_type,DRUG
High dose FRα vaccine,classified_as,OTHER
High dose FRα vaccine,targets,breast cancer
NCT06774027,sponsored_by,"University of California, San Francisco"
NCT06774027,has_status,NOT_YET_RECRUITING
NCT06774027,tests,Specimen collection
Specimen collection,has_type,DRUG
Specimen collection,classified_as,OTHER
Specimen collection,targets,her2-negative breast cancer
Specimen collection,targets,her2 negative breast carcinoma
Specimen collection,targets,metastatic triple-negative breast carcinoma
Specimen collection,targets,hr+ her2 breast cancer
Specimen collection,targets,metastatic breast cancer
Specimen collection,targets,metastatic triple negative breast cancers
Specimen collection,targets,TNBC
NCT06774027,tests,Non-Investigational Antibody-Drug Conjugates (ADC)
Non-Investigational Antibody-Drug Conjugates (ADC),has_type,DRUG
Non-Investigational Antibody-Drug Conjugates (ADC),classified_as,BIOLOGIC
Non-Investigational Antibody-Drug Conjugates (ADC),targets,her2-negative breast cancer
Non-Investigational Antibody-Drug Conjugates (ADC),targets,her2 negative breast carcinoma
Non-Investigational Antibody-Drug Conjugates (ADC),targets,metastatic triple-negative breast carcinoma
Non-Investigational Antibody-Drug Conjugates (ADC),targets,hr+ her2 breast cancer
Non-Investigational Antibody-Drug Conjugates (ADC),targets,metastatic breast cancer
Non-Investigational Antibody-Drug Conjugates (ADC),targets,metastatic triple negative breast cancers
Non-Investigational Antibody-Drug Conjugates (ADC),targets,TNBC
NCT06774027,tests,Medical Record Review
Medical Record Review,has_type,DRUG
Medical Record Review,classified_as,OTHER
Medical Record Review,targets,her2-negative breast cancer
Medical Record Review,targets,her2 negative breast carcinoma
Medical Record Review,targets,metastatic triple-negative breast carcinoma
Medical Record Review,targets,hr+ her2 breast cancer
Medical Record Review,targets,metastatic breast cancer
Medical Record Review,targets,metastatic triple negative breast cancers
Medical Record Review,targets,TNBC
NCT04437160,sponsored_by,Chinese Academy of Medical Sciences
NCT04437160,has_status,RECRUITING
NCT04437160,tests,Epirubicin or Pirarubicin
Epirubicin or Pirarubicin,has_type,DRUG
Epirubicin or Pirarubicin,classified_as,OTHER
Epirubicin or Pirarubicin,targets,triple negative breast cancer
Epirubicin or Pirarubicin,targets,TNBC
NCT04437160,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02883062,sponsored_by,National Cancer Institute (NCI)
NCT02883062,has_status,COMPLETED
NCT02883062,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,stage iii breast cancer ajcc v7
Atezolizumab,targets,stage ii breast cancer ajcc v6 and v7
Atezolizumab,targets,invasive breast carcinoma
Atezolizumab,targets,triple-negative breast carcinoma
Atezolizumab,targets,TNBC
NCT02883062,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,stage iii breast cancer ajcc v7
Biospecimen Collection,targets,stage ii breast cancer ajcc v6 and v7
Biospecimen Collection,targets,invasive breast carcinoma
Biospecimen Collection,targets,triple-negative breast carcinoma
Biospecimen Collection,targets,TNBC
NCT02883062,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,stage iii breast cancer ajcc v7
Carboplatin,targets,stage ii breast cancer ajcc v6 and v7
Carboplatin,targets,invasive breast carcinoma
Carboplatin,targets,triple-negative breast carcinoma
Carboplatin,targets,TNBC
NCT02883062,tests,Lumpectomy
Lumpectomy,has_type,DRUG
Lumpectomy,classified_as,OTHER
Lumpectomy,targets,stage iii breast cancer ajcc v7
Lumpectomy,targets,stage ii breast cancer ajcc v6 and v7
Lumpectomy,targets,invasive breast carcinoma
Lumpectomy,targets,triple-negative breast carcinoma
Lumpectomy,targets,TNBC
NCT02883062,tests,Mastectomy
Mastectomy,has_type,DRUG
Mastectomy,classified_as,OTHER
Mastectomy,targets,stage iii breast cancer ajcc v7
Mastectomy,targets,stage ii breast cancer ajcc v6 and v7
Mastectomy,targets,invasive breast carcinoma
Mastectomy,targets,triple-negative breast carcinoma
Mastectomy,targets,TNBC
NCT02883062,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,stage iii breast cancer ajcc v7
Paclitaxel,targets,stage ii breast cancer ajcc v6 and v7
Paclitaxel,targets,invasive breast carcinoma
Paclitaxel,targets,triple-negative breast carcinoma
Paclitaxel,targets,TNBC
NCT03289962,sponsored_by,"Genentech, Inc."
NCT03289962,has_status,COMPLETED
NCT03289962,tests,Autogene cevumeran
Autogene cevumeran,has_type,DRUG
Autogene cevumeran,classified_as,OTHER
Autogene cevumeran,targets,head and neck cancer
Autogene cevumeran,targets,melanoma
Autogene cevumeran,targets,non-small cell lung cancer
Autogene cevumeran,targets,triple negative breast cancer
Autogene cevumeran,targets,bladder cancer
Autogene cevumeran,targets,other solid cancers
Autogene cevumeran,targets,renal cancer
Autogene cevumeran,targets,colorectal cancer
Autogene cevumeran,targets,TNBC
NCT03289962,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,head and neck cancer
Atezolizumab,targets,melanoma
Atezolizumab,targets,non-small cell lung cancer
Atezolizumab,targets,triple negative breast cancer
Atezolizumab,targets,bladder cancer
Atezolizumab,targets,other solid cancers
Atezolizumab,targets,renal cancer
Atezolizumab,targets,colorectal cancer
Atezolizumab,targets,TNBC
NCT05680662,sponsored_by,"Ministry of Health, Saudi Arabia"
NCT05680662,has_status,UNKNOWN
NCT05680662,tests,"quercetin, EGCG, metformin , zinc"
"quercetin, EGCG, metformin , zinc",has_type,DRUG
"quercetin, EGCG, metformin , zinc",classified_as,OTHER
"quercetin, EGCG, metformin , zinc",targets,breast cancer female
"quercetin, EGCG, metformin , zinc",targets,triple negative breast cancer
"quercetin, EGCG, metformin , zinc",targets,TNBC
NCT03872791,sponsored_by,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd"
NCT03872791,has_status,COMPLETED
NCT03872791,tests,KN046
KN046,has_type,DRUG
KN046,classified_as,OTHER
KN046,targets,triple-negative breast cancer
KN046,targets,TNBC
NCT03872791,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple-negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT02719691,sponsored_by,"University of Colorado, Denver"
NCT02719691,has_status,COMPLETED
NCT02719691,tests,Alisertib
Alisertib,has_type,DRUG
Alisertib,classified_as,CHEMICAL
Alisertib,targets,solid tumors
Alisertib,targets,metastatic breast cancer
NCT02719691,tests,MLN0128
MLN0128,has_type,DRUG
MLN0128,classified_as,OTHER
MLN0128,targets,solid tumors
MLN0128,targets,metastatic breast cancer
NCT06418594,sponsored_by,Beijing 302 Hospital
NCT06418594,has_status,RECRUITING
NCT06418594,tests,Adebrelimab
Adebrelimab,has_type,DRUG
Adebrelimab,classified_as,BIOLOGIC
Adebrelimab,targets,her2-negative breast cancer brain metastases
NCT06418594,tests,Apatinib
Apatinib,has_type,DRUG
Apatinib,classified_as,CHEMICAL
Apatinib,targets,her2-negative breast cancer brain metastases
NCT06418594,tests,Etoposide
Etoposide,has_type,DRUG
Etoposide,classified_as,OTHER
Etoposide,targets,her2-negative breast cancer brain metastases
NCT03473691,sponsored_by,University of Virginia
NCT03473691,has_status,WITHDRAWN
NCT03473691,tests,Glembatumumab Vedotin
Glembatumumab Vedotin,has_type,DRUG
Glembatumumab Vedotin,classified_as,BIOLOGIC
Glembatumumab Vedotin,targets,triple negative breast cancer
Glembatumumab Vedotin,targets,TNBC
NCT02187991,sponsored_by,US Oncology Research
NCT02187991,has_status,COMPLETED
NCT02187991,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
Paclitaxel,targets,breast carcinoma
Paclitaxel,targets,breast tumors
Paclitaxel,targets,malignant neoplasm of breast
NCT02187991,tests,Alisertib
Alisertib,has_type,DRUG
Alisertib,classified_as,CHEMICAL
Alisertib,targets,breast cancer
Alisertib,targets,breast carcinoma
Alisertib,targets,breast tumors
Alisertib,targets,malignant neoplasm of breast
NCT04734262,sponsored_by,Fudan University
NCT04734262,has_status,ACTIVE_NOT_RECRUITING
NCT04734262,tests,Sitravatinib
Sitravatinib,has_type,DRUG
Sitravatinib,classified_as,CHEMICAL
Sitravatinib,targets,metastatic breast cancer
NCT04734262,tests,Tislelizumab
Tislelizumab,has_type,DRUG
Tislelizumab,classified_as,BIOLOGIC
Tislelizumab,targets,metastatic breast cancer
NCT04734262,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,metastatic breast cancer
NCT02689427,sponsored_by,M.D. Anderson Cancer Center
NCT02689427,has_status,COMPLETED
NCT02689427,tests,Axillary Lymph Node Dissection
Axillary Lymph Node Dissection,has_type,DRUG
Axillary Lymph Node Dissection,classified_as,OTHER
Axillary Lymph Node Dissection,targets,stage iiib breast cancer ajcc v7
Axillary Lymph Node Dissection,targets,stage i breast cancer ajcc v7
Axillary Lymph Node Dissection,targets,invasive breast carcinoma
Axillary Lymph Node Dissection,targets,stage iia breast cancer ajcc v6 and v7
Axillary Lymph Node Dissection,targets,stage iib breast cancer ajcc v6 and v7
Axillary Lymph Node Dissection,targets,stage iiia breast cancer ajcc v7
Axillary Lymph Node Dissection,targets,stage ia breast cancer ajcc v7
Axillary Lymph Node Dissection,targets,stage ii breast cancer ajcc v6 and v7
Axillary Lymph Node Dissection,targets,stage iiic breast cancer ajcc v7
Axillary Lymph Node Dissection,targets,stage iii breast cancer ajcc v7
Axillary Lymph Node Dissection,targets,stage ib breast cancer ajcc v7
Axillary Lymph Node Dissection,targets,triple-negative breast carcinoma
Axillary Lymph Node Dissection,targets,TNBC
NCT02689427,tests,Enzalutamide
Enzalutamide,has_type,DRUG
Enzalutamide,classified_as,OTHER
Enzalutamide,targets,stage iiib breast cancer ajcc v7
Enzalutamide,targets,stage i breast cancer ajcc v7
Enzalutamide,targets,invasive breast carcinoma
Enzalutamide,targets,stage iia breast cancer ajcc v6 and v7
Enzalutamide,targets,stage iib breast cancer ajcc v6 and v7
Enzalutamide,targets,stage iiia breast cancer ajcc v7
Enzalutamide,targets,stage ia breast cancer ajcc v7
Enzalutamide,targets,stage ii breast cancer ajcc v6 and v7
Enzalutamide,targets,stage iiic breast cancer ajcc v7
Enzalutamide,targets,stage iii breast cancer ajcc v7
Enzalutamide,targets,stage ib breast cancer ajcc v7
Enzalutamide,targets,triple-negative breast carcinoma
Enzalutamide,targets,TNBC
NCT02689427,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,stage iiib breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage i breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,invasive breast carcinoma
Laboratory Biomarker Analysis,targets,stage iia breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,stage iib breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,stage iiia breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage ia breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage ii breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,stage iiic breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage iii breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage ib breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,TNBC
NCT02689427,tests,Lymph Node Biopsy
Lymph Node Biopsy,has_type,DRUG
Lymph Node Biopsy,classified_as,OTHER
Lymph Node Biopsy,targets,stage iiib breast cancer ajcc v7
Lymph Node Biopsy,targets,stage i breast cancer ajcc v7
Lymph Node Biopsy,targets,invasive breast carcinoma
Lymph Node Biopsy,targets,stage iia breast cancer ajcc v6 and v7
Lymph Node Biopsy,targets,stage iib breast cancer ajcc v6 and v7
Lymph Node Biopsy,targets,stage iiia breast cancer ajcc v7
Lymph Node Biopsy,targets,stage ia breast cancer ajcc v7
Lymph Node Biopsy,targets,stage ii breast cancer ajcc v6 and v7
Lymph Node Biopsy,targets,stage iiic breast cancer ajcc v7
Lymph Node Biopsy,targets,stage iii breast cancer ajcc v7
Lymph Node Biopsy,targets,stage ib breast cancer ajcc v7
Lymph Node Biopsy,targets,triple-negative breast carcinoma
Lymph Node Biopsy,targets,TNBC
NCT02689427,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,stage iiib breast cancer ajcc v7
Paclitaxel,targets,stage i breast cancer ajcc v7
Paclitaxel,targets,invasive breast carcinoma
Paclitaxel,targets,stage iia breast cancer ajcc v6 and v7
Paclitaxel,targets,stage iib breast cancer ajcc v6 and v7
Paclitaxel,targets,stage iiia breast cancer ajcc v7
Paclitaxel,targets,stage ia breast cancer ajcc v7
Paclitaxel,targets,stage ii breast cancer ajcc v6 and v7
Paclitaxel,targets,stage iiic breast cancer ajcc v7
Paclitaxel,targets,stage iii breast cancer ajcc v7
Paclitaxel,targets,stage ib breast cancer ajcc v7
Paclitaxel,targets,triple-negative breast carcinoma
Paclitaxel,targets,TNBC
NCT02689427,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,DRUG
Therapeutic Conventional Surgery,classified_as,OTHER
Therapeutic Conventional Surgery,targets,stage iiib breast cancer ajcc v7
Therapeutic Conventional Surgery,targets,stage i breast cancer ajcc v7
Therapeutic Conventional Surgery,targets,invasive breast carcinoma
Therapeutic Conventional Surgery,targets,stage iia breast cancer ajcc v6 and v7
Therapeutic Conventional Surgery,targets,stage iib breast cancer ajcc v6 and v7
Therapeutic Conventional Surgery,targets,stage iiia breast cancer ajcc v7
Therapeutic Conventional Surgery,targets,stage ia breast cancer ajcc v7
Therapeutic Conventional Surgery,targets,stage ii breast cancer ajcc v6 and v7
Therapeutic Conventional Surgery,targets,stage iiic breast cancer ajcc v7
Therapeutic Conventional Surgery,targets,stage iii breast cancer ajcc v7
Therapeutic Conventional Surgery,targets,stage ib breast cancer ajcc v7
Therapeutic Conventional Surgery,targets,triple-negative breast carcinoma
Therapeutic Conventional Surgery,targets,TNBC
NCT06268327,sponsored_by,Assiut University
NCT06268327,has_status,NOT_YET_RECRUITING
NCT06268327,tests,Cisplatin injection and gemcitabine
Cisplatin injection and gemcitabine,has_type,DRUG
Cisplatin injection and gemcitabine,classified_as,CHEMICAL
Cisplatin injection and gemcitabine,targets,breast cancer
NCT06268327,tests,Capecitabine tablets
Capecitabine tablets,has_type,DRUG
Capecitabine tablets,classified_as,CHEMICAL
Capecitabine tablets,targets,breast cancer
NCT07018427,sponsored_by,Peking University Cancer Hospital & Institute
NCT07018427,has_status,ACTIVE_NOT_RECRUITING
NCT07018427,tests,Sacituzumab Govitecan Monotherapy or Combination Therapy
Sacituzumab Govitecan Monotherapy or Combination Therapy,has_type,DRUG
Sacituzumab Govitecan Monotherapy or Combination Therapy,classified_as,BIOLOGIC
Sacituzumab Govitecan Monotherapy or Combination Therapy,targets,breast neoplasms
Sacituzumab Govitecan Monotherapy or Combination Therapy,targets,breast cancer
Sacituzumab Govitecan Monotherapy or Combination Therapy,targets,"hr+, her2-, advanced breast cancer"
Sacituzumab Govitecan Monotherapy or Combination Therapy,targets,triple negative breast cancer
Sacituzumab Govitecan Monotherapy or Combination Therapy,targets,TNBC
NCT03674827,sponsored_by,Pfizer
NCT03674827,has_status,TERMINATED
NCT03674827,tests,PF-06936308
PF-06936308,has_type,DRUG
PF-06936308,classified_as,OTHER
PF-06936308,targets,non-small cell lung cancer
PF-06936308,targets,triple-negative breast cancer
PF-06936308,targets,TNBC
NCT02624973,sponsored_by,Haukeland University Hospital
NCT02624973,has_status,ACTIVE_NOT_RECRUITING
NCT02624973,tests,Neoadjuvant tamoxifen + goserelin (premenopausal women)
Neoadjuvant tamoxifen + goserelin (premenopausal women),has_type,DRUG
Neoadjuvant tamoxifen + goserelin (premenopausal women),classified_as,CHEMICAL
Neoadjuvant tamoxifen + goserelin (premenopausal women),targets,breast cancer
NCT02624973,tests,Neoadjuvant letrozole (postmenopausal women)
Neoadjuvant letrozole (postmenopausal women),has_type,DRUG
Neoadjuvant letrozole (postmenopausal women),classified_as,CHEMICAL
Neoadjuvant letrozole (postmenopausal women),targets,breast cancer
NCT02624973,tests,Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)
Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone),has_type,DRUG
Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone),classified_as,CHEMICAL
Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone),targets,breast cancer
NCT02624973,tests,Neoadjuvant docetaxel + cyclophosphamide
Neoadjuvant docetaxel + cyclophosphamide,has_type,DRUG
Neoadjuvant docetaxel + cyclophosphamide,classified_as,CHEMICAL
Neoadjuvant docetaxel + cyclophosphamide,targets,breast cancer
NCT02624973,tests,Neoadjuvant docetaxel
Neoadjuvant docetaxel,has_type,DRUG
Neoadjuvant docetaxel,classified_as,CHEMICAL
Neoadjuvant docetaxel,targets,breast cancer
NCT02624973,tests,Neoadjuvant docetaxel + trastuzumab + pertuzumab
Neoadjuvant docetaxel + trastuzumab + pertuzumab,has_type,DRUG
Neoadjuvant docetaxel + trastuzumab + pertuzumab,classified_as,BIOLOGIC
Neoadjuvant docetaxel + trastuzumab + pertuzumab,targets,breast cancer
NCT02624973,tests,Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab
Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab,has_type,DRUG
Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab,classified_as,BIOLOGIC
Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab,targets,breast cancer
NCT02624973,tests,Neoadjuvant olaparib
Neoadjuvant olaparib,has_type,DRUG
Neoadjuvant olaparib,classified_as,BIOLOGIC
Neoadjuvant olaparib,targets,breast cancer
NCT02624973,tests,Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)
Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone),has_type,DRUG
Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone),classified_as,BIOLOGIC
Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone),targets,breast cancer
NCT02624973,tests,Breast conserving surgery or mastectomy + SNB/axillary dissection
Breast conserving surgery or mastectomy + SNB/axillary dissection,has_type,DRUG
Breast conserving surgery or mastectomy + SNB/axillary dissection,classified_as,OTHER
Breast conserving surgery or mastectomy + SNB/axillary dissection,targets,breast cancer
NCT02624973,tests,Postoperative radiotherapy breast/chest wall + regional lymph nodes
Postoperative radiotherapy breast/chest wall + regional lymph nodes,has_type,DRUG
Postoperative radiotherapy breast/chest wall + regional lymph nodes,classified_as,OTHER
Postoperative radiotherapy breast/chest wall + regional lymph nodes,targets,breast cancer
NCT02624973,tests,Adjuvant trastuzumab
Adjuvant trastuzumab,has_type,DRUG
Adjuvant trastuzumab,classified_as,BIOLOGIC
Adjuvant trastuzumab,targets,breast cancer
NCT02624973,tests,Adjuvant letrozole (postmenopausal women)
Adjuvant letrozole (postmenopausal women),has_type,DRUG
Adjuvant letrozole (postmenopausal women),classified_as,CHEMICAL
Adjuvant letrozole (postmenopausal women),targets,breast cancer
NCT02624973,tests,Adjuvant tamoxifen + goserelin (premenopausal women)
Adjuvant tamoxifen + goserelin (premenopausal women),has_type,DRUG
Adjuvant tamoxifen + goserelin (premenopausal women),classified_as,CHEMICAL
Adjuvant tamoxifen + goserelin (premenopausal women),targets,breast cancer
NCT02624973,tests,Adjuvant palbociclib (if palbociclib given neoadjuvant)
Adjuvant palbociclib (if palbociclib given neoadjuvant),has_type,DRUG
Adjuvant palbociclib (if palbociclib given neoadjuvant),classified_as,CHEMICAL
Adjuvant palbociclib (if palbociclib given neoadjuvant),targets,breast cancer
NCT02624973,tests,Adjuvant Epirubicin+ Cyclophosphamide
Adjuvant Epirubicin+ Cyclophosphamide,has_type,DRUG
Adjuvant Epirubicin+ Cyclophosphamide,classified_as,CHEMICAL
Adjuvant Epirubicin+ Cyclophosphamide,targets,breast cancer
NCT06649331,sponsored_by,Fudan University
NCT06649331,has_status,RECRUITING
NCT06649331,tests,SHR-A1811
SHR-A1811,has_type,DRUG
SHR-A1811,classified_as,OTHER
SHR-A1811,targets,her2-negative breast cancer
SHR-A1811,targets,breast cancer
SHR-A1811,targets,advanced breast cancer
SHR-A1811,targets,triple negative breast cancer (tnbc)
SHR-A1811,targets,metastatic breast cancer
SHR-A1811,targets,TNBC
NCT06649331,tests,SHR-A1921
SHR-A1921,has_type,DRUG
SHR-A1921,classified_as,OTHER
SHR-A1921,targets,her2-negative breast cancer
SHR-A1921,targets,breast cancer
SHR-A1921,targets,advanced breast cancer
SHR-A1921,targets,triple negative breast cancer (tnbc)
SHR-A1921,targets,metastatic breast cancer
SHR-A1921,targets,TNBC
NCT06649331,tests,SHR-A2009
SHR-A2009,has_type,DRUG
SHR-A2009,classified_as,OTHER
SHR-A2009,targets,her2-negative breast cancer
SHR-A2009,targets,breast cancer
SHR-A2009,targets,advanced breast cancer
SHR-A2009,targets,triple negative breast cancer (tnbc)
SHR-A2009,targets,metastatic breast cancer
SHR-A2009,targets,TNBC
NCT06649331,tests,SHR-A2102
SHR-A2102,has_type,DRUG
SHR-A2102,classified_as,OTHER
SHR-A2102,targets,her2-negative breast cancer
SHR-A2102,targets,breast cancer
SHR-A2102,targets,advanced breast cancer
SHR-A2102,targets,triple negative breast cancer (tnbc)
SHR-A2102,targets,metastatic breast cancer
SHR-A2102,targets,TNBC
NCT02659631,sponsored_by,Pfizer
NCT02659631,has_status,TERMINATED
NCT02659631,tests,PF-06671008
PF-06671008,has_type,DRUG
PF-06671008,classified_as,OTHER
PF-06671008,targets,neoplasms
NCT02659631,tests,PF-06671008
PF-06671008,has_type,DRUG
PF-06671008,classified_as,OTHER
PF-06671008,targets,neoplasms
NCT07017673,sponsored_by,Cedars-Sinai Medical Center
NCT07017673,has_status,NOT_YET_RECRUITING
NCT07017673,tests,Ivonescimab
Ivonescimab,has_type,DRUG
Ivonescimab,classified_as,BIOLOGIC
Ivonescimab,targets,tnbc
Ivonescimab,targets,tnbc - triple-negative breast cancer
Ivonescimab,targets,early stage triple-negative breast carcinoma
Ivonescimab,targets,TNBC
NCT07017673,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,tnbc
Carboplatin,targets,tnbc - triple-negative breast cancer
Carboplatin,targets,early stage triple-negative breast carcinoma
Carboplatin,targets,TNBC
NCT07017673,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,tnbc
Docetaxel,targets,tnbc - triple-negative breast cancer
Docetaxel,targets,early stage triple-negative breast carcinoma
Docetaxel,targets,TNBC
NCT03241173,sponsored_by,Incyte Biosciences International Sàrl
NCT03241173,has_status,COMPLETED
NCT03241173,tests,INCAGN01949
INCAGN01949,has_type,DRUG
INCAGN01949,classified_as,OTHER
INCAGN01949,targets,advanced malignancies
NCT03241173,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,advanced malignancies
NCT03241173,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,advanced malignancies
NCT03911973,sponsored_by,Kari Wisinski
NCT03911973,has_status,ACTIVE_NOT_RECRUITING
NCT03911973,tests,Gedatolisib
Gedatolisib,has_type,DRUG
Gedatolisib,classified_as,CHEMICAL
Gedatolisib,targets,tnbc - triple-negative breast cancer
Gedatolisib,targets,TNBC
NCT03911973,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,tnbc - triple-negative breast cancer
Talazoparib,targets,TNBC
NCT03170960,sponsored_by,Exelixis
NCT03170960,has_status,UNKNOWN
NCT03170960,tests,cabozantinib
cabozantinib,has_type,DRUG
cabozantinib,classified_as,CHEMICAL
cabozantinib,targets,head and neck cancer
cabozantinib,targets,renal cell carcinoma
cabozantinib,targets,non-small cell lung cancer
cabozantinib,targets,gastric cancer
cabozantinib,targets,hepatocellular carcinoma
cabozantinib,targets,urothelial carcinoma
cabozantinib,targets,ovarian cancer
cabozantinib,targets,castration-resistant prostate cancer
cabozantinib,targets,triple negative breast cancer
cabozantinib,targets,lower esophageal cancer
cabozantinib,targets,differentiated thyroid cancer
cabozantinib,targets,endometrial cancer
cabozantinib,targets,gastroesophageal junction adenocarcinoma
cabozantinib,targets,colorectal cancer
cabozantinib,targets,TNBC
NCT03170960,tests,atezolizumab
atezolizumab,has_type,DRUG
atezolizumab,classified_as,BIOLOGIC
atezolizumab,targets,head and neck cancer
atezolizumab,targets,renal cell carcinoma
atezolizumab,targets,non-small cell lung cancer
atezolizumab,targets,gastric cancer
atezolizumab,targets,hepatocellular carcinoma
atezolizumab,targets,urothelial carcinoma
atezolizumab,targets,ovarian cancer
atezolizumab,targets,castration-resistant prostate cancer
atezolizumab,targets,triple negative breast cancer
atezolizumab,targets,lower esophageal cancer
atezolizumab,targets,differentiated thyroid cancer
atezolizumab,targets,endometrial cancer
atezolizumab,targets,gastroesophageal junction adenocarcinoma
atezolizumab,targets,colorectal cancer
atezolizumab,targets,TNBC
NCT03170960,tests,cabozantinib
cabozantinib,has_type,DRUG
cabozantinib,classified_as,CHEMICAL
cabozantinib,targets,head and neck cancer
cabozantinib,targets,renal cell carcinoma
cabozantinib,targets,non-small cell lung cancer
cabozantinib,targets,gastric cancer
cabozantinib,targets,hepatocellular carcinoma
cabozantinib,targets,urothelial carcinoma
cabozantinib,targets,ovarian cancer
cabozantinib,targets,castration-resistant prostate cancer
cabozantinib,targets,triple negative breast cancer
cabozantinib,targets,lower esophageal cancer
cabozantinib,targets,differentiated thyroid cancer
cabozantinib,targets,endometrial cancer
cabozantinib,targets,gastroesophageal junction adenocarcinoma
cabozantinib,targets,colorectal cancer
cabozantinib,targets,TNBC
NCT03170960,tests,cabozantinib
cabozantinib,has_type,DRUG
cabozantinib,classified_as,CHEMICAL
cabozantinib,targets,head and neck cancer
cabozantinib,targets,renal cell carcinoma
cabozantinib,targets,non-small cell lung cancer
cabozantinib,targets,gastric cancer
cabozantinib,targets,hepatocellular carcinoma
cabozantinib,targets,urothelial carcinoma
cabozantinib,targets,ovarian cancer
cabozantinib,targets,castration-resistant prostate cancer
cabozantinib,targets,triple negative breast cancer
cabozantinib,targets,lower esophageal cancer
cabozantinib,targets,differentiated thyroid cancer
cabozantinib,targets,endometrial cancer
cabozantinib,targets,gastroesophageal junction adenocarcinoma
cabozantinib,targets,colorectal cancer
cabozantinib,targets,TNBC
NCT05983094,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT05983094,has_status,NOT_YET_RECRUITING
NCT05983094,tests,Utidelone
Utidelone,has_type,DRUG
Utidelone,classified_as,OTHER
Utidelone,targets,breast cancer
Utidelone,targets,neoadjuvant therapy
NCT05983094,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,neoadjuvant therapy
NCT05983094,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,breast cancer
Epirubicin,targets,neoadjuvant therapy
NCT05983094,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,breast cancer
Trastuzumab,targets,neoadjuvant therapy
NCT05983094,tests,Pertuzumab
Pertuzumab,has_type,DRUG
Pertuzumab,classified_as,BIOLOGIC
Pertuzumab,targets,breast cancer
Pertuzumab,targets,neoadjuvant therapy
NCT03362060,sponsored_by,Massachusetts General Hospital
NCT03362060,has_status,ACTIVE_NOT_RECRUITING
NCT03362060,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic breast cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT03362060,tests,PVX-410
PVX-410,has_type,DRUG
PVX-410,classified_as,OTHER
PVX-410,targets,metastatic breast cancer
PVX-410,targets,triple negative breast cancer
PVX-410,targets,TNBC
NCT05627960,sponsored_by,A&G Pharmaceutical Inc.
NCT05627960,has_status,RECRUITING
NCT05627960,tests,AG-01 Compound
AG-01 Compound,has_type,DRUG
AG-01 Compound,classified_as,OTHER
AG-01 Compound,targets,mesothelioma
AG-01 Compound,targets,hormone-resistant breast cancer
AG-01 Compound,targets,non small cell lung cancer
AG-01 Compound,targets,triple negative breast cancer
AG-01 Compound,targets,TNBC
NCT05076760,sponsored_by,"Memgen, Inc."
NCT05076760,has_status,RECRUITING
NCT05076760,tests,MEM-288 Intratumoral Injection
MEM-288 Intratumoral Injection,has_type,DRUG
MEM-288 Intratumoral Injection,classified_as,OTHER
MEM-288 Intratumoral Injection,targets,head and neck cancer
MEM-288 Intratumoral Injection,targets,melanoma
MEM-288 Intratumoral Injection,targets,merkel cell carcinoma
MEM-288 Intratumoral Injection,targets,metastatic cancer
MEM-288 Intratumoral Injection,targets,solid tumor
MEM-288 Intratumoral Injection,targets,pancreatic cancer
MEM-288 Intratumoral Injection,targets,triple negative breast cancer
MEM-288 Intratumoral Injection,targets,advanced cancer
MEM-288 Intratumoral Injection,targets,cutaneous squamous cell carcinoma
MEM-288 Intratumoral Injection,targets,non small cell lung cancer
MEM-288 Intratumoral Injection,targets,TNBC
NCT05076760,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,head and neck cancer
Nivolumab,targets,melanoma
Nivolumab,targets,merkel cell carcinoma
Nivolumab,targets,metastatic cancer
Nivolumab,targets,solid tumor
Nivolumab,targets,pancreatic cancer
Nivolumab,targets,triple negative breast cancer
Nivolumab,targets,advanced cancer
Nivolumab,targets,cutaneous squamous cell carcinoma
Nivolumab,targets,non small cell lung cancer
Nivolumab,targets,TNBC
NCT05076760,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,head and neck cancer
Docetaxel,targets,melanoma
Docetaxel,targets,merkel cell carcinoma
Docetaxel,targets,metastatic cancer
Docetaxel,targets,solid tumor
Docetaxel,targets,pancreatic cancer
Docetaxel,targets,triple negative breast cancer
Docetaxel,targets,advanced cancer
Docetaxel,targets,cutaneous squamous cell carcinoma
Docetaxel,targets,non small cell lung cancer
Docetaxel,targets,TNBC
NCT02474173,sponsored_by,National Cancer Institute (NCI)
NCT02474173,has_status,TERMINATED
NCT02474173,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,stage iiib breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,advanced breast carcinoma
Laboratory Biomarker Analysis,targets,stage iiia breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage iiic breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,metastatic breast carcinoma
Laboratory Biomarker Analysis,targets,stage iii breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,stage iv breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,TNBC
NCT02474173,tests,Onalespib
Onalespib,has_type,DRUG
Onalespib,classified_as,CHEMICAL
Onalespib,targets,stage iiib breast cancer ajcc v7
Onalespib,targets,advanced breast carcinoma
Onalespib,targets,stage iiia breast cancer ajcc v7
Onalespib,targets,stage iiic breast cancer ajcc v7
Onalespib,targets,metastatic breast carcinoma
Onalespib,targets,stage iii breast cancer ajcc v7
Onalespib,targets,triple-negative breast carcinoma
Onalespib,targets,stage iv breast cancer ajcc v6 and v7
Onalespib,targets,TNBC
NCT02474173,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,stage iiib breast cancer ajcc v7
Paclitaxel,targets,advanced breast carcinoma
Paclitaxel,targets,stage iiia breast cancer ajcc v7
Paclitaxel,targets,stage iiic breast cancer ajcc v7
Paclitaxel,targets,metastatic breast carcinoma
Paclitaxel,targets,stage iii breast cancer ajcc v7
Paclitaxel,targets,triple-negative breast carcinoma
Paclitaxel,targets,stage iv breast cancer ajcc v6 and v7
Paclitaxel,targets,TNBC
NCT02474173,tests,Pharmacological Study
Pharmacological Study,has_type,DRUG
Pharmacological Study,classified_as,OTHER
Pharmacological Study,targets,stage iiib breast cancer ajcc v7
Pharmacological Study,targets,advanced breast carcinoma
Pharmacological Study,targets,stage iiia breast cancer ajcc v7
Pharmacological Study,targets,stage iiic breast cancer ajcc v7
Pharmacological Study,targets,metastatic breast carcinoma
Pharmacological Study,targets,stage iii breast cancer ajcc v7
Pharmacological Study,targets,triple-negative breast carcinoma
Pharmacological Study,targets,stage iv breast cancer ajcc v6 and v7
Pharmacological Study,targets,TNBC
NCT03316794,sponsored_by,AbbVie
NCT03316794,has_status,TERMINATED
NCT03316794,tests,SC-005
SC-005,has_type,DRUG
SC-005,classified_as,OTHER
SC-005,targets,breast cancer
NCT05422794,sponsored_by,National Cancer Institute (NCI)
NCT05422794,has_status,RECRUITING
NCT05422794,tests,BET Bromodomain Inhibitor ZEN-3694
BET Bromodomain Inhibitor ZEN-3694,has_type,DRUG
BET Bromodomain Inhibitor ZEN-3694,classified_as,CHEMICAL
BET Bromodomain Inhibitor ZEN-3694,targets,unresectable triple-negative breast carcinoma
BET Bromodomain Inhibitor ZEN-3694,targets,locally advanced triple-negative breast carcinoma
BET Bromodomain Inhibitor ZEN-3694,targets,anatomic stage iv breast cancer ajcc v8
BET Bromodomain Inhibitor ZEN-3694,targets,metastatic triple-negative breast carcinoma
BET Bromodomain Inhibitor ZEN-3694,targets,anatomic stage iii breast cancer ajcc v8
BET Bromodomain Inhibitor ZEN-3694,targets,TNBC
NCT05422794,tests,Biopsy Procedure
Biopsy Procedure,has_type,DRUG
Biopsy Procedure,classified_as,OTHER
Biopsy Procedure,targets,unresectable triple-negative breast carcinoma
Biopsy Procedure,targets,locally advanced triple-negative breast carcinoma
Biopsy Procedure,targets,anatomic stage iv breast cancer ajcc v8
Biopsy Procedure,targets,metastatic triple-negative breast carcinoma
Biopsy Procedure,targets,anatomic stage iii breast cancer ajcc v8
Biopsy Procedure,targets,TNBC
NCT05422794,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,unresectable triple-negative breast carcinoma
Biospecimen Collection,targets,locally advanced triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iv breast cancer ajcc v8
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iii breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT05422794,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,unresectable triple-negative breast carcinoma
Computed Tomography,targets,locally advanced triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iii breast cancer ajcc v8
Computed Tomography,targets,TNBC
NCT05422794,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,unresectable triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,locally advanced triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iv breast cancer ajcc v8
Magnetic Resonance Imaging,targets,metastatic triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iii breast cancer ajcc v8
Magnetic Resonance Imaging,targets,TNBC
NCT05422794,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,unresectable triple-negative breast carcinoma
Nab-paclitaxel,targets,locally advanced triple-negative breast carcinoma
Nab-paclitaxel,targets,anatomic stage iv breast cancer ajcc v8
Nab-paclitaxel,targets,metastatic triple-negative breast carcinoma
Nab-paclitaxel,targets,anatomic stage iii breast cancer ajcc v8
Nab-paclitaxel,targets,TNBC
NCT05422794,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,unresectable triple-negative breast carcinoma
Pembrolizumab,targets,locally advanced triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iv breast cancer ajcc v8
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iii breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT02993094,sponsored_by,Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT02993094,has_status,TERMINATED
NCT02993094,tests,Ixazomib
Ixazomib,has_type,DRUG
Ixazomib,classified_as,CHEMICAL
Ixazomib,targets,triple-negative breast cancer
Ixazomib,targets,TNBC
NCT02993094,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple-negative breast cancer
Carboplatin,targets,TNBC
NCT02263495,sponsored_by,Asan Medical Center
NCT02263495,has_status,COMPLETED
NCT02263495,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,metastatic breast cancer
NCT02263495,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,metastatic breast cancer
NCT02263495,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,metastatic breast cancer
NCT05374512,sponsored_by,AstraZeneca
NCT05374512,has_status,ACTIVE_NOT_RECRUITING
NCT05374512,tests,Dato-DXd
Dato-DXd,has_type,DRUG
Dato-DXd,classified_as,OTHER
Dato-DXd,targets,breast cancer
NCT05374512,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT05374512,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,breast cancer
NCT05374512,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
NCT05374512,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
NCT05374512,tests,Eribulin mesylate
Eribulin mesylate,has_type,DRUG
Eribulin mesylate,classified_as,CHEMICAL
Eribulin mesylate,targets,breast cancer
NCT03483012,sponsored_by,Dana-Farber Cancer Institute
NCT03483012,has_status,ACTIVE_NOT_RECRUITING
NCT03483012,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,breast cancer
NCT03483012,tests,Stereotactic radiosurgery (SRS)
Stereotactic radiosurgery (SRS),has_type,DRUG
Stereotactic radiosurgery (SRS),classified_as,OTHER
Stereotactic radiosurgery (SRS),targets,breast cancer
NCT06154291,sponsored_by,Xenothera SAS
NCT06154291,has_status,RECRUITING
NCT06154291,tests,XON7
XON7,has_type,DRUG
XON7,classified_as,OTHER
XON7,targets,advanced solid tumor
XON7,targets,metastatic cancer
NCT02425891,sponsored_by,Hoffmann-La Roche
NCT02425891,has_status,COMPLETED
NCT02425891,tests,"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",has_type,DRUG
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",classified_as,BIOLOGIC
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",targets,triple negative breast cancer
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",targets,TNBC
NCT02425891,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,triple negative breast cancer
Nab-Paclitaxel,targets,TNBC
NCT02425891,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast cancer
Placebo,targets,TNBC
NCT05852691,sponsored_by,Hoffmann-La Roche
NCT05852691,has_status,ACTIVE_NOT_RECRUITING
NCT05852691,tests,Tobemstomig
Tobemstomig,has_type,DRUG
Tobemstomig,classified_as,OTHER
Tobemstomig,targets,breast cancer
NCT05852691,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT05852691,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,breast cancer
NCT03564691,sponsored_by,Merck Sharp & Dohme LLC
NCT03564691,has_status,ACTIVE_NOT_RECRUITING
NCT03564691,tests,MK-4830
MK-4830,has_type,DRUG
MK-4830,classified_as,OTHER
MK-4830,targets,neoplasms
NCT03564691,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,neoplasms
NCT03564691,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,neoplasms
NCT03564691,tests,Pemetrexed
Pemetrexed,has_type,DRUG
Pemetrexed,classified_as,OTHER
Pemetrexed,targets,neoplasms
NCT03564691,tests,Lenvatinib
Lenvatinib,has_type,DRUG
Lenvatinib,classified_as,CHEMICAL
Lenvatinib,targets,neoplasms
NCT03564691,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,neoplasms
NCT03564691,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,neoplasms
NCT03564691,tests,MK-4830A
MK-4830A,has_type,DRUG
MK-4830A,classified_as,OTHER
MK-4830A,targets,neoplasms
NCT04664829,sponsored_by,"National Cancer Centre, Singapore"
NCT04664829,has_status,RECRUITING
NCT04664829,tests,Bexarotene
Bexarotene,has_type,DRUG
Bexarotene,classified_as,OTHER
Bexarotene,targets,metastatic triple-negative breast carcinoma
Bexarotene,targets,TNBC
NCT04664829,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,metastatic triple-negative breast carcinoma
Capecitabine,targets,TNBC
NCT02530489,sponsored_by,M.D. Anderson Cancer Center
NCT02530489,has_status,COMPLETED
NCT02530489,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,breast adenocarcinoma
Atezolizumab,targets,invasive breast carcinoma
Atezolizumab,targets,triple-negative breast carcinoma
Atezolizumab,targets,TNBC
NCT02530489,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,breast adenocarcinoma
Nab-paclitaxel,targets,invasive breast carcinoma
Nab-paclitaxel,targets,triple-negative breast carcinoma
Nab-paclitaxel,targets,TNBC
NCT05438329,sponsored_by,DualityBio Inc.
NCT05438329,has_status,RECRUITING
NCT05438329,tests,DB-1305/BNT325
DB-1305/BNT325,has_type,DRUG
DB-1305/BNT325,classified_as,OTHER
DB-1305/BNT325,targets,advanced solid tumor
NCT05438329,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,advanced solid tumor
NCT05438329,tests,BNT327
BNT327,has_type,DRUG
BNT327,classified_as,OTHER
BNT327,targets,advanced solid tumor
NCT02554812,sponsored_by,Pfizer
NCT02554812,has_status,TERMINATED
NCT02554812,tests,Avelumab
Avelumab,has_type,DRUG
Avelumab,classified_as,BIOLOGIC
Avelumab,targets,advanced cancer
NCT02554812,tests,Utomilumab
Utomilumab,has_type,DRUG
Utomilumab,classified_as,BIOLOGIC
Utomilumab,targets,advanced cancer
NCT02554812,tests,PF-04518600
PF-04518600,has_type,DRUG
PF-04518600,classified_as,OTHER
PF-04518600,targets,advanced cancer
NCT02554812,tests,PD 0360324
PD 0360324,has_type,DRUG
PD 0360324,classified_as,OTHER
PD 0360324,targets,advanced cancer
NCT02554812,tests,CMP-001
CMP-001,has_type,DRUG
CMP-001,classified_as,OTHER
CMP-001,targets,advanced cancer
NCT04584112,sponsored_by,Hoffmann-La Roche
NCT04584112,has_status,COMPLETED
NCT04584112,tests,Tiragolumab
Tiragolumab,has_type,DRUG
Tiragolumab,classified_as,BIOLOGIC
Tiragolumab,targets,triple-negative breast cancer
Tiragolumab,targets,TNBC
NCT04584112,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,triple-negative breast cancer
Atezolizumab,targets,TNBC
NCT04584112,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple-negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT04584112,tests,Tiragolumab
Tiragolumab,has_type,DRUG
Tiragolumab,classified_as,BIOLOGIC
Tiragolumab,targets,triple-negative breast cancer
Tiragolumab,targets,TNBC
NCT04584112,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,triple-negative breast cancer
Atezolizumab,targets,TNBC
NCT04584112,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple-negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT04584112,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple-negative breast cancer
Carboplatin,targets,TNBC
NCT04584112,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,triple-negative breast cancer
Doxorubicin,targets,TNBC
NCT04584112,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple-negative breast cancer
Cyclophosphamide,targets,TNBC
NCT04584112,tests,Granulocyte colony-stimulating factor (G-CSF)
Granulocyte colony-stimulating factor (G-CSF),has_type,DRUG
Granulocyte colony-stimulating factor (G-CSF),classified_as,OTHER
Granulocyte colony-stimulating factor (G-CSF),targets,triple-negative breast cancer
Granulocyte colony-stimulating factor (G-CSF),targets,TNBC
NCT04584112,tests,Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Granulocyte-macrophage colony-stimulating factor (GM-CSF),has_type,DRUG
Granulocyte-macrophage colony-stimulating factor (GM-CSF),classified_as,OTHER
Granulocyte-macrophage colony-stimulating factor (GM-CSF),targets,triple-negative breast cancer
Granulocyte-macrophage colony-stimulating factor (GM-CSF),targets,TNBC
NCT04434040,sponsored_by,Dana-Farber Cancer Institute
NCT04434040,has_status,ACTIVE_NOT_RECRUITING
NCT04434040,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,breast cancer
Atezolizumab,targets,circulating tumor dna
Atezolizumab,targets,residual cancer
Atezolizumab,targets,triple negative breast cancer
Atezolizumab,targets,TNBC
NCT04434040,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
Sacituzumab govitecan,classified_as,BIOLOGIC
Sacituzumab govitecan,targets,breast cancer
Sacituzumab govitecan,targets,circulating tumor dna
Sacituzumab govitecan,targets,residual cancer
Sacituzumab govitecan,targets,triple negative breast cancer
Sacituzumab govitecan,targets,TNBC
NCT06690840,sponsored_by,European Institute of Oncology
NCT06690840,has_status,NOT_YET_RECRUITING
NCT06690840,tests,Atezolizumab in combination with Cyclophosphamide and Vinorelbine
Atezolizumab in combination with Cyclophosphamide and Vinorelbine,has_type,DRUG
Atezolizumab in combination with Cyclophosphamide and Vinorelbine,classified_as,BIOLOGIC
Atezolizumab in combination with Cyclophosphamide and Vinorelbine,targets,triple negative breast cancer
Atezolizumab in combination with Cyclophosphamide and Vinorelbine,targets,TNBC
NCT05491226,sponsored_by,Stephen Shiao
NCT05491226,has_status,ACTIVE_NOT_RECRUITING
NCT05491226,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,tnbc - triple-negative breast cancer
Pembrolizumab,targets,TNBC
NCT05491226,tests,Radiation Therapy
Radiation Therapy,has_type,DRUG
Radiation Therapy,classified_as,OTHER
Radiation Therapy,targets,breast cancer
Radiation Therapy,targets,tnbc - triple-negative breast cancer
Radiation Therapy,targets,TNBC
NCT05491226,tests,Axatilimab
Axatilimab,has_type,DRUG
Axatilimab,classified_as,BIOLOGIC
Axatilimab,targets,breast cancer
Axatilimab,targets,tnbc - triple-negative breast cancer
Axatilimab,targets,TNBC
NCT05868226,sponsored_by,QuantumLeap Healthcare Collaborative
NCT05868226,has_status,RECRUITING
NCT05868226,tests,ALX148
ALX148,has_type,DRUG
ALX148,classified_as,OTHER
ALX148,targets,her2-positive metastatic breast cancer
ALX148,targets,metastatic cancer
ALX148,targets,her2-negative breast cancer
ALX148,targets,progesterone receptor-positive breast cancer
ALX148,targets,her-2 protein overexpression
ALX148,targets,her2 mutation-related tumors
ALX148,targets,"solid tumor, adult"
ALX148,targets,triple negative breast cancer
ALX148,targets,her2-positive breast cancer
ALX148,targets,solid tumor
ALX148,targets,estrogen receptor positive tumor
ALX148,targets,hormone receptor negative breast carcinoma
ALX148,targets,hormone receptor-positive breast cancer
ALX148,targets,her2 low breast carcinoma
ALX148,targets,her2 low breast cancer
ALX148,targets,er positive breast cancer
ALX148,targets,metastatic breast cancer
ALX148,targets,metastatic
ALX148,targets,pr-positive breast cancer
ALX148,targets,solid carcinoma
ALX148,targets,hr positive
ALX148,targets,TNBC
NCT05868226,tests,Fam-Trastuzumab Deruxtecan-Nxki
Fam-Trastuzumab Deruxtecan-Nxki,has_type,DRUG
Fam-Trastuzumab Deruxtecan-Nxki,classified_as,BIOLOGIC
Fam-Trastuzumab Deruxtecan-Nxki,targets,her2-positive metastatic breast cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,metastatic cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,her2-negative breast cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,progesterone receptor-positive breast cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,her-2 protein overexpression
Fam-Trastuzumab Deruxtecan-Nxki,targets,her2 mutation-related tumors
Fam-Trastuzumab Deruxtecan-Nxki,targets,"solid tumor, adult"
Fam-Trastuzumab Deruxtecan-Nxki,targets,triple negative breast cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,her2-positive breast cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,solid tumor
Fam-Trastuzumab Deruxtecan-Nxki,targets,estrogen receptor positive tumor
Fam-Trastuzumab Deruxtecan-Nxki,targets,hormone receptor negative breast carcinoma
Fam-Trastuzumab Deruxtecan-Nxki,targets,hormone receptor-positive breast cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,her2 low breast carcinoma
Fam-Trastuzumab Deruxtecan-Nxki,targets,her2 low breast cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,er positive breast cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,metastatic breast cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,metastatic
Fam-Trastuzumab Deruxtecan-Nxki,targets,pr-positive breast cancer
Fam-Trastuzumab Deruxtecan-Nxki,targets,solid carcinoma
Fam-Trastuzumab Deruxtecan-Nxki,targets,hr positive
Fam-Trastuzumab Deruxtecan-Nxki,targets,TNBC
NCT05868226,tests,Zanidatamab
Zanidatamab,has_type,DRUG
Zanidatamab,classified_as,BIOLOGIC
Zanidatamab,targets,her2-positive metastatic breast cancer
Zanidatamab,targets,metastatic cancer
Zanidatamab,targets,her2-negative breast cancer
Zanidatamab,targets,progesterone receptor-positive breast cancer
Zanidatamab,targets,her-2 protein overexpression
Zanidatamab,targets,her2 mutation-related tumors
Zanidatamab,targets,"solid tumor, adult"
Zanidatamab,targets,triple negative breast cancer
Zanidatamab,targets,her2-positive breast cancer
Zanidatamab,targets,solid tumor
Zanidatamab,targets,estrogen receptor positive tumor
Zanidatamab,targets,hormone receptor negative breast carcinoma
Zanidatamab,targets,hormone receptor-positive breast cancer
Zanidatamab,targets,her2 low breast carcinoma
Zanidatamab,targets,her2 low breast cancer
Zanidatamab,targets,er positive breast cancer
Zanidatamab,targets,metastatic breast cancer
Zanidatamab,targets,metastatic
Zanidatamab,targets,pr-positive breast cancer
Zanidatamab,targets,solid carcinoma
Zanidatamab,targets,hr positive
Zanidatamab,targets,TNBC
NCT05868226,tests,Tucatinib
Tucatinib,has_type,DRUG
Tucatinib,classified_as,CHEMICAL
Tucatinib,targets,her2-positive metastatic breast cancer
Tucatinib,targets,metastatic cancer
Tucatinib,targets,her2-negative breast cancer
Tucatinib,targets,progesterone receptor-positive breast cancer
Tucatinib,targets,her-2 protein overexpression
Tucatinib,targets,her2 mutation-related tumors
Tucatinib,targets,"solid tumor, adult"
Tucatinib,targets,triple negative breast cancer
Tucatinib,targets,her2-positive breast cancer
Tucatinib,targets,solid tumor
Tucatinib,targets,estrogen receptor positive tumor
Tucatinib,targets,hormone receptor negative breast carcinoma
Tucatinib,targets,hormone receptor-positive breast cancer
Tucatinib,targets,her2 low breast carcinoma
Tucatinib,targets,her2 low breast cancer
Tucatinib,targets,er positive breast cancer
Tucatinib,targets,metastatic breast cancer
Tucatinib,targets,metastatic
Tucatinib,targets,pr-positive breast cancer
Tucatinib,targets,solid carcinoma
Tucatinib,targets,hr positive
Tucatinib,targets,TNBC
NCT03932526,sponsored_by,Liaoning Cancer Hospital & Institute
NCT03932526,has_status,UNKNOWN
NCT03932526,tests,Vinorelbine + placebo
Vinorelbine + placebo,has_type,DRUG
Vinorelbine + placebo,classified_as,OTHER
Vinorelbine + placebo,targets,triple-negative breast cancer
Vinorelbine + placebo,targets,TNBC
NCT03932526,tests,Vinorelbine + Apatinib
Vinorelbine + Apatinib,has_type,DRUG
Vinorelbine + Apatinib,classified_as,CHEMICAL
Vinorelbine + Apatinib,targets,triple-negative breast cancer
Vinorelbine + Apatinib,targets,TNBC
NCT01928394,sponsored_by,Bristol-Myers Squibb
NCT01928394,has_status,COMPLETED
NCT01928394,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,advanced or metastatic solid tumors
NCT01928394,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,advanced or metastatic solid tumors
NCT01928394,tests,Cobimetinib
Cobimetinib,has_type,DRUG
Cobimetinib,classified_as,CHEMICAL
Cobimetinib,targets,advanced or metastatic solid tumors
NCT02536794,sponsored_by,Northwestern University
NCT02536794,has_status,COMPLETED
NCT02536794,tests,Anti-B7H1 Monoclonal Antibody MEDI4736
Anti-B7H1 Monoclonal Antibody MEDI4736,has_type,DRUG
Anti-B7H1 Monoclonal Antibody MEDI4736,classified_as,BIOLOGIC
Anti-B7H1 Monoclonal Antibody MEDI4736,targets,recurrent breast carcinoma
Anti-B7H1 Monoclonal Antibody MEDI4736,targets,estrogen receptor positive
Anti-B7H1 Monoclonal Antibody MEDI4736,targets,stage iv breast cancer
Anti-B7H1 Monoclonal Antibody MEDI4736,targets,estrogen receptor negative
Anti-B7H1 Monoclonal Antibody MEDI4736,targets,her2/neu negative
NCT02536794,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,recurrent breast carcinoma
Laboratory Biomarker Analysis,targets,estrogen receptor positive
Laboratory Biomarker Analysis,targets,stage iv breast cancer
Laboratory Biomarker Analysis,targets,estrogen receptor negative
Laboratory Biomarker Analysis,targets,her2/neu negative
NCT02536794,tests,Pharmacological Study
Pharmacological Study,has_type,DRUG
Pharmacological Study,classified_as,OTHER
Pharmacological Study,targets,recurrent breast carcinoma
Pharmacological Study,targets,estrogen receptor positive
Pharmacological Study,targets,stage iv breast cancer
Pharmacological Study,targets,estrogen receptor negative
Pharmacological Study,targets,her2/neu negative
NCT02536794,tests,Tremelimumab
Tremelimumab,has_type,DRUG
Tremelimumab,classified_as,BIOLOGIC
Tremelimumab,targets,recurrent breast carcinoma
Tremelimumab,targets,estrogen receptor positive
Tremelimumab,targets,stage iv breast cancer
Tremelimumab,targets,estrogen receptor negative
Tremelimumab,targets,her2/neu negative
NCT04464174,sponsored_by,MedSIR
NCT04464174,has_status,COMPLETED
NCT04464174,tests,Ipatasertib
Ipatasertib,has_type,DRUG
Ipatasertib,classified_as,CHEMICAL
Ipatasertib,targets,triple negative breast cancer
Ipatasertib,targets,TNBC
NCT04464174,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT04464174,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,triple negative breast cancer
Eribulin,targets,TNBC
NCT04464174,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT04464174,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast cancer
Gemcitabine,targets,TNBC
NCT04706962,sponsored_by,Theratechnologies
NCT04706962,has_status,ACTIVE_NOT_RECRUITING
NCT04706962,tests,TH1902
TH1902,has_type,DRUG
TH1902,classified_as,OTHER
TH1902,targets,sort1+ cancers
TH1902,targets,solid tumor
TH1902,targets,thyroid cancer
TH1902,targets,cutaneous melanoma
TH1902,targets,prostate cancer
TH1902,targets,tnbc - triple-negative breast cancer
TH1902,targets,epithelial ovarian cancer
TH1902,targets,hormone receptor-positive breast cancer
TH1902,targets,small-cell lung cancer
TH1902,targets,endometrial cancer
TH1902,targets,TNBC
NCT02071862,sponsored_by,"Calithera Biosciences, Inc"
NCT02071862,has_status,COMPLETED
NCT02071862,tests,CB-839
CB-839,has_type,DRUG
CB-839,classified_as,OTHER
CB-839,targets,renal cell carcinoma
CB-839,targets,tumors harboring amplifications in the cmyc gene
CB-839,targets,mesothelioma
CB-839,targets,succinate dehydrogenase (sdh)-deficient non-gastrointestinal stromal tumors
CB-839,targets,fumarate hydratase (fh)-deficient tumors
CB-839,targets,solid tumors
CB-839,targets,succinate dehydrogenase (sdh)-deficient gastrointestinal stromal tumors (gist)
CB-839,targets,tumors harboring isocitrate dehydrogenase-1 (idh1) and idh2 mutations
CB-839,targets,triple-negative breast cancer
CB-839,targets,non small cell lung cancer
CB-839,targets,TNBC
NCT02071862,tests,Pac-CB
Pac-CB,has_type,DRUG
Pac-CB,classified_as,OTHER
Pac-CB,targets,renal cell carcinoma
Pac-CB,targets,tumors harboring amplifications in the cmyc gene
Pac-CB,targets,mesothelioma
Pac-CB,targets,succinate dehydrogenase (sdh)-deficient non-gastrointestinal stromal tumors
Pac-CB,targets,fumarate hydratase (fh)-deficient tumors
Pac-CB,targets,solid tumors
Pac-CB,targets,succinate dehydrogenase (sdh)-deficient gastrointestinal stromal tumors (gist)
Pac-CB,targets,tumors harboring isocitrate dehydrogenase-1 (idh1) and idh2 mutations
Pac-CB,targets,triple-negative breast cancer
Pac-CB,targets,non small cell lung cancer
Pac-CB,targets,TNBC
NCT02071862,tests,CBE
CBE,has_type,DRUG
CBE,classified_as,OTHER
CBE,targets,renal cell carcinoma
CBE,targets,tumors harboring amplifications in the cmyc gene
CBE,targets,mesothelioma
CBE,targets,succinate dehydrogenase (sdh)-deficient non-gastrointestinal stromal tumors
CBE,targets,fumarate hydratase (fh)-deficient tumors
CBE,targets,solid tumors
CBE,targets,succinate dehydrogenase (sdh)-deficient gastrointestinal stromal tumors (gist)
CBE,targets,tumors harboring isocitrate dehydrogenase-1 (idh1) and idh2 mutations
CBE,targets,triple-negative breast cancer
CBE,targets,non small cell lung cancer
CBE,targets,TNBC
NCT02071862,tests,CB-Erl
CB-Erl,has_type,DRUG
CB-Erl,classified_as,OTHER
CB-Erl,targets,renal cell carcinoma
CB-Erl,targets,tumors harboring amplifications in the cmyc gene
CB-Erl,targets,mesothelioma
CB-Erl,targets,succinate dehydrogenase (sdh)-deficient non-gastrointestinal stromal tumors
CB-Erl,targets,fumarate hydratase (fh)-deficient tumors
CB-Erl,targets,solid tumors
CB-Erl,targets,succinate dehydrogenase (sdh)-deficient gastrointestinal stromal tumors (gist)
CB-Erl,targets,tumors harboring isocitrate dehydrogenase-1 (idh1) and idh2 mutations
CB-Erl,targets,triple-negative breast cancer
CB-Erl,targets,non small cell lung cancer
CB-Erl,targets,TNBC
NCT02071862,tests,CBD
CBD,has_type,DRUG
CBD,classified_as,OTHER
CBD,targets,renal cell carcinoma
CBD,targets,tumors harboring amplifications in the cmyc gene
CBD,targets,mesothelioma
CBD,targets,succinate dehydrogenase (sdh)-deficient non-gastrointestinal stromal tumors
CBD,targets,fumarate hydratase (fh)-deficient tumors
CBD,targets,solid tumors
CBD,targets,succinate dehydrogenase (sdh)-deficient gastrointestinal stromal tumors (gist)
CBD,targets,tumors harboring isocitrate dehydrogenase-1 (idh1) and idh2 mutations
CBD,targets,triple-negative breast cancer
CBD,targets,non small cell lung cancer
CBD,targets,TNBC
NCT02071862,tests,CB-Cabo
CB-Cabo,has_type,DRUG
CB-Cabo,classified_as,OTHER
CB-Cabo,targets,renal cell carcinoma
CB-Cabo,targets,tumors harboring amplifications in the cmyc gene
CB-Cabo,targets,mesothelioma
CB-Cabo,targets,succinate dehydrogenase (sdh)-deficient non-gastrointestinal stromal tumors
CB-Cabo,targets,fumarate hydratase (fh)-deficient tumors
CB-Cabo,targets,solid tumors
CB-Cabo,targets,succinate dehydrogenase (sdh)-deficient gastrointestinal stromal tumors (gist)
CB-Cabo,targets,tumors harboring isocitrate dehydrogenase-1 (idh1) and idh2 mutations
CB-Cabo,targets,triple-negative breast cancer
CB-Cabo,targets,non small cell lung cancer
CB-Cabo,targets,TNBC
NCT04548960,sponsored_by,Oncodesign SA
NCT04548960,has_status,UNKNOWN
NCT04548960,tests,cancer patients
cancer patients,has_type,DRUG
cancer patients,classified_as,OTHER
cancer patients,targets,cancer
NCT02698176,sponsored_by,Merck Sharp & Dohme LLC
NCT02698176,has_status,TERMINATED
NCT02698176,tests,Birabresib
Birabresib,has_type,DRUG
Birabresib,classified_as,CHEMICAL
Birabresib,targets,castration-resistant prostate cancer (crpc)
Birabresib,targets,non-small cell lung cancer (nsclc)
Birabresib,targets,triple negative breast cancer (tnbc)
Birabresib,targets,nut midline carcinoma (nmc)
Birabresib,targets,TNBC
NCT03010176,sponsored_by,Merck Sharp & Dohme LLC
NCT03010176,has_status,COMPLETED
NCT03010176,tests,Ulevostinag
Ulevostinag,has_type,DRUG
Ulevostinag,classified_as,OTHER
Ulevostinag,targets,solid tumors
Ulevostinag,targets,lymphoma
NCT03010176,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,solid tumors
Pembrolizumab,targets,lymphoma
NCT05806060,sponsored_by,Fudan University
NCT05806060,has_status,RECRUITING
NCT05806060,tests,"VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine"
"VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",has_type,DRUG
"VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",classified_as,CHEMICAL
"VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",targets,triple-negative breast cancer
"VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",targets,TNBC
NCT05806060,tests,"nab-paclitaxel, with maintenance of capecitabine"
"nab-paclitaxel, with maintenance of capecitabine",has_type,DRUG
"nab-paclitaxel, with maintenance of capecitabine",classified_as,CHEMICAL
"nab-paclitaxel, with maintenance of capecitabine",targets,triple-negative breast cancer
"nab-paclitaxel, with maintenance of capecitabine",targets,TNBC
NCT05806060,tests,Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1
Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1,has_type,DRUG
Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1,classified_as,CHEMICAL
Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1,targets,triple-negative breast cancer
Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1,targets,TNBC
NCT05806060,tests,VEGFR and TPC
VEGFR and TPC,has_type,DRUG
VEGFR and TPC,classified_as,OTHER
VEGFR and TPC,targets,triple-negative breast cancer
VEGFR and TPC,targets,TNBC
NCT04085276,sponsored_by,"Shanghai Junshi Bioscience Co., Ltd."
NCT04085276,has_status,ACTIVE_NOT_RECRUITING
NCT04085276,tests,JS001
JS001,has_type,DRUG
JS001,classified_as,OTHER
JS001,targets,triple-negative breast cancer
JS001,targets,TNBC
NCT04085276,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,triple-negative breast cancer
Nab-Paclitaxel,targets,TNBC
NCT04085276,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple-negative breast cancer
Placebo,targets,TNBC
NCT04085276,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,triple-negative breast cancer
Nab-Paclitaxel,targets,TNBC
NCT03150576,sponsored_by,Cambridge University Hospitals NHS Foundation Trust
NCT03150576,has_status,RECRUITING
NCT03150576,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,breast cancer
NCT03150576,tests,Paclitaxel and Carboplatin
Paclitaxel and Carboplatin,has_type,DRUG
Paclitaxel and Carboplatin,classified_as,CHEMICAL
Paclitaxel and Carboplatin,targets,breast cancer
NCT01732276,sponsored_by,Jiangmen Central Hospital
NCT01732276,has_status,UNKNOWN
NCT01732276,tests,gefitinib
gefitinib,has_type,DRUG
gefitinib,classified_as,CHEMICAL
gefitinib,targets,breast cancer
NCT02834403,sponsored_by,The Methodist Hospital Research Institute
NCT02834403,has_status,COMPLETED
NCT02834403,tests,L-NMMA
L-NMMA,has_type,DRUG
L-NMMA,classified_as,OTHER
L-NMMA,targets,metastatic triple negative breast cancer
L-NMMA,targets,TNBC
NCT02834403,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,metastatic triple negative breast cancer
Docetaxel,targets,TNBC
NCT02834403,tests,Amlodipine
Amlodipine,has_type,DRUG
Amlodipine,classified_as,OTHER
Amlodipine,targets,metastatic triple negative breast cancer
Amlodipine,targets,TNBC
NCT02834403,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
Pegfilgrastim,classified_as,OTHER
Pegfilgrastim,targets,metastatic triple negative breast cancer
Pegfilgrastim,targets,TNBC
NCT02834403,tests,Enteric-coated aspirin
Enteric-coated aspirin,has_type,DRUG
Enteric-coated aspirin,classified_as,OTHER
Enteric-coated aspirin,targets,metastatic triple negative breast cancer
Enteric-coated aspirin,targets,TNBC
NCT02447003,sponsored_by,Merck Sharp & Dohme LLC
NCT02447003,has_status,COMPLETED
NCT02447003,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT03815890,sponsored_by,The Netherlands Cancer Institute
NCT03815890,has_status,RECRUITING
NCT03815890,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,breast cancer
NCT03815890,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,breast cancer
NCT03815890,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,breast cancer
NCT05005403,sponsored_by,AbbVie
NCT05005403,has_status,RECRUITING
NCT05005403,tests,Azirkitug
Azirkitug,has_type,DRUG
Azirkitug,classified_as,OTHER
Azirkitug,targets,micro satellite stable colorectal cancer
Azirkitug,targets,non-small cell lung cancer
Azirkitug,targets,pancreatic cancer
Azirkitug,targets,triple negative breast cancer
Azirkitug,targets,head and neck squamous cell carcinoma
Azirkitug,targets,high-grade serous ovarian cancer
Azirkitug,targets,gastric/esophageal cancer
Azirkitug,targets,TNBC
NCT05005403,tests,Budigalimab
Budigalimab,has_type,DRUG
Budigalimab,classified_as,BIOLOGIC
Budigalimab,targets,micro satellite stable colorectal cancer
Budigalimab,targets,non-small cell lung cancer
Budigalimab,targets,pancreatic cancer
Budigalimab,targets,triple negative breast cancer
Budigalimab,targets,head and neck squamous cell carcinoma
Budigalimab,targets,high-grade serous ovarian cancer
Budigalimab,targets,gastric/esophageal cancer
Budigalimab,targets,TNBC
NCT05005403,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,micro satellite stable colorectal cancer
Bevacizumab,targets,non-small cell lung cancer
Bevacizumab,targets,pancreatic cancer
Bevacizumab,targets,triple negative breast cancer
Bevacizumab,targets,head and neck squamous cell carcinoma
Bevacizumab,targets,high-grade serous ovarian cancer
Bevacizumab,targets,gastric/esophageal cancer
Bevacizumab,targets,TNBC
NCT02981303,sponsored_by,"HiberCell, Inc."
NCT02981303,has_status,COMPLETED
NCT02981303,tests,Imprime PGG
Imprime PGG,has_type,DRUG
Imprime PGG,classified_as,OTHER
Imprime PGG,targets,advanced melanoma
Imprime PGG,targets,triple-negative breast cancer
Imprime PGG,targets,TNBC
NCT02981303,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,advanced melanoma
Pembrolizumab,targets,triple-negative breast cancer
Pembrolizumab,targets,TNBC
NCT02688803,sponsored_by,Ottawa Hospital Research Institute
NCT02688803,has_status,COMPLETED
NCT02688803,tests,Dose dense AC-P
Dose dense AC-P,has_type,DRUG
Dose dense AC-P,classified_as,OTHER
Dose dense AC-P,targets,breast cancer
NCT02688803,tests,Dose dense AC
Dose dense AC,has_type,DRUG
Dose dense AC,classified_as,OTHER
Dose dense AC,targets,breast cancer
NCT02688803,tests,FEC-D
FEC-D,has_type,DRUG
FEC-D,classified_as,OTHER
FEC-D,targets,breast cancer
NCT04461990,sponsored_by,Fudan University
NCT04461990,has_status,UNKNOWN
NCT04461990,tests,Multidisciplinary cooperative comprehensive treatment
Multidisciplinary cooperative comprehensive treatment,has_type,DRUG
Multidisciplinary cooperative comprehensive treatment,classified_as,OTHER
Multidisciplinary cooperative comprehensive treatment,targets,breast cancer
Multidisciplinary cooperative comprehensive treatment,targets,"image, body"
Multidisciplinary cooperative comprehensive treatment,targets,pathology
Multidisciplinary cooperative comprehensive treatment,targets,molecular typing
NCT03577743,sponsored_by,Assiut University
NCT03577743,has_status,COMPLETED
NCT03577743,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,safety issues
Bevacizumab,targets,efficacy
Bevacizumab,targets,metastatic triple negative breast cancer
Bevacizumab,targets,TNBC
NCT05089643,sponsored_by,Chinese Academy of Medical Sciences
NCT05089643,has_status,UNKNOWN
NCT05089643,tests,Anlotinib
Anlotinib,has_type,DRUG
Anlotinib,classified_as,CHEMICAL
Anlotinib,targets,metastatic triple-negative breast cancer
Anlotinib,targets,TNBC
NCT05089643,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,metastatic triple-negative breast cancer
Capecitabine,targets,TNBC
NCT01391143,sponsored_by,MacroGenics
NCT01391143,has_status,COMPLETED
NCT01391143,tests,MGA271
MGA271,has_type,DRUG
MGA271,classified_as,OTHER
MGA271,targets,head and neck cancer
MGA271,targets,melanoma
MGA271,targets,renal cell carcinoma
MGA271,targets,non-small cell lung cancer
MGA271,targets,prostate cancer
MGA271,targets,bladder cancer
MGA271,targets,triple-negative breast cancer
MGA271,targets,TNBC
NCT06084481,sponsored_by,AbbVie
NCT06084481,has_status,RECRUITING
NCT06084481,tests,ABBV-400
ABBV-400,has_type,DRUG
ABBV-400,classified_as,OTHER
ABBV-400,targets,platinum resistant high grade epithelial ovarian cancer
ABBV-400,targets,hormone receptor+/human epidermal growth factor receptor 2 negative breast cancer
ABBV-400,targets,biliary tract cancers
ABBV-400,targets,hepatocellular carcinoma
ABBV-400,targets,esophageal squamous cell carcinoma
ABBV-400,targets,triple negative breast cancer
ABBV-400,targets,head and neck squamous-cell carcinoma
ABBV-400,targets,pancreatic ductal adenocarcinoma
ABBV-400,targets,TNBC
NCT06889610,sponsored_by,Fudan University
NCT06889610,has_status,NOT_YET_RECRUITING
NCT06889610,tests,MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer
MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer,has_type,DRUG
MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer,classified_as,OTHER
MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer,targets,triple negative breast cancer metastatic
MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer,targets,melanoma metastatic
MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer,targets,TNBC
NCT06889610,tests,MTT(Multimodal Tumor Thermal Therapy System)- Melanoma
MTT(Multimodal Tumor Thermal Therapy System)- Melanoma,has_type,DRUG
MTT(Multimodal Tumor Thermal Therapy System)- Melanoma,classified_as,OTHER
MTT(Multimodal Tumor Thermal Therapy System)- Melanoma,targets,triple negative breast cancer metastatic
MTT(Multimodal Tumor Thermal Therapy System)- Melanoma,targets,melanoma metastatic
MTT(Multimodal Tumor Thermal Therapy System)- Melanoma,targets,TNBC
NCT03150810,sponsored_by,BeiGene
NCT03150810,has_status,COMPLETED
NCT03150810,tests,Pamiparib
Pamiparib,has_type,DRUG
Pamiparib,classified_as,CHEMICAL
Pamiparib,targets,locally advanced or metastatic solid tumors
NCT03150810,tests,Temozolomide
Temozolomide,has_type,DRUG
Temozolomide,classified_as,OTHER
Temozolomide,targets,locally advanced or metastatic solid tumors
NCT00031681,sponsored_by,National Cancer Institute (NCI)
NCT00031681,has_status,COMPLETED
NCT00031681,tests,7-hydroxystaurosporine
7-hydroxystaurosporine,has_type,DRUG
7-hydroxystaurosporine,classified_as,OTHER
7-hydroxystaurosporine,targets,"unspecified adult solid tumor, protocol specific"
7-hydroxystaurosporine,targets,recurrent non-small cell lung cancer
7-hydroxystaurosporine,targets,recurrent mucoepidermoid carcinoma of the oral cavity
7-hydroxystaurosporine,targets,recurrent cervical cancer
7-hydroxystaurosporine,targets,her2-negative breast cancer
7-hydroxystaurosporine,targets,recurrent extrahepatic bile duct cancer
7-hydroxystaurosporine,targets,recurrent rectal cancer
7-hydroxystaurosporine,targets,recurrent pancreatic cancer
7-hydroxystaurosporine,targets,stage iv gastric cancer
7-hydroxystaurosporine,targets,recurrent ovarian germ cell tumor
7-hydroxystaurosporine,targets,recurrent squamous cell carcinoma of the oropharynx
7-hydroxystaurosporine,targets,recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
7-hydroxystaurosporine,targets,recurrent squamous cell carcinoma of the nasopharynx
7-hydroxystaurosporine,targets,unresectable extrahepatic bile duct cancer
7-hydroxystaurosporine,targets,stage iv adenoid cystic carcinoma of the oral cavity
7-hydroxystaurosporine,targets,stage iv squamous cell carcinoma of the larynx
7-hydroxystaurosporine,targets,stage iv ovarian germ cell tumor
7-hydroxystaurosporine,targets,recurrent lymphoepithelioma of the nasopharynx
7-hydroxystaurosporine,targets,stage iv esophageal cancer
7-hydroxystaurosporine,targets,estrogen receptor-negative breast cancer
7-hydroxystaurosporine,targets,recurrent anal cancer
7-hydroxystaurosporine,targets,stage iva cervical cancer
7-hydroxystaurosporine,targets,recurrent squamous cell carcinoma of the larynx
7-hydroxystaurosporine,targets,recurrent small intestine cancer
7-hydroxystaurosporine,targets,stage iv non-small cell lung cancer
7-hydroxystaurosporine,targets,recurrent colon cancer
7-hydroxystaurosporine,targets,small intestine lymphoma
7-hydroxystaurosporine,targets,stage iv inverted papilloma of the paranasal sinus and nasal cavity
7-hydroxystaurosporine,targets,stage iv verrucous carcinoma of the larynx
7-hydroxystaurosporine,targets,stage iv midline lethal granuloma of the paranasal sinus and nasal cavity
7-hydroxystaurosporine,targets,gastrointestinal stromal tumor
7-hydroxystaurosporine,targets,recurrent basal cell carcinoma of the lip
7-hydroxystaurosporine,targets,small intestine adenocarcinoma
7-hydroxystaurosporine,targets,stage iv squamous cell carcinoma of the lip and oral cavity
7-hydroxystaurosporine,targets,stage iv lymphoepithelioma of the oropharynx
7-hydroxystaurosporine,targets,stage iv rectal cancer
7-hydroxystaurosporine,targets,stage iv prostate cancer
7-hydroxystaurosporine,targets,stage iv verrucous carcinoma of the oral cavity
7-hydroxystaurosporine,targets,recurrent verrucous carcinoma of the larynx
7-hydroxystaurosporine,targets,carcinoma of the appendix
7-hydroxystaurosporine,targets,stage iv borderline ovarian surface epithelial-stromal tumor
7-hydroxystaurosporine,targets,stage iv mucoepidermoid carcinoma of the oral cavity
7-hydroxystaurosporine,targets,stage iv colon cancer
7-hydroxystaurosporine,targets,recurrent verrucous carcinoma of the oral cavity
7-hydroxystaurosporine,targets,metastatic gastrointestinal carcinoid tumor
7-hydroxystaurosporine,targets,recurrent gastric cancer
7-hydroxystaurosporine,targets,recurrent prostate cancer
7-hydroxystaurosporine,targets,recurrent salivary gland cancer
7-hydroxystaurosporine,targets,stage iv esthesioneuroblastoma of the paranasal sinus and nasal cavity
7-hydroxystaurosporine,targets,recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
7-hydroxystaurosporine,targets,stage iv ovarian epithelial cancer
7-hydroxystaurosporine,targets,recurrent breast cancer
7-hydroxystaurosporine,targets,progesterone receptor-negative breast cancer
7-hydroxystaurosporine,targets,recurrent endometrial carcinoma
7-hydroxystaurosporine,targets,triple-negative breast cancer
7-hydroxystaurosporine,targets,recurrent squamous cell carcinoma of the hypopharynx
7-hydroxystaurosporine,targets,recurrent inverted papilloma of the paranasal sinus and nasal cavity
7-hydroxystaurosporine,targets,recurrent lymphoepithelioma of the oropharynx
7-hydroxystaurosporine,targets,stage iv breast cancer
7-hydroxystaurosporine,targets,recurrent adult primary liver cancer
7-hydroxystaurosporine,targets,recurrent metastatic squamous neck cancer with occult primary
7-hydroxystaurosporine,targets,ovarian sarcoma
7-hydroxystaurosporine,targets,ovarian stromal cancer
7-hydroxystaurosporine,targets,stage iv anal cancer
7-hydroxystaurosporine,targets,stage iv lymphoepithelioma of the nasopharynx
7-hydroxystaurosporine,targets,stage iv endometrial carcinoma
7-hydroxystaurosporine,targets,stage iv squamous cell carcinoma of the oropharynx
7-hydroxystaurosporine,targets,extensive stage small cell lung cancer
7-hydroxystaurosporine,targets,recurrent esophageal cancer
7-hydroxystaurosporine,targets,recurrent small cell lung cancer
7-hydroxystaurosporine,targets,recurrent adenoid cystic carcinoma of the oral cavity
7-hydroxystaurosporine,targets,stage iv squamous cell carcinoma of the nasopharynx
7-hydroxystaurosporine,targets,stage iv squamous cell carcinoma of the hypopharynx
7-hydroxystaurosporine,targets,untreated metastatic squamous neck cancer with occult primary
7-hydroxystaurosporine,targets,stage iv pancreatic cancer
7-hydroxystaurosporine,targets,recurrent gallbladder cancer
7-hydroxystaurosporine,targets,stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity
7-hydroxystaurosporine,targets,stage ivb cervical cancer
7-hydroxystaurosporine,targets,recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
7-hydroxystaurosporine,targets,stage iv salivary gland cancer
7-hydroxystaurosporine,targets,unresectable gallbladder cancer
7-hydroxystaurosporine,targets,small intestine leiomyosarcoma
7-hydroxystaurosporine,targets,recurrent squamous cell carcinoma of the lip and oral cavity
7-hydroxystaurosporine,targets,stage iv basal cell carcinoma of the lip
7-hydroxystaurosporine,targets,recurrent gastrointestinal carcinoid tumor
7-hydroxystaurosporine,targets,recurrent ovarian epithelial cancer
7-hydroxystaurosporine,targets,advanced adult primary liver cancer
7-hydroxystaurosporine,targets,recurrent borderline ovarian surface epithelial-stromal tumor
7-hydroxystaurosporine,targets,TNBC
NCT00031681,tests,irinotecan hydrochloride
irinotecan hydrochloride,has_type,DRUG
irinotecan hydrochloride,classified_as,OTHER
irinotecan hydrochloride,targets,"unspecified adult solid tumor, protocol specific"
irinotecan hydrochloride,targets,recurrent non-small cell lung cancer
irinotecan hydrochloride,targets,recurrent mucoepidermoid carcinoma of the oral cavity
irinotecan hydrochloride,targets,recurrent cervical cancer
irinotecan hydrochloride,targets,her2-negative breast cancer
irinotecan hydrochloride,targets,recurrent extrahepatic bile duct cancer
irinotecan hydrochloride,targets,recurrent rectal cancer
irinotecan hydrochloride,targets,recurrent pancreatic cancer
irinotecan hydrochloride,targets,stage iv gastric cancer
irinotecan hydrochloride,targets,recurrent ovarian germ cell tumor
irinotecan hydrochloride,targets,recurrent squamous cell carcinoma of the oropharynx
irinotecan hydrochloride,targets,recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
irinotecan hydrochloride,targets,recurrent squamous cell carcinoma of the nasopharynx
irinotecan hydrochloride,targets,unresectable extrahepatic bile duct cancer
irinotecan hydrochloride,targets,stage iv adenoid cystic carcinoma of the oral cavity
irinotecan hydrochloride,targets,stage iv squamous cell carcinoma of the larynx
irinotecan hydrochloride,targets,stage iv ovarian germ cell tumor
irinotecan hydrochloride,targets,recurrent lymphoepithelioma of the nasopharynx
irinotecan hydrochloride,targets,stage iv esophageal cancer
irinotecan hydrochloride,targets,estrogen receptor-negative breast cancer
irinotecan hydrochloride,targets,recurrent anal cancer
irinotecan hydrochloride,targets,stage iva cervical cancer
irinotecan hydrochloride,targets,recurrent squamous cell carcinoma of the larynx
irinotecan hydrochloride,targets,recurrent small intestine cancer
irinotecan hydrochloride,targets,stage iv non-small cell lung cancer
irinotecan hydrochloride,targets,recurrent colon cancer
irinotecan hydrochloride,targets,small intestine lymphoma
irinotecan hydrochloride,targets,stage iv inverted papilloma of the paranasal sinus and nasal cavity
irinotecan hydrochloride,targets,stage iv verrucous carcinoma of the larynx
irinotecan hydrochloride,targets,stage iv midline lethal granuloma of the paranasal sinus and nasal cavity
irinotecan hydrochloride,targets,gastrointestinal stromal tumor
irinotecan hydrochloride,targets,recurrent basal cell carcinoma of the lip
irinotecan hydrochloride,targets,small intestine adenocarcinoma
irinotecan hydrochloride,targets,stage iv squamous cell carcinoma of the lip and oral cavity
irinotecan hydrochloride,targets,stage iv lymphoepithelioma of the oropharynx
irinotecan hydrochloride,targets,stage iv rectal cancer
irinotecan hydrochloride,targets,stage iv prostate cancer
irinotecan hydrochloride,targets,stage iv verrucous carcinoma of the oral cavity
irinotecan hydrochloride,targets,recurrent verrucous carcinoma of the larynx
irinotecan hydrochloride,targets,carcinoma of the appendix
irinotecan hydrochloride,targets,stage iv borderline ovarian surface epithelial-stromal tumor
irinotecan hydrochloride,targets,stage iv mucoepidermoid carcinoma of the oral cavity
irinotecan hydrochloride,targets,stage iv colon cancer
irinotecan hydrochloride,targets,recurrent verrucous carcinoma of the oral cavity
irinotecan hydrochloride,targets,metastatic gastrointestinal carcinoid tumor
irinotecan hydrochloride,targets,recurrent gastric cancer
irinotecan hydrochloride,targets,recurrent prostate cancer
irinotecan hydrochloride,targets,recurrent salivary gland cancer
irinotecan hydrochloride,targets,stage iv esthesioneuroblastoma of the paranasal sinus and nasal cavity
irinotecan hydrochloride,targets,recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
irinotecan hydrochloride,targets,stage iv ovarian epithelial cancer
irinotecan hydrochloride,targets,recurrent breast cancer
irinotecan hydrochloride,targets,progesterone receptor-negative breast cancer
irinotecan hydrochloride,targets,recurrent endometrial carcinoma
irinotecan hydrochloride,targets,triple-negative breast cancer
irinotecan hydrochloride,targets,recurrent squamous cell carcinoma of the hypopharynx
irinotecan hydrochloride,targets,recurrent inverted papilloma of the paranasal sinus and nasal cavity
irinotecan hydrochloride,targets,recurrent lymphoepithelioma of the oropharynx
irinotecan hydrochloride,targets,stage iv breast cancer
irinotecan hydrochloride,targets,recurrent adult primary liver cancer
irinotecan hydrochloride,targets,recurrent metastatic squamous neck cancer with occult primary
irinotecan hydrochloride,targets,ovarian sarcoma
irinotecan hydrochloride,targets,ovarian stromal cancer
irinotecan hydrochloride,targets,stage iv anal cancer
irinotecan hydrochloride,targets,stage iv lymphoepithelioma of the nasopharynx
irinotecan hydrochloride,targets,stage iv endometrial carcinoma
irinotecan hydrochloride,targets,stage iv squamous cell carcinoma of the oropharynx
irinotecan hydrochloride,targets,extensive stage small cell lung cancer
irinotecan hydrochloride,targets,recurrent esophageal cancer
irinotecan hydrochloride,targets,recurrent small cell lung cancer
irinotecan hydrochloride,targets,recurrent adenoid cystic carcinoma of the oral cavity
irinotecan hydrochloride,targets,stage iv squamous cell carcinoma of the nasopharynx
irinotecan hydrochloride,targets,stage iv squamous cell carcinoma of the hypopharynx
irinotecan hydrochloride,targets,untreated metastatic squamous neck cancer with occult primary
irinotecan hydrochloride,targets,stage iv pancreatic cancer
irinotecan hydrochloride,targets,recurrent gallbladder cancer
irinotecan hydrochloride,targets,stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity
irinotecan hydrochloride,targets,stage ivb cervical cancer
irinotecan hydrochloride,targets,recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
irinotecan hydrochloride,targets,stage iv salivary gland cancer
irinotecan hydrochloride,targets,unresectable gallbladder cancer
irinotecan hydrochloride,targets,small intestine leiomyosarcoma
irinotecan hydrochloride,targets,recurrent squamous cell carcinoma of the lip and oral cavity
irinotecan hydrochloride,targets,stage iv basal cell carcinoma of the lip
irinotecan hydrochloride,targets,recurrent gastrointestinal carcinoid tumor
irinotecan hydrochloride,targets,recurrent ovarian epithelial cancer
irinotecan hydrochloride,targets,advanced adult primary liver cancer
irinotecan hydrochloride,targets,recurrent borderline ovarian surface epithelial-stromal tumor
irinotecan hydrochloride,targets,TNBC
NCT00031681,tests,diagnostic laboratory biomarker analysis
diagnostic laboratory biomarker analysis,has_type,DRUG
diagnostic laboratory biomarker analysis,classified_as,OTHER
diagnostic laboratory biomarker analysis,targets,"unspecified adult solid tumor, protocol specific"
diagnostic laboratory biomarker analysis,targets,recurrent non-small cell lung cancer
diagnostic laboratory biomarker analysis,targets,recurrent mucoepidermoid carcinoma of the oral cavity
diagnostic laboratory biomarker analysis,targets,recurrent cervical cancer
diagnostic laboratory biomarker analysis,targets,her2-negative breast cancer
diagnostic laboratory biomarker analysis,targets,recurrent extrahepatic bile duct cancer
diagnostic laboratory biomarker analysis,targets,recurrent rectal cancer
diagnostic laboratory biomarker analysis,targets,recurrent pancreatic cancer
diagnostic laboratory biomarker analysis,targets,stage iv gastric cancer
diagnostic laboratory biomarker analysis,targets,recurrent ovarian germ cell tumor
diagnostic laboratory biomarker analysis,targets,recurrent squamous cell carcinoma of the oropharynx
diagnostic laboratory biomarker analysis,targets,recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
diagnostic laboratory biomarker analysis,targets,recurrent squamous cell carcinoma of the nasopharynx
diagnostic laboratory biomarker analysis,targets,unresectable extrahepatic bile duct cancer
diagnostic laboratory biomarker analysis,targets,stage iv adenoid cystic carcinoma of the oral cavity
diagnostic laboratory biomarker analysis,targets,stage iv squamous cell carcinoma of the larynx
diagnostic laboratory biomarker analysis,targets,stage iv ovarian germ cell tumor
diagnostic laboratory biomarker analysis,targets,recurrent lymphoepithelioma of the nasopharynx
diagnostic laboratory biomarker analysis,targets,stage iv esophageal cancer
diagnostic laboratory biomarker analysis,targets,estrogen receptor-negative breast cancer
diagnostic laboratory biomarker analysis,targets,recurrent anal cancer
diagnostic laboratory biomarker analysis,targets,stage iva cervical cancer
diagnostic laboratory biomarker analysis,targets,recurrent squamous cell carcinoma of the larynx
diagnostic laboratory biomarker analysis,targets,recurrent small intestine cancer
diagnostic laboratory biomarker analysis,targets,stage iv non-small cell lung cancer
diagnostic laboratory biomarker analysis,targets,recurrent colon cancer
diagnostic laboratory biomarker analysis,targets,small intestine lymphoma
diagnostic laboratory biomarker analysis,targets,stage iv inverted papilloma of the paranasal sinus and nasal cavity
diagnostic laboratory biomarker analysis,targets,stage iv verrucous carcinoma of the larynx
diagnostic laboratory biomarker analysis,targets,stage iv midline lethal granuloma of the paranasal sinus and nasal cavity
diagnostic laboratory biomarker analysis,targets,gastrointestinal stromal tumor
diagnostic laboratory biomarker analysis,targets,recurrent basal cell carcinoma of the lip
diagnostic laboratory biomarker analysis,targets,small intestine adenocarcinoma
diagnostic laboratory biomarker analysis,targets,stage iv squamous cell carcinoma of the lip and oral cavity
diagnostic laboratory biomarker analysis,targets,stage iv lymphoepithelioma of the oropharynx
diagnostic laboratory biomarker analysis,targets,stage iv rectal cancer
diagnostic laboratory biomarker analysis,targets,stage iv prostate cancer
diagnostic laboratory biomarker analysis,targets,stage iv verrucous carcinoma of the oral cavity
diagnostic laboratory biomarker analysis,targets,recurrent verrucous carcinoma of the larynx
diagnostic laboratory biomarker analysis,targets,carcinoma of the appendix
diagnostic laboratory biomarker analysis,targets,stage iv borderline ovarian surface epithelial-stromal tumor
diagnostic laboratory biomarker analysis,targets,stage iv mucoepidermoid carcinoma of the oral cavity
diagnostic laboratory biomarker analysis,targets,stage iv colon cancer
diagnostic laboratory biomarker analysis,targets,recurrent verrucous carcinoma of the oral cavity
diagnostic laboratory biomarker analysis,targets,metastatic gastrointestinal carcinoid tumor
diagnostic laboratory biomarker analysis,targets,recurrent gastric cancer
diagnostic laboratory biomarker analysis,targets,recurrent prostate cancer
diagnostic laboratory biomarker analysis,targets,recurrent salivary gland cancer
diagnostic laboratory biomarker analysis,targets,stage iv esthesioneuroblastoma of the paranasal sinus and nasal cavity
diagnostic laboratory biomarker analysis,targets,recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
diagnostic laboratory biomarker analysis,targets,stage iv ovarian epithelial cancer
diagnostic laboratory biomarker analysis,targets,recurrent breast cancer
diagnostic laboratory biomarker analysis,targets,progesterone receptor-negative breast cancer
diagnostic laboratory biomarker analysis,targets,recurrent endometrial carcinoma
diagnostic laboratory biomarker analysis,targets,triple-negative breast cancer
diagnostic laboratory biomarker analysis,targets,recurrent squamous cell carcinoma of the hypopharynx
diagnostic laboratory biomarker analysis,targets,recurrent inverted papilloma of the paranasal sinus and nasal cavity
diagnostic laboratory biomarker analysis,targets,recurrent lymphoepithelioma of the oropharynx
diagnostic laboratory biomarker analysis,targets,stage iv breast cancer
diagnostic laboratory biomarker analysis,targets,recurrent adult primary liver cancer
diagnostic laboratory biomarker analysis,targets,recurrent metastatic squamous neck cancer with occult primary
diagnostic laboratory biomarker analysis,targets,ovarian sarcoma
diagnostic laboratory biomarker analysis,targets,ovarian stromal cancer
diagnostic laboratory biomarker analysis,targets,stage iv anal cancer
diagnostic laboratory biomarker analysis,targets,stage iv lymphoepithelioma of the nasopharynx
diagnostic laboratory biomarker analysis,targets,stage iv endometrial carcinoma
diagnostic laboratory biomarker analysis,targets,stage iv squamous cell carcinoma of the oropharynx
diagnostic laboratory biomarker analysis,targets,extensive stage small cell lung cancer
diagnostic laboratory biomarker analysis,targets,recurrent esophageal cancer
diagnostic laboratory biomarker analysis,targets,recurrent small cell lung cancer
diagnostic laboratory biomarker analysis,targets,recurrent adenoid cystic carcinoma of the oral cavity
diagnostic laboratory biomarker analysis,targets,stage iv squamous cell carcinoma of the nasopharynx
diagnostic laboratory biomarker analysis,targets,stage iv squamous cell carcinoma of the hypopharynx
diagnostic laboratory biomarker analysis,targets,untreated metastatic squamous neck cancer with occult primary
diagnostic laboratory biomarker analysis,targets,stage iv pancreatic cancer
diagnostic laboratory biomarker analysis,targets,recurrent gallbladder cancer
diagnostic laboratory biomarker analysis,targets,stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity
diagnostic laboratory biomarker analysis,targets,stage ivb cervical cancer
diagnostic laboratory biomarker analysis,targets,recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
diagnostic laboratory biomarker analysis,targets,stage iv salivary gland cancer
diagnostic laboratory biomarker analysis,targets,unresectable gallbladder cancer
diagnostic laboratory biomarker analysis,targets,small intestine leiomyosarcoma
diagnostic laboratory biomarker analysis,targets,recurrent squamous cell carcinoma of the lip and oral cavity
diagnostic laboratory biomarker analysis,targets,stage iv basal cell carcinoma of the lip
diagnostic laboratory biomarker analysis,targets,recurrent gastrointestinal carcinoid tumor
diagnostic laboratory biomarker analysis,targets,recurrent ovarian epithelial cancer
diagnostic laboratory biomarker analysis,targets,advanced adult primary liver cancer
diagnostic laboratory biomarker analysis,targets,recurrent borderline ovarian surface epithelial-stromal tumor
diagnostic laboratory biomarker analysis,targets,TNBC
NCT06385990,sponsored_by,Hunan Cancer Hospital
NCT06385990,has_status,RECRUITING
NCT06385990,tests,UTD1
UTD1,has_type,DRUG
UTD1,classified_as,OTHER
UTD1,targets,triple negative breast neoplasms
UTD1,targets,TNBC
NCT03861403,sponsored_by,"Leap Therapeutics, Inc."
NCT03861403,has_status,TERMINATED
NCT03861403,tests,TRX518
TRX518,has_type,DRUG
TRX518,classified_as,OTHER
TRX518,targets,advanced metastatic castration-resistant prostate cancer
TRX518,targets,advanced triple negative breast cancer
TRX518,targets,solid tumors
TRX518,targets,advanced hormone receptor positive/endocrine refractory breast cancer
TRX518,targets,advanced platinum-resistant ovarian cancer
TRX518,targets,TNBC
NCT03861403,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,advanced metastatic castration-resistant prostate cancer
Cyclophosphamide,targets,advanced triple negative breast cancer
Cyclophosphamide,targets,solid tumors
Cyclophosphamide,targets,advanced hormone receptor positive/endocrine refractory breast cancer
Cyclophosphamide,targets,advanced platinum-resistant ovarian cancer
Cyclophosphamide,targets,TNBC
NCT03861403,tests,Avelumab
Avelumab,has_type,DRUG
Avelumab,classified_as,BIOLOGIC
Avelumab,targets,advanced metastatic castration-resistant prostate cancer
Avelumab,targets,advanced triple negative breast cancer
Avelumab,targets,solid tumors
Avelumab,targets,advanced hormone receptor positive/endocrine refractory breast cancer
Avelumab,targets,advanced platinum-resistant ovarian cancer
Avelumab,targets,TNBC
NCT06612203,sponsored_by,MedSIR
NCT06612203,has_status,RECRUITING
NCT06612203,tests,Debio 0123 and Sacituzumab govitecan
Debio 0123 and Sacituzumab govitecan,has_type,DRUG
Debio 0123 and Sacituzumab govitecan,classified_as,BIOLOGIC
Debio 0123 and Sacituzumab govitecan,targets,advanced breast cancer
NCT01587703,sponsored_by,GlaxoSmithKline
NCT01587703,has_status,COMPLETED
NCT01587703,tests,GSK525762
GSK525762,has_type,DRUG
GSK525762,classified_as,OTHER
GSK525762,targets,"carcinoma, midline"
NCT04059003,sponsored_by,Shengjing Hospital
NCT04059003,has_status,UNKNOWN
NCT04059003,tests,Taxanes or/and anthracycline-based therapy
Taxanes or/and anthracycline-based therapy,has_type,DRUG
Taxanes or/and anthracycline-based therapy,classified_as,CHEMICAL
Taxanes or/and anthracycline-based therapy,targets,breast neoplasms
NCT01351103,sponsored_by,Novartis Pharmaceuticals
NCT01351103,has_status,COMPLETED
NCT01351103,tests,LGK974
LGK974,has_type,DRUG
LGK974,classified_as,OTHER
LGK974,targets,melanoma
LGK974,targets,pancreatic cancer
LGK974,targets,head and neck squamous cell cancer
LGK974,targets,cervical squamous cell cancer
LGK974,targets,triple negative breast cancer
LGK974,targets,lung squamous cell cancer
LGK974,targets,braf mutant colorectal cancer
LGK974,targets,esophageal squamous cell cancer
LGK974,targets,TNBC
NCT01351103,tests,PDR001
PDR001,has_type,DRUG
PDR001,classified_as,OTHER
PDR001,targets,melanoma
PDR001,targets,pancreatic cancer
PDR001,targets,head and neck squamous cell cancer
PDR001,targets,cervical squamous cell cancer
PDR001,targets,triple negative breast cancer
PDR001,targets,lung squamous cell cancer
PDR001,targets,braf mutant colorectal cancer
PDR001,targets,esophageal squamous cell cancer
PDR001,targets,TNBC
NCT04980690,sponsored_by,"SUNHO（China）BioPharmaceutical CO., Ltd."
NCT04980690,has_status,RECRUITING
NCT04980690,tests,IBC0966
IBC0966,has_type,DRUG
IBC0966,classified_as,CHEMICAL
IBC0966,targets,advanced malignant tumors
NCT01467310,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT01467310,has_status,COMPLETED
NCT01467310,tests,GSK1120212
GSK1120212,has_type,DRUG
GSK1120212,classified_as,OTHER
GSK1120212,targets,breast cancer
NCT04111510,sponsored_by,Yale University
NCT04111510,has_status,COMPLETED
NCT04111510,tests,Tumor infiltrating lymphocytes (TIL) LN-145
Tumor infiltrating lymphocytes (TIL) LN-145,has_type,DRUG
Tumor infiltrating lymphocytes (TIL) LN-145,classified_as,OTHER
Tumor infiltrating lymphocytes (TIL) LN-145,targets,metastatic triple negative breast cancer
Tumor infiltrating lymphocytes (TIL) LN-145,targets,TNBC
NCT05396612,sponsored_by,Abramson Cancer Center at Penn Medicine
NCT05396612,has_status,RECRUITING
NCT05396612,tests,Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.,has_type,DRUG
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.,classified_as,OTHER
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.,targets,breast cancer
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.,targets,her2-negative breast cancer
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.,targets,er positive breast cancer
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.,targets,tnbc - triple-negative breast cancer
Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.,targets,TNBC
NCT03126110,sponsored_by,Incyte Biosciences International Sàrl
NCT03126110,has_status,COMPLETED
NCT03126110,tests,INCAGN01876
INCAGN01876,has_type,DRUG
INCAGN01876,classified_as,OTHER
INCAGN01876,targets,advanced malignancies
INCAGN01876,targets,metastatic cancer
NCT03126110,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,advanced malignancies
Nivolumab,targets,metastatic cancer
NCT03126110,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,advanced malignancies
Ipilimumab,targets,metastatic cancer
NCT06405295,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT06405295,has_status,ENROLLING_BY_INVITATION
NCT06405295,tests,no intervention
no intervention,has_type,DRUG
no intervention,classified_as,OTHER
no intervention,targets,breast carcinoma
no intervention,targets,adjuvant drug therapy
no intervention,targets,brca mutation
NCT05390710,sponsored_by,Laekna Limited
NCT05390710,has_status,COMPLETED
NCT05390710,tests,LAE005 + Afuresertib + Nab-Paclitaxel
LAE005 + Afuresertib + Nab-Paclitaxel,has_type,DRUG
LAE005 + Afuresertib + Nab-Paclitaxel,classified_as,CHEMICAL
LAE005 + Afuresertib + Nab-Paclitaxel,targets,tnbc - triple-negative breast cancer
LAE005 + Afuresertib + Nab-Paclitaxel,targets,solid tumor
LAE005 + Afuresertib + Nab-Paclitaxel,targets,TNBC
NCT06627712,sponsored_by,West China Hospital
NCT06627712,has_status,NOT_YET_RECRUITING
NCT06627712,tests,SBRT+PD-1 Inhibitor + Chemotherapy
SBRT+PD-1 Inhibitor + Chemotherapy,has_type,DRUG
SBRT+PD-1 Inhibitor + Chemotherapy,classified_as,BIOLOGIC
SBRT+PD-1 Inhibitor + Chemotherapy,targets,tnbc - triple-negative breast cancer
SBRT+PD-1 Inhibitor + Chemotherapy,targets,TNBC
NCT06627712,tests,PD-1 Inhibitor + Chemotherapy
PD-1 Inhibitor + Chemotherapy,has_type,DRUG
PD-1 Inhibitor + Chemotherapy,classified_as,BIOLOGIC
PD-1 Inhibitor + Chemotherapy,targets,tnbc - triple-negative breast cancer
PD-1 Inhibitor + Chemotherapy,targets,TNBC
NCT03917381,sponsored_by,Genmab
NCT03917381,has_status,ACTIVE_NOT_RECRUITING
NCT03917381,tests,Acasunlimab
Acasunlimab,has_type,DRUG
Acasunlimab,classified_as,BIOLOGIC
Acasunlimab,targets,endometrial carcinoma
Acasunlimab,targets,non-small cell lung cancer
Acasunlimab,targets,urothelial carcinoma
Acasunlimab,targets,triple negative breast cancer
Acasunlimab,targets,solid tumors
Acasunlimab,targets,cervical cancer
Acasunlimab,targets,squamous cell carcinoma of the head and neck
Acasunlimab,targets,TNBC
NCT03917381,tests,Acasunlimab in combination with docetaxel (in a single expansion cohort)
Acasunlimab in combination with docetaxel (in a single expansion cohort),has_type,DRUG
Acasunlimab in combination with docetaxel (in a single expansion cohort),classified_as,BIOLOGIC
Acasunlimab in combination with docetaxel (in a single expansion cohort),targets,endometrial carcinoma
Acasunlimab in combination with docetaxel (in a single expansion cohort),targets,non-small cell lung cancer
Acasunlimab in combination with docetaxel (in a single expansion cohort),targets,urothelial carcinoma
Acasunlimab in combination with docetaxel (in a single expansion cohort),targets,triple negative breast cancer
Acasunlimab in combination with docetaxel (in a single expansion cohort),targets,solid tumors
Acasunlimab in combination with docetaxel (in a single expansion cohort),targets,cervical cancer
Acasunlimab in combination with docetaxel (in a single expansion cohort),targets,squamous cell carcinoma of the head and neck
Acasunlimab in combination with docetaxel (in a single expansion cohort),targets,TNBC
NCT03917381,tests,Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),has_type,DRUG
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),classified_as,BIOLOGIC
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),targets,endometrial carcinoma
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),targets,non-small cell lung cancer
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),targets,urothelial carcinoma
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),targets,triple negative breast cancer
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),targets,solid tumors
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),targets,cervical cancer
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),targets,squamous cell carcinoma of the head and neck
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),targets,TNBC
NCT03917381,tests,Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),has_type,DRUG
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),classified_as,BIOLOGIC
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),targets,endometrial carcinoma
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),targets,non-small cell lung cancer
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),targets,urothelial carcinoma
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),targets,triple negative breast cancer
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),targets,solid tumors
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),targets,cervical cancer
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),targets,squamous cell carcinoma of the head and neck
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),targets,TNBC
NCT01698281,sponsored_by,AEterna Zentaris
NCT01698281,has_status,TERMINATED
NCT01698281,tests,AEZS-108
AEZS-108,has_type,DRUG
AEZS-108,classified_as,OTHER
AEZS-108,targets,breast cancer
NCT01698281,tests,SCCC
SCCC,has_type,DRUG
SCCC,classified_as,OTHER
SCCC,targets,breast cancer
NCT01698281,tests,Dexamethasone
Dexamethasone,has_type,DRUG
Dexamethasone,classified_as,OTHER
Dexamethasone,targets,breast cancer
NCT02427581,sponsored_by,Washington University School of Medicine
NCT02427581,has_status,WITHDRAWN
NCT02427581,tests,Personalized synthetic long peptide vaccine (Poly ICLC)
Personalized synthetic long peptide vaccine (Poly ICLC),has_type,DRUG
Personalized synthetic long peptide vaccine (Poly ICLC),classified_as,BIOLOGIC
Personalized synthetic long peptide vaccine (Poly ICLC),targets,triple negative breast neoplasms
Personalized synthetic long peptide vaccine (Poly ICLC),targets,triple-negative breast cancer
Personalized synthetic long peptide vaccine (Poly ICLC),targets,triple negative breast cancer
Personalized synthetic long peptide vaccine (Poly ICLC),targets,TNBC
NCT02427581,tests,Poly ICLC
Poly ICLC,has_type,DRUG
Poly ICLC,classified_as,OTHER
Poly ICLC,targets,triple negative breast neoplasms
Poly ICLC,targets,triple-negative breast cancer
Poly ICLC,targets,triple negative breast cancer
Poly ICLC,targets,TNBC
NCT03613181,sponsored_by,Angiochem Inc
NCT03613181,has_status,UNKNOWN
NCT03613181,tests,ANG1005
ANG1005,has_type,DRUG
ANG1005,classified_as,OTHER
ANG1005,targets,leptomeningeal carcinomatosis
ANG1005,targets,brain metastases
ANG1005,targets,her2-negative breast cancer
ANG1005,targets,leptomeningeal metastases
NCT03613181,tests,Physician's Best Choice
Physician's Best Choice,has_type,DRUG
Physician's Best Choice,classified_as,OTHER
Physician's Best Choice,targets,leptomeningeal carcinomatosis
Physician's Best Choice,targets,brain metastases
Physician's Best Choice,targets,her2-negative breast cancer
Physician's Best Choice,targets,leptomeningeal metastases
NCT02575781,sponsored_by,Sanofi
NCT02575781,has_status,COMPLETED
NCT02575781,tests,SAR428926
SAR428926,has_type,DRUG
SAR428926,classified_as,OTHER
SAR428926,targets,neoplasm malignant
NCT06636981,sponsored_by,Fudan University
NCT06636981,has_status,RECRUITING
NCT06636981,tests,Cohort2: ATRA+Toripalimab+TPC
Cohort2: ATRA+Toripalimab+TPC,has_type,DRUG
Cohort2: ATRA+Toripalimab+TPC,classified_as,BIOLOGIC
Cohort2: ATRA+Toripalimab+TPC,targets,triple negative breast cancer (tnbc)
Cohort2: ATRA+Toripalimab+TPC,targets,TNBC
NCT06636981,tests,Cohort1: ATRA+Toripalimab+chemo
Cohort1: ATRA+Toripalimab+chemo,has_type,DRUG
Cohort1: ATRA+Toripalimab+chemo,classified_as,BIOLOGIC
Cohort1: ATRA+Toripalimab+chemo,targets,triple negative breast cancer (tnbc)
Cohort1: ATRA+Toripalimab+chemo,targets,TNBC
NCT03369223,sponsored_by,Bristol-Myers Squibb
NCT03369223,has_status,COMPLETED
NCT03369223,tests,BMS-986249
BMS-986249,has_type,DRUG
BMS-986249,classified_as,OTHER
BMS-986249,targets,advanced cancer
NCT03369223,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,advanced cancer
NCT03369223,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,advanced cancer
NCT01889238,sponsored_by,Pfizer
NCT01889238,has_status,COMPLETED
NCT01889238,tests,Enzalutamide
Enzalutamide,has_type,DRUG
Enzalutamide,classified_as,OTHER
Enzalutamide,targets,"advanced, androgen receptor positive triple negative breast cancer"
Enzalutamide,targets,TNBC
NCT04501523,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04501523,has_status,RECRUITING
NCT04501523,tests,Tislelizumab
Tislelizumab,has_type,DRUG
Tislelizumab,classified_as,BIOLOGIC
Tislelizumab,targets,triple-negative breast cancer
Tislelizumab,targets,TNBC
NCT04501523,tests,capecitabine
capecitabine,has_type,DRUG
capecitabine,classified_as,CHEMICAL
capecitabine,targets,triple-negative breast cancer
capecitabine,targets,TNBC
NCT03752723,sponsored_by,"Genexine, Inc."
NCT03752723,has_status,COMPLETED
NCT03752723,tests,GX-I7
GX-I7,has_type,DRUG
GX-I7,classified_as,OTHER
GX-I7,targets,triple negative breast cancer
GX-I7,targets,TNBC
NCT03752723,tests,Pembrolizumab(KEYTRUDA®)
Pembrolizumab(KEYTRUDA®),has_type,DRUG
Pembrolizumab(KEYTRUDA®),classified_as,BIOLOGIC
Pembrolizumab(KEYTRUDA®),targets,triple negative breast cancer
Pembrolizumab(KEYTRUDA®),targets,TNBC
NCT03752723,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02779855,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT02779855,has_status,ACTIVE_NOT_RECRUITING
NCT02779855,tests,Talimogene laherparepvec
Talimogene laherparepvec,has_type,DRUG
Talimogene laherparepvec,classified_as,OTHER
Talimogene laherparepvec,targets,breast cancer
Talimogene laherparepvec,targets,ductal carcinoma
Talimogene laherparepvec,targets,invasive breast carcinoma
Talimogene laherparepvec,targets,invasive ductal breast carcinoma
NCT02779855,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
Paclitaxel,targets,ductal carcinoma
Paclitaxel,targets,invasive breast carcinoma
Paclitaxel,targets,invasive ductal breast carcinoma
NCT02259114,sponsored_by,"Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)"
NCT02259114,has_status,COMPLETED
NCT02259114,tests,Birabresib
Birabresib,has_type,DRUG
Birabresib,classified_as,CHEMICAL
Birabresib,targets,nut midline carcinoma
Birabresib,targets,triple negative breast cancer
Birabresib,targets,pancreatic ductal adenocarcinoma
Birabresib,targets,castrate-resistant prostate cancer
Birabresib,targets,non-small cell lung cancer with rearranged alk gene/fusion protein or kras mutation
Birabresib,targets,crpc
Birabresib,targets,TNBC
NCT05309655,sponsored_by,Duke University
NCT05309655,has_status,RECRUITING
NCT05309655,tests,Adenosine Stress Cardiac Magnetic Resonance Imaging
Adenosine Stress Cardiac Magnetic Resonance Imaging,has_type,DRUG
Adenosine Stress Cardiac Magnetic Resonance Imaging,classified_as,OTHER
Adenosine Stress Cardiac Magnetic Resonance Imaging,targets,breast cancer
Adenosine Stress Cardiac Magnetic Resonance Imaging,targets,cardiovascular complications
Adenosine Stress Cardiac Magnetic Resonance Imaging,targets,triple negative breast cancer
Adenosine Stress Cardiac Magnetic Resonance Imaging,targets,TNBC
NCT05309655,tests,Electrocardiogram
Electrocardiogram,has_type,DRUG
Electrocardiogram,classified_as,OTHER
Electrocardiogram,targets,breast cancer
Electrocardiogram,targets,cardiovascular complications
Electrocardiogram,targets,triple negative breast cancer
Electrocardiogram,targets,TNBC
NCT05309655,tests,Computed Tomography Angiogram
Computed Tomography Angiogram,has_type,DRUG
Computed Tomography Angiogram,classified_as,OTHER
Computed Tomography Angiogram,targets,breast cancer
Computed Tomography Angiogram,targets,cardiovascular complications
Computed Tomography Angiogram,targets,triple negative breast cancer
Computed Tomography Angiogram,targets,TNBC
NCT05309655,tests,Laboratory Testing
Laboratory Testing,has_type,DRUG
Laboratory Testing,classified_as,OTHER
Laboratory Testing,targets,breast cancer
Laboratory Testing,targets,cardiovascular complications
Laboratory Testing,targets,triple negative breast cancer
Laboratory Testing,targets,TNBC
NCT05309655,tests,Quality of Life Survey
Quality of Life Survey,has_type,DRUG
Quality of Life Survey,classified_as,OTHER
Quality of Life Survey,targets,breast cancer
Quality of Life Survey,targets,cardiovascular complications
Quality of Life Survey,targets,triple negative breast cancer
Quality of Life Survey,targets,TNBC
NCT04584255,sponsored_by,Dana-Farber Cancer Institute
NCT04584255,has_status,ACTIVE_NOT_RECRUITING
NCT04584255,tests,Niraparib
Niraparib,has_type,DRUG
Niraparib,classified_as,CHEMICAL
Niraparib,targets,stage i breast cancer
Niraparib,targets,breast cancer
Niraparib,targets,stage iii breast cancer
Niraparib,targets,her2-negative breast cancer
Niraparib,targets,deleterious palb2 gene mutation
Niraparib,targets,stage ii breast cancer
Niraparib,targets,germline brca1 gene mutation
Niraparib,targets,germline brca2 gene mutation
NCT04584255,tests,Dostarlimab
Dostarlimab,has_type,DRUG
Dostarlimab,classified_as,BIOLOGIC
Dostarlimab,targets,stage i breast cancer
Dostarlimab,targets,breast cancer
Dostarlimab,targets,stage iii breast cancer
Dostarlimab,targets,her2-negative breast cancer
Dostarlimab,targets,deleterious palb2 gene mutation
Dostarlimab,targets,stage ii breast cancer
Dostarlimab,targets,germline brca1 gene mutation
Dostarlimab,targets,germline brca2 gene mutation
NCT04915755,sponsored_by,GlaxoSmithKline
NCT04915755,has_status,ACTIVE_NOT_RECRUITING
NCT04915755,tests,Niraparib
Niraparib,has_type,DRUG
Niraparib,classified_as,CHEMICAL
Niraparib,targets,"neoplasms, breast"
NCT04915755,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,"neoplasms, breast"
NCT02897050,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT02897050,has_status,SUSPENDED
NCT02897050,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,breast cancer
NCT02897050,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
NCT02897050,tests,Cyclophosphamide (tablet)
Cyclophosphamide (tablet),has_type,DRUG
Cyclophosphamide (tablet),classified_as,CHEMICAL
Cyclophosphamide (tablet),targets,breast cancer
NCT02897050,tests,Fluorouracil
Fluorouracil,has_type,DRUG
Fluorouracil,classified_as,OTHER
Fluorouracil,targets,breast cancer
NCT02897050,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,breast cancer
NCT02897050,tests,Cyclophosphamide (injection)
Cyclophosphamide (injection),has_type,DRUG
Cyclophosphamide (injection),classified_as,CHEMICAL
Cyclophosphamide (injection),targets,breast cancer
NCT03449108,sponsored_by,M.D. Anderson Cancer Center
NCT03449108,has_status,ACTIVE_NOT_RECRUITING
NCT03449108,tests,Aldesleukin
Aldesleukin,has_type,DRUG
Aldesleukin,classified_as,OTHER
Aldesleukin,targets,malignancy in giant cell tumor of bone
Aldesleukin,targets,thyroid gland anaplastic carcinoma
Aldesleukin,targets,ovarian carcinosarcoma
Aldesleukin,targets,poorly differentiated thyroid gland carcinoma
Aldesleukin,targets,thyroid gland squamous cell carcinoma
Aldesleukin,targets,dedifferentiated chondrosarcoma
Aldesleukin,targets,bone sarcoma
Aldesleukin,targets,recurrent osteosarcoma
Aldesleukin,targets,recurrent ovarian carcinoma
Aldesleukin,targets,undifferentiated high grade pleomorphic sarcoma of bone
Aldesleukin,targets,platinum-resistant ovarian carcinoma
Aldesleukin,targets,triple negative breast cancer
Aldesleukin,targets,refractory osteosarcoma
Aldesleukin,targets,soft tissue sarcoma
Aldesleukin,targets,giant cell tumor of bone
Aldesleukin,targets,malignant solid neoplasm
Aldesleukin,targets,TNBC
NCT03449108,tests,Autologous Tumor Infiltrating Lymphocytes LN-145
Autologous Tumor Infiltrating Lymphocytes LN-145,has_type,DRUG
Autologous Tumor Infiltrating Lymphocytes LN-145,classified_as,OTHER
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,malignancy in giant cell tumor of bone
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,thyroid gland anaplastic carcinoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,ovarian carcinosarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,poorly differentiated thyroid gland carcinoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,thyroid gland squamous cell carcinoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,dedifferentiated chondrosarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,bone sarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,recurrent osteosarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,recurrent ovarian carcinoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,undifferentiated high grade pleomorphic sarcoma of bone
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,platinum-resistant ovarian carcinoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,triple negative breast cancer
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,refractory osteosarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,soft tissue sarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,giant cell tumor of bone
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,malignant solid neoplasm
Autologous Tumor Infiltrating Lymphocytes LN-145,targets,TNBC
NCT03449108,tests,Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,has_type,DRUG
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,classified_as,OTHER
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,malignancy in giant cell tumor of bone
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,thyroid gland anaplastic carcinoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,ovarian carcinosarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,poorly differentiated thyroid gland carcinoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,thyroid gland squamous cell carcinoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,dedifferentiated chondrosarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,bone sarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,recurrent osteosarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,recurrent ovarian carcinoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,undifferentiated high grade pleomorphic sarcoma of bone
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,platinum-resistant ovarian carcinoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,triple negative breast cancer
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,refractory osteosarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,soft tissue sarcoma
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,giant cell tumor of bone
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,malignant solid neoplasm
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,targets,TNBC
NCT03449108,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,malignancy in giant cell tumor of bone
Cyclophosphamide,targets,thyroid gland anaplastic carcinoma
Cyclophosphamide,targets,ovarian carcinosarcoma
Cyclophosphamide,targets,poorly differentiated thyroid gland carcinoma
Cyclophosphamide,targets,thyroid gland squamous cell carcinoma
Cyclophosphamide,targets,dedifferentiated chondrosarcoma
Cyclophosphamide,targets,bone sarcoma
Cyclophosphamide,targets,recurrent osteosarcoma
Cyclophosphamide,targets,recurrent ovarian carcinoma
Cyclophosphamide,targets,undifferentiated high grade pleomorphic sarcoma of bone
Cyclophosphamide,targets,platinum-resistant ovarian carcinoma
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,refractory osteosarcoma
Cyclophosphamide,targets,soft tissue sarcoma
Cyclophosphamide,targets,giant cell tumor of bone
Cyclophosphamide,targets,malignant solid neoplasm
Cyclophosphamide,targets,TNBC
NCT03449108,tests,Fludarabine
Fludarabine,has_type,DRUG
Fludarabine,classified_as,OTHER
Fludarabine,targets,malignancy in giant cell tumor of bone
Fludarabine,targets,thyroid gland anaplastic carcinoma
Fludarabine,targets,ovarian carcinosarcoma
Fludarabine,targets,poorly differentiated thyroid gland carcinoma
Fludarabine,targets,thyroid gland squamous cell carcinoma
Fludarabine,targets,dedifferentiated chondrosarcoma
Fludarabine,targets,bone sarcoma
Fludarabine,targets,recurrent osteosarcoma
Fludarabine,targets,recurrent ovarian carcinoma
Fludarabine,targets,undifferentiated high grade pleomorphic sarcoma of bone
Fludarabine,targets,platinum-resistant ovarian carcinoma
Fludarabine,targets,triple negative breast cancer
Fludarabine,targets,refractory osteosarcoma
Fludarabine,targets,soft tissue sarcoma
Fludarabine,targets,giant cell tumor of bone
Fludarabine,targets,malignant solid neoplasm
Fludarabine,targets,TNBC
NCT03449108,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,malignancy in giant cell tumor of bone
Ipilimumab,targets,thyroid gland anaplastic carcinoma
Ipilimumab,targets,ovarian carcinosarcoma
Ipilimumab,targets,poorly differentiated thyroid gland carcinoma
Ipilimumab,targets,thyroid gland squamous cell carcinoma
Ipilimumab,targets,dedifferentiated chondrosarcoma
Ipilimumab,targets,bone sarcoma
Ipilimumab,targets,recurrent osteosarcoma
Ipilimumab,targets,recurrent ovarian carcinoma
Ipilimumab,targets,undifferentiated high grade pleomorphic sarcoma of bone
Ipilimumab,targets,platinum-resistant ovarian carcinoma
Ipilimumab,targets,triple negative breast cancer
Ipilimumab,targets,refractory osteosarcoma
Ipilimumab,targets,soft tissue sarcoma
Ipilimumab,targets,giant cell tumor of bone
Ipilimumab,targets,malignant solid neoplasm
Ipilimumab,targets,TNBC
NCT03449108,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,malignancy in giant cell tumor of bone
Nivolumab,targets,thyroid gland anaplastic carcinoma
Nivolumab,targets,ovarian carcinosarcoma
Nivolumab,targets,poorly differentiated thyroid gland carcinoma
Nivolumab,targets,thyroid gland squamous cell carcinoma
Nivolumab,targets,dedifferentiated chondrosarcoma
Nivolumab,targets,bone sarcoma
Nivolumab,targets,recurrent osteosarcoma
Nivolumab,targets,recurrent ovarian carcinoma
Nivolumab,targets,undifferentiated high grade pleomorphic sarcoma of bone
Nivolumab,targets,platinum-resistant ovarian carcinoma
Nivolumab,targets,triple negative breast cancer
Nivolumab,targets,refractory osteosarcoma
Nivolumab,targets,soft tissue sarcoma
Nivolumab,targets,giant cell tumor of bone
Nivolumab,targets,malignant solid neoplasm
Nivolumab,targets,TNBC
NCT03449108,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,DRUG
Quality-of-Life Assessment,classified_as,OTHER
Quality-of-Life Assessment,targets,malignancy in giant cell tumor of bone
Quality-of-Life Assessment,targets,thyroid gland anaplastic carcinoma
Quality-of-Life Assessment,targets,ovarian carcinosarcoma
Quality-of-Life Assessment,targets,poorly differentiated thyroid gland carcinoma
Quality-of-Life Assessment,targets,thyroid gland squamous cell carcinoma
Quality-of-Life Assessment,targets,dedifferentiated chondrosarcoma
Quality-of-Life Assessment,targets,bone sarcoma
Quality-of-Life Assessment,targets,recurrent osteosarcoma
Quality-of-Life Assessment,targets,recurrent ovarian carcinoma
Quality-of-Life Assessment,targets,undifferentiated high grade pleomorphic sarcoma of bone
Quality-of-Life Assessment,targets,platinum-resistant ovarian carcinoma
Quality-of-Life Assessment,targets,triple negative breast cancer
Quality-of-Life Assessment,targets,refractory osteosarcoma
Quality-of-Life Assessment,targets,soft tissue sarcoma
Quality-of-Life Assessment,targets,giant cell tumor of bone
Quality-of-Life Assessment,targets,malignant solid neoplasm
Quality-of-Life Assessment,targets,TNBC
NCT03449108,tests,Questionnaire Administration
Questionnaire Administration,has_type,DRUG
Questionnaire Administration,classified_as,OTHER
Questionnaire Administration,targets,malignancy in giant cell tumor of bone
Questionnaire Administration,targets,thyroid gland anaplastic carcinoma
Questionnaire Administration,targets,ovarian carcinosarcoma
Questionnaire Administration,targets,poorly differentiated thyroid gland carcinoma
Questionnaire Administration,targets,thyroid gland squamous cell carcinoma
Questionnaire Administration,targets,dedifferentiated chondrosarcoma
Questionnaire Administration,targets,bone sarcoma
Questionnaire Administration,targets,recurrent osteosarcoma
Questionnaire Administration,targets,recurrent ovarian carcinoma
Questionnaire Administration,targets,undifferentiated high grade pleomorphic sarcoma of bone
Questionnaire Administration,targets,platinum-resistant ovarian carcinoma
Questionnaire Administration,targets,triple negative breast cancer
Questionnaire Administration,targets,refractory osteosarcoma
Questionnaire Administration,targets,soft tissue sarcoma
Questionnaire Administration,targets,giant cell tumor of bone
Questionnaire Administration,targets,malignant solid neoplasm
Questionnaire Administration,targets,TNBC
NCT04690855,sponsored_by,"Mylin A. Torres, MD"
NCT04690855,has_status,TERMINATED
NCT04690855,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,breast cancer
Talazoparib,targets,triple negative breast cancer
Talazoparib,targets,TNBC
NCT04690855,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,breast cancer
Atezolizumab,targets,triple negative breast cancer
Atezolizumab,targets,TNBC
NCT04690855,tests,Radiation
Radiation,has_type,DRUG
Radiation,classified_as,OTHER
Radiation,targets,breast cancer
Radiation,targets,triple negative breast cancer
Radiation,targets,TNBC
NCT07046455,sponsored_by,Peking University Cancer Hospital & Institute
NCT07046455,has_status,RECRUITING
NCT07046455,tests,Sacituzumab Govitecan (SG)
Sacituzumab Govitecan (SG),has_type,DRUG
Sacituzumab Govitecan (SG),classified_as,BIOLOGIC
Sacituzumab Govitecan (SG),targets,tnbc - triple-negative breast cancer
Sacituzumab Govitecan (SG),targets,TNBC
NCT03301350,sponsored_by,"University of Wisconsin, Madison"
NCT03301350,has_status,COMPLETED
NCT03301350,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT03301350,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT03301350,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,breast cancer
Doxorubicin,targets,triple negative breast cancer
Doxorubicin,targets,TNBC
NCT03301350,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT03301350,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
Pegfilgrastim,classified_as,OTHER
Pegfilgrastim,targets,breast cancer
Pegfilgrastim,targets,triple negative breast cancer
Pegfilgrastim,targets,TNBC
NCT03301350,tests,Filgrastim
Filgrastim,has_type,DRUG
Filgrastim,classified_as,OTHER
Filgrastim,targets,breast cancer
Filgrastim,targets,triple negative breast cancer
Filgrastim,targets,TNBC
NCT06831955,sponsored_by,Universitaire Ziekenhuizen KU Leuven
NCT06831955,has_status,NOT_YET_RECRUITING
NCT06831955,tests,Exercise Therapy
Exercise Therapy,has_type,DRUG
Exercise Therapy,classified_as,OTHER
Exercise Therapy,targets,"triple negative breast cancer (tnbc), early setting"
Exercise Therapy,targets,TNBC
NCT06831955,tests,Fasting-Mimicking Diet
Fasting-Mimicking Diet,has_type,DRUG
Fasting-Mimicking Diet,classified_as,OTHER
Fasting-Mimicking Diet,targets,"triple negative breast cancer (tnbc), early setting"
Fasting-Mimicking Diet,targets,TNBC
NCT06831955,tests,SOC
SOC,has_type,DRUG
SOC,classified_as,OTHER
SOC,targets,"triple negative breast cancer (tnbc), early setting"
SOC,targets,TNBC
NCT06220214,sponsored_by,Alison Stopeck
NCT06220214,has_status,RECRUITING
NCT06220214,tests,CEDM
CEDM,has_type,DRUG
CEDM,classified_as,OTHER
CEDM,targets,breast cancer
CEDM,targets,triple negative breast cancer
CEDM,targets,her2-positive breast cancer
CEDM,targets,neoadjuvant chemotherapy
CEDM,targets,locally advanced breast cancer
CEDM,targets,"tnbc, triple negative breast cancer"
CEDM,targets,TNBC
NCT06220214,tests,CEDBT
CEDBT,has_type,DRUG
CEDBT,classified_as,OTHER
CEDBT,targets,breast cancer
CEDBT,targets,triple negative breast cancer
CEDBT,targets,her2-positive breast cancer
CEDBT,targets,neoadjuvant chemotherapy
CEDBT,targets,locally advanced breast cancer
CEDBT,targets,"tnbc, triple negative breast cancer"
CEDBT,targets,TNBC
NCT06220214,tests,Omnipaque 350mgI/mL Solution for Injection
Omnipaque 350mgI/mL Solution for Injection,has_type,DRUG
Omnipaque 350mgI/mL Solution for Injection,classified_as,OTHER
Omnipaque 350mgI/mL Solution for Injection,targets,breast cancer
Omnipaque 350mgI/mL Solution for Injection,targets,triple negative breast cancer
Omnipaque 350mgI/mL Solution for Injection,targets,her2-positive breast cancer
Omnipaque 350mgI/mL Solution for Injection,targets,neoadjuvant chemotherapy
Omnipaque 350mgI/mL Solution for Injection,targets,locally advanced breast cancer
Omnipaque 350mgI/mL Solution for Injection,targets,"tnbc, triple negative breast cancer"
Omnipaque 350mgI/mL Solution for Injection,targets,TNBC
NCT03893955,sponsored_by,AbbVie
NCT03893955,has_status,ACTIVE_NOT_RECRUITING
NCT03893955,tests,ABBV-927
ABBV-927,has_type,DRUG
ABBV-927,classified_as,OTHER
ABBV-927,targets,non-small-cell-lung-cancer (nsclc)
ABBV-927,targets,advanced solid tumors
ABBV-927,targets,metastatic solid tumors
ABBV-927,targets,cancer
ABBV-927,targets,triple-negative breast cancer (tnbc)
ABBV-927,targets,TNBC
NCT03893955,tests,ABBV-368
ABBV-368,has_type,DRUG
ABBV-368,classified_as,OTHER
ABBV-368,targets,non-small-cell-lung-cancer (nsclc)
ABBV-368,targets,advanced solid tumors
ABBV-368,targets,metastatic solid tumors
ABBV-368,targets,cancer
ABBV-368,targets,triple-negative breast cancer (tnbc)
ABBV-368,targets,TNBC
NCT03893955,tests,ABBV-181
ABBV-181,has_type,DRUG
ABBV-181,classified_as,OTHER
ABBV-181,targets,non-small-cell-lung-cancer (nsclc)
ABBV-181,targets,advanced solid tumors
ABBV-181,targets,metastatic solid tumors
ABBV-181,targets,cancer
ABBV-181,targets,triple-negative breast cancer (tnbc)
ABBV-181,targets,TNBC
NCT03893955,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,non-small-cell-lung-cancer (nsclc)
Carboplatin,targets,advanced solid tumors
Carboplatin,targets,metastatic solid tumors
Carboplatin,targets,cancer
Carboplatin,targets,triple-negative breast cancer (tnbc)
Carboplatin,targets,TNBC
NCT03893955,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,non-small-cell-lung-cancer (nsclc)
Nab-paclitaxel,targets,advanced solid tumors
Nab-paclitaxel,targets,metastatic solid tumors
Nab-paclitaxel,targets,cancer
Nab-paclitaxel,targets,triple-negative breast cancer (tnbc)
Nab-paclitaxel,targets,TNBC
NCT02574455,sponsored_by,Gilead Sciences
NCT02574455,has_status,COMPLETED
NCT02574455,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
Sacituzumab govitecan,classified_as,BIOLOGIC
Sacituzumab govitecan,targets,breast cancer
NCT02574455,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,breast cancer
NCT02574455,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
NCT02574455,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,breast cancer
NCT02574455,tests,Vinorelbine
Vinorelbine,has_type,DRUG
Vinorelbine,classified_as,OTHER
Vinorelbine,targets,breast cancer
NCT06618014,sponsored_by,Sun Yat-sen University
NCT06618014,has_status,COMPLETED
NCT06618014,tests,Toripalimab
Toripalimab,has_type,DRUG
Toripalimab,classified_as,BIOLOGIC
Toripalimab,targets,breast cancer
Toripalimab,targets,triple negative breast cancer
Toripalimab,targets,TNBC
NCT06618014,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,breast cancer
Docetaxel,targets,triple negative breast cancer
Docetaxel,targets,TNBC
NCT06618014,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT05916755,sponsored_by,Vall d'Hebron Institute of Oncology
NCT05916755,has_status,RECRUITING
NCT05916755,tests,Whole Genome Sequencing
Whole Genome Sequencing,has_type,DRUG
Whole Genome Sequencing,classified_as,OTHER
Whole Genome Sequencing,targets,triple negative breast cancer
Whole Genome Sequencing,targets,TNBC
NCT05916755,tests,RNA-Sequencing
RNA-Sequencing,has_type,DRUG
RNA-Sequencing,classified_as,OTHER
RNA-Sequencing,targets,triple negative breast cancer
RNA-Sequencing,targets,TNBC
NCT05916755,tests,Microbiome analysis
Microbiome analysis,has_type,DRUG
Microbiome analysis,classified_as,OTHER
Microbiome analysis,targets,triple negative breast cancer
Microbiome analysis,targets,TNBC
NCT05916755,tests,ctDNA analysis
ctDNA analysis,has_type,DRUG
ctDNA analysis,classified_as,OTHER
ctDNA analysis,targets,triple negative breast cancer
ctDNA analysis,targets,TNBC
NCT05916755,tests,TCR-β repertoire sequencing
TCR-β repertoire sequencing,has_type,DRUG
TCR-β repertoire sequencing,classified_as,OTHER
TCR-β repertoire sequencing,targets,triple negative breast cancer
TCR-β repertoire sequencing,targets,TNBC
NCT05916755,tests,PBMCs phenotyping
PBMCs phenotyping,has_type,DRUG
PBMCs phenotyping,classified_as,OTHER
PBMCs phenotyping,targets,triple negative breast cancer
PBMCs phenotyping,targets,TNBC
NCT05916755,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT05916755,tests,Chemotherapy
Chemotherapy,has_type,DRUG
Chemotherapy,classified_as,OTHER
Chemotherapy,targets,triple negative breast cancer
Chemotherapy,targets,TNBC
NCT05455658,sponsored_by,University of Washington
NCT05455658,has_status,RECRUITING
NCT05455658,tests,CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,has_type,DRUG
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,classified_as,BIOLOGIC
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,anatomic stage iia breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,anatomic stage iib breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,anatomic stage iiia breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,prognostic stage iiic breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,prognostic stage ii breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,prognostic stage ib breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,anatomic stage ib breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,anatomic stage iiib breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,prognostic stage iiib breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,anatomic stage iii breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,anatomic stage iiic breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,prognostic stage iib breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,anatomic stage ii breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,prognostic stage iia breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,prognostic stage iii breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,triple-negative breast carcinoma
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,prognostic stage iiia breast cancer ajcc v8
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine,targets,TNBC
NCT05455658,tests,Sargramostim
Sargramostim,has_type,DRUG
Sargramostim,classified_as,OTHER
Sargramostim,targets,anatomic stage iia breast cancer ajcc v8
Sargramostim,targets,anatomic stage iib breast cancer ajcc v8
Sargramostim,targets,anatomic stage iiia breast cancer ajcc v8
Sargramostim,targets,prognostic stage iiic breast cancer ajcc v8
Sargramostim,targets,prognostic stage ii breast cancer ajcc v8
Sargramostim,targets,prognostic stage ib breast cancer ajcc v8
Sargramostim,targets,anatomic stage ib breast cancer ajcc v8
Sargramostim,targets,anatomic stage iiib breast cancer ajcc v8
Sargramostim,targets,prognostic stage iiib breast cancer ajcc v8
Sargramostim,targets,anatomic stage iii breast cancer ajcc v8
Sargramostim,targets,anatomic stage iiic breast cancer ajcc v8
Sargramostim,targets,prognostic stage iib breast cancer ajcc v8
Sargramostim,targets,anatomic stage ii breast cancer ajcc v8
Sargramostim,targets,prognostic stage iia breast cancer ajcc v8
Sargramostim,targets,prognostic stage iii breast cancer ajcc v8
Sargramostim,targets,triple-negative breast carcinoma
Sargramostim,targets,prognostic stage iiia breast cancer ajcc v8
Sargramostim,targets,TNBC
NCT04243616,sponsored_by,Medical College of Wisconsin
NCT04243616,has_status,ACTIVE_NOT_RECRUITING
NCT04243616,tests,Cemiplimab
Cemiplimab,has_type,DRUG
Cemiplimab,classified_as,BIOLOGIC
Cemiplimab,targets,invasive breast cancer
NCT04243616,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,invasive breast cancer
NCT04243616,tests,Carboplatin (not mandatory)
Carboplatin (not mandatory),has_type,DRUG
Carboplatin (not mandatory),classified_as,CHEMICAL
Carboplatin (not mandatory),targets,invasive breast cancer
NCT04243616,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,invasive breast cancer
NCT04243616,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,invasive breast cancer
NCT06685796,sponsored_by,BeBetter Med Inc
NCT06685796,has_status,RECRUITING
NCT06685796,tests,BEBT-209 capsules
BEBT-209 capsules,has_type,DRUG
BEBT-209 capsules,classified_as,OTHER
BEBT-209 capsules,targets,advanced triple-negative breast cancer
BEBT-209 capsules,targets,TNBC
NCT06685796,tests,Carboplatin injection
Carboplatin injection,has_type,DRUG
Carboplatin injection,classified_as,CHEMICAL
Carboplatin injection,targets,advanced triple-negative breast cancer
Carboplatin injection,targets,TNBC
NCT06685796,tests,Gemcitabine hydrochloride for injection
Gemcitabine hydrochloride for injection,has_type,DRUG
Gemcitabine hydrochloride for injection,classified_as,OTHER
Gemcitabine hydrochloride for injection,targets,advanced triple-negative breast cancer
Gemcitabine hydrochloride for injection,targets,TNBC
NCT05377996,sponsored_by,Mersana Therapeutics
NCT05377996,has_status,RECRUITING
NCT05377996,tests,XMT-1660
XMT-1660,has_type,DRUG
XMT-1660,classified_as,OTHER
XMT-1660,targets,primary peritoneal cavity cancer
XMT-1660,targets,breast cancer
XMT-1660,targets,adenoid cystic carcinoma
XMT-1660,targets,ovarian cancer
XMT-1660,targets,triple negative breast cancer
XMT-1660,targets,fallopian tube cancer
XMT-1660,targets,endometrial cancer
XMT-1660,targets,TNBC
NCT06508216,sponsored_by,"Gustave Roussy, Cancer Campus, Grand Paris"
NCT06508216,has_status,RECRUITING
NCT06508216,tests,Dato-DXd
Dato-DXd,has_type,DRUG
Dato-DXd,classified_as,OTHER
Dato-DXd,targets,breast cancer
NCT06508216,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,breast cancer
NCT03184558,sponsored_by,BerGenBio ASA
NCT03184558,has_status,TERMINATED
NCT03184558,tests,Bemcentinib; pembrolizumab
Bemcentinib; pembrolizumab,has_type,DRUG
Bemcentinib; pembrolizumab,classified_as,BIOLOGIC
Bemcentinib; pembrolizumab,targets,inflammatory breast cancer stage iv
Bemcentinib; pembrolizumab,targets,triple negative breast cancer
Bemcentinib; pembrolizumab,targets,TNBC
NCT05498896,sponsored_by,Queen Mary University of London
NCT05498896,has_status,ACTIVE_NOT_RECRUITING
NCT05498896,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,triple negative breast cancer
Atezolizumab,targets,TNBC
NCT05498896,tests,Ipatasertib
Ipatasertib,has_type,DRUG
Ipatasertib,classified_as,CHEMICAL
Ipatasertib,targets,triple negative breast cancer
Ipatasertib,targets,TNBC
NCT05498896,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT05498896,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,triple negative breast cancer
Doxorubicin,targets,TNBC
NCT05498896,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT04301739,sponsored_by,Shanghai Henlius Biotech
NCT04301739,has_status,NOT_YET_RECRUITING
NCT04301739,tests,HLX10
HLX10,has_type,DRUG
HLX10,classified_as,OTHER
HLX10,targets,triple negative breast cancer
HLX10,targets,TNBC
NCT04301739,tests,"nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide"
"nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide",has_type,DRUG
"nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide",classified_as,CHEMICAL
"nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide",targets,triple negative breast cancer
"nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide",targets,TNBC
NCT04301739,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast cancer
Placebo,targets,TNBC
NCT05358639,sponsored_by,Sunnybrook Health Sciences Centre
NCT05358639,has_status,ACTIVE_NOT_RECRUITING
NCT05358639,tests,Olaparib tablet
Olaparib tablet,has_type,DRUG
Olaparib tablet,classified_as,BIOLOGIC
Olaparib tablet,targets,triple negative breast cancer
Olaparib tablet,targets,ovarian cancer
Olaparib tablet,targets,high grade serous carcinoma
Olaparib tablet,targets,TNBC
NCT05358639,tests,Navitoclax
Navitoclax,has_type,DRUG
Navitoclax,classified_as,OTHER
Navitoclax,targets,triple negative breast cancer
Navitoclax,targets,ovarian cancer
Navitoclax,targets,high grade serous carcinoma
Navitoclax,targets,TNBC
NCT01560663,sponsored_by,Miguel Martín Jiménez
NCT01560663,has_status,ACTIVE_NOT_RECRUITING
NCT01560663,tests,Docetaxel- Carboplatin
Docetaxel- Carboplatin,has_type,DRUG
Docetaxel- Carboplatin,classified_as,CHEMICAL
Docetaxel- Carboplatin,targets,breast cancer
Docetaxel- Carboplatin,targets,breast cancer stage ii-iii
NCT06797635,sponsored_by,Merck Sharp & Dohme LLC
NCT06797635,has_status,RECRUITING
NCT06797635,tests,Patritumab deruxtecan
Patritumab deruxtecan,has_type,DRUG
Patritumab deruxtecan,classified_as,BIOLOGIC
Patritumab deruxtecan,targets,breast neoplasms
Patritumab deruxtecan,targets,breast cancer
NCT06797635,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast neoplasms
Pembrolizumab,targets,breast cancer
NCT06797635,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast neoplasms
Paclitaxel,targets,breast cancer
NCT06797635,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast neoplasms
Carboplatin,targets,breast cancer
NCT06797635,tests,Doxorubicin hydrochloride
Doxorubicin hydrochloride,has_type,DRUG
Doxorubicin hydrochloride,classified_as,CHEMICAL
Doxorubicin hydrochloride,targets,breast neoplasms
Doxorubicin hydrochloride,targets,breast cancer
NCT06797635,tests,Epirubicin hydrochloride
Epirubicin hydrochloride,has_type,DRUG
Epirubicin hydrochloride,classified_as,OTHER
Epirubicin hydrochloride,targets,breast neoplasms
Epirubicin hydrochloride,targets,breast cancer
NCT06797635,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast neoplasms
Cyclophosphamide,targets,breast cancer
NCT06797635,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast neoplasms
Capecitabine,targets,breast cancer
NCT06797635,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,breast neoplasms
Olaparib,targets,breast cancer
NCT03735082,sponsored_by,Chinese Academy of Medical Sciences
NCT03735082,has_status,UNKNOWN
NCT03735082,tests,Apatinib
Apatinib,has_type,DRUG
Apatinib,classified_as,CHEMICAL
Apatinib,targets,breast cancer
NCT03735082,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT03735082,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
NCT05888831,sponsored_by,Bristol-Myers Squibb
NCT05888831,has_status,ACTIVE_NOT_RECRUITING
NCT05888831,tests,BMS-986449
BMS-986449,has_type,DRUG
BMS-986449,classified_as,OTHER
BMS-986449,targets,advanced solid tumors
NCT05888831,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,advanced solid tumors
NCT04750382,sponsored_by,Taizhou Hanzhong biomedical co. LTD
NCT04750382,has_status,UNKNOWN
NCT04750382,tests,HX008+Cisplatin+Gemcitabine
HX008+Cisplatin+Gemcitabine,has_type,DRUG
HX008+Cisplatin+Gemcitabine,classified_as,CHEMICAL
HX008+Cisplatin+Gemcitabine,targets,triple-negative breast cancer
HX008+Cisplatin+Gemcitabine,targets,TNBC
NCT06700382,sponsored_by,Shu Wang
NCT06700382,has_status,RECRUITING
NCT06700382,tests,capecitabine
capecitabine,has_type,DRUG
capecitabine,classified_as,CHEMICAL
capecitabine,targets,triple negative breast cancer
capecitabine,targets,TNBC
NCT05770531,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT05770531,has_status,RECRUITING
NCT05770531,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,metastatic her2-negative breast carcinoma
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,TNBC
NCT05770531,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,metastatic her2-negative breast carcinoma
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,TNBC
NCT05770531,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,metastatic her2-negative breast carcinoma
Magnetic Resonance Imaging,targets,metastatic triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,TNBC
NCT05770531,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,metastatic her2-negative breast carcinoma
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,TNBC
NCT05770531,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
Sacituzumab Govitecan,classified_as,BIOLOGIC
Sacituzumab Govitecan,targets,metastatic her2-negative breast carcinoma
Sacituzumab Govitecan,targets,metastatic triple-negative breast carcinoma
Sacituzumab Govitecan,targets,TNBC
NCT04136782,sponsored_by,Shengjing Hospital
NCT04136782,has_status,RECRUITING
NCT04136782,tests,Albumin-bound paclitaxel combined with carboplatin
Albumin-bound paclitaxel combined with carboplatin,has_type,DRUG
Albumin-bound paclitaxel combined with carboplatin,classified_as,CHEMICAL
Albumin-bound paclitaxel combined with carboplatin,targets,breast cancer
NCT04136782,tests,Epirubicin combined with docetaxel
Epirubicin combined with docetaxel,has_type,DRUG
Epirubicin combined with docetaxel,classified_as,CHEMICAL
Epirubicin combined with docetaxel,targets,breast cancer
NCT03576131,sponsored_by,Genmab
NCT03576131,has_status,TERMINATED
NCT03576131,tests,GEN1029 (HexaBody®-DR5/DR5)
GEN1029 (HexaBody®-DR5/DR5),has_type,DRUG
GEN1029 (HexaBody®-DR5/DR5),classified_as,OTHER
GEN1029 (HexaBody®-DR5/DR5),targets,gastric cancer
GEN1029 (HexaBody®-DR5/DR5),targets,non-small cell lung cancer
GEN1029 (HexaBody®-DR5/DR5),targets,renal cell carcinoma
GEN1029 (HexaBody®-DR5/DR5),targets,pancreatic cancer
GEN1029 (HexaBody®-DR5/DR5),targets,urothelial cancer
GEN1029 (HexaBody®-DR5/DR5),targets,triple negative breast cancer
GEN1029 (HexaBody®-DR5/DR5),targets,colorectal cancer
GEN1029 (HexaBody®-DR5/DR5),targets,TNBC
NCT03720431,sponsored_by,PharmAbcine
NCT03720431,has_status,UNKNOWN
NCT03720431,tests,TTAC-0001 and pembrolizumab combination
TTAC-0001 and pembrolizumab combination,has_type,DRUG
TTAC-0001 and pembrolizumab combination,classified_as,BIOLOGIC
TTAC-0001 and pembrolizumab combination,targets,triple negative breast cancer
TTAC-0001 and pembrolizumab combination,targets,TNBC
NCT06545331,sponsored_by,Exelixis
NCT06545331,has_status,RECRUITING
NCT06545331,tests,XB010
XB010,has_type,DRUG
XB010,classified_as,OTHER
XB010,targets,nsclc (non-small cell lung cancer)
XB010,targets,hormone-receptor-positive breast cancer
XB010,targets,head and neck squamous cell cancer
XB010,targets,locally advanced or metastatic solid tumors
XB010,targets,triple negative breast cancer (tnbc)
XB010,targets,esophageal squamous cell cancer
XB010,targets,TNBC
NCT06545331,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,nsclc (non-small cell lung cancer)
Pembrolizumab,targets,hormone-receptor-positive breast cancer
Pembrolizumab,targets,head and neck squamous cell cancer
Pembrolizumab,targets,locally advanced or metastatic solid tumors
Pembrolizumab,targets,triple negative breast cancer (tnbc)
Pembrolizumab,targets,esophageal squamous cell cancer
Pembrolizumab,targets,TNBC
NCT06885424,sponsored_by,A2 Biotherapeutics Inc.
NCT06885424,has_status,NOT_YET_RECRUITING
NCT06885424,tests,No additional intervention administered in this long term follow-up study
No additional intervention administered in this long term follow-up study,has_type,DRUG
No additional intervention administered in this long term follow-up study,classified_as,OTHER
No additional intervention administered in this long term follow-up study,targets,small cell lung cancer ( sclc )
No additional intervention administered in this long term follow-up study,targets,head and neck cancer
No additional intervention administered in this long term follow-up study,targets,ovarian carcinoma
No additional intervention administered in this long term follow-up study,targets,pancreatic cancer
No additional intervention administered in this long term follow-up study,targets,nsclc
No additional intervention administered in this long term follow-up study,targets,mesothelioma
No additional intervention administered in this long term follow-up study,targets,colorectal carcinoma (crc)
No additional intervention administered in this long term follow-up study,targets,"solid tumor, unspecified, adult"
No additional intervention administered in this long term follow-up study,targets,head and neck (hnscc)
No additional intervention administered in this long term follow-up study,targets,ovarian cancer
No additional intervention administered in this long term follow-up study,targets,colorectal carcinoma
No additional intervention administered in this long term follow-up study,targets,renal cell carcinoma (kidney cancer)
No additional intervention administered in this long term follow-up study,targets,triple negative breast cancer (tnbc)
No additional intervention administered in this long term follow-up study,targets,non small cell lung cancer
No additional intervention administered in this long term follow-up study,targets,solid tumor cancer
No additional intervention administered in this long term follow-up study,targets,TNBC
NCT03267316,sponsored_by,Cantargia AB
NCT03267316,has_status,COMPLETED
NCT03267316,tests,CAN04
CAN04,has_type,DRUG
CAN04,classified_as,OTHER
CAN04,targets,colorectal cancer
CAN04,targets,pancreatic ductal adenocarcinoma
CAN04,targets,non small cell lung cancer
CAN04,targets,triple negative breast cancer
CAN04,targets,TNBC
NCT03267316,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,colorectal cancer
Cisplatin,targets,pancreatic ductal adenocarcinoma
Cisplatin,targets,non small cell lung cancer
Cisplatin,targets,triple negative breast cancer
Cisplatin,targets,TNBC
NCT03267316,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,colorectal cancer
Gemcitabine,targets,pancreatic ductal adenocarcinoma
Gemcitabine,targets,non small cell lung cancer
Gemcitabine,targets,triple negative breast cancer
Gemcitabine,targets,TNBC
NCT03267316,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,colorectal cancer
Nab-paclitaxel,targets,pancreatic ductal adenocarcinoma
Nab-paclitaxel,targets,non small cell lung cancer
Nab-paclitaxel,targets,triple negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT03267316,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,colorectal cancer
Carboplatin,targets,pancreatic ductal adenocarcinoma
Carboplatin,targets,non small cell lung cancer
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT03267316,tests,Pemetrexed
Pemetrexed,has_type,DRUG
Pemetrexed,classified_as,OTHER
Pemetrexed,targets,colorectal cancer
Pemetrexed,targets,pancreatic ductal adenocarcinoma
Pemetrexed,targets,non small cell lung cancer
Pemetrexed,targets,triple negative breast cancer
Pemetrexed,targets,TNBC
NCT01216124,sponsored_by,Fudan University
NCT01216124,has_status,AVAILABLE
NCT01216124,tests,docetaxel oxaliplatin
docetaxel oxaliplatin,has_type,DRUG
docetaxel oxaliplatin,classified_as,CHEMICAL
docetaxel oxaliplatin,targets,triple negative local advanced breast cancer
docetaxel oxaliplatin,targets,TNBC
NCT05128734,sponsored_by,AHS Cancer Control Alberta
NCT05128734,has_status,NOT_YET_RECRUITING
NCT05128734,tests,Temozolomide
Temozolomide,has_type,DRUG
Temozolomide,classified_as,OTHER
Temozolomide,targets,breast cancer triple negative
Temozolomide,targets,TNBC
NCT05128734,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,breast cancer triple negative
Olaparib,targets,TNBC
NCT01287624,sponsored_by,Fudan University
NCT01287624,has_status,COMPLETED
NCT01287624,tests,"Gemcitabine,cisplatin"
"Gemcitabine,cisplatin",has_type,DRUG
"Gemcitabine,cisplatin",classified_as,CHEMICAL
"Gemcitabine,cisplatin",targets,breast cancer
NCT01287624,tests,"Gemcitabine, Paclitaxel"
"Gemcitabine, Paclitaxel",has_type,DRUG
"Gemcitabine, Paclitaxel",classified_as,CHEMICAL
"Gemcitabine, Paclitaxel",targets,breast cancer
NCT06299163,sponsored_by,Numab Therapeutics AG
NCT06299163,has_status,TERMINATED
NCT06299163,tests,NM32-2668
NM32-2668,has_type,DRUG
NM32-2668,classified_as,OTHER
NM32-2668,targets,peritoneal carcinoma
NM32-2668,targets,renal cell carcinoma
NM32-2668,targets,"mesothelioma, malignant"
NM32-2668,targets,ovarian carcinoma
NM32-2668,targets,"melanoma, malignant"
NM32-2668,targets,adenocarcinoma - gastroesophageal junction (gej)
NM32-2668,targets,triple negative breast cancer
NM32-2668,targets,fallopian tube carcinoma
NM32-2668,targets,adenocarcinoma of lung
NM32-2668,targets,liposarcoma
NM32-2668,targets,adenocarcinoma of the stomach
NM32-2668,targets,leiomyosarcoma
NM32-2668,targets,endometrial cancer
NM32-2668,targets,TNBC
NCT06962163,sponsored_by,Institut Cancerologie de l'Ouest
NCT06962163,has_status,NOT_YET_RECRUITING
NCT06962163,tests,[68Ga]Ga-PentixaFor PET/CT
[68Ga]Ga-PentixaFor PET/CT,has_type,DRUG
[68Ga]Ga-PentixaFor PET/CT,classified_as,OTHER
[68Ga]Ga-PentixaFor PET/CT,targets,metastatic breast cancer
NCT03821935,sponsored_by,AbbVie
NCT03821935,has_status,ACTIVE_NOT_RECRUITING
NCT03821935,tests,Livmoniplimab
Livmoniplimab,has_type,DRUG
Livmoniplimab,classified_as,BIOLOGIC
Livmoniplimab,targets,advanced solid tumors cancer
NCT03821935,tests,Budigalimab
Budigalimab,has_type,DRUG
Budigalimab,classified_as,BIOLOGIC
Budigalimab,targets,advanced solid tumors cancer
NCT06313463,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06313463,has_status,RECRUITING
NCT06313463,tests,Carrellizumab + Capecitabine
Carrellizumab + Capecitabine,has_type,DRUG
Carrellizumab + Capecitabine,classified_as,BIOLOGIC
Carrellizumab + Capecitabine,targets,breast neoplasms
NCT06313463,tests,Placebo + Capecitabine
Placebo + Capecitabine,has_type,DRUG
Placebo + Capecitabine,classified_as,CHEMICAL
Placebo + Capecitabine,targets,breast neoplasms
NCT02018458,sponsored_by,Baylor Research Institute
NCT02018458,has_status,COMPLETED
NCT02018458,tests,LA TNBC: DC vaccine+Preop chemo
LA TNBC: DC vaccine+Preop chemo,has_type,DRUG
LA TNBC: DC vaccine+Preop chemo,classified_as,OTHER
LA TNBC: DC vaccine+Preop chemo,targets,breast cancer
NCT02018458,tests,ER+/HER2-BC:DC vaccine+Preop chemo
ER+/HER2-BC:DC vaccine+Preop chemo,has_type,DRUG
ER+/HER2-BC:DC vaccine+Preop chemo,classified_as,OTHER
ER+/HER2-BC:DC vaccine+Preop chemo,targets,breast cancer
NCT03197935,sponsored_by,Hoffmann-La Roche
NCT03197935,has_status,COMPLETED
NCT03197935,tests,"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",has_type,DRUG
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",classified_as,BIOLOGIC
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",targets,triple-negative breast cancer
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",targets,TNBC
NCT03197935,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple-negative breast cancer
Placebo,targets,TNBC
NCT03197935,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple-negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT03197935,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,triple-negative breast cancer
Doxorubicin,targets,TNBC
NCT03197935,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple-negative breast cancer
Cyclophosphamide,targets,TNBC
NCT03197935,tests,Filgrastim
Filgrastim,has_type,DRUG
Filgrastim,classified_as,OTHER
Filgrastim,targets,triple-negative breast cancer
Filgrastim,targets,TNBC
NCT03197935,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
Pegfilgrastim,classified_as,OTHER
Pegfilgrastim,targets,triple-negative breast cancer
Pegfilgrastim,targets,TNBC
NCT06724263,sponsored_by,"Tasly Biopharmaceuticals Co., Ltd."
NCT06724263,has_status,NOT_YET_RECRUITING
NCT06724263,tests,B1962
B1962,has_type,DRUG
B1962,classified_as,OTHER
B1962,targets,non-squamous non-small cell lung cancer
B1962,targets,recurrent platinum-resistant epithelial ovarian cancer
B1962,targets,hepatocellular carcinoma (hcc)
B1962,targets,triple negative breast cancer (tnbc)
B1962,targets,small cell lung cancer
B1962,targets,cervical cancers
B1962,targets,colorectal cancer
B1962,targets,TNBC
NCT04577963,sponsored_by,Hutchison Medipharma Limited
NCT04577963,has_status,TERMINATED
NCT04577963,tests,Fruquintinib
Fruquintinib,has_type,DRUG
Fruquintinib,classified_as,CHEMICAL
Fruquintinib,targets,endometrial cancer
Fruquintinib,targets,"solid tumor, unspecified, adult"
Fruquintinib,targets,colorectal cancer
Fruquintinib,targets,triple negative breast cancer
Fruquintinib,targets,TNBC
NCT04577963,tests,Tislelizumab
Tislelizumab,has_type,DRUG
Tislelizumab,classified_as,BIOLOGIC
Tislelizumab,targets,endometrial cancer
Tislelizumab,targets,"solid tumor, unspecified, adult"
Tislelizumab,targets,colorectal cancer
Tislelizumab,targets,triple negative breast cancer
Tislelizumab,targets,TNBC
NCT02299635,sponsored_by,Pfizer
NCT02299635,has_status,TERMINATED
NCT02299635,tests,PF-03084014
PF-03084014,has_type,DRUG
PF-03084014,classified_as,OTHER
PF-03084014,targets,triple negative breast neoplasms
PF-03084014,targets,TNBC
NCT02299635,tests,PF-03084014
PF-03084014,has_type,DRUG
PF-03084014,classified_as,OTHER
PF-03084014,targets,triple negative breast neoplasms
PF-03084014,targets,TNBC
NCT02299635,tests,PF-03084014
PF-03084014,has_type,DRUG
PF-03084014,classified_as,OTHER
PF-03084014,targets,triple negative breast neoplasms
PF-03084014,targets,TNBC
NCT02347163,sponsored_by,Mario Negri Institute for Pharmacological Research
NCT02347163,has_status,TERMINATED
NCT02347163,tests,Zoledronate
Zoledronate,has_type,DRUG
Zoledronate,classified_as,OTHER
Zoledronate,targets,breast cancer
NCT04191135,sponsored_by,Merck Sharp & Dohme LLC
NCT04191135,has_status,ACTIVE_NOT_RECRUITING
NCT04191135,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,TNBC
NCT04191135,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,triple negative breast neoplasms
Olaparib,targets,TNBC
NCT04191135,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast neoplasms
Carboplatin,targets,TNBC
NCT04191135,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast neoplasms
Gemcitabine,targets,TNBC
NCT04083963,sponsored_by,University of Illinois at Chicago
NCT04083963,has_status,ACTIVE_NOT_RECRUITING
NCT04083963,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT04083963,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT04083963,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,triple negative breast cancer
Doxorubicin,targets,TNBC
NCT04083963,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02460224,sponsored_by,Novartis Pharmaceuticals
NCT02460224,has_status,COMPLETED
NCT02460224,tests,LAG525
LAG525,has_type,DRUG
LAG525,classified_as,OTHER
LAG525,targets,advanced solid tumors
NCT02460224,tests,PDR001
PDR001,has_type,DRUG
PDR001,classified_as,OTHER
PDR001,targets,advanced solid tumors
NCT00491816,sponsored_by,University of Kansas Medical Center
NCT00491816,has_status,UNKNOWN
NCT00491816,tests,Erlotinib with neoadjuvant chemotherapy
Erlotinib with neoadjuvant chemotherapy,has_type,DRUG
Erlotinib with neoadjuvant chemotherapy,classified_as,CHEMICAL
Erlotinib with neoadjuvant chemotherapy,targets,breast cancer
NCT03337724,sponsored_by,Hoffmann-La Roche
NCT03337724,has_status,COMPLETED
NCT03337724,tests,Ipatasertib
Ipatasertib,has_type,DRUG
Ipatasertib,classified_as,CHEMICAL
Ipatasertib,targets,breast cancer
NCT03337724,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT03337724,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,breast cancer
NCT03498716,sponsored_by,Hoffmann-La Roche
NCT03498716,has_status,TERMINATED
NCT03498716,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,triple negative breast cancer
Atezolizumab,targets,TNBC
NCT03498716,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT03498716,tests,Dose-dense Doxorubicin or dose-dense Epirubicin
Dose-dense Doxorubicin or dose-dense Epirubicin,has_type,DRUG
Dose-dense Doxorubicin or dose-dense Epirubicin,classified_as,CHEMICAL
Dose-dense Doxorubicin or dose-dense Epirubicin,targets,triple negative breast cancer
Dose-dense Doxorubicin or dose-dense Epirubicin,targets,TNBC
NCT03498716,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02978716,sponsored_by,"G1 Therapeutics, Inc."
NCT02978716,has_status,TERMINATED
NCT02978716,tests,Trilaciclib
Trilaciclib,has_type,DRUG
Trilaciclib,classified_as,CHEMICAL
Trilaciclib,targets,breast cancer
Trilaciclib,targets,breast neoplasm
Trilaciclib,targets,triple-negative breast cancer
Trilaciclib,targets,triple-negative breast neoplasms
Trilaciclib,targets,TNBC
NCT02978716,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,breast cancer
Gemcitabine,targets,breast neoplasm
Gemcitabine,targets,triple-negative breast cancer
Gemcitabine,targets,triple-negative breast neoplasms
Gemcitabine,targets,TNBC
NCT02978716,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,breast neoplasm
Carboplatin,targets,triple-negative breast cancer
Carboplatin,targets,triple-negative breast neoplasms
Carboplatin,targets,TNBC
NCT03729596,sponsored_by,MacroGenics
NCT03729596,has_status,TERMINATED
NCT03729596,tests,vobramitamab duocarmazine
vobramitamab duocarmazine,has_type,DRUG
vobramitamab duocarmazine,classified_as,BIOLOGIC
vobramitamab duocarmazine,targets,melanoma
vobramitamab duocarmazine,targets,squamous cell carcinoma of head and neck
vobramitamab duocarmazine,targets,triple negative breast cancer
vobramitamab duocarmazine,targets,"advanced solid tumor, adult"
vobramitamab duocarmazine,targets,non small cell lung cancer
vobramitamab duocarmazine,targets,metastatic castrate resistant prostate cancer
vobramitamab duocarmazine,targets,TNBC
NCT04504916,sponsored_by,"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)"
NCT04504916,has_status,TERMINATED
NCT04504916,tests,Zilovertamab vedotin
Zilovertamab vedotin,has_type,DRUG
Zilovertamab vedotin,classified_as,BIOLOGIC
Zilovertamab vedotin,targets,estrogen-receptor-positive breast cancer
Zilovertamab vedotin,targets,estrogen-receptor-negative breast cancer
Zilovertamab vedotin,targets,er-negative breast cancer
Zilovertamab vedotin,targets,platinum-resistant ovarian cancer
Zilovertamab vedotin,targets,progesterone-receptor negative breast cancer
Zilovertamab vedotin,targets,pr-negative breast cancer
Zilovertamab vedotin,targets,nsclc
Zilovertamab vedotin,targets,progesterone-receptor-positive breast cancer
Zilovertamab vedotin,targets,her2-negative breast cancer
Zilovertamab vedotin,targets,non-squamous non-small-cell lung cancer
Zilovertamab vedotin,targets,pancreatic cancer
Zilovertamab vedotin,targets,er-positive breast cancer
Zilovertamab vedotin,targets,pr-positive breast cancer
Zilovertamab vedotin,targets,gastric cancer
Zilovertamab vedotin,targets,triple-negative breast cancer
Zilovertamab vedotin,targets,TNBC
NCT02315196,sponsored_by,"Rutgers, The State University of New Jersey"
NCT02315196,has_status,ACTIVE_NOT_RECRUITING
NCT02315196,tests,pegylated liposomal doxorubicin hydrochloride
pegylated liposomal doxorubicin hydrochloride,has_type,DRUG
pegylated liposomal doxorubicin hydrochloride,classified_as,CHEMICAL
pegylated liposomal doxorubicin hydrochloride,targets,stage iiic breast cancer
pegylated liposomal doxorubicin hydrochloride,targets,progesterone receptor-negative breast cancer
pegylated liposomal doxorubicin hydrochloride,targets,her2-negative breast cancer
pegylated liposomal doxorubicin hydrochloride,targets,stage iiia breast cancer
pegylated liposomal doxorubicin hydrochloride,targets,estrogen receptor-negative breast cancer
pegylated liposomal doxorubicin hydrochloride,targets,stage iiib breast cancer
pegylated liposomal doxorubicin hydrochloride,targets,stage iia breast cancer
pegylated liposomal doxorubicin hydrochloride,targets,stage iib breast cancer
pegylated liposomal doxorubicin hydrochloride,targets,triple-negative breast cancer
pegylated liposomal doxorubicin hydrochloride,targets,TNBC
NCT02315196,tests,epirubicin hydrochloride
epirubicin hydrochloride,has_type,DRUG
epirubicin hydrochloride,classified_as,OTHER
epirubicin hydrochloride,targets,stage iiic breast cancer
epirubicin hydrochloride,targets,progesterone receptor-negative breast cancer
epirubicin hydrochloride,targets,her2-negative breast cancer
epirubicin hydrochloride,targets,stage iiia breast cancer
epirubicin hydrochloride,targets,estrogen receptor-negative breast cancer
epirubicin hydrochloride,targets,stage iiib breast cancer
epirubicin hydrochloride,targets,stage iia breast cancer
epirubicin hydrochloride,targets,stage iib breast cancer
epirubicin hydrochloride,targets,triple-negative breast cancer
epirubicin hydrochloride,targets,TNBC
NCT02315196,tests,carboplatin
carboplatin,has_type,DRUG
carboplatin,classified_as,CHEMICAL
carboplatin,targets,stage iiic breast cancer
carboplatin,targets,progesterone receptor-negative breast cancer
carboplatin,targets,her2-negative breast cancer
carboplatin,targets,stage iiia breast cancer
carboplatin,targets,estrogen receptor-negative breast cancer
carboplatin,targets,stage iiib breast cancer
carboplatin,targets,stage iia breast cancer
carboplatin,targets,stage iib breast cancer
carboplatin,targets,triple-negative breast cancer
carboplatin,targets,TNBC
NCT02315196,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,DRUG
therapeutic conventional surgery,classified_as,OTHER
therapeutic conventional surgery,targets,stage iiic breast cancer
therapeutic conventional surgery,targets,progesterone receptor-negative breast cancer
therapeutic conventional surgery,targets,her2-negative breast cancer
therapeutic conventional surgery,targets,stage iiia breast cancer
therapeutic conventional surgery,targets,estrogen receptor-negative breast cancer
therapeutic conventional surgery,targets,stage iiib breast cancer
therapeutic conventional surgery,targets,stage iia breast cancer
therapeutic conventional surgery,targets,stage iib breast cancer
therapeutic conventional surgery,targets,triple-negative breast cancer
therapeutic conventional surgery,targets,TNBC
NCT02315196,tests,paclitaxel
paclitaxel,has_type,DRUG
paclitaxel,classified_as,CHEMICAL
paclitaxel,targets,stage iiic breast cancer
paclitaxel,targets,progesterone receptor-negative breast cancer
paclitaxel,targets,her2-negative breast cancer
paclitaxel,targets,stage iiia breast cancer
paclitaxel,targets,estrogen receptor-negative breast cancer
paclitaxel,targets,stage iiib breast cancer
paclitaxel,targets,stage iia breast cancer
paclitaxel,targets,stage iib breast cancer
paclitaxel,targets,triple-negative breast cancer
paclitaxel,targets,TNBC
NCT02315196,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,DRUG
laboratory biomarker analysis,classified_as,OTHER
laboratory biomarker analysis,targets,stage iiic breast cancer
laboratory biomarker analysis,targets,progesterone receptor-negative breast cancer
laboratory biomarker analysis,targets,her2-negative breast cancer
laboratory biomarker analysis,targets,stage iiia breast cancer
laboratory biomarker analysis,targets,estrogen receptor-negative breast cancer
laboratory biomarker analysis,targets,stage iiib breast cancer
laboratory biomarker analysis,targets,stage iia breast cancer
laboratory biomarker analysis,targets,stage iib breast cancer
laboratory biomarker analysis,targets,triple-negative breast cancer
laboratory biomarker analysis,targets,TNBC
NCT02315196,tests,quality-of-life assessment
quality-of-life assessment,has_type,DRUG
quality-of-life assessment,classified_as,OTHER
quality-of-life assessment,targets,stage iiic breast cancer
quality-of-life assessment,targets,progesterone receptor-negative breast cancer
quality-of-life assessment,targets,her2-negative breast cancer
quality-of-life assessment,targets,stage iiia breast cancer
quality-of-life assessment,targets,estrogen receptor-negative breast cancer
quality-of-life assessment,targets,stage iiib breast cancer
quality-of-life assessment,targets,stage iia breast cancer
quality-of-life assessment,targets,stage iib breast cancer
quality-of-life assessment,targets,triple-negative breast cancer
quality-of-life assessment,targets,TNBC
NCT06538896,sponsored_by,Zhejiang Cancer Hospital
NCT06538896,has_status,RECRUITING
NCT06538896,tests,Tislelizumab + Nab-Paclitaxel
Tislelizumab + Nab-Paclitaxel,has_type,DRUG
Tislelizumab + Nab-Paclitaxel,classified_as,BIOLOGIC
Tislelizumab + Nab-Paclitaxel,targets,bone metastases
Tislelizumab + Nab-Paclitaxel,targets,triple-negative breast cancer
Tislelizumab + Nab-Paclitaxel,targets,TNBC
NCT06538896,tests,Rankl inhibitor
Rankl inhibitor,has_type,DRUG
Rankl inhibitor,classified_as,CHEMICAL
Rankl inhibitor,targets,bone metastases
Rankl inhibitor,targets,triple-negative breast cancer
Rankl inhibitor,targets,TNBC
NCT05101096,sponsored_by,Gilead Sciences
NCT05101096,has_status,ACTIVE_NOT_RECRUITING
NCT05101096,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
Sacituzumab Govitecan-hziy,classified_as,BIOLOGIC
Sacituzumab Govitecan-hziy,targets,advanced solid tumor
Sacituzumab Govitecan-hziy,targets,hr+/her2- metastatic breast cancer
Sacituzumab Govitecan-hziy,targets,metastatic urothelial cancer
Sacituzumab Govitecan-hziy,targets,metastatic triple-negative breast cancer
Sacituzumab Govitecan-hziy,targets,TNBC
NCT05383196,sponsored_by,"Antonio Giordano, MD"
NCT05383196,has_status,ACTIVE_NOT_RECRUITING
NCT05383196,tests,Onvansertib
Onvansertib,has_type,DRUG
Onvansertib,classified_as,CHEMICAL
Onvansertib,targets,invasive breast cancer
Onvansertib,targets,inflammatory breast cancer
Onvansertib,targets,breast cancer
Onvansertib,targets,her2-negative breast cancer
Onvansertib,targets,hormone receptor/growth factor receptor-negative breast cancer
Onvansertib,targets,hormone receptor negative breast carcinoma
Onvansertib,targets,locally advanced breast cancer
Onvansertib,targets,triple negative breast cancer (tnbc)
Onvansertib,targets,metastatic breast cancer
Onvansertib,targets,unresectable breast carcinoma
Onvansertib,targets,TNBC
NCT05383196,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,invasive breast cancer
Paclitaxel,targets,inflammatory breast cancer
Paclitaxel,targets,breast cancer
Paclitaxel,targets,her2-negative breast cancer
Paclitaxel,targets,hormone receptor/growth factor receptor-negative breast cancer
Paclitaxel,targets,hormone receptor negative breast carcinoma
Paclitaxel,targets,locally advanced breast cancer
Paclitaxel,targets,triple negative breast cancer (tnbc)
Paclitaxel,targets,metastatic breast cancer
Paclitaxel,targets,unresectable breast carcinoma
Paclitaxel,targets,TNBC
NCT05388435,sponsored_by,"SK Life Science, Inc."
NCT05388435,has_status,TERMINATED
NCT05388435,tests,SKL27969
SKL27969,has_type,DRUG
SKL27969,classified_as,OTHER
SKL27969,targets,advanced solid tumor
NCT06604858,sponsored_by,MedSIR
NCT06604858,has_status,RECRUITING
NCT06604858,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT06604858,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT06604858,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT05233696,sponsored_by,"University of Colorado, Denver"
NCT05233696,has_status,WITHDRAWN
NCT05233696,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,pd-l1 gene mutation
Nab-paclitaxel,targets,triple negative breast cancer
Nab-paclitaxel,targets,locally advanced breast cancer
Nab-paclitaxel,targets,metastatic breast cancer
Nab-paclitaxel,targets,unresectable breast carcinoma
Nab-paclitaxel,targets,TNBC
NCT05233696,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,pd-l1 gene mutation
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,locally advanced breast cancer
Paclitaxel,targets,metastatic breast cancer
Paclitaxel,targets,unresectable breast carcinoma
Paclitaxel,targets,TNBC
NCT05233696,tests,Radiation Therapy
Radiation Therapy,has_type,DRUG
Radiation Therapy,classified_as,OTHER
Radiation Therapy,targets,pd-l1 gene mutation
Radiation Therapy,targets,triple negative breast cancer
Radiation Therapy,targets,locally advanced breast cancer
Radiation Therapy,targets,metastatic breast cancer
Radiation Therapy,targets,unresectable breast carcinoma
Radiation Therapy,targets,TNBC
NCT05233696,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,pd-l1 gene mutation
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,locally advanced breast cancer
Pembrolizumab,targets,metastatic breast cancer
Pembrolizumab,targets,unresectable breast carcinoma
Pembrolizumab,targets,TNBC
NCT02521363,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02521363,has_status,COMPLETED
NCT02521363,tests,KIBUR MICRODEVICE
KIBUR MICRODEVICE,has_type,DRUG
KIBUR MICRODEVICE,classified_as,CHEMICAL
KIBUR MICRODEVICE,targets,breast cancer
NCT02521363,tests,anthracycline and taxane based chemotherapy
anthracycline and taxane based chemotherapy,has_type,DRUG
anthracycline and taxane based chemotherapy,classified_as,CHEMICAL
anthracycline and taxane based chemotherapy,targets,breast cancer
NCT03876886,sponsored_by,Chinese Academy of Medical Sciences
NCT03876886,has_status,UNKNOWN
NCT03876886,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,triple negative breast cancer
Epirubicin,targets,TNBC
NCT03876886,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT03876886,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT03876886,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT03876886,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT01495663,sponsored_by,"Cellectar Biosciences, Inc."
NCT01495663,has_status,COMPLETED
NCT01495663,tests,I-131-CLR1404
I-131-CLR1404,has_type,DRUG
I-131-CLR1404,classified_as,OTHER
I-131-CLR1404,targets,cancer
NCT05774886,sponsored_by,Dana-Farber Cancer Institute
NCT05774886,has_status,WITHDRAWN
NCT05774886,tests,Implantable Microdevice (IMD)
Implantable Microdevice (IMD),has_type,DRUG
Implantable Microdevice (IMD),classified_as,OTHER
Implantable Microdevice (IMD),targets,breast carcinoma
Implantable Microdevice (IMD),targets,breast cancer
Implantable Microdevice (IMD),targets,breast neoplasms
Implantable Microdevice (IMD),targets,early stage triple-negative breast carcinoma
Implantable Microdevice (IMD),targets,triple negative breast cancer
Implantable Microdevice (IMD),targets,breast cancer stage iii
Implantable Microdevice (IMD),targets,breast cancer stage ii
Implantable Microdevice (IMD),targets,TNBC
NCT03316586,sponsored_by,Dana-Farber Cancer Institute
NCT03316586,has_status,COMPLETED
NCT03316586,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,breast cancer
NCT03316586,tests,Cabozantinib
Cabozantinib,has_type,DRUG
Cabozantinib,classified_as,CHEMICAL
Cabozantinib,targets,breast cancer
NCT01752686,sponsored_by,Severance Hospital
NCT01752686,has_status,UNKNOWN
NCT01752686,tests,carboplatin
carboplatin,has_type,DRUG
carboplatin,classified_as,CHEMICAL
carboplatin,targets,breast cancer
NCT06246786,sponsored_by,Virginia G. Kaklamani
NCT06246786,has_status,RECRUITING
NCT06246786,tests,Cyclosporin A
Cyclosporin A,has_type,DRUG
Cyclosporin A,classified_as,OTHER
Cyclosporin A,targets,dna damage repair deficiency
Cyclosporin A,targets,triple negative breast cancer
Cyclosporin A,targets,TNBC
NCT05821686,sponsored_by,Nova Scotia Health Authority
NCT05821686,has_status,NOT_YET_RECRUITING
NCT05821686,tests,Human Interleukin-2 (IL-2) (Proleukin)
Human Interleukin-2 (IL-2) (Proleukin),has_type,DRUG
Human Interleukin-2 (IL-2) (Proleukin),classified_as,OTHER
Human Interleukin-2 (IL-2) (Proleukin),targets,triple negative breast cancer
Human Interleukin-2 (IL-2) (Proleukin),targets,TNBC
NCT05783622,sponsored_by,Janux Therapeutics
NCT05783622,has_status,RECRUITING
NCT05783622,tests,JANX008
JANX008,has_type,DRUG
JANX008,classified_as,OTHER
JANX008,targets,renal cell carcinoma
JANX008,targets,non-small cell lung cancer
JANX008,targets,colorectal carcinoma
JANX008,targets,pancreatic ductal adenocarcinoma
JANX008,targets,small cell lung cancer
JANX008,targets,squamous cell carcinoma of the head and neck
JANX008,targets,triple-negative breast cancer
JANX008,targets,TNBC
NCT06606730,sponsored_by,UNICANCER
NCT06606730,has_status,NOT_YET_RECRUITING
NCT06606730,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer (tnbc)
Pembrolizumab,targets,breast cancers
Pembrolizumab,targets,TNBC
NCT06606730,tests,Deescalation
Deescalation,has_type,DRUG
Deescalation,classified_as,OTHER
Deescalation,targets,triple negative breast cancer (tnbc)
Deescalation,targets,breast cancers
Deescalation,targets,TNBC
NCT05067530,sponsored_by,Medical University of Gdansk
NCT05067530,has_status,NOT_YET_RECRUITING
NCT05067530,tests,Palbociclib
Palbociclib,has_type,DRUG
Palbociclib,classified_as,CHEMICAL
Palbociclib,targets,triple negative breast neoplasms
Palbociclib,targets,TNBC
NCT05067530,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast neoplasms
Paclitaxel,targets,TNBC
NCT05067530,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast neoplasms
Carboplatin,targets,TNBC
NCT04699630,sponsored_by,"SCRI Development Innovations, LLC"
NCT04699630,has_status,COMPLETED
NCT04699630,tests,U3-1402
U3-1402,has_type,DRUG
U3-1402,classified_as,OTHER
U3-1402,targets,locally advanced breast cancer
U3-1402,targets,metastatic breast cancer
NCT05037825,sponsored_by,VastBiome
NCT05037825,has_status,RECRUITING
NCT05037825,tests,"Checkpoint Inhibitor, Immune"
"Checkpoint Inhibitor, Immune",has_type,DRUG
"Checkpoint Inhibitor, Immune",classified_as,BIOLOGIC
"Checkpoint Inhibitor, Immune",targets,malignant melanoma
"Checkpoint Inhibitor, Immune",targets,renal cell carcinoma
"Checkpoint Inhibitor, Immune",targets,triple-negative breast cancer
"Checkpoint Inhibitor, Immune",targets,non-small-cell lung carcinoma
"Checkpoint Inhibitor, Immune",targets,TNBC
NCT02996825,sponsored_by,City of Hope Medical Center
NCT02996825,has_status,COMPLETED
NCT02996825,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,recurrent breast carcinoma
Gemcitabine,targets,triple-negative breast carcinoma
Gemcitabine,targets,recurrent ovarian carcinoma
Gemcitabine,targets,recurrent fallopian tube carcinoma
Gemcitabine,targets,recurrent uterine corpus carcinoma
Gemcitabine,targets,recurrent primary peritoneal carcinoma
Gemcitabine,targets,TNBC
NCT02996825,tests,Gemcitabine Hydrochloride
Gemcitabine Hydrochloride,has_type,DRUG
Gemcitabine Hydrochloride,classified_as,OTHER
Gemcitabine Hydrochloride,targets,recurrent breast carcinoma
Gemcitabine Hydrochloride,targets,triple-negative breast carcinoma
Gemcitabine Hydrochloride,targets,recurrent ovarian carcinoma
Gemcitabine Hydrochloride,targets,recurrent fallopian tube carcinoma
Gemcitabine Hydrochloride,targets,recurrent uterine corpus carcinoma
Gemcitabine Hydrochloride,targets,recurrent primary peritoneal carcinoma
Gemcitabine Hydrochloride,targets,TNBC
NCT02996825,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,recurrent breast carcinoma
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,recurrent ovarian carcinoma
Laboratory Biomarker Analysis,targets,recurrent fallopian tube carcinoma
Laboratory Biomarker Analysis,targets,recurrent uterine corpus carcinoma
Laboratory Biomarker Analysis,targets,recurrent primary peritoneal carcinoma
Laboratory Biomarker Analysis,targets,TNBC
NCT02996825,tests,Mirvetuximab Soravtansine
Mirvetuximab Soravtansine,has_type,DRUG
Mirvetuximab Soravtansine,classified_as,BIOLOGIC
Mirvetuximab Soravtansine,targets,recurrent breast carcinoma
Mirvetuximab Soravtansine,targets,triple-negative breast carcinoma
Mirvetuximab Soravtansine,targets,recurrent ovarian carcinoma
Mirvetuximab Soravtansine,targets,recurrent fallopian tube carcinoma
Mirvetuximab Soravtansine,targets,recurrent uterine corpus carcinoma
Mirvetuximab Soravtansine,targets,recurrent primary peritoneal carcinoma
Mirvetuximab Soravtansine,targets,TNBC
NCT02996825,tests,Pharmacological Study
Pharmacological Study,has_type,DRUG
Pharmacological Study,classified_as,OTHER
Pharmacological Study,targets,recurrent breast carcinoma
Pharmacological Study,targets,triple-negative breast carcinoma
Pharmacological Study,targets,recurrent ovarian carcinoma
Pharmacological Study,targets,recurrent fallopian tube carcinoma
Pharmacological Study,targets,recurrent uterine corpus carcinoma
Pharmacological Study,targets,recurrent primary peritoneal carcinoma
Pharmacological Study,targets,TNBC
NCT01204125,sponsored_by,Sanofi
NCT01204125,has_status,COMPLETED
NCT01204125,tests,paclitaxel
paclitaxel,has_type,DRUG
paclitaxel,classified_as,CHEMICAL
paclitaxel,targets,breast cancer female
NCT01204125,tests,Iniparib (SAR2405550 -BSI-201)
Iniparib (SAR2405550 -BSI-201),has_type,DRUG
Iniparib (SAR2405550 -BSI-201),classified_as,CHEMICAL
Iniparib (SAR2405550 -BSI-201),targets,breast cancer female
NCT05402722,sponsored_by,Beijing 302 Hospital
NCT05402722,has_status,UNKNOWN
NCT05402722,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,tnbc - triple-negative breast cancer
Eribulin,targets,TNBC
NCT05402722,tests,anti-PD-1 antibody
anti-PD-1 antibody,has_type,DRUG
anti-PD-1 antibody,classified_as,BIOLOGIC
anti-PD-1 antibody,targets,tnbc - triple-negative breast cancer
anti-PD-1 antibody,targets,TNBC
NCT04039230,sponsored_by,Massachusetts General Hospital
NCT04039230,has_status,RECRUITING
NCT04039230,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,breast cancer
NCT04039230,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
Sacituzumab Govitecan,classified_as,BIOLOGIC
Sacituzumab Govitecan,targets,breast cancer
NCT03444025,sponsored_by,Kasr El Aini Hospital
NCT03444025,has_status,UNKNOWN
NCT03444025,tests,Goserelin
Goserelin,has_type,DRUG
Goserelin,classified_as,OTHER
Goserelin,targets,breast cancer triple negative
Goserelin,targets,TNBC
NCT05453825,sponsored_by,"OncXerna Theraputics, Inc."
NCT05453825,has_status,UNKNOWN
NCT05453825,tests,navicixizumab+paclitaxel
navicixizumab+paclitaxel,has_type,DRUG
navicixizumab+paclitaxel,classified_as,BIOLOGIC
navicixizumab+paclitaxel,targets,gastric cancer
navicixizumab+paclitaxel,targets,triple negative breast cancer
navicixizumab+paclitaxel,targets,ovarian cancer
navicixizumab+paclitaxel,targets,colorectal cancer
navicixizumab+paclitaxel,targets,TNBC
NCT05453825,tests,navicixizumab+irinotecan
navicixizumab+irinotecan,has_type,DRUG
navicixizumab+irinotecan,classified_as,BIOLOGIC
navicixizumab+irinotecan,targets,gastric cancer
navicixizumab+irinotecan,targets,triple negative breast cancer
navicixizumab+irinotecan,targets,ovarian cancer
navicixizumab+irinotecan,targets,colorectal cancer
navicixizumab+irinotecan,targets,TNBC
NCT05453825,tests,navicixizumab monotherapy
navicixizumab monotherapy,has_type,DRUG
navicixizumab monotherapy,classified_as,BIOLOGIC
navicixizumab monotherapy,targets,gastric cancer
navicixizumab monotherapy,targets,triple negative breast cancer
navicixizumab monotherapy,targets,ovarian cancer
navicixizumab monotherapy,targets,colorectal cancer
navicixizumab monotherapy,targets,TNBC
NCT06817525,sponsored_by,Henan Cancer Hospital
NCT06817525,has_status,RECRUITING
NCT06817525,tests,6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1),has_type,DRUG
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1),classified_as,OTHER
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1),targets,triple-negative breast cancer
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1),targets,TNBC
NCT06817525,tests,"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)"
"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)",has_type,DRUG
"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)",classified_as,OTHER
"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)",targets,triple-negative breast cancer
"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)",targets,TNBC
NCT06817525,tests,6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1),has_type,DRUG
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1),classified_as,BIOLOGIC
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1),targets,triple-negative breast cancer
6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1),targets,TNBC
NCT06817525,tests,"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)"
"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)",has_type,DRUG
"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)",classified_as,BIOLOGIC
"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)",targets,triple-negative breast cancer
"6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)",targets,TNBC
NCT06878625,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT06878625,has_status,RECRUITING
NCT06878625,tests,Sacituzumab Govitecan combined with Toripalimab
Sacituzumab Govitecan combined with Toripalimab,has_type,DRUG
Sacituzumab Govitecan combined with Toripalimab,classified_as,BIOLOGIC
Sacituzumab Govitecan combined with Toripalimab,targets,evaluating the efficacy of trop-2 adc combination therapy in advanced triple-negative breast cancer
Sacituzumab Govitecan combined with Toripalimab,targets,TNBC
NCT06878625,tests,Sacituzumab govitecan combined with anti-angiogenesis
Sacituzumab govitecan combined with anti-angiogenesis,has_type,DRUG
Sacituzumab govitecan combined with anti-angiogenesis,classified_as,BIOLOGIC
Sacituzumab govitecan combined with anti-angiogenesis,targets,evaluating the efficacy of trop-2 adc combination therapy in advanced triple-negative breast cancer
Sacituzumab govitecan combined with anti-angiogenesis,targets,TNBC
NCT05830539,sponsored_by,"InxMed (Shanghai) Co., Ltd."
NCT05830539,has_status,COMPLETED
NCT05830539,tests,IN10018+PLD
IN10018+PLD,has_type,DRUG
IN10018+PLD,classified_as,OTHER
IN10018+PLD,targets,locally advanced or metastatic solid tumors
NCT05830539,tests,IN10018+PLD+Toripalimab
IN10018+PLD+Toripalimab,has_type,DRUG
IN10018+PLD+Toripalimab,classified_as,BIOLOGIC
IN10018+PLD+Toripalimab,targets,locally advanced or metastatic solid tumors
NCT04803539,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04803539,has_status,RECRUITING
NCT04803539,tests,capecitabine
capecitabine,has_type,DRUG
capecitabine,classified_as,CHEMICAL
capecitabine,targets,breast cancer
NCT04803539,tests,capecitabine + camrelizumab + apatinib
capecitabine + camrelizumab + apatinib,has_type,DRUG
capecitabine + camrelizumab + apatinib,classified_as,BIOLOGIC
capecitabine + camrelizumab + apatinib,targets,breast cancer
NCT02676986,sponsored_by,Queen Mary University of London
NCT02676986,has_status,COMPLETED
NCT02676986,tests,Enzalutamide
Enzalutamide,has_type,DRUG
Enzalutamide,classified_as,OTHER
Enzalutamide,targets,primary breast cancer er+ve
Enzalutamide,targets,primary breast cancer ar+ve tnbn
NCT02676986,tests,Exemestane
Exemestane,has_type,DRUG
Exemestane,classified_as,OTHER
Exemestane,targets,primary breast cancer er+ve
Exemestane,targets,primary breast cancer ar+ve tnbn
NCT03616886,sponsored_by,Jules Bordet Institute
NCT03616886,has_status,ACTIVE_NOT_RECRUITING
NCT03616886,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT03616886,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT03616886,tests,MEDI4736
MEDI4736,has_type,DRUG
MEDI4736,classified_as,OTHER
MEDI4736,targets,triple negative breast cancer
MEDI4736,targets,TNBC
NCT03616886,tests,MEDI9447
MEDI9447,has_type,DRUG
MEDI9447,classified_as,OTHER
MEDI9447,targets,triple negative breast cancer
MEDI9447,targets,TNBC
NCT06393374,sponsored_by,Merck Sharp & Dohme LLC
NCT06393374,has_status,RECRUITING
NCT06393374,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple-negative breast cancer
Pembrolizumab,targets,TNBC
NCT06393374,tests,Sacituzumab tirumotecan
Sacituzumab tirumotecan,has_type,DRUG
Sacituzumab tirumotecan,classified_as,BIOLOGIC
Sacituzumab tirumotecan,targets,triple-negative breast cancer
Sacituzumab tirumotecan,targets,TNBC
NCT06393374,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple-negative breast cancer
Capecitabine,targets,TNBC
NCT03090165,sponsored_by,Kari Wisinski
NCT03090165,has_status,RECRUITING
NCT03090165,tests,ribociclib
ribociclib,has_type,DRUG
ribociclib,classified_as,CHEMICAL
ribociclib,targets,triple negative breast cancer
ribociclib,targets,TNBC
NCT03090165,tests,ribociclib
ribociclib,has_type,DRUG
ribociclib,classified_as,CHEMICAL
ribociclib,targets,triple negative breast cancer
ribociclib,targets,TNBC
NCT03090165,tests,Bicalutamide
Bicalutamide,has_type,DRUG
Bicalutamide,classified_as,OTHER
Bicalutamide,targets,triple negative breast cancer
Bicalutamide,targets,TNBC
NCT04224922,sponsored_by,AZ-VUB
NCT04224922,has_status,COMPLETED
NCT04224922,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT04224922,tests,Carboplatinum
Carboplatinum,has_type,DRUG
Carboplatinum,classified_as,CHEMICAL
Carboplatinum,targets,breast cancer
NCT04224922,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,breast cancer
NCT04224922,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
NCT05957939,sponsored_by,"Ministry of Health, Saudi Arabia"
NCT05957939,has_status,UNKNOWN
NCT05957939,tests,Alkaline Glucosodiene Molecules
Alkaline Glucosodiene Molecules,has_type,DRUG
Alkaline Glucosodiene Molecules,classified_as,OTHER
Alkaline Glucosodiene Molecules,targets,tnbc - triple-negative breast cancer
Alkaline Glucosodiene Molecules,targets,TNBC
NCT04768426,sponsored_by,Stanford University
NCT04768426,has_status,RECRUITING
NCT04768426,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT03102320,sponsored_by,Bayer
NCT03102320,has_status,COMPLETED
NCT03102320,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,neoplasms
NCT03102320,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,neoplasms
NCT03102320,tests,Anetumab ravtansine (BAY94-9343)
Anetumab ravtansine (BAY94-9343),has_type,DRUG
Anetumab ravtansine (BAY94-9343),classified_as,BIOLOGIC
Anetumab ravtansine (BAY94-9343),targets,neoplasms
NCT04442126,sponsored_by,Numab Therapeutics AG
NCT04442126,has_status,TERMINATED
NCT04442126,tests,NM21-1480
NM21-1480,has_type,DRUG
NM21-1480,classified_as,OTHER
NM21-1480,targets,peritoneal carcinoma
NM21-1480,targets,non-small cell lung cancer
NM21-1480,targets,ovarian carcinoma
NM21-1480,targets,advanced solid tumor
NM21-1480,targets,squamous cell carcinoma
NM21-1480,targets,triple negative breast cancer
NM21-1480,targets,head and neck squamous cell carcinoma
NM21-1480,targets,fallopian tube cancer
NM21-1480,targets,colorectal cancer
NM21-1480,targets,TNBC
NCT03071757,sponsored_by,AbbVie
NCT03071757,has_status,COMPLETED
NCT03071757,tests,ABBV-368
ABBV-368,has_type,DRUG
ABBV-368,classified_as,OTHER
ABBV-368,targets,advanced solid tumors cancer
NCT03071757,tests,ABBV-181
ABBV-181,has_type,DRUG
ABBV-181,classified_as,OTHER
ABBV-181,targets,advanced solid tumors cancer
NCT04432857,sponsored_by,"Adlai Nortye Biopharma Co., Ltd."
NCT04432857,has_status,ACTIVE_NOT_RECRUITING
NCT04432857,tests,AN0025
AN0025,has_type,DRUG
AN0025,classified_as,OTHER
AN0025,targets,"nsclc, squamous or non-squamous"
AN0025,targets,microsatellite stable (mss) colorectal cancer (crc)
AN0025,targets,cervical cancer
AN0025,targets,urothelial carcinoma of the bladder
AN0025,targets,triple-negative breast cancer
AN0025,targets,TNBC
NCT04432857,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,"nsclc, squamous or non-squamous"
Pembrolizumab,targets,microsatellite stable (mss) colorectal cancer (crc)
Pembrolizumab,targets,cervical cancer
Pembrolizumab,targets,urothelial carcinoma of the bladder
Pembrolizumab,targets,triple-negative breast cancer
Pembrolizumab,targets,TNBC
NCT05088057,sponsored_by,Aiping Shi
NCT05088057,has_status,UNKNOWN
NCT05088057,tests,Camrelizumab
Camrelizumab,has_type,DRUG
Camrelizumab,classified_as,BIOLOGIC
Camrelizumab,targets,triple negative breast cancer (tnbc)
Camrelizumab,targets,TNBC
NCT05088057,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,triple negative breast cancer (tnbc)
Doxorubicin,targets,TNBC
NCT05088057,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer (tnbc)
Cyclophosphamide,targets,TNBC
NCT05088057,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,triple negative breast cancer (tnbc)
Docetaxel,targets,TNBC
NCT02456857,sponsored_by,M.D. Anderson Cancer Center
NCT02456857,has_status,COMPLETED
NCT02456857,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,invasive breast carcinoma
Bevacizumab,targets,triple-negative breast carcinoma
Bevacizumab,targets,TNBC
NCT02456857,tests,Everolimus
Everolimus,has_type,DRUG
Everolimus,classified_as,OTHER
Everolimus,targets,invasive breast carcinoma
Everolimus,targets,triple-negative breast carcinoma
Everolimus,targets,TNBC
NCT02456857,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,invasive breast carcinoma
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,TNBC
NCT02456857,tests,Pegylated Liposomal Doxorubicin Hydrochloride
Pegylated Liposomal Doxorubicin Hydrochloride,has_type,DRUG
Pegylated Liposomal Doxorubicin Hydrochloride,classified_as,CHEMICAL
Pegylated Liposomal Doxorubicin Hydrochloride,targets,invasive breast carcinoma
Pegylated Liposomal Doxorubicin Hydrochloride,targets,triple-negative breast carcinoma
Pegylated Liposomal Doxorubicin Hydrochloride,targets,TNBC
NCT03797326,sponsored_by,Merck Sharp & Dohme LLC
NCT03797326,has_status,COMPLETED
NCT03797326,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,gastric cancer
Pembrolizumab,targets,glioblastoma
Pembrolizumab,targets,pancreatic cancer
Pembrolizumab,targets,biliary tract cancers
Pembrolizumab,targets,advanced solid tumors
Pembrolizumab,targets,ovarian cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,colorectal cancer
Pembrolizumab,targets,TNBC
NCT03797326,tests,Lenvatinib
Lenvatinib,has_type,DRUG
Lenvatinib,classified_as,CHEMICAL
Lenvatinib,targets,gastric cancer
Lenvatinib,targets,glioblastoma
Lenvatinib,targets,pancreatic cancer
Lenvatinib,targets,biliary tract cancers
Lenvatinib,targets,advanced solid tumors
Lenvatinib,targets,ovarian cancer
Lenvatinib,targets,triple negative breast cancer
Lenvatinib,targets,colorectal cancer
Lenvatinib,targets,TNBC
NCT05981326,sponsored_by,Institut Cancerologie de l'Ouest
NCT05981326,has_status,RECRUITING
NCT05981326,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,breast cancer
NCT05981326,tests,Blood samples
Blood samples,has_type,DRUG
Blood samples,classified_as,OTHER
Blood samples,targets,breast cancer
NCT05981326,tests,Questionnaires
Questionnaires,has_type,DRUG
Questionnaires,classified_as,OTHER
Questionnaires,targets,breast cancer
NCT02178722,sponsored_by,Incyte Corporation
NCT02178722,has_status,COMPLETED
NCT02178722,tests,MK-3475
MK-3475,has_type,DRUG
MK-3475,classified_as,OTHER
MK-3475,targets,head and neck cancer
MK-3475,targets,gastric cancer
MK-3475,targets,melanoma
MK-3475,targets,uc (urothelial cancer)
MK-3475,targets,microsatellite-instability (msi) high colorectal cancer (crc)
MK-3475,targets,lung cancer
MK-3475,targets,ovarian cancer
MK-3475,targets,bladder cancer
MK-3475,targets,solid tumors
MK-3475,targets,renal cell carcinoma (rcc)
MK-3475,targets,hepatocellular carcinoma (hcc)
MK-3475,targets,lymphoma
MK-3475,targets,triple negative breast cancer (tnbc)
MK-3475,targets,endometrial cancer
MK-3475,targets,TNBC
NCT02178722,tests,INCB024360
INCB024360,has_type,DRUG
INCB024360,classified_as,OTHER
INCB024360,targets,head and neck cancer
INCB024360,targets,gastric cancer
INCB024360,targets,melanoma
INCB024360,targets,uc (urothelial cancer)
INCB024360,targets,microsatellite-instability (msi) high colorectal cancer (crc)
INCB024360,targets,lung cancer
INCB024360,targets,ovarian cancer
INCB024360,targets,bladder cancer
INCB024360,targets,solid tumors
INCB024360,targets,renal cell carcinoma (rcc)
INCB024360,targets,hepatocellular carcinoma (hcc)
INCB024360,targets,lymphoma
INCB024360,targets,triple negative breast cancer (tnbc)
INCB024360,targets,endometrial cancer
INCB024360,targets,TNBC
NCT06657222,sponsored_by,Tubulis GmbH
NCT06657222,has_status,RECRUITING
NCT06657222,tests,TUB-030
TUB-030,has_type,DRUG
TUB-030,classified_as,OTHER
TUB-030,targets,nsclc
TUB-030,targets,advanced solid tumors
TUB-030,targets,crc
TUB-030,targets,tnbc - triple-negative breast cancer
TUB-030,targets,sclc
TUB-030,targets,hnscc
TUB-030,targets,TNBC
NCT06787339,sponsored_by,Fudan University
NCT06787339,has_status,NOT_YET_RECRUITING
NCT06787339,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
NCT02222922,sponsored_by,Pfizer
NCT02222922,has_status,COMPLETED
NCT02222922,tests,PF-06647020 Q3W
PF-06647020 Q3W,has_type,DRUG
PF-06647020 Q3W,classified_as,OTHER
PF-06647020 Q3W,targets,neoplasms
NCT02222922,tests,fluconazole
fluconazole,has_type,DRUG
fluconazole,classified_as,CHEMICAL
fluconazole,targets,neoplasms
NCT02222922,tests,PF-06647020 Q2W
PF-06647020 Q2W,has_type,DRUG
PF-06647020 Q2W,classified_as,OTHER
PF-06647020 Q2W,targets,neoplasms
NCT02222922,tests,PF-06647020 combined with Avelumab
PF-06647020 combined with Avelumab,has_type,DRUG
PF-06647020 combined with Avelumab,classified_as,BIOLOGIC
PF-06647020 combined with Avelumab,targets,neoplasms
NCT06404736,sponsored_by,Fudan University
NCT06404736,has_status,NOT_YET_RECRUITING
NCT06404736,tests,Bispecific antibody (bsAb) targeting PD-1 and CLTA-4
Bispecific antibody (bsAb) targeting PD-1 and CLTA-4,has_type,DRUG
Bispecific antibody (bsAb) targeting PD-1 and CLTA-4,classified_as,BIOLOGIC
Bispecific antibody (bsAb) targeting PD-1 and CLTA-4,targets,early breast cancer
Bispecific antibody (bsAb) targeting PD-1 and CLTA-4,targets,"tnbc, triple negative breast cancer"
Bispecific antibody (bsAb) targeting PD-1 and CLTA-4,targets,neoadjuvant therapy
Bispecific antibody (bsAb) targeting PD-1 and CLTA-4,targets,TNBC
NCT06404736,tests,Albumin-bound paclitaxel
Albumin-bound paclitaxel,has_type,DRUG
Albumin-bound paclitaxel,classified_as,CHEMICAL
Albumin-bound paclitaxel,targets,early breast cancer
Albumin-bound paclitaxel,targets,"tnbc, triple negative breast cancer"
Albumin-bound paclitaxel,targets,neoadjuvant therapy
Albumin-bound paclitaxel,targets,TNBC
NCT06404736,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,early breast cancer
Carboplatin,targets,"tnbc, triple negative breast cancer"
Carboplatin,targets,neoadjuvant therapy
Carboplatin,targets,TNBC
NCT04345913,sponsored_by,National Cancer Institute (NCI)
NCT04345913,has_status,ACTIVE_NOT_RECRUITING
NCT04345913,tests,Biopsy Procedure
Biopsy Procedure,has_type,DRUG
Biopsy Procedure,classified_as,OTHER
Biopsy Procedure,targets,metastatic triple-negative breast carcinoma
Biopsy Procedure,targets,unresectable triple-negative breast carcinoma
Biopsy Procedure,targets,anatomic stage iii breast cancer ajcc v8
Biopsy Procedure,targets,anatomic stage iv breast cancer ajcc v8
Biopsy Procedure,targets,TNBC
NCT04345913,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,unresectable triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iii breast cancer ajcc v8
Biospecimen Collection,targets,anatomic stage iv breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT04345913,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,unresectable triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iii breast cancer ajcc v8
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,TNBC
NCT04345913,tests,Copanlisib Hydrochloride
Copanlisib Hydrochloride,has_type,DRUG
Copanlisib Hydrochloride,classified_as,CHEMICAL
Copanlisib Hydrochloride,targets,metastatic triple-negative breast carcinoma
Copanlisib Hydrochloride,targets,unresectable triple-negative breast carcinoma
Copanlisib Hydrochloride,targets,anatomic stage iii breast cancer ajcc v8
Copanlisib Hydrochloride,targets,anatomic stage iv breast cancer ajcc v8
Copanlisib Hydrochloride,targets,TNBC
NCT04345913,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
Eribulin Mesylate,classified_as,CHEMICAL
Eribulin Mesylate,targets,metastatic triple-negative breast carcinoma
Eribulin Mesylate,targets,unresectable triple-negative breast carcinoma
Eribulin Mesylate,targets,anatomic stage iii breast cancer ajcc v8
Eribulin Mesylate,targets,anatomic stage iv breast cancer ajcc v8
Eribulin Mesylate,targets,TNBC
NCT04345913,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,metastatic triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,unresectable triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iii breast cancer ajcc v8
Magnetic Resonance Imaging,targets,anatomic stage iv breast cancer ajcc v8
Magnetic Resonance Imaging,targets,TNBC
NCT03742349,sponsored_by,Novartis Pharmaceuticals
NCT03742349,has_status,TERMINATED
NCT03742349,tests,spartalizumab
spartalizumab,has_type,DRUG
spartalizumab,classified_as,BIOLOGIC
spartalizumab,targets,triple negative breast cancer (tnbc)
spartalizumab,targets,TNBC
NCT03742349,tests,LAG525
LAG525,has_type,DRUG
LAG525,classified_as,OTHER
LAG525,targets,triple negative breast cancer (tnbc)
LAG525,targets,TNBC
NCT03742349,tests,NIR178
NIR178,has_type,DRUG
NIR178,classified_as,OTHER
NIR178,targets,triple negative breast cancer (tnbc)
NIR178,targets,TNBC
NCT03742349,tests,capmatinib
capmatinib,has_type,DRUG
capmatinib,classified_as,CHEMICAL
capmatinib,targets,triple negative breast cancer (tnbc)
capmatinib,targets,TNBC
NCT03742349,tests,MCS110
MCS110,has_type,DRUG
MCS110,classified_as,OTHER
MCS110,targets,triple negative breast cancer (tnbc)
MCS110,targets,TNBC
NCT03742349,tests,canakinumab
canakinumab,has_type,DRUG
canakinumab,classified_as,BIOLOGIC
canakinumab,targets,triple negative breast cancer (tnbc)
canakinumab,targets,TNBC
NCT06637306,sponsored_by,Rima Patel
NCT06637306,has_status,RECRUITING
NCT06637306,tests,Dupilumab
Dupilumab,has_type,DRUG
Dupilumab,classified_as,BIOLOGIC
Dupilumab,targets,tnbc - triple-negative breast cancer
Dupilumab,targets,locally advanced triple negative breast cancer
Dupilumab,targets,TNBC
NCT06637306,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,tnbc - triple-negative breast cancer
Pembrolizumab,targets,locally advanced triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT06637306,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,tnbc - triple-negative breast cancer
Paclitaxel,targets,locally advanced triple negative breast cancer
Paclitaxel,targets,TNBC
NCT06637306,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,tnbc - triple-negative breast cancer
Carboplatin,targets,locally advanced triple negative breast cancer
Carboplatin,targets,TNBC
NCT05180006,sponsored_by,"Gustave Roussy, Cancer Campus, Grand Paris"
NCT05180006,has_status,RECRUITING
NCT05180006,tests,Atezolizumab Injection
Atezolizumab Injection,has_type,DRUG
Atezolizumab Injection,classified_as,BIOLOGIC
Atezolizumab Injection,targets,breast cancer
NCT05180006,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,breast cancer
NCT05180006,tests,Pertuzumab
Pertuzumab,has_type,DRUG
Pertuzumab,classified_as,BIOLOGIC
Pertuzumab,targets,breast cancer
NCT05180006,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,breast cancer
NCT04333706,sponsored_by,University of Southern California
NCT04333706,has_status,RECRUITING
NCT04333706,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,disseminated tumor cell
Capecitabine,targets,metastatic
Capecitabine,targets,cancer
Capecitabine,targets,triple negative
Capecitabine,targets,breast
NCT04333706,tests,Sarilumab 150mg or 200 mg plus Capecitabine
Sarilumab 150mg or 200 mg plus Capecitabine,has_type,DRUG
Sarilumab 150mg or 200 mg plus Capecitabine,classified_as,BIOLOGIC
Sarilumab 150mg or 200 mg plus Capecitabine,targets,disseminated tumor cell
Sarilumab 150mg or 200 mg plus Capecitabine,targets,metastatic
Sarilumab 150mg or 200 mg plus Capecitabine,targets,cancer
Sarilumab 150mg or 200 mg plus Capecitabine,targets,triple negative
Sarilumab 150mg or 200 mg plus Capecitabine,targets,breast
NCT04333706,tests,Sarilumab 150mg plus Capecitabine
Sarilumab 150mg plus Capecitabine,has_type,DRUG
Sarilumab 150mg plus Capecitabine,classified_as,BIOLOGIC
Sarilumab 150mg plus Capecitabine,targets,disseminated tumor cell
Sarilumab 150mg plus Capecitabine,targets,metastatic
Sarilumab 150mg plus Capecitabine,targets,cancer
Sarilumab 150mg plus Capecitabine,targets,triple negative
Sarilumab 150mg plus Capecitabine,targets,breast
NCT02203513,sponsored_by,National Cancer Institute (NCI)
NCT02203513,has_status,TERMINATED
NCT02203513,tests,LY2606368
LY2606368,has_type,DRUG
LY2606368,classified_as,OTHER
LY2606368,targets,breast cancer
LY2606368,targets,prostate cancer
LY2606368,targets,ovarian cancer
NCT01953536,sponsored_by,Endocyte
NCT01953536,has_status,WITHDRAWN
NCT01953536,tests,Vintafolide 2.5 mg
Vintafolide 2.5 mg,has_type,DRUG
Vintafolide 2.5 mg,classified_as,OTHER
Vintafolide 2.5 mg,targets,breast neoplasms
NCT01953536,tests,Paclitaxel 80 mg/m^2
Paclitaxel 80 mg/m^2,has_type,DRUG
Paclitaxel 80 mg/m^2,classified_as,CHEMICAL
Paclitaxel 80 mg/m^2,targets,breast neoplasms
NCT01953536,tests,Etarfolatide
Etarfolatide,has_type,DRUG
Etarfolatide,classified_as,OTHER
Etarfolatide,targets,breast neoplasms
NCT01953536,tests,Folic acid
Folic acid,has_type,DRUG
Folic acid,classified_as,OTHER
Folic acid,targets,breast neoplasms
NCT01953536,tests,Premedication for Paclitaxel
Premedication for Paclitaxel,has_type,DRUG
Premedication for Paclitaxel,classified_as,CHEMICAL
Premedication for Paclitaxel,targets,breast neoplasms
NCT04485013,sponsored_by,"Tizona Therapeutics, Inc"
NCT04485013,has_status,RECRUITING
NCT04485013,tests,TTX-080
TTX-080,has_type,DRUG
TTX-080,classified_as,OTHER
TTX-080,targets,cancer
NCT04485013,tests,TTX-080
TTX-080,has_type,DRUG
TTX-080,classified_as,OTHER
TTX-080,targets,cancer
NCT04485013,tests,pembrolizumab
pembrolizumab,has_type,DRUG
pembrolizumab,classified_as,BIOLOGIC
pembrolizumab,targets,cancer
NCT04485013,tests,cetuximab
cetuximab,has_type,DRUG
cetuximab,classified_as,BIOLOGIC
cetuximab,targets,cancer
NCT04485013,tests,FOLFIRI
FOLFIRI,has_type,DRUG
FOLFIRI,classified_as,OTHER
FOLFIRI,targets,cancer
NCT04485013,tests,cetuximab
cetuximab,has_type,DRUG
cetuximab,classified_as,BIOLOGIC
cetuximab,targets,cancer
NCT04485013,tests,TTX-080
TTX-080,has_type,DRUG
TTX-080,classified_as,OTHER
TTX-080,targets,cancer
NCT03800836,sponsored_by,Hoffmann-La Roche
NCT03800836,has_status,COMPLETED
NCT03800836,tests,Ipatasertib
Ipatasertib,has_type,DRUG
Ipatasertib,classified_as,CHEMICAL
Ipatasertib,targets,breast cancer
NCT03800836,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT03800836,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,breast cancer
NCT03800836,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,breast cancer
NCT03800836,tests,AC
AC,has_type,DRUG
AC,classified_as,OTHER
AC,targets,breast cancer
NCT03343613,sponsored_by,Eli Lilly and Company
NCT03343613,has_status,TERMINATED
NCT03343613,tests,LY3381916
LY3381916,has_type,DRUG
LY3381916,classified_as,OTHER
LY3381916,targets,renal cell carcinoma
LY3381916,targets,triple negative breast cancer
LY3381916,targets,non small cell lung cancer
LY3381916,targets,solid tumor
LY3381916,targets,TNBC
NCT03343613,tests,LY3300054
LY3300054,has_type,DRUG
LY3300054,classified_as,OTHER
LY3300054,targets,renal cell carcinoma
LY3300054,targets,triple negative breast cancer
LY3300054,targets,non small cell lung cancer
LY3300054,targets,solid tumor
LY3300054,targets,TNBC
NCT05999149,sponsored_by,Fudan University
NCT05999149,has_status,RECRUITING
NCT05999149,tests,Camrelizumab Plus Chemotherapy and Famitinib
Camrelizumab Plus Chemotherapy and Famitinib,has_type,DRUG
Camrelizumab Plus Chemotherapy and Famitinib,classified_as,BIOLOGIC
Camrelizumab Plus Chemotherapy and Famitinib,targets,tnbc - triple-negative breast cancer
Camrelizumab Plus Chemotherapy and Famitinib,targets,TNBC
NCT05999149,tests,Camrelizumab Plus Chemotherapy
Camrelizumab Plus Chemotherapy,has_type,DRUG
Camrelizumab Plus Chemotherapy,classified_as,BIOLOGIC
Camrelizumab Plus Chemotherapy,targets,tnbc - triple-negative breast cancer
Camrelizumab Plus Chemotherapy,targets,TNBC
NCT05555706,sponsored_by,"Shanghai Jiaolian Drug Research and Development Co., Ltd"
NCT05555706,has_status,COMPLETED
NCT05555706,tests,B013+Nab-Paclitaxel
B013+Nab-Paclitaxel,has_type,DRUG
B013+Nab-Paclitaxel,classified_as,CHEMICAL
B013+Nab-Paclitaxel,targets,triple negative breast cancer (tnbc)
B013+Nab-Paclitaxel,targets,TNBC
NCT00998036,sponsored_by,Columbia University
NCT00998036,has_status,COMPLETED
NCT00998036,tests,Temsirolimus
Temsirolimus,has_type,DRUG
Temsirolimus,classified_as,OTHER
Temsirolimus,targets,triple negative breast cancer
Temsirolimus,targets,TNBC
NCT00998036,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,triple negative breast cancer
Cisplatin,targets,TNBC
NCT00998036,tests,Erlotinib
Erlotinib,has_type,DRUG
Erlotinib,classified_as,CHEMICAL
Erlotinib,targets,triple negative breast cancer
Erlotinib,targets,TNBC
NCT03875313,sponsored_by,"Calithera Biosciences, Inc"
NCT03875313,has_status,TERMINATED
NCT03875313,tests,CB-839
CB-839,has_type,DRUG
CB-839,classified_as,OTHER
CB-839,targets,clear cell renal cell carcinoma
CB-839,targets,solid tumor
CB-839,targets,crc
CB-839,targets,tnbc - triple-negative breast cancer
CB-839,targets,rcc
CB-839,targets,ccrcc
CB-839,targets,colorectal cancer
CB-839,targets,TNBC
NCT03875313,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,clear cell renal cell carcinoma
Talazoparib,targets,solid tumor
Talazoparib,targets,crc
Talazoparib,targets,tnbc - triple-negative breast cancer
Talazoparib,targets,rcc
Talazoparib,targets,ccrcc
Talazoparib,targets,colorectal cancer
Talazoparib,targets,TNBC
NCT04360941,sponsored_by,Royal Marsden NHS Foundation Trust
NCT04360941,has_status,RECRUITING
NCT04360941,tests,Palbociclib
Palbociclib,has_type,DRUG
Palbociclib,classified_as,CHEMICAL
Palbociclib,targets,triple negative breast cancer
Palbociclib,targets,her2-positive breast cancer
Palbociclib,targets,locally advanced breast cancer
Palbociclib,targets,recurrent breast cancer
Palbociclib,targets,metastatic breast cancer
Palbociclib,targets,er+ breast cancer
Palbociclib,targets,TNBC
NCT04360941,tests,Avelumab
Avelumab,has_type,DRUG
Avelumab,classified_as,BIOLOGIC
Avelumab,targets,triple negative breast cancer
Avelumab,targets,her2-positive breast cancer
Avelumab,targets,locally advanced breast cancer
Avelumab,targets,recurrent breast cancer
Avelumab,targets,metastatic breast cancer
Avelumab,targets,er+ breast cancer
Avelumab,targets,TNBC
NCT02404441,sponsored_by,Novartis Pharmaceuticals
NCT02404441,has_status,COMPLETED
NCT02404441,tests,PDR001
PDR001,has_type,DRUG
PDR001,classified_as,OTHER
PDR001,targets,melanoma
PDR001,targets,other solid tumors
PDR001,targets,non-small sell lung cancer (nsclc)
PDR001,targets,triple negative breast cancer
PDR001,targets,anaplastic thyroid cancer
PDR001,targets,TNBC
NCT04225117,sponsored_by,"Astellas Pharma Global Development, Inc."
NCT04225117,has_status,ACTIVE_NOT_RECRUITING
NCT04225117,tests,enfortumab vedotin
enfortumab vedotin,has_type,DRUG
enfortumab vedotin,classified_as,BIOLOGIC
enfortumab vedotin,targets,locally advanced or metastatic malignant solid tumors
NCT04225117,tests,pembrolizumab
pembrolizumab,has_type,DRUG
pembrolizumab,classified_as,BIOLOGIC
pembrolizumab,targets,locally advanced or metastatic malignant solid tumors
NCT03371017,sponsored_by,Hoffmann-La Roche
NCT03371017,has_status,COMPLETED
NCT03371017,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,triple negative breast neoplasms
Atezolizumab,targets,TNBC
NCT03371017,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast neoplasms
Placebo,targets,TNBC
NCT03371017,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast neoplasms
Gemcitabine,targets,TNBC
NCT03371017,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple negative breast neoplasms
Capecitabine,targets,TNBC
NCT03371017,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast neoplasms
Carboplatin,targets,TNBC
NCT04498793,sponsored_by,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
NCT04498793,has_status,UNKNOWN
NCT04498793,tests,Tislelizumab
Tislelizumab,has_type,DRUG
Tislelizumab,classified_as,BIOLOGIC
Tislelizumab,targets,her2-negative breast cancer
NCT04498793,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
Nab paclitaxel,classified_as,CHEMICAL
Nab paclitaxel,targets,her2-negative breast cancer
NCT04498793,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,her2-negative breast cancer
NCT04498793,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,her2-negative breast cancer
NCT04498793,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,her2-negative breast cancer
NCT05891171,sponsored_by,"Arcus Biosciences, Inc."
NCT05891171,has_status,RECRUITING
NCT05891171,tests,AB598
AB598,has_type,DRUG
AB598,classified_as,OTHER
AB598,targets,gastric cancer
AB598,targets,advanced malignancies
AB598,targets,head and neck squamous cell carcinoma (hnscc)
AB598,targets,ovarian cancer
AB598,targets,bladder cancer
AB598,targets,non-small cell lung cancer (nsclc)
AB598,targets,esophageal cancer
AB598,targets,advanced cancer
AB598,targets,cervical cancer
AB598,targets,gastroesophageal-junction cancer (gej)
AB598,targets,renal cell carcinoma (rcc)
AB598,targets,triple negative breast cancer (tnbc)
AB598,targets,TNBC
NCT05891171,tests,Zimberelimab
Zimberelimab,has_type,DRUG
Zimberelimab,classified_as,BIOLOGIC
Zimberelimab,targets,gastric cancer
Zimberelimab,targets,advanced malignancies
Zimberelimab,targets,head and neck squamous cell carcinoma (hnscc)
Zimberelimab,targets,ovarian cancer
Zimberelimab,targets,bladder cancer
Zimberelimab,targets,non-small cell lung cancer (nsclc)
Zimberelimab,targets,esophageal cancer
Zimberelimab,targets,advanced cancer
Zimberelimab,targets,cervical cancer
Zimberelimab,targets,gastroesophageal-junction cancer (gej)
Zimberelimab,targets,renal cell carcinoma (rcc)
Zimberelimab,targets,triple negative breast cancer (tnbc)
Zimberelimab,targets,TNBC
NCT05891171,tests,Fluorouracil
Fluorouracil,has_type,DRUG
Fluorouracil,classified_as,OTHER
Fluorouracil,targets,gastric cancer
Fluorouracil,targets,advanced malignancies
Fluorouracil,targets,head and neck squamous cell carcinoma (hnscc)
Fluorouracil,targets,ovarian cancer
Fluorouracil,targets,bladder cancer
Fluorouracil,targets,non-small cell lung cancer (nsclc)
Fluorouracil,targets,esophageal cancer
Fluorouracil,targets,advanced cancer
Fluorouracil,targets,cervical cancer
Fluorouracil,targets,gastroesophageal-junction cancer (gej)
Fluorouracil,targets,renal cell carcinoma (rcc)
Fluorouracil,targets,triple negative breast cancer (tnbc)
Fluorouracil,targets,TNBC
NCT05891171,tests,Leucovorin
Leucovorin,has_type,DRUG
Leucovorin,classified_as,OTHER
Leucovorin,targets,gastric cancer
Leucovorin,targets,advanced malignancies
Leucovorin,targets,head and neck squamous cell carcinoma (hnscc)
Leucovorin,targets,ovarian cancer
Leucovorin,targets,bladder cancer
Leucovorin,targets,non-small cell lung cancer (nsclc)
Leucovorin,targets,esophageal cancer
Leucovorin,targets,advanced cancer
Leucovorin,targets,cervical cancer
Leucovorin,targets,gastroesophageal-junction cancer (gej)
Leucovorin,targets,renal cell carcinoma (rcc)
Leucovorin,targets,triple negative breast cancer (tnbc)
Leucovorin,targets,TNBC
NCT05891171,tests,Oxaliplatin
Oxaliplatin,has_type,DRUG
Oxaliplatin,classified_as,CHEMICAL
Oxaliplatin,targets,gastric cancer
Oxaliplatin,targets,advanced malignancies
Oxaliplatin,targets,head and neck squamous cell carcinoma (hnscc)
Oxaliplatin,targets,ovarian cancer
Oxaliplatin,targets,bladder cancer
Oxaliplatin,targets,non-small cell lung cancer (nsclc)
Oxaliplatin,targets,esophageal cancer
Oxaliplatin,targets,advanced cancer
Oxaliplatin,targets,cervical cancer
Oxaliplatin,targets,gastroesophageal-junction cancer (gej)
Oxaliplatin,targets,renal cell carcinoma (rcc)
Oxaliplatin,targets,triple negative breast cancer (tnbc)
Oxaliplatin,targets,TNBC
NCT04790305,sponsored_by,Fudan University
NCT04790305,has_status,RECRUITING
NCT04790305,tests,Huaier Granule
Huaier Granule,has_type,DRUG
Huaier Granule,classified_as,OTHER
Huaier Granule,targets,"invasive ductal carcinoma, breast"
Huaier Granule,targets,triple-negative breast cancer
Huaier Granule,targets,carcinoma breast
Huaier Granule,targets,TNBC
NCT05192798,sponsored_by,The First Affiliated Hospital of Bengbu Medical University
NCT05192798,has_status,RECRUITING
NCT05192798,tests,Albumin-Bound Paclitaxel
Albumin-Bound Paclitaxel,has_type,DRUG
Albumin-Bound Paclitaxel,classified_as,CHEMICAL
Albumin-Bound Paclitaxel,targets,triple-negative breast cancer
Albumin-Bound Paclitaxel,targets,TNBC
NCT05192798,tests,Apatinib Mesylate
Apatinib Mesylate,has_type,DRUG
Apatinib Mesylate,classified_as,CHEMICAL
Apatinib Mesylate,targets,triple-negative breast cancer
Apatinib Mesylate,targets,TNBC
NCT05192798,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,triple-negative breast cancer
Bevacizumab,targets,TNBC
NCT06632405,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06632405,has_status,NOT_YET_RECRUITING
NCT06632405,tests,Camrelizumab
Camrelizumab,has_type,DRUG
Camrelizumab,classified_as,BIOLOGIC
Camrelizumab,targets,breast cancer
NCT06632405,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
Nab paclitaxel,classified_as,CHEMICAL
Nab paclitaxel,targets,breast cancer
NCT06632405,tests,Levocetirizine Hydrochloride
Levocetirizine Hydrochloride,has_type,DRUG
Levocetirizine Hydrochloride,classified_as,OTHER
Levocetirizine Hydrochloride,targets,breast cancer
NCT03756298,sponsored_by,"National Cancer Center, Korea"
NCT03756298,has_status,ACTIVE_NOT_RECRUITING
NCT03756298,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,triple negative breast cancer
Atezolizumab,targets,TNBC
NCT03756298,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT02129205,sponsored_by,Pfizer
NCT02129205,has_status,TERMINATED
NCT02129205,tests,PF-06650808
PF-06650808,has_type,DRUG
PF-06650808,classified_as,OTHER
PF-06650808,targets,breast cancer
PF-06650808,targets,neoplasms
NCT02129205,tests,PF-06650808
PF-06650808,has_type,DRUG
PF-06650808,classified_as,OTHER
PF-06650808,targets,breast cancer
PF-06650808,targets,neoplasms
NCT02543645,sponsored_by,Celldex Therapeutics
NCT02543645,has_status,TERMINATED
NCT02543645,tests,Combination of Varlilumab and Atezolizumab
Combination of Varlilumab and Atezolizumab,has_type,DRUG
Combination of Varlilumab and Atezolizumab,classified_as,BIOLOGIC
Combination of Varlilumab and Atezolizumab,targets,head and neck cancer
Combination of Varlilumab and Atezolizumab,targets,melanoma
Combination of Varlilumab and Atezolizumab,targets,kidney diseases
Combination of Varlilumab and Atezolizumab,targets,urologic neoplasms
Combination of Varlilumab and Atezolizumab,targets,neoplasms by histologic type
Combination of Varlilumab and Atezolizumab,targets,clear-cell metastatic renal cell carcinoma
Combination of Varlilumab and Atezolizumab,targets,non-small cell lung cancer
Combination of Varlilumab and Atezolizumab,targets,triple negative breast cancer
Combination of Varlilumab and Atezolizumab,targets,urologic diseases
Combination of Varlilumab and Atezolizumab,targets,kidney neoplasms
Combination of Varlilumab and Atezolizumab,targets,"carcinoma, renal cell"
Combination of Varlilumab and Atezolizumab,targets,bladder cancer
Combination of Varlilumab and Atezolizumab,targets,neoplasms
Combination of Varlilumab and Atezolizumab,targets,urogenital neoplasms
Combination of Varlilumab and Atezolizumab,targets,TNBC
NCT02834247,sponsored_by,"Calithera Biosciences, Inc"
NCT02834247,has_status,TERMINATED
NCT02834247,tests,TAK-659
TAK-659,has_type,DRUG
TAK-659,classified_as,OTHER
TAK-659,targets,"carcinoma, non-small-cell lung"
TAK-659,targets,advanced solid tumors
TAK-659,targets,"head and neck carcinoma, squamous cell"
TAK-659,targets,triple-negative breast neoplasms
TAK-659,targets,TNBC
NCT02834247,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,"carcinoma, non-small-cell lung"
Nivolumab,targets,advanced solid tumors
Nivolumab,targets,"head and neck carcinoma, squamous cell"
Nivolumab,targets,triple-negative breast neoplasms
Nivolumab,targets,TNBC
NCT02983045,sponsored_by,Nektar Therapeutics
NCT02983045,has_status,COMPLETED
NCT02983045,tests,Dose Escalation Doublet: Combination of NKTR-214 + nivolumab
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,has_type,DRUG
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,classified_as,BIOLOGIC
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,targets,melanoma
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,targets,renal cell carcinoma
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,targets,hr+/her2- breast cancer
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,targets,gastric cancer
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,targets,urothelial carcinoma
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,targets,triple negative breast cancer
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,targets,non small cell lung cancer
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,targets,TNBC
NCT02983045,tests,Dose Expansion Doublet: Combination of NKTR-214 + nivolumab
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,has_type,DRUG
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,classified_as,BIOLOGIC
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,targets,melanoma
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,targets,renal cell carcinoma
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,targets,hr+/her2- breast cancer
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,targets,gastric cancer
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,targets,urothelial carcinoma
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,targets,triple negative breast cancer
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,targets,non small cell lung cancer
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,targets,TNBC
NCT02983045,tests,Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,has_type,DRUG
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,classified_as,BIOLOGIC
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,melanoma
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,renal cell carcinoma
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,hr+/her2- breast cancer
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,gastric cancer
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,urothelial carcinoma
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,triple negative breast cancer
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,non small cell lung cancer
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,TNBC
NCT02983045,tests,Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,has_type,DRUG
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,classified_as,BIOLOGIC
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,melanoma
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,renal cell carcinoma
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,hr+/her2- breast cancer
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,gastric cancer
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,urothelial carcinoma
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,triple negative breast cancer
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,non small cell lung cancer
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,targets,TNBC
NCT02401347,sponsored_by,Melinda Telli
NCT02401347,has_status,COMPLETED
NCT02401347,tests,Talazoparib Tosylate
Talazoparib Tosylate,has_type,DRUG
Talazoparib Tosylate,classified_as,CHEMICAL
Talazoparib Tosylate,targets,her2/neu negative
Talazoparib Tosylate,targets,advanced breast cancer
Talazoparib Tosylate,targets,triple-negative breast cancer
Talazoparib Tosylate,targets,TNBC
NCT02511847,sponsored_by,National Taiwan University Hospital
NCT02511847,has_status,UNKNOWN
NCT02511847,tests,Afatinib
Afatinib,has_type,DRUG
Afatinib,classified_as,CHEMICAL
Afatinib,targets,triple negative breast cancer
Afatinib,targets,TNBC
NCT05001347,sponsored_by,I-Mab Biopharma US Limited
NCT05001347,has_status,COMPLETED
NCT05001347,tests,TJ004309
TJ004309,has_type,DRUG
TJ004309,classified_as,OTHER
TJ004309,targets,head and neck cancer
TJ004309,targets,ovarian carcinoma
TJ004309,targets,gastrointestinal cancer
TJ004309,targets,ovarian cancer
TJ004309,targets,triple negative breast cancer
TJ004309,targets,non small cell lung cancer
TJ004309,targets,TNBC
NCT03330847,sponsored_by,AstraZeneca
NCT03330847,has_status,ACTIVE_NOT_RECRUITING
NCT03330847,tests,Olaparib Continuous (28-Day cycle) 300 mg BD.
Olaparib Continuous (28-Day cycle) 300 mg BD.,has_type,DRUG
Olaparib Continuous (28-Day cycle) 300 mg BD.,classified_as,BIOLOGIC
Olaparib Continuous (28-Day cycle) 300 mg BD.,targets,metastatic triple negative breast cancer
Olaparib Continuous (28-Day cycle) 300 mg BD.,targets,TNBC
NCT03330847,tests,Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).,has_type,DRUG
Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).,classified_as,BIOLOGIC
Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).,targets,metastatic triple negative breast cancer
Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).,targets,TNBC
NCT03330847,tests,Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).,has_type,DRUG
Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).,classified_as,BIOLOGIC
Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).,targets,metastatic triple negative breast cancer
Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).,targets,TNBC
NCT05203445,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT05203445,has_status,ACTIVE_NOT_RECRUITING
NCT05203445,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,breast cancer
NCT05203445,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT04683445,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04683445,has_status,UNKNOWN
NCT04683445,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,breast cancer
NCT04683445,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,breast cancer
NCT04683445,tests,pertuzumab
pertuzumab,has_type,DRUG
pertuzumab,classified_as,BIOLOGIC
pertuzumab,targets,breast cancer
NCT04683445,tests,Pyrotinib
Pyrotinib,has_type,DRUG
Pyrotinib,classified_as,CHEMICAL
Pyrotinib,targets,breast cancer
NCT04683445,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT04683445,tests,Camerlizumab
Camerlizumab,has_type,DRUG
Camerlizumab,classified_as,BIOLOGIC
Camerlizumab,targets,breast cancer
NCT05491083,sponsored_by,"National University Hospital, Singapore"
NCT05491083,has_status,RECRUITING
NCT05491083,tests,Pembrolizumab & ADG106 (Phase Ib)
Pembrolizumab & ADG106 (Phase Ib),has_type,DRUG
Pembrolizumab & ADG106 (Phase Ib),classified_as,BIOLOGIC
Pembrolizumab & ADG106 (Phase Ib),targets,advanced solid tumor
Pembrolizumab & ADG106 (Phase Ib),targets,triple negative breast cancer
Pembrolizumab & ADG106 (Phase Ib),targets,TNBC
NCT05491083,tests,Pembrolizumab & ADG106 (Phase II)
Pembrolizumab & ADG106 (Phase II),has_type,DRUG
Pembrolizumab & ADG106 (Phase II),classified_as,BIOLOGIC
Pembrolizumab & ADG106 (Phase II),targets,advanced solid tumor
Pembrolizumab & ADG106 (Phase II),targets,triple negative breast cancer
Pembrolizumab & ADG106 (Phase II),targets,TNBC
NCT03348098,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT03348098,has_status,UNKNOWN
NCT03348098,tests,Apatinib
Apatinib,has_type,DRUG
Apatinib,classified_as,CHEMICAL
Apatinib,targets,triple negative breast cancer
Apatinib,targets,TNBC
NCT03348098,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT04248998,sponsored_by,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"
NCT04248998,has_status,UNKNOWN
NCT04248998,tests,Fasting-mimicking diet
Fasting-mimicking diet,has_type,DRUG
Fasting-mimicking diet,classified_as,OTHER
Fasting-mimicking diet,targets,triple-negative breast cancer
Fasting-mimicking diet,targets,TNBC
NCT04248998,tests,Metformin
Metformin,has_type,DRUG
Metformin,classified_as,OTHER
Metformin,targets,triple-negative breast cancer
Metformin,targets,TNBC
NCT04248998,tests,Preoperative chemotherapy
Preoperative chemotherapy,has_type,DRUG
Preoperative chemotherapy,classified_as,OTHER
Preoperative chemotherapy,targets,triple-negative breast cancer
Preoperative chemotherapy,targets,TNBC
NCT03961698,sponsored_by,"Infinity Pharmaceuticals, Inc."
NCT03961698,has_status,ACTIVE_NOT_RECRUITING
NCT03961698,tests,IPI-549 (eganelisib)
IPI-549 (eganelisib),has_type,DRUG
IPI-549 (eganelisib),classified_as,CHEMICAL
IPI-549 (eganelisib),targets,breast cancer
IPI-549 (eganelisib),targets,renal cell carcinoma
NCT03961698,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,breast cancer
Atezolizumab,targets,renal cell carcinoma
NCT03961698,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
nab-paclitaxel,classified_as,CHEMICAL
nab-paclitaxel,targets,breast cancer
nab-paclitaxel,targets,renal cell carcinoma
NCT03961698,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,breast cancer
Bevacizumab,targets,renal cell carcinoma
NCT04405505,sponsored_by,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd."
NCT04405505,has_status,UNKNOWN
NCT04405505,tests,TQB2450
TQB2450,has_type,DRUG
TQB2450,classified_as,OTHER
TQB2450,targets,triple negative breast cancer
TQB2450,targets,TNBC
NCT04405505,tests,Anlotinib
Anlotinib,has_type,DRUG
Anlotinib,classified_as,CHEMICAL
Anlotinib,targets,triple negative breast cancer
Anlotinib,targets,TNBC
NCT04405505,tests,Paclitaxel for Injection (albumin bound)
Paclitaxel for Injection (albumin bound),has_type,DRUG
Paclitaxel for Injection (albumin bound),classified_as,CHEMICAL
Paclitaxel for Injection (albumin bound),targets,triple negative breast cancer
Paclitaxel for Injection (albumin bound),targets,TNBC
NCT03330405,sponsored_by,Pfizer
NCT03330405,has_status,TERMINATED
NCT03330405,tests,Avelumab Phase 1b
Avelumab Phase 1b,has_type,DRUG
Avelumab Phase 1b,classified_as,BIOLOGIC
Avelumab Phase 1b,targets,avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors
NCT03330405,tests,Talazoparib Phase 1b
Talazoparib Phase 1b,has_type,DRUG
Talazoparib Phase 1b,classified_as,CHEMICAL
Talazoparib Phase 1b,targets,avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors
NCT03330405,tests,Avelumab Phase 2
Avelumab Phase 2,has_type,DRUG
Avelumab Phase 2,classified_as,BIOLOGIC
Avelumab Phase 2,targets,avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors
NCT03330405,tests,Talazoparib Phase 2
Talazoparib Phase 2,has_type,DRUG
Talazoparib Phase 2,classified_as,CHEMICAL
Talazoparib Phase 2,targets,avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors
NCT03424005,sponsored_by,Hoffmann-La Roche
NCT03424005,has_status,RECRUITING
NCT03424005,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,metastatic breast cancer
NCT03424005,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,metastatic breast cancer
NCT03424005,tests,Ipatasertib
Ipatasertib,has_type,DRUG
Ipatasertib,classified_as,CHEMICAL
Ipatasertib,targets,metastatic breast cancer
NCT03424005,tests,SGN-LIV1A
SGN-LIV1A,has_type,DRUG
SGN-LIV1A,classified_as,OTHER
SGN-LIV1A,targets,metastatic breast cancer
NCT03424005,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,metastatic breast cancer
NCT03424005,tests,Chemotherapy (Gemcitabine + Carboplatin or Eribulin)
Chemotherapy (Gemcitabine + Carboplatin or Eribulin),has_type,DRUG
Chemotherapy (Gemcitabine + Carboplatin or Eribulin),classified_as,CHEMICAL
Chemotherapy (Gemcitabine + Carboplatin or Eribulin),targets,metastatic breast cancer
NCT03424005,tests,Selicrelumab
Selicrelumab,has_type,DRUG
Selicrelumab,classified_as,BIOLOGIC
Selicrelumab,targets,metastatic breast cancer
NCT03424005,tests,Tocilizumab
Tocilizumab,has_type,DRUG
Tocilizumab,classified_as,BIOLOGIC
Tocilizumab,targets,metastatic breast cancer
NCT03424005,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,metastatic breast cancer
NCT03424005,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
Sacituzumab Govitecan,classified_as,BIOLOGIC
Sacituzumab Govitecan,targets,metastatic breast cancer
NCT03424005,tests,Abemaciclib
Abemaciclib,has_type,DRUG
Abemaciclib,classified_as,CHEMICAL
Abemaciclib,targets,metastatic breast cancer
NCT03424005,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,metastatic breast cancer
NCT03424005,tests,Ribociclib (dose #1)
Ribociclib (dose #1),has_type,DRUG
Ribociclib (dose #1),classified_as,CHEMICAL
Ribociclib (dose #1),targets,metastatic breast cancer
NCT03424005,tests,Inavolisib (dose #2)
Inavolisib (dose #2),has_type,DRUG
Inavolisib (dose #2),classified_as,CHEMICAL
Inavolisib (dose #2),targets,metastatic breast cancer
NCT03424005,tests,Trastuzumab Deruxtecan
Trastuzumab Deruxtecan,has_type,DRUG
Trastuzumab Deruxtecan,classified_as,BIOLOGIC
Trastuzumab Deruxtecan,targets,metastatic breast cancer
NCT03424005,tests,Ribociclib (dose #2)
Ribociclib (dose #2),has_type,DRUG
Ribociclib (dose #2),classified_as,CHEMICAL
Ribociclib (dose #2),targets,metastatic breast cancer
NCT03424005,tests,Letrozole
Letrozole,has_type,DRUG
Letrozole,classified_as,CHEMICAL
Letrozole,targets,metastatic breast cancer
NCT03424005,tests,Inavolisib (dose #1)
Inavolisib (dose #1),has_type,DRUG
Inavolisib (dose #1),classified_as,CHEMICAL
Inavolisib (dose #1),targets,metastatic breast cancer
NCT03424005,tests,Inavolisib
Inavolisib,has_type,DRUG
Inavolisib,classified_as,CHEMICAL
Inavolisib,targets,metastatic breast cancer
NCT05660083,sponsored_by,The Methodist Hospital Research Institute
NCT05660083,has_status,RECRUITING
NCT05660083,tests,L-NMMA
L-NMMA,has_type,DRUG
L-NMMA,classified_as,OTHER
L-NMMA,targets,her2-negative breast cancer
L-NMMA,targets,metaplastic breast carcinoma
L-NMMA,targets,tnbc - triple-negative breast cancer
L-NMMA,targets,metastatic breast cancer
L-NMMA,targets,TNBC
NCT03004183,sponsored_by,The Methodist Hospital Research Institute
NCT03004183,has_status,COMPLETED
NCT03004183,tests,ADV/HSV-tk
ADV/HSV-tk,has_type,DRUG
ADV/HSV-tk,classified_as,OTHER
ADV/HSV-tk,targets,metastatic triple-negative breast cancer
ADV/HSV-tk,targets,metastatic non-small cell lung cancer
ADV/HSV-tk,targets,TNBC
NCT03004183,tests,Valacyclovir
Valacyclovir,has_type,DRUG
Valacyclovir,classified_as,OTHER
Valacyclovir,targets,metastatic triple-negative breast cancer
Valacyclovir,targets,metastatic non-small cell lung cancer
Valacyclovir,targets,TNBC
NCT03004183,tests,SBRT
SBRT,has_type,DRUG
SBRT,classified_as,OTHER
SBRT,targets,metastatic triple-negative breast cancer
SBRT,targets,metastatic non-small cell lung cancer
SBRT,targets,TNBC
NCT03004183,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic triple-negative breast cancer
Pembrolizumab,targets,metastatic non-small cell lung cancer
Pembrolizumab,targets,TNBC
NCT04213898,sponsored_by,Henan Cancer Hospital
NCT04213898,has_status,UNKNOWN
NCT04213898,tests,SHR-1210+Albumin-bound paclitaxel + epirubicin
SHR-1210+Albumin-bound paclitaxel + epirubicin,has_type,DRUG
SHR-1210+Albumin-bound paclitaxel + epirubicin,classified_as,CHEMICAL
SHR-1210+Albumin-bound paclitaxel + epirubicin,targets,triple-negative breast cancer
SHR-1210+Albumin-bound paclitaxel + epirubicin,targets,TNBC
NCT06460298,sponsored_by,"ProDa BioTech, LLC"
NCT06460298,has_status,RECRUITING
NCT06460298,tests,"ProAgio Dose Levels (DL) 1,2,3,4"
"ProAgio Dose Levels (DL) 1,2,3,4",has_type,DRUG
"ProAgio Dose Levels (DL) 1,2,3,4",classified_as,OTHER
"ProAgio Dose Levels (DL) 1,2,3,4",targets,triple negative breast cancer
"ProAgio Dose Levels (DL) 1,2,3,4",targets,TNBC
NCT06460298,tests,ProAgio Dose Expansion
ProAgio Dose Expansion,has_type,DRUG
ProAgio Dose Expansion,classified_as,OTHER
ProAgio Dose Expansion,targets,triple negative breast cancer
ProAgio Dose Expansion,targets,TNBC
NCT03396445,sponsored_by,Merck Sharp & Dohme LLC
NCT03396445,has_status,COMPLETED
NCT03396445,tests,Boserolimab
Boserolimab,has_type,DRUG
Boserolimab,classified_as,BIOLOGIC
Boserolimab,targets,"carcinoma, non-small-cell lung"
Boserolimab,targets,pharmacokinetics
Boserolimab,targets,triple negative breast neoplasms
Boserolimab,targets,solid tumor
Boserolimab,targets,TNBC
NCT03396445,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,"carcinoma, non-small-cell lung"
Pembrolizumab,targets,pharmacokinetics
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,solid tumor
Pembrolizumab,targets,TNBC
NCT03396445,tests,Pemetrexed
Pemetrexed,has_type,DRUG
Pemetrexed,classified_as,OTHER
Pemetrexed,targets,"carcinoma, non-small-cell lung"
Pemetrexed,targets,pharmacokinetics
Pemetrexed,targets,triple negative breast neoplasms
Pemetrexed,targets,solid tumor
Pemetrexed,targets,TNBC
NCT03396445,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,"carcinoma, non-small-cell lung"
Carboplatin,targets,pharmacokinetics
Carboplatin,targets,triple negative breast neoplasms
Carboplatin,targets,solid tumor
Carboplatin,targets,TNBC
NCT03396445,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,"carcinoma, non-small-cell lung"
Nab-paclitaxel,targets,pharmacokinetics
Nab-paclitaxel,targets,triple negative breast neoplasms
Nab-paclitaxel,targets,solid tumor
Nab-paclitaxel,targets,TNBC
NCT06782698,sponsored_by,Centro Hospitalar Universitário de Santo António
NCT06782698,has_status,ACTIVE_NOT_RECRUITING
NCT06782698,tests,Home-based exercise program
Home-based exercise program,has_type,DRUG
Home-based exercise program,classified_as,OTHER
Home-based exercise program,targets,early breast cancer
Home-based exercise program,targets,quality of life (qol)
Home-based exercise program,targets,her2-positive breast cancer
Home-based exercise program,targets,cancer-related fatigue
Home-based exercise program,targets,triple negative breast cancer (tnbc)
Home-based exercise program,targets,TNBC
NCT06782698,tests,Promotion of Healthy Physical Activity
Promotion of Healthy Physical Activity,has_type,DRUG
Promotion of Healthy Physical Activity,classified_as,OTHER
Promotion of Healthy Physical Activity,targets,early breast cancer
Promotion of Healthy Physical Activity,targets,quality of life (qol)
Promotion of Healthy Physical Activity,targets,her2-positive breast cancer
Promotion of Healthy Physical Activity,targets,cancer-related fatigue
Promotion of Healthy Physical Activity,targets,triple negative breast cancer (tnbc)
Promotion of Healthy Physical Activity,targets,TNBC
NCT05035745,sponsored_by,"National University Hospital, Singapore"
NCT05035745,has_status,RECRUITING
NCT05035745,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,metastatic triple negative breast cancers
Talazoparib,targets,advanced triple negative breast cancers
Talazoparib,targets,advanced refractory solid tumors
Talazoparib,targets,TNBC
NCT05035745,tests,Selinexor
Selinexor,has_type,DRUG
Selinexor,classified_as,OTHER
Selinexor,targets,metastatic triple negative breast cancers
Selinexor,targets,advanced triple negative breast cancers
Selinexor,targets,advanced refractory solid tumors
Selinexor,targets,TNBC
NCT03601897,sponsored_by,"Deciphera Pharmaceuticals, LLC"
NCT03601897,has_status,TERMINATED
NCT03601897,tests,Rebastinib
Rebastinib,has_type,DRUG
Rebastinib,classified_as,CHEMICAL
Rebastinib,targets,locally advanced or metastatic solid tumor
NCT03601897,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,locally advanced or metastatic solid tumor
NCT06963905,sponsored_by,Yale University
NCT06963905,has_status,NOT_YET_RECRUITING
NCT06963905,tests,Relatlimab FDC + Nivolumab
Relatlimab FDC + Nivolumab,has_type,DRUG
Relatlimab FDC + Nivolumab,classified_as,BIOLOGIC
Relatlimab FDC + Nivolumab,targets,metastatic triple-negative breast cancer
Relatlimab FDC + Nivolumab,targets,TNBC
NCT06963905,tests,Sacituzumab Govitecan (SG)
Sacituzumab Govitecan (SG),has_type,DRUG
Sacituzumab Govitecan (SG),classified_as,BIOLOGIC
Sacituzumab Govitecan (SG),targets,metastatic triple-negative breast cancer
Sacituzumab Govitecan (SG),targets,TNBC
NCT06963905,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,metastatic triple-negative breast cancer
Nivolumab,targets,TNBC
NCT06492005,sponsored_by,"Mabwell (Shanghai) Bioscience Co., Ltd."
NCT06492005,has_status,RECRUITING
NCT06492005,tests,9MW2821
9MW2821,has_type,DRUG
9MW2821,classified_as,OTHER
9MW2821,targets,triple-negative breast cancer
9MW2821,targets,TNBC
NCT06492005,tests,PD-1 inhibitior
PD-1 inhibitior,has_type,DRUG
PD-1 inhibitior,classified_as,BIOLOGIC
PD-1 inhibitior,targets,triple-negative breast cancer
PD-1 inhibitior,targets,TNBC
NCT03872505,sponsored_by,Cedars-Sinai Medical Center
NCT03872505,has_status,WITHDRAWN
NCT03872505,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,breast cancer
Durvalumab,targets,triple negative breast cancer
Durvalumab,targets,TNBC
NCT03872505,tests,Radiation Therapy
Radiation Therapy,has_type,DRUG
Radiation Therapy,classified_as,OTHER
Radiation Therapy,targets,breast cancer
Radiation Therapy,targets,triple negative breast cancer
Radiation Therapy,targets,TNBC
NCT03872505,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT03872505,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT06468098,sponsored_by,Innovent Biologics (Suzhou) Co. Ltd.
NCT06468098,has_status,RECRUITING
NCT06468098,tests,IBI363 + chemotherapy
IBI363 + chemotherapy,has_type,DRUG
IBI363 + chemotherapy,classified_as,CHEMICAL
IBI363 + chemotherapy,targets,advanced malignancies
NCT06468098,tests,IBI363 + Investigator's Choice SOC
IBI363 + Investigator's Choice SOC,has_type,DRUG
IBI363 + Investigator's Choice SOC,classified_as,CHEMICAL
IBI363 + Investigator's Choice SOC,targets,advanced malignancies
NCT06353997,sponsored_by,Providence Health & Services
NCT06353997,has_status,RECRUITING
NCT06353997,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT06353997,tests,INBRX-106
INBRX-106,has_type,DRUG
INBRX-106,classified_as,OTHER
INBRX-106,targets,triple negative breast cancer
INBRX-106,targets,TNBC
NCT03652077,sponsored_by,Incyte Corporation
NCT03652077,has_status,COMPLETED
NCT03652077,tests,INCAGN02390
INCAGN02390,has_type,DRUG
INCAGN02390,classified_as,OTHER
INCAGN02390,targets,stomach cancer
INCAGN02390,targets,melanoma
INCAGN02390,targets,merkel cell carcinoma
INCAGN02390,targets,urothelial carcinoma
INCAGN02390,targets,cervical cancer
INCAGN02390,targets,gastroesophageal junction cancer
INCAGN02390,targets,hepatocellular carcinoma
INCAGN02390,targets,msi
INCAGN02390,targets,rcc
INCAGN02390,targets,triple-negative breast cancer
INCAGN02390,targets,gastric cancer
INCAGN02390,targets,non-small cell lung cancer
INCAGN02390,targets,nsclc
INCAGN02390,targets,mesothelioma
INCAGN02390,targets,ovarian cancer
INCAGN02390,targets,small cell lung cancer
INCAGN02390,targets,squamous cell carcinoma of the head and neck
INCAGN02390,targets,renal cell carcinoma
INCAGN02390,targets,uveal melanoma
INCAGN02390,targets,mismatch repair deficiency
INCAGN02390,targets,esophageal cancer
INCAGN02390,targets,TNBC
NCT02641847,sponsored_by,Fudan University
NCT02641847,has_status,ACTIVE_NOT_RECRUITING
NCT02641847,tests,docetaxel
docetaxel,has_type,DRUG
docetaxel,classified_as,CHEMICAL
docetaxel,targets,breast cancer
docetaxel,targets,triple negative breast cancer
docetaxel,targets,TNBC
NCT02641847,tests,doxorubicin or epirubicin
doxorubicin or epirubicin,has_type,DRUG
doxorubicin or epirubicin,classified_as,CHEMICAL
doxorubicin or epirubicin,targets,breast cancer
doxorubicin or epirubicin,targets,triple negative breast cancer
doxorubicin or epirubicin,targets,TNBC
NCT02641847,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
cyclophosphamide,classified_as,CHEMICAL
cyclophosphamide,targets,breast cancer
cyclophosphamide,targets,triple negative breast cancer
cyclophosphamide,targets,TNBC
NCT02641847,tests,gemcitabine
gemcitabine,has_type,DRUG
gemcitabine,classified_as,OTHER
gemcitabine,targets,breast cancer
gemcitabine,targets,triple negative breast cancer
gemcitabine,targets,TNBC
NCT02641847,tests,cisplatin
cisplatin,has_type,DRUG
cisplatin,classified_as,CHEMICAL
cisplatin,targets,breast cancer
cisplatin,targets,triple negative breast cancer
cisplatin,targets,TNBC
NCT04348747,sponsored_by,Roswell Park Cancer Institute
NCT04348747,has_status,RECRUITING
NCT04348747,tests,Anti-HER2/HER3 Dendritic Cell Vaccine
Anti-HER2/HER3 Dendritic Cell Vaccine,has_type,DRUG
Anti-HER2/HER3 Dendritic Cell Vaccine,classified_as,BIOLOGIC
Anti-HER2/HER3 Dendritic Cell Vaccine,targets,metastatic malignant neoplasm in the brain
Anti-HER2/HER3 Dendritic Cell Vaccine,targets,metastatic triple-negative breast carcinoma
Anti-HER2/HER3 Dendritic Cell Vaccine,targets,prognostic stage iv breast cancer ajcc v8
Anti-HER2/HER3 Dendritic Cell Vaccine,targets,anatomic stage iv breast cancer ajcc v8
Anti-HER2/HER3 Dendritic Cell Vaccine,targets,TNBC
NCT04348747,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic malignant neoplasm in the brain
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,prognostic stage iv breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage iv breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT02032277,sponsored_by,AbbVie
NCT02032277,has_status,COMPLETED
NCT02032277,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02032277,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast cancer
Placebo,targets,TNBC
NCT02032277,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,triple negative breast cancer
Doxorubicin,targets,TNBC
NCT02032277,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT02032277,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT02032277,tests,Veliparib
Veliparib,has_type,DRUG
Veliparib,classified_as,CHEMICAL
Veliparib,targets,triple negative breast cancer
Veliparib,targets,TNBC
NCT02032277,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast cancer
Placebo,targets,TNBC
NCT05498597,sponsored_by,Multitude Therapeutics Inc.
NCT05498597,has_status,RECRUITING
NCT05498597,tests,AMT-151
AMT-151,has_type,DRUG
AMT-151,classified_as,OTHER
AMT-151,targets,ovarian mucinous adenocarcinoma
AMT-151,targets,ovarian carcinoma
AMT-151,targets,pancreatic ductal adenocarcinoma
AMT-151,targets,ovarian clear cell carcinoma
AMT-151,targets,malignant pleural mesothelioma
AMT-151,targets,triple negative breast cancer
AMT-151,targets,ovarian epithelial cancer
AMT-151,targets,lung adenocarcinoma
AMT-151,targets,advanced solid tumor
AMT-151,targets,advanced carcinoma
AMT-151,targets,endometrial endometrioid adenocarcinoma
AMT-151,targets,ovarian cancer
AMT-151,targets,ovarian endometrioid adenocarcinoma
AMT-151,targets,advanced cancer
AMT-151,targets,ovarian clear cell adenocarcinoma
AMT-151,targets,endometrial cancer
AMT-151,targets,endometrial adenocarcinoma
AMT-151,targets,endometrial clear cell adenocarcinoma
AMT-151,targets,endometrial serous adenocarcinoma
AMT-151,targets,TNBC
NCT03106077,sponsored_by,M.D. Anderson Cancer Center
NCT03106077,has_status,COMPLETED
NCT03106077,tests,Mirvetuximab Soravtansine
Mirvetuximab Soravtansine,has_type,DRUG
Mirvetuximab Soravtansine,classified_as,BIOLOGIC
Mirvetuximab Soravtansine,targets,anatomic stage iia breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,anatomic stage iiib breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,progesterone receptor negative
Mirvetuximab Soravtansine,targets,prognostic stage iia breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,anatomic stage iib breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,anatomic stage iiia breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,prognostic stage ii breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,anatomic stage iv breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,prognostic stage iib breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,anatomic stage ii breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,folate receptor alpha positive
Mirvetuximab Soravtansine,targets,prognostic stage iiic breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,anatomic stage iii breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,her2/neu negative
Mirvetuximab Soravtansine,targets,prognostic stage iii breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,prognostic stage iv breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,prognostic stage iiia breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,prognostic stage iiib breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,anatomic stage iiic breast cancer ajcc v8
Mirvetuximab Soravtansine,targets,estrogen receptor negative
Mirvetuximab Soravtansine,targets,triple-negative breast carcinoma
Mirvetuximab Soravtansine,targets,TNBC
NCT04099277,sponsored_by,Eli Lilly and Company
NCT04099277,has_status,TERMINATED
NCT04099277,tests,LY3435151
LY3435151,has_type,DRUG
LY3435151,classified_as,OTHER
LY3435151,targets,solid tumor
LY3435151,targets,undifferentiated pleomorphic sarcoma
LY3435151,targets,hepatocellular carcinoma
LY3435151,targets,high grade serous ovarian carcinoma
LY3435151,targets,head and neck squamous cell carcinoma
LY3435151,targets,leiomyosarcoma
LY3435151,targets,triple-negative breast cancer
LY3435151,targets,cervical carcinoma
LY3435151,targets,gastric adenocarcinoma
LY3435151,targets,TNBC
NCT04099277,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,solid tumor
Pembrolizumab,targets,undifferentiated pleomorphic sarcoma
Pembrolizumab,targets,hepatocellular carcinoma
Pembrolizumab,targets,high grade serous ovarian carcinoma
Pembrolizumab,targets,head and neck squamous cell carcinoma
Pembrolizumab,targets,leiomyosarcoma
Pembrolizumab,targets,triple-negative breast cancer
Pembrolizumab,targets,cervical carcinoma
Pembrolizumab,targets,gastric adenocarcinoma
Pembrolizumab,targets,TNBC
NCT06367088,sponsored_by,"Wuhan Union Hospital, China"
NCT06367088,has_status,RECRUITING
NCT06367088,tests,Cadonilimab
Cadonilimab,has_type,DRUG
Cadonilimab,classified_as,BIOLOGIC
Cadonilimab,targets,cadonilimab
Cadonilimab,targets,triple-negative breast cancer
Cadonilimab,targets,TNBC
NCT03036488,sponsored_by,Merck Sharp & Dohme LLC
NCT03036488,has_status,ACTIVE_NOT_RECRUITING
NCT03036488,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,TNBC
NCT03036488,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast neoplasms
Carboplatin,targets,TNBC
NCT03036488,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast neoplasms
Paclitaxel,targets,TNBC
NCT03036488,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,triple negative breast neoplasms
Doxorubicin,targets,TNBC
NCT03036488,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,triple negative breast neoplasms
Epirubicin,targets,TNBC
NCT03036488,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast neoplasms
Cyclophosphamide,targets,TNBC
NCT03036488,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast neoplasms
Placebo,targets,TNBC
NCT03036488,tests,Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim,has_type,DRUG
Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim,classified_as,OTHER
Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim,targets,triple negative breast neoplasms
Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim,targets,TNBC
NCT04148911,sponsored_by,Hoffmann-La Roche
NCT04148911,has_status,COMPLETED
NCT04148911,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,triple-negative breast cancer
Atezolizumab,targets,TNBC
NCT04148911,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,triple-negative breast cancer
Nab-Paclitaxel,targets,TNBC
NCT06908928,sponsored_by,"Mabwell (Shanghai) Bioscience Co., Ltd."
NCT06908928,has_status,NOT_YET_RECRUITING
NCT06908928,tests,bulumtatug fuvedotin
bulumtatug fuvedotin,has_type,DRUG
bulumtatug fuvedotin,classified_as,OTHER
bulumtatug fuvedotin,targets,triple negative breast cancer
bulumtatug fuvedotin,targets,TNBC
NCT06908928,tests,bulumtatug fuvedotin
bulumtatug fuvedotin,has_type,DRUG
bulumtatug fuvedotin,classified_as,OTHER
bulumtatug fuvedotin,targets,triple negative breast cancer
bulumtatug fuvedotin,targets,TNBC
NCT05989828,sponsored_by,University of Southern California
NCT05989828,has_status,RECRUITING
NCT05989828,tests,Aldesleukin
Aldesleukin,has_type,DRUG
Aldesleukin,classified_as,OTHER
Aldesleukin,targets,triple negative breast cancer
Aldesleukin,targets,TNBC
NCT05989828,tests,Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes
Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes,has_type,DRUG
Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes,classified_as,OTHER
Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes,targets,triple negative breast cancer
Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes,targets,TNBC
NCT05989828,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,triple negative breast cancer
Biopsy,targets,TNBC
NCT05989828,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,triple negative breast cancer
Biospecimen Collection,targets,TNBC
NCT05989828,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,triple negative breast cancer
Computed Tomography,targets,TNBC
NCT05989828,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT05989828,tests,Echocardiography
Echocardiography,has_type,DRUG
Echocardiography,classified_as,OTHER
Echocardiography,targets,triple negative breast cancer
Echocardiography,targets,TNBC
NCT05989828,tests,Fludarabine
Fludarabine,has_type,DRUG
Fludarabine,classified_as,OTHER
Fludarabine,targets,triple negative breast cancer
Fludarabine,targets,TNBC
NCT05989828,tests,Leukapheresis
Leukapheresis,has_type,DRUG
Leukapheresis,classified_as,OTHER
Leukapheresis,targets,triple negative breast cancer
Leukapheresis,targets,TNBC
NCT05989828,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,triple negative breast cancer
Magnetic Resonance Imaging,targets,TNBC
NCT05989828,tests,Mammogram
Mammogram,has_type,DRUG
Mammogram,classified_as,OTHER
Mammogram,targets,triple negative breast cancer
Mammogram,targets,TNBC
NCT05989828,tests,Multigated Acquisition Scan
Multigated Acquisition Scan,has_type,DRUG
Multigated Acquisition Scan,classified_as,OTHER
Multigated Acquisition Scan,targets,triple negative breast cancer
Multigated Acquisition Scan,targets,TNBC
NCT05989828,tests,Ultrasound Imaging
Ultrasound Imaging,has_type,DRUG
Ultrasound Imaging,classified_as,OTHER
Ultrasound Imaging,targets,triple negative breast cancer
Ultrasound Imaging,targets,TNBC
NCT07021261,sponsored_by,Fudan University
NCT07021261,has_status,NOT_YET_RECRUITING
NCT07021261,tests,Utidelone plus capecitabine
Utidelone plus capecitabine,has_type,DRUG
Utidelone plus capecitabine,classified_as,CHEMICAL
Utidelone plus capecitabine,targets,breast cancer
Utidelone plus capecitabine,targets,tnbc
NCT07021261,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
Capecitabine,targets,tnbc
NCT05111561,sponsored_by,National Cancer Institute (NCI)
NCT05111561,has_status,RECRUITING
NCT05111561,tests,BET Bromodomain Inhibitor ZEN-3694
BET Bromodomain Inhibitor ZEN-3694,has_type,DRUG
BET Bromodomain Inhibitor ZEN-3694,classified_as,CHEMICAL
BET Bromodomain Inhibitor ZEN-3694,targets,refractory malignant solid neoplasm
BET Bromodomain Inhibitor ZEN-3694,targets,metastatic malignant solid neoplasm
BET Bromodomain Inhibitor ZEN-3694,targets,advanced malignant solid neoplasm
BET Bromodomain Inhibitor ZEN-3694,targets,unresectable malignant solid neoplasm
BET Bromodomain Inhibitor ZEN-3694,targets,triple-negative breast carcinoma
BET Bromodomain Inhibitor ZEN-3694,targets,TNBC
NCT05111561,tests,Binimetinib
Binimetinib,has_type,DRUG
Binimetinib,classified_as,CHEMICAL
Binimetinib,targets,refractory malignant solid neoplasm
Binimetinib,targets,metastatic malignant solid neoplasm
Binimetinib,targets,advanced malignant solid neoplasm
Binimetinib,targets,unresectable malignant solid neoplasm
Binimetinib,targets,triple-negative breast carcinoma
Binimetinib,targets,TNBC
NCT05111561,tests,Biopsy Procedure
Biopsy Procedure,has_type,DRUG
Biopsy Procedure,classified_as,OTHER
Biopsy Procedure,targets,refractory malignant solid neoplasm
Biopsy Procedure,targets,metastatic malignant solid neoplasm
Biopsy Procedure,targets,advanced malignant solid neoplasm
Biopsy Procedure,targets,unresectable malignant solid neoplasm
Biopsy Procedure,targets,triple-negative breast carcinoma
Biopsy Procedure,targets,TNBC
NCT05111561,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,refractory malignant solid neoplasm
Biospecimen Collection,targets,metastatic malignant solid neoplasm
Biospecimen Collection,targets,advanced malignant solid neoplasm
Biospecimen Collection,targets,unresectable malignant solid neoplasm
Biospecimen Collection,targets,triple-negative breast carcinoma
Biospecimen Collection,targets,TNBC
NCT05111561,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,refractory malignant solid neoplasm
Computed Tomography,targets,metastatic malignant solid neoplasm
Computed Tomography,targets,advanced malignant solid neoplasm
Computed Tomography,targets,unresectable malignant solid neoplasm
Computed Tomography,targets,triple-negative breast carcinoma
Computed Tomography,targets,TNBC
NCT05111561,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,refractory malignant solid neoplasm
Magnetic Resonance Imaging,targets,metastatic malignant solid neoplasm
Magnetic Resonance Imaging,targets,advanced malignant solid neoplasm
Magnetic Resonance Imaging,targets,unresectable malignant solid neoplasm
Magnetic Resonance Imaging,targets,triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,TNBC
NCT01920061,sponsored_by,Pfizer
NCT01920061,has_status,COMPLETED
NCT01920061,tests,PF-05212384 (gedatolisib)
PF-05212384 (gedatolisib),has_type,DRUG
PF-05212384 (gedatolisib),classified_as,CHEMICAL
PF-05212384 (gedatolisib),targets,neoplasm
NCT01920061,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,neoplasm
NCT01920061,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,neoplasm
NCT01920061,tests,Dacomitinib
Dacomitinib,has_type,DRUG
Dacomitinib,classified_as,CHEMICAL
Dacomitinib,targets,neoplasm
NCT03251378,sponsored_by,Hutchison Medipharma Limited
NCT03251378,has_status,COMPLETED
NCT03251378,tests,Fruquintinib (HMPL-013)
Fruquintinib (HMPL-013),has_type,DRUG
Fruquintinib (HMPL-013),classified_as,CHEMICAL
Fruquintinib (HMPL-013),targets,metastatic colon cancer
Fruquintinib (HMPL-013),targets,rectal cancer
Fruquintinib (HMPL-013),targets,her2-negative breast cancer
Fruquintinib (HMPL-013),targets,advanced solid tumors
Fruquintinib (HMPL-013),targets,triple negative breast cancer
Fruquintinib (HMPL-013),targets,hormone receptor positive breast carcinoma
Fruquintinib (HMPL-013),targets,metastatic breast cancer
Fruquintinib (HMPL-013),targets,TNBC
NCT03918278,sponsored_by,Merck Sharp & Dohme LLC
NCT03918278,has_status,COMPLETED
NCT03918278,tests,MK-0482
MK-0482,has_type,DRUG
MK-0482,classified_as,OTHER
MK-0482,targets,neoplasms
NCT03918278,tests,pembrolizumab
pembrolizumab,has_type,DRUG
pembrolizumab,classified_as,BIOLOGIC
pembrolizumab,targets,neoplasms
NCT03918278,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,neoplasms
NCT03918278,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,neoplasms
NCT03918278,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,neoplasms
NCT03918278,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,neoplasms
NCT03918278,tests,Pemetrexed
Pemetrexed,has_type,DRUG
Pemetrexed,classified_as,OTHER
Pemetrexed,targets,neoplasms
NCT04180371,sponsored_by,BicycleTx Limited
NCT04180371,has_status,RECRUITING
NCT04180371,tests,BT5528
BT5528,has_type,DRUG
BT5528,classified_as,OTHER
BT5528,targets,head and neck cancer
BT5528,targets,gastric/upper gastrointestinal cancer
BT5528,targets,non-small cell lung cancer
BT5528,targets,urothelial cancer
BT5528,targets,ovarian cancer
BT5528,targets,triple negative breast cancer
BT5528,targets,advanced solid tumor historically known for high epha2 expression
BT5528,targets,TNBC
NCT04180371,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,head and neck cancer
Nivolumab,targets,gastric/upper gastrointestinal cancer
Nivolumab,targets,non-small cell lung cancer
Nivolumab,targets,urothelial cancer
Nivolumab,targets,ovarian cancer
Nivolumab,targets,triple negative breast cancer
Nivolumab,targets,advanced solid tumor historically known for high epha2 expression
Nivolumab,targets,TNBC
NCT03205761,sponsored_by,Spanish Breast Cancer Research Group
NCT03205761,has_status,COMPLETED
NCT03205761,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,advanced breast cancer
NCT03123211,sponsored_by,AbbVie
NCT03123211,has_status,NO_LONGER_AVAILABLE
NCT03123211,tests,Veliparib
Veliparib,has_type,DRUG
Veliparib,classified_as,CHEMICAL
Veliparib,targets,"solid tumors with documented brca, bard, or palb or other acceptable dna mutations or anomalies that are scientifically sound"
Veliparib,targets,high grade serous ovarian cancer
Veliparib,targets,triple negative breast cancer (tnbc)
Veliparib,targets,patients requiring veliparib suspension formulation
Veliparib,targets,TNBC
NCT04610528,sponsored_by,SOLTI Breast Cancer Research Group
NCT04610528,has_status,UNKNOWN
NCT04610528,tests,U3 1402
U3 1402,has_type,DRUG
U3 1402,classified_as,OTHER
U3 1402,targets,breast cancer
NCT04610528,tests,U3 1402
U3 1402,has_type,DRUG
U3 1402,classified_as,OTHER
U3 1402,targets,breast cancer
NCT07045311,sponsored_by,"Shanghai Junshi Bioscience Co., Ltd."
NCT07045311,has_status,NOT_YET_RECRUITING
NCT07045311,tests,JS207 in combination with 9MW2821
JS207 in combination with 9MW2821,has_type,DRUG
JS207 in combination with 9MW2821,classified_as,OTHER
JS207 in combination with 9MW2821,targets,triple-negative breast cancer
JS207 in combination with 9MW2821,targets,TNBC
NCT07045311,tests,JS207 in combination with Albumin paclitaxel
JS207 in combination with Albumin paclitaxel,has_type,DRUG
JS207 in combination with Albumin paclitaxel,classified_as,CHEMICAL
JS207 in combination with Albumin paclitaxel,targets,triple-negative breast cancer
JS207 in combination with Albumin paclitaxel,targets,TNBC
NCT05746728,sponsored_by,Huihua Xiong
NCT05746728,has_status,NOT_YET_RECRUITING
NCT05746728,tests,Surufatinib
Surufatinib,has_type,DRUG
Surufatinib,classified_as,CHEMICAL
Surufatinib,targets,metastatic triple-negative breast cancer
Surufatinib,targets,TNBC
NCT05746728,tests,Tislelizumab
Tislelizumab,has_type,DRUG
Tislelizumab,classified_as,BIOLOGIC
Tislelizumab,targets,metastatic triple-negative breast cancer
Tislelizumab,targets,TNBC
NCT03538028,sponsored_by,Incyte Biosciences International Sàrl
NCT03538028,has_status,COMPLETED
NCT03538028,tests,INCAGN02385
INCAGN02385,has_type,DRUG
INCAGN02385,classified_as,OTHER
INCAGN02385,targets,microsatellite instability (msi)-high endometrial cancer
INCAGN02385,targets,gastric cancer (including stomach and gastroesophageal junction [gej])
INCAGN02385,targets,merkel cell carcinoma
INCAGN02385,targets,hepatocellular carcinoma
INCAGN02385,targets,mesothelioma
INCAGN02385,targets,urothelial carcinoma
INCAGN02385,targets,ovarian cancer
INCAGN02385,targets,non-small cell lung cancer (nsclc)
INCAGN02385,targets,esophageal cancer
INCAGN02385,targets,cervical cancer
INCAGN02385,targets,melanoma (uveal melanoma excluded)
INCAGN02385,targets,squamous cell carcinoma of the head and neck (scchn)
INCAGN02385,targets,renal cell carcinoma (rcc)
INCAGN02385,targets,msi-high colorectal cancer
INCAGN02385,targets,diffuse large b-cell lymphoma
INCAGN02385,targets,small cell lung cancer (sclc)
INCAGN02385,targets,triple-negative breast cancer
INCAGN02385,targets,TNBC
NCT06889688,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06889688,has_status,ACTIVE_NOT_RECRUITING
NCT06889688,tests,Camrelizumab+Apatinib+Eribulin
Camrelizumab+Apatinib+Eribulin,has_type,DRUG
Camrelizumab+Apatinib+Eribulin,classified_as,BIOLOGIC
Camrelizumab+Apatinib+Eribulin,targets,breast cancer stage iv
NCT06889688,tests,Physician's choice chemotherapy
Physician's choice chemotherapy,has_type,DRUG
Physician's choice chemotherapy,classified_as,OTHER
Physician's choice chemotherapy,targets,breast cancer stage iv
NCT04879888,sponsored_by,Universidad Nacional de Colombia
NCT04879888,has_status,COMPLETED
NCT04879888,tests,Peptide pulsed Dendritic cell
Peptide pulsed Dendritic cell,has_type,DRUG
Peptide pulsed Dendritic cell,classified_as,BIOLOGIC
Peptide pulsed Dendritic cell,targets,breast cancer female
NCT03872388,sponsored_by,M.D. Anderson Cancer Center
NCT03872388,has_status,TERMINATED
NCT03872388,tests,Atorvastatin
Atorvastatin,has_type,DRUG
Atorvastatin,classified_as,OTHER
Atorvastatin,targets,anatomic stage iiib breast cancer ajcc v8
Atorvastatin,targets,stage iii breast cancer ajcc v7
Atorvastatin,targets,progesterone receptor negative
Atorvastatin,targets,inflammatory breast carcinoma
Atorvastatin,targets,anatomic stage iib breast cancer ajcc v8
Atorvastatin,targets,anatomic stage iiia breast cancer ajcc v8
Atorvastatin,targets,prognostic stage iib breast cancer ajcc v8
Atorvastatin,targets,prognostic stage iiic breast cancer ajcc v8
Atorvastatin,targets,stage iib breast cancer ajcc v6 and v7
Atorvastatin,targets,anatomic stage iii breast cancer ajcc v8
Atorvastatin,targets,her2/neu negative
Atorvastatin,targets,prognostic stage iii breast cancer ajcc v8
Atorvastatin,targets,prognostic stage iiia breast cancer ajcc v8
Atorvastatin,targets,stage iiib breast cancer ajcc v7
Atorvastatin,targets,stage iiia breast cancer ajcc v7
Atorvastatin,targets,prognostic stage iiib breast cancer ajcc v8
Atorvastatin,targets,stage iiic breast cancer ajcc v7
Atorvastatin,targets,anatomic stage iiic breast cancer ajcc v8
Atorvastatin,targets,estrogen receptor negative
Atorvastatin,targets,triple-negative breast carcinoma
Atorvastatin,targets,TNBC
NCT03872388,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,anatomic stage iiib breast cancer ajcc v8
Capecitabine,targets,stage iii breast cancer ajcc v7
Capecitabine,targets,progesterone receptor negative
Capecitabine,targets,inflammatory breast carcinoma
Capecitabine,targets,anatomic stage iib breast cancer ajcc v8
Capecitabine,targets,anatomic stage iiia breast cancer ajcc v8
Capecitabine,targets,prognostic stage iib breast cancer ajcc v8
Capecitabine,targets,prognostic stage iiic breast cancer ajcc v8
Capecitabine,targets,stage iib breast cancer ajcc v6 and v7
Capecitabine,targets,anatomic stage iii breast cancer ajcc v8
Capecitabine,targets,her2/neu negative
Capecitabine,targets,prognostic stage iii breast cancer ajcc v8
Capecitabine,targets,prognostic stage iiia breast cancer ajcc v8
Capecitabine,targets,stage iiib breast cancer ajcc v7
Capecitabine,targets,stage iiia breast cancer ajcc v7
Capecitabine,targets,prognostic stage iiib breast cancer ajcc v8
Capecitabine,targets,stage iiic breast cancer ajcc v7
Capecitabine,targets,anatomic stage iiic breast cancer ajcc v8
Capecitabine,targets,estrogen receptor negative
Capecitabine,targets,triple-negative breast carcinoma
Capecitabine,targets,TNBC
NCT03504488,sponsored_by,"BioAtla, Inc."
NCT03504488,has_status,COMPLETED
NCT03504488,tests,CAB-ROR2-ADC
CAB-ROR2-ADC,has_type,DRUG
CAB-ROR2-ADC,classified_as,OTHER
CAB-ROR2-ADC,targets,head and neck cancer
CAB-ROR2-ADC,targets,melanoma
CAB-ROR2-ADC,targets,non small cell lung cancer
CAB-ROR2-ADC,targets,triple negative breast cancer
CAB-ROR2-ADC,targets,TNBC
NCT03504488,tests,PD-1 inhibitor
PD-1 inhibitor,has_type,DRUG
PD-1 inhibitor,classified_as,BIOLOGIC
PD-1 inhibitor,targets,head and neck cancer
PD-1 inhibitor,targets,melanoma
PD-1 inhibitor,targets,non small cell lung cancer
PD-1 inhibitor,targets,triple negative breast cancer
PD-1 inhibitor,targets,TNBC
NCT06371807,sponsored_by,Fundacao Champalimaud
NCT06371807,has_status,NOT_YET_RECRUITING
NCT06371807,tests,Pembrolizumab injection
Pembrolizumab injection,has_type,DRUG
Pembrolizumab injection,classified_as,BIOLOGIC
Pembrolizumab injection,targets,early breast cancer
Pembrolizumab injection,targets,triple negative breast cancer
Pembrolizumab injection,targets,TNBC
NCT04230109,sponsored_by,Massachusetts General Hospital
NCT04230109,has_status,RECRUITING
NCT04230109,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
Sacituzumab Govitecan,classified_as,BIOLOGIC
Sacituzumab Govitecan,targets,invasive breast cancer
Sacituzumab Govitecan,targets,pr-negative breast cancer
Sacituzumab Govitecan,targets,her2-negative breast cancer
Sacituzumab Govitecan,targets,triple negative breast cancer
Sacituzumab Govitecan,targets,er-negative breast cancer
Sacituzumab Govitecan,targets,TNBC
NCT04230109,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,invasive breast cancer
Pembrolizumab,targets,pr-negative breast cancer
Pembrolizumab,targets,her2-negative breast cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,er-negative breast cancer
Pembrolizumab,targets,TNBC
NCT06154109,sponsored_by,Zhiyu Wang
NCT06154109,has_status,NOT_YET_RECRUITING
NCT06154109,tests,Xiaopi granules
Xiaopi granules,has_type,DRUG
Xiaopi granules,classified_as,OTHER
Xiaopi granules,targets,triple negative breast neoplasms
Xiaopi granules,targets,TNBC
NCT06154109,tests,Xiaopi decoction
Xiaopi decoction,has_type,DRUG
Xiaopi decoction,classified_as,OTHER
Xiaopi decoction,targets,triple negative breast neoplasms
Xiaopi decoction,targets,TNBC
NCT06154109,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast neoplasms
Placebo,targets,TNBC
NCT03554109,sponsored_by,"ImmunityBio, Inc."
NCT03554109,has_status,WITHDRAWN
NCT03554109,tests,Leucovorin
Leucovorin,has_type,DRUG
Leucovorin,classified_as,OTHER
Leucovorin,targets,triple negative breast cancer (tnbc)
Leucovorin,targets,TNBC
NCT03554109,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
5-Fluorouracil,classified_as,CHEMICAL
5-Fluorouracil,targets,triple negative breast cancer (tnbc)
5-Fluorouracil,targets,TNBC
NCT03554109,tests,Aldoxorubicin HCl
Aldoxorubicin HCl,has_type,DRUG
Aldoxorubicin HCl,classified_as,CHEMICAL
Aldoxorubicin HCl,targets,triple negative breast cancer (tnbc)
Aldoxorubicin HCl,targets,TNBC
NCT03554109,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
nab-Paclitaxel,classified_as,CHEMICAL
nab-Paclitaxel,targets,triple negative breast cancer (tnbc)
nab-Paclitaxel,targets,TNBC
NCT03554109,tests,ETBX-011
ETBX-011,has_type,DRUG
ETBX-011,classified_as,OTHER
ETBX-011,targets,triple negative breast cancer (tnbc)
ETBX-011,targets,TNBC
NCT03554109,tests,ETBX-051
ETBX-051,has_type,DRUG
ETBX-051,classified_as,OTHER
ETBX-051,targets,triple negative breast cancer (tnbc)
ETBX-051,targets,TNBC
NCT03554109,tests,ETBX-061
ETBX-061,has_type,DRUG
ETBX-061,classified_as,OTHER
ETBX-061,targets,triple negative breast cancer (tnbc)
ETBX-061,targets,TNBC
NCT03554109,tests,GI-4000
GI-4000,has_type,DRUG
GI-4000,classified_as,OTHER
GI-4000,targets,triple negative breast cancer (tnbc)
GI-4000,targets,TNBC
NCT03554109,tests,GI-6207
GI-6207,has_type,DRUG
GI-6207,classified_as,OTHER
GI-6207,targets,triple negative breast cancer (tnbc)
GI-6207,targets,TNBC
NCT03554109,tests,GI-6301
GI-6301,has_type,DRUG
GI-6301,classified_as,OTHER
GI-6301,targets,triple negative breast cancer (tnbc)
GI-6301,targets,TNBC
NCT03554109,tests,Avelumab
Avelumab,has_type,DRUG
Avelumab,classified_as,BIOLOGIC
Avelumab,targets,triple negative breast cancer (tnbc)
Avelumab,targets,TNBC
NCT03554109,tests,ALT-803
ALT-803,has_type,DRUG
ALT-803,classified_as,OTHER
ALT-803,targets,triple negative breast cancer (tnbc)
ALT-803,targets,TNBC
NCT03554109,tests,haNK
haNK,has_type,DRUG
haNK,classified_as,OTHER
haNK,targets,triple negative breast cancer (tnbc)
haNK,targets,TNBC
NCT03554109,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer (tnbc)
Cyclophosphamide,targets,TNBC
NCT03554109,tests,Doxorubicin HCL
Doxorubicin HCL,has_type,DRUG
Doxorubicin HCL,classified_as,CHEMICAL
Doxorubicin HCL,targets,triple negative breast cancer (tnbc)
Doxorubicin HCL,targets,TNBC
NCT03554109,tests,paclitaxel
paclitaxel,has_type,DRUG
paclitaxel,classified_as,CHEMICAL
paclitaxel,targets,triple negative breast cancer (tnbc)
paclitaxel,targets,TNBC
NCT04254107,sponsored_by,Seagen Inc.
NCT04254107,has_status,TERMINATED
NCT04254107,tests,SEA-TGT
SEA-TGT,has_type,DRUG
SEA-TGT,classified_as,OTHER
SEA-TGT,targets,non-small cell lung cancer
SEA-TGT,targets,gastric carcinoma
SEA-TGT,targets,cutaneous melanoma
SEA-TGT,targets,gastroesophageal junction carcinoma
SEA-TGT,targets,ovarian cancer
SEA-TGT,targets,triple negative breast cancer
SEA-TGT,targets,bladder cancer
SEA-TGT,targets,diffuse large b-cell lymphoma
SEA-TGT,targets,cervical cancer
SEA-TGT,targets,head and neck squamous cell carcinoma
SEA-TGT,targets,classical hodgkin lymphoma
SEA-TGT,targets,peripheral t-cell lymphoma
SEA-TGT,targets,TNBC
NCT04254107,tests,sasanlimab
sasanlimab,has_type,DRUG
sasanlimab,classified_as,BIOLOGIC
sasanlimab,targets,non-small cell lung cancer
sasanlimab,targets,gastric carcinoma
sasanlimab,targets,cutaneous melanoma
sasanlimab,targets,gastroesophageal junction carcinoma
sasanlimab,targets,ovarian cancer
sasanlimab,targets,triple negative breast cancer
sasanlimab,targets,bladder cancer
sasanlimab,targets,diffuse large b-cell lymphoma
sasanlimab,targets,cervical cancer
sasanlimab,targets,head and neck squamous cell carcinoma
sasanlimab,targets,classical hodgkin lymphoma
sasanlimab,targets,peripheral t-cell lymphoma
sasanlimab,targets,TNBC
NCT04254107,tests,brentuximab vedotin
brentuximab vedotin,has_type,DRUG
brentuximab vedotin,classified_as,BIOLOGIC
brentuximab vedotin,targets,non-small cell lung cancer
brentuximab vedotin,targets,gastric carcinoma
brentuximab vedotin,targets,cutaneous melanoma
brentuximab vedotin,targets,gastroesophageal junction carcinoma
brentuximab vedotin,targets,ovarian cancer
brentuximab vedotin,targets,triple negative breast cancer
brentuximab vedotin,targets,bladder cancer
brentuximab vedotin,targets,diffuse large b-cell lymphoma
brentuximab vedotin,targets,cervical cancer
brentuximab vedotin,targets,head and neck squamous cell carcinoma
brentuximab vedotin,targets,classical hodgkin lymphoma
brentuximab vedotin,targets,peripheral t-cell lymphoma
brentuximab vedotin,targets,TNBC
NCT05504707,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT05504707,has_status,ACTIVE_NOT_RECRUITING
NCT05504707,tests,HER2 - primed Dendritic cells
HER2 - primed Dendritic cells,has_type,DRUG
HER2 - primed Dendritic cells,classified_as,OTHER
HER2 - primed Dendritic cells,targets,her2-negative breast cancer
HER2 - primed Dendritic cells,targets,triple negative breast cancer
HER2 - primed Dendritic cells,targets,TNBC
NCT05504707,tests,HER3 - primed Dendritic cells
HER3 - primed Dendritic cells,has_type,DRUG
HER3 - primed Dendritic cells,classified_as,OTHER
HER3 - primed Dendritic cells,targets,her2-negative breast cancer
HER3 - primed Dendritic cells,targets,triple negative breast cancer
HER3 - primed Dendritic cells,targets,TNBC
NCT02509507,sponsored_by,Amgen
NCT02509507,has_status,COMPLETED
NCT02509507,tests,Talimogene Laherparepvec
Talimogene Laherparepvec,has_type,DRUG
Talimogene Laherparepvec,classified_as,OTHER
Talimogene Laherparepvec,targets,liver tumors
Talimogene Laherparepvec,targets,hepatocellular carcinoma
Talimogene Laherparepvec,targets,cutaneous or subcutaneous lymph node
Talimogene Laherparepvec,targets,liver metastases
NCT02509507,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,liver tumors
Pembrolizumab,targets,hepatocellular carcinoma
Pembrolizumab,targets,cutaneous or subcutaneous lymph node
Pembrolizumab,targets,liver metastases
NCT02158507,sponsored_by,University of Alabama at Birmingham
NCT02158507,has_status,COMPLETED
NCT02158507,tests,Combination of Veliparib + Lapatinib
Combination of Veliparib + Lapatinib,has_type,DRUG
Combination of Veliparib + Lapatinib,classified_as,CHEMICAL
Combination of Veliparib + Lapatinib,targets,metastatic triple negative breast cancer
Combination of Veliparib + Lapatinib,targets,TNBC
NCT04722978,sponsored_by,Sun Yat-sen University
NCT04722978,has_status,RECRUITING
NCT04722978,tests,Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
Gemcitabine and carboplatin plus antibiotic (moxifloxacin),has_type,DRUG
Gemcitabine and carboplatin plus antibiotic (moxifloxacin),classified_as,CHEMICAL
Gemcitabine and carboplatin plus antibiotic (moxifloxacin),targets,triple negative breast cancer
Gemcitabine and carboplatin plus antibiotic (moxifloxacin),targets,TNBC
NCT04722978,tests,Gemcitabine combined with carboplatin plus placebo
Gemcitabine combined with carboplatin plus placebo,has_type,DRUG
Gemcitabine combined with carboplatin plus placebo,classified_as,CHEMICAL
Gemcitabine combined with carboplatin plus placebo,targets,triple negative breast cancer
Gemcitabine combined with carboplatin plus placebo,targets,TNBC
NCT03971409,sponsored_by,"Laura Huppert, MD, BA"
NCT03971409,has_status,RECRUITING
NCT03971409,tests,Anti-OX40 Antibody PF-04518600
Anti-OX40 Antibody PF-04518600,has_type,DRUG
Anti-OX40 Antibody PF-04518600,classified_as,CHEMICAL
Anti-OX40 Antibody PF-04518600,targets,stage iiic breast cancer
Anti-OX40 Antibody PF-04518600,targets,invasive breast carcinoma
Anti-OX40 Antibody PF-04518600,targets,recurrent breast carcinoma
Anti-OX40 Antibody PF-04518600,targets,stage iii breast cancer
Anti-OX40 Antibody PF-04518600,targets,stage iiia breast cancer
Anti-OX40 Antibody PF-04518600,targets,stage iv breast cancer
Anti-OX40 Antibody PF-04518600,targets,stage iiib breast cancer
Anti-OX40 Antibody PF-04518600,targets,triple-negative breast carcinoma
Anti-OX40 Antibody PF-04518600,targets,unresectable breast carcinoma
Anti-OX40 Antibody PF-04518600,targets,TNBC
NCT03971409,tests,Avelumab
Avelumab,has_type,DRUG
Avelumab,classified_as,BIOLOGIC
Avelumab,targets,stage iiic breast cancer
Avelumab,targets,invasive breast carcinoma
Avelumab,targets,recurrent breast carcinoma
Avelumab,targets,stage iii breast cancer
Avelumab,targets,stage iiia breast cancer
Avelumab,targets,stage iv breast cancer
Avelumab,targets,stage iiib breast cancer
Avelumab,targets,triple-negative breast carcinoma
Avelumab,targets,unresectable breast carcinoma
Avelumab,targets,TNBC
NCT03971409,tests,Binimetinib
Binimetinib,has_type,DRUG
Binimetinib,classified_as,CHEMICAL
Binimetinib,targets,stage iiic breast cancer
Binimetinib,targets,invasive breast carcinoma
Binimetinib,targets,recurrent breast carcinoma
Binimetinib,targets,stage iii breast cancer
Binimetinib,targets,stage iiia breast cancer
Binimetinib,targets,stage iv breast cancer
Binimetinib,targets,stage iiib breast cancer
Binimetinib,targets,triple-negative breast carcinoma
Binimetinib,targets,unresectable breast carcinoma
Binimetinib,targets,TNBC
NCT03971409,tests,Utomilumab
Utomilumab,has_type,DRUG
Utomilumab,classified_as,BIOLOGIC
Utomilumab,targets,stage iiic breast cancer
Utomilumab,targets,invasive breast carcinoma
Utomilumab,targets,recurrent breast carcinoma
Utomilumab,targets,stage iii breast cancer
Utomilumab,targets,stage iiia breast cancer
Utomilumab,targets,stage iv breast cancer
Utomilumab,targets,stage iiib breast cancer
Utomilumab,targets,triple-negative breast carcinoma
Utomilumab,targets,unresectable breast carcinoma
Utomilumab,targets,TNBC
NCT03971409,tests,Liposomal Doxorubicin
Liposomal Doxorubicin,has_type,DRUG
Liposomal Doxorubicin,classified_as,CHEMICAL
Liposomal Doxorubicin,targets,stage iiic breast cancer
Liposomal Doxorubicin,targets,invasive breast carcinoma
Liposomal Doxorubicin,targets,recurrent breast carcinoma
Liposomal Doxorubicin,targets,stage iii breast cancer
Liposomal Doxorubicin,targets,stage iiia breast cancer
Liposomal Doxorubicin,targets,stage iv breast cancer
Liposomal Doxorubicin,targets,stage iiib breast cancer
Liposomal Doxorubicin,targets,triple-negative breast carcinoma
Liposomal Doxorubicin,targets,unresectable breast carcinoma
Liposomal Doxorubicin,targets,TNBC
NCT03971409,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
Sacituzumab Govitecan,classified_as,BIOLOGIC
Sacituzumab Govitecan,targets,stage iiic breast cancer
Sacituzumab Govitecan,targets,invasive breast carcinoma
Sacituzumab Govitecan,targets,recurrent breast carcinoma
Sacituzumab Govitecan,targets,stage iii breast cancer
Sacituzumab Govitecan,targets,stage iiia breast cancer
Sacituzumab Govitecan,targets,stage iv breast cancer
Sacituzumab Govitecan,targets,stage iiib breast cancer
Sacituzumab Govitecan,targets,triple-negative breast carcinoma
Sacituzumab Govitecan,targets,unresectable breast carcinoma
Sacituzumab Govitecan,targets,TNBC
NCT02341911,sponsored_by,Fudan University
NCT02341911,has_status,UNKNOWN
NCT02341911,tests,"Gemcitabine,cisplatin"
"Gemcitabine,cisplatin",has_type,DRUG
"Gemcitabine,cisplatin",classified_as,CHEMICAL
"Gemcitabine,cisplatin",targets,breast cancer
NCT02341911,tests,"Gemcitabine,carboplatin"
"Gemcitabine,carboplatin",has_type,DRUG
"Gemcitabine,carboplatin",classified_as,CHEMICAL
"Gemcitabine,carboplatin",targets,breast cancer
NCT01216111,sponsored_by,Fudan University
NCT01216111,has_status,COMPLETED
NCT01216111,tests,Paclitaxel Cisplatin
Paclitaxel Cisplatin,has_type,DRUG
Paclitaxel Cisplatin,classified_as,CHEMICAL
Paclitaxel Cisplatin,targets,triple negative breast cancer
Paclitaxel Cisplatin,targets,TNBC
NCT01216111,tests,fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T),has_type,DRUG
fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T),classified_as,CHEMICAL
fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T),targets,triple negative breast cancer
fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T),targets,TNBC
NCT05760378,sponsored_by,Fudan University
NCT05760378,has_status,RECRUITING
NCT05760378,tests,Famitinib
Famitinib,has_type,DRUG
Famitinib,classified_as,CHEMICAL
Famitinib,targets,triple-negative breast cancer
Famitinib,targets,TNBC
NCT05760378,tests,Camrelizumab
Camrelizumab,has_type,DRUG
Camrelizumab,classified_as,BIOLOGIC
Camrelizumab,targets,triple-negative breast cancer
Camrelizumab,targets,TNBC
NCT05760378,tests,nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin
nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin,has_type,DRUG
nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin,classified_as,CHEMICAL
nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin,targets,triple-negative breast cancer
nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin,targets,TNBC
NCT02682693,sponsored_by,GBG Forschungs GmbH
NCT02682693,has_status,COMPLETED
NCT02682693,tests,Denosumab
Denosumab,has_type,DRUG
Denosumab,classified_as,BIOLOGIC
Denosumab,targets,tubular breast cancer stage iii
Denosumab,targets,breast cancer female nos
Denosumab,targets,inflammatory breast cancer
Denosumab,targets,invasive ductal breast cancer
Denosumab,targets,tubular breast cancer stage ii
Denosumab,targets,mucinous breast cancer stage ii
Denosumab,targets,her2 positive breast cancer
NCT02682693,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
nab-Paclitaxel,classified_as,CHEMICAL
nab-Paclitaxel,targets,tubular breast cancer stage iii
nab-Paclitaxel,targets,breast cancer female nos
nab-Paclitaxel,targets,inflammatory breast cancer
nab-Paclitaxel,targets,invasive ductal breast cancer
nab-Paclitaxel,targets,tubular breast cancer stage ii
nab-Paclitaxel,targets,mucinous breast cancer stage ii
nab-Paclitaxel,targets,her2 positive breast cancer
NCT02682693,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,tubular breast cancer stage iii
Epirubicin,targets,breast cancer female nos
Epirubicin,targets,inflammatory breast cancer
Epirubicin,targets,invasive ductal breast cancer
Epirubicin,targets,tubular breast cancer stage ii
Epirubicin,targets,mucinous breast cancer stage ii
Epirubicin,targets,her2 positive breast cancer
NCT02682693,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,tubular breast cancer stage iii
Cyclophosphamide,targets,breast cancer female nos
Cyclophosphamide,targets,inflammatory breast cancer
Cyclophosphamide,targets,invasive ductal breast cancer
Cyclophosphamide,targets,tubular breast cancer stage ii
Cyclophosphamide,targets,mucinous breast cancer stage ii
Cyclophosphamide,targets,her2 positive breast cancer
NCT02682693,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,tubular breast cancer stage iii
Carboplatin,targets,breast cancer female nos
Carboplatin,targets,inflammatory breast cancer
Carboplatin,targets,invasive ductal breast cancer
Carboplatin,targets,tubular breast cancer stage ii
Carboplatin,targets,mucinous breast cancer stage ii
Carboplatin,targets,her2 positive breast cancer
NCT02682693,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,tubular breast cancer stage iii
Trastuzumab,targets,breast cancer female nos
Trastuzumab,targets,inflammatory breast cancer
Trastuzumab,targets,invasive ductal breast cancer
Trastuzumab,targets,tubular breast cancer stage ii
Trastuzumab,targets,mucinous breast cancer stage ii
Trastuzumab,targets,her2 positive breast cancer
NCT02682693,tests,Pertuzumab
Pertuzumab,has_type,DRUG
Pertuzumab,classified_as,BIOLOGIC
Pertuzumab,targets,tubular breast cancer stage iii
Pertuzumab,targets,breast cancer female nos
Pertuzumab,targets,inflammatory breast cancer
Pertuzumab,targets,invasive ductal breast cancer
Pertuzumab,targets,tubular breast cancer stage ii
Pertuzumab,targets,mucinous breast cancer stage ii
Pertuzumab,targets,her2 positive breast cancer
NCT06176261,sponsored_by,"Sarah Sammons, MD"
NCT06176261,has_status,RECRUITING
NCT06176261,tests,Datopotamab Deruxtecan
Datopotamab Deruxtecan,has_type,DRUG
Datopotamab Deruxtecan,classified_as,BIOLOGIC
Datopotamab Deruxtecan,targets,er-negative breast cancer
Datopotamab Deruxtecan,targets,breast cancer
Datopotamab Deruxtecan,targets,her2-negative breast cancer
Datopotamab Deruxtecan,targets,metastatic triple-negative breast carcinoma
Datopotamab Deruxtecan,targets,breast cancer female
Datopotamab Deruxtecan,targets,er positive breast cancer
Datopotamab Deruxtecan,targets,her2 negative breast carcinoma
Datopotamab Deruxtecan,targets,TNBC
NCT04468061,sponsored_by,Dana-Farber Cancer Institute
NCT04468061,has_status,RECRUITING
NCT04468061,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
Sacituzumab Govitecan,classified_as,BIOLOGIC
Sacituzumab Govitecan,targets,breast cancer
Sacituzumab Govitecan,targets,pd-l1 negative
Sacituzumab Govitecan,targets,triple negative breast cancer
Sacituzumab Govitecan,targets,TNBC
NCT04468061,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,pd-l1 negative
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT03201861,sponsored_by,RenJi Hospital
NCT03201861,has_status,RECRUITING
NCT03201861,tests,"Paclitaxel, Cisplatin"
"Paclitaxel, Cisplatin",has_type,DRUG
"Paclitaxel, Cisplatin",classified_as,CHEMICAL
"Paclitaxel, Cisplatin",targets,tubular breast cancer
"Paclitaxel, Cisplatin",targets,invasive duct carcinoma of breast
"Paclitaxel, Cisplatin",targets,mucinous breast cancer
NCT03201861,tests,EC to docetaxel or paclitaxel
EC to docetaxel or paclitaxel,has_type,DRUG
EC to docetaxel or paclitaxel,classified_as,CHEMICAL
EC to docetaxel or paclitaxel,targets,tubular breast cancer
EC to docetaxel or paclitaxel,targets,invasive duct carcinoma of breast
EC to docetaxel or paclitaxel,targets,mucinous breast cancer
NCT06387628,sponsored_by,Fudan University
NCT06387628,has_status,RECRUITING
NCT06387628,tests,LM-108
LM-108,has_type,DRUG
LM-108,classified_as,OTHER
LM-108,targets,tnbc - triple-negative breast cancer
LM-108,targets,TNBC
NCT06387628,tests,Toripalimab
Toripalimab,has_type,DRUG
Toripalimab,classified_as,BIOLOGIC
Toripalimab,targets,tnbc - triple-negative breast cancer
Toripalimab,targets,TNBC
NCT06387628,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,tnbc - triple-negative breast cancer
Eribulin,targets,TNBC
NCT06387628,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
Nab paclitaxel,classified_as,CHEMICAL
Nab paclitaxel,targets,tnbc - triple-negative breast cancer
Nab paclitaxel,targets,TNBC
NCT02971761,sponsored_by,City of Hope Medical Center
NCT02971761,has_status,COMPLETED
NCT02971761,tests,Enobosarm
Enobosarm,has_type,DRUG
Enobosarm,classified_as,OTHER
Enobosarm,targets,metastatic triple-negative breast carcinoma
Enobosarm,targets,estrogen receptor negative
Enobosarm,targets,progesterone receptor negative
Enobosarm,targets,androgen receptor positive
Enobosarm,targets,her2/neu negative
Enobosarm,targets,stage iv breast cancer ajcc v6 and v7
Enobosarm,targets,TNBC
NCT02971761,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,metastatic triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,estrogen receptor negative
Laboratory Biomarker Analysis,targets,progesterone receptor negative
Laboratory Biomarker Analysis,targets,androgen receptor positive
Laboratory Biomarker Analysis,targets,her2/neu negative
Laboratory Biomarker Analysis,targets,stage iv breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,TNBC
NCT02971761,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,estrogen receptor negative
Pembrolizumab,targets,progesterone receptor negative
Pembrolizumab,targets,androgen receptor positive
Pembrolizumab,targets,her2/neu negative
Pembrolizumab,targets,stage iv breast cancer ajcc v6 and v7
Pembrolizumab,targets,TNBC
NCT06067061,sponsored_by,Institut Curie
NCT06067061,has_status,TERMINATED
NCT06067061,tests,Atezolizumab + RP1
Atezolizumab + RP1,has_type,DRUG
Atezolizumab + RP1,classified_as,BIOLOGIC
Atezolizumab + RP1,targets,triple negative breast neoplasms
Atezolizumab + RP1,targets,TNBC
NCT02089854,sponsored_by,Peking Union Medical College Hospital
NCT02089854,has_status,UNKNOWN
NCT02089854,tests,Toremifene; Anastrozole
Toremifene; Anastrozole,has_type,DRUG
Toremifene; Anastrozole,classified_as,CHEMICAL
Toremifene; Anastrozole,targets,female breast cancer
NCT05570253,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT05570253,has_status,RECRUITING
NCT05570253,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,breast cancer
Eribulin,targets,metastatic triple-negative breast cancer
Eribulin,targets,TNBC
NCT05570253,tests,SDX-7320
SDX-7320,has_type,DRUG
SDX-7320,classified_as,OTHER
SDX-7320,targets,breast cancer
SDX-7320,targets,metastatic triple-negative breast cancer
SDX-7320,targets,TNBC
NCT05570253,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,breast cancer
Placebo,targets,metastatic triple-negative breast cancer
Placebo,targets,TNBC
NCT06684054,sponsored_by,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT06684054,has_status,NOT_YET_RECRUITING
NCT06684054,tests,"docetaxel, anthracycline, cyclophosphamide"
"docetaxel, anthracycline, cyclophosphamide",has_type,DRUG
"docetaxel, anthracycline, cyclophosphamide",classified_as,CHEMICAL
"docetaxel, anthracycline, cyclophosphamide",targets,chemotherapy effect
"docetaxel, anthracycline, cyclophosphamide",targets,t-cell dysfunction
"docetaxel, anthracycline, cyclophosphamide",targets,adverse events
NCT01238133,sponsored_by,National Cancer Institute (NCI)
NCT01238133,has_status,TERMINATED
NCT01238133,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,stage iiic breast cancer
Carboplatin,targets,stage iiib breast cancer
Carboplatin,targets,stage iiia breast cancer
Carboplatin,targets,estrogen receptor negative
Carboplatin,targets,progesterone receptor negative
Carboplatin,targets,her2/neu negative
Carboplatin,targets,stage iia breast cancer
Carboplatin,targets,stage iib breast cancer
Carboplatin,targets,triple-negative breast carcinoma
Carboplatin,targets,TNBC
NCT01238133,tests,Gamma-Secretase Inhibitor RO4929097
Gamma-Secretase Inhibitor RO4929097,has_type,DRUG
Gamma-Secretase Inhibitor RO4929097,classified_as,CHEMICAL
Gamma-Secretase Inhibitor RO4929097,targets,stage iiic breast cancer
Gamma-Secretase Inhibitor RO4929097,targets,stage iiib breast cancer
Gamma-Secretase Inhibitor RO4929097,targets,stage iiia breast cancer
Gamma-Secretase Inhibitor RO4929097,targets,estrogen receptor negative
Gamma-Secretase Inhibitor RO4929097,targets,progesterone receptor negative
Gamma-Secretase Inhibitor RO4929097,targets,her2/neu negative
Gamma-Secretase Inhibitor RO4929097,targets,stage iia breast cancer
Gamma-Secretase Inhibitor RO4929097,targets,stage iib breast cancer
Gamma-Secretase Inhibitor RO4929097,targets,triple-negative breast carcinoma
Gamma-Secretase Inhibitor RO4929097,targets,TNBC
NCT01238133,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,stage iiic breast cancer
Laboratory Biomarker Analysis,targets,stage iiib breast cancer
Laboratory Biomarker Analysis,targets,stage iiia breast cancer
Laboratory Biomarker Analysis,targets,estrogen receptor negative
Laboratory Biomarker Analysis,targets,progesterone receptor negative
Laboratory Biomarker Analysis,targets,her2/neu negative
Laboratory Biomarker Analysis,targets,stage iia breast cancer
Laboratory Biomarker Analysis,targets,stage iib breast cancer
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,TNBC
NCT01238133,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,stage iiic breast cancer
Paclitaxel,targets,stage iiib breast cancer
Paclitaxel,targets,stage iiia breast cancer
Paclitaxel,targets,estrogen receptor negative
Paclitaxel,targets,progesterone receptor negative
Paclitaxel,targets,her2/neu negative
Paclitaxel,targets,stage iia breast cancer
Paclitaxel,targets,stage iib breast cancer
Paclitaxel,targets,triple-negative breast carcinoma
Paclitaxel,targets,TNBC
NCT01238133,tests,Pharmacological Study
Pharmacological Study,has_type,DRUG
Pharmacological Study,classified_as,OTHER
Pharmacological Study,targets,stage iiic breast cancer
Pharmacological Study,targets,stage iiib breast cancer
Pharmacological Study,targets,stage iiia breast cancer
Pharmacological Study,targets,estrogen receptor negative
Pharmacological Study,targets,progesterone receptor negative
Pharmacological Study,targets,her2/neu negative
Pharmacological Study,targets,stage iia breast cancer
Pharmacological Study,targets,stage iib breast cancer
Pharmacological Study,targets,triple-negative breast carcinoma
Pharmacological Study,targets,TNBC
NCT01238133,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,DRUG
Therapeutic Conventional Surgery,classified_as,OTHER
Therapeutic Conventional Surgery,targets,stage iiic breast cancer
Therapeutic Conventional Surgery,targets,stage iiib breast cancer
Therapeutic Conventional Surgery,targets,stage iiia breast cancer
Therapeutic Conventional Surgery,targets,estrogen receptor negative
Therapeutic Conventional Surgery,targets,progesterone receptor negative
Therapeutic Conventional Surgery,targets,her2/neu negative
Therapeutic Conventional Surgery,targets,stage iia breast cancer
Therapeutic Conventional Surgery,targets,stage iib breast cancer
Therapeutic Conventional Surgery,targets,triple-negative breast carcinoma
Therapeutic Conventional Surgery,targets,TNBC
NCT05403554,sponsored_by,Light Chain Bioscience - Novimmune SA
NCT05403554,has_status,RECRUITING
NCT05403554,tests,Biological NI-1801
Biological NI-1801,has_type,DRUG
Biological NI-1801,classified_as,OTHER
Biological NI-1801,targets,non-squamous non-small-cell lung cancer
Biological NI-1801,targets,triple negative breast cancer
Biological NI-1801,targets,epithelial ovarian cancer
Biological NI-1801,targets,pancreatic adenocarcinoma (ductal adenocarcinoma)
Biological NI-1801,targets,endometrioid ovarian cancer
Biological NI-1801,targets,TNBC
NCT05403554,tests,NI-1801 in combination with anti-PD1 (Pembrolizumab)
NI-1801 in combination with anti-PD1 (Pembrolizumab),has_type,DRUG
NI-1801 in combination with anti-PD1 (Pembrolizumab),classified_as,BIOLOGIC
NI-1801 in combination with anti-PD1 (Pembrolizumab),targets,non-squamous non-small-cell lung cancer
NI-1801 in combination with anti-PD1 (Pembrolizumab),targets,triple negative breast cancer
NI-1801 in combination with anti-PD1 (Pembrolizumab),targets,epithelial ovarian cancer
NI-1801 in combination with anti-PD1 (Pembrolizumab),targets,pancreatic adenocarcinoma (ductal adenocarcinoma)
NI-1801 in combination with anti-PD1 (Pembrolizumab),targets,endometrioid ovarian cancer
NI-1801 in combination with anti-PD1 (Pembrolizumab),targets,TNBC
NCT05403554,tests,NI-1801 in combination with paclitaxel
NI-1801 in combination with paclitaxel,has_type,DRUG
NI-1801 in combination with paclitaxel,classified_as,CHEMICAL
NI-1801 in combination with paclitaxel,targets,non-squamous non-small-cell lung cancer
NI-1801 in combination with paclitaxel,targets,triple negative breast cancer
NI-1801 in combination with paclitaxel,targets,epithelial ovarian cancer
NI-1801 in combination with paclitaxel,targets,pancreatic adenocarcinoma (ductal adenocarcinoma)
NI-1801 in combination with paclitaxel,targets,endometrioid ovarian cancer
NI-1801 in combination with paclitaxel,targets,TNBC
NCT05403554,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,non-squamous non-small-cell lung cancer
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,epithelial ovarian cancer
Paclitaxel,targets,pancreatic adenocarcinoma (ductal adenocarcinoma)
Paclitaxel,targets,endometrioid ovarian cancer
Paclitaxel,targets,TNBC
NCT05918133,sponsored_by,Biotheus Inc.
NCT05918133,has_status,ACTIVE_NOT_RECRUITING
NCT05918133,tests,PM8002
PM8002,has_type,DRUG
PM8002,classified_as,OTHER
PM8002,targets,tnbc
NCT05918133,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
nab-paclitaxel,classified_as,CHEMICAL
nab-paclitaxel,targets,tnbc
NCT04676997,sponsored_by,Shandong Cancer Hospital and Institute
NCT04676997,has_status,UNKNOWN
NCT04676997,tests,Camrelizumab
Camrelizumab,has_type,DRUG
Camrelizumab,classified_as,BIOLOGIC
Camrelizumab,targets,triple negative breast cancer
Camrelizumab,targets,TNBC
NCT04676997,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
Nab paclitaxel,classified_as,CHEMICAL
Nab paclitaxel,targets,triple negative breast cancer
Nab paclitaxel,targets,TNBC
NCT04676997,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,triple negative breast cancer
Epirubicin,targets,TNBC
NCT04676997,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT05955105,sponsored_by,Innolake Biopharm
NCT05955105,has_status,RECRUITING
NCT05955105,tests,ILB-2109
ILB-2109,has_type,DRUG
ILB-2109,classified_as,OTHER
ILB-2109,targets,head and neck cancer
ILB-2109,targets,melanoma
ILB-2109,targets,nasopharyngeal carcinoma
ILB-2109,targets,ovarian cancer
ILB-2109,targets,soft tissue sarcoma
ILB-2109,targets,triple negative breast cancer
ILB-2109,targets,cervical cancer
ILB-2109,targets,endometrial cancer
ILB-2109,targets,classic hodgkin lymphoma
ILB-2109,targets,non small cell lung cancer
ILB-2109,targets,TNBC
NCT05955105,tests,Toripalimab
Toripalimab,has_type,DRUG
Toripalimab,classified_as,BIOLOGIC
Toripalimab,targets,head and neck cancer
Toripalimab,targets,melanoma
Toripalimab,targets,nasopharyngeal carcinoma
Toripalimab,targets,ovarian cancer
Toripalimab,targets,soft tissue sarcoma
Toripalimab,targets,triple negative breast cancer
Toripalimab,targets,cervical cancer
Toripalimab,targets,endometrial cancer
Toripalimab,targets,classic hodgkin lymphoma
Toripalimab,targets,non small cell lung cancer
Toripalimab,targets,TNBC
NCT02984683,sponsored_by,Sanofi
NCT02984683,has_status,TERMINATED
NCT02984683,tests,SAR566658 (ACT14884)
SAR566658 (ACT14884),has_type,DRUG
SAR566658 (ACT14884),classified_as,OTHER
SAR566658 (ACT14884),targets,triple negative breast cancer
SAR566658 (ACT14884),targets,TNBC
NCT02441933,sponsored_by,Yonsei University
NCT02441933,has_status,ACTIVE_NOT_RECRUITING
NCT02441933,tests,taxane plus carboplatin
taxane plus carboplatin,has_type,DRUG
taxane plus carboplatin,classified_as,CHEMICAL
taxane plus carboplatin,targets,breast cancer
NCT02441933,tests,Taxane
Taxane,has_type,DRUG
Taxane,classified_as,OTHER
Taxane,targets,breast cancer
NCT04251533,sponsored_by,Novartis Pharmaceuticals
NCT04251533,has_status,ACTIVE_NOT_RECRUITING
NCT04251533,tests,alpelisib
alpelisib,has_type,DRUG
alpelisib,classified_as,BIOLOGIC
alpelisib,targets,triple negative breast neoplasms
alpelisib,targets,TNBC
NCT04251533,tests,placebo
placebo,has_type,DRUG
placebo,classified_as,OTHER
placebo,targets,triple negative breast neoplasms
placebo,targets,TNBC
NCT04251533,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
nab-paclitaxel,classified_as,CHEMICAL
nab-paclitaxel,targets,triple negative breast neoplasms
nab-paclitaxel,targets,TNBC
NCT06224387,sponsored_by,"CytosinLab Therapeutics Co., Ltd."
NCT06224387,has_status,RECRUITING
NCT06224387,tests,CTS2190 capsules
CTS2190 capsules,has_type,DRUG
CTS2190 capsules,classified_as,OTHER
CTS2190 capsules,targets,non-small cell lung cancer
CTS2190 capsules,targets,solid tumors
CTS2190 capsules,targets,triple-negative breast cancer
CTS2190 capsules,targets,pancreatic cancer
CTS2190 capsules,targets,TNBC
NCT06238687,sponsored_by,"Tasly Pharmaceutical Group Co., Ltd"
NCT06238687,has_status,RECRUITING
NCT06238687,tests,STRO-002
STRO-002,has_type,DRUG
STRO-002,classified_as,OTHER
STRO-002,targets,neoplasm malignant
NCT02547987,sponsored_by,Mothaffar Rimawi
NCT02547987,has_status,ACTIVE_NOT_RECRUITING
NCT02547987,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,breast cancer
NCT02547987,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
NCT01378533,sponsored_by,Chinese Academy of Medical Sciences
NCT01378533,has_status,UNKNOWN
NCT01378533,tests,"epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF"
"epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF",has_type,DRUG
"epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF",classified_as,CHEMICAL
"epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF",targets,breast cancer
NCT00371254,sponsored_by,Bristol-Myers Squibb
NCT00371254,has_status,COMPLETED
NCT00371254,tests,Dasatinib
Dasatinib,has_type,DRUG
Dasatinib,classified_as,CHEMICAL
Dasatinib,targets,breast cancer
Dasatinib,targets,metastasis
NCT00371254,tests,Dasatinib
Dasatinib,has_type,DRUG
Dasatinib,classified_as,CHEMICAL
Dasatinib,targets,breast cancer
Dasatinib,targets,metastasis
NCT02622074,sponsored_by,Merck Sharp & Dohme LLC
NCT02622074,has_status,COMPLETED
NCT02622074,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,TNBC
NCT02622074,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple negative breast neoplasms
Nab-paclitaxel,targets,TNBC
NCT02622074,tests,Anthracycline (doxorubicin)
Anthracycline (doxorubicin),has_type,DRUG
Anthracycline (doxorubicin),classified_as,CHEMICAL
Anthracycline (doxorubicin),targets,triple negative breast neoplasms
Anthracycline (doxorubicin),targets,TNBC
NCT02622074,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast neoplasms
Cyclophosphamide,targets,TNBC
NCT02622074,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast neoplasms
Carboplatin,targets,TNBC
NCT02622074,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast neoplasms
Paclitaxel,targets,TNBC
NCT06744465,sponsored_by,Indiana University
NCT06744465,has_status,RECRUITING
NCT06744465,tests,NearWave monitoring
NearWave monitoring,has_type,DRUG
NearWave monitoring,classified_as,OTHER
NearWave monitoring,targets,invasive breast carcinoma
NearWave monitoring,targets,breast cancer
NearWave monitoring,targets,her2-negative breast cancer
NearWave monitoring,targets,her2-positive breast cancer
NearWave monitoring,targets,tnbc - triple-negative breast cancer
NearWave monitoring,targets,TNBC
NCT03575065,sponsored_by,BeiGene
NCT03575065,has_status,COMPLETED
NCT03575065,tests,BGB-290
BGB-290,has_type,DRUG
BGB-290,classified_as,OTHER
BGB-290,targets,her2-negative breast cancer
NCT02833766,sponsored_by,Swiss Group for Clinical Cancer Research
NCT02833766,has_status,TERMINATED
NCT02833766,tests,anti-EGFR-IL-dox
anti-EGFR-IL-dox,has_type,DRUG
anti-EGFR-IL-dox,classified_as,OTHER
anti-EGFR-IL-dox,targets,breast cancer
NCT05933265,sponsored_by,Lantern Pharma Inc.
NCT05933265,has_status,RECRUITING
NCT05933265,tests,LP-184
LP-184,has_type,DRUG
LP-184,classified_as,OTHER
LP-184,targets,gbm
LP-184,targets,nsclc
LP-184,targets,ddr gene mutation
LP-184,targets,advanced solid tumor
LP-184,targets,metastatic solid tumor
LP-184,targets,tnbc - triple-negative breast cancer
LP-184,targets,pancreatic adenocarcinoma
LP-184,targets,TNBC
NCT05933265,tests,Spironolactone
Spironolactone,has_type,DRUG
Spironolactone,classified_as,OTHER
Spironolactone,targets,gbm
Spironolactone,targets,nsclc
Spironolactone,targets,ddr gene mutation
Spironolactone,targets,advanced solid tumor
Spironolactone,targets,metastatic solid tumor
Spironolactone,targets,tnbc - triple-negative breast cancer
Spironolactone,targets,pancreatic adenocarcinoma
Spironolactone,targets,TNBC
NCT05933265,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,gbm
Olaparib,targets,nsclc
Olaparib,targets,ddr gene mutation
Olaparib,targets,advanced solid tumor
Olaparib,targets,metastatic solid tumor
Olaparib,targets,tnbc - triple-negative breast cancer
Olaparib,targets,pancreatic adenocarcinoma
Olaparib,targets,TNBC
NCT04595565,sponsored_by,GBG Forschungs GmbH
NCT04595565,has_status,ACTIVE_NOT_RECRUITING
NCT04595565,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,her2-negative breast cancer
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT04595565,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,her2-negative breast cancer
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT04595565,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,her2-negative breast cancer
Cisplatin,targets,triple negative breast cancer
Cisplatin,targets,TNBC
NCT04595565,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
Sacituzumab govitecan,classified_as,BIOLOGIC
Sacituzumab govitecan,targets,her2-negative breast cancer
Sacituzumab govitecan,targets,triple negative breast cancer
Sacituzumab govitecan,targets,TNBC
NCT05255666,sponsored_by,Washington University School of Medicine
NCT05255666,has_status,WITHDRAWN
NCT05255666,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,brain metastases
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT05255666,tests,Liposomal Irinotecan
Liposomal Irinotecan,has_type,DRUG
Liposomal Irinotecan,classified_as,OTHER
Liposomal Irinotecan,targets,brain metastases
Liposomal Irinotecan,targets,triple negative breast cancer
Liposomal Irinotecan,targets,TNBC
NCT02954874,sponsored_by,National Cancer Institute (NCI)
NCT02954874,has_status,ACTIVE_NOT_RECRUITING
NCT02954874,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,stage i breast cancer ajcc v7
Biospecimen Collection,targets,invasive breast carcinoma
Biospecimen Collection,targets,stage iii breast cancer ajcc v7
Biospecimen Collection,targets,stage ii breast cancer ajcc v6 and v7
Biospecimen Collection,targets,triple-negative breast carcinoma
Biospecimen Collection,targets,stage 0 breast cancer ajcc v6 and v7
Biospecimen Collection,targets,TNBC
NCT02954874,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,stage i breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,invasive breast carcinoma
Laboratory Biomarker Analysis,targets,stage iii breast cancer ajcc v7
Laboratory Biomarker Analysis,targets,stage ii breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,stage 0 breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,TNBC
NCT02954874,tests,Patient Observation
Patient Observation,has_type,DRUG
Patient Observation,classified_as,OTHER
Patient Observation,targets,stage i breast cancer ajcc v7
Patient Observation,targets,invasive breast carcinoma
Patient Observation,targets,stage iii breast cancer ajcc v7
Patient Observation,targets,stage ii breast cancer ajcc v6 and v7
Patient Observation,targets,triple-negative breast carcinoma
Patient Observation,targets,stage 0 breast cancer ajcc v6 and v7
Patient Observation,targets,TNBC
NCT02954874,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,stage i breast cancer ajcc v7
Pembrolizumab,targets,invasive breast carcinoma
Pembrolizumab,targets,stage iii breast cancer ajcc v7
Pembrolizumab,targets,stage ii breast cancer ajcc v6 and v7
Pembrolizumab,targets,triple-negative breast carcinoma
Pembrolizumab,targets,stage 0 breast cancer ajcc v6 and v7
Pembrolizumab,targets,TNBC
NCT02954874,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,DRUG
Quality-of-Life Assessment,classified_as,OTHER
Quality-of-Life Assessment,targets,stage i breast cancer ajcc v7
Quality-of-Life Assessment,targets,invasive breast carcinoma
Quality-of-Life Assessment,targets,stage iii breast cancer ajcc v7
Quality-of-Life Assessment,targets,stage ii breast cancer ajcc v6 and v7
Quality-of-Life Assessment,targets,triple-negative breast carcinoma
Quality-of-Life Assessment,targets,stage 0 breast cancer ajcc v6 and v7
Quality-of-Life Assessment,targets,TNBC
NCT02954874,tests,Questionnaire Administration
Questionnaire Administration,has_type,DRUG
Questionnaire Administration,classified_as,OTHER
Questionnaire Administration,targets,stage i breast cancer ajcc v7
Questionnaire Administration,targets,invasive breast carcinoma
Questionnaire Administration,targets,stage iii breast cancer ajcc v7
Questionnaire Administration,targets,stage ii breast cancer ajcc v6 and v7
Questionnaire Administration,targets,triple-negative breast carcinoma
Questionnaire Administration,targets,stage 0 breast cancer ajcc v6 and v7
Questionnaire Administration,targets,TNBC
NCT02954874,tests,Radiation Therapy
Radiation Therapy,has_type,DRUG
Radiation Therapy,classified_as,OTHER
Radiation Therapy,targets,stage i breast cancer ajcc v7
Radiation Therapy,targets,invasive breast carcinoma
Radiation Therapy,targets,stage iii breast cancer ajcc v7
Radiation Therapy,targets,stage ii breast cancer ajcc v6 and v7
Radiation Therapy,targets,triple-negative breast carcinoma
Radiation Therapy,targets,stage 0 breast cancer ajcc v6 and v7
Radiation Therapy,targets,TNBC
NCT05062174,sponsored_by,Indiana University
NCT05062174,has_status,WITHDRAWN
NCT05062174,tests,Mifepristone 200 MG
Mifepristone 200 MG,has_type,DRUG
Mifepristone 200 MG,classified_as,OTHER
Mifepristone 200 MG,targets,high-grade serous ovarian cancer
Mifepristone 200 MG,targets,tnbc - triple-negative breast cancer
Mifepristone 200 MG,targets,brca1 mutation
Mifepristone 200 MG,targets,TNBC
NCT05062174,tests,Prophylactic mastectomy
Prophylactic mastectomy,has_type,DRUG
Prophylactic mastectomy,classified_as,OTHER
Prophylactic mastectomy,targets,high-grade serous ovarian cancer
Prophylactic mastectomy,targets,tnbc - triple-negative breast cancer
Prophylactic mastectomy,targets,brca1 mutation
Prophylactic mastectomy,targets,TNBC
NCT02576665,sponsored_by,Tocagen Inc.
NCT02576665,has_status,TERMINATED
NCT02576665,tests,Toca 511
Toca 511,has_type,DRUG
Toca 511,classified_as,OTHER
Toca 511,targets,head and neck cancer
Toca 511,targets,melanoma
Toca 511,targets,non-small cell lung cancer
Toca 511,targets,pancreatic cancer
Toca 511,targets,idh1 mutated solid tumors
Toca 511,targets,ovarian cancer
Toca 511,targets,sarcoma
Toca 511,targets,triple negative breast cancer
Toca 511,targets,idh1 mutated or mgmt methylated recurrent hgg (not recruiting)
Toca 511,targets,bladder cancer
Toca 511,targets,lymphoma
Toca 511,targets,colorectal cancer
Toca 511,targets,TNBC
NCT02576665,tests,Toca FC
Toca FC,has_type,DRUG
Toca FC,classified_as,OTHER
Toca FC,targets,head and neck cancer
Toca FC,targets,melanoma
Toca FC,targets,non-small cell lung cancer
Toca FC,targets,pancreatic cancer
Toca FC,targets,idh1 mutated solid tumors
Toca FC,targets,ovarian cancer
Toca FC,targets,sarcoma
Toca FC,targets,triple negative breast cancer
Toca FC,targets,idh1 mutated or mgmt methylated recurrent hgg (not recruiting)
Toca FC,targets,bladder cancer
Toca FC,targets,lymphoma
Toca FC,targets,colorectal cancer
Toca FC,targets,TNBC
NCT03487666,sponsored_by,Georgetown University
NCT03487666,has_status,COMPLETED
NCT03487666,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,triple negative breast cancer
Nivolumab,targets,TNBC
NCT03487666,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT02616848,sponsored_by,Istituti Ospitalieri di Cremona
NCT02616848,has_status,UNKNOWN
NCT02616848,tests,Everolimus
Everolimus,has_type,DRUG
Everolimus,classified_as,OTHER
Everolimus,targets,triple negative breast cancer
Everolimus,targets,TNBC
NCT02616848,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,triple negative breast cancer
Eribulin,targets,TNBC
NCT06399757,sponsored_by,Apollo Therapeutics Ltd
NCT06399757,has_status,RECRUITING
NCT06399757,tests,APL-5125
APL-5125,has_type,DRUG
APL-5125,classified_as,OTHER
APL-5125,targets,endometrial adenocarcinoma
APL-5125,targets,prostate cancer
APL-5125,targets,ovarian cancer
APL-5125,targets,triple negative breast cancer
APL-5125,targets,appendiceal adenocarcinoma
APL-5125,targets,cholangiocarcinoma
APL-5125,targets,pancreatic adenocarcinoma
APL-5125,targets,gastric adenocarcinoma
APL-5125,targets,colorectal cancer
APL-5125,targets,TNBC
NCT04176848,sponsored_by,Canadian Cancer Trials Group
NCT04176848,has_status,ACTIVE_NOT_RECRUITING
NCT04176848,tests,CFI-400945
CFI-400945,has_type,DRUG
CFI-400945,classified_as,OTHER
CFI-400945,targets,breast cancer
NCT04176848,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,breast cancer
NCT01986426,sponsored_by,Lytix Biopharma AS
NCT01986426,has_status,COMPLETED
NCT01986426,tests,LTX-315 consecutive lesions
LTX-315 consecutive lesions,has_type,DRUG
LTX-315 consecutive lesions,classified_as,OTHER
LTX-315 consecutive lesions,targets,head and neck cancer
LTX-315 consecutive lesions,targets,melanoma
LTX-315 consecutive lesions,targets,breast cancer
LTX-315 consecutive lesions,targets,cancer
LTX-315 consecutive lesions,targets,lymphoma
LTX-315 consecutive lesions,targets,triple-negative breast cancer
LTX-315 consecutive lesions,targets,TNBC
NCT01986426,tests,LTX-315
LTX-315,has_type,DRUG
LTX-315,classified_as,OTHER
LTX-315,targets,head and neck cancer
LTX-315,targets,melanoma
LTX-315,targets,breast cancer
LTX-315,targets,cancer
LTX-315,targets,lymphoma
LTX-315,targets,triple-negative breast cancer
LTX-315,targets,TNBC
NCT01986426,tests,LTX-315 + ipilimumab
LTX-315 + ipilimumab,has_type,DRUG
LTX-315 + ipilimumab,classified_as,BIOLOGIC
LTX-315 + ipilimumab,targets,head and neck cancer
LTX-315 + ipilimumab,targets,melanoma
LTX-315 + ipilimumab,targets,breast cancer
LTX-315 + ipilimumab,targets,cancer
LTX-315 + ipilimumab,targets,lymphoma
LTX-315 + ipilimumab,targets,triple-negative breast cancer
LTX-315 + ipilimumab,targets,TNBC
NCT01986426,tests,LTX-315 + pembrolizumab
LTX-315 + pembrolizumab,has_type,DRUG
LTX-315 + pembrolizumab,classified_as,BIOLOGIC
LTX-315 + pembrolizumab,targets,head and neck cancer
LTX-315 + pembrolizumab,targets,melanoma
LTX-315 + pembrolizumab,targets,breast cancer
LTX-315 + pembrolizumab,targets,cancer
LTX-315 + pembrolizumab,targets,lymphoma
LTX-315 + pembrolizumab,targets,triple-negative breast cancer
LTX-315 + pembrolizumab,targets,TNBC
NCT01982448,sponsored_by,Dana-Farber Cancer Institute
NCT01982448,has_status,COMPLETED
NCT01982448,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,triple negative breast cancer
Cisplatin,targets,TNBC
NCT01982448,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT02580448,sponsored_by,Innocrin Pharmaceutical
NCT02580448,has_status,COMPLETED
NCT02580448,tests,Seviteronel
Seviteronel,has_type,DRUG
Seviteronel,classified_as,OTHER
Seviteronel,targets,breast cancer
Seviteronel,targets,advanced breast cancer
Seviteronel,targets,male breast cancer
Seviteronel,targets,triple negative breast cancer
Seviteronel,targets,cancer of the breast
Seviteronel,targets,metastatic breast cancer
Seviteronel,targets,er+ breast cancer
Seviteronel,targets,TNBC
NCT04443348,sponsored_by,"Laura M. Spring, MD"
NCT04443348,has_status,RECRUITING
NCT04443348,tests,Radiation Therapy Boost
Radiation Therapy Boost,has_type,DRUG
Radiation Therapy Boost,classified_as,OTHER
Radiation Therapy Boost,targets,"hormone receptor positive (hr+), her2-negative breast cancer"
Radiation Therapy Boost,targets,"biopsy-proven, positive lymph node(s)"
Radiation Therapy Boost,targets,triple negative breast cancer
Radiation Therapy Boost,targets,TNBC
NCT04443348,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,"hormone receptor positive (hr+), her2-negative breast cancer"
Pembrolizumab,targets,"biopsy-proven, positive lymph node(s)"
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT04443348,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,"hormone receptor positive (hr+), her2-negative breast cancer"
Paclitaxel,targets,"biopsy-proven, positive lymph node(s)"
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT04443348,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,"hormone receptor positive (hr+), her2-negative breast cancer"
Carboplatin,targets,"biopsy-proven, positive lymph node(s)"
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT04443348,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,"hormone receptor positive (hr+), her2-negative breast cancer"
Cyclophosphamide,targets,"biopsy-proven, positive lymph node(s)"
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT04443348,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,"hormone receptor positive (hr+), her2-negative breast cancer"
Doxorubicin,targets,"biopsy-proven, positive lymph node(s)"
Doxorubicin,targets,triple negative breast cancer
Doxorubicin,targets,TNBC
NCT04443348,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,"hormone receptor positive (hr+), her2-negative breast cancer"
Capecitabine,targets,"biopsy-proven, positive lymph node(s)"
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT06802757,sponsored_by,Shandong Cancer Hospital and Institute
NCT06802757,has_status,RECRUITING
NCT06802757,tests,Posaconazole
Posaconazole,has_type,DRUG
Posaconazole,classified_as,CHEMICAL
Posaconazole,targets,breast cancer
NCT06802757,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,breast cancer
NCT06802757,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
NCT06802757,tests,Anthracycline
Anthracycline,has_type,DRUG
Anthracycline,classified_as,CHEMICAL
Anthracycline,targets,breast cancer
NCT06802757,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
NCT06802757,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT03639948,sponsored_by,University of Kansas Medical Center
NCT03639948,has_status,ACTIVE_NOT_RECRUITING
NCT03639948,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple-negative breast cancer
Carboplatin,targets,TNBC
NCT03639948,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,triple-negative breast cancer
Docetaxel,targets,TNBC
NCT03639948,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple-negative breast cancer
Pembrolizumab,targets,TNBC
NCT03639948,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
Pegfilgrastim,classified_as,OTHER
Pegfilgrastim,targets,triple-negative breast cancer
Pegfilgrastim,targets,TNBC
NCT05539365,sponsored_by,Roswell Park Cancer Institute
NCT05539365,has_status,WITHDRAWN
NCT05539365,tests,Alpha-type-1 Polarized Dendritic Cells
Alpha-type-1 Polarized Dendritic Cells,has_type,DRUG
Alpha-type-1 Polarized Dendritic Cells,classified_as,OTHER
Alpha-type-1 Polarized Dendritic Cells,targets,metastatic triple-negative breast carcinoma
Alpha-type-1 Polarized Dendritic Cells,targets,unresectable triple-negative breast carcinoma
Alpha-type-1 Polarized Dendritic Cells,targets,anatomic stage iii breast cancer ajcc v8
Alpha-type-1 Polarized Dendritic Cells,targets,anatomic stage iv breast cancer ajcc v8
Alpha-type-1 Polarized Dendritic Cells,targets,TNBC
NCT05539365,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,metastatic triple-negative breast carcinoma
Biopsy,targets,unresectable triple-negative breast carcinoma
Biopsy,targets,anatomic stage iii breast cancer ajcc v8
Biopsy,targets,anatomic stage iv breast cancer ajcc v8
Biopsy,targets,TNBC
NCT05539365,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,unresectable triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iii breast cancer ajcc v8
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,TNBC
NCT05539365,tests,Leukapheresis
Leukapheresis,has_type,DRUG
Leukapheresis,classified_as,OTHER
Leukapheresis,targets,metastatic triple-negative breast carcinoma
Leukapheresis,targets,unresectable triple-negative breast carcinoma
Leukapheresis,targets,anatomic stage iii breast cancer ajcc v8
Leukapheresis,targets,anatomic stage iv breast cancer ajcc v8
Leukapheresis,targets,TNBC
NCT05539365,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,unresectable triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iii breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage iv breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT05539365,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,DRUG
Quality-of-Life Assessment,classified_as,OTHER
Quality-of-Life Assessment,targets,metastatic triple-negative breast carcinoma
Quality-of-Life Assessment,targets,unresectable triple-negative breast carcinoma
Quality-of-Life Assessment,targets,anatomic stage iii breast cancer ajcc v8
Quality-of-Life Assessment,targets,anatomic stage iv breast cancer ajcc v8
Quality-of-Life Assessment,targets,TNBC
NCT05097248,sponsored_by,"Wuhan Union Hospital, China"
NCT05097248,has_status,UNKNOWN
NCT05097248,tests,Camrelizumab
Camrelizumab,has_type,DRUG
Camrelizumab,classified_as,BIOLOGIC
Camrelizumab,targets,breast cancer
NCT05097248,tests,Liposomal Doxorubicin
Liposomal Doxorubicin,has_type,DRUG
Liposomal Doxorubicin,classified_as,CHEMICAL
Liposomal Doxorubicin,targets,breast cancer
NCT05097248,tests,Losartan
Losartan,has_type,DRUG
Losartan,classified_as,OTHER
Losartan,targets,breast cancer
NCT03310957,sponsored_by,Seagen Inc.
NCT03310957,has_status,COMPLETED
NCT03310957,tests,ladiratuzumab vedotin
ladiratuzumab vedotin,has_type,DRUG
ladiratuzumab vedotin,classified_as,BIOLOGIC
ladiratuzumab vedotin,targets,triple negative breast neoplasms
ladiratuzumab vedotin,targets,TNBC
NCT03310957,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,TNBC
NCT06878248,sponsored_by,"Calibr, a division of Scripps Research"
NCT06878248,has_status,RECRUITING
NCT06878248,tests,Two Component Product CLBR001 + ABBV-461
Two Component Product CLBR001 + ABBV-461,has_type,DRUG
Two Component Product CLBR001 + ABBV-461,classified_as,OTHER
Two Component Product CLBR001 + ABBV-461,targets,her2 + breast cancer
Two Component Product CLBR001 + ABBV-461,targets,breast cancer metastatic
Two Component Product CLBR001 + ABBV-461,targets,triple negative breast cancer (tnbc)
Two Component Product CLBR001 + ABBV-461,targets,hormone receptor-positive breast cancer
Two Component Product CLBR001 + ABBV-461,targets,malignant neoplasm of breast
Two Component Product CLBR001 + ABBV-461,targets,locally advanced breast cancer (labc)
Two Component Product CLBR001 + ABBV-461,targets,TNBC
NCT04985357,sponsored_by,Travera Inc
NCT04985357,has_status,WITHDRAWN
NCT06249048,sponsored_by,Strand Therapeutics Inc.
NCT06249048,has_status,RECRUITING
NCT06249048,tests,STX-001
STX-001,has_type,DRUG
STX-001,classified_as,OTHER
STX-001,targets,advanced solid tumor
NCT06249048,tests,Keytruda®
Keytruda®,has_type,DRUG
Keytruda®,classified_as,OTHER
Keytruda®,targets,advanced solid tumor
NCT03941730,sponsored_by,Mayo Clinic
NCT03941730,has_status,ACTIVE_NOT_RECRUITING
NCT03941730,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,recurrent breast carcinoma
Biopsy,targets,anatomic stage iv breast cancer ajcc v8
Biopsy,targets,metastatic triple-negative breast carcinoma
Biopsy,targets,advanced triple-negative breast carcinoma
Biopsy,targets,anatomic stage iii breast cancer ajcc v8
Biopsy,targets,TNBC
NCT03941730,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,recurrent breast carcinoma
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,advanced triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iii breast cancer ajcc v8
Computed Tomography,targets,TNBC
NCT03941730,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,recurrent breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iv breast cancer ajcc v8
Magnetic Resonance Imaging,targets,metastatic triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,advanced triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iii breast cancer ajcc v8
Magnetic Resonance Imaging,targets,TNBC
NCT03941730,tests,Positron Emission Tomography
Positron Emission Tomography,has_type,DRUG
Positron Emission Tomography,classified_as,OTHER
Positron Emission Tomography,targets,recurrent breast carcinoma
Positron Emission Tomography,targets,anatomic stage iv breast cancer ajcc v8
Positron Emission Tomography,targets,metastatic triple-negative breast carcinoma
Positron Emission Tomography,targets,advanced triple-negative breast carcinoma
Positron Emission Tomography,targets,anatomic stage iii breast cancer ajcc v8
Positron Emission Tomography,targets,TNBC
NCT03941730,tests,Therapeutic Estradiol
Therapeutic Estradiol,has_type,DRUG
Therapeutic Estradiol,classified_as,OTHER
Therapeutic Estradiol,targets,recurrent breast carcinoma
Therapeutic Estradiol,targets,anatomic stage iv breast cancer ajcc v8
Therapeutic Estradiol,targets,metastatic triple-negative breast carcinoma
Therapeutic Estradiol,targets,advanced triple-negative breast carcinoma
Therapeutic Estradiol,targets,anatomic stage iii breast cancer ajcc v8
Therapeutic Estradiol,targets,TNBC
NCT02632448,sponsored_by,Esperas Pharma Inc.
NCT02632448,has_status,COMPLETED
NCT02632448,tests,LY2880070
LY2880070,has_type,DRUG
LY2880070,classified_as,OTHER
LY2880070,targets,rectal cancer
LY2880070,targets,pancreatic cancer
LY2880070,targets,breast cancer
LY2880070,targets,ovarian cancer
LY2880070,targets,soft tissue sarcoma
LY2880070,targets,triple negative breast cancer
LY2880070,targets,pancreas cancer
LY2880070,targets,solid tumors
LY2880070,targets,neoplasms
LY2880070,targets,endometrial cancer
LY2880070,targets,colon cancer
LY2880070,targets,colorectal cancer
LY2880070,targets,TNBC
NCT02632448,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,rectal cancer
Gemcitabine,targets,pancreatic cancer
Gemcitabine,targets,breast cancer
Gemcitabine,targets,ovarian cancer
Gemcitabine,targets,soft tissue sarcoma
Gemcitabine,targets,triple negative breast cancer
Gemcitabine,targets,pancreas cancer
Gemcitabine,targets,solid tumors
Gemcitabine,targets,neoplasms
Gemcitabine,targets,endometrial cancer
Gemcitabine,targets,colon cancer
Gemcitabine,targets,colorectal cancer
Gemcitabine,targets,TNBC
NCT02627430,sponsored_by,National Cancer Institute (NCI)
NCT02627430,has_status,WITHDRAWN
NCT02627430,tests,Hsp90 Inhibitor AT13387
Hsp90 Inhibitor AT13387,has_type,DRUG
Hsp90 Inhibitor AT13387,classified_as,CHEMICAL
Hsp90 Inhibitor AT13387,targets,ovarian serous adenocarcinoma
Hsp90 Inhibitor AT13387,targets,fallopian tube serous neoplasm
Hsp90 Inhibitor AT13387,targets,adult solid neoplasm
Hsp90 Inhibitor AT13387,targets,primary peritoneal serous adenocarcinoma
Hsp90 Inhibitor AT13387,targets,recurrent breast carcinoma
Hsp90 Inhibitor AT13387,targets,triple-negative breast carcinoma
Hsp90 Inhibitor AT13387,targets,recurrent ovarian carcinoma
Hsp90 Inhibitor AT13387,targets,recurrent primary peritoneal carcinoma
Hsp90 Inhibitor AT13387,targets,estrogen receptor negative
Hsp90 Inhibitor AT13387,targets,progesterone receptor negative
Hsp90 Inhibitor AT13387,targets,her2/neu negative
Hsp90 Inhibitor AT13387,targets,ovarian serous tumor
Hsp90 Inhibitor AT13387,targets,recurrent fallopian tube carcinoma
Hsp90 Inhibitor AT13387,targets,TNBC
NCT02627430,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,ovarian serous adenocarcinoma
Laboratory Biomarker Analysis,targets,fallopian tube serous neoplasm
Laboratory Biomarker Analysis,targets,adult solid neoplasm
Laboratory Biomarker Analysis,targets,primary peritoneal serous adenocarcinoma
Laboratory Biomarker Analysis,targets,recurrent breast carcinoma
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,recurrent ovarian carcinoma
Laboratory Biomarker Analysis,targets,recurrent primary peritoneal carcinoma
Laboratory Biomarker Analysis,targets,estrogen receptor negative
Laboratory Biomarker Analysis,targets,progesterone receptor negative
Laboratory Biomarker Analysis,targets,her2/neu negative
Laboratory Biomarker Analysis,targets,ovarian serous tumor
Laboratory Biomarker Analysis,targets,recurrent fallopian tube carcinoma
Laboratory Biomarker Analysis,targets,TNBC
NCT02627430,tests,Pharmacological Study
Pharmacological Study,has_type,DRUG
Pharmacological Study,classified_as,OTHER
Pharmacological Study,targets,ovarian serous adenocarcinoma
Pharmacological Study,targets,fallopian tube serous neoplasm
Pharmacological Study,targets,adult solid neoplasm
Pharmacological Study,targets,primary peritoneal serous adenocarcinoma
Pharmacological Study,targets,recurrent breast carcinoma
Pharmacological Study,targets,triple-negative breast carcinoma
Pharmacological Study,targets,recurrent ovarian carcinoma
Pharmacological Study,targets,recurrent primary peritoneal carcinoma
Pharmacological Study,targets,estrogen receptor negative
Pharmacological Study,targets,progesterone receptor negative
Pharmacological Study,targets,her2/neu negative
Pharmacological Study,targets,ovarian serous tumor
Pharmacological Study,targets,recurrent fallopian tube carcinoma
Pharmacological Study,targets,TNBC
NCT02627430,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,ovarian serous adenocarcinoma
Talazoparib,targets,fallopian tube serous neoplasm
Talazoparib,targets,adult solid neoplasm
Talazoparib,targets,primary peritoneal serous adenocarcinoma
Talazoparib,targets,recurrent breast carcinoma
Talazoparib,targets,triple-negative breast carcinoma
Talazoparib,targets,recurrent ovarian carcinoma
Talazoparib,targets,recurrent primary peritoneal carcinoma
Talazoparib,targets,estrogen receptor negative
Talazoparib,targets,progesterone receptor negative
Talazoparib,targets,her2/neu negative
Talazoparib,targets,ovarian serous tumor
Talazoparib,targets,recurrent fallopian tube carcinoma
Talazoparib,targets,TNBC
NCT01639248,sponsored_by,"CASI Pharmaceuticals, Inc."
NCT01639248,has_status,COMPLETED
NCT01639248,tests,ENMD-2076
ENMD-2076,has_type,DRUG
ENMD-2076,classified_as,OTHER
ENMD-2076,targets,triple negative breast cancer
ENMD-2076,targets,TNBC
NCT03044730,sponsored_by,Northwestern University
NCT03044730,has_status,UNKNOWN
NCT03044730,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,stage iiic breast cancer
Capecitabine,targets,recurrent breast carcinoma
Capecitabine,targets,stage iiib breast cancer
Capecitabine,targets,stage iii breast cancer
Capecitabine,targets,stage iiia breast cancer
Capecitabine,targets,stage iv breast cancer
Capecitabine,targets,estrogen receptor negative
Capecitabine,targets,progesterone receptor negative
Capecitabine,targets,her2/neu negative
Capecitabine,targets,triple-negative breast carcinoma
Capecitabine,targets,TNBC
NCT03044730,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,stage iiic breast cancer
Laboratory Biomarker Analysis,targets,recurrent breast carcinoma
Laboratory Biomarker Analysis,targets,stage iiib breast cancer
Laboratory Biomarker Analysis,targets,stage iii breast cancer
Laboratory Biomarker Analysis,targets,stage iiia breast cancer
Laboratory Biomarker Analysis,targets,stage iv breast cancer
Laboratory Biomarker Analysis,targets,estrogen receptor negative
Laboratory Biomarker Analysis,targets,progesterone receptor negative
Laboratory Biomarker Analysis,targets,her2/neu negative
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,TNBC
NCT03044730,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,stage iiic breast cancer
Pembrolizumab,targets,recurrent breast carcinoma
Pembrolizumab,targets,stage iiib breast cancer
Pembrolizumab,targets,stage iii breast cancer
Pembrolizumab,targets,stage iiia breast cancer
Pembrolizumab,targets,stage iv breast cancer
Pembrolizumab,targets,estrogen receptor negative
Pembrolizumab,targets,progesterone receptor negative
Pembrolizumab,targets,her2/neu negative
Pembrolizumab,targets,triple-negative breast carcinoma
Pembrolizumab,targets,TNBC
NCT05076682,sponsored_by,Fudan University
NCT05076682,has_status,UNKNOWN
NCT05076682,tests,Choline
Choline,has_type,DRUG
Choline,classified_as,OTHER
Choline,targets,triple-negative breast cancer
Choline,targets,TNBC
NCT05076682,tests,anti-PD-1 antibody and chemotherapy
anti-PD-1 antibody and chemotherapy,has_type,DRUG
anti-PD-1 antibody and chemotherapy,classified_as,BIOLOGIC
anti-PD-1 antibody and chemotherapy,targets,triple-negative breast cancer
anti-PD-1 antibody and chemotherapy,targets,TNBC
NCT05076682,tests,Sodium Cromoglicate
Sodium Cromoglicate,has_type,DRUG
Sodium Cromoglicate,classified_as,OTHER
Sodium Cromoglicate,targets,triple-negative breast cancer
Sodium Cromoglicate,targets,TNBC
NCT05076682,tests,Efavirenz
Efavirenz,has_type,DRUG
Efavirenz,classified_as,OTHER
Efavirenz,targets,triple-negative breast cancer
Efavirenz,targets,TNBC
NCT05834582,sponsored_by,The First Affiliated Hospital with Nanjing Medical University
NCT05834582,has_status,RECRUITING
NCT05834582,tests,Fluzoparib+Paclitaxel
Fluzoparib+Paclitaxel,has_type,DRUG
Fluzoparib+Paclitaxel,classified_as,CHEMICAL
Fluzoparib+Paclitaxel,targets,tnbc - triple-negative breast cancer
Fluzoparib+Paclitaxel,targets,TNBC
NCT05834582,tests,Epirubicin+Cyclophosphamide
Epirubicin+Cyclophosphamide,has_type,DRUG
Epirubicin+Cyclophosphamide,classified_as,CHEMICAL
Epirubicin+Cyclophosphamide,targets,tnbc - triple-negative breast cancer
Epirubicin+Cyclophosphamide,targets,TNBC
NCT03175666,sponsored_by,"ImmunityBio, Inc."
NCT03175666,has_status,WITHDRAWN
NCT03175666,tests,avelumab
avelumab,has_type,DRUG
avelumab,classified_as,BIOLOGIC
avelumab,targets,triple negative breast cancer
avelumab,targets,TNBC
NCT03175666,tests,bevacizumab
bevacizumab,has_type,DRUG
bevacizumab,classified_as,BIOLOGIC
bevacizumab,targets,triple negative breast cancer
bevacizumab,targets,TNBC
NCT03175666,tests,capecitabine
capecitabine,has_type,DRUG
capecitabine,classified_as,CHEMICAL
capecitabine,targets,triple negative breast cancer
capecitabine,targets,TNBC
NCT03175666,tests,cisplatin
cisplatin,has_type,DRUG
cisplatin,classified_as,CHEMICAL
cisplatin,targets,triple negative breast cancer
cisplatin,targets,TNBC
NCT03175666,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
cyclophosphamide,classified_as,CHEMICAL
cyclophosphamide,targets,triple negative breast cancer
cyclophosphamide,targets,TNBC
NCT03175666,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
5-Fluorouracil,classified_as,CHEMICAL
5-Fluorouracil,targets,triple negative breast cancer
5-Fluorouracil,targets,TNBC
NCT03175666,tests,Leucovorin
Leucovorin,has_type,DRUG
Leucovorin,classified_as,OTHER
Leucovorin,targets,triple negative breast cancer
Leucovorin,targets,TNBC
NCT03175666,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
nab-paclitaxel,classified_as,CHEMICAL
nab-paclitaxel,targets,triple negative breast cancer
nab-paclitaxel,targets,TNBC
NCT03175666,tests,Lovaza
Lovaza,has_type,DRUG
Lovaza,classified_as,OTHER
Lovaza,targets,triple negative breast cancer
Lovaza,targets,TNBC
NCT03175666,tests,Stereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapy,has_type,DRUG
Stereotactic Body Radiation Therapy,classified_as,OTHER
Stereotactic Body Radiation Therapy,targets,triple negative breast cancer
Stereotactic Body Radiation Therapy,targets,TNBC
NCT03175666,tests,ALT-803
ALT-803,has_type,DRUG
ALT-803,classified_as,OTHER
ALT-803,targets,triple negative breast cancer
ALT-803,targets,TNBC
NCT03175666,tests,ETBX-011
ETBX-011,has_type,DRUG
ETBX-011,classified_as,OTHER
ETBX-011,targets,triple negative breast cancer
ETBX-011,targets,TNBC
NCT03175666,tests,ETBX-051
ETBX-051,has_type,DRUG
ETBX-051,classified_as,OTHER
ETBX-051,targets,triple negative breast cancer
ETBX-051,targets,TNBC
NCT03175666,tests,ETBX-061
ETBX-061,has_type,DRUG
ETBX-061,classified_as,OTHER
ETBX-061,targets,triple negative breast cancer
ETBX-061,targets,TNBC
NCT03175666,tests,GI-4000
GI-4000,has_type,DRUG
GI-4000,classified_as,OTHER
GI-4000,targets,triple negative breast cancer
GI-4000,targets,TNBC
NCT03175666,tests,GI-6207
GI-6207,has_type,DRUG
GI-6207,classified_as,OTHER
GI-6207,targets,triple negative breast cancer
GI-6207,targets,TNBC
NCT03175666,tests,GI-6301
GI-6301,has_type,DRUG
GI-6301,classified_as,OTHER
GI-6301,targets,triple negative breast cancer
GI-6301,targets,TNBC
NCT03175666,tests,haNK
haNK,has_type,DRUG
haNK,classified_as,OTHER
haNK,targets,triple negative breast cancer
haNK,targets,TNBC
NCT03719326,sponsored_by,"Arcus Biosciences, Inc."
NCT03719326,has_status,COMPLETED
NCT03719326,tests,Etrumadenant
Etrumadenant,has_type,DRUG
Etrumadenant,classified_as,OTHER
Etrumadenant,targets,tnbc - triple-negative breast cancer
Etrumadenant,targets,ovarian cancer
Etrumadenant,targets,TNBC
NCT03719326,tests,IPI-549
IPI-549,has_type,DRUG
IPI-549,classified_as,OTHER
IPI-549,targets,tnbc - triple-negative breast cancer
IPI-549,targets,ovarian cancer
IPI-549,targets,TNBC
NCT03719326,tests,Pegylated liposomal doxorubicin (PLD)
Pegylated liposomal doxorubicin (PLD),has_type,DRUG
Pegylated liposomal doxorubicin (PLD),classified_as,CHEMICAL
Pegylated liposomal doxorubicin (PLD),targets,tnbc - triple-negative breast cancer
Pegylated liposomal doxorubicin (PLD),targets,ovarian cancer
Pegylated liposomal doxorubicin (PLD),targets,TNBC
NCT03719326,tests,nanoparticle albumin-bound paclitaxel (NP)
nanoparticle albumin-bound paclitaxel (NP),has_type,DRUG
nanoparticle albumin-bound paclitaxel (NP),classified_as,CHEMICAL
nanoparticle albumin-bound paclitaxel (NP),targets,tnbc - triple-negative breast cancer
nanoparticle albumin-bound paclitaxel (NP),targets,ovarian cancer
nanoparticle albumin-bound paclitaxel (NP),targets,TNBC
NCT05756166,sponsored_by,Roswell Park Cancer Institute
NCT05756166,has_status,TERMINATED
NCT05756166,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,metastatic triple-negative breast carcinoma
Biopsy,targets,unresectable triple-negative breast carcinoma
Biopsy,targets,anatomic stage iv breast cancer ajcc v8
Biopsy,targets,TNBC
NCT05756166,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,unresectable triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iv breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT05756166,tests,Celecoxib
Celecoxib,has_type,DRUG
Celecoxib,classified_as,CHEMICAL
Celecoxib,targets,metastatic triple-negative breast carcinoma
Celecoxib,targets,unresectable triple-negative breast carcinoma
Celecoxib,targets,anatomic stage iv breast cancer ajcc v8
Celecoxib,targets,TNBC
NCT05756166,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,unresectable triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,TNBC
NCT05756166,tests,Interferon Alpha-2
Interferon Alpha-2,has_type,DRUG
Interferon Alpha-2,classified_as,OTHER
Interferon Alpha-2,targets,metastatic triple-negative breast carcinoma
Interferon Alpha-2,targets,unresectable triple-negative breast carcinoma
Interferon Alpha-2,targets,anatomic stage iv breast cancer ajcc v8
Interferon Alpha-2,targets,TNBC
NCT05756166,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,metastatic triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,unresectable triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iv breast cancer ajcc v8
Magnetic Resonance Imaging,targets,TNBC
NCT05756166,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,unresectable triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iv breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT05756166,tests,Rintatolimod
Rintatolimod,has_type,DRUG
Rintatolimod,classified_as,OTHER
Rintatolimod,targets,metastatic triple-negative breast carcinoma
Rintatolimod,targets,unresectable triple-negative breast carcinoma
Rintatolimod,targets,anatomic stage iv breast cancer ajcc v8
Rintatolimod,targets,TNBC
NCT05485766,sponsored_by,Okayama University
NCT05485766,has_status,RECRUITING
NCT05485766,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,brca mutation
Pembrolizumab,targets,breast neoplasms
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,brca-associated breast carcinoma
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,brca1 mutation
Pembrolizumab,targets,brca2 mutation
Pembrolizumab,targets,TNBC
NCT05485766,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,brca mutation
Paclitaxel,targets,breast neoplasms
Paclitaxel,targets,breast cancer
Paclitaxel,targets,brca-associated breast carcinoma
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,triple negative breast neoplasms
Paclitaxel,targets,brca1 mutation
Paclitaxel,targets,brca2 mutation
Paclitaxel,targets,TNBC
NCT05485766,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,brca mutation
Carboplatin,targets,breast neoplasms
Carboplatin,targets,breast cancer
Carboplatin,targets,brca-associated breast carcinoma
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,triple negative breast neoplasms
Carboplatin,targets,brca1 mutation
Carboplatin,targets,brca2 mutation
Carboplatin,targets,TNBC
NCT05485766,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,brca mutation
Olaparib,targets,breast neoplasms
Olaparib,targets,breast cancer
Olaparib,targets,brca-associated breast carcinoma
Olaparib,targets,triple negative breast cancer
Olaparib,targets,triple negative breast neoplasms
Olaparib,targets,brca1 mutation
Olaparib,targets,brca2 mutation
Olaparib,targets,TNBC
NCT05485766,tests,Definitive Surgery
Definitive Surgery,has_type,DRUG
Definitive Surgery,classified_as,OTHER
Definitive Surgery,targets,brca mutation
Definitive Surgery,targets,breast neoplasms
Definitive Surgery,targets,breast cancer
Definitive Surgery,targets,brca-associated breast carcinoma
Definitive Surgery,targets,triple negative breast cancer
Definitive Surgery,targets,triple negative breast neoplasms
Definitive Surgery,targets,brca1 mutation
Definitive Surgery,targets,brca2 mutation
Definitive Surgery,targets,TNBC
NCT04140526,sponsored_by,"OncoC4, Inc."
NCT04140526,has_status,ACTIVE_NOT_RECRUITING
NCT04140526,tests,ONC-392
ONC-392,has_type,DRUG
ONC-392,classified_as,OTHER
ONC-392,targets,salivary gland cancer
ONC-392,targets,urothelial carcinoma
ONC-392,targets,sarcomas
ONC-392,targets,cervical cancer
ONC-392,targets,adenoid cystic carcinoma
ONC-392,targets,metastatic renal cell carcinoma
ONC-392,targets,metastatic melanoma
ONC-392,targets,gastric cancer
ONC-392,targets,advanced solid tumor
ONC-392,targets,ovarian cancer
ONC-392,targets,metastatic head and neck carcinoma
ONC-392,targets,small cell lung cancer
ONC-392,targets,metastatic breast cancer
ONC-392,targets,metastatic prostate cancer
ONC-392,targets,metastatic colorectal cancer
ONC-392,targets,esophageal cancer
ONC-392,targets,pancreas cancer
ONC-392,targets,gastroesophageal junction adenocarcinoma
ONC-392,targets,non small cell lung cancer
NCT04140526,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,salivary gland cancer
Pembrolizumab,targets,urothelial carcinoma
Pembrolizumab,targets,sarcomas
Pembrolizumab,targets,cervical cancer
Pembrolizumab,targets,adenoid cystic carcinoma
Pembrolizumab,targets,metastatic renal cell carcinoma
Pembrolizumab,targets,metastatic melanoma
Pembrolizumab,targets,gastric cancer
Pembrolizumab,targets,advanced solid tumor
Pembrolizumab,targets,ovarian cancer
Pembrolizumab,targets,metastatic head and neck carcinoma
Pembrolizumab,targets,small cell lung cancer
Pembrolizumab,targets,metastatic breast cancer
Pembrolizumab,targets,metastatic prostate cancer
Pembrolizumab,targets,metastatic colorectal cancer
Pembrolizumab,targets,esophageal cancer
Pembrolizumab,targets,pancreas cancer
Pembrolizumab,targets,gastroesophageal junction adenocarcinoma
Pembrolizumab,targets,non small cell lung cancer
NCT04140526,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,salivary gland cancer
Docetaxel,targets,urothelial carcinoma
Docetaxel,targets,sarcomas
Docetaxel,targets,cervical cancer
Docetaxel,targets,adenoid cystic carcinoma
Docetaxel,targets,metastatic renal cell carcinoma
Docetaxel,targets,metastatic melanoma
Docetaxel,targets,gastric cancer
Docetaxel,targets,advanced solid tumor
Docetaxel,targets,ovarian cancer
Docetaxel,targets,metastatic head and neck carcinoma
Docetaxel,targets,small cell lung cancer
Docetaxel,targets,metastatic breast cancer
Docetaxel,targets,metastatic prostate cancer
Docetaxel,targets,metastatic colorectal cancer
Docetaxel,targets,esophageal cancer
Docetaxel,targets,pancreas cancer
Docetaxel,targets,gastroesophageal junction adenocarcinoma
Docetaxel,targets,non small cell lung cancer
NCT05113966,sponsored_by,"G1 Therapeutics, Inc."
NCT05113966,has_status,TERMINATED
NCT05113966,tests,Trilaciclib
Trilaciclib,has_type,DRUG
Trilaciclib,classified_as,CHEMICAL
Trilaciclib,targets,triple negative breast cancer
Trilaciclib,targets,TNBC
NCT05113966,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
Sacituzumab Govitecan-hziy,classified_as,BIOLOGIC
Sacituzumab Govitecan-hziy,targets,triple negative breast cancer
Sacituzumab Govitecan-hziy,targets,TNBC
NCT05464082,sponsored_by,University of Utah
NCT05464082,has_status,RECRUITING
NCT05464082,tests,Functional Precision Oncology
Functional Precision Oncology,has_type,DRUG
Functional Precision Oncology,classified_as,OTHER
Functional Precision Oncology,targets,breast cancer recurrent
NCT04455620,sponsored_by,BioNTech SE
NCT04455620,has_status,TERMINATED
NCT04455620,tests,BNT151
BNT151,has_type,DRUG
BNT151,classified_as,OTHER
BNT151,targets,solid tumor
NCT04105582,sponsored_by,Universidad Nacional de Colombia
NCT04105582,has_status,COMPLETED
NCT04105582,tests,Neo-antigen pulsed Dendritic cell
Neo-antigen pulsed Dendritic cell,has_type,DRUG
Neo-antigen pulsed Dendritic cell,classified_as,OTHER
Neo-antigen pulsed Dendritic cell,targets,breast cancer
Neo-antigen pulsed Dendritic cell,targets,triple negative breast cancer
Neo-antigen pulsed Dendritic cell,targets,TNBC
NCT02227082,sponsored_by,The Netherlands Cancer Institute
NCT02227082,has_status,COMPLETED
NCT02227082,tests,radiotherapy
radiotherapy,has_type,DRUG
radiotherapy,classified_as,OTHER
radiotherapy,targets,triple-negative invasive breast carcinoma
radiotherapy,targets,inflammatory breast carcinoma
radiotherapy,targets,locally advanced malignant neoplasm
radiotherapy,targets,TNBC
NCT02227082,tests,olaparib
olaparib,has_type,DRUG
olaparib,classified_as,BIOLOGIC
olaparib,targets,triple-negative invasive breast carcinoma
olaparib,targets,inflammatory breast carcinoma
olaparib,targets,locally advanced malignant neoplasm
olaparib,targets,TNBC
NCT03567720,sponsored_by,OncoSec Medical Incorporated
NCT03567720,has_status,UNKNOWN
NCT03567720,tests,tavokinogene telseplasmid
tavokinogene telseplasmid,has_type,DRUG
tavokinogene telseplasmid,classified_as,BIOLOGIC
tavokinogene telseplasmid,targets,triple negative breast cancer
tavokinogene telseplasmid,targets,TNBC
NCT03567720,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT03567720,tests,Immunopulse
Immunopulse,has_type,DRUG
Immunopulse,classified_as,OTHER
Immunopulse,targets,triple negative breast cancer
Immunopulse,targets,TNBC
NCT03567720,tests,nab paclitaxel
nab paclitaxel,has_type,DRUG
nab paclitaxel,classified_as,CHEMICAL
nab paclitaxel,targets,triple negative breast cancer
nab paclitaxel,targets,TNBC
NCT03567720,tests,gemcitabine plus carboplatin
gemcitabine plus carboplatin,has_type,DRUG
gemcitabine plus carboplatin,classified_as,CHEMICAL
gemcitabine plus carboplatin,targets,triple negative breast cancer
gemcitabine plus carboplatin,targets,TNBC
NCT03621982,sponsored_by,ADC Therapeutics S.A.
NCT03621982,has_status,TERMINATED
NCT03621982,tests,ADCT-301
ADCT-301,has_type,DRUG
ADCT-301,classified_as,OTHER
ADCT-301,targets,gastric cancer
ADCT-301,targets,non-small cell lung cancer
ADCT-301,targets,renal cell carcinoma
ADCT-301,targets,melanoma
ADCT-301,targets,colo-rectal cancer
ADCT-301,targets,head and neck cancer squamous cell carcinoma
ADCT-301,targets,ovarian cancer
ADCT-301,targets,bladder cancer
ADCT-301,targets,esophageal cancer
ADCT-301,targets,pancreas cancer
ADCT-301,targets,fallopian tube cancer
ADCT-301,targets,triple-negative breast cancer
ADCT-301,targets,TNBC
NCT03621982,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,gastric cancer
Pembrolizumab,targets,non-small cell lung cancer
Pembrolizumab,targets,renal cell carcinoma
Pembrolizumab,targets,melanoma
Pembrolizumab,targets,colo-rectal cancer
Pembrolizumab,targets,head and neck cancer squamous cell carcinoma
Pembrolizumab,targets,ovarian cancer
Pembrolizumab,targets,bladder cancer
Pembrolizumab,targets,esophageal cancer
Pembrolizumab,targets,pancreas cancer
Pembrolizumab,targets,fallopian tube cancer
Pembrolizumab,targets,triple-negative breast cancer
Pembrolizumab,targets,TNBC
NCT06926920,sponsored_by,Gilead Sciences
NCT06926920,has_status,RECRUITING
NCT06926920,tests,Sacituzumab Govitecan-hziy (SG)
Sacituzumab Govitecan-hziy (SG),has_type,DRUG
Sacituzumab Govitecan-hziy (SG),classified_as,BIOLOGIC
Sacituzumab Govitecan-hziy (SG),targets,triple negative breast cancer
Sacituzumab Govitecan-hziy (SG),targets,TNBC
NCT04725331,sponsored_by,Transgene
NCT04725331,has_status,RECRUITING
NCT04725331,tests,BT-001
BT-001,has_type,DRUG
BT-001,classified_as,OTHER
BT-001,targets,melanoma
BT-001,targets,merkel cell carcinoma
BT-001,targets,metastatic cancer
BT-001,targets,triple negative breast cancer
BT-001,targets,soft tissue sarcoma
BT-001,targets,non small cell lung cancer
BT-001,targets,TNBC
NCT04725331,tests,Pembrolizumab [KEYTRUDA®]
Pembrolizumab [KEYTRUDA®],has_type,DRUG
Pembrolizumab [KEYTRUDA®],classified_as,BIOLOGIC
Pembrolizumab [KEYTRUDA®],targets,melanoma
Pembrolizumab [KEYTRUDA®],targets,merkel cell carcinoma
Pembrolizumab [KEYTRUDA®],targets,metastatic cancer
Pembrolizumab [KEYTRUDA®],targets,triple negative breast cancer
Pembrolizumab [KEYTRUDA®],targets,soft tissue sarcoma
Pembrolizumab [KEYTRUDA®],targets,non small cell lung cancer
Pembrolizumab [KEYTRUDA®],targets,TNBC
NCT02685657,sponsored_by,Russian Academy of Medical Sciences
NCT02685657,has_status,UNKNOWN
NCT02685657,tests,Drug: Selumetinib
Drug: Selumetinib,has_type,DRUG
Drug: Selumetinib,classified_as,CHEMICAL
Drug: Selumetinib,targets,triple negative breast cancer
Drug: Selumetinib,targets,TNBC
NCT02685657,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,triple negative breast cancer
Doxorubicin,targets,TNBC
NCT02685657,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02685657,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,triple negative breast cancer
Docetaxel,targets,TNBC
NCT05978648,sponsored_by,wang shusen
NCT05978648,has_status,RECRUITING
NCT05978648,tests,Trilaciclib
Trilaciclib,has_type,DRUG
Trilaciclib,classified_as,CHEMICAL
Trilaciclib,targets,breast neoplasms
NCT05978648,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,breast neoplasms
NCT05978648,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast neoplasms
NCT05978648,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast neoplasms
NCT05978648,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,breast neoplasms
NCT05978648,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast neoplasms
NCT05978648,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,breast neoplasms
NCT05978648,tests,Pertuzumab
Pertuzumab,has_type,DRUG
Pertuzumab,classified_as,BIOLOGIC
Pertuzumab,targets,breast neoplasms
NCT03000257,sponsored_by,AbbVie
NCT03000257,has_status,COMPLETED
NCT03000257,tests,Venetoclax
Venetoclax,has_type,DRUG
Venetoclax,classified_as,OTHER
Venetoclax,targets,advanced solid tumors
NCT03000257,tests,Rovalpituzumab Tesirine
Rovalpituzumab Tesirine,has_type,DRUG
Rovalpituzumab Tesirine,classified_as,BIOLOGIC
Rovalpituzumab Tesirine,targets,advanced solid tumors
NCT03000257,tests,ABBV-181
ABBV-181,has_type,DRUG
ABBV-181,classified_as,OTHER
ABBV-181,targets,advanced solid tumors
NCT04152057,sponsored_by,West China Hospital
NCT04152057,has_status,UNKNOWN
NCT04152057,tests,Pyrotinib Maleate Tablets
Pyrotinib Maleate Tablets,has_type,DRUG
Pyrotinib Maleate Tablets,classified_as,CHEMICAL
Pyrotinib Maleate Tablets,targets,breast cancer
Pyrotinib Maleate Tablets,targets,her2 positive
Pyrotinib Maleate Tablets,targets,combination chemotherapy
NCT04152057,tests,Albumin Paclitaxel
Albumin Paclitaxel,has_type,DRUG
Albumin Paclitaxel,classified_as,CHEMICAL
Albumin Paclitaxel,targets,breast cancer
Albumin Paclitaxel,targets,her2 positive
Albumin Paclitaxel,targets,combination chemotherapy
NCT04152057,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,breast cancer
Trastuzumab,targets,her2 positive
Trastuzumab,targets,combination chemotherapy
NCT02316457,sponsored_by,BioNTech SE
NCT02316457,has_status,COMPLETED
NCT02316457,tests,IVAC_W_bre1_uID
IVAC_W_bre1_uID,has_type,DRUG
IVAC_W_bre1_uID,classified_as,OTHER
IVAC_W_bre1_uID,targets,breast cancer (triple negative breast cancer (tnbc))
IVAC_W_bre1_uID,targets,TNBC
NCT02316457,tests,IVAC_W_bre1_uID/IVAC_M_uID
IVAC_W_bre1_uID/IVAC_M_uID,has_type,DRUG
IVAC_W_bre1_uID/IVAC_M_uID,classified_as,OTHER
IVAC_W_bre1_uID/IVAC_M_uID,targets,breast cancer (triple negative breast cancer (tnbc))
IVAC_W_bre1_uID/IVAC_M_uID,targets,TNBC
NCT06586957,sponsored_by,"NiKang Therapeutics, Inc."
NCT06586957,has_status,RECRUITING
NCT06586957,tests,NKT3964
NKT3964,has_type,DRUG
NKT3964,classified_as,OTHER
NKT3964,targets,platinum-resistant ovarian cancer
NKT3964,targets,ovarian carcinoma
NKT3964,targets,endometrial neoplasms
NKT3964,targets,small cell lung carcinoma
NKT3964,targets,ovarian neoplasms
NKT3964,targets,"solid tumor, adult"
NKT3964,targets,progesterone-receptor-positive breast cancer
NKT3964,targets,endometrial diseases
NKT3964,targets,triple negative breast cancer
NKT3964,targets,advanced gastric carcinoma
NKT3964,targets,advanced ovarian carcinoma
NKT3964,targets,metastatic tumor
NKT3964,targets,gastric cancer
NKT3964,targets,solid tumor
NKT3964,targets,metastatic ovarian carcinoma
NKT3964,targets,advanced solid tumor
NKT3964,targets,platinum-refractory ovarian carcinoma
NKT3964,targets,ovarian cancer
NKT3964,targets,ccne1 amplification
NKT3964,targets,hormone receptor negative breast carcinoma
NKT3964,targets,triple negative breast neoplasms
NKT3964,targets,small cell lung cancer
NKT3964,targets,advanced endometrial carcinoma
NKT3964,targets,metastatic gastric cancer
NKT3964,targets,metastatic endometrial carcinoma
NKT3964,targets,metastatic gastric carcinoma
NKT3964,targets,human epidermal growth factor 2 negative carcinoma of breast
NKT3964,targets,metastatic endometrial cancer
NKT3964,targets,TNBC
NCT05579366,sponsored_by,Genmab
NCT05579366,has_status,RECRUITING
NCT05579366,tests,Rina-S
Rina-S,has_type,DRUG
Rina-S,classified_as,OTHER
Rina-S,targets,non-small cell lung cancer
Rina-S,targets,uterine cancer
Rina-S,targets,platinum sensitive ovarian cancer (psoc)
Rina-S,targets,primary peritoneal carcinoma
Rina-S,targets,fallopian tube cancer
Rina-S,targets,mesothelioma
Rina-S,targets,primary refractory ovarian cancer
Rina-S,targets,triple negative breast cancer
Rina-S,targets,epidermal growth factor receptor (egfr)-mutated non-small cell lung cancer (nsclc)
Rina-S,targets,high grade epithelial ovarian cancer
Rina-S,targets,hormone receptor-positive/her2 negative breast cancer
Rina-S,targets,breast adenocarcinoma
Rina-S,targets,high grade serous ovarian cancer
Rina-S,targets,endometrial cancer
Rina-S,targets,platinum-resistant ovarian cancer (proc)
Rina-S,targets,TNBC
NCT05579366,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,non-small cell lung cancer
Carboplatin,targets,uterine cancer
Carboplatin,targets,platinum sensitive ovarian cancer (psoc)
Carboplatin,targets,primary peritoneal carcinoma
Carboplatin,targets,fallopian tube cancer
Carboplatin,targets,mesothelioma
Carboplatin,targets,primary refractory ovarian cancer
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,epidermal growth factor receptor (egfr)-mutated non-small cell lung cancer (nsclc)
Carboplatin,targets,high grade epithelial ovarian cancer
Carboplatin,targets,hormone receptor-positive/her2 negative breast cancer
Carboplatin,targets,breast adenocarcinoma
Carboplatin,targets,high grade serous ovarian cancer
Carboplatin,targets,endometrial cancer
Carboplatin,targets,platinum-resistant ovarian cancer (proc)
Carboplatin,targets,TNBC
NCT05579366,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,non-small cell lung cancer
Bevacizumab,targets,uterine cancer
Bevacizumab,targets,platinum sensitive ovarian cancer (psoc)
Bevacizumab,targets,primary peritoneal carcinoma
Bevacizumab,targets,fallopian tube cancer
Bevacizumab,targets,mesothelioma
Bevacizumab,targets,primary refractory ovarian cancer
Bevacizumab,targets,triple negative breast cancer
Bevacizumab,targets,epidermal growth factor receptor (egfr)-mutated non-small cell lung cancer (nsclc)
Bevacizumab,targets,high grade epithelial ovarian cancer
Bevacizumab,targets,hormone receptor-positive/her2 negative breast cancer
Bevacizumab,targets,breast adenocarcinoma
Bevacizumab,targets,high grade serous ovarian cancer
Bevacizumab,targets,endometrial cancer
Bevacizumab,targets,platinum-resistant ovarian cancer (proc)
Bevacizumab,targets,TNBC
NCT05579366,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,non-small cell lung cancer
Pembrolizumab,targets,uterine cancer
Pembrolizumab,targets,platinum sensitive ovarian cancer (psoc)
Pembrolizumab,targets,primary peritoneal carcinoma
Pembrolizumab,targets,fallopian tube cancer
Pembrolizumab,targets,mesothelioma
Pembrolizumab,targets,primary refractory ovarian cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,epidermal growth factor receptor (egfr)-mutated non-small cell lung cancer (nsclc)
Pembrolizumab,targets,high grade epithelial ovarian cancer
Pembrolizumab,targets,hormone receptor-positive/her2 negative breast cancer
Pembrolizumab,targets,breast adenocarcinoma
Pembrolizumab,targets,high grade serous ovarian cancer
Pembrolizumab,targets,endometrial cancer
Pembrolizumab,targets,platinum-resistant ovarian cancer (proc)
Pembrolizumab,targets,TNBC
NCT06371274,sponsored_by,First Affiliated Hospital of Zhejiang University
NCT06371274,has_status,NOT_YET_RECRUITING
NCT06371274,tests,ATRA
ATRA,has_type,DRUG
ATRA,classified_as,OTHER
ATRA,targets,triple-negative breast cancer
ATRA,targets,TNBC
NCT06371274,tests,Toripalimab
Toripalimab,has_type,DRUG
Toripalimab,classified_as,BIOLOGIC
Toripalimab,targets,triple-negative breast cancer
Toripalimab,targets,TNBC
NCT01337765,sponsored_by,Pfizer
NCT01337765,has_status,COMPLETED
NCT01337765,tests,BEZ235 + MEK162
BEZ235 + MEK162,has_type,DRUG
BEZ235 + MEK162,classified_as,OTHER
BEZ235 + MEK162,targets,"unspecified adult solid tumor, protocol specific"
BEZ235 + MEK162,targets,solid tumor
NCT04138719,sponsored_by,Hebei Medical University Fourth Hospital
NCT04138719,has_status,UNKNOWN
NCT04138719,tests,Nab-paclitaxel + Carboplatin
Nab-paclitaxel + Carboplatin,has_type,DRUG
Nab-paclitaxel + Carboplatin,classified_as,CHEMICAL
Nab-paclitaxel + Carboplatin,targets,breast cancer
Nab-paclitaxel + Carboplatin,targets,nab-paclitaxel
Nab-paclitaxel + Carboplatin,targets,triple-negative breast cancer
Nab-paclitaxel + Carboplatin,targets,TNBC
NCT04138719,tests,Nab-paclitaxel + Epirubicin
Nab-paclitaxel + Epirubicin,has_type,DRUG
Nab-paclitaxel + Epirubicin,classified_as,CHEMICAL
Nab-paclitaxel + Epirubicin,targets,breast cancer
Nab-paclitaxel + Epirubicin,targets,nab-paclitaxel
Nab-paclitaxel + Epirubicin,targets,triple-negative breast cancer
Nab-paclitaxel + Epirubicin,targets,TNBC
NCT02546934,sponsored_by,Fudan University
NCT02546934,has_status,COMPLETED
NCT02546934,tests,"ABX, cisplatin"
"ABX, cisplatin",has_type,DRUG
"ABX, cisplatin",classified_as,CHEMICAL
"ABX, cisplatin",targets,breast cancer
NCT02546934,tests,"Gemcitabine, Cisplatin"
"Gemcitabine, Cisplatin",has_type,DRUG
"Gemcitabine, Cisplatin",classified_as,CHEMICAL
"Gemcitabine, Cisplatin",targets,breast cancer
NCT01848834,sponsored_by,Merck Sharp & Dohme LLC
NCT01848834,has_status,COMPLETED
NCT01848834,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,cancer
Pembrolizumab,targets,solid tumor
NCT04722718,sponsored_by,Jiuda Zhao
NCT04722718,has_status,UNKNOWN
NCT04722718,tests,Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin
Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin,has_type,DRUG
Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin,classified_as,BIOLOGIC
Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin,targets,breast cancer
NCT02819518,sponsored_by,Merck Sharp & Dohme LLC
NCT02819518,has_status,COMPLETED
NCT02819518,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer (tnbc)
Pembrolizumab,targets,TNBC
NCT02819518,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple negative breast cancer (tnbc)
Nab-paclitaxel,targets,TNBC
NCT02819518,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer (tnbc)
Paclitaxel,targets,TNBC
NCT02819518,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast cancer (tnbc)
Gemcitabine,targets,TNBC
NCT02819518,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer (tnbc)
Carboplatin,targets,TNBC
NCT02819518,tests,Normale Saline Solution
Normale Saline Solution,has_type,DRUG
Normale Saline Solution,classified_as,OTHER
Normale Saline Solution,targets,triple negative breast cancer (tnbc)
Normale Saline Solution,targets,TNBC
NCT05057013,sponsored_by,Cancer Research UK
NCT05057013,has_status,RECRUITING
NCT05057013,tests,HMBD-001
HMBD-001,has_type,DRUG
HMBD-001,classified_as,OTHER
HMBD-001,targets,gastric cancer
HMBD-001,targets,melanoma
HMBD-001,targets,ras wild type colorectal cancer
HMBD-001,targets,oesophageal cancer
HMBD-001,targets,pancreatic cancer
HMBD-001,targets,squamous cell cancer of the head and neck
HMBD-001,targets,ovarian cancer
HMBD-001,targets,castration-resistant prostate cancer
HMBD-001,targets,triple negative breast cancer
HMBD-001,targets,bladder cancer
HMBD-001,targets,non-small cell lung cancer (nsclc)
HMBD-001,targets,cervical cancer
HMBD-001,targets,hepatocellular carcinoma (hcc)
HMBD-001,targets,endometrial cancer
HMBD-001,targets,TNBC
NCT05057013,tests,HMBD-001 and enzalutamide
HMBD-001 and enzalutamide,has_type,DRUG
HMBD-001 and enzalutamide,classified_as,OTHER
HMBD-001 and enzalutamide,targets,gastric cancer
HMBD-001 and enzalutamide,targets,melanoma
HMBD-001 and enzalutamide,targets,ras wild type colorectal cancer
HMBD-001 and enzalutamide,targets,oesophageal cancer
HMBD-001 and enzalutamide,targets,pancreatic cancer
HMBD-001 and enzalutamide,targets,squamous cell cancer of the head and neck
HMBD-001 and enzalutamide,targets,ovarian cancer
HMBD-001 and enzalutamide,targets,castration-resistant prostate cancer
HMBD-001 and enzalutamide,targets,triple negative breast cancer
HMBD-001 and enzalutamide,targets,bladder cancer
HMBD-001 and enzalutamide,targets,non-small cell lung cancer (nsclc)
HMBD-001 and enzalutamide,targets,cervical cancer
HMBD-001 and enzalutamide,targets,hepatocellular carcinoma (hcc)
HMBD-001 and enzalutamide,targets,endometrial cancer
HMBD-001 and enzalutamide,targets,TNBC
NCT04159818,sponsored_by,The Netherlands Cancer Institute
NCT04159818,has_status,RECRUITING
NCT04159818,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,metastatic breast cancer
NCT04159818,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,metastatic breast cancer
NCT04159818,tests,Low dose doxorubicin
Low dose doxorubicin,has_type,DRUG
Low dose doxorubicin,classified_as,CHEMICAL
Low dose doxorubicin,targets,metastatic breast cancer
NCT02527434,sponsored_by,AstraZeneca
NCT02527434,has_status,COMPLETED
NCT02527434,tests,Tremelimumab monotherapy
Tremelimumab monotherapy,has_type,DRUG
Tremelimumab monotherapy,classified_as,BIOLOGIC
Tremelimumab monotherapy,targets,urothelial bladder cancer
Tremelimumab monotherapy,targets,triple-negative breast cancer
Tremelimumab monotherapy,targets,pancreatic ductal adenocarcinoma
Tremelimumab monotherapy,targets,TNBC
NCT02527434,tests,MEDI4736 monotherapy
MEDI4736 monotherapy,has_type,DRUG
MEDI4736 monotherapy,classified_as,OTHER
MEDI4736 monotherapy,targets,urothelial bladder cancer
MEDI4736 monotherapy,targets,triple-negative breast cancer
MEDI4736 monotherapy,targets,pancreatic ductal adenocarcinoma
MEDI4736 monotherapy,targets,TNBC
NCT02527434,tests,MEDI4736 + tremelimumab combination therapy
MEDI4736 + tremelimumab combination therapy,has_type,DRUG
MEDI4736 + tremelimumab combination therapy,classified_as,BIOLOGIC
MEDI4736 + tremelimumab combination therapy,targets,urothelial bladder cancer
MEDI4736 + tremelimumab combination therapy,targets,triple-negative breast cancer
MEDI4736 + tremelimumab combination therapy,targets,pancreatic ductal adenocarcinoma
MEDI4736 + tremelimumab combination therapy,targets,TNBC
NCT05585034,sponsored_by,"Xencor, Inc."
NCT05585034,has_status,ACTIVE_NOT_RECRUITING
NCT05585034,tests,XmAb®808
XmAb®808,has_type,DRUG
XmAb®808,classified_as,BIOLOGIC
XmAb®808,targets,melanoma excluding uveal melanoma
XmAb®808,targets,urothelial carcinoma
XmAb®808,targets,"renal cell carcinoma, clear cell"
XmAb®808,targets,"non-small cell lung cancer, squamous or non-squamous"
XmAb®808,targets,castration-resistant prostate cancer
XmAb®808,targets,tnbc - triple-negative breast cancer
XmAb®808,targets,head and neck squamous cell carcinoma
XmAb®808,targets,"ovarian cancer, epithelial"
XmAb®808,targets,colorectal cancer
XmAb®808,targets,TNBC
NCT05585034,tests,Keytruda® (pembrolizumab)
Keytruda® (pembrolizumab),has_type,DRUG
Keytruda® (pembrolizumab),classified_as,BIOLOGIC
Keytruda® (pembrolizumab),targets,melanoma excluding uveal melanoma
Keytruda® (pembrolizumab),targets,urothelial carcinoma
Keytruda® (pembrolizumab),targets,"renal cell carcinoma, clear cell"
Keytruda® (pembrolizumab),targets,"non-small cell lung cancer, squamous or non-squamous"
Keytruda® (pembrolizumab),targets,castration-resistant prostate cancer
Keytruda® (pembrolizumab),targets,tnbc - triple-negative breast cancer
Keytruda® (pembrolizumab),targets,head and neck squamous cell carcinoma
Keytruda® (pembrolizumab),targets,"ovarian cancer, epithelial"
Keytruda® (pembrolizumab),targets,colorectal cancer
Keytruda® (pembrolizumab),targets,TNBC
NCT04234113,sponsored_by,SOTIO Biotech AG
NCT04234113,has_status,TERMINATED
NCT04234113,tests,Nanrilkefusp alfa
Nanrilkefusp alfa,has_type,DRUG
Nanrilkefusp alfa,classified_as,OTHER
Nanrilkefusp alfa,targets,melanoma
Nanrilkefusp alfa,targets,merkel cell carcinoma
Nanrilkefusp alfa,targets,thymic cancer
Nanrilkefusp alfa,targets,cervical cancer
Nanrilkefusp alfa,targets,microsatellite instability high
Nanrilkefusp alfa,targets,small-cell lung cancer
Nanrilkefusp alfa,targets,hepatocellular carcinoma
Nanrilkefusp alfa,targets,triple negative breast cancer
Nanrilkefusp alfa,targets,biliary tract cancer
Nanrilkefusp alfa,targets,skin squamous cell carcinoma
Nanrilkefusp alfa,targets,gastric cancer
Nanrilkefusp alfa,targets,thyroid cancer
Nanrilkefusp alfa,targets,mesothelioma
Nanrilkefusp alfa,targets,ovarian cancer
Nanrilkefusp alfa,targets,bladder cancer
Nanrilkefusp alfa,targets,renal cell carcinoma
Nanrilkefusp alfa,targets,anal cancer
Nanrilkefusp alfa,targets,head and neck squamous cell carcinoma
Nanrilkefusp alfa,targets,non small cell lung cancer
Nanrilkefusp alfa,targets,TNBC
NCT04234113,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,melanoma
Pembrolizumab,targets,merkel cell carcinoma
Pembrolizumab,targets,thymic cancer
Pembrolizumab,targets,cervical cancer
Pembrolizumab,targets,microsatellite instability high
Pembrolizumab,targets,small-cell lung cancer
Pembrolizumab,targets,hepatocellular carcinoma
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,biliary tract cancer
Pembrolizumab,targets,skin squamous cell carcinoma
Pembrolizumab,targets,gastric cancer
Pembrolizumab,targets,thyroid cancer
Pembrolizumab,targets,mesothelioma
Pembrolizumab,targets,ovarian cancer
Pembrolizumab,targets,bladder cancer
Pembrolizumab,targets,renal cell carcinoma
Pembrolizumab,targets,anal cancer
Pembrolizumab,targets,head and neck squamous cell carcinoma
Pembrolizumab,targets,non small cell lung cancer
Pembrolizumab,targets,TNBC
NCT06505018,sponsored_by,UNICANCER
NCT06505018,has_status,RECRUITING
NCT06505018,tests,Cureety techcare
Cureety techcare,has_type,DRUG
Cureety techcare,classified_as,OTHER
Cureety techcare,targets,metastatic triple-negative breast carcinoma
Cureety techcare,targets,TNBC
NCT04102618,sponsored_by,Oncolytics Biotech
NCT04102618,has_status,TERMINATED
NCT04102618,tests,Pelareorep
Pelareorep,has_type,DRUG
Pelareorep,classified_as,OTHER
Pelareorep,targets,breast cancer
NCT04102618,tests,Letrozole
Letrozole,has_type,DRUG
Letrozole,classified_as,CHEMICAL
Letrozole,targets,breast cancer
NCT04102618,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,breast cancer
NCT04102618,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,breast cancer
NCT05565417,sponsored_by,Immunitas Therapeutics
NCT05565417,has_status,RECRUITING
NCT05565417,tests,IMT-009
IMT-009,has_type,DRUG
IMT-009,classified_as,OTHER
IMT-009,targets,follicular lymphoma
IMT-009,targets,diffuse large b cell lymphoma
IMT-009,targets,triple negative breast cancer
IMT-009,targets,small bowel cancer
IMT-009,targets,hormone receptor positive breast carcinoma
IMT-009,targets,esophageal cancer
IMT-009,targets,head and neck squamous cell carcinoma
IMT-009,targets,burkitt lymphoma
IMT-009,targets,cutaneous squamous cell carcinoma
IMT-009,targets,hodgkin lymphoma
IMT-009,targets,non small cell lung cancer
IMT-009,targets,colorectal cancer
IMT-009,targets,TNBC
NCT05565417,tests,Fruquintinib
Fruquintinib,has_type,DRUG
Fruquintinib,classified_as,CHEMICAL
Fruquintinib,targets,follicular lymphoma
Fruquintinib,targets,diffuse large b cell lymphoma
Fruquintinib,targets,triple negative breast cancer
Fruquintinib,targets,small bowel cancer
Fruquintinib,targets,hormone receptor positive breast carcinoma
Fruquintinib,targets,esophageal cancer
Fruquintinib,targets,head and neck squamous cell carcinoma
Fruquintinib,targets,burkitt lymphoma
Fruquintinib,targets,cutaneous squamous cell carcinoma
Fruquintinib,targets,hodgkin lymphoma
Fruquintinib,targets,non small cell lung cancer
Fruquintinib,targets,colorectal cancer
Fruquintinib,targets,TNBC
NCT05720117,sponsored_by,"Pyxis Oncology, Inc"
NCT05720117,has_status,RECRUITING
NCT05720117,tests,PYX-201
PYX-201,has_type,DRUG
PYX-201,classified_as,OTHER
PYX-201,targets,advanced solid tumor
PYX-201,targets,solid tumor
NCT01624441,sponsored_by,National Cancer Institute (NCI)
NCT01624441,has_status,COMPLETED
NCT01624441,tests,Dinaciclib
Dinaciclib,has_type,DRUG
Dinaciclib,classified_as,CHEMICAL
Dinaciclib,targets,recurrent breast carcinoma
Dinaciclib,targets,triple-negative breast carcinoma
Dinaciclib,targets,estrogen receptor negative
Dinaciclib,targets,progesterone receptor negative
Dinaciclib,targets,her2/neu negative
Dinaciclib,targets,male breast carcinoma
Dinaciclib,targets,stage iv breast cancer ajcc v6 and v7
Dinaciclib,targets,TNBC
NCT01624441,tests,Epirubicin Hydrochloride
Epirubicin Hydrochloride,has_type,DRUG
Epirubicin Hydrochloride,classified_as,OTHER
Epirubicin Hydrochloride,targets,recurrent breast carcinoma
Epirubicin Hydrochloride,targets,triple-negative breast carcinoma
Epirubicin Hydrochloride,targets,estrogen receptor negative
Epirubicin Hydrochloride,targets,progesterone receptor negative
Epirubicin Hydrochloride,targets,her2/neu negative
Epirubicin Hydrochloride,targets,male breast carcinoma
Epirubicin Hydrochloride,targets,stage iv breast cancer ajcc v6 and v7
Epirubicin Hydrochloride,targets,TNBC
NCT01624441,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,recurrent breast carcinoma
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,estrogen receptor negative
Laboratory Biomarker Analysis,targets,progesterone receptor negative
Laboratory Biomarker Analysis,targets,her2/neu negative
Laboratory Biomarker Analysis,targets,male breast carcinoma
Laboratory Biomarker Analysis,targets,stage iv breast cancer ajcc v6 and v7
Laboratory Biomarker Analysis,targets,TNBC
NCT04303741,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04303741,has_status,UNKNOWN
NCT04303741,tests,Camrelizumab
Camrelizumab,has_type,DRUG
Camrelizumab,classified_as,BIOLOGIC
Camrelizumab,targets,breast cancer
NCT04303741,tests,Apatinib
Apatinib,has_type,DRUG
Apatinib,classified_as,CHEMICAL
Apatinib,targets,breast cancer
NCT04303741,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,breast cancer
NCT06845319,sponsored_by,Medical University of South Carolina
NCT06845319,has_status,NOT_YET_RECRUITING
NCT06845319,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT06845319,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT06845319,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT06203119,sponsored_by,Peking University Cancer Hospital & Institute
NCT06203119,has_status,RECRUITING
NCT05905341,sponsored_by,Pfizer
NCT05905341,has_status,WITHDRAWN
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
PF-07224826,classified_as,OTHER
PF-07224826,targets,breast cancer
PF-07224826,targets,ovarian cancer
PF-07224826,targets,endometrial
PF-07224826,targets,liposarcoma
PF-07224826,targets,non-small cell lung cancer (nsclc)
PF-07224826,targets,solid tumors
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,breast cancer
Fulvestrant,targets,ovarian cancer
Fulvestrant,targets,endometrial
Fulvestrant,targets,liposarcoma
Fulvestrant,targets,non-small cell lung cancer (nsclc)
Fulvestrant,targets,solid tumors
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
PF-07224826,classified_as,OTHER
PF-07224826,targets,breast cancer
PF-07224826,targets,ovarian cancer
PF-07224826,targets,endometrial
PF-07224826,targets,liposarcoma
PF-07224826,targets,non-small cell lung cancer (nsclc)
PF-07224826,targets,solid tumors
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,breast cancer
Fulvestrant,targets,ovarian cancer
Fulvestrant,targets,endometrial
Fulvestrant,targets,liposarcoma
Fulvestrant,targets,non-small cell lung cancer (nsclc)
Fulvestrant,targets,solid tumors
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
PF-07224826,classified_as,OTHER
PF-07224826,targets,breast cancer
PF-07224826,targets,ovarian cancer
PF-07224826,targets,endometrial
PF-07224826,targets,liposarcoma
PF-07224826,targets,non-small cell lung cancer (nsclc)
PF-07224826,targets,solid tumors
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,breast cancer
Fulvestrant,targets,ovarian cancer
Fulvestrant,targets,endometrial
Fulvestrant,targets,liposarcoma
Fulvestrant,targets,non-small cell lung cancer (nsclc)
Fulvestrant,targets,solid tumors
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
PF-07224826,classified_as,OTHER
PF-07224826,targets,breast cancer
PF-07224826,targets,ovarian cancer
PF-07224826,targets,endometrial
PF-07224826,targets,liposarcoma
PF-07224826,targets,non-small cell lung cancer (nsclc)
PF-07224826,targets,solid tumors
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,breast cancer
Fulvestrant,targets,ovarian cancer
Fulvestrant,targets,endometrial
Fulvestrant,targets,liposarcoma
Fulvestrant,targets,non-small cell lung cancer (nsclc)
Fulvestrant,targets,solid tumors
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
PF-07224826,classified_as,OTHER
PF-07224826,targets,breast cancer
PF-07224826,targets,ovarian cancer
PF-07224826,targets,endometrial
PF-07224826,targets,liposarcoma
PF-07224826,targets,non-small cell lung cancer (nsclc)
PF-07224826,targets,solid tumors
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,breast cancer
Fulvestrant,targets,ovarian cancer
Fulvestrant,targets,endometrial
Fulvestrant,targets,liposarcoma
Fulvestrant,targets,non-small cell lung cancer (nsclc)
Fulvestrant,targets,solid tumors
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
PF-07224826,classified_as,OTHER
PF-07224826,targets,breast cancer
PF-07224826,targets,ovarian cancer
PF-07224826,targets,endometrial
PF-07224826,targets,liposarcoma
PF-07224826,targets,non-small cell lung cancer (nsclc)
PF-07224826,targets,solid tumors
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,breast cancer
Fulvestrant,targets,ovarian cancer
Fulvestrant,targets,endometrial
Fulvestrant,targets,liposarcoma
Fulvestrant,targets,non-small cell lung cancer (nsclc)
Fulvestrant,targets,solid tumors
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
PF-07224826,classified_as,OTHER
PF-07224826,targets,breast cancer
PF-07224826,targets,ovarian cancer
PF-07224826,targets,endometrial
PF-07224826,targets,liposarcoma
PF-07224826,targets,non-small cell lung cancer (nsclc)
PF-07224826,targets,solid tumors
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,breast cancer
Fulvestrant,targets,ovarian cancer
Fulvestrant,targets,endometrial
Fulvestrant,targets,liposarcoma
Fulvestrant,targets,non-small cell lung cancer (nsclc)
Fulvestrant,targets,solid tumors
NCT03733119,sponsored_by,"University of Wisconsin, Madison"
NCT03733119,has_status,TERMINATED
NCT03733119,tests,Akt/ERK Inhibitor ONC201
Akt/ERK Inhibitor ONC201,has_type,DRUG
Akt/ERK Inhibitor ONC201,classified_as,CHEMICAL
Akt/ERK Inhibitor ONC201,targets,triple negative breast cancer
Akt/ERK Inhibitor ONC201,targets,TNBC
NCT03733119,tests,Methionine-Restricted Diet
Methionine-Restricted Diet,has_type,DRUG
Methionine-Restricted Diet,classified_as,OTHER
Methionine-Restricted Diet,targets,triple negative breast cancer
Methionine-Restricted Diet,targets,TNBC
NCT01939418,sponsored_by,"National Cancer Center, Korea"
NCT01939418,has_status,TERMINATED
NCT01939418,tests,RAD001
RAD001,has_type,DRUG
RAD001,classified_as,OTHER
RAD001,targets,metastatic breast cancer
NCT01939418,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,metastatic breast cancer
NCT01939418,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,metastatic breast cancer
NCT06195618,sponsored_by,Universidad Nacional de Colombia
NCT06195618,has_status,NOT_YET_RECRUITING
NCT06195618,tests,Peptide (neoantigen) pulsed autologous Dendritic cell
Peptide (neoantigen) pulsed autologous Dendritic cell,has_type,DRUG
Peptide (neoantigen) pulsed autologous Dendritic cell,classified_as,BIOLOGIC
Peptide (neoantigen) pulsed autologous Dendritic cell,targets,breast cancer female
NCT01445418,sponsored_by,National Cancer Institute (NCI)
NCT01445418,has_status,COMPLETED
NCT01445418,tests,AZ2281 + Carboplatin
AZ2281 + Carboplatin,has_type,DRUG
AZ2281 + Carboplatin,classified_as,CHEMICAL
AZ2281 + Carboplatin,targets,breast cancer
AZ2281 + Carboplatin,targets,ovarian cancer
NCT04424641,sponsored_by,Genmab
NCT04424641,has_status,TERMINATED
NCT04424641,tests,GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,has_type,DRUG
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,classified_as,CHEMICAL
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,targets,uterine cancer
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,targets,squamous cell carcinoma of head and neck (scchn)
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,targets,prostate cancer
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,targets,bladder cancer
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,targets,non-small cell lung cancer (nsclc)
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,targets,esophageal cancer
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,targets,triple negative breast cancer (tnbc)
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,targets,locally advanced or metastatic solid tumor(s)
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,targets,TNBC
NCT03289819,sponsored_by,Institut fuer Frauengesundheit
NCT03289819,has_status,COMPLETED
NCT03289819,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,malignant neoplasm of breast
NCT03289819,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
nab-paclitaxel,classified_as,CHEMICAL
nab-paclitaxel,targets,malignant neoplasm of breast
NCT03289819,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,malignant neoplasm of breast
NCT03289819,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,malignant neoplasm of breast
NCT02539017,sponsored_by,First Affiliated Hospital Xi'an Jiaotong University
NCT02539017,has_status,WITHDRAWN
NCT02539017,tests,Chemo
Chemo,has_type,DRUG
Chemo,classified_as,OTHER
Chemo,targets,triple negative breast neoplasms
Chemo,targets,TNBC
NCT02539017,tests,Immunotherapy
Immunotherapy,has_type,DRUG
Immunotherapy,classified_as,BIOLOGIC
Immunotherapy,targets,triple negative breast neoplasms
Immunotherapy,targets,TNBC
NCT05969041,sponsored_by,Myeloid Therapeutics
NCT05969041,has_status,RECRUITING
NCT05969041,tests,MT-302 (A)
MT-302 (A),has_type,DRUG
MT-302 (A),classified_as,OTHER
MT-302 (A),targets,"epithelial tumors, malignant"
NCT05068141,sponsored_by,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."
NCT05068141,has_status,UNKNOWN
NCT05068141,tests,SG001
SG001,has_type,DRUG
SG001,classified_as,OTHER
SG001,targets,triple negative breast cancer
SG001,targets,TNBC
NCT05068141,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT06786026,sponsored_by,Fudan University
NCT06786026,has_status,RECRUITING
NCT06786026,tests,bevacizumab
bevacizumab,has_type,DRUG
bevacizumab,classified_as,BIOLOGIC
bevacizumab,targets,"tnbc, triple negative breast cancer"
bevacizumab,targets,TNBC
NCT06786026,tests,QL1706
QL1706,has_type,DRUG
QL1706,classified_as,OTHER
QL1706,targets,"tnbc, triple negative breast cancer"
QL1706,targets,TNBC
NCT06786026,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
Nab paclitaxel,classified_as,CHEMICAL
Nab paclitaxel,targets,"tnbc, triple negative breast cancer"
Nab paclitaxel,targets,TNBC
NCT03358017,sponsored_by,Mario Negri Institute for Pharmacological Research
NCT03358017,has_status,COMPLETED
NCT03358017,tests,Zoledronate
Zoledronate,has_type,DRUG
Zoledronate,classified_as,OTHER
Zoledronate,targets,triple negative breast cancer
Zoledronate,targets,TNBC
NCT03358017,tests,Atorvastatin 80mg
Atorvastatin 80mg,has_type,DRUG
Atorvastatin 80mg,classified_as,OTHER
Atorvastatin 80mg,targets,triple negative breast cancer
Atorvastatin 80mg,targets,TNBC
NCT03358017,tests,Standard neoadjuvant cht
Standard neoadjuvant cht,has_type,DRUG
Standard neoadjuvant cht,classified_as,OTHER
Standard neoadjuvant cht,targets,triple negative breast cancer
Standard neoadjuvant cht,targets,TNBC
NCT03544125,sponsored_by,OHSU Knight Cancer Institute
NCT03544125,has_status,COMPLETED
NCT03544125,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,anatomic stage iv breast cancer ajcc v8
Durvalumab,targets,estrogen receptor negative
Durvalumab,targets,progesterone receptor negative
Durvalumab,targets,her2/neu negative
Durvalumab,targets,prognostic stage iv breast cancer ajcc v8
Durvalumab,targets,triple-negative breast carcinoma
Durvalumab,targets,TNBC
NCT03544125,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,anatomic stage iv breast cancer ajcc v8
Olaparib,targets,estrogen receptor negative
Olaparib,targets,progesterone receptor negative
Olaparib,targets,her2/neu negative
Olaparib,targets,prognostic stage iv breast cancer ajcc v8
Olaparib,targets,triple-negative breast carcinoma
Olaparib,targets,TNBC
NCT05238922,sponsored_by,Incyte Corporation
NCT05238922,has_status,RECRUITING
NCT05238922,tests,INCB0123667
INCB0123667,has_type,DRUG
INCB0123667,classified_as,OTHER
INCB0123667,targets,solid tumors
NCT05238922,tests,Palbociclib
Palbociclib,has_type,DRUG
Palbociclib,classified_as,CHEMICAL
Palbociclib,targets,solid tumors
NCT05238922,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,solid tumors
NCT05238922,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,solid tumors
NCT05238922,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,solid tumors
NCT05238922,tests,Ribociclib
Ribociclib,has_type,DRUG
Ribociclib,classified_as,CHEMICAL
Ribociclib,targets,solid tumors
NCT05238922,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,solid tumors
NCT02413320,sponsored_by,Priyanka Sharma
NCT02413320,has_status,COMPLETED
NCT02413320,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple-negative breast cancer
Paclitaxel,targets,TNBC
NCT02413320,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple-negative breast cancer
Carboplatin,targets,TNBC
NCT02413320,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,triple-negative breast cancer
Doxorubicin,targets,TNBC
NCT02413320,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple-negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02413320,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,triple-negative breast cancer
Docetaxel,targets,TNBC
NCT05333874,sponsored_by,"Rutgers, The State University of New Jersey"
NCT05333874,has_status,ACTIVE_NOT_RECRUITING
NCT05333874,tests,Neoadjuvant chemotherapy administered before surgical extraction of a tumor
Neoadjuvant chemotherapy administered before surgical extraction of a tumor,has_type,DRUG
Neoadjuvant chemotherapy administered before surgical extraction of a tumor,classified_as,OTHER
Neoadjuvant chemotherapy administered before surgical extraction of a tumor,targets,"breast cancer, early-onset"
NCT05333874,tests,Observational
Observational,has_type,DRUG
Observational,classified_as,OTHER
Observational,targets,"breast cancer, early-onset"
NCT05107674,sponsored_by,"Nurix Therapeutics, Inc."
NCT05107674,has_status,RECRUITING
NCT05107674,tests,NX-1607
NX-1607,has_type,DRUG
NX-1607,classified_as,OTHER
NX-1607,targets,gastric cancer
NX-1607,targets,microsatellite stable colorectal carcinoma
NX-1607,targets,metastatic or unresectable melanoma
NX-1607,targets,diffuse large b cell lymphoma (dlbcl)
NX-1607,targets,richter transformation
NX-1607,targets,metastatic urothelial carcinoma
NX-1607,targets,gastroesophageal junction (gej) cancer
NX-1607,targets,non-small cell lung cancer (nsclc)
NX-1607,targets,cervical cancer
NX-1607,targets,head and neck squamous cell carcinoma
NX-1607,targets,malignant pleural mesothelioma (mpm)
NX-1607,targets,"ovarian cancer, epithelial"
NX-1607,targets,triple negative breast cancer (tnbc)
NX-1607,targets,metastatic castration-resistant prostate cancer (mcrpc)
NX-1607,targets,TNBC
NCT05107674,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,gastric cancer
Paclitaxel,targets,microsatellite stable colorectal carcinoma
Paclitaxel,targets,metastatic or unresectable melanoma
Paclitaxel,targets,diffuse large b cell lymphoma (dlbcl)
Paclitaxel,targets,richter transformation
Paclitaxel,targets,metastatic urothelial carcinoma
Paclitaxel,targets,gastroesophageal junction (gej) cancer
Paclitaxel,targets,non-small cell lung cancer (nsclc)
Paclitaxel,targets,cervical cancer
Paclitaxel,targets,head and neck squamous cell carcinoma
Paclitaxel,targets,malignant pleural mesothelioma (mpm)
Paclitaxel,targets,"ovarian cancer, epithelial"
Paclitaxel,targets,triple negative breast cancer (tnbc)
Paclitaxel,targets,metastatic castration-resistant prostate cancer (mcrpc)
Paclitaxel,targets,TNBC
NCT02737475,sponsored_by,Bristol-Myers Squibb
NCT02737475,has_status,COMPLETED
NCT02737475,tests,BMS-986178
BMS-986178,has_type,DRUG
BMS-986178,classified_as,OTHER
BMS-986178,targets,advanced cancer
NCT02737475,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,advanced cancer
NCT02737475,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,advanced cancer
NCT02737475,tests,Tetanus vaccine
Tetanus vaccine,has_type,DRUG
Tetanus vaccine,classified_as,OTHER
Tetanus vaccine,targets,advanced cancer
NCT02737475,tests,DPV-001 vaccine
DPV-001 vaccine,has_type,DRUG
DPV-001 vaccine,classified_as,OTHER
DPV-001 vaccine,targets,advanced cancer
NCT02737475,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,advanced cancer
NCT01898117,sponsored_by,The Netherlands Cancer Institute
NCT01898117,has_status,ACTIVE_NOT_RECRUITING
NCT01898117,tests,Carbo/cyclo
Carbo/cyclo,has_type,DRUG
Carbo/cyclo,classified_as,OTHER
Carbo/cyclo,targets,breast cancer
NCT01898117,tests,Carbo/cyclo + atezolizumab
Carbo/cyclo + atezolizumab,has_type,DRUG
Carbo/cyclo + atezolizumab,classified_as,BIOLOGIC
Carbo/cyclo + atezolizumab,targets,breast cancer
NCT01898117,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT01898117,tests,Paclitaxel + Atezolizumab
Paclitaxel + Atezolizumab,has_type,DRUG
Paclitaxel + Atezolizumab,classified_as,BIOLOGIC
Paclitaxel + Atezolizumab,targets,breast cancer
NCT07020117,sponsored_by,"Aktis Oncology, Inc."
NCT07020117,has_status,RECRUITING
NCT07020117,tests,[225Ac]Ac-AKY-1189 (therapeutic)
[225Ac]Ac-AKY-1189 (therapeutic),has_type,DRUG
[225Ac]Ac-AKY-1189 (therapeutic),classified_as,OTHER
[225Ac]Ac-AKY-1189 (therapeutic),targets,head and neck cancer
[225Ac]Ac-AKY-1189 (therapeutic),targets,hormone receptor positive breast adenocarcinoma
[225Ac]Ac-AKY-1189 (therapeutic),targets,cervical adenocarcinoma
[225Ac]Ac-AKY-1189 (therapeutic),targets,colorectal adenocarcinoma
[225Ac]Ac-AKY-1189 (therapeutic),targets,triple negative breast cancer (tnbc)
[225Ac]Ac-AKY-1189 (therapeutic),targets,urothelial carcinoma bladder
[225Ac]Ac-AKY-1189 (therapeutic),targets,non small cell lung cancer
[225Ac]Ac-AKY-1189 (therapeutic),targets,TNBC
NCT07020117,tests,[64Cu]Cu-AKY-1189 (imaging)
[64Cu]Cu-AKY-1189 (imaging),has_type,DRUG
[64Cu]Cu-AKY-1189 (imaging),classified_as,OTHER
[64Cu]Cu-AKY-1189 (imaging),targets,head and neck cancer
[64Cu]Cu-AKY-1189 (imaging),targets,hormone receptor positive breast adenocarcinoma
[64Cu]Cu-AKY-1189 (imaging),targets,cervical adenocarcinoma
[64Cu]Cu-AKY-1189 (imaging),targets,colorectal adenocarcinoma
[64Cu]Cu-AKY-1189 (imaging),targets,triple negative breast cancer (tnbc)
[64Cu]Cu-AKY-1189 (imaging),targets,urothelial carcinoma bladder
[64Cu]Cu-AKY-1189 (imaging),targets,non small cell lung cancer
[64Cu]Cu-AKY-1189 (imaging),targets,TNBC
NCT06167317,sponsored_by,Gilead Sciences
NCT06167317,has_status,RECRUITING
NCT06167317,tests,GS-0201
GS-0201,has_type,DRUG
GS-0201,classified_as,OTHER
GS-0201,targets,advanced solid tumors
NCT06167317,tests,Sacituzumab Govitecan
Sacituzumab Govitecan,has_type,DRUG
Sacituzumab Govitecan,classified_as,BIOLOGIC
Sacituzumab Govitecan,targets,advanced solid tumors
NCT04602117,sponsored_by,QuantumLeap Healthcare Collaborative
NCT04602117,has_status,WITHDRAWN
NCT04602117,tests,Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,has_type,DRUG
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,classified_as,BIOLOGIC
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,metastatic gastrointestinal carcinoid tumor
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,her2-positive metastatic breast cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,ovarian carcinoma
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,metastatic cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,progesterone receptor-positive breast cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,her-2 protein overexpression
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,her2 low hr positive
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,gastroesophageal adenocarcinoma
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,syd985
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,her2 mutation-related tumors
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,triple negative breast cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,her2-positive breast cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,gastroesophageal cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,syd-985
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,her2-positive gastric cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,ovarian cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,estrogen receptor positive tumor
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,hormone receptor negative breast carcinoma
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,bladder cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,hormone receptor-positive breast cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,her2 low breast cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,her2 low
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,metastatic breast cancer
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,metastatic
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,vic-trastuzumab duocarmazine
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,endometrium tumor
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,hr positive
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,targets,TNBC
NCT05288127,sponsored_by,University of Malaya
NCT05288127,has_status,RECRUITING
NCT05288127,tests,Talazoparib
Talazoparib,has_type,DRUG
Talazoparib,classified_as,CHEMICAL
Talazoparib,targets,hrd 100 gene expression high
Talazoparib,targets,triple negative breast cancer
Talazoparib,targets,TNBC
NCT03775850,sponsored_by,"Evelo Biosciences, Inc."
NCT03775850,has_status,COMPLETED
NCT03775850,tests,EDP1503
EDP1503,has_type,DRUG
EDP1503,classified_as,OTHER
EDP1503,targets,renal cell carcinoma
EDP1503,targets,colorectal cancer metastatic
EDP1503,targets,triple negative breast cancer
EDP1503,targets,gastroesophageal cancer
EDP1503,targets,bladder cancer
EDP1503,targets,msi-h
EDP1503,targets,non small cell lung cancer
EDP1503,targets,TNBC
NCT03775850,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,renal cell carcinoma
Pembrolizumab,targets,colorectal cancer metastatic
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,gastroesophageal cancer
Pembrolizumab,targets,bladder cancer
Pembrolizumab,targets,msi-h
Pembrolizumab,targets,non small cell lung cancer
Pembrolizumab,targets,TNBC
NCT02783300,sponsored_by,GlaxoSmithKline
NCT02783300,has_status,COMPLETED
NCT02783300,tests,GSK3326595
GSK3326595,has_type,DRUG
GSK3326595,classified_as,OTHER
GSK3326595,targets,neoplasms
NCT02783300,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,neoplasms
NCT05673200,sponsored_by,National Cancer Institute (NCI)
NCT05673200,has_status,SUSPENDED
NCT05673200,tests,Biopsy Procedure
Biopsy Procedure,has_type,DRUG
Biopsy Procedure,classified_as,OTHER
Biopsy Procedure,targets,metastatic triple-negative breast carcinoma
Biopsy Procedure,targets,unresectable triple-negative breast carcinoma
Biopsy Procedure,targets,anatomic stage iii breast cancer ajcc v8
Biopsy Procedure,targets,anatomic stage iv breast cancer ajcc v8
Biopsy Procedure,targets,TNBC
NCT05673200,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,unresectable triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iii breast cancer ajcc v8
Biospecimen Collection,targets,anatomic stage iv breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT05673200,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,unresectable triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iii breast cancer ajcc v8
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,TNBC
NCT05673200,tests,Decitabine and Cedazuridine
Decitabine and Cedazuridine,has_type,DRUG
Decitabine and Cedazuridine,classified_as,OTHER
Decitabine and Cedazuridine,targets,metastatic triple-negative breast carcinoma
Decitabine and Cedazuridine,targets,unresectable triple-negative breast carcinoma
Decitabine and Cedazuridine,targets,anatomic stage iii breast cancer ajcc v8
Decitabine and Cedazuridine,targets,anatomic stage iv breast cancer ajcc v8
Decitabine and Cedazuridine,targets,TNBC
NCT05673200,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,metastatic triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,unresectable triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iii breast cancer ajcc v8
Magnetic Resonance Imaging,targets,anatomic stage iv breast cancer ajcc v8
Magnetic Resonance Imaging,targets,TNBC
NCT05673200,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,metastatic triple-negative breast carcinoma
Paclitaxel,targets,unresectable triple-negative breast carcinoma
Paclitaxel,targets,anatomic stage iii breast cancer ajcc v8
Paclitaxel,targets,anatomic stage iv breast cancer ajcc v8
Paclitaxel,targets,TNBC
NCT05673200,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,unresectable triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iii breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage iv breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT03542175,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT03542175,has_status,ACTIVE_NOT_RECRUITING
NCT03542175,tests,Rucaparib
Rucaparib,has_type,DRUG
Rucaparib,classified_as,CHEMICAL
Rucaparib,targets,breast cancer
NCT03542175,tests,Radiotherapy
Radiotherapy,has_type,DRUG
Radiotherapy,classified_as,OTHER
Radiotherapy,targets,breast cancer
NCT06966700,sponsored_by,Merck Sharp & Dohme LLC
NCT06966700,has_status,NOT_YET_RECRUITING
NCT06966700,tests,Sacituzumab tirumotecan
Sacituzumab tirumotecan,has_type,DRUG
Sacituzumab tirumotecan,classified_as,BIOLOGIC
Sacituzumab tirumotecan,targets,breast neoplasms
Sacituzumab tirumotecan,targets,triple negative breast neoplasms
Sacituzumab tirumotecan,targets,hr low-positive/her2-negative breast neoplasms
Sacituzumab tirumotecan,targets,TNBC
NCT06966700,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast neoplasms
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,hr low-positive/her2-negative breast neoplasms
Pembrolizumab,targets,TNBC
NCT06966700,tests,Rescue Medication
Rescue Medication,has_type,DRUG
Rescue Medication,classified_as,OTHER
Rescue Medication,targets,breast neoplasms
Rescue Medication,targets,triple negative breast neoplasms
Rescue Medication,targets,hr low-positive/her2-negative breast neoplasms
Rescue Medication,targets,TNBC
NCT06966700,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast neoplasms
Carboplatin,targets,triple negative breast neoplasms
Carboplatin,targets,hr low-positive/her2-negative breast neoplasms
Carboplatin,targets,TNBC
NCT06966700,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast neoplasms
Paclitaxel,targets,triple negative breast neoplasms
Paclitaxel,targets,hr low-positive/her2-negative breast neoplasms
Paclitaxel,targets,TNBC
NCT06966700,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,breast neoplasms
Doxorubicin,targets,triple negative breast neoplasms
Doxorubicin,targets,hr low-positive/her2-negative breast neoplasms
Doxorubicin,targets,TNBC
NCT06966700,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,breast neoplasms
Epirubicin,targets,triple negative breast neoplasms
Epirubicin,targets,hr low-positive/her2-negative breast neoplasms
Epirubicin,targets,TNBC
NCT06966700,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast neoplasms
Cyclophosphamide,targets,triple negative breast neoplasms
Cyclophosphamide,targets,hr low-positive/her2-negative breast neoplasms
Cyclophosphamide,targets,TNBC
NCT06966700,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast neoplasms
Capecitabine,targets,triple negative breast neoplasms
Capecitabine,targets,hr low-positive/her2-negative breast neoplasms
Capecitabine,targets,TNBC
NCT06966700,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,breast neoplasms
Olaparib,targets,triple negative breast neoplasms
Olaparib,targets,hr low-positive/her2-negative breast neoplasms
Olaparib,targets,TNBC
NCT04691375,sponsored_by,Ikena Oncology
NCT04691375,has_status,TERMINATED
NCT04691375,tests,PY314
PY314,has_type,DRUG
PY314,classified_as,OTHER
PY314,targets,renal cell carcinoma
PY314,targets,lung adenocarcinoma
PY314,targets,breast cancer
PY314,targets,advanced solid tumor
PY314,targets,ovarian cancer
PY314,targets,hormone receptor/growth factor receptor-negative breast cancer
PY314,targets,triple negative breast cancer
PY314,targets,gynecologic cancer
PY314,targets,colorectal cancer
PY314,targets,TNBC
NCT04691375,tests,Combination Therapy: PY314 + Pembrolizumab
Combination Therapy: PY314 + Pembrolizumab,has_type,DRUG
Combination Therapy: PY314 + Pembrolizumab,classified_as,BIOLOGIC
Combination Therapy: PY314 + Pembrolizumab,targets,renal cell carcinoma
Combination Therapy: PY314 + Pembrolizumab,targets,lung adenocarcinoma
Combination Therapy: PY314 + Pembrolizumab,targets,breast cancer
Combination Therapy: PY314 + Pembrolizumab,targets,advanced solid tumor
Combination Therapy: PY314 + Pembrolizumab,targets,ovarian cancer
Combination Therapy: PY314 + Pembrolizumab,targets,hormone receptor/growth factor receptor-negative breast cancer
Combination Therapy: PY314 + Pembrolizumab,targets,triple negative breast cancer
Combination Therapy: PY314 + Pembrolizumab,targets,gynecologic cancer
Combination Therapy: PY314 + Pembrolizumab,targets,colorectal cancer
Combination Therapy: PY314 + Pembrolizumab,targets,TNBC
NCT00601159,sponsored_by,Fudan University
NCT00601159,has_status,COMPLETED
NCT00601159,tests,gemcitabine and cisplatin
gemcitabine and cisplatin,has_type,DRUG
gemcitabine and cisplatin,classified_as,CHEMICAL
gemcitabine and cisplatin,targets,metastatic breast cancer
NCT02685059,sponsored_by,GBG Forschungs GmbH
NCT02685059,has_status,COMPLETED
NCT02685059,tests,MEDI4736 (Anti PD-L1)
MEDI4736 (Anti PD-L1),has_type,DRUG
MEDI4736 (Anti PD-L1),classified_as,OTHER
MEDI4736 (Anti PD-L1),targets,breast cancer
NCT02685059,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,breast cancer
NCT02685059,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
nab-Paclitaxel,classified_as,CHEMICAL
nab-Paclitaxel,targets,breast cancer
NCT02685059,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,breast cancer
NCT02685059,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
NCT05082259,sponsored_by,"Institute of Cancer Research, United Kingdom"
NCT05082259,has_status,RECRUITING
NCT05082259,tests,ASTX660
ASTX660,has_type,DRUG
ASTX660,classified_as,OTHER
ASTX660,targets,cervical cancer
ASTX660,targets,advanced cancer
ASTX660,targets,triple negative breast cancer
ASTX660,targets,TNBC
NCT05082259,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,cervical cancer
Pembrolizumab,targets,advanced cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT06492759,sponsored_by,Emory University
NCT06492759,has_status,NOT_YET_RECRUITING
NCT06492759,tests,Radiation Therapy
Radiation Therapy,has_type,DRUG
Radiation Therapy,classified_as,OTHER
Radiation Therapy,targets,metastatic triple-negative breast carcinoma
Radiation Therapy,targets,anatomic stage iv breast cancer ajcc v8
Radiation Therapy,targets,TNBC
NCT06492759,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iv breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT06492759,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,metastatic triple-negative breast carcinoma
Nab-paclitaxel,targets,anatomic stage iv breast cancer ajcc v8
Nab-paclitaxel,targets,TNBC
NCT06492759,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,metastatic triple-negative breast carcinoma
Paclitaxel,targets,anatomic stage iv breast cancer ajcc v8
Paclitaxel,targets,TNBC
NCT06492759,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,metastatic triple-negative breast carcinoma
Carboplatin,targets,anatomic stage iv breast cancer ajcc v8
Carboplatin,targets,TNBC
NCT06492759,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,metastatic triple-negative breast carcinoma
Gemcitabine,targets,anatomic stage iv breast cancer ajcc v8
Gemcitabine,targets,TNBC
NCT06492759,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,metastatic triple-negative breast carcinoma
Biopsy,targets,anatomic stage iv breast cancer ajcc v8
Biopsy,targets,TNBC
NCT06492759,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,TNBC
NCT06492759,tests,Bone Scan
Bone Scan,has_type,DRUG
Bone Scan,classified_as,OTHER
Bone Scan,targets,metastatic triple-negative breast carcinoma
Bone Scan,targets,anatomic stage iv breast cancer ajcc v8
Bone Scan,targets,TNBC
NCT06492759,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iv breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT06492759,tests,Medical Chart Review
Medical Chart Review,has_type,DRUG
Medical Chart Review,classified_as,OTHER
Medical Chart Review,targets,metastatic triple-negative breast carcinoma
Medical Chart Review,targets,anatomic stage iv breast cancer ajcc v8
Medical Chart Review,targets,TNBC
NCT06793332,sponsored_by,Fudan University
NCT06793332,has_status,RECRUITING
NCT06793332,tests,Ivonescimab Combined With TROP2 ADC
Ivonescimab Combined With TROP2 ADC,has_type,DRUG
Ivonescimab Combined With TROP2 ADC,classified_as,BIOLOGIC
Ivonescimab Combined With TROP2 ADC,targets,triple-negative breast cancer (tnbc)
Ivonescimab Combined With TROP2 ADC,targets,brain metastases
Ivonescimab Combined With TROP2 ADC,targets,TNBC
NCT01155453,sponsored_by,Novartis Pharmaceuticals
NCT01155453,has_status,COMPLETED
NCT01155453,tests,BKM120
BKM120,has_type,DRUG
BKM120,classified_as,OTHER
BKM120,targets,advanced and selected solid tumors
NCT01155453,tests,GSK1120212
GSK1120212,has_type,DRUG
GSK1120212,classified_as,OTHER
GSK1120212,targets,advanced and selected solid tumors
NCT05253053,sponsored_by,"TransThera Sciences (Nanjing), Inc."
NCT05253053,has_status,COMPLETED
NCT05253053,tests,TT-00420
TT-00420,has_type,DRUG
TT-00420,classified_as,OTHER
TT-00420,targets,gastric cancer
TT-00420,targets,biliary tract cancer
TT-00420,targets,thyroid cancer
TT-00420,targets,her2-negative breast cancer
TT-00420,targets,advanced solid tumor
TT-00420,targets,prostate cancer
TT-00420,targets,triple negative breast cancer
TT-00420,targets,bladder cancer
TT-00420,targets,small-cell lung cancer
TT-00420,targets,cholangiocarcinoma
TT-00420,targets,gallbladder cancer
TT-00420,targets,TNBC
NCT05253053,tests,Combination Product: Atezolizumab
Combination Product: Atezolizumab,has_type,DRUG
Combination Product: Atezolizumab,classified_as,BIOLOGIC
Combination Product: Atezolizumab,targets,gastric cancer
Combination Product: Atezolizumab,targets,biliary tract cancer
Combination Product: Atezolizumab,targets,thyroid cancer
Combination Product: Atezolizumab,targets,her2-negative breast cancer
Combination Product: Atezolizumab,targets,advanced solid tumor
Combination Product: Atezolizumab,targets,prostate cancer
Combination Product: Atezolizumab,targets,triple negative breast cancer
Combination Product: Atezolizumab,targets,bladder cancer
Combination Product: Atezolizumab,targets,small-cell lung cancer
Combination Product: Atezolizumab,targets,cholangiocarcinoma
Combination Product: Atezolizumab,targets,gallbladder cancer
Combination Product: Atezolizumab,targets,TNBC
NCT05253053,tests,Combination Product: Nab-Paclitaxel
Combination Product: Nab-Paclitaxel,has_type,DRUG
Combination Product: Nab-Paclitaxel,classified_as,CHEMICAL
Combination Product: Nab-Paclitaxel,targets,gastric cancer
Combination Product: Nab-Paclitaxel,targets,biliary tract cancer
Combination Product: Nab-Paclitaxel,targets,thyroid cancer
Combination Product: Nab-Paclitaxel,targets,her2-negative breast cancer
Combination Product: Nab-Paclitaxel,targets,advanced solid tumor
Combination Product: Nab-Paclitaxel,targets,prostate cancer
Combination Product: Nab-Paclitaxel,targets,triple negative breast cancer
Combination Product: Nab-Paclitaxel,targets,bladder cancer
Combination Product: Nab-Paclitaxel,targets,small-cell lung cancer
Combination Product: Nab-Paclitaxel,targets,cholangiocarcinoma
Combination Product: Nab-Paclitaxel,targets,gallbladder cancer
Combination Product: Nab-Paclitaxel,targets,TNBC
NCT01111175,sponsored_by,US Oncology Research
NCT01111175,has_status,COMPLETED
NCT04836156,sponsored_by,Peking University People's Hospital
NCT04836156,has_status,RECRUITING
NCT04836156,tests,neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer,has_type,DRUG
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer,classified_as,OTHER
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer,targets,her2-negative early breast cancer
NCT04836156,tests,neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer,has_type,DRUG
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer,classified_as,OTHER
neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer,targets,her2-negative early breast cancer
NCT06955156,sponsored_by,QIAO LI
NCT06955156,has_status,RECRUITING
NCT06955156,tests,Trilaciclib
Trilaciclib,has_type,DRUG
Trilaciclib,classified_as,CHEMICAL
Trilaciclib,targets,triple negative breast cancer
Trilaciclib,targets,TNBC
NCT04913571,sponsored_by,Fudan University
NCT04913571,has_status,UNKNOWN
NCT04913571,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,triple negative breast cancer
Eribulin,targets,TNBC
NCT04913571,tests,Tislelizumab
Tislelizumab,has_type,DRUG
Tislelizumab,classified_as,BIOLOGIC
Tislelizumab,targets,triple negative breast cancer
Tislelizumab,targets,TNBC
NCT04771871,sponsored_by,"University College Hospital, Ibadan"
NCT04771871,has_status,UNKNOWN
NCT04771871,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,triple negative breast cancer
Epirubicin,targets,TNBC
NCT04771871,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT04771871,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT04771871,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT06894771,sponsored_by,Merck Sharp & Dohme LLC
NCT06894771,has_status,RECRUITING
NCT06894771,tests,MK-4700
MK-4700,has_type,DRUG
MK-4700,classified_as,OTHER
MK-4700,targets,malignant neoplasm
NCT06894771,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,malignant neoplasm
NCT03519178,sponsored_by,Pfizer
NCT03519178,has_status,TERMINATED
NCT03519178,tests,PF-06873600
PF-06873600,has_type,DRUG
PF-06873600,classified_as,OTHER
PF-06873600,targets,"hr+ her2- metastatic breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, triple negative breast cancer, male breast cancer"
PF-06873600,targets,TNBC
NCT03519178,tests,Endocrine Therapy 1
Endocrine Therapy 1,has_type,DRUG
Endocrine Therapy 1,classified_as,OTHER
Endocrine Therapy 1,targets,"hr+ her2- metastatic breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, triple negative breast cancer, male breast cancer"
Endocrine Therapy 1,targets,TNBC
NCT03519178,tests,Endocrine Therapy 2
Endocrine Therapy 2,has_type,DRUG
Endocrine Therapy 2,classified_as,OTHER
Endocrine Therapy 2,targets,"hr+ her2- metastatic breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, triple negative breast cancer, male breast cancer"
Endocrine Therapy 2,targets,TNBC
NCT03740893,sponsored_by,"Institute of Cancer Research, United Kingdom"
NCT03740893,has_status,RECRUITING
NCT03740893,tests,AZD6738
AZD6738,has_type,DRUG
AZD6738,classified_as,OTHER
AZD6738,targets,breast neoplasm
NCT03740893,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,breast neoplasm
NCT03740893,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,breast neoplasm
NCT02014337,sponsored_by,Corcept Therapeutics
NCT02014337,has_status,COMPLETED
NCT02014337,tests,Mifepristone and Eribulin in combination
Mifepristone and Eribulin in combination,has_type,DRUG
Mifepristone and Eribulin in combination,classified_as,CHEMICAL
Mifepristone and Eribulin in combination,targets,non-small cell lung cancer
Mifepristone and Eribulin in combination,targets,breast cancer
Mifepristone and Eribulin in combination,targets,"carcinoma, transitional cell"
Mifepristone and Eribulin in combination,targets,prostate cancer
Mifepristone and Eribulin in combination,targets,sarcoma
Mifepristone and Eribulin in combination,targets,ovarian epithelial cancer recurrent
Mifepristone and Eribulin in combination,targets,prostatic neoplasms
NCT06959537,sponsored_by,M.D. Anderson Cancer Center
NCT06959537,has_status,NOT_YET_RECRUITING
NCT06959537,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
NCT06959537,tests,Axatilimab (SNDX-6352)
Axatilimab (SNDX-6352),has_type,DRUG
Axatilimab (SNDX-6352),classified_as,BIOLOGIC
Axatilimab (SNDX-6352),targets,breast cancer
NCT06959537,tests,Retifanlimab
Retifanlimab,has_type,DRUG
Retifanlimab,classified_as,BIOLOGIC
Retifanlimab,targets,breast cancer
NCT04609215,sponsored_by,Henrik Ditzel
NCT04609215,has_status,UNKNOWN
NCT04609215,tests,ALECSAT
ALECSAT,has_type,DRUG
ALECSAT,classified_as,OTHER
ALECSAT,targets,breast cancer
ALECSAT,targets,metastatic breast cancer
ALECSAT,targets,triple negative breast cancer
ALECSAT,targets,TNBC
NCT06829199,sponsored_by,Merck Sharp & Dohme LLC
NCT06829199,has_status,WITHDRAWN
NCT06829199,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,early triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT06829199,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,early triple negative breast cancer
Paclitaxel,targets,TNBC
NCT06829199,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,early triple negative breast cancer
Carboplatin,targets,TNBC
NCT06829199,tests,Doxorubicin (hydrochloride)
Doxorubicin (hydrochloride),has_type,DRUG
Doxorubicin (hydrochloride),classified_as,CHEMICAL
Doxorubicin (hydrochloride),targets,early triple negative breast cancer
Doxorubicin (hydrochloride),targets,TNBC
NCT06829199,tests,Boserolimab
Boserolimab,has_type,DRUG
Boserolimab,classified_as,BIOLOGIC
Boserolimab,targets,early triple negative breast cancer
Boserolimab,targets,TNBC
NCT06829199,tests,Epirubicin Hydrochloride
Epirubicin Hydrochloride,has_type,DRUG
Epirubicin Hydrochloride,classified_as,OTHER
Epirubicin Hydrochloride,targets,early triple negative breast cancer
Epirubicin Hydrochloride,targets,TNBC
NCT06829199,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,early triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT06829199,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,early triple negative breast cancer
Capecitabine,targets,TNBC
NCT06829199,tests,Olaparib (if approved/available locally)
Olaparib (if approved/available locally),has_type,DRUG
Olaparib (if approved/available locally),classified_as,BIOLOGIC
Olaparib (if approved/available locally),targets,early triple negative breast cancer
Olaparib (if approved/available locally),targets,TNBC
NCT05582499,sponsored_by,Fudan University
NCT05582499,has_status,RECRUITING
NCT05582499,tests,Dalpiciclib
Dalpiciclib,has_type,DRUG
Dalpiciclib,classified_as,CHEMICAL
Dalpiciclib,targets,breast neoplasm
Dalpiciclib,targets,hormone receptor positive tumor
Dalpiciclib,targets,breast cancer
Dalpiciclib,targets,her2-negative breast cancer
Dalpiciclib,targets,early-stage breast cancer
Dalpiciclib,targets,hormone receptor negative tumor
Dalpiciclib,targets,breast tumors
Dalpiciclib,targets,her2-positive breast cancer
Dalpiciclib,targets,triple-negative breast cancer (tnbc)
Dalpiciclib,targets,locally advanced breast cancer
Dalpiciclib,targets,TNBC
NCT05582499,tests,Pyrotinib
Pyrotinib,has_type,DRUG
Pyrotinib,classified_as,CHEMICAL
Pyrotinib,targets,breast neoplasm
Pyrotinib,targets,hormone receptor positive tumor
Pyrotinib,targets,breast cancer
Pyrotinib,targets,her2-negative breast cancer
Pyrotinib,targets,early-stage breast cancer
Pyrotinib,targets,hormone receptor negative tumor
Pyrotinib,targets,breast tumors
Pyrotinib,targets,her2-positive breast cancer
Pyrotinib,targets,triple-negative breast cancer (tnbc)
Pyrotinib,targets,locally advanced breast cancer
Pyrotinib,targets,TNBC
NCT05582499,tests,SHR-A1811
SHR-A1811,has_type,DRUG
SHR-A1811,classified_as,OTHER
SHR-A1811,targets,breast neoplasm
SHR-A1811,targets,hormone receptor positive tumor
SHR-A1811,targets,breast cancer
SHR-A1811,targets,her2-negative breast cancer
SHR-A1811,targets,early-stage breast cancer
SHR-A1811,targets,hormone receptor negative tumor
SHR-A1811,targets,breast tumors
SHR-A1811,targets,her2-positive breast cancer
SHR-A1811,targets,triple-negative breast cancer (tnbc)
SHR-A1811,targets,locally advanced breast cancer
SHR-A1811,targets,TNBC
NCT05582499,tests,SHR-1316
SHR-1316,has_type,DRUG
SHR-1316,classified_as,OTHER
SHR-1316,targets,breast neoplasm
SHR-1316,targets,hormone receptor positive tumor
SHR-1316,targets,breast cancer
SHR-1316,targets,her2-negative breast cancer
SHR-1316,targets,early-stage breast cancer
SHR-1316,targets,hormone receptor negative tumor
SHR-1316,targets,breast tumors
SHR-1316,targets,her2-positive breast cancer
SHR-1316,targets,triple-negative breast cancer (tnbc)
SHR-1316,targets,locally advanced breast cancer
SHR-1316,targets,TNBC
NCT05582499,tests,Camrelizumab
Camrelizumab,has_type,DRUG
Camrelizumab,classified_as,BIOLOGIC
Camrelizumab,targets,breast neoplasm
Camrelizumab,targets,hormone receptor positive tumor
Camrelizumab,targets,breast cancer
Camrelizumab,targets,her2-negative breast cancer
Camrelizumab,targets,early-stage breast cancer
Camrelizumab,targets,hormone receptor negative tumor
Camrelizumab,targets,breast tumors
Camrelizumab,targets,her2-positive breast cancer
Camrelizumab,targets,triple-negative breast cancer (tnbc)
Camrelizumab,targets,locally advanced breast cancer
Camrelizumab,targets,TNBC
NCT05582499,tests,SHR-A1921
SHR-A1921,has_type,DRUG
SHR-A1921,classified_as,OTHER
SHR-A1921,targets,breast neoplasm
SHR-A1921,targets,hormone receptor positive tumor
SHR-A1921,targets,breast cancer
SHR-A1921,targets,her2-negative breast cancer
SHR-A1921,targets,early-stage breast cancer
SHR-A1921,targets,hormone receptor negative tumor
SHR-A1921,targets,breast tumors
SHR-A1921,targets,her2-positive breast cancer
SHR-A1921,targets,triple-negative breast cancer (tnbc)
SHR-A1921,targets,locally advanced breast cancer
SHR-A1921,targets,TNBC
NCT05582499,tests,Pertuzumab
Pertuzumab,has_type,DRUG
Pertuzumab,classified_as,BIOLOGIC
Pertuzumab,targets,breast neoplasm
Pertuzumab,targets,hormone receptor positive tumor
Pertuzumab,targets,breast cancer
Pertuzumab,targets,her2-negative breast cancer
Pertuzumab,targets,early-stage breast cancer
Pertuzumab,targets,hormone receptor negative tumor
Pertuzumab,targets,breast tumors
Pertuzumab,targets,her2-positive breast cancer
Pertuzumab,targets,triple-negative breast cancer (tnbc)
Pertuzumab,targets,locally advanced breast cancer
Pertuzumab,targets,TNBC
NCT05582499,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,breast neoplasm
Trastuzumab,targets,hormone receptor positive tumor
Trastuzumab,targets,breast cancer
Trastuzumab,targets,her2-negative breast cancer
Trastuzumab,targets,early-stage breast cancer
Trastuzumab,targets,hormone receptor negative tumor
Trastuzumab,targets,breast tumors
Trastuzumab,targets,her2-positive breast cancer
Trastuzumab,targets,triple-negative breast cancer (tnbc)
Trastuzumab,targets,locally advanced breast cancer
Trastuzumab,targets,TNBC
NCT05582499,tests,Goserelin
Goserelin,has_type,DRUG
Goserelin,classified_as,OTHER
Goserelin,targets,breast neoplasm
Goserelin,targets,hormone receptor positive tumor
Goserelin,targets,breast cancer
Goserelin,targets,her2-negative breast cancer
Goserelin,targets,early-stage breast cancer
Goserelin,targets,hormone receptor negative tumor
Goserelin,targets,breast tumors
Goserelin,targets,her2-positive breast cancer
Goserelin,targets,triple-negative breast cancer (tnbc)
Goserelin,targets,locally advanced breast cancer
Goserelin,targets,TNBC
NCT05582499,tests,Letrozole
Letrozole,has_type,DRUG
Letrozole,classified_as,CHEMICAL
Letrozole,targets,breast neoplasm
Letrozole,targets,hormone receptor positive tumor
Letrozole,targets,breast cancer
Letrozole,targets,her2-negative breast cancer
Letrozole,targets,early-stage breast cancer
Letrozole,targets,hormone receptor negative tumor
Letrozole,targets,breast tumors
Letrozole,targets,her2-positive breast cancer
Letrozole,targets,triple-negative breast cancer (tnbc)
Letrozole,targets,locally advanced breast cancer
Letrozole,targets,TNBC
NCT05582499,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
Nab paclitaxel,classified_as,CHEMICAL
Nab paclitaxel,targets,breast neoplasm
Nab paclitaxel,targets,hormone receptor positive tumor
Nab paclitaxel,targets,breast cancer
Nab paclitaxel,targets,her2-negative breast cancer
Nab paclitaxel,targets,early-stage breast cancer
Nab paclitaxel,targets,hormone receptor negative tumor
Nab paclitaxel,targets,breast tumors
Nab paclitaxel,targets,her2-positive breast cancer
Nab paclitaxel,targets,triple-negative breast cancer (tnbc)
Nab paclitaxel,targets,locally advanced breast cancer
Nab paclitaxel,targets,TNBC
NCT05582499,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast neoplasm
Carboplatin,targets,hormone receptor positive tumor
Carboplatin,targets,breast cancer
Carboplatin,targets,her2-negative breast cancer
Carboplatin,targets,early-stage breast cancer
Carboplatin,targets,hormone receptor negative tumor
Carboplatin,targets,breast tumors
Carboplatin,targets,her2-positive breast cancer
Carboplatin,targets,triple-negative breast cancer (tnbc)
Carboplatin,targets,locally advanced breast cancer
Carboplatin,targets,TNBC
NCT05582499,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,breast neoplasm
Epirubicin,targets,hormone receptor positive tumor
Epirubicin,targets,breast cancer
Epirubicin,targets,her2-negative breast cancer
Epirubicin,targets,early-stage breast cancer
Epirubicin,targets,hormone receptor negative tumor
Epirubicin,targets,breast tumors
Epirubicin,targets,her2-positive breast cancer
Epirubicin,targets,triple-negative breast cancer (tnbc)
Epirubicin,targets,locally advanced breast cancer
Epirubicin,targets,TNBC
NCT05582499,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast neoplasm
Cyclophosphamide,targets,hormone receptor positive tumor
Cyclophosphamide,targets,breast cancer
Cyclophosphamide,targets,her2-negative breast cancer
Cyclophosphamide,targets,early-stage breast cancer
Cyclophosphamide,targets,hormone receptor negative tumor
Cyclophosphamide,targets,breast tumors
Cyclophosphamide,targets,her2-positive breast cancer
Cyclophosphamide,targets,triple-negative breast cancer (tnbc)
Cyclophosphamide,targets,locally advanced breast cancer
Cyclophosphamide,targets,TNBC
NCT05582499,tests,Fluzoparib
Fluzoparib,has_type,DRUG
Fluzoparib,classified_as,CHEMICAL
Fluzoparib,targets,breast neoplasm
Fluzoparib,targets,hormone receptor positive tumor
Fluzoparib,targets,breast cancer
Fluzoparib,targets,her2-negative breast cancer
Fluzoparib,targets,early-stage breast cancer
Fluzoparib,targets,hormone receptor negative tumor
Fluzoparib,targets,breast tumors
Fluzoparib,targets,her2-positive breast cancer
Fluzoparib,targets,triple-negative breast cancer (tnbc)
Fluzoparib,targets,locally advanced breast cancer
Fluzoparib,targets,TNBC
NCT05582499,tests,Apatinib
Apatinib,has_type,DRUG
Apatinib,classified_as,CHEMICAL
Apatinib,targets,breast neoplasm
Apatinib,targets,hormone receptor positive tumor
Apatinib,targets,breast cancer
Apatinib,targets,her2-negative breast cancer
Apatinib,targets,early-stage breast cancer
Apatinib,targets,hormone receptor negative tumor
Apatinib,targets,breast tumors
Apatinib,targets,her2-positive breast cancer
Apatinib,targets,triple-negative breast cancer (tnbc)
Apatinib,targets,locally advanced breast cancer
Apatinib,targets,TNBC
NCT05582499,tests,Famitinib
Famitinib,has_type,DRUG
Famitinib,classified_as,CHEMICAL
Famitinib,targets,breast neoplasm
Famitinib,targets,hormone receptor positive tumor
Famitinib,targets,breast cancer
Famitinib,targets,her2-negative breast cancer
Famitinib,targets,early-stage breast cancer
Famitinib,targets,hormone receptor negative tumor
Famitinib,targets,breast tumors
Famitinib,targets,her2-positive breast cancer
Famitinib,targets,triple-negative breast cancer (tnbc)
Famitinib,targets,locally advanced breast cancer
Famitinib,targets,TNBC
NCT06270706,sponsored_by,"Pliant Therapeutics, Inc."
NCT06270706,has_status,RECRUITING
NCT06270706,tests,PLN-101095
PLN-101095,has_type,DRUG
PLN-101095,classified_as,OTHER
PLN-101095,targets,metastatic solid tumor
NCT06270706,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic solid tumor
NCT04879849,sponsored_by,Takeda
NCT04879849,has_status,COMPLETED
NCT04879849,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,"carcinoma, non-small-cell lung"
Pembrolizumab,targets,squamous cell carcinoma of head and neck
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,TNBC
NCT04879849,tests,TAK-676
TAK-676,has_type,DRUG
TAK-676,classified_as,OTHER
TAK-676,targets,"carcinoma, non-small-cell lung"
TAK-676,targets,squamous cell carcinoma of head and neck
TAK-676,targets,triple negative breast neoplasms
TAK-676,targets,TNBC
NCT04879849,tests,Image-guided radiation therapy
Image-guided radiation therapy,has_type,DRUG
Image-guided radiation therapy,classified_as,OTHER
Image-guided radiation therapy,targets,"carcinoma, non-small-cell lung"
Image-guided radiation therapy,targets,squamous cell carcinoma of head and neck
Image-guided radiation therapy,targets,triple negative breast neoplasms
Image-guided radiation therapy,targets,TNBC
NCT06182306,sponsored_by,"Ourotech, Inc."
NCT06182306,has_status,RECRUITING
NCT06182306,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,breast cancer
Biopsy,targets,triple negative breast cancer
Biopsy,targets,TNBC
NCT03805399,sponsored_by,Fudan University
NCT03805399,has_status,UNKNOWN
NCT03805399,tests,Pyrotinib with Capecitabine
Pyrotinib with Capecitabine,has_type,DRUG
Pyrotinib with Capecitabine,classified_as,CHEMICAL
Pyrotinib with Capecitabine,targets,triple-negative breast cancer
Pyrotinib with Capecitabine,targets,TNBC
NCT03805399,tests,"AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)"
"AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)",has_type,DRUG
"AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)",classified_as,CHEMICAL
"AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)",targets,triple-negative breast cancer
"AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)",targets,TNBC
NCT03805399,tests,anti PD-1 with nab-paclitaxel
anti PD-1 with nab-paclitaxel,has_type,DRUG
anti PD-1 with nab-paclitaxel,classified_as,BIOLOGIC
anti PD-1 with nab-paclitaxel,targets,triple-negative breast cancer
anti PD-1 with nab-paclitaxel,targets,TNBC
NCT03805399,tests,PARP inhibitor included therapy
PARP inhibitor included therapy,has_type,DRUG
PARP inhibitor included therapy,classified_as,BIOLOGIC
PARP inhibitor included therapy,targets,triple-negative breast cancer
PARP inhibitor included therapy,targets,TNBC
NCT03805399,tests,BLIS with anti-VEGFR included therapy
BLIS with anti-VEGFR included therapy,has_type,DRUG
BLIS with anti-VEGFR included therapy,classified_as,OTHER
BLIS with anti-VEGFR included therapy,targets,triple-negative breast cancer
BLIS with anti-VEGFR included therapy,targets,TNBC
NCT03805399,tests,MES with anti-VEGFR included therapy
MES with anti-VEGFR included therapy,has_type,DRUG
MES with anti-VEGFR included therapy,classified_as,OTHER
MES with anti-VEGFR included therapy,targets,triple-negative breast cancer
MES with anti-VEGFR included therapy,targets,TNBC
NCT03805399,tests,mTOR inhibitor with nab-paclitaxel
mTOR inhibitor with nab-paclitaxel,has_type,DRUG
mTOR inhibitor with nab-paclitaxel,classified_as,CHEMICAL
mTOR inhibitor with nab-paclitaxel,targets,triple-negative breast cancer
mTOR inhibitor with nab-paclitaxel,targets,TNBC
NCT01623349,sponsored_by,Dana-Farber Cancer Institute
NCT01623349,has_status,COMPLETED
NCT01623349,tests,BKM120 and Olaparib
BKM120 and Olaparib,has_type,DRUG
BKM120 and Olaparib,classified_as,BIOLOGIC
BKM120 and Olaparib,targets,breast cancer
BKM120 and Olaparib,targets,ovarian cancer
NCT01623349,tests,BYL719 and Olaparib
BYL719 and Olaparib,has_type,DRUG
BYL719 and Olaparib,classified_as,BIOLOGIC
BYL719 and Olaparib,targets,breast cancer
BYL719 and Olaparib,targets,ovarian cancer
NCT07016399,sponsored_by,Vandana Abramson
NCT07016399,has_status,NOT_YET_RECRUITING
NCT07016399,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,anatomic stage ii breast cancer ajcc v8
Biospecimen Collection,targets,triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iiia breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT07016399,tests,Breast Biopsy Procedure
Breast Biopsy Procedure,has_type,DRUG
Breast Biopsy Procedure,classified_as,OTHER
Breast Biopsy Procedure,targets,anatomic stage ii breast cancer ajcc v8
Breast Biopsy Procedure,targets,triple-negative breast carcinoma
Breast Biopsy Procedure,targets,anatomic stage iiia breast cancer ajcc v8
Breast Biopsy Procedure,targets,TNBC
NCT07016399,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,anatomic stage ii breast cancer ajcc v8
Carboplatin,targets,triple-negative breast carcinoma
Carboplatin,targets,anatomic stage iiia breast cancer ajcc v8
Carboplatin,targets,TNBC
NCT07016399,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,anatomic stage ii breast cancer ajcc v8
Cyclophosphamide,targets,triple-negative breast carcinoma
Cyclophosphamide,targets,anatomic stage iiia breast cancer ajcc v8
Cyclophosphamide,targets,TNBC
NCT07016399,tests,Darolutamide
Darolutamide,has_type,DRUG
Darolutamide,classified_as,OTHER
Darolutamide,targets,anatomic stage ii breast cancer ajcc v8
Darolutamide,targets,triple-negative breast carcinoma
Darolutamide,targets,anatomic stage iiia breast cancer ajcc v8
Darolutamide,targets,TNBC
NCT07016399,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,anatomic stage ii breast cancer ajcc v8
Doxorubicin,targets,triple-negative breast carcinoma
Doxorubicin,targets,anatomic stage iiia breast cancer ajcc v8
Doxorubicin,targets,TNBC
NCT07016399,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,anatomic stage ii breast cancer ajcc v8
Epirubicin,targets,triple-negative breast carcinoma
Epirubicin,targets,anatomic stage iiia breast cancer ajcc v8
Epirubicin,targets,TNBC
NCT07016399,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,anatomic stage ii breast cancer ajcc v8
Magnetic Resonance Imaging,targets,triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iiia breast cancer ajcc v8
Magnetic Resonance Imaging,targets,TNBC
NCT07016399,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,anatomic stage ii breast cancer ajcc v8
Paclitaxel,targets,triple-negative breast carcinoma
Paclitaxel,targets,anatomic stage iiia breast cancer ajcc v8
Paclitaxel,targets,TNBC
NCT07016399,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,anatomic stage ii breast cancer ajcc v8
Pembrolizumab,targets,triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage iiia breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT07016399,tests,Surgical Procedure
Surgical Procedure,has_type,DRUG
Surgical Procedure,classified_as,OTHER
Surgical Procedure,targets,anatomic stage ii breast cancer ajcc v8
Surgical Procedure,targets,triple-negative breast carcinoma
Surgical Procedure,targets,anatomic stage iiia breast cancer ajcc v8
Surgical Procedure,targets,TNBC
NCT07016399,tests,Ultrasound Imaging
Ultrasound Imaging,has_type,DRUG
Ultrasound Imaging,classified_as,OTHER
Ultrasound Imaging,targets,anatomic stage ii breast cancer ajcc v8
Ultrasound Imaging,targets,triple-negative breast carcinoma
Ultrasound Imaging,targets,anatomic stage iiia breast cancer ajcc v8
Ultrasound Imaging,targets,TNBC
NCT04954599,sponsored_by,Maastricht University Medical Center
NCT04954599,has_status,RECRUITING
NCT04954599,tests,CP-506
CP-506,has_type,DRUG
CP-506,classified_as,OTHER
CP-506,targets,"unspecified adult solid tumor, protocol specific"
NCT04954599,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,"unspecified adult solid tumor, protocol specific"
NCT04954599,tests,Immune checkpoint inhibitor
Immune checkpoint inhibitor,has_type,DRUG
Immune checkpoint inhibitor,classified_as,BIOLOGIC
Immune checkpoint inhibitor,targets,"unspecified adult solid tumor, protocol specific"
NCT05438706,sponsored_by,Fudan University
NCT05438706,has_status,UNKNOWN
NCT05438706,tests,chidamide
chidamide,has_type,DRUG
chidamide,classified_as,OTHER
chidamide,targets,triple-negative breast cancer
chidamide,targets,TNBC
NCT05438706,tests,camrelizumab
camrelizumab,has_type,DRUG
camrelizumab,classified_as,BIOLOGIC
camrelizumab,targets,triple-negative breast cancer
camrelizumab,targets,TNBC
NCT05438706,tests,carboplatin
carboplatin,has_type,DRUG
carboplatin,classified_as,CHEMICAL
carboplatin,targets,triple-negative breast cancer
carboplatin,targets,TNBC
NCT05438706,tests,capecitabine
capecitabine,has_type,DRUG
capecitabine,classified_as,CHEMICAL
capecitabine,targets,triple-negative breast cancer
capecitabine,targets,TNBC
NCT06150885,sponsored_by,"Ever Supreme Bio Technology Co., Ltd."
NCT06150885,has_status,RECRUITING
NCT06150885,tests,HLA-G-CAR.BiTE allogeneic γδ T cells
HLA-G-CAR.BiTE allogeneic γδ T cells,has_type,DRUG
HLA-G-CAR.BiTE allogeneic γδ T cells,classified_as,OTHER
HLA-G-CAR.BiTE allogeneic γδ T cells,targets,solid tumor
NCT01138085,sponsored_by,GlaxoSmithKline
NCT01138085,has_status,COMPLETED
NCT01138085,tests,GSK1120212
GSK1120212,has_type,DRUG
GSK1120212,classified_as,OTHER
GSK1120212,targets,cancer
NCT01138085,tests,GSK2141795
GSK2141795,has_type,DRUG
GSK2141795,classified_as,OTHER
GSK2141795,targets,cancer
NCT05629585,sponsored_by,AstraZeneca
NCT05629585,has_status,ACTIVE_NOT_RECRUITING
NCT05629585,tests,Dato-DXd
Dato-DXd,has_type,DRUG
Dato-DXd,classified_as,OTHER
Dato-DXd,targets,breast cancer
NCT05629585,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,breast cancer
NCT05629585,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
NCT05629585,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT01884285,sponsored_by,AstraZeneca
NCT01884285,has_status,COMPLETED
NCT01884285,tests,Part A: AZD8186 monotherapy
Part A: AZD8186 monotherapy,has_type,DRUG
Part A: AZD8186 monotherapy,classified_as,OTHER
Part A: AZD8186 monotherapy,targets,squamous non-small cell lung cancer sqnsclc
Part A: AZD8186 monotherapy,targets,advanced castrate-resistant prostate cancer crpc
Part A: AZD8186 monotherapy,targets,triple negative breast cancer tnbc
Part A: AZD8186 monotherapy,targets,TNBC
NCT01884285,tests,Part B: AZD8186 monotherapy
Part B: AZD8186 monotherapy,has_type,DRUG
Part B: AZD8186 monotherapy,classified_as,OTHER
Part B: AZD8186 monotherapy,targets,squamous non-small cell lung cancer sqnsclc
Part B: AZD8186 monotherapy,targets,advanced castrate-resistant prostate cancer crpc
Part B: AZD8186 monotherapy,targets,triple negative breast cancer tnbc
Part B: AZD8186 monotherapy,targets,TNBC
NCT01884285,tests,Part C1: Abiraterone acetate combination with AZD8186
Part C1: Abiraterone acetate combination with AZD8186,has_type,DRUG
Part C1: Abiraterone acetate combination with AZD8186,classified_as,OTHER
Part C1: Abiraterone acetate combination with AZD8186,targets,squamous non-small cell lung cancer sqnsclc
Part C1: Abiraterone acetate combination with AZD8186,targets,advanced castrate-resistant prostate cancer crpc
Part C1: Abiraterone acetate combination with AZD8186,targets,triple negative breast cancer tnbc
Part C1: Abiraterone acetate combination with AZD8186,targets,TNBC
NCT01884285,tests,Part D1: AZD2014 combination with AZD8186
Part D1: AZD2014 combination with AZD8186,has_type,DRUG
Part D1: AZD2014 combination with AZD8186,classified_as,OTHER
Part D1: AZD2014 combination with AZD8186,targets,squamous non-small cell lung cancer sqnsclc
Part D1: AZD2014 combination with AZD8186,targets,advanced castrate-resistant prostate cancer crpc
Part D1: AZD2014 combination with AZD8186,targets,triple negative breast cancer tnbc
Part D1: AZD2014 combination with AZD8186,targets,TNBC
NCT01884285,tests,Part D2 AZD2014 combination with AZD8186
Part D2 AZD2014 combination with AZD8186,has_type,DRUG
Part D2 AZD2014 combination with AZD8186,classified_as,OTHER
Part D2 AZD2014 combination with AZD8186,targets,squamous non-small cell lung cancer sqnsclc
Part D2 AZD2014 combination with AZD8186,targets,advanced castrate-resistant prostate cancer crpc
Part D2 AZD2014 combination with AZD8186,targets,triple negative breast cancer tnbc
Part D2 AZD2014 combination with AZD8186,targets,TNBC
NCT01884285,tests,Part C2: Abiraterone acetate combination with AZD8186
Part C2: Abiraterone acetate combination with AZD8186,has_type,DRUG
Part C2: Abiraterone acetate combination with AZD8186,classified_as,OTHER
Part C2: Abiraterone acetate combination with AZD8186,targets,squamous non-small cell lung cancer sqnsclc
Part C2: Abiraterone acetate combination with AZD8186,targets,advanced castrate-resistant prostate cancer crpc
Part C2: Abiraterone acetate combination with AZD8186,targets,triple negative breast cancer tnbc
Part C2: Abiraterone acetate combination with AZD8186,targets,TNBC
NCT06104085,sponsored_by,Peking Union Medical College Hospital
NCT06104085,has_status,RECRUITING
NCT06104085,tests,99mTc-MY6349 SPECT/CT scan
99mTc-MY6349 SPECT/CT scan,has_type,DRUG
99mTc-MY6349 SPECT/CT scan,classified_as,OTHER
99mTc-MY6349 SPECT/CT scan,targets,breast cancer
NCT04580485,sponsored_by,Incyte Corporation
NCT04580485,has_status,COMPLETED
NCT04580485,tests,INCB106385
INCB106385,has_type,DRUG
INCB106385,classified_as,OTHER
INCB106385,targets,squamous carcinoma of the anal canal
INCB106385,targets,hepatocellular carcinoma
INCB106385,targets,squamous cell carcinoma of head and neck
INCB106385,targets,ovarian cancer
INCB106385,targets,triple negative breast cancer
INCB106385,targets,bladder cancer
INCB106385,targets,castration resistant prostate cancer
INCB106385,targets,gastric/ gastroesophageal junction
INCB106385,targets,pancreatic ductal adenocarcinoma
INCB106385,targets,non small cell lung cancer
INCB106385,targets,colorectal cancer
INCB106385,targets,TNBC
NCT04580485,tests,INCMGA00012
INCMGA00012,has_type,DRUG
INCMGA00012,classified_as,OTHER
INCMGA00012,targets,squamous carcinoma of the anal canal
INCMGA00012,targets,hepatocellular carcinoma
INCMGA00012,targets,squamous cell carcinoma of head and neck
INCMGA00012,targets,ovarian cancer
INCMGA00012,targets,triple negative breast cancer
INCMGA00012,targets,bladder cancer
INCMGA00012,targets,castration resistant prostate cancer
INCMGA00012,targets,gastric/ gastroesophageal junction
INCMGA00012,targets,pancreatic ductal adenocarcinoma
INCMGA00012,targets,non small cell lung cancer
INCMGA00012,targets,colorectal cancer
INCMGA00012,targets,TNBC
NCT02720185,sponsored_by,"University of Wisconsin, Madison"
NCT02720185,has_status,TERMINATED
NCT02720185,tests,Dasatinib
Dasatinib,has_type,DRUG
Dasatinib,classified_as,CHEMICAL
Dasatinib,targets,breast neoplasms
Dasatinib,targets,triple negative breast neoplasms
Dasatinib,targets,TNBC
NCT02720185,tests,Conventional Surgery
Conventional Surgery,has_type,DRUG
Conventional Surgery,classified_as,OTHER
Conventional Surgery,targets,breast neoplasms
Conventional Surgery,targets,triple negative breast neoplasms
Conventional Surgery,targets,TNBC
NCT02720185,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,breast neoplasms
Laboratory Biomarker Analysis,targets,triple negative breast neoplasms
Laboratory Biomarker Analysis,targets,TNBC
NCT03717415,sponsored_by,"Deciphera Pharmaceuticals, LLC"
NCT03717415,has_status,TERMINATED
NCT03717415,tests,Rebastinib
Rebastinib,has_type,DRUG
Rebastinib,classified_as,CHEMICAL
Rebastinib,targets,locally advanced or metastatic solid tumor
NCT03717415,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,locally advanced or metastatic solid tumor
NCT01074970,sponsored_by,Hoosier Cancer Research Network
NCT01074970,has_status,COMPLETED
NCT01074970,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,breast cancer
NCT01074970,tests,Rucaparib
Rucaparib,has_type,DRUG
Rucaparib,classified_as,CHEMICAL
Rucaparib,targets,breast cancer
NCT01074970,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,breast cancer
NCT05954442,sponsored_by,Fudan University
NCT05954442,has_status,RECRUITING
NCT05954442,tests,Everolimus
Everolimus,has_type,DRUG
Everolimus,classified_as,OTHER
Everolimus,targets,mutation
Everolimus,targets,metastatic breast cancer
Everolimus,targets,triple negative breast cancer
Everolimus,targets,TNBC
NCT05954442,tests,Investigator's Choice of Chemotherapy
Investigator's Choice of Chemotherapy,has_type,DRUG
Investigator's Choice of Chemotherapy,classified_as,OTHER
Investigator's Choice of Chemotherapy,targets,mutation
Investigator's Choice of Chemotherapy,targets,metastatic breast cancer
Investigator's Choice of Chemotherapy,targets,triple negative breast cancer
Investigator's Choice of Chemotherapy,targets,TNBC
NCT04159142,sponsored_by,Hebei Medical University Fourth Hospital
NCT04159142,has_status,UNKNOWN
NCT04159142,tests,Nab-paclitaxel + Carboplatin
Nab-paclitaxel + Carboplatin,has_type,DRUG
Nab-paclitaxel + Carboplatin,classified_as,CHEMICAL
Nab-paclitaxel + Carboplatin,targets,nab-paclitaxel
Nab-paclitaxel + Carboplatin,targets,triple negative breast cancer
Nab-paclitaxel + Carboplatin,targets,TNBC
NCT04159142,tests,Nab-paclitaxel + Capecitabine
Nab-paclitaxel + Capecitabine,has_type,DRUG
Nab-paclitaxel + Capecitabine,classified_as,CHEMICAL
Nab-paclitaxel + Capecitabine,targets,nab-paclitaxel
Nab-paclitaxel + Capecitabine,targets,triple negative breast cancer
Nab-paclitaxel + Capecitabine,targets,TNBC
NCT04892342,sponsored_by,"Shanghai Escugen Biotechnology Co., Ltd"
NCT04892342,has_status,RECRUITING
NCT04892342,tests,ESG401
ESG401,has_type,DRUG
ESG401,classified_as,OTHER
ESG401,targets,"neoplasms, bladder"
ESG401,targets,neoplasm of stomach
ESG401,targets,"neoplasms, breast"
ESG401,targets,"neoplasms,colorectal"
ESG401,targets,"neoplasms, lung"
ESG401,targets,"neoplasms,ovarian"
NCT04739670,sponsored_by,"Peter MacCallum Cancer Centre, Australia"
NCT04739670,has_status,RECRUITING
NCT04739670,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,metastatic triple negative breast cancer
Atezolizumab,targets,TNBC
NCT04739670,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,metastatic triple negative breast cancer
Bevacizumab,targets,TNBC
NCT04739670,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,metastatic triple negative breast cancer
Gemcitabine,targets,TNBC
NCT04739670,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,metastatic triple negative breast cancer
Carboplatin,targets,TNBC
NCT06382142,sponsored_by,"Sichuan Baili Pharmaceutical Co., Ltd."
NCT06382142,has_status,RECRUITING
NCT06382142,tests,BL-B01D1
BL-B01D1,has_type,DRUG
BL-B01D1,classified_as,OTHER
BL-B01D1,targets,triple-negative breast cancer
BL-B01D1,targets,TNBC
NCT06382142,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,triple-negative breast cancer
Eribulin,targets,TNBC
NCT06382142,tests,Vinorelbine
Vinorelbine,has_type,DRUG
Vinorelbine,classified_as,OTHER
Vinorelbine,targets,triple-negative breast cancer
Vinorelbine,targets,TNBC
NCT06382142,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple-negative breast cancer
Gemcitabine,targets,TNBC
NCT06382142,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple-negative breast cancer
Capecitabine,targets,TNBC
NCT04296942,sponsored_by,National Cancer Institute (NCI)
NCT04296942,has_status,TERMINATED
NCT04296942,tests,Brachyury-TRICOM
Brachyury-TRICOM,has_type,DRUG
Brachyury-TRICOM,classified_as,OTHER
Brachyury-TRICOM,targets,hormone receptor negative breast cancer
Brachyury-TRICOM,targets,breast cancer
Brachyury-TRICOM,targets,triple negative breast cancer
Brachyury-TRICOM,targets,metastatic breast cancer
Brachyury-TRICOM,targets,her2+ breast cancer
Brachyury-TRICOM,targets,TNBC
NCT04296942,tests,Entinostat
Entinostat,has_type,DRUG
Entinostat,classified_as,OTHER
Entinostat,targets,hormone receptor negative breast cancer
Entinostat,targets,breast cancer
Entinostat,targets,triple negative breast cancer
Entinostat,targets,metastatic breast cancer
Entinostat,targets,her2+ breast cancer
Entinostat,targets,TNBC
NCT04296942,tests,M7824
M7824,has_type,DRUG
M7824,classified_as,OTHER
M7824,targets,hormone receptor negative breast cancer
M7824,targets,breast cancer
M7824,targets,triple negative breast cancer
M7824,targets,metastatic breast cancer
M7824,targets,her2+ breast cancer
M7824,targets,TNBC
NCT04296942,tests,Ado-trastuzumab emtansine
Ado-trastuzumab emtansine,has_type,DRUG
Ado-trastuzumab emtansine,classified_as,BIOLOGIC
Ado-trastuzumab emtansine,targets,hormone receptor negative breast cancer
Ado-trastuzumab emtansine,targets,breast cancer
Ado-trastuzumab emtansine,targets,triple negative breast cancer
Ado-trastuzumab emtansine,targets,metastatic breast cancer
Ado-trastuzumab emtansine,targets,her2+ breast cancer
Ado-trastuzumab emtansine,targets,TNBC
NCT01097642,sponsored_by,The Methodist Hospital Research Institute
NCT01097642,has_status,COMPLETED
NCT01097642,tests,Cetuximab
Cetuximab,has_type,DRUG
Cetuximab,classified_as,BIOLOGIC
Cetuximab,targets,breast cancer
NCT01097642,tests,Ixabepilone
Ixabepilone,has_type,DRUG
Ixabepilone,classified_as,OTHER
Ixabepilone,targets,breast cancer
NCT04787042,sponsored_by,"Simcha IL-18, Inc."
NCT04787042,has_status,RECRUITING
NCT04787042,tests,ST-067
ST-067,has_type,DRUG
ST-067,classified_as,OTHER
ST-067,targets,msi-high
ST-067,targets,melanoma
ST-067,targets,renal cell carcinoma
ST-067,targets,solid tumor
ST-067,targets,carcinoma
ST-067,targets,cancer
ST-067,targets,squamous cell carcinoma of the head and neck
ST-067,targets,triple-negative breast cancer
ST-067,targets,non small cell lung cancer
ST-067,targets,TNBC
NCT04787042,tests,Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],has_type,DRUG
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],classified_as,BIOLOGIC
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],targets,msi-high
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],targets,melanoma
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],targets,renal cell carcinoma
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],targets,solid tumor
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],targets,carcinoma
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],targets,cancer
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],targets,squamous cell carcinoma of the head and neck
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],targets,triple-negative breast cancer
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],targets,non small cell lung cancer
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA],targets,TNBC
NCT04787042,tests,pembrolizumab
pembrolizumab,has_type,DRUG
pembrolizumab,classified_as,BIOLOGIC
pembrolizumab,targets,msi-high
pembrolizumab,targets,melanoma
pembrolizumab,targets,renal cell carcinoma
pembrolizumab,targets,solid tumor
pembrolizumab,targets,carcinoma
pembrolizumab,targets,cancer
pembrolizumab,targets,squamous cell carcinoma of the head and neck
pembrolizumab,targets,triple-negative breast cancer
pembrolizumab,targets,non small cell lung cancer
pembrolizumab,targets,TNBC
NCT06519370,sponsored_by,"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
NCT06519370,has_status,RECRUITING
NCT06519370,tests,FDA018-ADC
FDA018-ADC,has_type,DRUG
FDA018-ADC,classified_as,OTHER
FDA018-ADC,targets,triple negative breast cancer
FDA018-ADC,targets,TNBC
NCT06519370,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,triple negative breast cancer
Eribulin,targets,TNBC
NCT06519370,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT06519370,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast cancer
Gemcitabine,targets,TNBC
NCT06519370,tests,Vinorelbine
Vinorelbine,has_type,DRUG
Vinorelbine,classified_as,OTHER
Vinorelbine,targets,triple negative breast cancer
Vinorelbine,targets,TNBC
NCT02938442,sponsored_by,University of Arkansas
NCT02938442,has_status,COMPLETED
NCT02938442,tests,P10s-PADRE with MONTANIDE™ ISA 51 VG
P10s-PADRE with MONTANIDE™ ISA 51 VG,has_type,DRUG
P10s-PADRE with MONTANIDE™ ISA 51 VG,classified_as,OTHER
P10s-PADRE with MONTANIDE™ ISA 51 VG,targets,breast neoplasms
P10s-PADRE with MONTANIDE™ ISA 51 VG,targets,triple negative breast cancer
P10s-PADRE with MONTANIDE™ ISA 51 VG,targets,TNBC
NCT02938442,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,breast neoplasms
Doxorubicin,targets,triple negative breast cancer
Doxorubicin,targets,TNBC
NCT02938442,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast neoplasms
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02938442,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast neoplasms
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT03464942,sponsored_by,"Peter MacCallum Cancer Centre, Australia"
NCT03464942,has_status,COMPLETED
NCT03464942,tests,SABR
SABR,has_type,DRUG
SABR,classified_as,OTHER
SABR,targets,breast cancer
NCT03464942,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,breast cancer
NCT04452370,sponsored_by,Chinese Academy of Medical Sciences
NCT04452370,has_status,UNKNOWN
NCT04452370,tests,oral etoposide + anlotinib
oral etoposide + anlotinib,has_type,DRUG
oral etoposide + anlotinib,classified_as,CHEMICAL
oral etoposide + anlotinib,targets,triple negative breast cancer
oral etoposide + anlotinib,targets,TNBC
NCT03674242,sponsored_by,ERYtech Pharma
NCT03674242,has_status,TERMINATED
NCT03674242,tests,eryaspase (L-asparaginase encapsulated in red blood cells)
eryaspase (L-asparaginase encapsulated in red blood cells),has_type,DRUG
eryaspase (L-asparaginase encapsulated in red blood cells),classified_as,OTHER
eryaspase (L-asparaginase encapsulated in red blood cells),targets,triple negative breast cancer
eryaspase (L-asparaginase encapsulated in red blood cells),targets,TNBC
NCT03674242,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast cancer
Gemcitabine,targets,TNBC
NCT03674242,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,TNBC
NCT07054242,sponsored_by,Yantai Yuhuangding Hospital
NCT07054242,has_status,NOT_YET_RECRUITING
NCT07054242,tests,Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab
Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab,has_type,DRUG
Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab,classified_as,BIOLOGIC
Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab,targets,neoadjuvant therapy
Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab,targets,stage ii to iii (t1cn1-2 or t2-4n0-2) tnbc breast cancer
NCT02593175,sponsored_by,M.D. Anderson Cancer Center
NCT02593175,has_status,COMPLETED
NCT02593175,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,stage iiib breast cancer ajcc v7
Carboplatin,targets,stage i breast cancer ajcc v7
Carboplatin,targets,stage iia breast cancer ajcc v6 and v7
Carboplatin,targets,stage iib breast cancer ajcc v6 and v7
Carboplatin,targets,stage iiia breast cancer ajcc v7
Carboplatin,targets,stage ia breast cancer ajcc v7
Carboplatin,targets,stage ii breast cancer ajcc v6 and v7
Carboplatin,targets,stage iiic breast cancer ajcc v7
Carboplatin,targets,stage iii breast cancer ajcc v7
Carboplatin,targets,stage ib breast cancer ajcc v7
Carboplatin,targets,triple-negative breast carcinoma
Carboplatin,targets,TNBC
NCT02593175,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,stage iiib breast cancer ajcc v7
Paclitaxel,targets,stage i breast cancer ajcc v7
Paclitaxel,targets,stage iia breast cancer ajcc v6 and v7
Paclitaxel,targets,stage iib breast cancer ajcc v6 and v7
Paclitaxel,targets,stage iiia breast cancer ajcc v7
Paclitaxel,targets,stage ia breast cancer ajcc v7
Paclitaxel,targets,stage ii breast cancer ajcc v6 and v7
Paclitaxel,targets,stage iiic breast cancer ajcc v7
Paclitaxel,targets,stage iii breast cancer ajcc v7
Paclitaxel,targets,stage ib breast cancer ajcc v7
Paclitaxel,targets,triple-negative breast carcinoma
Paclitaxel,targets,TNBC
NCT02593175,tests,Panitumumab
Panitumumab,has_type,DRUG
Panitumumab,classified_as,BIOLOGIC
Panitumumab,targets,stage iiib breast cancer ajcc v7
Panitumumab,targets,stage i breast cancer ajcc v7
Panitumumab,targets,stage iia breast cancer ajcc v6 and v7
Panitumumab,targets,stage iib breast cancer ajcc v6 and v7
Panitumumab,targets,stage iiia breast cancer ajcc v7
Panitumumab,targets,stage ia breast cancer ajcc v7
Panitumumab,targets,stage ii breast cancer ajcc v6 and v7
Panitumumab,targets,stage iiic breast cancer ajcc v7
Panitumumab,targets,stage iii breast cancer ajcc v7
Panitumumab,targets,stage ib breast cancer ajcc v7
Panitumumab,targets,triple-negative breast carcinoma
Panitumumab,targets,TNBC
NCT05383170,sponsored_by,Cytovation AS
NCT05383170,has_status,COMPLETED
NCT05383170,tests,CyPep-1
CyPep-1,has_type,DRUG
CyPep-1,classified_as,OTHER
CyPep-1,targets,advanced melanoma
CyPep-1,targets,advanced breast cancer
CyPep-1,targets,advanced head and neck squamous cell carcinoma
NCT05383170,tests,Pembrolizumab 25 MG/ML [KEYTRUDA®]
Pembrolizumab 25 MG/ML [KEYTRUDA®],has_type,DRUG
Pembrolizumab 25 MG/ML [KEYTRUDA®],classified_as,BIOLOGIC
Pembrolizumab 25 MG/ML [KEYTRUDA®],targets,advanced melanoma
Pembrolizumab 25 MG/ML [KEYTRUDA®],targets,advanced breast cancer
Pembrolizumab 25 MG/ML [KEYTRUDA®],targets,advanced head and neck squamous cell carcinoma
NCT06134375,sponsored_by,Dartmouth-Hitchcock Medical Center
NCT06134375,has_status,RECRUITING
NCT06134375,tests,Tetrathiomolybdate
Tetrathiomolybdate,has_type,DRUG
Tetrathiomolybdate,classified_as,OTHER
Tetrathiomolybdate,targets,residual disease
Tetrathiomolybdate,targets,triple negative breast cancer
Tetrathiomolybdate,targets,TNBC
NCT06134375,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,residual disease
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT06134375,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,residual disease
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT02685306,sponsored_by,Peregrine Pharmaceuticals
NCT02685306,has_status,WITHDRAWN
NCT02685306,tests,Bavituximab
Bavituximab,has_type,DRUG
Bavituximab,classified_as,BIOLOGIC
Bavituximab,targets,er-negative pr-negative her2-negative breast cancer
Bavituximab,targets,breast cancer
Bavituximab,targets,triple negative breast cancer
Bavituximab,targets,triple-negative breast neoplasm
Bavituximab,targets,triple negative breast neoplasms
Bavituximab,targets,triple-negative breast cancer
Bavituximab,targets,er-negative pr-negative her2-negative breast neoplasms
Bavituximab,targets,TNBC
NCT02685306,tests,Taxane
Taxane,has_type,DRUG
Taxane,classified_as,OTHER
Taxane,targets,er-negative pr-negative her2-negative breast cancer
Taxane,targets,breast cancer
Taxane,targets,triple negative breast cancer
Taxane,targets,triple-negative breast neoplasm
Taxane,targets,triple negative breast neoplasms
Taxane,targets,triple-negative breast cancer
Taxane,targets,er-negative pr-negative her2-negative breast neoplasms
Taxane,targets,TNBC
NCT06851299,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06851299,has_status,RECRUITING
NCT06851299,tests,trop2-ADC
trop2-ADC,has_type,DRUG
trop2-ADC,classified_as,OTHER
trop2-ADC,targets,metastatic triple-negative breast cancer
trop2-ADC,targets,TNBC
NCT06851299,tests,ADC +anti-angiogenic drug
ADC +anti-angiogenic drug,has_type,DRUG
ADC +anti-angiogenic drug,classified_as,OTHER
ADC +anti-angiogenic drug,targets,metastatic triple-negative breast cancer
ADC +anti-angiogenic drug,targets,TNBC
NCT06851299,tests,ADC + PD1 monoclonal antibody +anti-angiogenic drug
ADC + PD1 monoclonal antibody +anti-angiogenic drug,has_type,DRUG
ADC + PD1 monoclonal antibody +anti-angiogenic drug,classified_as,BIOLOGIC
ADC + PD1 monoclonal antibody +anti-angiogenic drug,targets,metastatic triple-negative breast cancer
ADC + PD1 monoclonal antibody +anti-angiogenic drug,targets,TNBC
NCT04060342,sponsored_by,"GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc."
NCT04060342,has_status,TERMINATED
NCT04060342,tests,GB1275
GB1275,has_type,DRUG
GB1275,classified_as,OTHER
GB1275,targets,renal cell carcinoma
GB1275,targets,non-small cell lung cancer
GB1275,targets,hepatocellular carcinoma
GB1275,targets,urothelial carcinoma
GB1275,targets,microsatellite stable colorectal cancer
GB1275,targets,esophageal squamous cell carcinoma
GB1275,targets,triple negative breast cancer
GB1275,targets,castration-resistant prostate cancer
GB1275,targets,head and neck squamous cell carcinoma
GB1275,targets,esophageal adenocarcinoma
GB1275,targets,small-cell lung cancer
GB1275,targets,pancreatic adenocarcinoma
GB1275,targets,gastroesophageal junction adenocarcinoma
GB1275,targets,gastric adenocarcinoma
GB1275,targets,TNBC
NCT04060342,tests,nab-paclitaxel and gemcitabine
nab-paclitaxel and gemcitabine,has_type,DRUG
nab-paclitaxel and gemcitabine,classified_as,CHEMICAL
nab-paclitaxel and gemcitabine,targets,renal cell carcinoma
nab-paclitaxel and gemcitabine,targets,non-small cell lung cancer
nab-paclitaxel and gemcitabine,targets,hepatocellular carcinoma
nab-paclitaxel and gemcitabine,targets,urothelial carcinoma
nab-paclitaxel and gemcitabine,targets,microsatellite stable colorectal cancer
nab-paclitaxel and gemcitabine,targets,esophageal squamous cell carcinoma
nab-paclitaxel and gemcitabine,targets,triple negative breast cancer
nab-paclitaxel and gemcitabine,targets,castration-resistant prostate cancer
nab-paclitaxel and gemcitabine,targets,head and neck squamous cell carcinoma
nab-paclitaxel and gemcitabine,targets,esophageal adenocarcinoma
nab-paclitaxel and gemcitabine,targets,small-cell lung cancer
nab-paclitaxel and gemcitabine,targets,pancreatic adenocarcinoma
nab-paclitaxel and gemcitabine,targets,gastroesophageal junction adenocarcinoma
nab-paclitaxel and gemcitabine,targets,gastric adenocarcinoma
nab-paclitaxel and gemcitabine,targets,TNBC
NCT04060342,tests,pembrolizumab
pembrolizumab,has_type,DRUG
pembrolizumab,classified_as,BIOLOGIC
pembrolizumab,targets,renal cell carcinoma
pembrolizumab,targets,non-small cell lung cancer
pembrolizumab,targets,hepatocellular carcinoma
pembrolizumab,targets,urothelial carcinoma
pembrolizumab,targets,microsatellite stable colorectal cancer
pembrolizumab,targets,esophageal squamous cell carcinoma
pembrolizumab,targets,triple negative breast cancer
pembrolizumab,targets,castration-resistant prostate cancer
pembrolizumab,targets,head and neck squamous cell carcinoma
pembrolizumab,targets,esophageal adenocarcinoma
pembrolizumab,targets,small-cell lung cancer
pembrolizumab,targets,pancreatic adenocarcinoma
pembrolizumab,targets,gastroesophageal junction adenocarcinoma
pembrolizumab,targets,gastric adenocarcinoma
pembrolizumab,targets,TNBC
NCT06700070,sponsored_by,Pure Biologics S.A.
NCT06700070,has_status,NOT_YET_RECRUITING
NCT06700070,tests,PBA-0111
PBA-0111,has_type,DRUG
PBA-0111,classified_as,OTHER
PBA-0111,targets,soft tissue sarcoma adult
PBA-0111,targets,head and neck squamous cell carcinoma
PBA-0111,targets,triple negative breast cancer
PBA-0111,targets,TNBC
NCT03499899,sponsored_by,Novartis Pharmaceuticals
NCT03499899,has_status,COMPLETED
NCT03499899,tests,LAG525
LAG525,has_type,DRUG
LAG525,classified_as,OTHER
LAG525,targets,triple-negative breast cancer
LAG525,targets,TNBC
NCT03499899,tests,PDR001
PDR001,has_type,DRUG
PDR001,classified_as,OTHER
PDR001,targets,triple-negative breast cancer
PDR001,targets,TNBC
NCT03499899,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple-negative breast cancer
Carboplatin,targets,TNBC
NCT02583542,sponsored_by,Queen Mary University of London
NCT02583542,has_status,UNKNOWN
NCT02583542,tests,AZD2014
AZD2014,has_type,DRUG
AZD2014,classified_as,OTHER
AZD2014,targets,non-squamous cell lung cancer with wild-type kras
AZD2014,targets,non-squamous cell lung cancer with kras mutations
AZD2014,targets,squamous cell lung cancer
AZD2014,targets,triple-negative breast cancer
AZD2014,targets,TNBC
NCT02583542,tests,AZD6244
AZD6244,has_type,DRUG
AZD6244,classified_as,OTHER
AZD6244,targets,non-squamous cell lung cancer with wild-type kras
AZD6244,targets,non-squamous cell lung cancer with kras mutations
AZD6244,targets,squamous cell lung cancer
AZD6244,targets,triple-negative breast cancer
AZD6244,targets,TNBC
NCT03393416,sponsored_by,HRYZ Biotech Co.
NCT03393416,has_status,UNKNOWN
NCT03393416,tests,MASCT-I
MASCT-I,has_type,DRUG
MASCT-I,classified_as,OTHER
MASCT-I,targets,advanced gastric cancer
NCT03393416,tests,PD1 antibody
PD1 antibody,has_type,DRUG
PD1 antibody,classified_as,CHEMICAL
PD1 antibody,targets,advanced gastric cancer
NCT04677816,sponsored_by,Wake Forest University Health Sciences
NCT04677816,has_status,RECRUITING
NCT04677816,tests,Standard of Care Neoadjuvant Chemotherapy (NAC)
Standard of Care Neoadjuvant Chemotherapy (NAC),has_type,DRUG
Standard of Care Neoadjuvant Chemotherapy (NAC),classified_as,OTHER
Standard of Care Neoadjuvant Chemotherapy (NAC),targets,invasive breast cancer
Standard of Care Neoadjuvant Chemotherapy (NAC),targets,vitamin d deficiency
Standard of Care Neoadjuvant Chemotherapy (NAC),targets,triple negative breast cancer
Standard of Care Neoadjuvant Chemotherapy (NAC),targets,TNBC
NCT04677816,tests,Vitamin D3
Vitamin D3,has_type,DRUG
Vitamin D3,classified_as,OTHER
Vitamin D3,targets,invasive breast cancer
Vitamin D3,targets,vitamin d deficiency
Vitamin D3,targets,triple negative breast cancer
Vitamin D3,targets,TNBC
NCT04677816,tests,Drug Diary
Drug Diary,has_type,DRUG
Drug Diary,classified_as,OTHER
Drug Diary,targets,invasive breast cancer
Drug Diary,targets,vitamin d deficiency
Drug Diary,targets,triple negative breast cancer
Drug Diary,targets,TNBC
NCT04441099,sponsored_by,NBE-Therapeutics AG
NCT04441099,has_status,TERMINATED
NCT04441099,tests,NBE-002
NBE-002,has_type,DRUG
NBE-002,classified_as,OTHER
NBE-002,targets,advanced solid tumor
NBE-002,targets,advanced cancer
NBE-002,targets,triple negative breast cancer
NBE-002,targets,TNBC
NCT02221999,sponsored_by,RenJi Hospital
NCT02221999,has_status,ACTIVE_NOT_RECRUITING
NCT02221999,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,tubular breast cancer
Paclitaxel,targets,invasive ductal breast cancer
Paclitaxel,targets,inflammatory breast cancer
Paclitaxel,targets,mucinous breast cancer
NCT02221999,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,tubular breast cancer
Cisplatin,targets,invasive ductal breast cancer
Cisplatin,targets,inflammatory breast cancer
Cisplatin,targets,mucinous breast cancer
NCT02221999,tests,Gonadotropin-releasing hormone agonist
Gonadotropin-releasing hormone agonist,has_type,DRUG
Gonadotropin-releasing hormone agonist,classified_as,OTHER
Gonadotropin-releasing hormone agonist,targets,tubular breast cancer
Gonadotropin-releasing hormone agonist,targets,invasive ductal breast cancer
Gonadotropin-releasing hormone agonist,targets,inflammatory breast cancer
Gonadotropin-releasing hormone agonist,targets,mucinous breast cancer
NCT02221999,tests,Letrozole
Letrozole,has_type,DRUG
Letrozole,classified_as,CHEMICAL
Letrozole,targets,tubular breast cancer
Letrozole,targets,invasive ductal breast cancer
Letrozole,targets,inflammatory breast cancer
Letrozole,targets,mucinous breast cancer
NCT02225470,sponsored_by,"Eisai Co., Ltd."
NCT02225470,has_status,COMPLETED
NCT02225470,tests,E7389 (Eribulin Mesylate)
E7389 (Eribulin Mesylate),has_type,DRUG
E7389 (Eribulin Mesylate),classified_as,CHEMICAL
E7389 (Eribulin Mesylate),targets,cancer of breast
E7389 (Eribulin Mesylate),targets,her2-negative breast cancer
E7389 (Eribulin Mesylate),targets,breast cancer
E7389 (Eribulin Mesylate),targets,triple negative breast cancer
E7389 (Eribulin Mesylate),targets,breast tumors
E7389 (Eribulin Mesylate),targets,TNBC
NCT02225470,tests,Vinorelbine injection
Vinorelbine injection,has_type,DRUG
Vinorelbine injection,classified_as,OTHER
Vinorelbine injection,targets,cancer of breast
Vinorelbine injection,targets,her2-negative breast cancer
Vinorelbine injection,targets,breast cancer
Vinorelbine injection,targets,triple negative breast cancer
Vinorelbine injection,targets,breast tumors
Vinorelbine injection,targets,TNBC
NCT02101385,sponsored_by,"Bryan Schneider, MD"
NCT02101385,has_status,COMPLETED
NCT02101385,tests,Genomically Directed Monotherapy
Genomically Directed Monotherapy,has_type,DRUG
Genomically Directed Monotherapy,classified_as,OTHER
Genomically Directed Monotherapy,targets,breast cancer
Genomically Directed Monotherapy,targets,malignant neoplasm of breast
NCT02101385,tests,Observation/Standard Therapy
Observation/Standard Therapy,has_type,DRUG
Observation/Standard Therapy,classified_as,OTHER
Observation/Standard Therapy,targets,breast cancer
Observation/Standard Therapy,targets,malignant neoplasm of breast
NCT05806385,sponsored_by,Texas Tech University Health Sciences Center
NCT05806385,has_status,NOT_YET_RECRUITING
NCT05806385,tests,Cryoablation
Cryoablation,has_type,DRUG
Cryoablation,classified_as,OTHER
Cryoablation,targets,triple negative breast cancer
Cryoablation,targets,TNBC
NCT05806385,tests,Cryoablation combined with PD1 Inhibitor
Cryoablation combined with PD1 Inhibitor,has_type,DRUG
Cryoablation combined with PD1 Inhibitor,classified_as,CHEMICAL
Cryoablation combined with PD1 Inhibitor,targets,triple negative breast cancer
Cryoablation combined with PD1 Inhibitor,targets,TNBC
NCT06039956,sponsored_by,Nova Scotia Health Authority
NCT06039956,has_status,NOT_YET_RECRUITING
NCT06039956,tests,Sentinel lymph Node Biopsy
Sentinel lymph Node Biopsy,has_type,DRUG
Sentinel lymph Node Biopsy,classified_as,OTHER
Sentinel lymph Node Biopsy,targets,breast cancer
Sentinel lymph Node Biopsy,targets,axilla; breast
NCT04958785,sponsored_by,Gilead Sciences
NCT04958785,has_status,TERMINATED
NCT04958785,tests,Magrolimab
Magrolimab,has_type,DRUG
Magrolimab,classified_as,BIOLOGIC
Magrolimab,targets,triple-negative breast cancer
Magrolimab,targets,TNBC
NCT04958785,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,triple-negative breast cancer
Nab-Paclitaxel,targets,TNBC
NCT04958785,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple-negative breast cancer
Paclitaxel,targets,TNBC
NCT04958785,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
Sacituzumab Govitecan-hziy,classified_as,BIOLOGIC
Sacituzumab Govitecan-hziy,targets,triple-negative breast cancer
Sacituzumab Govitecan-hziy,targets,TNBC
NCT05339685,sponsored_by,"Sichuan Baili Pharmaceutical Co., Ltd."
NCT05339685,has_status,RECRUITING
NCT05339685,tests,BL-M02D1
BL-M02D1,has_type,DRUG
BL-M02D1,classified_as,OTHER
BL-M02D1,targets,breast cancer
NCT03387085,sponsored_by,"ImmunityBio, Inc."
NCT03387085,has_status,TERMINATED
NCT03387085,tests,Aldoxorubicin HCl
Aldoxorubicin HCl,has_type,DRUG
Aldoxorubicin HCl,classified_as,CHEMICAL
Aldoxorubicin HCl,targets,triple negative breast cancer
Aldoxorubicin HCl,targets,TNBC
NCT03387085,tests,N-803
N-803,has_type,DRUG
N-803,classified_as,OTHER
N-803,targets,triple negative breast cancer
N-803,targets,TNBC
NCT03387085,tests,ETBX-011
ETBX-011,has_type,DRUG
ETBX-011,classified_as,OTHER
ETBX-011,targets,triple negative breast cancer
ETBX-011,targets,TNBC
NCT03387085,tests,ETBX-051
ETBX-051,has_type,DRUG
ETBX-051,classified_as,OTHER
ETBX-051,targets,triple negative breast cancer
ETBX-051,targets,TNBC
NCT03387085,tests,ETBX-061
ETBX-061,has_type,DRUG
ETBX-061,classified_as,OTHER
ETBX-061,targets,triple negative breast cancer
ETBX-061,targets,TNBC
NCT03387085,tests,GI-4000
GI-4000,has_type,DRUG
GI-4000,classified_as,OTHER
GI-4000,targets,triple negative breast cancer
GI-4000,targets,TNBC
NCT03387085,tests,GI-6207
GI-6207,has_type,DRUG
GI-6207,classified_as,OTHER
GI-6207,targets,triple negative breast cancer
GI-6207,targets,TNBC
NCT03387085,tests,GI-6301
GI-6301,has_type,DRUG
GI-6301,classified_as,OTHER
GI-6301,targets,triple negative breast cancer
GI-6301,targets,TNBC
NCT03387085,tests,haNK for Infusion
haNK for Infusion,has_type,DRUG
haNK for Infusion,classified_as,OTHER
haNK for Infusion,targets,triple negative breast cancer
haNK for Infusion,targets,TNBC
NCT03387085,tests,avelumab
avelumab,has_type,DRUG
avelumab,classified_as,BIOLOGIC
avelumab,targets,triple negative breast cancer
avelumab,targets,TNBC
NCT03387085,tests,bevacizumab
bevacizumab,has_type,DRUG
bevacizumab,classified_as,BIOLOGIC
bevacizumab,targets,triple negative breast cancer
bevacizumab,targets,TNBC
NCT03387085,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT03387085,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,triple negative breast cancer
Cisplatin,targets,TNBC
NCT03387085,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,TNBC
NCT03387085,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
5-Fluorouracil,classified_as,CHEMICAL
5-Fluorouracil,targets,triple negative breast cancer
5-Fluorouracil,targets,TNBC
NCT03387085,tests,Leucovorin
Leucovorin,has_type,DRUG
Leucovorin,classified_as,OTHER
Leucovorin,targets,triple negative breast cancer
Leucovorin,targets,TNBC
NCT03387085,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
nab-Paclitaxel,classified_as,CHEMICAL
nab-Paclitaxel,targets,triple negative breast cancer
nab-Paclitaxel,targets,TNBC
NCT03387085,tests,SBRT
SBRT,has_type,DRUG
SBRT,classified_as,OTHER
SBRT,targets,triple negative breast cancer
SBRT,targets,TNBC
NCT02038699,sponsored_by,Chimerix
NCT02038699,has_status,WITHDRAWN
NCT02038699,tests,ONC201
ONC201,has_type,DRUG
ONC201,classified_as,OTHER
ONC201,targets,advanced triple-negative breast cancer
ONC201,targets,advanced glioblastoma
ONC201,targets,advanced non-small cell lung cancer
ONC201,targets,advanced colorectal cancer
ONC201,targets,TNBC
NCT04669899,sponsored_by,"Jounce Therapeutics, Inc."
NCT04669899,has_status,COMPLETED
NCT04669899,tests,JTX-8064
JTX-8064,has_type,DRUG
JTX-8064,classified_as,OTHER
JTX-8064,targets,cancer
NCT04669899,tests,pimivalimab
pimivalimab,has_type,DRUG
pimivalimab,classified_as,BIOLOGIC
pimivalimab,targets,cancer
NCT02302742,sponsored_by,University of Kansas Medical Center
NCT02302742,has_status,RECRUITING
NCT04152499,sponsored_by,Klus Pharma Inc.
NCT04152499,has_status,ACTIVE_NOT_RECRUITING
NCT04152499,tests,SKB264
SKB264,has_type,DRUG
SKB264,classified_as,OTHER
SKB264,targets,endometrial carcinoma
SKB264,targets,non-small cell lung cancer
SKB264,targets,breast cancer
SKB264,targets,urothelial carcinoma
SKB264,targets,epithelial ovarian cancer
SKB264,targets,cervical cancer
SKB264,targets,head and neck squamous cell carcinoma
SKB264,targets,small-cell lung cancer
SKB264,targets,gastroesophageal junction adenocarcinoma
SKB264,targets,gastric adenocarcinoma
NCT02752685,sponsored_by,NYU Langone Health
NCT02752685,has_status,ACTIVE_NOT_RECRUITING
NCT02752685,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
NCT02752685,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
Nab-Paclitaxel,classified_as,CHEMICAL
Nab-Paclitaxel,targets,breast cancer
NCT03345485,sponsored_by,Mundipharma Research Limited
NCT03345485,has_status,COMPLETED
NCT03345485,tests,Tinostamustine 60mg/m2 over 30min
Tinostamustine 60mg/m2 over 30min,has_type,DRUG
Tinostamustine 60mg/m2 over 30min,classified_as,OTHER
Tinostamustine 60mg/m2 over 30min,targets,ovarian cancer
Tinostamustine 60mg/m2 over 30min,targets,soft tissue sarcoma
Tinostamustine 60mg/m2 over 30min,targets,small cell lung cancer
Tinostamustine 60mg/m2 over 30min,targets,endometrial cancer
Tinostamustine 60mg/m2 over 30min,targets,triple-negative breast cancer
Tinostamustine 60mg/m2 over 30min,targets,TNBC
NCT03345485,tests,Tinostamustine 80mg/m2 over 30min
Tinostamustine 80mg/m2 over 30min,has_type,DRUG
Tinostamustine 80mg/m2 over 30min,classified_as,OTHER
Tinostamustine 80mg/m2 over 30min,targets,ovarian cancer
Tinostamustine 80mg/m2 over 30min,targets,soft tissue sarcoma
Tinostamustine 80mg/m2 over 30min,targets,small cell lung cancer
Tinostamustine 80mg/m2 over 30min,targets,endometrial cancer
Tinostamustine 80mg/m2 over 30min,targets,triple-negative breast cancer
Tinostamustine 80mg/m2 over 30min,targets,TNBC
NCT03345485,tests,Tinostamustine 100mg/m2 over 30min
Tinostamustine 100mg/m2 over 30min,has_type,DRUG
Tinostamustine 100mg/m2 over 30min,classified_as,OTHER
Tinostamustine 100mg/m2 over 30min,targets,ovarian cancer
Tinostamustine 100mg/m2 over 30min,targets,soft tissue sarcoma
Tinostamustine 100mg/m2 over 30min,targets,small cell lung cancer
Tinostamustine 100mg/m2 over 30min,targets,endometrial cancer
Tinostamustine 100mg/m2 over 30min,targets,triple-negative breast cancer
Tinostamustine 100mg/m2 over 30min,targets,TNBC
NCT03345485,tests,Tinostamustine 60mg/m2 over 60min
Tinostamustine 60mg/m2 over 60min,has_type,DRUG
Tinostamustine 60mg/m2 over 60min,classified_as,OTHER
Tinostamustine 60mg/m2 over 60min,targets,ovarian cancer
Tinostamustine 60mg/m2 over 60min,targets,soft tissue sarcoma
Tinostamustine 60mg/m2 over 60min,targets,small cell lung cancer
Tinostamustine 60mg/m2 over 60min,targets,endometrial cancer
Tinostamustine 60mg/m2 over 60min,targets,triple-negative breast cancer
Tinostamustine 60mg/m2 over 60min,targets,TNBC
NCT03345485,tests,Tinostamustine 80mg/m2 over 60min
Tinostamustine 80mg/m2 over 60min,has_type,DRUG
Tinostamustine 80mg/m2 over 60min,classified_as,OTHER
Tinostamustine 80mg/m2 over 60min,targets,ovarian cancer
Tinostamustine 80mg/m2 over 60min,targets,soft tissue sarcoma
Tinostamustine 80mg/m2 over 60min,targets,small cell lung cancer
Tinostamustine 80mg/m2 over 60min,targets,endometrial cancer
Tinostamustine 80mg/m2 over 60min,targets,triple-negative breast cancer
Tinostamustine 80mg/m2 over 60min,targets,TNBC
NCT03345485,tests,Tinostamustine 100mg/m2 over 60min
Tinostamustine 100mg/m2 over 60min,has_type,DRUG
Tinostamustine 100mg/m2 over 60min,classified_as,OTHER
Tinostamustine 100mg/m2 over 60min,targets,ovarian cancer
Tinostamustine 100mg/m2 over 60min,targets,soft tissue sarcoma
Tinostamustine 100mg/m2 over 60min,targets,small cell lung cancer
Tinostamustine 100mg/m2 over 60min,targets,endometrial cancer
Tinostamustine 100mg/m2 over 60min,targets,triple-negative breast cancer
Tinostamustine 100mg/m2 over 60min,targets,TNBC
NCT03345485,tests,Tinostamustine 80mg/m2 over 80min
Tinostamustine 80mg/m2 over 80min,has_type,DRUG
Tinostamustine 80mg/m2 over 80min,classified_as,OTHER
Tinostamustine 80mg/m2 over 80min,targets,ovarian cancer
Tinostamustine 80mg/m2 over 80min,targets,soft tissue sarcoma
Tinostamustine 80mg/m2 over 80min,targets,small cell lung cancer
Tinostamustine 80mg/m2 over 80min,targets,endometrial cancer
Tinostamustine 80mg/m2 over 80min,targets,triple-negative breast cancer
Tinostamustine 80mg/m2 over 80min,targets,TNBC
NCT03818685,sponsored_by,Centre Leon Berard
NCT03818685,has_status,ACTIVE_NOT_RECRUITING
NCT03818685,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,breast cancer
Nivolumab,targets,triple negative breast neoplasms
Nivolumab,targets,TNBC
NCT03818685,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,breast cancer
Ipilimumab,targets,triple negative breast neoplasms
Ipilimumab,targets,TNBC
NCT03818685,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
Capecitabine,targets,triple negative breast neoplasms
Capecitabine,targets,TNBC
NCT04460456,sponsored_by,Silverback Therapeutics
NCT04460456,has_status,UNKNOWN
NCT04460456,tests,SBT6050
SBT6050,has_type,DRUG
SBT6050,classified_as,OTHER
SBT6050,targets,her2 positive solid tumors
NCT04460456,tests,pembrolizumab
pembrolizumab,has_type,DRUG
pembrolizumab,classified_as,BIOLOGIC
pembrolizumab,targets,her2 positive solid tumors
NCT04460456,tests,Cemiplimab
Cemiplimab,has_type,DRUG
Cemiplimab,classified_as,BIOLOGIC
Cemiplimab,targets,her2 positive solid tumors
NCT04300556,sponsored_by,Eisai Inc.
NCT04300556,has_status,RECRUITING
NCT04300556,tests,Farletuzumab ecteribulin
Farletuzumab ecteribulin,has_type,DRUG
Farletuzumab ecteribulin,classified_as,BIOLOGIC
Farletuzumab ecteribulin,targets,solid tumor
NCT04300556,tests,Prednisone
Prednisone,has_type,DRUG
Prednisone,classified_as,OTHER
Prednisone,targets,solid tumor
NCT04300556,tests,Prednisolone
Prednisolone,has_type,DRUG
Prednisolone,classified_as,OTHER
Prednisolone,targets,solid tumor
NCT04300556,tests,Dexamethasone
Dexamethasone,has_type,DRUG
Dexamethasone,classified_as,OTHER
Dexamethasone,targets,solid tumor
NCT05272709,sponsored_by,Cancer Research UK
NCT05272709,has_status,RECRUITING
NCT05272709,tests,TT-702
TT-702,has_type,DRUG
TT-702,classified_as,OTHER
TT-702,targets,advanced solid tumors
NCT05272709,tests,Darolutamide
Darolutamide,has_type,DRUG
Darolutamide,classified_as,OTHER
Darolutamide,targets,advanced solid tumors
NCT06078670,sponsored_by,Fujian Cancer Hospital
NCT06078670,has_status,NOT_YET_RECRUITING
NCT06078670,tests,CVL218
CVL218,has_type,DRUG
CVL218,classified_as,OTHER
CVL218,targets,advanced solid tumor
NCT06746870,sponsored_by,ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NCT06746870,has_status,NOT_YET_RECRUITING
NCT06746870,tests,IMM2510
IMM2510,has_type,DRUG
IMM2510,classified_as,OTHER
IMM2510,targets,tnbc
IMM2510,targets,nsclc
NCT06746870,tests,Chemotherapy (pemetrexed + cisplatin/carboplatin)
Chemotherapy (pemetrexed + cisplatin/carboplatin),has_type,DRUG
Chemotherapy (pemetrexed + cisplatin/carboplatin),classified_as,CHEMICAL
Chemotherapy (pemetrexed + cisplatin/carboplatin),targets,tnbc
Chemotherapy (pemetrexed + cisplatin/carboplatin),targets,nsclc
NCT06746870,tests,Chemotherapy (paclitaxel + cisplatin/carboplatin)
Chemotherapy (paclitaxel + cisplatin/carboplatin),has_type,DRUG
Chemotherapy (paclitaxel + cisplatin/carboplatin),classified_as,CHEMICAL
Chemotherapy (paclitaxel + cisplatin/carboplatin),targets,tnbc
Chemotherapy (paclitaxel + cisplatin/carboplatin),targets,nsclc
NCT06746870,tests,Chemotherapy(Nab-paclitaxel)
Chemotherapy(Nab-paclitaxel),has_type,DRUG
Chemotherapy(Nab-paclitaxel),classified_as,CHEMICAL
Chemotherapy(Nab-paclitaxel),targets,tnbc
Chemotherapy(Nab-paclitaxel),targets,nsclc
NCT04745975,sponsored_by,Fudan University
NCT04745975,has_status,UNKNOWN
NCT04745975,tests,Personalized treatment guided by mini-PDX and RNA sequencing
Personalized treatment guided by mini-PDX and RNA sequencing,has_type,DRUG
Personalized treatment guided by mini-PDX and RNA sequencing,classified_as,OTHER
Personalized treatment guided by mini-PDX and RNA sequencing,targets,triple negative breast cancer
Personalized treatment guided by mini-PDX and RNA sequencing,targets,TNBC
NCT04745975,tests,Nab paclitaxel
Nab paclitaxel,has_type,DRUG
Nab paclitaxel,classified_as,CHEMICAL
Nab paclitaxel,targets,triple negative breast cancer
Nab paclitaxel,targets,TNBC
NCT04745975,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,triple negative breast cancer
Eribulin,targets,TNBC
NCT04745975,tests,Vinorelbine
Vinorelbine,has_type,DRUG
Vinorelbine,classified_as,OTHER
Vinorelbine,targets,triple negative breast cancer
Vinorelbine,targets,TNBC
NCT04745975,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast cancer
Gemcitabine,targets,TNBC
NCT04745975,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,triple negative breast cancer
Capecitabine,targets,TNBC
NCT03401385,sponsored_by,"Daiichi Sankyo Co., Ltd."
NCT03401385,has_status,ACTIVE_NOT_RECRUITING
NCT03401385,tests,Datopotamab Deruxtecan (Dato-DXd)
Datopotamab Deruxtecan (Dato-DXd),has_type,DRUG
Datopotamab Deruxtecan (Dato-DXd),classified_as,BIOLOGIC
Datopotamab Deruxtecan (Dato-DXd),targets,hormone receptor positive breast cancer
Datopotamab Deruxtecan (Dato-DXd),targets,non-small cell lung cancer
Datopotamab Deruxtecan (Dato-DXd),targets,triple negative breast cancer
Datopotamab Deruxtecan (Dato-DXd),targets,TNBC
NCT03401385,tests,Steroid Containing Mouthwash
Steroid Containing Mouthwash,has_type,DRUG
Steroid Containing Mouthwash,classified_as,OTHER
Steroid Containing Mouthwash,targets,hormone receptor positive breast cancer
Steroid Containing Mouthwash,targets,non-small cell lung cancer
Steroid Containing Mouthwash,targets,triple negative breast cancer
Steroid Containing Mouthwash,targets,TNBC
NCT03401385,tests,Non-Steroid Containing Mouthwash
Non-Steroid Containing Mouthwash,has_type,DRUG
Non-Steroid Containing Mouthwash,classified_as,OTHER
Non-Steroid Containing Mouthwash,targets,hormone receptor positive breast cancer
Non-Steroid Containing Mouthwash,targets,non-small cell lung cancer
Non-Steroid Containing Mouthwash,targets,triple negative breast cancer
Non-Steroid Containing Mouthwash,targets,TNBC
NCT01395056,sponsored_by,Peking University Cancer Hospital & Institute
NCT01395056,has_status,COMPLETED
NCT00546156,sponsored_by,"Ian E. Krop, MD, PhD"
NCT00546156,has_status,COMPLETED
NCT00546156,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,breast cancer
NCT00546156,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
NCT00546156,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
NCT00546156,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,breast cancer
NCT02411656,sponsored_by,M.D. Anderson Cancer Center
NCT02411656,has_status,ACTIVE_NOT_RECRUITING
NCT02411656,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,recurrent inflammatory breast carcinoma
Laboratory Biomarker Analysis,targets,progesterone receptor negative
Laboratory Biomarker Analysis,targets,erythema
Laboratory Biomarker Analysis,targets,edema
Laboratory Biomarker Analysis,targets,estrogen receptor negative
Laboratory Biomarker Analysis,targets,peau d'orange
Laboratory Biomarker Analysis,targets,her2/neu negative
Laboratory Biomarker Analysis,targets,stage iv inflammatory breast carcinoma
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,TNBC
NCT02411656,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,recurrent inflammatory breast carcinoma
Pembrolizumab,targets,progesterone receptor negative
Pembrolizumab,targets,erythema
Pembrolizumab,targets,edema
Pembrolizumab,targets,estrogen receptor negative
Pembrolizumab,targets,peau d'orange
Pembrolizumab,targets,her2/neu negative
Pembrolizumab,targets,stage iv inflammatory breast carcinoma
Pembrolizumab,targets,triple-negative breast carcinoma
Pembrolizumab,targets,TNBC
NCT03746431,sponsored_by,Fusion Pharmaceuticals Inc.
NCT03746431,has_status,RECRUITING
NCT03746431,tests,[111In]-FPI-1547 Injection
[111In]-FPI-1547 Injection,has_type,DRUG
[111In]-FPI-1547 Injection,classified_as,OTHER
[111In]-FPI-1547 Injection,targets,head and neck squamous cell carcinoma (hnscc)
[111In]-FPI-1547 Injection,targets,uveal melanoma
[111In]-FPI-1547 Injection,targets,adrenocortical carcinoma
[111In]-FPI-1547 Injection,targets,breast cancer
[111In]-FPI-1547 Injection,targets,her2-negative breast cancer
[111In]-FPI-1547 Injection,targets,ovarian cancer
[111In]-FPI-1547 Injection,targets,advanced solid tumours
[111In]-FPI-1547 Injection,targets,cervical cancer
[111In]-FPI-1547 Injection,targets,triple negative breast cancer (tnbc)
[111In]-FPI-1547 Injection,targets,endometrial cancer
[111In]-FPI-1547 Injection,targets,TNBC
NCT03746431,tests,[225Ac]-FPI-1434 Injection multi-dose
[225Ac]-FPI-1434 Injection multi-dose,has_type,DRUG
[225Ac]-FPI-1434 Injection multi-dose,classified_as,OTHER
[225Ac]-FPI-1434 Injection multi-dose,targets,head and neck squamous cell carcinoma (hnscc)
[225Ac]-FPI-1434 Injection multi-dose,targets,uveal melanoma
[225Ac]-FPI-1434 Injection multi-dose,targets,adrenocortical carcinoma
[225Ac]-FPI-1434 Injection multi-dose,targets,breast cancer
[225Ac]-FPI-1434 Injection multi-dose,targets,her2-negative breast cancer
[225Ac]-FPI-1434 Injection multi-dose,targets,ovarian cancer
[225Ac]-FPI-1434 Injection multi-dose,targets,advanced solid tumours
[225Ac]-FPI-1434 Injection multi-dose,targets,cervical cancer
[225Ac]-FPI-1434 Injection multi-dose,targets,triple negative breast cancer (tnbc)
[225Ac]-FPI-1434 Injection multi-dose,targets,endometrial cancer
[225Ac]-FPI-1434 Injection multi-dose,targets,TNBC
NCT03746431,tests,FPI-1175 Infusion
FPI-1175 Infusion,has_type,DRUG
FPI-1175 Infusion,classified_as,OTHER
FPI-1175 Infusion,targets,head and neck squamous cell carcinoma (hnscc)
FPI-1175 Infusion,targets,uveal melanoma
FPI-1175 Infusion,targets,adrenocortical carcinoma
FPI-1175 Infusion,targets,breast cancer
FPI-1175 Infusion,targets,her2-negative breast cancer
FPI-1175 Infusion,targets,ovarian cancer
FPI-1175 Infusion,targets,advanced solid tumours
FPI-1175 Infusion,targets,cervical cancer
FPI-1175 Infusion,targets,triple negative breast cancer (tnbc)
FPI-1175 Infusion,targets,endometrial cancer
FPI-1175 Infusion,targets,TNBC
NCT03746431,tests,[225Ac]-FPI-1434 Injection single-dose
[225Ac]-FPI-1434 Injection single-dose,has_type,DRUG
[225Ac]-FPI-1434 Injection single-dose,classified_as,OTHER
[225Ac]-FPI-1434 Injection single-dose,targets,head and neck squamous cell carcinoma (hnscc)
[225Ac]-FPI-1434 Injection single-dose,targets,uveal melanoma
[225Ac]-FPI-1434 Injection single-dose,targets,adrenocortical carcinoma
[225Ac]-FPI-1434 Injection single-dose,targets,breast cancer
[225Ac]-FPI-1434 Injection single-dose,targets,her2-negative breast cancer
[225Ac]-FPI-1434 Injection single-dose,targets,ovarian cancer
[225Ac]-FPI-1434 Injection single-dose,targets,advanced solid tumours
[225Ac]-FPI-1434 Injection single-dose,targets,cervical cancer
[225Ac]-FPI-1434 Injection single-dose,targets,triple negative breast cancer (tnbc)
[225Ac]-FPI-1434 Injection single-dose,targets,endometrial cancer
[225Ac]-FPI-1434 Injection single-dose,targets,TNBC
NCT02338531,sponsored_by,Jules Bordet Institute
NCT02338531,has_status,WITHDRAWN
NCT02338531,tests,PF-03084014
PF-03084014,has_type,DRUG
PF-03084014,classified_as,OTHER
PF-03084014,targets,breast cancer
NCT02338531,tests,Breast cancer surgery
Breast cancer surgery,has_type,DRUG
Breast cancer surgery,classified_as,OTHER
Breast cancer surgery,targets,breast cancer
NCT03992131,sponsored_by,pharmaand GmbH
NCT03992131,has_status,TERMINATED
NCT03992131,tests,Rucaparib
Rucaparib,has_type,DRUG
Rucaparib,classified_as,CHEMICAL
Rucaparib,targets,urothelial carcinoma
Rucaparib,targets,triple-negative breast cancer
Rucaparib,targets,ovarian cancer
Rucaparib,targets,solid tumor
Rucaparib,targets,TNBC
NCT03992131,tests,Lucitanib
Lucitanib,has_type,DRUG
Lucitanib,classified_as,CHEMICAL
Lucitanib,targets,urothelial carcinoma
Lucitanib,targets,triple-negative breast cancer
Lucitanib,targets,ovarian cancer
Lucitanib,targets,solid tumor
Lucitanib,targets,TNBC
NCT03992131,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
Sacituzumab govitecan,classified_as,BIOLOGIC
Sacituzumab govitecan,targets,urothelial carcinoma
Sacituzumab govitecan,targets,triple-negative breast cancer
Sacituzumab govitecan,targets,ovarian cancer
Sacituzumab govitecan,targets,solid tumor
Sacituzumab govitecan,targets,TNBC
NCT04556773,sponsored_by,AstraZeneca
NCT04556773,has_status,ACTIVE_NOT_RECRUITING
NCT04556773,tests,Trastuzumab deruxtecan
Trastuzumab deruxtecan,has_type,DRUG
Trastuzumab deruxtecan,classified_as,BIOLOGIC
Trastuzumab deruxtecan,targets,metastatic breast cancer
NCT04556773,tests,Durvalumab
Durvalumab,has_type,DRUG
Durvalumab,classified_as,BIOLOGIC
Durvalumab,targets,metastatic breast cancer
NCT04556773,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,metastatic breast cancer
NCT04556773,tests,Capivasertib
Capivasertib,has_type,DRUG
Capivasertib,classified_as,CHEMICAL
Capivasertib,targets,metastatic breast cancer
NCT04556773,tests,Anastrozole
Anastrozole,has_type,DRUG
Anastrozole,classified_as,CHEMICAL
Anastrozole,targets,metastatic breast cancer
NCT04556773,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,metastatic breast cancer
NCT04556773,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,metastatic breast cancer
NCT06590558,sponsored_by,National Cancer Institute (NCI)
NCT06590558,has_status,WITHDRAWN
NCT06590558,tests,Biopsy Procedure
Biopsy Procedure,has_type,DRUG
Biopsy Procedure,classified_as,OTHER
Biopsy Procedure,targets,locally advanced hormone receptor-positive breast carcinoma
Biopsy Procedure,targets,invasive breast carcinoma
Biopsy Procedure,targets,metastatic hormone receptor-positive breast carcinoma
Biopsy Procedure,targets,unresectable hormone receptor-positive breast carcinoma
Biopsy Procedure,targets,unresectable triple-negative breast carcinoma
Biopsy Procedure,targets,locally advanced her2-negative breast carcinoma
Biopsy Procedure,targets,locally advanced triple-negative breast carcinoma
Biopsy Procedure,targets,anatomic stage iv breast cancer ajcc v8
Biopsy Procedure,targets,metastatic her2-negative breast carcinoma
Biopsy Procedure,targets,metastatic triple-negative breast carcinoma
Biopsy Procedure,targets,anatomic stage iii breast cancer ajcc v8
Biopsy Procedure,targets,unresectable her2-negative breast carcinoma
Biopsy Procedure,targets,TNBC
NCT06590558,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,locally advanced hormone receptor-positive breast carcinoma
Biospecimen Collection,targets,invasive breast carcinoma
Biospecimen Collection,targets,metastatic hormone receptor-positive breast carcinoma
Biospecimen Collection,targets,unresectable hormone receptor-positive breast carcinoma
Biospecimen Collection,targets,unresectable triple-negative breast carcinoma
Biospecimen Collection,targets,locally advanced her2-negative breast carcinoma
Biospecimen Collection,targets,locally advanced triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iv breast cancer ajcc v8
Biospecimen Collection,targets,metastatic her2-negative breast carcinoma
Biospecimen Collection,targets,metastatic triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage iii breast cancer ajcc v8
Biospecimen Collection,targets,unresectable her2-negative breast carcinoma
Biospecimen Collection,targets,TNBC
NCT06590558,tests,Computed Tomography
Computed Tomography,has_type,DRUG
Computed Tomography,classified_as,OTHER
Computed Tomography,targets,locally advanced hormone receptor-positive breast carcinoma
Computed Tomography,targets,invasive breast carcinoma
Computed Tomography,targets,metastatic hormone receptor-positive breast carcinoma
Computed Tomography,targets,unresectable hormone receptor-positive breast carcinoma
Computed Tomography,targets,unresectable triple-negative breast carcinoma
Computed Tomography,targets,locally advanced her2-negative breast carcinoma
Computed Tomography,targets,locally advanced triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iv breast cancer ajcc v8
Computed Tomography,targets,metastatic her2-negative breast carcinoma
Computed Tomography,targets,metastatic triple-negative breast carcinoma
Computed Tomography,targets,anatomic stage iii breast cancer ajcc v8
Computed Tomography,targets,unresectable her2-negative breast carcinoma
Computed Tomography,targets,TNBC
NCT06590558,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
Eribulin Mesylate,classified_as,CHEMICAL
Eribulin Mesylate,targets,locally advanced hormone receptor-positive breast carcinoma
Eribulin Mesylate,targets,invasive breast carcinoma
Eribulin Mesylate,targets,metastatic hormone receptor-positive breast carcinoma
Eribulin Mesylate,targets,unresectable hormone receptor-positive breast carcinoma
Eribulin Mesylate,targets,unresectable triple-negative breast carcinoma
Eribulin Mesylate,targets,locally advanced her2-negative breast carcinoma
Eribulin Mesylate,targets,locally advanced triple-negative breast carcinoma
Eribulin Mesylate,targets,anatomic stage iv breast cancer ajcc v8
Eribulin Mesylate,targets,metastatic her2-negative breast carcinoma
Eribulin Mesylate,targets,metastatic triple-negative breast carcinoma
Eribulin Mesylate,targets,anatomic stage iii breast cancer ajcc v8
Eribulin Mesylate,targets,unresectable her2-negative breast carcinoma
Eribulin Mesylate,targets,TNBC
NCT06590558,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,DRUG
Magnetic Resonance Imaging,classified_as,OTHER
Magnetic Resonance Imaging,targets,locally advanced hormone receptor-positive breast carcinoma
Magnetic Resonance Imaging,targets,invasive breast carcinoma
Magnetic Resonance Imaging,targets,metastatic hormone receptor-positive breast carcinoma
Magnetic Resonance Imaging,targets,unresectable hormone receptor-positive breast carcinoma
Magnetic Resonance Imaging,targets,unresectable triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,locally advanced her2-negative breast carcinoma
Magnetic Resonance Imaging,targets,locally advanced triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iv breast cancer ajcc v8
Magnetic Resonance Imaging,targets,metastatic her2-negative breast carcinoma
Magnetic Resonance Imaging,targets,metastatic triple-negative breast carcinoma
Magnetic Resonance Imaging,targets,anatomic stage iii breast cancer ajcc v8
Magnetic Resonance Imaging,targets,unresectable her2-negative breast carcinoma
Magnetic Resonance Imaging,targets,TNBC
NCT06590558,tests,Tolinapant
Tolinapant,has_type,DRUG
Tolinapant,classified_as,OTHER
Tolinapant,targets,locally advanced hormone receptor-positive breast carcinoma
Tolinapant,targets,invasive breast carcinoma
Tolinapant,targets,metastatic hormone receptor-positive breast carcinoma
Tolinapant,targets,unresectable hormone receptor-positive breast carcinoma
Tolinapant,targets,unresectable triple-negative breast carcinoma
Tolinapant,targets,locally advanced her2-negative breast carcinoma
Tolinapant,targets,locally advanced triple-negative breast carcinoma
Tolinapant,targets,anatomic stage iv breast cancer ajcc v8
Tolinapant,targets,metastatic her2-negative breast carcinoma
Tolinapant,targets,metastatic triple-negative breast carcinoma
Tolinapant,targets,anatomic stage iii breast cancer ajcc v8
Tolinapant,targets,unresectable her2-negative breast carcinoma
Tolinapant,targets,TNBC
NCT06590558,tests,X-Ray Imaging
X-Ray Imaging,has_type,DRUG
X-Ray Imaging,classified_as,OTHER
X-Ray Imaging,targets,locally advanced hormone receptor-positive breast carcinoma
X-Ray Imaging,targets,invasive breast carcinoma
X-Ray Imaging,targets,metastatic hormone receptor-positive breast carcinoma
X-Ray Imaging,targets,unresectable hormone receptor-positive breast carcinoma
X-Ray Imaging,targets,unresectable triple-negative breast carcinoma
X-Ray Imaging,targets,locally advanced her2-negative breast carcinoma
X-Ray Imaging,targets,locally advanced triple-negative breast carcinoma
X-Ray Imaging,targets,anatomic stage iv breast cancer ajcc v8
X-Ray Imaging,targets,metastatic her2-negative breast carcinoma
X-Ray Imaging,targets,metastatic triple-negative breast carcinoma
X-Ray Imaging,targets,anatomic stage iii breast cancer ajcc v8
X-Ray Imaging,targets,unresectable her2-negative breast carcinoma
X-Ray Imaging,targets,TNBC
NCT02375958,sponsored_by,Novartis Pharmaceuticals
NCT02375958,has_status,COMPLETED
NCT02375958,tests,PCA062
PCA062,has_type,DRUG
PCA062,classified_as,OTHER
PCA062,targets,esophageal cancer
PCA062,targets,head & neck cancer
PCA062,targets,triple negative breast cancer
PCA062,targets,TNBC
NCT04626635,sponsored_by,Regeneron Pharmaceuticals
NCT04626635,has_status,RECRUITING
NCT04626635,tests,REGN7075
REGN7075,has_type,DRUG
REGN7075,classified_as,OTHER
REGN7075,targets,advanced solid tumors
NCT04626635,tests,Cemiplimab
Cemiplimab,has_type,DRUG
Cemiplimab,classified_as,BIOLOGIC
Cemiplimab,targets,advanced solid tumors
NCT04626635,tests,Platinum-based doublet chemotherapy
Platinum-based doublet chemotherapy,has_type,DRUG
Platinum-based doublet chemotherapy,classified_as,CHEMICAL
Platinum-based doublet chemotherapy,targets,advanced solid tumors
NCT04626635,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,advanced solid tumors
NCT04626635,tests,Trifluridine-tipiracil
Trifluridine-tipiracil,has_type,DRUG
Trifluridine-tipiracil,classified_as,OTHER
Trifluridine-tipiracil,targets,advanced solid tumors
NCT06224673,sponsored_by,"Laura Huppert, MD, BA"
NCT06224673,has_status,NOT_YET_RECRUITING
NCT06224673,tests,ARX788
ARX788,has_type,DRUG
ARX788,classified_as,OTHER
ARX788,targets,her2 low breast carcinoma
ARX788,targets,hormone receptor positive breast carcinoma
ARX788,targets,hormone-receptor-positive breast cancer
ARX788,targets,triple negative breast cancer
ARX788,targets,TNBC
NCT06224673,tests,Computed Tomography (CT)
Computed Tomography (CT),has_type,DRUG
Computed Tomography (CT),classified_as,OTHER
Computed Tomography (CT),targets,her2 low breast carcinoma
Computed Tomography (CT),targets,hormone receptor positive breast carcinoma
Computed Tomography (CT),targets,hormone-receptor-positive breast cancer
Computed Tomography (CT),targets,triple negative breast cancer
Computed Tomography (CT),targets,TNBC
NCT06224673,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,her2 low breast carcinoma
Biospecimen Collection,targets,hormone receptor positive breast carcinoma
Biospecimen Collection,targets,hormone-receptor-positive breast cancer
Biospecimen Collection,targets,triple negative breast cancer
Biospecimen Collection,targets,TNBC
NCT06224673,tests,Amiloride
Amiloride,has_type,DRUG
Amiloride,classified_as,OTHER
Amiloride,targets,her2 low breast carcinoma
Amiloride,targets,hormone receptor positive breast carcinoma
Amiloride,targets,hormone-receptor-positive breast cancer
Amiloride,targets,triple negative breast cancer
Amiloride,targets,TNBC
NCT06767527,sponsored_by,Akeso
NCT06767527,has_status,NOT_YET_RECRUITING
NCT06767527,tests,AK112
AK112,has_type,DRUG
AK112,classified_as,OTHER
AK112,targets,triple-negative breast cancer (tnbc)
AK112,targets,TNBC
NCT06767527,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple-negative breast cancer (tnbc)
Nab-paclitaxel,targets,TNBC
NCT06767527,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple-negative breast cancer (tnbc)
Placebo,targets,TNBC
NCT05491694,sponsored_by,The First Affiliated Hospital with Nanjing Medical University
NCT05491694,has_status,UNKNOWN
NCT05491694,tests,Toripalimab
Toripalimab,has_type,DRUG
Toripalimab,classified_as,BIOLOGIC
Toripalimab,targets,breast cancer
Toripalimab,targets,tnbc - triple-negative breast cancer
Toripalimab,targets,TNBC
NCT05491694,tests,Epirubicin
Epirubicin,has_type,DRUG
Epirubicin,classified_as,OTHER
Epirubicin,targets,breast cancer
Epirubicin,targets,tnbc - triple-negative breast cancer
Epirubicin,targets,TNBC
NCT05491694,tests,High Intensity Focused Ultrasoun
High Intensity Focused Ultrasoun,has_type,DRUG
High Intensity Focused Ultrasoun,classified_as,OTHER
High Intensity Focused Ultrasoun,targets,breast cancer
High Intensity Focused Ultrasoun,targets,tnbc - triple-negative breast cancer
High Intensity Focused Ultrasoun,targets,TNBC
NCT05491694,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer
Cyclophosphamide,targets,tnbc - triple-negative breast cancer
Cyclophosphamide,targets,TNBC
NCT05491694,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,tnbc - triple-negative breast cancer
Carboplatin,targets,TNBC
NCT05491694,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,breast cancer
Nab-paclitaxel,targets,tnbc - triple-negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT04799249,sponsored_by,"G1 Therapeutics, Inc."
NCT04799249,has_status,COMPLETED
NCT04799249,tests,Trilaciclib
Trilaciclib,has_type,DRUG
Trilaciclib,classified_as,CHEMICAL
Trilaciclib,targets,breast cancer
Trilaciclib,targets,tnbc - triple-negative breast cancer
Trilaciclib,targets,TNBC
NCT04799249,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,breast cancer
Placebo,targets,tnbc - triple-negative breast cancer
Placebo,targets,TNBC
NCT04799249,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,breast cancer
Gemcitabine,targets,tnbc - triple-negative breast cancer
Gemcitabine,targets,TNBC
NCT04799249,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,tnbc - triple-negative breast cancer
Carboplatin,targets,TNBC
NCT05451849,sponsored_by,TCR2 Therapeutics
NCT05451849,has_status,ACTIVE_NOT_RECRUITING
NCT05451849,tests,TC-510
TC-510,has_type,DRUG
TC-510,classified_as,OTHER
TC-510,targets,ovarian serous adenocarcinoma
TC-510,targets,mesothelioma peritoneum
TC-510,targets,"mesothelioma, malignant"
TC-510,targets,pancreatic cancer
TC-510,targets,mesotheliomas pleural
TC-510,targets,mesothelioma
TC-510,targets,ovarian cancer
TC-510,targets,triple negative breast cancer
TC-510,targets,ovarian adenocarcinoma
TC-510,targets,colorectal neoplasms
TC-510,targets,tnbc - triple-negative breast cancer
TC-510,targets,ovarian neoplasms
TC-510,targets,cholangiocarcinoma
TC-510,targets,pancreatic neoplasms
TC-510,targets,non small cell lung cancer
TC-510,targets,pancreatic adenocarcinoma
TC-510,targets,colorectal cancer
TC-510,targets,TNBC
NCT05451849,tests,Fludarabine
Fludarabine,has_type,DRUG
Fludarabine,classified_as,OTHER
Fludarabine,targets,ovarian serous adenocarcinoma
Fludarabine,targets,mesothelioma peritoneum
Fludarabine,targets,"mesothelioma, malignant"
Fludarabine,targets,pancreatic cancer
Fludarabine,targets,mesotheliomas pleural
Fludarabine,targets,mesothelioma
Fludarabine,targets,ovarian cancer
Fludarabine,targets,triple negative breast cancer
Fludarabine,targets,ovarian adenocarcinoma
Fludarabine,targets,colorectal neoplasms
Fludarabine,targets,tnbc - triple-negative breast cancer
Fludarabine,targets,ovarian neoplasms
Fludarabine,targets,cholangiocarcinoma
Fludarabine,targets,pancreatic neoplasms
Fludarabine,targets,non small cell lung cancer
Fludarabine,targets,pancreatic adenocarcinoma
Fludarabine,targets,colorectal cancer
Fludarabine,targets,TNBC
NCT05451849,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,ovarian serous adenocarcinoma
Cyclophosphamide,targets,mesothelioma peritoneum
Cyclophosphamide,targets,"mesothelioma, malignant"
Cyclophosphamide,targets,pancreatic cancer
Cyclophosphamide,targets,mesotheliomas pleural
Cyclophosphamide,targets,mesothelioma
Cyclophosphamide,targets,ovarian cancer
Cyclophosphamide,targets,triple negative breast cancer
Cyclophosphamide,targets,ovarian adenocarcinoma
Cyclophosphamide,targets,colorectal neoplasms
Cyclophosphamide,targets,tnbc - triple-negative breast cancer
Cyclophosphamide,targets,ovarian neoplasms
Cyclophosphamide,targets,cholangiocarcinoma
Cyclophosphamide,targets,pancreatic neoplasms
Cyclophosphamide,targets,non small cell lung cancer
Cyclophosphamide,targets,pancreatic adenocarcinoma
Cyclophosphamide,targets,colorectal cancer
Cyclophosphamide,targets,TNBC
NCT05112536,sponsored_by,"G1 Therapeutics, Inc."
NCT05112536,has_status,COMPLETED
NCT05112536,tests,Trilaciclib
Trilaciclib,has_type,DRUG
Trilaciclib,classified_as,CHEMICAL
Trilaciclib,targets,breast cancer
Trilaciclib,targets,triple negative breast cancer
Trilaciclib,targets,TNBC
NCT05112536,tests,Cylophosphamide
Cylophosphamide,has_type,DRUG
Cylophosphamide,classified_as,OTHER
Cylophosphamide,targets,breast cancer
Cylophosphamide,targets,triple negative breast cancer
Cylophosphamide,targets,TNBC
NCT05112536,tests,Doxorubicin
Doxorubicin,has_type,DRUG
Doxorubicin,classified_as,CHEMICAL
Doxorubicin,targets,breast cancer
Doxorubicin,targets,triple negative breast cancer
Doxorubicin,targets,TNBC
NCT05112536,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT05112536,tests,Carboplatin (Investigator discretion)
Carboplatin (Investigator discretion),has_type,DRUG
Carboplatin (Investigator discretion),classified_as,CHEMICAL
Carboplatin (Investigator discretion),targets,breast cancer
Carboplatin (Investigator discretion),targets,triple negative breast cancer
Carboplatin (Investigator discretion),targets,TNBC
NCT05112536,tests,Pembrolizumab (Investigator discretion)
Pembrolizumab (Investigator discretion),has_type,DRUG
Pembrolizumab (Investigator discretion),classified_as,BIOLOGIC
Pembrolizumab (Investigator discretion),targets,breast cancer
Pembrolizumab (Investigator discretion),targets,triple negative breast cancer
Pembrolizumab (Investigator discretion),targets,TNBC
NCT02048059,sponsored_by,Angiochem Inc
NCT02048059,has_status,COMPLETED
NCT02048059,tests,ANG1005
ANG1005,has_type,DRUG
ANG1005,classified_as,OTHER
ANG1005,targets,breast cancer
ANG1005,targets,brain metastases
NCT04244552,sponsored_by,"Atreca, Inc."
NCT04244552,has_status,TERMINATED
NCT04244552,tests,ATRC-101
ATRC-101,has_type,DRUG
ATRC-101,classified_as,OTHER
ATRC-101,targets,acral lentiginous melanoma
ATRC-101,targets,non-small cell lung cancer
ATRC-101,targets,melanoma
ATRC-101,targets,msi-h colorectal cancer
ATRC-101,targets,breast cancer
ATRC-101,targets,hepatocellular carcinoma
ATRC-101,targets,dmmr colorectal cancer
ATRC-101,targets,urothelial carcinoma
ATRC-101,targets,platinum-resistant primary peritoneal carcinoma
ATRC-101,targets,ovarian cancer
ATRC-101,targets,esophageal squamous cell carcinoma
ATRC-101,targets,platinum-resistant fallopian tube carcinoma
ATRC-101,targets,platinum-resistant epithelial ovarian cancer
ATRC-101,targets,triple negative breast cancer
ATRC-101,targets,head and neck squamous cell carcinoma
ATRC-101,targets,colorectal cancer
ATRC-101,targets,TNBC
NCT04244552,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,acral lentiginous melanoma
Pembrolizumab,targets,non-small cell lung cancer
Pembrolizumab,targets,melanoma
Pembrolizumab,targets,msi-h colorectal cancer
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,hepatocellular carcinoma
Pembrolizumab,targets,dmmr colorectal cancer
Pembrolizumab,targets,urothelial carcinoma
Pembrolizumab,targets,platinum-resistant primary peritoneal carcinoma
Pembrolizumab,targets,ovarian cancer
Pembrolizumab,targets,esophageal squamous cell carcinoma
Pembrolizumab,targets,platinum-resistant fallopian tube carcinoma
Pembrolizumab,targets,platinum-resistant epithelial ovarian cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,head and neck squamous cell carcinoma
Pembrolizumab,targets,colorectal cancer
Pembrolizumab,targets,TNBC
NCT04244552,tests,Pegylated liposomal doxorubicin (PLD)
Pegylated liposomal doxorubicin (PLD),has_type,DRUG
Pegylated liposomal doxorubicin (PLD),classified_as,CHEMICAL
Pegylated liposomal doxorubicin (PLD),targets,acral lentiginous melanoma
Pegylated liposomal doxorubicin (PLD),targets,non-small cell lung cancer
Pegylated liposomal doxorubicin (PLD),targets,melanoma
Pegylated liposomal doxorubicin (PLD),targets,msi-h colorectal cancer
Pegylated liposomal doxorubicin (PLD),targets,breast cancer
Pegylated liposomal doxorubicin (PLD),targets,hepatocellular carcinoma
Pegylated liposomal doxorubicin (PLD),targets,dmmr colorectal cancer
Pegylated liposomal doxorubicin (PLD),targets,urothelial carcinoma
Pegylated liposomal doxorubicin (PLD),targets,platinum-resistant primary peritoneal carcinoma
Pegylated liposomal doxorubicin (PLD),targets,ovarian cancer
Pegylated liposomal doxorubicin (PLD),targets,esophageal squamous cell carcinoma
Pegylated liposomal doxorubicin (PLD),targets,platinum-resistant fallopian tube carcinoma
Pegylated liposomal doxorubicin (PLD),targets,platinum-resistant epithelial ovarian cancer
Pegylated liposomal doxorubicin (PLD),targets,triple negative breast cancer
Pegylated liposomal doxorubicin (PLD),targets,head and neck squamous cell carcinoma
Pegylated liposomal doxorubicin (PLD),targets,colorectal cancer
Pegylated liposomal doxorubicin (PLD),targets,TNBC
NCT06165900,sponsored_by,Shengjing Hospital
NCT06165900,has_status,RECRUITING
NCT06165900,tests,adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),has_type,DRUG
adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),classified_as,BIOLOGIC
adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),targets,breast cancer
adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),targets,stereotactic radiotherapy
adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),targets,immunotherapy
NCT06165900,tests,adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),has_type,DRUG
adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),classified_as,BIOLOGIC
adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),targets,breast cancer
adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),targets,stereotactic radiotherapy
adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin),targets,immunotherapy
NCT03095352,sponsored_by,"Laura Huppert, MD, BA"
NCT03095352,has_status,COMPLETED
NCT03095352,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,chest wall disease
NCT03095352,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,chest wall disease
NCT03095352,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,breast cancer
Trastuzumab,targets,chest wall disease
NCT01790932,sponsored_by,Dana-Farber Cancer Institute
NCT01790932,has_status,COMPLETED
NCT01790932,tests,BKM120
BKM120,has_type,DRUG
BKM120,classified_as,OTHER
BKM120,targets,breast cancer
NCT03277352,sponsored_by,Incyte Biosciences International Sàrl
NCT03277352,has_status,TERMINATED
NCT03277352,tests,INCAGN01876
INCAGN01876,has_type,DRUG
INCAGN01876,classified_as,OTHER
INCAGN01876,targets,advanced malignancies
INCAGN01876,targets,metastatic cancer
NCT03277352,tests,Epacadostat
Epacadostat,has_type,DRUG
Epacadostat,classified_as,OTHER
Epacadostat,targets,advanced malignancies
Epacadostat,targets,metastatic cancer
NCT03277352,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,advanced malignancies
Pembrolizumab,targets,metastatic cancer
NCT06351332,sponsored_by,"Filipa Lynce, MD"
NCT06351332,has_status,RECRUITING
NCT06351332,tests,Azenosertib
Azenosertib,has_type,DRUG
Azenosertib,classified_as,CHEMICAL
Azenosertib,targets,breast cancer
Azenosertib,targets,her2-negative breast cancer
Azenosertib,targets,triple negative breast cancer
Azenosertib,targets,breast cancer female
Azenosertib,targets,hormone receptor negative malignant tumor breast triple
Azenosertib,targets,TNBC
NCT06351332,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
Carboplatin,targets,her2-negative breast cancer
Carboplatin,targets,triple negative breast cancer
Carboplatin,targets,breast cancer female
Carboplatin,targets,hormone receptor negative malignant tumor breast triple
Carboplatin,targets,TNBC
NCT06351332,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,her2-negative breast cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,breast cancer female
Pembrolizumab,targets,hormone receptor negative malignant tumor breast triple
Pembrolizumab,targets,TNBC
NCT01401959,sponsored_by,"SCRI Development Innovations, LLC"
NCT01401959,has_status,COMPLETED
NCT01401959,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,metastatic breast cancer
NCT01401959,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,metastatic breast cancer
NCT01669252,sponsored_by,SOLTI Breast Cancer Research Group
NCT01669252,has_status,COMPLETED
NCT01669252,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,breast cancer
NCT02624700,sponsored_by,Virginia Commonwealth University
NCT02624700,has_status,TERMINATED
NCT02624700,tests,Experimental Arm A: Pemetrexed
Experimental Arm A: Pemetrexed,has_type,DRUG
Experimental Arm A: Pemetrexed,classified_as,OTHER
Experimental Arm A: Pemetrexed,targets,breast cancer
Experimental Arm A: Pemetrexed,targets,recurrent breast cancer
Experimental Arm A: Pemetrexed,targets,metastatic breast cancer
NCT02624700,tests,Experimental Arm A: Sorafenib
Experimental Arm A: Sorafenib,has_type,DRUG
Experimental Arm A: Sorafenib,classified_as,CHEMICAL
Experimental Arm A: Sorafenib,targets,breast cancer
Experimental Arm A: Sorafenib,targets,recurrent breast cancer
Experimental Arm A: Sorafenib,targets,metastatic breast cancer
NCT02624700,tests,Experimental Arm B: Pemetrexed
Experimental Arm B: Pemetrexed,has_type,DRUG
Experimental Arm B: Pemetrexed,classified_as,OTHER
Experimental Arm B: Pemetrexed,targets,breast cancer
Experimental Arm B: Pemetrexed,targets,recurrent breast cancer
Experimental Arm B: Pemetrexed,targets,metastatic breast cancer
NCT02624700,tests,Experimental Arm B: Sorafenib
Experimental Arm B: Sorafenib,has_type,DRUG
Experimental Arm B: Sorafenib,classified_as,CHEMICAL
Experimental Arm B: Sorafenib,targets,breast cancer
Experimental Arm B: Sorafenib,targets,recurrent breast cancer
Experimental Arm B: Sorafenib,targets,metastatic breast cancer
NCT01631552,sponsored_by,Gilead Sciences
NCT01631552,has_status,COMPLETED
NCT01631552,tests,Sacituzumab Govitecan-hziy (SG)
Sacituzumab Govitecan-hziy (SG),has_type,DRUG
Sacituzumab Govitecan-hziy (SG),classified_as,BIOLOGIC
Sacituzumab Govitecan-hziy (SG),targets,non-small cell lung cancer
Sacituzumab Govitecan-hziy (SG),targets,head and neck cancers- squamous cell
Sacituzumab Govitecan-hziy (SG),targets,glioblastoma multiforme
Sacituzumab Govitecan-hziy (SG),targets,pancreatic cancer
Sacituzumab Govitecan-hziy (SG),targets,carcinoma breast stage iv
Sacituzumab Govitecan-hziy (SG),targets,hepatocellular carcinoma
Sacituzumab Govitecan-hziy (SG),targets,hormone-refractory prostate cancer
Sacituzumab Govitecan-hziy (SG),targets,renal cell cancer
Sacituzumab Govitecan-hziy (SG),targets,urinary bladder neoplasms
Sacituzumab Govitecan-hziy (SG),targets,triple negative breast cancer
Sacituzumab Govitecan-hziy (SG),targets,esophageal cancer
Sacituzumab Govitecan-hziy (SG),targets,cervical cancer
Sacituzumab Govitecan-hziy (SG),targets,ovarian epithelial cancer
Sacituzumab Govitecan-hziy (SG),targets,small cell lung cancer
Sacituzumab Govitecan-hziy (SG),targets,endometrial cancer
Sacituzumab Govitecan-hziy (SG),targets,gastric adenocarcinoma
Sacituzumab Govitecan-hziy (SG),targets,TNBC
NCT04986852,sponsored_by,PharmAbcine
NCT04986852,has_status,RECRUITING
NCT04986852,tests,Olinvacimab
Olinvacimab,has_type,DRUG
Olinvacimab,classified_as,BIOLOGIC
Olinvacimab,targets,metastatic triple-negative breast cancer
Olinvacimab,targets,TNBC
NCT05329532,sponsored_by,Scancell Ltd
NCT05329532,has_status,RECRUITING
NCT05329532,tests,Modi-1/Modi-1v
Modi-1/Modi-1v,has_type,DRUG
Modi-1/Modi-1v,classified_as,OTHER
Modi-1/Modi-1v,targets,renal cell cancer
Modi-1/Modi-1v,targets,squamous cell carcinoma of the head and neck
Modi-1/Modi-1v,targets,high grade ovarian serous adenocarcinoma
Modi-1/Modi-1v,targets,triple negative breast cancer
Modi-1/Modi-1v,targets,TNBC
NCT05329532,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,renal cell cancer
Pembrolizumab,targets,squamous cell carcinoma of the head and neck
Pembrolizumab,targets,high grade ovarian serous adenocarcinoma
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT05329532,tests,MicronJet600™ microneedle device (NanoPass)
MicronJet600™ microneedle device (NanoPass),has_type,DRUG
MicronJet600™ microneedle device (NanoPass),classified_as,OTHER
MicronJet600™ microneedle device (NanoPass),targets,renal cell cancer
MicronJet600™ microneedle device (NanoPass),targets,squamous cell carcinoma of the head and neck
MicronJet600™ microneedle device (NanoPass),targets,high grade ovarian serous adenocarcinoma
MicronJet600™ microneedle device (NanoPass),targets,triple negative breast cancer
MicronJet600™ microneedle device (NanoPass),targets,TNBC
NCT06052852,sponsored_by,"Bolt Biotherapeutics, Inc."
NCT06052852,has_status,ACTIVE_NOT_RECRUITING
NCT06052852,tests,BDC-3042
BDC-3042,has_type,DRUG
BDC-3042,classified_as,OTHER
BDC-3042,targets,head and neck cancer
BDC-3042,targets,melanoma
BDC-3042,targets,non-small cell lung cancer
BDC-3042,targets,clear cell renal cell carcinoma
BDC-3042,targets,ovarian cancer
BDC-3042,targets,triple negative breast cancer
BDC-3042,targets,colorectal cancer
BDC-3042,targets,TNBC
NCT06052852,tests,Cemiplimab
Cemiplimab,has_type,DRUG
Cemiplimab,classified_as,BIOLOGIC
Cemiplimab,targets,head and neck cancer
Cemiplimab,targets,melanoma
Cemiplimab,targets,non-small cell lung cancer
Cemiplimab,targets,clear cell renal cell carcinoma
Cemiplimab,targets,ovarian cancer
Cemiplimab,targets,triple negative breast cancer
Cemiplimab,targets,colorectal cancer
Cemiplimab,targets,TNBC
NCT01234532,sponsored_by,"University of Maryland, Baltimore"
NCT01234532,has_status,TERMINATED
NCT01234532,tests,entinostat
entinostat,has_type,DRUG
entinostat,classified_as,OTHER
entinostat,targets,progesterone receptor-negative breast cancer
entinostat,targets,stage i breast cancer
entinostat,targets,her2-negative breast cancer
entinostat,targets,stage iiia breast cancer
entinostat,targets,estrogen receptor-negative breast cancer
entinostat,targets,stage ii breast cancer
entinostat,targets,triple-negative breast cancer
entinostat,targets,TNBC
NCT01234532,tests,anastrozole
anastrozole,has_type,DRUG
anastrozole,classified_as,CHEMICAL
anastrozole,targets,progesterone receptor-negative breast cancer
anastrozole,targets,stage i breast cancer
anastrozole,targets,her2-negative breast cancer
anastrozole,targets,stage iiia breast cancer
anastrozole,targets,estrogen receptor-negative breast cancer
anastrozole,targets,stage ii breast cancer
anastrozole,targets,triple-negative breast cancer
anastrozole,targets,TNBC
NCT01234532,tests,diagnostic laboratory biomarker analysis
diagnostic laboratory biomarker analysis,has_type,DRUG
diagnostic laboratory biomarker analysis,classified_as,OTHER
diagnostic laboratory biomarker analysis,targets,progesterone receptor-negative breast cancer
diagnostic laboratory biomarker analysis,targets,stage i breast cancer
diagnostic laboratory biomarker analysis,targets,her2-negative breast cancer
diagnostic laboratory biomarker analysis,targets,stage iiia breast cancer
diagnostic laboratory biomarker analysis,targets,estrogen receptor-negative breast cancer
diagnostic laboratory biomarker analysis,targets,stage ii breast cancer
diagnostic laboratory biomarker analysis,targets,triple-negative breast cancer
diagnostic laboratory biomarker analysis,targets,TNBC
NCT01234532,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,DRUG
therapeutic conventional surgery,classified_as,OTHER
therapeutic conventional surgery,targets,progesterone receptor-negative breast cancer
therapeutic conventional surgery,targets,stage i breast cancer
therapeutic conventional surgery,targets,her2-negative breast cancer
therapeutic conventional surgery,targets,stage iiia breast cancer
therapeutic conventional surgery,targets,estrogen receptor-negative breast cancer
therapeutic conventional surgery,targets,stage ii breast cancer
therapeutic conventional surgery,targets,triple-negative breast cancer
therapeutic conventional surgery,targets,TNBC
NCT06273852,sponsored_by,Pure Biologics S.A.
NCT06273852,has_status,RECRUITING
NCT06273852,tests,PBA-0405
PBA-0405,has_type,DRUG
PBA-0405,classified_as,OTHER
PBA-0405,targets,soft tissue sarcoma adult
PBA-0405,targets,head and neck squamous cell carcinoma
PBA-0405,targets,triple negative breast cancer
PBA-0405,targets,TNBC
NCT05174832,sponsored_by,Fudan University
NCT05174832,has_status,UNKNOWN
NCT05174832,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,triple negative breast cancer
Cisplatin,targets,TNBC
NCT05174832,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT05174832,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT05174832,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,triple negative breast cancer
Olaparib,targets,TNBC
NCT05556200,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05556200,has_status,RECRUITING
NCT05556200,tests,Anti-PD-1 monoclonal antibody
Anti-PD-1 monoclonal antibody,has_type,DRUG
Anti-PD-1 monoclonal antibody,classified_as,BIOLOGIC
Anti-PD-1 monoclonal antibody,targets,breast cancer
Anti-PD-1 monoclonal antibody,targets,triple-negative breast cancer
Anti-PD-1 monoclonal antibody,targets,TNBC
NCT05556200,tests,VEGFR2 Tyrosine Kinase Inhibitor
VEGFR2 Tyrosine Kinase Inhibitor,has_type,DRUG
VEGFR2 Tyrosine Kinase Inhibitor,classified_as,BIOLOGIC
VEGFR2 Tyrosine Kinase Inhibitor,targets,breast cancer
VEGFR2 Tyrosine Kinase Inhibitor,targets,triple-negative breast cancer
VEGFR2 Tyrosine Kinase Inhibitor,targets,TNBC
NCT03057600,sponsored_by,"Calithera Biosciences, Inc"
NCT03057600,has_status,COMPLETED
NCT03057600,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,tnbc - triple-negative breast cancer
Paclitaxel,targets,triple negative breast cancer
Paclitaxel,targets,TNBC
NCT03057600,tests,CB-839
CB-839,has_type,DRUG
CB-839,classified_as,OTHER
CB-839,targets,tnbc - triple-negative breast cancer
CB-839,targets,triple negative breast cancer
CB-839,targets,TNBC
NCT03121352,sponsored_by,Case Comprehensive Cancer Center
NCT03121352,has_status,COMPLETED
NCT03121352,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,metastatic triple negative breast cancer
Carboplatin,targets,TNBC
NCT03121352,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,metastatic triple negative breast cancer
Nab-paclitaxel,targets,TNBC
NCT03121352,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,metastatic triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT03295552,sponsored_by,Shanghai Jiao Tong University School of Medicine
NCT03295552,has_status,TERMINATED
NCT03295552,tests,Decitabine
Decitabine,has_type,DRUG
Decitabine,classified_as,OTHER
Decitabine,targets,breast neoplasm
NCT03295552,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast neoplasm
NCT02639832,sponsored_by,Cynvenio Biosystems
NCT02639832,has_status,UNKNOWN
NCT02639832,tests,"LiquidBiopsy®, NK VueTM"
"LiquidBiopsy®, NK VueTM",has_type,DRUG
"LiquidBiopsy®, NK VueTM",classified_as,OTHER
"LiquidBiopsy®, NK VueTM",targets,natural killer cells
"LiquidBiopsy®, NK VueTM",targets,brca mutation
"LiquidBiopsy®, NK VueTM",targets,triple negative breast cancer
"LiquidBiopsy®, NK VueTM",targets,TNBC
NCT03549000,sponsored_by,Novartis Pharmaceuticals
NCT03549000,has_status,TERMINATED
NCT03549000,tests,NZV930
NZV930,has_type,DRUG
NZV930,classified_as,OTHER
NZV930,targets,pancreatic ductal adenocarcinoma (pdac)
NZV930,targets,metastatic castration resistant prostate cancer (mcrpc)
NZV930,targets,ovarian cancer
NZV930,targets,colorectal cancer microsatellite stable (mss)
NZV930,targets,non-small cell lung cancer (nsclc)
NZV930,targets,renal cell carcinoma (rcc)
NZV930,targets,triple negative breast cancer (tnbc)
NZV930,targets,TNBC
NCT03549000,tests,PDR001
PDR001,has_type,DRUG
PDR001,classified_as,OTHER
PDR001,targets,pancreatic ductal adenocarcinoma (pdac)
PDR001,targets,metastatic castration resistant prostate cancer (mcrpc)
PDR001,targets,ovarian cancer
PDR001,targets,colorectal cancer microsatellite stable (mss)
PDR001,targets,non-small cell lung cancer (nsclc)
PDR001,targets,renal cell carcinoma (rcc)
PDR001,targets,triple negative breast cancer (tnbc)
PDR001,targets,TNBC
NCT03549000,tests,NIR178
NIR178,has_type,DRUG
NIR178,classified_as,OTHER
NIR178,targets,pancreatic ductal adenocarcinoma (pdac)
NIR178,targets,metastatic castration resistant prostate cancer (mcrpc)
NIR178,targets,ovarian cancer
NIR178,targets,colorectal cancer microsatellite stable (mss)
NIR178,targets,non-small cell lung cancer (nsclc)
NIR178,targets,renal cell carcinoma (rcc)
NIR178,targets,triple negative breast cancer (tnbc)
NIR178,targets,TNBC
NCT04726332,sponsored_by,Exelixis
NCT04726332,has_status,TERMINATED
NCT04726332,tests,XL102
XL102,has_type,DRUG
XL102,classified_as,OTHER
XL102,targets,metastatic castration-resistant prostate cancer
XL102,targets,triple negative breast cancer
XL102,targets,epithelial ovarian cancer
XL102,targets,hormone receptor positive breast carcinoma
XL102,targets,neoplasm malignant
XL102,targets,TNBC
NCT04726332,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,metastatic castration-resistant prostate cancer
Fulvestrant,targets,triple negative breast cancer
Fulvestrant,targets,epithelial ovarian cancer
Fulvestrant,targets,hormone receptor positive breast carcinoma
Fulvestrant,targets,neoplasm malignant
Fulvestrant,targets,TNBC
NCT04726332,tests,Abiraterone
Abiraterone,has_type,DRUG
Abiraterone,classified_as,OTHER
Abiraterone,targets,metastatic castration-resistant prostate cancer
Abiraterone,targets,triple negative breast cancer
Abiraterone,targets,epithelial ovarian cancer
Abiraterone,targets,hormone receptor positive breast carcinoma
Abiraterone,targets,neoplasm malignant
Abiraterone,targets,TNBC
NCT04726332,tests,Prednisone
Prednisone,has_type,DRUG
Prednisone,classified_as,OTHER
Prednisone,targets,metastatic castration-resistant prostate cancer
Prednisone,targets,triple negative breast cancer
Prednisone,targets,epithelial ovarian cancer
Prednisone,targets,hormone receptor positive breast carcinoma
Prednisone,targets,neoplasm malignant
Prednisone,targets,TNBC
NCT00630032,sponsored_by,UNICANCER
NCT00630032,has_status,COMPLETED
NCT00630032,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
cyclophosphamide,classified_as,CHEMICAL
cyclophosphamide,targets,breast cancer
NCT00630032,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,breast cancer
NCT00630032,tests,epirubicin hydrochloride
epirubicin hydrochloride,has_type,DRUG
epirubicin hydrochloride,classified_as,OTHER
epirubicin hydrochloride,targets,breast cancer
NCT00630032,tests,fluorouracil
fluorouracil,has_type,DRUG
fluorouracil,classified_as,OTHER
fluorouracil,targets,breast cancer
NCT00630032,tests,ixabepilone
ixabepilone,has_type,DRUG
ixabepilone,classified_as,OTHER
ixabepilone,targets,breast cancer
NCT02078752,sponsored_by,Pfizer
NCT02078752,has_status,TERMINATED
NCT02078752,tests,PF-06647263
PF-06647263,has_type,DRUG
PF-06647263,classified_as,OTHER
PF-06647263,targets,neoplasms
PF-06647263,targets,triple-negative breast cancer
PF-06647263,targets,TNBC
NCT02078752,tests,PF-06647263
PF-06647263,has_type,DRUG
PF-06647263,classified_as,OTHER
PF-06647263,targets,neoplasms
PF-06647263,targets,triple-negative breast cancer
PF-06647263,targets,TNBC
NCT01306032,sponsored_by,National Cancer Institute (NCI)
NCT01306032,has_status,COMPLETED
NCT01306032,tests,ABT-888
ABT-888,has_type,DRUG
ABT-888,classified_as,OTHER
ABT-888,targets,ovarian cancer
ABT-888,targets,primary peritoneal cancer
ABT-888,targets,serous carcinoma cancer
ABT-888,targets,fallopian tube cancer
ABT-888,targets,triple-negative breast cancer
ABT-888,targets,TNBC
NCT01306032,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,ovarian cancer
Cyclophosphamide,targets,primary peritoneal cancer
Cyclophosphamide,targets,serous carcinoma cancer
Cyclophosphamide,targets,fallopian tube cancer
Cyclophosphamide,targets,triple-negative breast cancer
Cyclophosphamide,targets,TNBC
NCT02531932,sponsored_by,Amy Tiersten
NCT02531932,has_status,COMPLETED
NCT02531932,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer
NCT02531932,tests,Everolimus
Everolimus,has_type,DRUG
Everolimus,classified_as,OTHER
Everolimus,targets,breast cancer
NCT04454437,sponsored_by,Gilead Sciences
NCT04454437,has_status,ACTIVE_NOT_RECRUITING
NCT04454437,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
Sacituzumab Govitecan-hziy,classified_as,BIOLOGIC
Sacituzumab Govitecan-hziy,targets,metastatic triple-negative breast cancer
Sacituzumab Govitecan-hziy,targets,TNBC
NCT03333915,sponsored_by,BeiGene
NCT03333915,has_status,COMPLETED
NCT03333915,tests,Pamiparib
Pamiparib,has_type,DRUG
Pamiparib,classified_as,CHEMICAL
Pamiparib,targets,advanced high-grade ovarian cancer
Pamiparib,targets,triple negative breast cancer
Pamiparib,targets,TNBC
NCT06342037,sponsored_by,The Netherlands Cancer Institute
NCT06342037,has_status,RECRUITING
NCT06342037,tests,Tiragolumab
Tiragolumab,has_type,DRUG
Tiragolumab,classified_as,BIOLOGIC
Tiragolumab,targets,metastatic breast cancer
NCT06342037,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,metastatic breast cancer
NCT06342037,tests,Ipilimumab
Ipilimumab,has_type,DRUG
Ipilimumab,classified_as,BIOLOGIC
Ipilimumab,targets,metastatic breast cancer
NCT05768932,sponsored_by,"SillaJen, Inc."
NCT05768932,has_status,RECRUITING
NCT05768932,tests,BAL0891
BAL0891,has_type,DRUG
BAL0891,classified_as,OTHER
BAL0891,targets,gastric cancer
BAL0891,targets,advanced solid tumor
BAL0891,targets,tnbc - triple-negative breast cancer
BAL0891,targets,leukemia acute myeloid leukemia (aml)
BAL0891,targets,TNBC
NCT05768932,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,gastric cancer
Carboplatin,targets,advanced solid tumor
Carboplatin,targets,tnbc - triple-negative breast cancer
Carboplatin,targets,leukemia acute myeloid leukemia (aml)
Carboplatin,targets,TNBC
NCT05768932,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,gastric cancer
Paclitaxel,targets,advanced solid tumor
Paclitaxel,targets,tnbc - triple-negative breast cancer
Paclitaxel,targets,leukemia acute myeloid leukemia (aml)
Paclitaxel,targets,TNBC
NCT01130259,sponsored_by,Sanofi
NCT01130259,has_status,NO_LONGER_AVAILABLE
NCT01130259,tests,iniparib
iniparib,has_type,DRUG
iniparib,classified_as,CHEMICAL
iniparib,targets,breast cancer
NCT03361800,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT03361800,has_status,TERMINATED
NCT03361800,tests,Entinostat
Entinostat,has_type,DRUG
Entinostat,classified_as,OTHER
Entinostat,targets,breast cancer
Entinostat,targets,er-negative pr-negative her2-negative breast cancer
Entinostat,targets,invasive breast cancer
NCT02661100,sponsored_by,Case Comprehensive Cancer Center
NCT02661100,has_status,WITHDRAWN
NCT02661100,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,urothelial cancer
Pembrolizumab,targets,mesothelioma
Pembrolizumab,targets,advanced triple negative breast cancer
Pembrolizumab,targets,malignant melanoma
Pembrolizumab,targets,small cell lung cancer
Pembrolizumab,targets,non small cell lung cancer
Pembrolizumab,targets,TNBC
NCT02661100,tests,CDX-1401
CDX-1401,has_type,DRUG
CDX-1401,classified_as,OTHER
CDX-1401,targets,urothelial cancer
CDX-1401,targets,mesothelioma
CDX-1401,targets,advanced triple negative breast cancer
CDX-1401,targets,malignant melanoma
CDX-1401,targets,small cell lung cancer
CDX-1401,targets,non small cell lung cancer
CDX-1401,targets,TNBC
NCT02661100,tests,Poly-ICLC
Poly-ICLC,has_type,DRUG
Poly-ICLC,classified_as,OTHER
Poly-ICLC,targets,urothelial cancer
Poly-ICLC,targets,mesothelioma
Poly-ICLC,targets,advanced triple negative breast cancer
Poly-ICLC,targets,malignant melanoma
Poly-ICLC,targets,small cell lung cancer
Poly-ICLC,targets,non small cell lung cancer
Poly-ICLC,targets,TNBC
NCT02130700,sponsored_by,Innocrin Pharmaceutical
NCT02130700,has_status,COMPLETED
NCT02130700,tests,VT-464: given orally twice daily in 28-day cycles
VT-464: given orally twice daily in 28-day cycles,has_type,DRUG
VT-464: given orally twice daily in 28-day cycles,classified_as,OTHER
VT-464: given orally twice daily in 28-day cycles,targets,prostate cancer
NCT02130700,tests,VT-464: given orally once daily in 28-day cycles
VT-464: given orally once daily in 28-day cycles,has_type,DRUG
VT-464: given orally once daily in 28-day cycles,classified_as,OTHER
VT-464: given orally once daily in 28-day cycles,targets,prostate cancer
NCT01104259,sponsored_by,University of Washington
NCT01104259,has_status,COMPLETED
NCT01104259,tests,veliparib
veliparib,has_type,DRUG
veliparib,classified_as,CHEMICAL
veliparib,targets,progesterone receptor-negative breast cancer
veliparib,targets,her2-negative breast cancer
veliparib,targets,male breast cancer
veliparib,targets,stage iv breast cancer
veliparib,targets,estrogen receptor-negative breast cancer
veliparib,targets,hereditary breast/ovarian cancer - brca2
veliparib,targets,recurrent breast cancer
veliparib,targets,triple-negative breast cancer
veliparib,targets,hereditary breast/ovarian cancer - brca1
veliparib,targets,TNBC
NCT01104259,tests,cisplatin
cisplatin,has_type,DRUG
cisplatin,classified_as,CHEMICAL
cisplatin,targets,progesterone receptor-negative breast cancer
cisplatin,targets,her2-negative breast cancer
cisplatin,targets,male breast cancer
cisplatin,targets,stage iv breast cancer
cisplatin,targets,estrogen receptor-negative breast cancer
cisplatin,targets,hereditary breast/ovarian cancer - brca2
cisplatin,targets,recurrent breast cancer
cisplatin,targets,triple-negative breast cancer
cisplatin,targets,hereditary breast/ovarian cancer - brca1
cisplatin,targets,TNBC
NCT01104259,tests,vinorelbine tartrate
vinorelbine tartrate,has_type,DRUG
vinorelbine tartrate,classified_as,OTHER
vinorelbine tartrate,targets,progesterone receptor-negative breast cancer
vinorelbine tartrate,targets,her2-negative breast cancer
vinorelbine tartrate,targets,male breast cancer
vinorelbine tartrate,targets,stage iv breast cancer
vinorelbine tartrate,targets,estrogen receptor-negative breast cancer
vinorelbine tartrate,targets,hereditary breast/ovarian cancer - brca2
vinorelbine tartrate,targets,recurrent breast cancer
vinorelbine tartrate,targets,triple-negative breast cancer
vinorelbine tartrate,targets,hereditary breast/ovarian cancer - brca1
vinorelbine tartrate,targets,TNBC
NCT01104259,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,DRUG
laboratory biomarker analysis,classified_as,OTHER
laboratory biomarker analysis,targets,progesterone receptor-negative breast cancer
laboratory biomarker analysis,targets,her2-negative breast cancer
laboratory biomarker analysis,targets,male breast cancer
laboratory biomarker analysis,targets,stage iv breast cancer
laboratory biomarker analysis,targets,estrogen receptor-negative breast cancer
laboratory biomarker analysis,targets,hereditary breast/ovarian cancer - brca2
laboratory biomarker analysis,targets,recurrent breast cancer
laboratory biomarker analysis,targets,triple-negative breast cancer
laboratory biomarker analysis,targets,hereditary breast/ovarian cancer - brca1
laboratory biomarker analysis,targets,TNBC
NCT01104259,tests,pharmacological study
pharmacological study,has_type,DRUG
pharmacological study,classified_as,OTHER
pharmacological study,targets,progesterone receptor-negative breast cancer
pharmacological study,targets,her2-negative breast cancer
pharmacological study,targets,male breast cancer
pharmacological study,targets,stage iv breast cancer
pharmacological study,targets,estrogen receptor-negative breast cancer
pharmacological study,targets,hereditary breast/ovarian cancer - brca2
pharmacological study,targets,recurrent breast cancer
pharmacological study,targets,triple-negative breast cancer
pharmacological study,targets,hereditary breast/ovarian cancer - brca1
pharmacological study,targets,TNBC
NCT03253575,sponsored_by,"Mitra RxDx, Inc."
NCT03253575,has_status,SUSPENDED
NCT03253575,tests,CANscript
CANscript,has_type,DRUG
CANscript,classified_as,OTHER
CANscript,targets,adult solid tumor
NCT06431100,sponsored_by,"Beijing Geekgene Technology Co., LTD"
NCT06431100,has_status,RECRUITING
NCT06431100,tests,TCR T-cells
TCR T-cells,has_type,DRUG
TCR T-cells,classified_as,OTHER
TCR T-cells,targets,gastric cancer
TCR T-cells,targets,esophageal cancer
TCR T-cells,targets,non-small cell lung cancer nsclc
TCR T-cells,targets,cervical cancer
TCR T-cells,targets,triple negative breast cancer tnbc
TCR T-cells,targets,TNBC
NCT05776875,sponsored_by,Yale University
NCT05776875,has_status,TERMINATED
NCT05776875,tests,Atezolizumab Injection
Atezolizumab Injection,has_type,DRUG
Atezolizumab Injection,classified_as,BIOLOGIC
Atezolizumab Injection,targets,hepatocellular carcinoma
Atezolizumab Injection,targets,bclc stage b hepatocellular carcinoma
NCT05776875,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,hepatocellular carcinoma
Bevacizumab,targets,bclc stage b hepatocellular carcinoma
NCT05776875,tests,Transarterial chemoembolization
Transarterial chemoembolization,has_type,DRUG
Transarterial chemoembolization,classified_as,OTHER
Transarterial chemoembolization,targets,hepatocellular carcinoma
Transarterial chemoembolization,targets,bclc stage b hepatocellular carcinoma
NCT06189209,sponsored_by,Rhizen Pharmaceuticals SA
NCT06189209,has_status,RECRUITING
NCT06189209,tests,Tenalisib
Tenalisib,has_type,DRUG
Tenalisib,classified_as,CHEMICAL
Tenalisib,targets,triple negative breast cancer (tnbc)
Tenalisib,targets,TNBC
NCT02670109,sponsored_by,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
NCT02670109,has_status,UNKNOWN
NCT02670109,tests,Carmustine
Carmustine,has_type,DRUG
Carmustine,classified_as,OTHER
Carmustine,targets,triple-negative invasive breast carcinoma
Carmustine,targets,residual tumor
Carmustine,targets,TNBC
NCT02670109,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,triple-negative invasive breast carcinoma
Cyclophosphamide,targets,residual tumor
Cyclophosphamide,targets,TNBC
NCT02670109,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple-negative invasive breast carcinoma
Carboplatin,targets,residual tumor
Carboplatin,targets,TNBC
NCT02670109,tests,Autologous Hematopoietic Stem Cell Transplantation
Autologous Hematopoietic Stem Cell Transplantation,has_type,DRUG
Autologous Hematopoietic Stem Cell Transplantation,classified_as,OTHER
Autologous Hematopoietic Stem Cell Transplantation,targets,triple-negative invasive breast carcinoma
Autologous Hematopoietic Stem Cell Transplantation,targets,residual tumor
Autologous Hematopoietic Stem Cell Transplantation,targets,TNBC
NCT02670109,tests,Busulfan
Busulfan,has_type,DRUG
Busulfan,classified_as,OTHER
Busulfan,targets,triple-negative invasive breast carcinoma
Busulfan,targets,residual tumor
Busulfan,targets,TNBC
NCT02353988,sponsored_by,"Jinling Hospital, China"
NCT02353988,has_status,UNKNOWN
NCT02353988,tests,Bicalutamide
Bicalutamide,has_type,DRUG
Bicalutamide,classified_as,OTHER
Bicalutamide,targets,breast neoplasms
NCT02353988,tests,Physician's Choice
Physician's Choice,has_type,DRUG
Physician's Choice,classified_as,OTHER
Physician's Choice,targets,breast neoplasms
NCT05812807,sponsored_by,Alliance for Clinical Trials in Oncology
NCT05812807,has_status,RECRUITING
NCT05812807,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,early stage triple-negative breast carcinoma
Pembrolizumab,targets,anatomic stage ii breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage i breast cancer ajcc v8
Pembrolizumab,targets,anatomic stage iii breast cancer ajcc v8
Pembrolizumab,targets,TNBC
NCT05812807,tests,Patient Observation
Patient Observation,has_type,DRUG
Patient Observation,classified_as,OTHER
Patient Observation,targets,early stage triple-negative breast carcinoma
Patient Observation,targets,anatomic stage ii breast cancer ajcc v8
Patient Observation,targets,anatomic stage i breast cancer ajcc v8
Patient Observation,targets,anatomic stage iii breast cancer ajcc v8
Patient Observation,targets,TNBC
NCT05812807,tests,Biopsy
Biopsy,has_type,DRUG
Biopsy,classified_as,OTHER
Biopsy,targets,early stage triple-negative breast carcinoma
Biopsy,targets,anatomic stage ii breast cancer ajcc v8
Biopsy,targets,anatomic stage i breast cancer ajcc v8
Biopsy,targets,anatomic stage iii breast cancer ajcc v8
Biopsy,targets,TNBC
NCT05812807,tests,Biospecimen Collection
Biospecimen Collection,has_type,DRUG
Biospecimen Collection,classified_as,OTHER
Biospecimen Collection,targets,early stage triple-negative breast carcinoma
Biospecimen Collection,targets,anatomic stage ii breast cancer ajcc v8
Biospecimen Collection,targets,anatomic stage i breast cancer ajcc v8
Biospecimen Collection,targets,anatomic stage iii breast cancer ajcc v8
Biospecimen Collection,targets,TNBC
NCT05812807,tests,Questionnaire Administration
Questionnaire Administration,has_type,DRUG
Questionnaire Administration,classified_as,OTHER
Questionnaire Administration,targets,early stage triple-negative breast carcinoma
Questionnaire Administration,targets,anatomic stage ii breast cancer ajcc v8
Questionnaire Administration,targets,anatomic stage i breast cancer ajcc v8
Questionnaire Administration,targets,anatomic stage iii breast cancer ajcc v8
Questionnaire Administration,targets,TNBC
NCT05812807,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,DRUG
Quality-of-Life Assessment,classified_as,OTHER
Quality-of-Life Assessment,targets,early stage triple-negative breast carcinoma
Quality-of-Life Assessment,targets,anatomic stage ii breast cancer ajcc v8
Quality-of-Life Assessment,targets,anatomic stage i breast cancer ajcc v8
Quality-of-Life Assessment,targets,anatomic stage iii breast cancer ajcc v8
Quality-of-Life Assessment,targets,TNBC
NCT05749588,sponsored_by,Fudan University
NCT05749588,has_status,RECRUITING
NCT05749588,tests,A1: SHR-A1811
A1: SHR-A1811,has_type,DRUG
A1: SHR-A1811,classified_as,OTHER
A1: SHR-A1811,targets,triple-negative breast cancer
A1: SHR-A1811,targets,TNBC
NCT05749588,tests,A2: SHR-A1811 with Camrelizumab
A2: SHR-A1811 with Camrelizumab,has_type,DRUG
A2: SHR-A1811 with Camrelizumab,classified_as,BIOLOGIC
A2: SHR-A1811 with Camrelizumab,targets,triple-negative breast cancer
A2: SHR-A1811 with Camrelizumab,targets,TNBC
NCT05749588,tests,B1: TROP2 ADC
B1: TROP2 ADC,has_type,DRUG
B1: TROP2 ADC,classified_as,OTHER
B1: TROP2 ADC,targets,triple-negative breast cancer
B1: TROP2 ADC,targets,TNBC
NCT05749588,tests,B2: TROP2 ADC with Camrelizumab
B2: TROP2 ADC with Camrelizumab,has_type,DRUG
B2: TROP2 ADC with Camrelizumab,classified_as,BIOLOGIC
B2: TROP2 ADC with Camrelizumab,targets,triple-negative breast cancer
B2: TROP2 ADC with Camrelizumab,targets,TNBC
NCT05749588,tests,C1: SHR-A1811
C1: SHR-A1811,has_type,DRUG
C1: SHR-A1811,classified_as,OTHER
C1: SHR-A1811,targets,triple-negative breast cancer
C1: SHR-A1811,targets,TNBC
NCT05749588,tests,C2: SHR-A1811 with BP102
C2: SHR-A1811 with BP102,has_type,DRUG
C2: SHR-A1811 with BP102,classified_as,OTHER
C2: SHR-A1811 with BP102,targets,triple-negative breast cancer
C2: SHR-A1811 with BP102,targets,TNBC
NCT05749588,tests,D1: TROP2 ADC
D1: TROP2 ADC,has_type,DRUG
D1: TROP2 ADC,classified_as,OTHER
D1: TROP2 ADC,targets,triple-negative breast cancer
D1: TROP2 ADC,targets,TNBC
NCT05749588,tests,D2: TROP2 ADC with BP102
D2: TROP2 ADC with BP102,has_type,DRUG
D2: TROP2 ADC with BP102,classified_as,OTHER
D2: TROP2 ADC with BP102,targets,triple-negative breast cancer
D2: TROP2 ADC with BP102,targets,TNBC
NCT05749588,tests,E1: SHR-A1811
E1: SHR-A1811,has_type,DRUG
E1: SHR-A1811,classified_as,OTHER
E1: SHR-A1811,targets,triple-negative breast cancer
E1: SHR-A1811,targets,TNBC
NCT05749588,tests,F1: TROP2 ADC
F1: TROP2 ADC,has_type,DRUG
F1: TROP2 ADC,classified_as,OTHER
F1: TROP2 ADC,targets,triple-negative breast cancer
F1: TROP2 ADC,targets,TNBC
NCT05749588,tests,G1: SHR-A1811
G1: SHR-A1811,has_type,DRUG
G1: SHR-A1811,classified_as,OTHER
G1: SHR-A1811,targets,triple-negative breast cancer
G1: SHR-A1811,targets,TNBC
NCT05749588,tests,H1: TROP2 ADC
H1: TROP2 ADC,has_type,DRUG
H1: TROP2 ADC,classified_as,OTHER
H1: TROP2 ADC,targets,triple-negative breast cancer
H1: TROP2 ADC,targets,TNBC
NCT04268693,sponsored_by,George Washington University
NCT04268693,has_status,WITHDRAWN
NCT04268693,tests,urine collection
urine collection,has_type,DRUG
urine collection,classified_as,OTHER
urine collection,targets,triple negative breast cancer
urine collection,targets,TNBC
NCT05475678,sponsored_by,Zhenzhen Liu
NCT05475678,has_status,RECRUITING
NCT05475678,tests,（Carrelizumab + TCb） regimen
（Carrelizumab + TCb） regimen,has_type,DRUG
（Carrelizumab + TCb） regimen,classified_as,BIOLOGIC
（Carrelizumab + TCb） regimen,targets,breast cancer
（Carrelizumab + TCb） regimen,targets,camrelizumab
（Carrelizumab + TCb） regimen,targets,triple negative breast cancer
（Carrelizumab + TCb） regimen,targets,TNBC
NCT05475678,tests,TCb regimen
TCb regimen,has_type,DRUG
TCb regimen,classified_as,OTHER
TCb regimen,targets,breast cancer
TCb regimen,targets,camrelizumab
TCb regimen,targets,triple negative breast cancer
TCb regimen,targets,TNBC
NCT03045393,sponsored_by,Duke University
NCT03045393,has_status,WITHDRAWN
NCT03045393,tests,Mirvetuximab Soravtansine (IMGN853)
Mirvetuximab Soravtansine (IMGN853),has_type,DRUG
Mirvetuximab Soravtansine (IMGN853),classified_as,BIOLOGIC
Mirvetuximab Soravtansine (IMGN853),targets,breast cancer triple negative
Mirvetuximab Soravtansine (IMGN853),targets,TNBC
NCT04427293,sponsored_by,University of Illinois at Chicago
NCT04427293,has_status,RECRUITING
NCT04427293,tests,Lenvatinib
Lenvatinib,has_type,DRUG
Lenvatinib,classified_as,CHEMICAL
Lenvatinib,targets,triple negative breast cancer
Lenvatinib,targets,TNBC
NCT04427293,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT03363893,sponsored_by,Carrick Therapeutics Limited
NCT03363893,has_status,COMPLETED
NCT03363893,tests,CT7001
CT7001,has_type,DRUG
CT7001,classified_as,OTHER
CT7001,targets,advanced solid malignancies
NCT03363893,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,advanced solid malignancies
NCT06682793,sponsored_by,A2 Biotherapeutics Inc.
NCT06682793,has_status,RECRUITING
NCT06682793,tests,A2B395
A2B395,has_type,DRUG
A2B395,classified_as,OTHER
A2B395,targets,renal cell carcinoma
A2B395,targets,nsclc (non-small cell lung cancer)
A2B395,targets,non-small cell lung
A2B395,targets,"solid tumor, adult"
A2B395,targets,rectal cancer
A2B395,targets,colorectal adenocarcinoma
A2B395,targets,head and neck squamous cell cancer
A2B395,targets,cancer
A2B395,targets,lung cancer
A2B395,targets,triple negative breast cancer
A2B395,targets,crc
A2B395,targets,rcc
A2B395,targets,kidney cancer
A2B395,targets,hnscc
A2B395,targets,tnbc
A2B395,targets,colon cancer
A2B395,targets,colorectal cancer
A2B395,targets,TNBC
NCT06682793,tests,xT CDx with HLA-LOH assay
xT CDx with HLA-LOH assay,has_type,DRUG
xT CDx with HLA-LOH assay,classified_as,OTHER
xT CDx with HLA-LOH assay,targets,renal cell carcinoma
xT CDx with HLA-LOH assay,targets,nsclc (non-small cell lung cancer)
xT CDx with HLA-LOH assay,targets,non-small cell lung
xT CDx with HLA-LOH assay,targets,"solid tumor, adult"
xT CDx with HLA-LOH assay,targets,rectal cancer
xT CDx with HLA-LOH assay,targets,colorectal adenocarcinoma
xT CDx with HLA-LOH assay,targets,head and neck squamous cell cancer
xT CDx with HLA-LOH assay,targets,cancer
xT CDx with HLA-LOH assay,targets,lung cancer
xT CDx with HLA-LOH assay,targets,triple negative breast cancer
xT CDx with HLA-LOH assay,targets,crc
xT CDx with HLA-LOH assay,targets,rcc
xT CDx with HLA-LOH assay,targets,kidney cancer
xT CDx with HLA-LOH assay,targets,hnscc
xT CDx with HLA-LOH assay,targets,tnbc
xT CDx with HLA-LOH assay,targets,colon cancer
xT CDx with HLA-LOH assay,targets,colorectal cancer
xT CDx with HLA-LOH assay,targets,TNBC
NCT03812393,sponsored_by,West Cancer Center
NCT03812393,has_status,ACTIVE_NOT_RECRUITING
NCT03812393,tests,Neratinib
Neratinib,has_type,DRUG
Neratinib,classified_as,CHEMICAL
Neratinib,targets,her2-positive breast cancer
Neratinib,targets,early-stage breast cancer
Neratinib,targets,triple negative breast cancer
Neratinib,targets,TNBC
NCT06965361,sponsored_by,Ziauddin University
NCT06965361,has_status,COMPLETED
NCT06965361,tests,carboplatin
carboplatin,has_type,DRUG
carboplatin,classified_as,CHEMICAL
carboplatin,targets,triple negative breast cancer
carboplatin,targets,TNBC
NCT06965361,tests,carboplatin
carboplatin,has_type,DRUG
carboplatin,classified_as,CHEMICAL
carboplatin,targets,triple negative breast cancer
carboplatin,targets,TNBC
NCT03411161,sponsored_by,Institut de Recherches Internationales Servier
NCT03411161,has_status,COMPLETED
NCT03411161,tests,Combination therapy (S81694 + paclitaxel) phase I
Combination therapy (S81694 + paclitaxel) phase I,has_type,DRUG
Combination therapy (S81694 + paclitaxel) phase I,classified_as,CHEMICAL
Combination therapy (S81694 + paclitaxel) phase I,targets,metastatic breast cancer
Combination therapy (S81694 + paclitaxel) phase I,targets,metastatic triple negative breast cancer
Combination therapy (S81694 + paclitaxel) phase I,targets,TNBC
NCT03411161,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,metastatic breast cancer
Paclitaxel,targets,metastatic triple negative breast cancer
Paclitaxel,targets,TNBC
NCT03411161,tests,Combination therapy (S81694 + paclitaxel) phase II
Combination therapy (S81694 + paclitaxel) phase II,has_type,DRUG
Combination therapy (S81694 + paclitaxel) phase II,classified_as,CHEMICAL
Combination therapy (S81694 + paclitaxel) phase II,targets,metastatic breast cancer
Combination therapy (S81694 + paclitaxel) phase II,targets,metastatic triple negative breast cancer
Combination therapy (S81694 + paclitaxel) phase II,targets,TNBC
NCT06781983,sponsored_by,Innate Pharma
NCT06781983,has_status,RECRUITING
NCT06781983,tests,IPH4502
IPH4502,has_type,DRUG
IPH4502,classified_as,OTHER
IPH4502,targets,advanced or metastatic solid tumors
NCT07005583,sponsored_by,Tianjin Medical University Cancer Institute and Hospital
NCT07005583,has_status,NOT_YET_RECRUITING
NCT07005583,tests,QL1706 Plus Olaparib
QL1706 Plus Olaparib,has_type,DRUG
QL1706 Plus Olaparib,classified_as,BIOLOGIC
QL1706 Plus Olaparib,targets,triple-negative breast cancer (tnbc)
QL1706 Plus Olaparib,targets,TNBC
NCT04158583,sponsored_by,Hoffmann-La Roche
NCT04158583,has_status,TERMINATED
NCT04158583,tests,RO7296682
RO7296682,has_type,DRUG
RO7296682,classified_as,OTHER
RO7296682,targets,solid tumors
NCT04574583,sponsored_by,National Cancer Institute (NCI)
NCT04574583,has_status,COMPLETED
NCT04574583,tests,SX-682
SX-682,has_type,DRUG
SX-682,classified_as,OTHER
SX-682,targets,solid tumors
SX-682,targets,metastatic cancer
NCT04574583,tests,M7824
M7824,has_type,DRUG
M7824,classified_as,OTHER
M7824,targets,solid tumors
M7824,targets,metastatic cancer
NCT04574583,tests,MVA-BN-CV301
MVA-BN-CV301,has_type,DRUG
MVA-BN-CV301,classified_as,OTHER
MVA-BN-CV301,targets,solid tumors
MVA-BN-CV301,targets,metastatic cancer
NCT04574583,tests,recombinant fowlpox viral (FPV)-CV301
recombinant fowlpox viral (FPV)-CV301,has_type,DRUG
recombinant fowlpox viral (FPV)-CV301,classified_as,OTHER
recombinant fowlpox viral (FPV)-CV301,targets,solid tumors
recombinant fowlpox viral (FPV)-CV301,targets,metastatic cancer
NCT03394287,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT03394287,has_status,COMPLETED
NCT03394287,tests,SHR-1210
SHR-1210,has_type,DRUG
SHR-1210,classified_as,OTHER
SHR-1210,targets,breast cancer
NCT03394287,tests,Apatinib
Apatinib,has_type,DRUG
Apatinib,classified_as,CHEMICAL
Apatinib,targets,breast cancer
NCT02744053,sponsored_by,M.D. Anderson Cancer Center
NCT02744053,has_status,ACTIVE_NOT_RECRUITING
NCT02744053,tests,Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Dynamic Contrast-Enhanced Magnetic Resonance Imaging,has_type,DRUG
Dynamic Contrast-Enhanced Magnetic Resonance Imaging,classified_as,OTHER
Dynamic Contrast-Enhanced Magnetic Resonance Imaging,targets,progesterone receptor negative
Dynamic Contrast-Enhanced Magnetic Resonance Imaging,targets,her2/neu negative
Dynamic Contrast-Enhanced Magnetic Resonance Imaging,targets,triple-negative breast carcinoma
Dynamic Contrast-Enhanced Magnetic Resonance Imaging,targets,estrogen receptor negative
Dynamic Contrast-Enhanced Magnetic Resonance Imaging,targets,TNBC
NCT02744053,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,DRUG
Laboratory Biomarker Analysis,classified_as,OTHER
Laboratory Biomarker Analysis,targets,progesterone receptor negative
Laboratory Biomarker Analysis,targets,her2/neu negative
Laboratory Biomarker Analysis,targets,triple-negative breast carcinoma
Laboratory Biomarker Analysis,targets,estrogen receptor negative
Laboratory Biomarker Analysis,targets,TNBC
NCT02744053,tests,Scintimammography
Scintimammography,has_type,DRUG
Scintimammography,classified_as,OTHER
Scintimammography,targets,progesterone receptor negative
Scintimammography,targets,her2/neu negative
Scintimammography,targets,triple-negative breast carcinoma
Scintimammography,targets,estrogen receptor negative
Scintimammography,targets,TNBC
NCT02744053,tests,Technetium Tc-99m Sestamibi
Technetium Tc-99m Sestamibi,has_type,DRUG
Technetium Tc-99m Sestamibi,classified_as,CHEMICAL
Technetium Tc-99m Sestamibi,targets,progesterone receptor negative
Technetium Tc-99m Sestamibi,targets,her2/neu negative
Technetium Tc-99m Sestamibi,targets,triple-negative breast carcinoma
Technetium Tc-99m Sestamibi,targets,estrogen receptor negative
Technetium Tc-99m Sestamibi,targets,TNBC
NCT01770353,sponsored_by,Ipsen
NCT01770353,has_status,COMPLETED
NCT01770353,tests,Ferumoxytol
Ferumoxytol,has_type,DRUG
Ferumoxytol,classified_as,OTHER
Ferumoxytol,targets,metastatic breast cancer with active brain metastasis
Ferumoxytol,targets,triple negative breast cancer
Ferumoxytol,targets,solid tumors
Ferumoxytol,targets,er/pr positive breast cancer
Ferumoxytol,targets,TNBC
NCT01770353,tests,MM-398
MM-398,has_type,DRUG
MM-398,classified_as,OTHER
MM-398,targets,metastatic breast cancer with active brain metastasis
MM-398,targets,triple negative breast cancer
MM-398,targets,solid tumors
MM-398,targets,er/pr positive breast cancer
MM-398,targets,TNBC
NCT04137653,sponsored_by,Shengjing Hospital
NCT04137653,has_status,RECRUITING
NCT04137653,tests,nab-Paclitaxel+carboplatin
nab-Paclitaxel+carboplatin,has_type,DRUG
nab-Paclitaxel+carboplatin,classified_as,CHEMICAL
nab-Paclitaxel+carboplatin,targets,breast cancer
NCT04137653,tests,Paclitaxel+carboplatin
Paclitaxel+carboplatin,has_type,DRUG
Paclitaxel+carboplatin,classified_as,CHEMICAL
Paclitaxel+carboplatin,targets,breast cancer
NCT06840483,sponsored_by,BicycleTx Limited
NCT06840483,has_status,RECRUITING
NCT06840483,tests,Zelenectide pevedotin (BT8009)
Zelenectide pevedotin (BT8009),has_type,DRUG
Zelenectide pevedotin (BT8009),classified_as,OTHER
Zelenectide pevedotin (BT8009),targets,breast cancer
NCT07011654,sponsored_by,M.D. Anderson Cancer Center
NCT07011654,has_status,NOT_YET_RECRUITING
NCT07011654,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
Sacituzumab govitecan,classified_as,BIOLOGIC
Sacituzumab govitecan,targets,metastatic triple-negative breast cancer
Sacituzumab govitecan,targets,TNBC
NCT07011654,tests,Naxitamab
Naxitamab,has_type,DRUG
Naxitamab,classified_as,BIOLOGIC
Naxitamab,targets,metastatic triple-negative breast cancer
Naxitamab,targets,TNBC
NCT01876251,sponsored_by,Pfizer
NCT01876251,has_status,TERMINATED
NCT01876251,tests,PF-03084014
PF-03084014,has_type,DRUG
PF-03084014,classified_as,OTHER
PF-03084014,targets,breast cancer metastatic
NCT01876251,tests,PF-03084014
PF-03084014,has_type,DRUG
PF-03084014,classified_as,OTHER
PF-03084014,targets,breast cancer metastatic
NCT01876251,tests,PF-03084014
PF-03084014,has_type,DRUG
PF-03084014,classified_as,OTHER
PF-03084014,targets,breast cancer metastatic
NCT01876251,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,breast cancer metastatic
NCT01876251,tests,Docetaxel
Docetaxel,has_type,DRUG
Docetaxel,classified_as,CHEMICAL
Docetaxel,targets,breast cancer metastatic
NCT03281954,sponsored_by,NSABP Foundation Inc
NCT03281954,has_status,ACTIVE_NOT_RECRUITING
NCT03281954,tests,Placebo
Placebo,has_type,DRUG
Placebo,classified_as,OTHER
Placebo,targets,triple negative breast cancer
Placebo,targets,TNBC
NCT03281954,tests,Atezolizumab
Atezolizumab,has_type,DRUG
Atezolizumab,classified_as,BIOLOGIC
Atezolizumab,targets,triple negative breast cancer
Atezolizumab,targets,TNBC
NCT02368951,sponsored_by,Bayer
NCT02368951,has_status,TERMINATED
NCT02368951,tests,BAY1187982
BAY1187982,has_type,DRUG
BAY1187982,classified_as,OTHER
BAY1187982,targets,medical oncology
NCT03821454,sponsored_by,Zhejiang Cancer Hospital
NCT03821454,has_status,UNKNOWN
NCT03821454,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer
NCT03821454,tests,Placebos
Placebos,has_type,DRUG
Placebos,classified_as,OTHER
Placebos,targets,breast cancer
NCT03925233,sponsored_by,Xijing Hospital
NCT03925233,has_status,UNKNOWN
NCT03925233,tests,Trastuzumab
Trastuzumab,has_type,DRUG
Trastuzumab,classified_as,BIOLOGIC
Trastuzumab,targets,breast cancer organoids
NCT03925233,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
Doxorubicin Hydrochloride,classified_as,CHEMICAL
Doxorubicin Hydrochloride,targets,breast cancer organoids
NCT03925233,tests,Epirubicin hydrochloride
Epirubicin hydrochloride,has_type,DRUG
Epirubicin hydrochloride,classified_as,OTHER
Epirubicin hydrochloride,targets,breast cancer organoids
NCT03925233,tests,Fluorouracil
Fluorouracil,has_type,DRUG
Fluorouracil,classified_as,OTHER
Fluorouracil,targets,breast cancer organoids
NCT03925233,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,breast cancer organoids
NCT03925233,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,breast cancer organoids
NCT03925233,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,breast cancer organoids
NCT03925233,tests,Recombinant Human Endostatin
Recombinant Human Endostatin,has_type,DRUG
Recombinant Human Endostatin,classified_as,OTHER
Recombinant Human Endostatin,targets,breast cancer organoids
NCT03925233,tests,Pirarubicin hydrochloride
Pirarubicin hydrochloride,has_type,DRUG
Pirarubicin hydrochloride,classified_as,OTHER
Pirarubicin hydrochloride,targets,breast cancer organoids
NCT03925233,tests,Pyrrolidine
Pyrrolidine,has_type,DRUG
Pyrrolidine,classified_as,OTHER
Pyrrolidine,targets,breast cancer organoids
NCT03925233,tests,Ixabepilone
Ixabepilone,has_type,DRUG
Ixabepilone,classified_as,OTHER
Ixabepilone,targets,breast cancer organoids
NCT03925233,tests,Tamoxifen citrate
Tamoxifen citrate,has_type,DRUG
Tamoxifen citrate,classified_as,CHEMICAL
Tamoxifen citrate,targets,breast cancer organoids
NCT03925233,tests,Vinorelbine tartrate
Vinorelbine tartrate,has_type,DRUG
Vinorelbine tartrate,classified_as,OTHER
Vinorelbine tartrate,targets,breast cancer organoids
NCT03925233,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast cancer organoids
NCT03925233,tests,Methotrexate
Methotrexate,has_type,DRUG
Methotrexate,classified_as,CHEMICAL
Methotrexate,targets,breast cancer organoids
NCT03925233,tests,Eribulin mesylate
Eribulin mesylate,has_type,DRUG
Eribulin mesylate,classified_as,CHEMICAL
Eribulin mesylate,targets,breast cancer organoids
NCT03925233,tests,Toremifene citrate
Toremifene citrate,has_type,DRUG
Toremifene citrate,classified_as,OTHER
Toremifene citrate,targets,breast cancer organoids
NCT03925233,tests,Anastrozole
Anastrozole,has_type,DRUG
Anastrozole,classified_as,CHEMICAL
Anastrozole,targets,breast cancer organoids
NCT03925233,tests,Letrozole
Letrozole,has_type,DRUG
Letrozole,classified_as,CHEMICAL
Letrozole,targets,breast cancer organoids
NCT03925233,tests,Exemestane
Exemestane,has_type,DRUG
Exemestane,classified_as,OTHER
Exemestane,targets,breast cancer organoids
NCT03925233,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,breast cancer organoids
NCT03925233,tests,Olaparib
Olaparib,has_type,DRUG
Olaparib,classified_as,BIOLOGIC
Olaparib,targets,breast cancer organoids
NCT03925233,tests,Bevacizumab
Bevacizumab,has_type,DRUG
Bevacizumab,classified_as,BIOLOGIC
Bevacizumab,targets,breast cancer organoids
NCT03925233,tests,Apatinib mesylate
Apatinib mesylate,has_type,DRUG
Apatinib mesylate,classified_as,CHEMICAL
Apatinib mesylate,targets,breast cancer organoids
NCT03925233,tests,Pattozumab
Pattozumab,has_type,DRUG
Pattozumab,classified_as,BIOLOGIC
Pattozumab,targets,breast cancer organoids
NCT03925233,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,breast cancer organoids
NCT03925233,tests,Ear particles
Ear particles,has_type,DRUG
Ear particles,classified_as,OTHER
Ear particles,targets,breast cancer organoids
NCT03925233,tests,Aidi Injection
Aidi Injection,has_type,DRUG
Aidi Injection,classified_as,OTHER
Aidi Injection,targets,breast cancer organoids
NCT03925233,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
Cyclophosphamide,classified_as,CHEMICAL
Cyclophosphamide,targets,breast cancer organoids
NCT06431633,sponsored_by,Fundación GECP
NCT06431633,has_status,RECRUITING
NCT06431633,tests,Zimberelimab
Zimberelimab,has_type,DRUG
Zimberelimab,classified_as,BIOLOGIC
Zimberelimab,targets,lung diseases
Zimberelimab,targets,"carcinoma, non-small-cell lung"
Zimberelimab,targets,resectable lung non-small cell carcinoma
NCT06431633,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
Sacituzumab govitecan,classified_as,BIOLOGIC
Sacituzumab govitecan,targets,lung diseases
Sacituzumab govitecan,targets,"carcinoma, non-small-cell lung"
Sacituzumab govitecan,targets,resectable lung non-small cell carcinoma
NCT06431633,tests,Cisplatin
Cisplatin,has_type,DRUG
Cisplatin,classified_as,CHEMICAL
Cisplatin,targets,lung diseases
Cisplatin,targets,"carcinoma, non-small-cell lung"
Cisplatin,targets,resectable lung non-small cell carcinoma
NCT06431633,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,lung diseases
Carboplatin,targets,"carcinoma, non-small-cell lung"
Carboplatin,targets,resectable lung non-small cell carcinoma
NCT02309177,sponsored_by,Celgene
NCT02309177,has_status,COMPLETED
NCT02309177,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
nab-Paclitaxel,classified_as,CHEMICAL
nab-Paclitaxel,targets,breast neoplasms
nab-Paclitaxel,targets,pancreatic neoplasms
NCT02309177,tests,Nivolumab
Nivolumab,has_type,DRUG
Nivolumab,classified_as,BIOLOGIC
Nivolumab,targets,breast neoplasms
Nivolumab,targets,pancreatic neoplasms
NCT02309177,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,breast neoplasms
Gemcitabine,targets,pancreatic neoplasms
NCT02309177,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,breast neoplasms
Carboplatin,targets,pancreatic neoplasms
NCT06731153,sponsored_by,Fudan University
NCT06731153,has_status,NOT_YET_RECRUITING
NCT06731153,tests,Ivarmacitinib
Ivarmacitinib,has_type,DRUG
Ivarmacitinib,classified_as,CHEMICAL
Ivarmacitinib,targets,metastatic breast cancer
Ivarmacitinib,targets,triple negative breast cancer (tnbc)
Ivarmacitinib,targets,TNBC
NCT06731153,tests,Camrelizumab (SHR-1210)
Camrelizumab (SHR-1210),has_type,DRUG
Camrelizumab (SHR-1210),classified_as,BIOLOGIC
Camrelizumab (SHR-1210),targets,metastatic breast cancer
Camrelizumab (SHR-1210),targets,triple negative breast cancer (tnbc)
Camrelizumab (SHR-1210),targets,TNBC
NCT06731153,tests,Eribulin
Eribulin,has_type,DRUG
Eribulin,classified_as,CHEMICAL
Eribulin,targets,metastatic breast cancer
Eribulin,targets,triple negative breast cancer (tnbc)
Eribulin,targets,TNBC
NCT03454451,sponsored_by,"Corvus Pharmaceuticals, Inc."
NCT03454451,has_status,COMPLETED
NCT03454451,tests,CPI-006
CPI-006,has_type,DRUG
CPI-006,classified_as,OTHER
CPI-006,targets,non-small cell lung cancer
CPI-006,targets,squamous cell carcinoma of the head and neck
CPI-006,targets,pancreatic cancer
CPI-006,targets,renal cell cancer
CPI-006,targets,ovarian cancer
CPI-006,targets,sarcoma
CPI-006,targets,triple negative breast cancer
CPI-006,targets,bladder cancer
CPI-006,targets,cervical cancer
CPI-006,targets,non-hodgkin lymphoma
CPI-006,targets,metastatic castration resistant prostate cancer
CPI-006,targets,endometrial cancer
CPI-006,targets,colorectal cancer
CPI-006,targets,TNBC
NCT03454451,tests,CPI-006 + ciforadenant
CPI-006 + ciforadenant,has_type,DRUG
CPI-006 + ciforadenant,classified_as,OTHER
CPI-006 + ciforadenant,targets,non-small cell lung cancer
CPI-006 + ciforadenant,targets,squamous cell carcinoma of the head and neck
CPI-006 + ciforadenant,targets,pancreatic cancer
CPI-006 + ciforadenant,targets,renal cell cancer
CPI-006 + ciforadenant,targets,ovarian cancer
CPI-006 + ciforadenant,targets,sarcoma
CPI-006 + ciforadenant,targets,triple negative breast cancer
CPI-006 + ciforadenant,targets,bladder cancer
CPI-006 + ciforadenant,targets,cervical cancer
CPI-006 + ciforadenant,targets,non-hodgkin lymphoma
CPI-006 + ciforadenant,targets,metastatic castration resistant prostate cancer
CPI-006 + ciforadenant,targets,endometrial cancer
CPI-006 + ciforadenant,targets,colorectal cancer
CPI-006 + ciforadenant,targets,TNBC
NCT03454451,tests,CPI-006 + pembrolizumab
CPI-006 + pembrolizumab,has_type,DRUG
CPI-006 + pembrolizumab,classified_as,BIOLOGIC
CPI-006 + pembrolizumab,targets,non-small cell lung cancer
CPI-006 + pembrolizumab,targets,squamous cell carcinoma of the head and neck
CPI-006 + pembrolizumab,targets,pancreatic cancer
CPI-006 + pembrolizumab,targets,renal cell cancer
CPI-006 + pembrolizumab,targets,ovarian cancer
CPI-006 + pembrolizumab,targets,sarcoma
CPI-006 + pembrolizumab,targets,triple negative breast cancer
CPI-006 + pembrolizumab,targets,bladder cancer
CPI-006 + pembrolizumab,targets,cervical cancer
CPI-006 + pembrolizumab,targets,non-hodgkin lymphoma
CPI-006 + pembrolizumab,targets,metastatic castration resistant prostate cancer
CPI-006 + pembrolizumab,targets,endometrial cancer
CPI-006 + pembrolizumab,targets,colorectal cancer
CPI-006 + pembrolizumab,targets,TNBC
NCT03454451,tests,CPI-006
CPI-006,has_type,DRUG
CPI-006,classified_as,OTHER
CPI-006,targets,non-small cell lung cancer
CPI-006,targets,squamous cell carcinoma of the head and neck
CPI-006,targets,pancreatic cancer
CPI-006,targets,renal cell cancer
CPI-006,targets,ovarian cancer
CPI-006,targets,sarcoma
CPI-006,targets,triple negative breast cancer
CPI-006,targets,bladder cancer
CPI-006,targets,cervical cancer
CPI-006,targets,non-hodgkin lymphoma
CPI-006,targets,metastatic castration resistant prostate cancer
CPI-006,targets,endometrial cancer
CPI-006,targets,colorectal cancer
CPI-006,targets,TNBC
NCT03454451,tests,CPI-006 + ciforadenant
CPI-006 + ciforadenant,has_type,DRUG
CPI-006 + ciforadenant,classified_as,OTHER
CPI-006 + ciforadenant,targets,non-small cell lung cancer
CPI-006 + ciforadenant,targets,squamous cell carcinoma of the head and neck
CPI-006 + ciforadenant,targets,pancreatic cancer
CPI-006 + ciforadenant,targets,renal cell cancer
CPI-006 + ciforadenant,targets,ovarian cancer
CPI-006 + ciforadenant,targets,sarcoma
CPI-006 + ciforadenant,targets,triple negative breast cancer
CPI-006 + ciforadenant,targets,bladder cancer
CPI-006 + ciforadenant,targets,cervical cancer
CPI-006 + ciforadenant,targets,non-hodgkin lymphoma
CPI-006 + ciforadenant,targets,metastatic castration resistant prostate cancer
CPI-006 + ciforadenant,targets,endometrial cancer
CPI-006 + ciforadenant,targets,colorectal cancer
CPI-006 + ciforadenant,targets,TNBC
NCT03454451,tests,CPI-006 + pembrolizumab
CPI-006 + pembrolizumab,has_type,DRUG
CPI-006 + pembrolizumab,classified_as,BIOLOGIC
CPI-006 + pembrolizumab,targets,non-small cell lung cancer
CPI-006 + pembrolizumab,targets,squamous cell carcinoma of the head and neck
CPI-006 + pembrolizumab,targets,pancreatic cancer
CPI-006 + pembrolizumab,targets,renal cell cancer
CPI-006 + pembrolizumab,targets,ovarian cancer
CPI-006 + pembrolizumab,targets,sarcoma
CPI-006 + pembrolizumab,targets,triple negative breast cancer
CPI-006 + pembrolizumab,targets,bladder cancer
CPI-006 + pembrolizumab,targets,cervical cancer
CPI-006 + pembrolizumab,targets,non-hodgkin lymphoma
CPI-006 + pembrolizumab,targets,metastatic castration resistant prostate cancer
CPI-006 + pembrolizumab,targets,endometrial cancer
CPI-006 + pembrolizumab,targets,colorectal cancer
CPI-006 + pembrolizumab,targets,TNBC
NCT06435351,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT06435351,has_status,RECRUITING
NCT06435351,tests,Leukapheresis
Leukapheresis,has_type,DRUG
Leukapheresis,classified_as,OTHER
Leukapheresis,targets,breast cancer
Leukapheresis,targets,triple negative breast cancer
Leukapheresis,targets,TNBC
NCT06435351,tests,Dendritic Cell (DC) Vaccine
Dendritic Cell (DC) Vaccine,has_type,DRUG
Dendritic Cell (DC) Vaccine,classified_as,OTHER
Dendritic Cell (DC) Vaccine,targets,breast cancer
Dendritic Cell (DC) Vaccine,targets,triple negative breast cancer
Dendritic Cell (DC) Vaccine,targets,TNBC
NCT03193853,sponsored_by,Joyce O'Shaughnessy
NCT03193853,has_status,COMPLETED
NCT03193853,tests,Tak-228 & Tak-117
Tak-228 & Tak-117,has_type,DRUG
Tak-228 & Tak-117,classified_as,OTHER
Tak-228 & Tak-117,targets,triple negative breast cancer
Tak-228 & Tak-117,targets,TNBC
NCT03193853,tests,Cisplatin & Nab Paclitaxel
Cisplatin & Nab Paclitaxel,has_type,DRUG
Cisplatin & Nab Paclitaxel,classified_as,CHEMICAL
Cisplatin & Nab Paclitaxel,targets,triple negative breast cancer
Cisplatin & Nab Paclitaxel,targets,TNBC
NCT06841354,sponsored_by,Merck Sharp & Dohme LLC
NCT06841354,has_status,RECRUITING
NCT06841354,tests,Sacituzumab tirumotecan
Sacituzumab tirumotecan,has_type,DRUG
Sacituzumab tirumotecan,classified_as,BIOLOGIC
Sacituzumab tirumotecan,targets,triple negative breast neoplasms
Sacituzumab tirumotecan,targets,TNBC
NCT06841354,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,triple negative breast neoplasms
Pembrolizumab,targets,TNBC
NCT06841354,tests,Rescue Medication
Rescue Medication,has_type,DRUG
Rescue Medication,classified_as,OTHER
Rescue Medication,targets,triple negative breast neoplasms
Rescue Medication,targets,TNBC
NCT06841354,tests,Paclitaxel
Paclitaxel,has_type,DRUG
Paclitaxel,classified_as,CHEMICAL
Paclitaxel,targets,triple negative breast neoplasms
Paclitaxel,targets,TNBC
NCT06841354,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
Nab-paclitaxel,classified_as,CHEMICAL
Nab-paclitaxel,targets,triple negative breast neoplasms
Nab-paclitaxel,targets,TNBC
NCT06841354,tests,Gemcitabine
Gemcitabine,has_type,DRUG
Gemcitabine,classified_as,OTHER
Gemcitabine,targets,triple negative breast neoplasms
Gemcitabine,targets,TNBC
NCT06841354,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,triple negative breast neoplasms
Carboplatin,targets,TNBC
NCT04332653,sponsored_by,NeoImmuneTech
NCT04332653,has_status,ACTIVE_NOT_RECRUITING
NCT04332653,tests,NT-I7
NT-I7,has_type,DRUG
NT-I7,classified_as,OTHER
NT-I7,targets,pancreatic cancer
NT-I7,targets,microsatellite stable colorectal cancer
NT-I7,targets,ovarian cancer
NT-I7,targets,triple negative breast cancer
NT-I7,targets,any advanced solid tumors
NT-I7,targets,small cell lung cancer
NT-I7,targets,non small cell lung cancer
NT-I7,targets,TNBC
NCT04332653,tests,pembrolizumab (KEYTRUDA®)
pembrolizumab (KEYTRUDA®),has_type,DRUG
pembrolizumab (KEYTRUDA®),classified_as,BIOLOGIC
pembrolizumab (KEYTRUDA®),targets,pancreatic cancer
pembrolizumab (KEYTRUDA®),targets,microsatellite stable colorectal cancer
pembrolizumab (KEYTRUDA®),targets,ovarian cancer
pembrolizumab (KEYTRUDA®),targets,triple negative breast cancer
pembrolizumab (KEYTRUDA®),targets,any advanced solid tumors
pembrolizumab (KEYTRUDA®),targets,small cell lung cancer
pembrolizumab (KEYTRUDA®),targets,non small cell lung cancer
pembrolizumab (KEYTRUDA®),targets,TNBC
NCT01997333,sponsored_by,Celldex Therapeutics
NCT01997333,has_status,COMPLETED
NCT01997333,tests,CDX-011
CDX-011,has_type,DRUG
CDX-011,classified_as,OTHER
CDX-011,targets,metastatic gpnmb over-expressing triple negative breast cancer
CDX-011,targets,TNBC
NCT01997333,tests,Capecitabine
Capecitabine,has_type,DRUG
Capecitabine,classified_as,CHEMICAL
Capecitabine,targets,metastatic gpnmb over-expressing triple negative breast cancer
Capecitabine,targets,TNBC
NCT06709651,sponsored_by,University College Cork
NCT06709651,has_status,RECRUITING
NCT01676753,sponsored_by,Jo Chien
NCT01676753,has_status,COMPLETED
NCT01676753,tests,Dinaciclib
Dinaciclib,has_type,DRUG
Dinaciclib,classified_as,CHEMICAL
Dinaciclib,targets,advanced or metastatic breast cancer
Dinaciclib,targets,triple negative breast cancer
Dinaciclib,targets,TNBC
NCT01676753,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,advanced or metastatic breast cancer
Pembrolizumab,targets,triple negative breast cancer
Pembrolizumab,targets,TNBC
NCT04638751,sponsored_by,Persephone Biosciences
NCT04638751,has_status,RECRUITING
NCT04638751,tests,Immunotherapy
Immunotherapy,has_type,DRUG
Immunotherapy,classified_as,BIOLOGIC
Immunotherapy,targets,triple negative breast cancer
Immunotherapy,targets,non-small cell lung cancer
Immunotherapy,targets,pancreas cancer
Immunotherapy,targets,colorectal cancer
Immunotherapy,targets,TNBC
NCT04638751,tests,Chemotherapy
Chemotherapy,has_type,DRUG
Chemotherapy,classified_as,OTHER
Chemotherapy,targets,triple negative breast cancer
Chemotherapy,targets,non-small cell lung cancer
Chemotherapy,targets,pancreas cancer
Chemotherapy,targets,colorectal cancer
Chemotherapy,targets,TNBC
NCT04638751,tests,CRC surgical resection
CRC surgical resection,has_type,DRUG
CRC surgical resection,classified_as,OTHER
CRC surgical resection,targets,triple negative breast cancer
CRC surgical resection,targets,non-small cell lung cancer
CRC surgical resection,targets,pancreas cancer
CRC surgical resection,targets,colorectal cancer
CRC surgical resection,targets,TNBC
NCT04638751,tests,Colonoscopy
Colonoscopy,has_type,DRUG
Colonoscopy,classified_as,OTHER
Colonoscopy,targets,triple negative breast cancer
Colonoscopy,targets,non-small cell lung cancer
Colonoscopy,targets,pancreas cancer
Colonoscopy,targets,colorectal cancer
Colonoscopy,targets,TNBC
NCT04142554,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT04142554,has_status,WITHDRAWN
NCT04142554,tests,Parsaclisib
Parsaclisib,has_type,DRUG
Parsaclisib,classified_as,CHEMICAL
Parsaclisib,targets,breast cancer
Parsaclisib,targets,her2-positive breast cancer
Parsaclisib,targets,breast neoplasms
Parsaclisib,targets,triple negative breast cancer
Parsaclisib,targets,TNBC
NCT03983954,sponsored_by,NeoTX Therapeutics Ltd.
NCT03983954,has_status,RECRUITING
NCT03983954,tests,"Obinutuzumab, naptumomab estafenatox and durvalumab"
"Obinutuzumab, naptumomab estafenatox and durvalumab",has_type,DRUG
"Obinutuzumab, naptumomab estafenatox and durvalumab",classified_as,BIOLOGIC
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,melanoma
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,her2-negative breast cancer
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,pancreatic adenocarcinoma
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,hepatocellular carcinoma
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,triple negative breast cancer
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,gastroesophageal cancer
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,er+ breast cancer
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,nsclc
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,mesothelioma
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,prostate cancer
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,cervical squamous cell carcinoma
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,ovarian cancer
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,bladder cancer
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,endometrial cancer
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,renal cell carcinoma
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,urothelial cancer
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,nscl2 gene mutation
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,esophageal cancer
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,head and neck squamous cell carcinoma
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,colorectal cancer metastatic
"Obinutuzumab, naptumomab estafenatox and durvalumab",targets,TNBC
NCT03983954,tests,Naptumomab estafenatox and durvalumab
Naptumomab estafenatox and durvalumab,has_type,DRUG
Naptumomab estafenatox and durvalumab,classified_as,BIOLOGIC
Naptumomab estafenatox and durvalumab,targets,melanoma
Naptumomab estafenatox and durvalumab,targets,her2-negative breast cancer
Naptumomab estafenatox and durvalumab,targets,pancreatic adenocarcinoma
Naptumomab estafenatox and durvalumab,targets,hepatocellular carcinoma
Naptumomab estafenatox and durvalumab,targets,triple negative breast cancer
Naptumomab estafenatox and durvalumab,targets,gastroesophageal cancer
Naptumomab estafenatox and durvalumab,targets,er+ breast cancer
Naptumomab estafenatox and durvalumab,targets,nsclc
Naptumomab estafenatox and durvalumab,targets,mesothelioma
Naptumomab estafenatox and durvalumab,targets,prostate cancer
Naptumomab estafenatox and durvalumab,targets,cervical squamous cell carcinoma
Naptumomab estafenatox and durvalumab,targets,ovarian cancer
Naptumomab estafenatox and durvalumab,targets,bladder cancer
Naptumomab estafenatox and durvalumab,targets,endometrial cancer
Naptumomab estafenatox and durvalumab,targets,renal cell carcinoma
Naptumomab estafenatox and durvalumab,targets,urothelial cancer
Naptumomab estafenatox and durvalumab,targets,nscl2 gene mutation
Naptumomab estafenatox and durvalumab,targets,esophageal cancer
Naptumomab estafenatox and durvalumab,targets,head and neck squamous cell carcinoma
Naptumomab estafenatox and durvalumab,targets,colorectal cancer metastatic
Naptumomab estafenatox and durvalumab,targets,TNBC
NCT07015853,sponsored_by,Stephen Shiao
NCT07015853,has_status,NOT_YET_RECRUITING
NCT07015853,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
Pembrolizumab,classified_as,BIOLOGIC
Pembrolizumab,targets,breast cancer
Pembrolizumab,targets,tnbc - triple-negative breast cancer
Pembrolizumab,targets,TNBC
NCT07015853,tests,Radiotherapy
Radiotherapy,has_type,DRUG
Radiotherapy,classified_as,OTHER
Radiotherapy,targets,breast cancer
Radiotherapy,targets,tnbc - triple-negative breast cancer
Radiotherapy,targets,TNBC
NCT07015853,tests,Axatilimab
Axatilimab,has_type,DRUG
Axatilimab,classified_as,BIOLOGIC
Axatilimab,targets,breast cancer
Axatilimab,targets,tnbc - triple-negative breast cancer
Axatilimab,targets,TNBC
NCT05867251,sponsored_by,"Avenzo Therapeutics, Inc."
NCT05867251,has_status,RECRUITING
NCT05867251,tests,AVZO-021
AVZO-021,has_type,DRUG
AVZO-021,classified_as,OTHER
AVZO-021,targets,hr+/her2- breast cancer
AVZO-021,targets,advanced solid tumor
AVZO-021,targets,ccne1 amplification
AVZO-021,targets,epithelial ovarian cancer
AVZO-021,targets,tnbc - triple-negative breast cancer
AVZO-021,targets,primary peritoneal cancer
AVZO-021,targets,fallopian tube cancer
AVZO-021,targets,endometrial cancer
AVZO-021,targets,"hr+, her2-, advanced breast cancer"
AVZO-021,targets,TNBC
NCT05867251,tests,Palbociclib
Palbociclib,has_type,DRUG
Palbociclib,classified_as,CHEMICAL
Palbociclib,targets,hr+/her2- breast cancer
Palbociclib,targets,advanced solid tumor
Palbociclib,targets,ccne1 amplification
Palbociclib,targets,epithelial ovarian cancer
Palbociclib,targets,tnbc - triple-negative breast cancer
Palbociclib,targets,primary peritoneal cancer
Palbociclib,targets,fallopian tube cancer
Palbociclib,targets,endometrial cancer
Palbociclib,targets,"hr+, her2-, advanced breast cancer"
Palbociclib,targets,TNBC
NCT05867251,tests,Fulvestrant
Fulvestrant,has_type,DRUG
Fulvestrant,classified_as,BIOLOGIC
Fulvestrant,targets,hr+/her2- breast cancer
Fulvestrant,targets,advanced solid tumor
Fulvestrant,targets,ccne1 amplification
Fulvestrant,targets,epithelial ovarian cancer
Fulvestrant,targets,tnbc - triple-negative breast cancer
Fulvestrant,targets,primary peritoneal cancer
Fulvestrant,targets,fallopian tube cancer
Fulvestrant,targets,endometrial cancer
Fulvestrant,targets,"hr+, her2-, advanced breast cancer"
Fulvestrant,targets,TNBC
NCT05867251,tests,Letrozole
Letrozole,has_type,DRUG
Letrozole,classified_as,CHEMICAL
Letrozole,targets,hr+/her2- breast cancer
Letrozole,targets,advanced solid tumor
Letrozole,targets,ccne1 amplification
Letrozole,targets,epithelial ovarian cancer
Letrozole,targets,tnbc - triple-negative breast cancer
Letrozole,targets,primary peritoneal cancer
Letrozole,targets,fallopian tube cancer
Letrozole,targets,endometrial cancer
Letrozole,targets,"hr+, her2-, advanced breast cancer"
Letrozole,targets,TNBC
NCT05867251,tests,Ribociclib
Ribociclib,has_type,DRUG
Ribociclib,classified_as,CHEMICAL
Ribociclib,targets,hr+/her2- breast cancer
Ribociclib,targets,advanced solid tumor
Ribociclib,targets,ccne1 amplification
Ribociclib,targets,epithelial ovarian cancer
Ribociclib,targets,tnbc - triple-negative breast cancer
Ribociclib,targets,primary peritoneal cancer
Ribociclib,targets,fallopian tube cancer
Ribociclib,targets,endometrial cancer
Ribociclib,targets,"hr+, her2-, advanced breast cancer"
Ribociclib,targets,TNBC
NCT05867251,tests,Abemaciclib
Abemaciclib,has_type,DRUG
Abemaciclib,classified_as,CHEMICAL
Abemaciclib,targets,hr+/her2- breast cancer
Abemaciclib,targets,advanced solid tumor
Abemaciclib,targets,ccne1 amplification
Abemaciclib,targets,epithelial ovarian cancer
Abemaciclib,targets,tnbc - triple-negative breast cancer
Abemaciclib,targets,primary peritoneal cancer
Abemaciclib,targets,fallopian tube cancer
Abemaciclib,targets,endometrial cancer
Abemaciclib,targets,"hr+, her2-, advanced breast cancer"
Abemaciclib,targets,TNBC
NCT05867251,tests,Carboplatin
Carboplatin,has_type,DRUG
Carboplatin,classified_as,CHEMICAL
Carboplatin,targets,hr+/her2- breast cancer
Carboplatin,targets,advanced solid tumor
Carboplatin,targets,ccne1 amplification
Carboplatin,targets,epithelial ovarian cancer
Carboplatin,targets,tnbc - triple-negative breast cancer
Carboplatin,targets,primary peritoneal cancer
Carboplatin,targets,fallopian tube cancer
Carboplatin,targets,endometrial cancer
Carboplatin,targets,"hr+, her2-, advanced breast cancer"
Carboplatin,targets,TNBC
NCT05867251,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
Sacituzumab Govitecan-hziy,classified_as,BIOLOGIC
Sacituzumab Govitecan-hziy,targets,hr+/her2- breast cancer
Sacituzumab Govitecan-hziy,targets,advanced solid tumor
Sacituzumab Govitecan-hziy,targets,ccne1 amplification
Sacituzumab Govitecan-hziy,targets,epithelial ovarian cancer
Sacituzumab Govitecan-hziy,targets,tnbc - triple-negative breast cancer
Sacituzumab Govitecan-hziy,targets,primary peritoneal cancer
Sacituzumab Govitecan-hziy,targets,fallopian tube cancer
Sacituzumab Govitecan-hziy,targets,endometrial cancer
Sacituzumab Govitecan-hziy,targets,"hr+, her2-, advanced breast cancer"
Sacituzumab Govitecan-hziy,targets,TNBC
